<SEC-DOCUMENT>0001108205-21-000012.txt : 20211109
<SEC-HEADER>0001108205-21-000012.hdr.sgml : 20211109
<ACCEPTANCE-DATETIME>20211109165131
ACCESSION NUMBER:		0001108205-21-000012
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		61
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211109
DATE AS OF CHANGE:		20211109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CURIS INC
		CENTRAL INDEX KEY:			0001108205
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				043505116
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30347
		FILM NUMBER:		211392982

	BUSINESS ADDRESS:	
		STREET 1:		128 SPRING STREET
		STREET 2:		BUILDING C, SUITE 500
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
		BUSINESS PHONE:		617-503-6500

	MAIL ADDRESS:	
		STREET 1:		128 SPRING STREET
		STREET 2:		BUILDING C, SUITE 500
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cris-20210930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:67cd88cd-4961-40fd-b7ee-f0e04fb032e1,g:de03038a-bcb1-460d-82b7-20721bd560b4,d:90810bc68d594941912c6cfda631781c--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:cris="http://www.curis.com/20210930" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cris-20210930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180L2ZyYWc6ODRkNTRiNTY3Y2QwNDM4NmIxYTVkMWJmOGNjZDYyOTQvdGFibGU6MGU5MzRmNjA4OTBmNDMwNThjZDBiMDQxNDQxYWQ0ZjQvdGFibGVyYW5nZTowZTkzNGY2MDg5MGY0MzA1OGNkMGIwNDE0NDFhZDRmNF80LTEtMS0xLTE_eb3793de-e082-4f8e-a4d7-6693b85ce2fb">false</ix:nonNumeric><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180L2ZyYWc6ODRkNTRiNTY3Y2QwNDM4NmIxYTVkMWJmOGNjZDYyOTQvdGFibGU6MGU5MzRmNjA4OTBmNDMwNThjZDBiMDQxNDQxYWQ0ZjQvdGFibGVyYW5nZTowZTkzNGY2MDg5MGY0MzA1OGNkMGIwNDE0NDFhZDRmNF81LTEtMS0xLTE_74a00d1c-0299-4891-864e-42dedd52a511">2021</ix:nonNumeric><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180L2ZyYWc6ODRkNTRiNTY3Y2QwNDM4NmIxYTVkMWJmOGNjZDYyOTQvdGFibGU6MGU5MzRmNjA4OTBmNDMwNThjZDBiMDQxNDQxYWQ0ZjQvdGFibGVyYW5nZTowZTkzNGY2MDg5MGY0MzA1OGNkMGIwNDE0NDFhZDRmNF82LTEtMS0xLTE_4162c52d-fc80-4b32-9609-51c99d99008f">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180L2ZyYWc6ODRkNTRiNTY3Y2QwNDM4NmIxYTVkMWJmOGNjZDYyOTQvdGFibGU6MGU5MzRmNjA4OTBmNDMwNThjZDBiMDQxNDQxYWQ0ZjQvdGFibGVyYW5nZTowZTkzNGY2MDg5MGY0MzA1OGNkMGIwNDE0NDFhZDRmNF83LTEtMS0xLTE_125de36d-3315-4949-863e-b68eeb0f3a00">0001108205</ix:nonNumeric><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180L2ZyYWc6ODRkNTRiNTY3Y2QwNDM4NmIxYTVkMWJmOGNjZDYyOTQvdGFibGU6MGU5MzRmNjA4OTBmNDMwNThjZDBiMDQxNDQxYWQ0ZjQvdGFibGVyYW5nZTowZTkzNGY2MDg5MGY0MzA1OGNkMGIwNDE0NDFhZDRmNF84LTEtMS0xLTE_5bf0634f-7d82-4532-aca9-eea9b8c1bdc4">--12-31</ix:nonNumeric><ix:nonFraction unitRef="segment" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="INF" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNy9mcmFnOmJiOTI1MGY5Nzc1NzQ2ZGU4NDY4NjljOGE3NTIxYTk5L3RhYmxlOjA2NmMwODE2ZjliYTRjNjc4YWQyZTA2MmIxOTJmNzJmL3RhYmxlcmFuZ2U6MDY2YzA4MTZmOWJhNGM2NzhhZDJlMDYyYjE5MmY3MmZfMi0xLTEtMS0x_2946d669-7a86-4afc-aa07-921c6b069d0a">1</ix:nonFraction><ix:nonNumeric contextRef="ibfc1f9ad461d4835b6ff18f84a6e7ea8_D20210101-20210930" name="cris:AvailableForSaleSecuritiesDateRange" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RleHRyZWdpb246NDRkZTEwMzQzNmIyNDYwYThkZGRiZmU2ZDExMjM4OGNfMTk3_cb80bf15-17b4-45da-ba01-4fb8b0381751">P1M</ix:nonNumeric><ix:nonNumeric contextRef="i06b66b7f05424af0a5f75ecabde108be_D20200101-20201231" name="cris:AvailableForSaleSecuritiesDateRange" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RleHRyZWdpb246NDRkZTEwMzQzNmIyNDYwYThkZGRiZmU2ZDExMjM4OGNfNTEx_4f659141-f01a-4310-9378-77affc0e77d5">P1M</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cris-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i4622e98fdb9241eca259fdf1067c64c6_I20211102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i11c1bbbe971845e8b341c2dce21185d6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4ae33930dfd48de8c0c9dab2d240035_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i533a446c7b4c4bbd9762a2f0852c2191_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:GrossRoyaltyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e6bc48882e74b6dbc7edc5bfb61e854_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:GrossRoyaltyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i430322671c674a2e9ecf19555642b870_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:GrossRoyaltyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdd8513423b24617ae9145402fcccf5e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:GrossRoyaltyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7059a303d18b4097838037b575847c70_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:OtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i995dfcf8f34847c9b9eac02305265435_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:OtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia720d94f508f4eb2a4f3c307eedfe435_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:OtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fe8f17e9bca46a08a36d1be114833e2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:OtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4d63a2bfd9a446bb2f258585206efff_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:ContraRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2377a33c77ce4828b22b332828013bd7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:ContraRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic76462d861cb47cc9c192a17cca41dd6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:ContraRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac7eb7aada544feeb409a3508f46d4a8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:ContraRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67dd4d38bbfc42dcac4661194af3c1b4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ca78b914bf041dc884674999397831a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50c937c85a114412bbb18451d45b1f0b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc7b92e171e5450db55aa4c462149d6d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60293bf8d8b34ce2b686154bc0dc8870_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id12cf2f5b2304c4187ba46547f160ae5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if39a3310599b4dc48df4759fd2f23b75_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfe15ac9fbdb4c41a9436d65053dd823_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6273ec08929c4042b363f75dc65c925f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ad6fa8151644284ba6c19774592e6d0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id26880c55f3b45a6ad8a5ccba68564a1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcd76ade8392457889758a7b96e60905_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a966410bb90428a843d3f569be9b164_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8d1462eadbb4aa1a9833bece5ae287b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8fc6b4c7394423b8ec79ccd7eae0b2a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d24421a8b204e50b645dcdee96de56f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib83f38159c0d47a39e7ba5f026425795_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7aab08630ed447578b4a6fabcff3af4a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57052d63d35b413e91d2037ed469551b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c2d8b06604949d8b1946a6b3626e498_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if008f4d0347f4f1e96cd9a5e2c5bc985_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife718f47b62e4c3687c07aa35e307ce2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i373c682106604fba9c0c257203578939_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a91365e4a5949bf9ba583bd68d30198_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1556c61df1fe4774856be3b37d7866b3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if16ae74c3f204c54a9fdb59324c1a8c1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib819b69ecf0d4a69af2a5cfdb3d3f29d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i496aa636a74449e6bb23b783bf1af401_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59c5613ca42840cd90b239dfeb0d2776_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c0d8228dd6c47dc8835400718fb7794_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id82880f87ee44511a970554ad14e0b2c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c7dd4eefa794b288e0e2911576a70f1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59d2a236085c4461b444f9e731b5d83a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77cd53b4f6e44e56bc18efef6b6c48fe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff6f88189e6c489fadca834518204877_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60b1a5740938422195d69fe89e22dbc2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74e73d5375984977b6347e5a763139d0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i773b93e5620347e1ab3d326166347a05_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3df11fcc545447489bc72b8df5ec6a5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b54cebb2076495ebc3a6534669720f4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i668eb741fed8462b9be0b59ca9b25135_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00fcba8a8a6049a0b2dd2926f0f9f9d3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf69f9380ea04321ac14ce6785b41f7c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c1929f827ff4826a126b14efa9ed807_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5f6802b38e34cdca4064f21d5ed6f28_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab83bec3cf434ed190d72f069b95e844_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3398a93d47d24500ab8ab9d0d4a0aae0_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3db7b202b9742b4ba2ad6c5070f5d3a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7587529ce7947f8ba47ac622a4fc47e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e195d3203824b3d9aab16f7ec0f0922_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74f2b1fab46944cf9e3f63c1971776bf_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i160c6a5048d844c1bb83e8a5d34a79cb_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4a6ffee772a437a8a6979d274823c5a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb5feb63bb884b278199f05efec2e882_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1145ae8cfec46ea9d2ea1ff2a92e958_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fdb43e2101b443f8adf0e0948bf2820_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79eb58664af1462c86740522e97626dc_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81c6a9cdd6304647889f68d7fc513971_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e2324829cfe492bb1ce3a18540cabae_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5696cc43a1414c5eb951ffb14fe34541_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id551d22461aa42b4ac2f10c2d9ef6e0d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied34bb1c61f14a14b532c5987fe42f4d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68950601d26a41dca198d584853b5317_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:DemandSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5d45aa56d6e4b4888724ffa54069f9a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:DemandSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i243b02ffde754d02a51ddcf82577ece7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:DemandSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6334c899a5394f309f5ba35f98753e11_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84408fe3e0ed4336aa0f6ff3095dd860_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i484203a4a3aa47f5a945b8781929feb6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7fc2a9a1f5c430ab65ea66663c830cd_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1072f132f4d4820b9dfdf6759a5c275_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice8c0d0a4a4c414b80040c8507090a61_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i115d55a1156e4c969b9b8083b7760eb1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6b5f21400a142dd92d6458b6bc2b0f9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0585c12f68584892a486dd533b6667ce_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37f437e27c6c449b80dcb3c731463e31_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cris:DirectPlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a2d864386944501a52823fe60a6ac4a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cris:DirectPlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae11a3b9f70d4d8b8470bb42b3f5c915_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cris:DemandSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica18ded6bc544002a83550782ca17ceb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cris:DemandSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="program"><xbrli:measure>cris:program</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i36015b0cc9094033ad0afc16178a75cf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cris:GenentechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a46a72b07d94f83a96cc1ed91d2c92c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cris:GenentechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e17706f12e14935b7a015a9bceda833_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cris:GenentechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i262850aa677c403ba7f59d77493f79af_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cris:GenentechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cris:segment</xbrli:measure></xbrli:unit><xbrli:context id="i3df875ea96bc4acbbb5cb6759aaf23a8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i752919577506410ea7bba33998b02ae8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cdf5782b2f94b21b2601d416cac0370_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43a2dff08c424d20b371f99c387f9552_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad40040d3fdb4825b2d3d57150804fd8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cris:CorporateCommercialPaperStockBondsAndNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2274a8be63ab428c82beb8aa7d63ef65_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cris:CorporateCommercialPaperStockBondsAndNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if877b50a8b61448bab75f25dec242c52_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cris:CorporateCommercialPaperStockBondsAndNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibba7a650ba3e471bad9894814e905a1f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cris:CorporateCommercialPaperStockBondsAndNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91bffd463f9a491d809bd7007380675e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48c7eb38239442ad99050fe29f702ff5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f14473beda6447099b0a6cd272baf6a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifadf6a4b0d22481ba0be83763d78d4c5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90b3b70b1ebe49e3b4887be14abc4f66_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b067bfcfb3e48039d044d6458bfd391_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadb4da6453d243de9db7f2235495b30b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6ed47efff4d435ca7a150ad517661c2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e4fd250bac14a99a97209435af04856_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cris:CorporateCommercialPaperStockBondsAndNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6695b4c7cf4241ad83f88137c23fe102_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cris:CorporateCommercialPaperStockBondsAndNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id80a7c2a02984bf79a96da6df2e5a2b6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cris:CorporateCommercialPaperStockBondsAndNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52426bd73b8d4aea9d57fb272e80b022_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cris:CorporateCommercialPaperStockBondsAndNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c228f3130b24ff3970c7f263b1d41aa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b1c769aefa947ec9c248070d8b405b2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51d5333ea5724b6b9ff7023272b24535_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4fdd2d8901b4eaca49139aa5b83e7bb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4abc2d093e574952b5b7a754de257c3a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb8359146f7d40bdae64e9071788d92a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfc1f9ad461d4835b6ff18f84a6e7ea8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d85f4c8792a4a81a3945294a14918cf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9957a5ac4bf142e78afb996c95c0ac64_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d10b233f290481a9f06412946f6a2ce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa1a4b9cd2ed47249f51596f460164a4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06b66b7f05424af0a5f75ecabde108be_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5de88db29d3e498087f6e6443e27c84c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e5764c869674f6eaf807f9f08528150_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f243344a43a416aa68d31546bb3c8b8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27e768c412c64fadbdb2a523fde1e521_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d950297b01b4b72ae513d1a9aba345e_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cris:CaresActPPPLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb1c5fdb8979488fbe5bdf7ab44b6d01_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cris:CaresActPPPLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8446755412e84406a49c98064e52b988_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cris:CaresActPPPLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5375dfdc8ee412588936e837f459f29_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:OberlandCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffa498edbc73462ba0ffcf6335f33a3b_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:OberlandCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cris:ContingentPaymentBenchmarkAxis">cris:RoyaltyAmountsIn2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib033bd6eec734cf1826c9d37348e3df6_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:OberlandCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cris:ContingentPaymentBenchmarkAxis">cris:AggregateNetRoyaltiesPriorTo2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1df2f708d5694cd7803b3b1cdb822461_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:OberlandCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6e3f1f585a2476fb48ab5c48b4b4c0c_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a3b34007b0a4945b84b16df5abc4a37_I20030630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2003-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3a04e3a472f4d30b82d08fe43d2c0b7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i481f7ee4adb0442a9066ccee54707fa3_D20030601-20030630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2003-06-01</xbrli:startDate><xbrli:endDate>2003-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1554d4e73abd4dabac3fe396586aa6c2_D20030601-20030630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2003-06-01</xbrli:startDate><xbrli:endDate>2003-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic26067fcb23449e68eba5cd92cb0a49e_D20030601-20030630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2003-06-01</xbrli:startDate><xbrli:endDate>2003-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia877710393f94f3f8c7e7cd08300f3eb_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:GrossRoyaltyRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied01dcd8f0fb415ba2f14add0c9df964_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:GrossRoyaltyRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bffc8f5f047450b936f6e0e45ee38ee_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:GrossRoyaltyRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i867de25d3dc74fc8a9604601d285b12c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:GrossRoyaltyRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f251344683f457e89a14215c76f8256_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if18f2dacb57041919fa0284b6d6a3fd4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46169f75ca7f4f9db86ac1e7a209d5bf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79ee3f9f0f4d480d8caee067d86e3ca8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if99565915c7247d696c1777c7a44e409_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a557708fb604f12961074aec6ae2ddc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3409ba719834a2f9e98876189a4ceb1_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bcee2e8132f40f29d06994aa69d5c75_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:ThirdandFourthProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i460702ed242d4892b13fa83e2f82d10c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55779509759a4442aa49e025489ef439_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:IRAK4PD1VISTAPD1TIM3ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b4c90b7e43448599c53fc40d6662bc3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:MasterDevelopmentAndManufacturingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8625a7feacd4c3f8ea2bbf25583364c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:MasterDevelopmentAndManufacturingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if724acf7f886498f936922f1b813133c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:MasterDevelopmentAndManufacturingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1233820bbb0f46f1ae495b371f0da3a3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c0e449c262a4c9fb7ac84a67ca508ed_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2553b5bece3047dca87c108aef6cfd51_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:ImmuNextMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae8e02ce92e14a61a403e503c35b7dd3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:ImmuNextMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e926263e5b843dba11e03bf2ac934c5_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i389b853ef28c48bfb67d977144cea2be_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13cd005f3b784a00a03427270ff13a4e_I20210316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d46809b9cf44e11972741a203406eb1_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2634e1ed79549308ba035250ef761a1_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i005697a4b0824bddb4df769ee739b32c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i531d173b436149d0977c73c89cfa4e0b_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0104cbc441b344aa8d7670c779cd19fc_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2e46877fa284075af8f8cd02a331c87_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia64c5dfac95a49f2be056702512a4950_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9dc8759604c4487a95552d9277d2945_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:DemandSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4c44bc6307042429eb5deaab3627f34_I20200304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:DemandSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia614167954ff4147a511fd404c79e22a_D20201209-20201209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:DemandSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-09</xbrli:startDate><xbrli:endDate>2020-12-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f43d279bfc346499189eea5974d7564_I20201209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:DemandSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59313702068b4ee9a458942cc6de5f0a_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4d61c5f1c1a4c7b8b490d4990b8c9a1_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e2fb16ab10247c7bb59f0e0bb3f5e91_D20200226-20200226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-26</xbrli:startDate><xbrli:endDate>2020-02-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i509ac601c8cb4988976c395f2c180da2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e79259145d846dfb9168818ded77f22_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e1d7b28e07045f8b69914b45905559b_I20200226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd185c48c5a14633a53cc897fedfc27f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic667076e7a4a430c82568988e947ba95_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i298a95e35ee2477b900f65f112daddfd_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8feff43f83394d56b56b4cc6fe8050aa_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plan"><xbrli:measure>cris:plan</xbrli:measure></xbrli:unit><xbrli:context id="id1737ae1a00346e48a3f3c4d2b81c90d_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:AmendedAndRestatedTwoThousandTenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f5c7a7ab0a4454988d74c383e8d95c1_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:AmendedAndRestatedTwoThousandTenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec9ed577995e4041bf1893f19ed4df11_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:AmendedAndRestatedTwoThousandTenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cris:StockOptionsorStockAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d9cc7f517654e6a955f1150754f9212_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:AmendedAndRestatedTwoThousandTenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cris:RestrictedStockRSUsOtherStockBasedAwardsOrPerformanceAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f1f0ba40401473facc35d4c0efc7dbc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:AmendedAndRestatedTwoThousandTenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1219b3d01e7b42a58ca53018ecff778b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:TwoThousandAndTenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8de22fdc1364771a9ce096bd4828f96_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:TwoThousandAndTenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic13e507f88684f5ca74c1614332fef14_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:TwoThousandAndTenPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07e1ce19861a4ae59be352c43fd153c5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e4ba76c11bd4f45b6687b17d856c8d6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cris:NonEmployeeDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:TwoThousandAndTenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b2ded813e3c47c0b1ea5d0064b18933_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cris:NonEmployeeDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:TwoThousandAndTenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d000460f02348d9a57c3b6ac2c6626a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if92fd01d600549e3966881e1346c980d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82ceafb1c6a24cca84ef9a0241a19879_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19989054788e4da19d8b3a02d19f3af8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cris:OfficersAndNonEmployeeDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab7e84e85b8043f69c8eee23b3053c8a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cris:OfficersAndNonEmployeeDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20919e06b4f743a294203290cd8726b2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb5cbdbb686f429fb1f8c8cc33874d76_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="purchase_period"><xbrli:measure>cris:purchase_period</xbrli:measure></xbrli:unit><xbrli:context id="iace147228c5946e7856c18ea03d6b20c_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb9ad9cc9e894c4a8591a01bc5b0e7a3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bcecdf0c0fb4a72b6e837d5f3fe2504_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7e33ac900a448798f0a8d5fac3e7c9a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e0e7bd086684b51905901766d082679_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ed4bd4d72e5471aae94ac0a3df1cd55_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9179bb8d8abc4e7a966aa44e418032fa_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d1e27447c134e8b8836cf1c2b82cc83_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19eea75f02854b849783be2ececc8962_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1569ff1a3c7e4c1a828aa4de4ce7b739_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb8cdae355c147d78b1f92ad1395fbb7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1569a19d3534733a5351d7321844968_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85ee1298708f4cd9b83af95152514d48_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10387d0e7a2b43aea7787dd2ecda9786_D20181018-20181018"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:EpiCurePharmaceuticalsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cris:AgreementWithHeadOfResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-18</xbrli:startDate><xbrli:endDate>2018-10-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i272602d3cc7643438ce9826f03bb4e8d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:EpiCurePharmaceuticalsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cris:AgreementWithHeadOfResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>cris:day</xbrli:measure></xbrli:unit><xbrli:context id="i1b869695d75c4d90a845094790292154_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:EpiCurePharmaceuticalsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i476e1229fc4b40faa3024587e5c8cf5c_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:EpiCurePharmaceuticalsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i90810bc68d594941912c6cfda631781c_1"></div><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGV4dHJlZ2lvbjoyZWUxYWNkYTI4ZWY0NWRjODVlMGUzNjg0ODA5ZjI3Zl8xOTg4_48ea47d7-2d1b-48b7-a08b-151bbfa301cd">10-Q</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark one)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6ZTNiZWI0N2YxZTg3NDAxNTljZGViNTVhOThjYzkzZjEvdGFibGVyYW5nZTplM2JlYjQ3ZjFlODc0MDE1OWNkZWI1NWE5OGNjOTNmMV8wLTAtMS0xLTE_a1674305-716e-4856-91b5-0c7be8e4630a">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGV4dHJlZ2lvbjoyZWUxYWNkYTI4ZWY0NWRjODVlMGUzNjg0ODA5ZjI3Zl82NTk3MDY5NzY4Njk3_07e4b86d-f8d4-475c-a455-a99755394de0">September 30, 2021</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6YTE2MGUzM2NlMTI0NDM1N2EyNDY1ZWJkYmMwNmUzZDkvdGFibGVyYW5nZTphMTYwZTMzY2UxMjQ0MzU3YTI0NjVlYmRiYzA2ZTNkOV8wLTAtMS0xLTE_c4e8402f-5d39-40a2-9179-5e2e6952cbd7">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGV4dHJlZ2lvbjoyZWUxYWNkYTI4ZWY0NWRjODVlMGUzNjg0ODA5ZjI3Zl8xOTg5_cad2f032-eda0-4d2e-bcb3-929ef46eee6b">000-30347</ix:nonNumeric></span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.654%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGV4dHJlZ2lvbjoyZWUxYWNkYTI4ZWY0NWRjODVlMGUzNjg0ODA5ZjI3Zl8xOTkw_b0f46d63-9b15-4733-a519-6a03d3d17627">CURIS, INC.</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-bottom:4pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.654%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6ZTNhN2I0NDU5NjcwNDJhY2I2Y2FhYjJhM2IwYzljYjEvdGFibGVyYW5nZTplM2E3YjQ0NTk2NzA0MmFjYjZjYWFiMmEzYjBjOWNiMV8wLTAtMS0xLTE_3ab66f53-881e-45c7-8301-b4a4de749e2c">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6ZTNhN2I0NDU5NjcwNDJhY2I2Y2FhYjJhM2IwYzljYjEvdGFibGVyYW5nZTplM2E3YjQ0NTk2NzA0MmFjYjZjYWFiMmEzYjBjOWNiMV8wLTItMS0xLTE_a5e57da2-9f4b-4bfc-aab3-6f8298e87666">04-3505116</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of<br/>Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6ZTNhN2I0NDU5NjcwNDJhY2I2Y2FhYjJhM2IwYzljYjEvdGFibGVyYW5nZTplM2E3YjQ0NTk2NzA0MmFjYjZjYWFiMmEzYjBjOWNiMV8zLTAtMS0xLTEvdGV4dHJlZ2lvbjoyOGEyYzQxMWEwZWM0YmYxYmNhYzc4NzYyYmExZWFkZV80_b1f27d8a-0500-47cb-8c04-76cfe61510d2">128 Spring Street</ix:nonNumeric>, <ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6ZTNhN2I0NDU5NjcwNDJhY2I2Y2FhYjJhM2IwYzljYjEvdGFibGVyYW5nZTplM2E3YjQ0NTk2NzA0MmFjYjZjYWFiMmEzYjBjOWNiMV8zLTAtMS0xLTEvdGV4dHJlZ2lvbjoyOGEyYzQxMWEwZWM0YmYxYmNhYzc4NzYyYmExZWFkZV84_d96e81f5-b65f-458c-9685-e98c1c4b749b">Building C - Suite 500</ix:nonNumeric>, <ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6ZTNhN2I0NDU5NjcwNDJhY2I2Y2FhYjJhM2IwYzljYjEvdGFibGVyYW5nZTplM2E3YjQ0NTk2NzA0MmFjYjZjYWFiMmEzYjBjOWNiMV8zLTAtMS0xLTEvdGV4dHJlZ2lvbjoyOGEyYzQxMWEwZWM0YmYxYmNhYzc4NzYyYmExZWFkZV8xMg_65d426e8-251c-42db-aaaf-ab9cddbbb3fb">Lexington</ix:nonNumeric>, <ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6ZTNhN2I0NDU5NjcwNDJhY2I2Y2FhYjJhM2IwYzljYjEvdGFibGVyYW5nZTplM2E3YjQ0NTk2NzA0MmFjYjZjYWFiMmEzYjBjOWNiMV8zLTAtMS0xLTEvdGV4dHJlZ2lvbjoyOGEyYzQxMWEwZWM0YmYxYmNhYzc4NzYyYmExZWFkZV8xNg_c05b95b2-6d7d-4237-9ade-a2463779d41f">Massachusetts</ix:nonNumeric> <ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6ZTNhN2I0NDU5NjcwNDJhY2I2Y2FhYjJhM2IwYzljYjEvdGFibGVyYW5nZTplM2E3YjQ0NTk2NzA0MmFjYjZjYWFiMmEzYjBjOWNiMV8zLTAtMS0xLTEvdGV4dHJlZ2lvbjoyOGEyYzQxMWEwZWM0YmYxYmNhYzc4NzYyYmExZWFkZV8xOQ_e8a5bc39-23b6-4dfd-a212-f2e03175f3eb">02421</ix:nonNumeric></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices) (Zip Code)</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code: (<ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGV4dHJlZ2lvbjoyZWUxYWNkYTI4ZWY0NWRjODVlMGUzNjg0ODA5ZjI3Zl8xOTkx_bbb2ddcb-c5ec-4479-b2f2-e4940a2bf9b4">617</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGV4dHJlZ2lvbjoyZWUxYWNkYTI4ZWY0NWRjODVlMGUzNjg0ODA5ZjI3Zl8xOTk3_3515f063-b620-4e06-a964-8878bbcb2241">503-6500</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.654%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:36.717%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6YTU1NGQ5YjQ5NWZmNGFjZWI4YjBkNjliNGI3ODA1ZWUvdGFibGVyYW5nZTphNTU0ZDliNDk1ZmY0YWNlYjhiMGQ2OWI0Yjc4MDVlZV8xLTAtMS0xLTE_652a179a-d889-4104-ba84-c85b66ebefa2">Common Stock, Par Value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6YTU1NGQ5YjQ5NWZmNGFjZWI4YjBkNjliNGI3ODA1ZWUvdGFibGVyYW5nZTphNTU0ZDliNDk1ZmY0YWNlYjhiMGQ2OWI0Yjc4MDVlZV8xLTItMS0xLTE_624980a7-3186-4523-aba9-afe7e43a7262">CRIS</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6YTU1NGQ5YjQ5NWZmNGFjZWI4YjBkNjliNGI3ODA1ZWUvdGFibGVyYW5nZTphNTU0ZDliNDk1ZmY0YWNlYjhiMGQ2OWI0Yjc4MDVlZV8xLTQtMS0xLTE_c6b200d3-a146-4ce6-a689-ec3d141fecfe">Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGV4dHJlZ2lvbjoyZWUxYWNkYTI4ZWY0NWRjODVlMGUzNjg0ODA5ZjI3Zl8xOTky_990da9bd-3883-43d0-9b2c-7d7ec63f49a6">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;No</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGV4dHJlZ2lvbjoyZWUxYWNkYTI4ZWY0NWRjODVlMGUzNjg0ODA5ZjI3Zl8xOTkz_2e231068-f2d9-49bc-a461-4963fc87206b">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;No</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.:</span></div><div style="margin-top:11pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:21.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.013%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large accelerated filer&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6ZDFkZjI0MGVhMWE3NDkyYTk0NDRhNjVmZTg3ZDQzZjMvdGFibGVyYW5nZTpkMWRmMjQwZWExYTc0OTJhOTQ0NGE2NWZlODdkNDNmM18wLTItMS0xLTEvdGV4dHJlZ2lvbjo2NDgxOTcyYWYwNWY0MzdlYWI5MmMzOGQ5YzJmYzdmN180_506727d9-7d7f-48ae-b76b-58c7d0449e07">Non-accelerated filer</ix:nonNumeric> &#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6ZDFkZjI0MGVhMWE3NDkyYTk0NDRhNjVmZTg3ZDQzZjMvdGFibGVyYW5nZTpkMWRmMjQwZWExYTc0OTJhOTQ0NGE2NWZlODdkNDNmM18wLTMtMS0xLTEvdGV4dHJlZ2lvbjpjMDNlMWJiOWM4Mjg0YzdlYmVlNzIwNTJlZTkzNTlhM18zMw_8f1521b6-bd9b-42d5-ad9e-9eade9c26821">&#9746;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company&#160;&#160;&#160;<ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6ZDFkZjI0MGVhMWE3NDkyYTk0NDRhNjVmZTg3ZDQzZjMvdGFibGVyYW5nZTpkMWRmMjQwZWExYTc0OTJhOTQ0NGE2NWZlODdkNDNmM18xLTMtMS0xLTEvdGV4dHJlZ2lvbjpiNjg4NTA4YWM4MzQ0ZjM0YjE5NjBkYzBhYmI5OGE5NV8zMA_37ebf728-39cc-4697-a8e7-91e9a96a074a">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;Yes&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" format="ixt:fixed-false" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGV4dHJlZ2lvbjoyZWUxYWNkYTI4ZWY0NWRjODVlMGUzNjg0ODA5ZjI3Zl8xOTk0_9a831897-52b2-4868-9391-6cbfc6a77202">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;No</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of November&#160;2, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i4622e98fdb9241eca259fdf1067c64c6_I20211102" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGV4dHJlZ2lvbjoyZWUxYWNkYTI4ZWY0NWRjODVlMGUzNjg0ODA5ZjI3Zl8xMDk5NTExNjI5Nzk0_c20a7ae7-8a41-4844-baae-372aff65c734">91,609,165</ix:nonFraction> shares of the registrant&#8217;s common stock, par value $0.01 per share, outstanding.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i90810bc68d594941912c6cfda631781c_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURIS, INC. AND SUBSIDIARIES QUARTERLY REPORT ON FORM 10-Q</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page<br/>Number</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;I.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FINANCIAL INFORMATION</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_13">Unaudited Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_13">6</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_16">Condensed Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_16">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_16"> 30, 2021 and December 31, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_16">6</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_19">Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_19">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_19"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_19">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_19"> 30, 2021 and 2020 </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_19">7</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_19">Condensed Consolidated Statements of Stockholders' Equity (Deficit) for the Three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_19">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_19"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_19">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_19"> 30, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_22">8</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_25">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_25">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_25"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_25">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_25"> 30, 2021 and 2020 </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_25">10</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_28">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_28">11</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_79">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_79">25</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_109">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_109">37</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_112">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_112">37</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;II.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_115">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_118">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_118">37</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_121">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_121">38</a></span></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_124">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_124">39</a></span></div></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Note Regarding Forward-Looking Statements and Industry Data </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. All statements other than statements of historical fact contained in this report are statements that could be deemed forward-looking statements, including without limitation any statements with respect to the plans, strategies and objectives of management for future operations; statements concerning product research, development and commercialization plans, timelines and anticipated results; statements of expectation or belief; statements with respect to clinical trials and studies; statements with respect to royalties and milestones; statements with respect to the therapeutic potential of drug candidates; expectations of revenue, expenses, earnings or losses from operations, or other financial results; and statements of assumptions underlying any of the foregoing. Without limiting the foregoing, the words &#8220;anticipate(s)&#8221;, &#8220;believe(s)&#8221;, &#8220;focus(es)&#8221;, &#8220;could&#8221;, &#8220;estimate(s)&#8221;, &#8220;expect(s)&#8221;, &#8220;intend(s)&#8221;, &#8220;may&#8221;, &#8220;plan(s)&#8221;, &#8220;seek(s)&#8221;, &#8220;will&#8221;, &#8220;strategy&#8221;, &#8220;mission&#8221;, &#8220;potential&#8221;, &#8220;should&#8221;, &#8220;would" and other similar language, whether in the negative or affirmative, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements may include, but are not limited to, statements about:</span></div><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, timing, progress and results of future preclinical studies and clinical trials, and our research and development programs;</span></div><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to develop and commercialize our drug candidates;</span></div><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our collaborators&#8217; plans to commercialize Erivedge;</span></div><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations or obtain additional funding;</span></div><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the timing or likelihood of regulatory filings and approvals;</span></div><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the implementation of our business model, strategic plans for our business, drug candidates and technology;</span></div><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our commercialization, marketing and manufacturing capabilities and strategy;</span></div><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our products;</span></div><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our competitive position;</span></div><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our intellectual property position;</span></div><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">developments and projections relating to our competitors and our industry;</span></div><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the potential of CA-4948, CI-8993, CA-170, fimepinostat, CA-327, and other drug candidates that we in-license, or may elect to in-license, or may acquire in the future;</span></div><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates of the period in which we anticipate that existing cash and cash equivalents will enable us to fund our current and planned operations;</span></div><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">impacts resulting from the COVID-19 pandemic and responsive actions relating thereto;</span></div><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain our listing on the Nasdaq Global Market; and </span></div><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. We therefore caution you against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in these forward-looking statements include the factors discussed below under the heading &#8220;Risk Factor Summary,&#8221; and the risk factors detailed further in Item 1A, "Risk Factors" of Part I of our Annual Report on Form 10-K for the year ended December 31, 2020 and, if applicable, those included under Part II, Item 1A of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This report includes statistical and other industry and market data that we obtained from industry publications and research, surveys, and studies conducted by third parties as well as our own estimates. All of the market data used in this report involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities for our drug candidates include several key assumptions based on our industry knowledge, industry publications, third-party research, and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The forward-looking statements included in this report represent our estimates as of the filing date of this report. We specifically disclaim any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing our estimates or views as of any date subsequent to the date of this report.</span></div><div style="margin-top:9pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk Factor Summary</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in our securities involves risk. You should carefully consider the following summary of what we believe to be the principal risks facing our business, in addition to the risks described more fully in Item 1A, &#8220;Risk Factors&#8221; of Part I of our Annual Report on Form 10-K for the year ended December 31, 2020, and, if applicable, those included under Part II, Item 1A of this Quarterly Report on Form 10-Q and other information included in this report. The risks and uncertainties described below are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us or that we presently deem less significant may also impair our business operations. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of the following risks occurs, our business, financial condition, and results of operations and future growth prospects could be materially and adversely affected, and the actual outcomes of matters as to which forward-looking statements are made in this report could be materially different from those anticipated in such forward-looking statements.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred substantial losses, expect to incur substantial losses for the foreseeable future and may never generate significant revenue or achieve or maintain profitability.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will require substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our drug development programs or commercialization efforts.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face risks related to the novel coronavirus pandemic, COVID-19, which has delayed and may continue to delay our ability to complete our ongoing clinical trials and the enrollment and initiation of future clinical trials, and may disrupt regulatory activities, cause substantial disruption in the financial markets and economy, or have other adverse effects on our business and operations. </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face substantial competition, and our competitors may discover, develop or commercialize drugs before or more successfully than we do. Furthermore, the amount of royalty revenue we received from sales of Erivedge has been adversely affected by a competing drug, and may be further affected in the future.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend heavily on the success of our most advanced drug candidates, including CA-4948 and CI-8993. If we are unable to initiate or complete the clinical development of, obtain marketing approval for or successfully commercialize our drug candidates, either alone or with a collaborator, or if we experience significant delays in doing so, our business will be materially harmed. </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If clinical trials of any drug candidates that we, or any collaborators, may develop fail to satisfactorily demonstrate safety and efficacy to the U.S. Food and Drug Administration, or FDA, and other regulators, we, or any collaborators, may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of these drug candidates.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adverse events or undesirable side effects caused by, or other unexpected properties of, drug candidates that we develop may be identified during development and could delay or prevent their marketing approval or limit their use.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on Genentech and Roche for the successful commercialization of Erivedge, and if they do not successfully commercialize Erivedge for advanced basal cell carcinoma, or BCC, our future prospects may be substantially harmed.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely in part on third parties to conduct clinical trials of our internally-developed and in-licensed product candidates and for the research, development and commercialization of certain programs, and those third parties may not perform satisfactorily, including by failing to meet deadlines for the completion of such trials, research or testing. </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the event of a default by us or Curis Royalty under the Oberland Purchase Agreement, we could, among other consequences, lose our retained rights to future royalty and royalty related payments on commercial sales of Erivedge, and our ability to enter into future arrangements may be inhibited, all of which could have a material adverse effect on our business, financial condition and stock price. </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain and maintain sufficient patent protection for our technologies and drugs, or our licensors are not able to obtain and maintain sufficient patent protection for the technologies or drugs that we license from them, or if the scope of the patent protection is not sufficiently broad, our competitors could develop and commercialize drugs similar or identical to ours, and our ability to successfully commercialize our drug candidates may be adversely affected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we or our collaborators are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we or they will not be able to commercialize, or will be delayed in commercializing, our drug candidates, and our ability to generate revenue will be materially impaired.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8195;</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i90810bc68d594941912c6cfda631781c_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="i90810bc68d594941912c6cfda631781c_13"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;UNAUDITED FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div id="i90810bc68d594941912c6cfda631781c_16"></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURIS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMy0xLTEtMS0x_f7a8fb85-ffea-4d1b-bc48-9f9fc8678e07">53,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMy0zLTEtMS0x_5ac399b5-f6bc-4ed2-a200-1ca9192dcbee">129,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfNS0xLTEtMS0x_f9549b9d-fa32-406b-8e44-5c38aa87ecc2">75,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfNS0zLTEtMS0x_298a942e-a215-49e7-8406-30c22160a732">38,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfNi0xLTEtMS0x_6ede449b-c863-48c2-b099-6127dceac2e5">2,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfNi0zLTEtMS0x_83ab3699-18ba-4d86-9ecf-bb9e56f3f167">3,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfNy0xLTEtMS0x_dc01fc9e-297d-4633-bed1-84c4e28c096e">3,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfNy0zLTEtMS0x_e9269b87-a87b-4841-8acd-a2b5901fc112">1,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfOC0xLTEtMS0x_0bb6645e-02ea-48ea-b621-1ff16e4df5ee">134,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfOC0zLTEtMS0x_2c09340d-80c1-4431-9460-2c067dfd1a8d">172,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfOS0xLTEtMS0x_2021d83e-ebf8-4de5-911b-c9e37e10cd2e">20,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfOS0zLTEtMS0x_5294755c-6d15-439c-a160-43d6f6250b44">14,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTAtMS0xLTEtMQ_bcd416ab-7d73-4358-9124-31b934e633c4">543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTAtMy0xLTEtMQ_d0476770-5a6a-49ce-943d-7c618bd6abc8">663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTEtMS0xLTEtMQ_f4c3fbdb-0fae-4436-b87b-2ce591d119f7">726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTEtMy0xLTEtMQ_23ab8ce1-f887-4d8c-b569-5abd47c21d13">816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTItMS0xLTEtMQ_959e52b0-30bd-44eb-81d5-980fc2af5253">5,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTItMy0xLTEtMQ_4a260ff0-92d0-49b1-85c9-78253970281f">6,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTMtMS0xLTEtMQ_ea294f73-7a07-4eb7-b095-b8ed8056d379">8,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTMtMy0xLTEtMQ_aaa02bd9-46f4-495c-a825-1805d445e90c">8,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTQtMS0xLTEtMQ_8352c01d-1dc6-4595-a5ee-6e532bec4790">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTQtMy0xLTEtMQ_ae7ae001-8b8e-4c26-8a23-9de2fe7c603d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTUtMS0xLTEtMQ_4c78bfb8-3d98-4414-ba75-4703b3891bd9">172,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTUtMy0xLTEtMQ_095c264c-a8b9-45a4-8c2b-de8110cc595b">204,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTgtMS0xLTEtMQ_f03851be-5712-4036-b227-522564c8c628">3,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTgtMy0xLTEtMQ_c994859c-9d65-4dd9-991f-70b8a9018f97">4,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTktMS0xLTEtMQ_7101b87b-d6f6-4d34-a435-b84bdad5a4d9">5,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTktMy0xLTEtMQ_9bd66892-9f5d-4970-9e65-e659aea71d12">3,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjAtMS0xLTEtMQ_7227175f-0baa-44cd-b010-ac9531039981">657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjAtMy0xLTEtMQ_af675bbb-3799-4e06-873c-426242b10bf5">1,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjEtMS0xLTEtMQ_739be440-d7d3-49a9-af57-bf5a61abd3e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjEtMy0xLTEtMQ_e9632cc5-83dd-495e-8605-cabb5e2417e1">557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjItMS0xLTEtMQ_42313092-5107-4a21-810c-76edef873fee">9,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjItMy0xLTEtMQ_539afb27-354d-4bbb-b207-9f3d8db97230">10,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjMtMS0xLTEtMQ_36ced6aa-43eb-4992-9e6d-dfc2bd5d8a4b">4,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjMtMy0xLTEtMQ_e64a5361-e0b1-4b1c-8aab-2e7c298722d0">5,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future royalties, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="cris:RoyaltyGuaranteesCommitmentsAmountNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjQtMS0xLTEtMQ_d148339a-47fd-4846-b47d-d95d2516d1a7">55,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="cris:RoyaltyGuaranteesCommitmentsAmountNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjQtMy0xLTEtMQ_0bbc9daa-7909-4238-b4f9-02d7212dd878">58,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjUtMS0xLTEtMQ_da9ac315-b57e-49b2-8f7d-ed758f935fa9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjUtMy0xLTEtMQ_abb9ed97-efa9-4c75-824a-9e078ec2c2ae">334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjYtMS0xLTEtMQ_897256d5-fc21-4911-a445-73b69051b65f">69,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjYtMy0xLTEtMQ_78d79ca5-7521-48aa-ac86-7171c7fc78a1">73,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOjMxMWMwNmMzMjQwZDQ1MDE4ODE0YmI0ZTk2YzFmZGQzXzE4_0f3a4caa-6dcc-47d5-b826-7894aac92919"><ix:nonFraction unitRef="usdPerShare" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOjMxMWMwNmMzMjQwZDQ1MDE4ODE0YmI0ZTk2YzFmZGQzXzE4_2d149b57-a4d8-4cdf-b58c-0d70197a7532">0.01</ix:nonFraction></ix:nonFraction> par value&#8212;<ix:nonFraction unitRef="shares" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOjMxMWMwNmMzMjQwZDQ1MDE4ODE0YmI0ZTk2YzFmZGQzXzMx_73cdac74-8170-4f71-a166-34c3105f214f">227,812,500</ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOjMxMWMwNmMzMjQwZDQ1MDE4ODE0YmI0ZTk2YzFmZGQzXzUz_371de6eb-d3c0-4af4-a5f1-666bc4fad68f"><ix:nonFraction unitRef="shares" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOjMxMWMwNmMzMjQwZDQ1MDE4ODE0YmI0ZTk2YzFmZGQzXzUz_49b99050-8df2-431b-8d83-c20d95df91ed">91,609,165</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September 30, 2021; <ix:nonFraction unitRef="shares" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOjMxMWMwNmMzMjQwZDQ1MDE4ODE0YmI0ZTk2YzFmZGQzXzkz_ad6c0b8b-ab56-455a-a804-cc3d5e2bec93">151,875,000</ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOjMxMWMwNmMzMjQwZDQ1MDE4ODE0YmI0ZTk2YzFmZGQzXzExNg_1ae39130-1e82-42a5-a922-d5bd7a677574"><ix:nonFraction unitRef="shares" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOjMxMWMwNmMzMjQwZDQ1MDE4ODE0YmI0ZTk2YzFmZGQzXzExNg_adf7dee7-67bf-4404-8f15-397a4099dd71">91,502,461</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjgtMS0xLTEtMQ_765fc52d-21ed-4656-a338-ffc357f58414">916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjgtMy0xLTEtMQ_60d61621-4f41-4bcc-ade9-52c0c99ad63d">915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjktMS0xLTEtMQ_ee42f761-dd69-4568-94ba-1bb26c92f183">1,180,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjktMy0xLTEtMQ_01a30a6f-a521-4dc9-b6fb-a4c44cc3c215">1,176,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMzAtMS0xLTEtMQ_4bdc5ab6-9a7d-4f2c-8296-c605b5efa1dc">1,078,705</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMzAtMy0xLTEtMQ_758c1afc-3f74-470c-871e-ab5316b19c53">1,046,889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMzEtMS0xLTEtMQ_7885240a-5cca-4bfd-9a4a-4cdb76425b22">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMzEtMy0xLTEtMQ_eb25793d-63d4-4db3-9fbf-a641ce7bb856">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMzItMS0xLTEtMQ_8f70447d-ea1e-4ad4-a4fd-7cb713230973">102,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMzItMy0xLTEtMQ_e0e4193f-2333-4032-b94f-d0f056608124">130,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMzMtMS0xLTEtMQ_c69c0f30-a08e-48fc-b2a0-08c0581bc068">172,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMzMtMy0xLTEtMQ_c6b8b572-9e5a-43ae-ad43-7d7ee71c8581">204,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i90810bc68d594941912c6cfda631781c_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURIS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i533a446c7b4c4bbd9762a2f0852c2191_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMy0xLTEtMS0x_1a5dddd0-26a1-46fc-97a7-958b1482693f">3,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e6bc48882e74b6dbc7edc5bfb61e854_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMy0zLTEtMS0x_60e09de3-42ba-475e-85ba-f7714eb0dc97">2,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i430322671c674a2e9ecf19555642b870_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMy01LTEtMS0x_66eb645c-d3a7-408d-b8df-e885ac86632b">7,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdd8513423b24617ae9145402fcccf5e_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMy03LTEtMS0x_887a0df2-faf0-4a95-b395-c84c37e9e6ee">7,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7059a303d18b4097838037b575847c70_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfNC0xLTEtMS0x_719969bf-65da-40f1-87db-9af5eb606c28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i995dfcf8f34847c9b9eac02305265435_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfNC0zLTEtMS0x_8fca9709-614d-4b05-8cdc-1a4fd7bf0b30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia720d94f508f4eb2a4f3c307eedfe435_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfNC01LTEtMS0x_f79d72af-8c4c-475d-805c-3ffac3c271d6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe8f17e9bca46a08a36d1be114833e2_D20200101-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfNC03LTEtMS0x_0c922229-7abf-4029-a0fe-3ff33b413046">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contra revenue, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4d63a2bfd9a446bb2f258585206efff_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfNS0xLTEtMS0x_c523432a-9317-4d80-89e2-a1da898fb015">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2377a33c77ce4828b22b332828013bd7_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfNS0zLTEtMS0x_342a7d57-312b-4f39-958f-de3b496064aa">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic76462d861cb47cc9c192a17cca41dd6_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfNS01LTEtMS0x_3ba71975-23b5-41a7-b8d6-db06f8888796">80</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac7eb7aada544feeb409a3508f46d4a8_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfNS03LTEtMS0x_776ec87d-dfff-48ba-a2a9-b8d386dc94c0">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfNi0xLTEtMS0x_58c41428-bbee-4833-b538-35dee5200c01">3,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfNi0zLTEtMS0x_2d731600-2c0a-43e5-86e5-da75d63abe11">2,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfNi01LTEtMS0x_d31511ed-66b5-4684-bac6-e7cb7325fbbb">7,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfNi03LTEtMS0x_cda4ef74-4af0-4c30-a5e7-3ec6fa3c7288">7,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930" decimals="-3" name="us-gaap:RoyaltyExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfOC0xLTEtMS0x_7b497f64-5f79-40b6-bc29-56133db6fae4">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930" decimals="-3" name="us-gaap:RoyaltyExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfOC0zLTEtMS0x_4781b3af-7386-4fe1-b5d2-4ff795d3a1ac">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" name="us-gaap:RoyaltyExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfOC01LTEtMS0x_005ec0e5-4508-45e9-875e-e5202ad18e71">376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" name="us-gaap:RoyaltyExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfOC03LTEtMS0x_d7881fd5-38af-47b5-b7a2-925f0b9ad2e4">382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfOS0xLTEtMS0x_72da1a50-0d60-4d30-a6c9-850a097ee299">8,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfOS0zLTEtMS0x_d4d4c6da-4347-4ab2-b32e-bf7ffcac1484">4,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfOS01LTEtMS0x_eb2b3cc4-a9d5-444d-bd59-4593e240435b">24,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfOS03LTEtMS0x_060d4ec9-ab81-464d-bdf5-e33332c78eb2">17,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTAtMS0xLTEtMQ_9d6ba295-2234-4ed7-ad21-80000559f267">4,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTAtMy0xLTEtMQ_e6f58e87-2ce5-4d05-a1bf-bdbdfe3d4c07">2,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTAtNS0xLTEtMQ_9761cbaf-4208-41af-8b83-d9e69344e2db">12,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTAtNy0xLTEtMQ_d0ba81c0-5dcd-4592-b074-5bc709259f5d">8,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTEtMS0xLTEtMQ_3de959d7-4ca2-4d21-91d2-ff6419ea3bb8">13,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTEtMy0xLTEtMQ_67ae12da-1451-48bb-9354-427d05de7d3c">7,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTEtNS0xLTEtMQ_c2c4fd13-ea92-49f4-a886-3d65072959c1">37,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTEtNy0xLTEtMQ_9cc7ad24-204c-4632-96a1-32a5b6953f73">26,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTItMS0xLTEtMQ_6eb1528e-0c29-47b6-ad86-3046472bcec9">10,048</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTItMy0xLTEtMQ_31880012-8f34-468c-94d3-068699cab8be">4,711</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTItNS0xLTEtMQ_4f90b711-aa41-4981-b51b-2b5fedd82b4c">29,498</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTItNy0xLTEtMQ_002fbd01-5574-4414-90da-6b5e60134592">18,623</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTUtMS0xLTEtMQ_5b206c56-5ae6-4adf-9b92-b7cff0332866">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTUtMy0xLTEtMQ_e435ab4c-af61-4280-b4bf-211ff15f6a8c">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTUtNS0xLTEtMQ_a8591bc4-7021-4d68-a33c-910508790c7e">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTUtNy0xLTEtMQ_9972646c-a135-4769-a475-893fd7da056b">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest expense related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="cris:NonCashImputedInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTYtMS0xLTEtMQ_17fb27d6-440b-4979-9ac3-35e10ff699f6">1,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="cris:NonCashImputedInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTYtMy0xLTEtMQ_4fbd7f48-c92a-4882-8a2f-e4b2e1ab69b4">1,266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="cris:NonCashImputedInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTYtNS0xLTEtMQ_bacc5402-cc3a-4ebf-ac5e-41d059bc34e0">3,366</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="cris:NonCashImputedInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTYtNy0xLTEtMQ_bcc17653-505e-4244-8f0d-00c38948b6c2">3,848</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTgtMS0xLTEtMQ_080edac3-6fbd-4500-ac80-e6c9aef83789">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTgtMy0xLTEtMQ_4e2450f9-3961-41db-b9e8-3f37501e2719">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTgtNS0xLTEtMQ_171557b9-0a86-400a-9339-c5883f153f13">890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTgtNy0xLTEtMQ_39759f57-7dd0-45a1-9f64-164f27cd490d">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTktMS0xLTEtMQ_b8592d25-eae1-4d1d-b375-b3fd3b8e6c43">1,003</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTktMy0xLTEtMQ_6ce84aa3-080c-40f5-8df0-b6862e710779">1,263</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTktNS0xLTEtMQ_862d37d6-5985-4b13-959a-4b67832745ca">2,318</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTktNy0xLTEtMQ_c8ed7974-225f-49c1-ad4c-f6cae945509c">3,768</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjAtMS0xLTEtMQ_abd02570-76d7-49b4-9fe7-ea6d138b20cb">11,051</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjAtMy0xLTEtMQ_572120dc-0bcb-4fcf-8b68-bc725ce41ad1">5,974</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjAtNS0xLTEtMQ_cd7b07c1-2b6a-4707-84a5-5f132320b985">31,816</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjAtNy0xLTEtMQ_6b44677d-a22f-4842-878f-cee9c7682dff">22,391</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share (basic and diluted)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjEtMS0xLTEtMQ_7c6cbfff-c096-44d9-9137-84dab33fca64"><ix:nonFraction unitRef="usdPerShare" contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjEtMS0xLTEtMQ_cad53d5e-2c55-4751-a497-37229a166723">0.12</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjEtMy0xLTEtMQ_49ea4a5f-cdbd-4471-925e-43ade6289321"><ix:nonFraction unitRef="usdPerShare" contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjEtMy0xLTEtMQ_9032a96d-81c9-4827-ae28-799a2bb10bf3">0.11</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjEtNS0xLTEtMQ_9f46e4dc-828d-412f-a5d7-6a37c8d9bb3f"><ix:nonFraction unitRef="usdPerShare" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjEtNS0xLTEtMQ_f4d96ebb-c19b-4535-aca4-def9e6a4f818">0.35</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjEtNy0xLTEtMQ_8d79d997-215b-403f-8458-f19c61396ec0"><ix:nonFraction unitRef="usdPerShare" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjEtNy0xLTEtMQ_aaadeaa4-5a4c-4f4a-9245-0adbabd66388">0.52</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares (basic and diluted)</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjItMS0xLTEtMQ_d3da5b63-1970-4dde-b403-8ffd43b1965d"><ix:nonFraction unitRef="shares" contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjItMS0xLTEtMQ_dd19bf7b-ebe2-4da5-8f59-3c5147857876">91,601,362</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjItMy0xLTEtMQ_25605c8a-6152-4c04-95db-461d33770a10"><ix:nonFraction unitRef="shares" contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjItMy0xLTEtMQ_c2bb0358-6328-4698-bec8-72474e72bb20">54,554,129</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjItNS0xLTEtMQ_0143a8cb-54e5-48a4-be9e-324389a28cb7"><ix:nonFraction unitRef="shares" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjItNS0xLTEtMQ_13b4c177-676c-491d-abcb-7944e75ae438">91,552,433</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjItNy0xLTEtMQ_0c5e2b20-ba1b-413e-9702-fe3830edeb97"><ix:nonFraction unitRef="shares" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjItNy0xLTEtMQ_466f9453-57a5-448f-9d5d-14fc06a6f88d">42,884,201</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjMtMS0xLTEtMQ_bbfda567-30ee-4a1e-893b-2e657d55f932">11,051</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjMtMy0xLTEtMQ_b7af17d9-26b9-4d07-9ecc-ad6dda628c6c">5,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjMtNS0xLTEtMQ_1ee188ee-06f6-44e4-bc79-3c80983a1407">31,816</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjMtNy0xLTEtMQ_809bde1a-f0c5-44f8-978b-fa050c34c5d2">22,391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjUtMS0xLTEtMQ_1165e9e1-b70c-4f9f-bfba-b576724435e2"><ix:nonFraction unitRef="usd" contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjUtMS0xLTEtMQ_3cd2fa83-cadd-473e-8cef-1982a23f0515">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjUtMy0xLTEtMQ_ebd11549-b1a6-4ec7-82d7-9da3364ccb1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjUtNS0xLTEtMQ_783988be-2329-4473-9dd9-1a47978d2785">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjUtNy0xLTEtMQ_4ef329c1-6bf6-49b8-a2d7-33d5a3dd5bc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjYtMS0xLTEtMQ_04f30df2-5e3e-4719-a42c-d988dc6257f5">11,051</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjYtMy0xLTEtMQ_fa5cde1a-5b63-4589-a072-6941342ea86b">5,974</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjYtNS0xLTEtMQ_aff3ea17-0010-43f3-8f0b-8ff2485f35a7">31,816</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjYtNy0xLTEtMQ_a185a1ff-5518-42ba-bb9b-acc31d754d4b">22,391</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i90810bc68d594941912c6cfda631781c_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURIS, INC. AND SUBSIDIARIES</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share data)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.628%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive (Loss) Income</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67dd4d38bbfc42dcac4661194af3c1b4_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMi0xLTEtMS0x_f71fd034-9d35-42ed-82a1-b89ea22f30f5">91,502,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67dd4d38bbfc42dcac4661194af3c1b4_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMi0zLTEtMS0x_a9021486-6557-47cd-ab9e-e2b96b6e7030">915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca78b914bf041dc884674999397831a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMi01LTEtMS0x_9e08a794-4537-4f19-8f5b-ef3fa5dbb394">1,176,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50c937c85a114412bbb18451d45b1f0b_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMi05LTEtMS0x_fa675838-2fd6-4f1a-9b98-cd0136c0c183">1,046,889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc7b92e171e5450db55aa4c462149d6d_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMi0xMS0xLTEtMQ_8c388e28-97cc-4000-959e-a0edac573033">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMi0xMy0xLTEtMQ_92c888f7-948e-4b11-bd36-52cde119e653">130,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60293bf8d8b34ce2b686154bc0dc8870_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMy01LTEtMS0x_660658f9-7b65-4d99-a1b3-e7dbbd5ce7c2">1,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id12cf2f5b2304c4187ba46547f160ae5_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMy0xMy0xLTEtMQ_03c6d208-3dad-4b32-844e-5c901f159b6d">1,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if39a3310599b4dc48df4759fd2f23b75_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfNS0xLTEtMS0x_b6828ad9-59f4-4fb0-b626-1d8fd1a97f4d">31,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if39a3310599b4dc48df4759fd2f23b75_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfNS0zLTEtMS0x_7e61601d-8bdb-45f9-bee7-4ceef62077c2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60293bf8d8b34ce2b686154bc0dc8870_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfNS01LTEtMS0x_e380dbec-6600-42b0-8ad1-cf994637b6a6">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id12cf2f5b2304c4187ba46547f160ae5_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfNS0xMy0xLTEtMQ_762e1eac-4318-4e37-a3ec-09e7a6168538">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfe15ac9fbdb4c41a9436d65053dd823_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfNi0xMS0xLTEtMQ_a035d22c-ccda-4377-858f-fed89aa93d52"><ix:nonFraction unitRef="usd" contextRef="ibfe15ac9fbdb4c41a9436d65053dd823_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfNi0xMS0xLTEtMQ_a6967f0f-c7a2-4c99-a2f6-29592c9258e6">6</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id12cf2f5b2304c4187ba46547f160ae5_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfNi0xMy0xLTEtMQ_2f469768-cfd7-48a7-a64e-a8034cebc3ca">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6273ec08929c4042b363f75dc65c925f_D20210101-20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfNy05LTEtMS0x_d13481e3-eaf9-4144-8cb6-08415e5cd3d1">9,927</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id12cf2f5b2304c4187ba46547f160ae5_D20210101-20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfNy0xMy0xLTEtMQ_ce1c4137-fb02-4fa0-886b-8bb983e934d3">9,927</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ad6fa8151644284ba6c19774592e6d0_I20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfOC0xLTEtMS0x_fab203c4-9f04-4013-91c7-ae77b32b9a4f">91,534,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ad6fa8151644284ba6c19774592e6d0_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfOC0zLTEtMS0x_444b45d7-28e3-400c-8bb9-7d7d25949adb">916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id26880c55f3b45a6ad8a5ccba68564a1_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfOC01LTEtMS0x_cf5e4392-2ddf-4d41-a0a8-c320d7ed4133">1,177,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcd76ade8392457889758a7b96e60905_I20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfOC05LTEtMS0x_8c32eba0-04a1-4fd2-a57f-034c5bfa26c3">1,056,816</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a966410bb90428a843d3f569be9b164_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfOC0xMS0xLTEtMQ_20b4affb-e8a7-4989-be9e-e1495aa3e360">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8d1462eadbb4aa1a9833bece5ae287b_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfOC0xMy0xLTEtMQ_5e4a4c23-1139-434f-8f42-ee067f727f1e">121,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fc6b4c7394423b8ec79ccd7eae0b2a_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfOS01LTEtMS0x_917cd12d-d904-4b5b-b05c-5f5820472fe7">1,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d24421a8b204e50b645dcdee96de56f_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfOS0xMy0xLTEtMQ_9c73c48d-3cf9-482c-9b1d-dc25146fc405">1,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of stock under Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib83f38159c0d47a39e7ba5f026425795_D20210401-20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTAtMS0xLTEtMQ_c126fdb1-082a-4a8c-83d2-f62d81ce9b00">20,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fc6b4c7394423b8ec79ccd7eae0b2a_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTAtNS0xLTEtMQ_2a57e9e4-0c7e-4c15-b329-fcc1f8d374a2">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d24421a8b204e50b645dcdee96de56f_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTAtMTMtMS0xLTE_42f3a5e6-9456-409d-a4f5-ca012eb9469d">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib83f38159c0d47a39e7ba5f026425795_D20210401-20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTEtMS0xLTEtMQ_1d6e3173-f476-4bdb-813f-1f785c5be796">41,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fc6b4c7394423b8ec79ccd7eae0b2a_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTEtNS0xLTEtMQ_1ef68075-4735-4d04-b17e-1b12e67f9c54">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d24421a8b204e50b645dcdee96de56f_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTEtMTMtMS0xLTE_63b1d1ae-e521-4eb3-bd54-64954bbbd9e6">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7aab08630ed447578b4a6fabcff3af4a_D20210401-20210630" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTItMTEtMS0xLTE_667535f7-5d2b-417a-8c9e-8f3970e5a8d3">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d24421a8b204e50b645dcdee96de56f_D20210401-20210630" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTItMTMtMS0xLTE_93546e31-cc84-491d-a648-270032f8d97d">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57052d63d35b413e91d2037ed469551b_D20210401-20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTMtOS0xLTEtMQ_cf366dee-8606-491d-81bb-f3030ec2f167">10,838</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d24421a8b204e50b645dcdee96de56f_D20210401-20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTMtMTMtMS0xLTE_1252c9c2-f475-4203-95bd-0698b8811029">10,838</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c2d8b06604949d8b1946a6b3626e498_I20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTQtMS0xLTEtMQ_814bff76-f548-47c3-a851-b771934bf2cd">91,596,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2d8b06604949d8b1946a6b3626e498_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTQtMy0xLTEtMQ_2fe3fa72-c80f-4040-93f1-c49aa6a43c57">916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if008f4d0347f4f1e96cd9a5e2c5bc985_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTQtNS0xLTEtMQ_4b186679-25fd-4276-845e-3cc8175e4ea9">1,179,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife718f47b62e4c3687c07aa35e307ce2_I20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTQtOS0xLTEtMQ_53c502b6-9fd1-41b2-829a-ce3d25211c0a">1,067,654</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i373c682106604fba9c0c257203578939_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTQtMTEtMS0xLTE_d62f10be-27fa-422c-b570-2a7b44ee1601">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a91365e4a5949bf9ba583bd68d30198_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTQtMTMtMS0xLTE_50bbc24b-22ed-47d5-9f4e-40a26ed0d685">112,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1556c61df1fe4774856be3b37d7866b3_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTUtNS0xLTEtMTMxMDA_6c2ed5ba-54e0-41af-b7dc-240df8ab66e7">1,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTUtMTMtMS0xLTEzMTAz_d1372263-89aa-4dd1-be0a-ac6efc3e6f4d">1,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if16ae74c3f204c54a9fdb59324c1a8c1_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTYtMS0xLTEtMTMxMDU_022f1e5b-52db-4ec5-9d27-da98ccbae7d9">12,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1556c61df1fe4774856be3b37d7866b3_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTYtNS0xLTEtMTMxMDk_5fffb685-f3a3-4c05-b3b5-abb89ea9b4af">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTYtMTMtMS0xLTEzMTEx_924dddd0-f775-421d-9398-cc37a5ce7bad">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib819b69ecf0d4a69af2a5cfdb3d3f29d_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTctMTEtMS0xLTEzMTEz_2ccc5fe1-8316-419c-8460-d71747130a1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTctMTMtMS0xLTEzMTIz_8b43d1c2-6b72-4c3e-a759-edc75c63b048">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i496aa636a74449e6bb23b783bf1af401_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTgtOS0xLTEtMTM4MDg_28fefd93-6ff0-46d8-893d-911733fefed9">11,051</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTgtMTMtMS0xLTE0MDY1_91b93d7d-3ecd-41c2-ba3c-7651d70cfea9">11,051</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i59c5613ca42840cd90b239dfeb0d2776_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTgtMS0xLTEtMTMxMjE_9ca93a86-8cdd-4640-934d-40fd1230c6b2">91,609,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59c5613ca42840cd90b239dfeb0d2776_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTgtMy0xLTEtMTMxMTk_9e1dbe94-f751-48cf-b5c4-17283963fc34">916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c0d8228dd6c47dc8835400718fb7794_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTgtNS0xLTEtMTMxMTc_46132b07-3492-410f-82a7-1ed234c37566">1,180,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id82880f87ee44511a970554ad14e0b2c_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTgtOS0xLTEtMTMxMTU_4f237f2a-030e-45f9-b674-9a1183f86f1c">1,078,705</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c7dd4eefa794b288e0e2911576a70f1_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTgtMTEtMS0xLTEzMTEz_38943766-7359-486c-998c-84a46cbfe63a">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTgtMTMtMS0xLTEzMTIz_f4e1e9f0-8ec9-4b5f-8501-a929c24ca49f">102,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.628%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive (Loss) Income</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Deficit</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i59d2a236085c4461b444f9e731b5d83a_I20191231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMi0xLTEtMS0x_402de9ff-dd79-4566-9f5f-7fc64cb72ba8">33,241,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59d2a236085c4461b444f9e731b5d83a_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMi0zLTEtMS0x_4b18682a-714a-479b-aa4a-b5f506e1b5df">332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77cd53b4f6e44e56bc18efef6b6c48fe_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMi01LTEtMS0x_ae706281-c040-4cbc-affb-f8736df1c838">982,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff6f88189e6c489fadca834518204877_I20191231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMi05LTEtMS0x_99805ccc-b897-43b9-9d3f-5451cb1aedd4">1,016,981</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b1a5740938422195d69fe89e22dbc2_I20191231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMi0xMS0xLTEtMQ_a59dc1a5-594f-4821-a8c8-3757bbc725c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74e73d5375984977b6347e5a763139d0_I20191231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMi0xMy0xLTEtMQ_67e8ca0a-8faf-43c6-8dd0-7230a8d2cef4">33,911</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i773b93e5620347e1ab3d326166347a05_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMy01LTEtMS0x_acf062c2-d799-47d0-82f0-b1350a8aaf58">625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3df11fcc545447489bc72b8df5ec6a5_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMy0xMy0xLTEtMQ_a8058031-f91b-4f3b-bc9c-0c6731dc94cf">625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares in connection with Aspire Capital Agreement, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b54cebb2076495ebc3a6534669720f4_D20200101-20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNC0xLTEtMS0x_b502dd7e-7aff-4ce4-aee2-9857ef21c987">3,340,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b54cebb2076495ebc3a6534669720f4_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNC0zLTEtMS0x_ad8eaeae-b51c-4e51-8d3b-e2c1549430cc">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i668eb741fed8462b9be0b59ca9b25135_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNC01LTEtMS0x_2b51cf1f-40e6-4c61-aa2b-1c783c961ab1">2,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00fcba8a8a6049a0b2dd2926f0f9f9d3_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNC0xMy0xLTEtMQ_321e3602-90ec-4f5b-a5c5-cad74ce4f2c3">2,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf69f9380ea04321ac14ce6785b41f7c_D20200101-20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNS05LTEtMS0x_39ebe2a6-8ea7-4f14-8103-1e0a6ee97346">9,709</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3df11fcc545447489bc72b8df5ec6a5_D20200101-20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNS0xMy0xLTEtMQ_7c2ad8fe-4d96-4e38-898a-6be4ed5fe0c1">9,709</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c1929f827ff4826a126b14efa9ed807_I20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNi0xLTEtMS0x_f6bf93ab-f1b6-496e-960d-f7ccd3873968">36,582,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1929f827ff4826a126b14efa9ed807_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNi0zLTEtMS0x_fd824020-da15-41ed-aa91-dcaa8df4de66">366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5f6802b38e34cdca4064f21d5ed6f28_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNi01LTEtMS0x_943bc33a-ae56-41cb-a757-3e6ded5e8f13">986,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab83bec3cf434ed190d72f069b95e844_I20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNi05LTEtMS0x_66e20a9f-f621-4140-a2c9-a56873a23a85">1,026,690</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3398a93d47d24500ab8ab9d0d4a0aae0_I20200331" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNi0xMS0xLTEtMQ_fb17ba1a-94d4-48af-8d80-4a3af57c5cd1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3db7b202b9742b4ba2ad6c5070f5d3a_I20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNi0xMy0xLTEtMQ_934001c8-1a51-4ee8-95e4-086fe64303ae">40,269</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of stock under registered direct offering, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7587529ce7947f8ba47ac622a4fc47e_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNy0xLTEtMS0x_25b7faf7-b4cf-4f20-839b-5cad24a71209">14,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7587529ce7947f8ba47ac622a4fc47e_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNy0zLTEtMS0x_b29b5f06-f3a9-48de-b725-634aa646ed89">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e195d3203824b3d9aab16f7ec0f0922_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNy01LTEtMS0x_0ab037ab-79f8-43aa-b819-e7c79edb9225">15,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74f2b1fab46944cf9e3f63c1971776bf_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNy0xMy0xLTEtMQ_8a70f610-8698-4e8e-a406-64459d166691">15,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i160c6a5048d844c1bb83e8a5d34a79cb_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfOC01LTEtMS0x_1bf4f013-06c8-4e5f-bb92-eaf0568977f2">585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74f2b1fab46944cf9e3f63c1971776bf_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfOC0xMy0xLTEtMQ_8717edff-6302-47d2-ba7b-f7731e4a21b5">585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of stock under Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id4a6ffee772a437a8a6979d274823c5a_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfOS0xLTEtMS0x_086a5135-9475-4536-9cb2-713645f0e2fa">41,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i160c6a5048d844c1bb83e8a5d34a79cb_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfOS01LTEtMS0x_44d144db-dfa7-4e4a-8a29-7de32eb04336">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74f2b1fab46944cf9e3f63c1971776bf_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfOS0xMy0xLTEtMQ_11a8de38-012f-419a-bd71-be92c82a8e27">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id4a6ffee772a437a8a6979d274823c5a_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTAtMS0xLTEtMQ_c5066ef1-60b9-47f9-acf5-d812c859f5a6">15,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i160c6a5048d844c1bb83e8a5d34a79cb_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTAtNS0xLTEtMQ_94fbd24b-a0d4-4bfc-88ae-175d67007372">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74f2b1fab46944cf9e3f63c1971776bf_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTAtMTMtMS0xLTE_e1e690fe-bd56-4cb4-bbd0-2cfee36f3a95">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb5feb63bb884b278199f05efec2e882_D20200401-20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTEtOS0xLTEtMQ_d69e9881-1c88-4a46-8e26-1a22e7e355de">6,708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74f2b1fab46944cf9e3f63c1971776bf_D20200401-20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTEtMTMtMS0xLTE_19e5200d-1108-4156-8601-5263de4bff54">6,708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib1145ae8cfec46ea9d2ea1ff2a92e958_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTItMS0xLTEtMQ_801b3deb-9121-4d93-b3e4-90c38fde8970">50,639,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1145ae8cfec46ea9d2ea1ff2a92e958_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTItMy0xLTEtMQ_1181a579-c14e-4dee-9e45-83e713756f2a">506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fdb43e2101b443f8adf0e0948bf2820_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTItNS0xLTEtMQ_7c9eea90-503c-45fb-9d50-5564282dd202">1,002,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79eb58664af1462c86740522e97626dc_I20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTItOS0xLTEtMQ_905029b3-be7b-4b23-9ace-284b6f6c4f72">1,033,398</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81c6a9cdd6304647889f68d7fc513971_I20200630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTItMTEtMS0xLTE_fdede2d9-484b-4368-bd4d-e92ad5228e8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e2324829cfe492bb1ce3a18540cabae_I20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTItMTMtMS0xLTE_26a89107-1e71-47ad-9ac2-fcfe2d116341">30,380</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares in connection with Aspire Capital Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5696cc43a1414c5eb951ffb14fe34541_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTMtMS0xLTEtMTMxMjU_0ffa63b8-2fe8-4e34-9828-1d5a06225850">3,600,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5696cc43a1414c5eb951ffb14fe34541_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTMtMy0xLTEtMTMxMzI_387258a1-5f5e-4b29-ab79-9922951b78a6">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id551d22461aa42b4ac2f10c2d9ef6e0d_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTMtNS0xLTEtMTMxMzQ_8036ccae-bfb7-4298-ab31-31720139b4d5">4,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied34bb1c61f14a14b532c5987fe42f4d_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTMtMTMtMS0xLTEzMTM2_09647e65-085e-4cc8-8c56-b85152591528">4,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares in connection with Capital on Demand&#8482; Sales Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i68950601d26a41dca198d584853b5317_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTQtMS0xLTEtMTMxMjU_2175b051-a637-43af-9bca-743d2913be95">2,413,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68950601d26a41dca198d584853b5317_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTQtMy0xLTEtMTMxMzI_c6d03fd8-e858-463a-857f-2cb487d78598">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d45aa56d6e4b4888724ffa54069f9a_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTQtNS0xLTEtMTMxMzQ_45cae60a-5002-4f1a-adea-47622afc0be2">3,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i243b02ffde754d02a51ddcf82577ece7_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTQtMTMtMS0xLTEzMTM2_361415e5-bede-46df-825c-8ce1ba8922b2">3,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fees for issuance of shares in connection with Capital on Demand&#8482; Sales Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6334c899a5394f309f5ba35f98753e11_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTUtNS0xLTEtMTMxMzQ_c57ab141-3ca7-4a85-b5bf-c6041977fe54">262</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTUtMTMtMS0xLTEzMTM2_13358417-9e31-4f80-9f50-e63e5e7b0b35">262</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6334c899a5394f309f5ba35f98753e11_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTYtNS0xLTEtMTMxMzQ_ad747adc-ffc6-4bf8-b316-005c99ed4cdb">624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTYtMTMtMS0xLTEzMTM2_0d91ea61-b275-45a8-a9e3-3d082f34bbc4">624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84408fe3e0ed4336aa0f6ff3095dd860_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTctOS0xLTEtMTMxNDQ_caff020d-1edf-4535-b21a-a9b3a8c82bf0">5,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTctMTMtMS0xLTEzMTM2_cd193b2c-b13c-4565-942a-47f293097242">5,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i484203a4a3aa47f5a945b8781929feb6_I20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTgtMS0xLTEtMTMxNDg_04e4cd23-83e1-438c-89e4-ba27afd7165a">56,652,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i484203a4a3aa47f5a945b8781929feb6_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTgtMy0xLTEtMTMxNDY_dc7dcc97-d50f-4455-a08d-b3fe814caf3b">566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7fc2a9a1f5c430ab65ea66663c830cd_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTgtNS0xLTEtMTMxNDI_0b120048-b5f8-4113-84a1-8b2c40c27b79">1,010,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1072f132f4d4820b9dfdf6759a5c275_I20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTgtOS0xLTEtMTMxNDA_eb75bad2-4bc5-4487-988f-fe63561682c7">1,039,372</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice8c0d0a4a4c414b80040c8507090a61_I20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTgtMTEtMS0xLTEzMTM4_5dfd096e-aaff-4b9d-b4d1-8e99c133578f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i115d55a1156e4c969b9b8083b7760eb1_I20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTgtMTMtMS0xLTEzMTM2_15237eaf-8156-4790-b139-3c9355cebd59">28,608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i90810bc68d594941912c6cfda631781c_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CURIS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMy0xLTEtMS0x_a9c82b75-6783-4e9c-ac0e-6add4ed8ed63">31,816</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMy0zLTEtMS0x_7dc0ba1b-5263-4c3b-8d32-0ed9a3c172d7">22,391</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNS0xLTEtMS0x_d0f02373-9143-48f5-a0cc-967a443ffd3d">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNS0zLTEtMS0x_4cb32c90-9d45-4b3d-aa7c-f1ffe5dad370">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" name="cris:NonCashLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNi0xLTEtMS0x_309c2586-6559-4971-9691-c29be66f9fa0">616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" name="cris:NonCashLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNi0zLTEtMS0x_509cdb44-174e-400f-87f1-65266914b45f">431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfOC0xLTEtMS0x_1dfa9714-3bb4-41b0-8510-b5cc00abe858">3,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfOC0zLTEtMS0x_df831e21-c972-4a2d-9ef5-4c12a9bdd6f8">1,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash imputed interest expense related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" name="cris:NonCashImputedInterestExpenseNetOfImputedInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMTAtMS0xLTEtMQ_c6c5e976-4c5e-4b23-8ab5-4f35a2f42a22">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" name="cris:NonCashImputedInterestExpenseNetOfImputedInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMTAtMy0xLTEtMQ_d9f69067-5f82-4842-b7a6-0e6b3262e4ea">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amortization of premiums and discounts on marketable securities<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br/></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMTEtMS0xLTEtMQ_4906fa24-2495-4421-a6f1-9fa98f86b75a">1,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMTEtMy0xLTEtMQ_28eb8d53-d526-4a93-a63d-3e770d2fce3f">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on forgiveness of PPP Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMTItMS0xLTEtMQ_13dc9571-b5c2-454d-a6ce-aad71642716b">890</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMTItMy0xLTEtMQ_77caafb0-ac24-4c77-baba-c2958628172a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMTctMS0xLTEtMQ_1972d2ee-47ac-4af3-a2c6-2dc26fdf5eaa">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMTctMy0xLTEtMQ_e608bb19-3205-4dd6-ab29-01d3c8d36c55">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMTgtMS0xLTEtMQ_42cbb44b-5763-41b6-a7fa-517179732890">1,870</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMTgtMy0xLTEtMQ_25e5589e-e26c-499e-bbe3-9eedbebfe10c">940</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMTktMS0xLTEtMQ_770a61dd-0cf4-4bb1-bfb0-fa22e235bc9f">1,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMTktMy0xLTEtMQ_0e9771fb-351f-4954-b3f2-7bfa8dca3ae4">684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="cris:IncreaseDecreaseOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjAtMS0xLTEtMQ_c52da20f-97ac-40bf-bc9b-390e6f7a4be7">1,577</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" sign="-" name="cris:IncreaseDecreaseOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjAtMy0xLTEtMQ_3fccf853-044e-41e0-a462-b8262e092d6a">327</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjEtMS0xLTEtMQ_2faa0017-96c5-4e57-b5c6-32a14a348200">2,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjEtMy0xLTEtMQ_f90f91c8-391c-41c9-8465-27433ebd7eed">2,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjItMS0xLTEtMQ_e088dc81-14fb-4aa3-bed6-28dea51d46ee">29,448</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjItMy0xLTEtMQ_6d81583e-e1ad-4eaf-a2c1-1e75d30e6602">20,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjQtMS0xLTEtMQ_6e6aa8fc-0710-4ff8-89e6-7f4f670be779">70,977</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjQtMy0xLTEtMQ_005113b6-7ee3-426b-8837-9a9c0586a241">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales and maturities of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjUtMS0xLTEtMQ_1a8932fe-1518-46ed-be1f-dafa70015b67">26,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjUtMy0xLTEtMQ_52408dcd-db6f-4e15-b65b-d83dca2234df">5,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjYtMS0xLTEtMQ_a3ae6a56-f87a-4765-a2ae-3cef32c366a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjYtMy0xLTEtMQ_ff3ad1a6-b240-4785-a1c6-227477836767">657</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjctMS0xLTEtMQ_3b28d406-391d-4adb-9c97-133f9a5b9eff">44,372</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjctMy0xLTEtMQ_221da1f2-ddee-4679-8335-496e3b9e44b7">4,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from PPP Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjktMS0xLTEtMQ_617e1675-54ec-4754-befa-af186259cb27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjktMy0xLTEtMQ_27ceb1ce-df5e-4623-9ee7-8cb152c5037f">890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds of Aspire Capital Agreement, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6b5f21400a142dd92d6458b6bc2b0f9_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMzAtMS0xLTEtMQ_91c9d7b0-c430-4bee-b73f-df0aeaf28238">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0585c12f68584892a486dd533b6667ce_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMzAtMy0xLTEtMQ_1feec0d1-7d31-43a7-834c-ab038715d91a">6,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds of direct placement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="cris:ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMzEtMS0xLTEtMQ_91151e14-88d5-4534-b732-3c9b3b3e23f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="cris:ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMzEtMy0xLTEtMQ_2d22d2f3-8b7d-40ce-9e11-6e94976fa209">17,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of issuance costs on direct placement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37f437e27c6c449b80dcb3c731463e31_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMzItMS0xLTEtMQ_4b0da77b-4bf4-464b-8aa5-32cc163fb018">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a2d864386944501a52823fe60a6ac4a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMzItMy0xLTEtMQ_5463d56f-b050-4975-8062-f8a8d3ff4cfb">1,535</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock associated with Capital on Demand&#8482; Sales Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae11a3b9f70d4d8b8470bb42b3f5c915_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMzMtMS0xLTEtMQ_566e3327-ba56-4831-87f1-3c2d9bfbb26e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica18ded6bc544002a83550782ca17ceb_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMzMtMy0xLTEtMQ_03c330e8-2534-4f86-aea3-cb2ec62d85eb">3,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of issuance costs associated with Capital on Demand&#8482; Sales Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae11a3b9f70d4d8b8470bb42b3f5c915_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMzQtMS0xLTEtMQ_b863964c-4f0c-4799-9fff-032845a5747b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica18ded6bc544002a83550782ca17ceb_D20200101-20200930" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMzQtMy0xLTEtMQ_b70d610f-fc90-42eb-bfd6-0110e648a3c0">262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under the Company's share-based compensation plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMzctMS0xLTEtMQ_3e7ee391-bb15-4dcf-9582-f32c349fb1a9">217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMzctMy0xLTEtMQ_18794500-020c-4d85-ab34-6102add3cc8a">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of liability of future royalties, net of imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="cris:PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMzgtMS0xLTEtMQ_36516709-206c-4493-aa4d-a44ae6319fc8">3,077</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="cris:PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMzgtMy0xLTEtMQ_15cc7e29-8ef7-49d8-8ae8-62f00923f669">3,175</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNDEtMS0xLTEtMQ_4955a435-c093-4946-a825-6c2ee1fc36bd">2,860</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNDEtMy0xLTEtMQ_8120f708-e659-4ce8-8d90-1db44d6ded50">23,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNDItMS0xLTEtMQ_967f1ccb-b281-4ad3-a2ac-18a59f128303">76,680</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNDItMy0xLTEtMQ_b2d6ffb0-c020-4585-ae0e-222c675da55f">7,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNDMtMS0xLTEtMQ_4567205d-cb6c-4424-819c-e1316330850b">130,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74e73d5375984977b6347e5a763139d0_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNDMtMy0xLTEtMQ_568b13ec-7cf9-4fdb-9078-672b6179680a">16,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNDQtMS0xLTEtMQ_0229d211-1ea4-4273-ba92-23bb6aa5273c">53,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i115d55a1156e4c969b9b8083b7760eb1_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNDQtMy0xLTEtMQ_33dd2a2d-8147-42fc-9da8-3fff03505c55">24,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental cash flow data:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNDgtMS0xLTEtMQ_a1c4a613-bfb7-4712-983c-8701c3aa46d4">3,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNDgtMy0xLTEtMQ_4ce8b44b-c1c9-4673-b29a-71ae922e10bd">3,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash commitment shares issued to Aspire Capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="cris:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNDktMS0xLTEtMQ_bf94f9b2-7ee4-415a-9e38-79d418dc1795">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" name="cris:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNDktMy0xLTEtMQ_225f89e3-252d-4ee4-b2ca-c82d3b86bb15">900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNTAtMS0xLTEtMQ_7790bf2d-2fe9-4177-b9cc-f9e06673f17b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNTAtMy0xLTEtMQ_0e5838e1-e3ff-4b48-b875-cd0464ee6972">7,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i90810bc68d594941912c6cfda631781c_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURIS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share data)</span></div><div id="i90810bc68d594941912c6cfda631781c_31"></div><div style="margin-top:10pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zMS9mcmFnOjQxZmZhMTQyNzBkYTRkOGJiMzJmYTE4MjJiY2JlNmQyL3RleHRyZWdpb246NDFmZmExNDI3MGRhNGQ4YmIzMmZhMTgyMmJjYmU2ZDJfOTk0Mg_84760732-13a9-45a5-9096-60deb1ed6a00" continuedAt="i9b94e9e545024f5d84d52ab1a8419a1a" escape="true">Nature of Business</ix:nonNumeric></span></div><ix:continuation id="i9b94e9e545024f5d84d52ab1a8419a1a" continuedAt="i11e7e685a9274461a7f2753be89e27ad"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Curis, Inc. is a biotechnology company focused on the development of first-in-class and innovative therapeutics for the treatment of cancer. Throughout these Condensed Consolidated Financial Statements, Curis, Inc. and its wholly owned subsidiaries are collectively referred to as &#8220;the Company&#8221; or &#8220;Curis.&#8221;</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducts its research and development programs both internally and through strategic collaborations. The Company&#8217;s clinical stage drug candidates are:</span></div><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">CA-4948, an orally available  small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 ("IRAK4"), which is currently undergoing testing in a Phase 1/2 open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas, including those with myeloid Differentiation Primary Response Protein 88 (&#8220;MYD88&#8221;) alterations. The trial was amended to include a combination study of CA-4948 and ibrutinib, a BTK inhibitor, in patients with non-Hodgkin lymphomas for which the Company enrolled the first patient in February 2021. The Company is also conducting a separate Phase 1/2 open-label, single arm dose escalating and expansion trial in patients with acute myeloid leukemia (&#8220;AML&#8221;) and myelodysplastic syndromes (&#8220;MDS&#8221;). The study was amended in April 2021 to include dose escalation cohorts of CA-4948 in combination with azacitidine or venetoclax. In April 2021, CA-4948 was granted Orphan Drug Designation for the treatment of AML and MDS by the U.S. Food and Drug Administration ("FDA"). In June 2021, we reported updated preliminary clinical data from the Phase 1/2 study in patients with AML or MDS and announced the recommended Phase 2 dose for monotherapy dose expansion.</span></div><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation (&#8220;VISTA&#8221;) signaling pathway. In June 2020, the Company announced that the FDA had cleared its Investigational New Drug (&#8220;IND&#8221;) application for CI-8993. In September 2020, enrollment for a Phase 1 trial in patients with solid tumors commenced. The Company has an option to license CI-8993 from ImmuNext, Inc. ("ImmuNext").</span></div><div style="margin-top:6pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s pipeline also includes the following:</span></div><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fimepinostat, a small molecule that potently inhibits the activity of histone deacetylase and phosphotidyl-inositol 3 kinase enzymes, which has been granted Orphan Drug Designation and Fast Track Designation for the treatment of diffuse large B-cell lymphoma and nuclear protein in testis (NUT) midline carcinoma. The Company is currently evaluating future studies for fimepinostat.</span></div><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CA-170, a small molecule antagonist of VISTA and PDL1, for which the Company announced initial data from a clinical study in patients with mesothelioma, in conjunction with the Society of lmmunotherapy of Cancer conference in November 2019. Based on this data, no further patients will be enrolled in the study. The Company is currently evaluating future studies for CA-170.</span></div><div style="margin-top:9pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CA-327, a small molecule antagonist of TIM3 and PDL1, is a pre-IND stage oncology drug candidate.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a collaboration with Genentech Inc. (&#8220;Genentech&#8221;), a member of the Roche Group, under which Genentech and F. Hoffmann-La Roche Ltd (&#8220;Roche&#8221;) are commercializing Erivedge&#174; (vismodegib), a first-in-class orally administered small molecule Hedgehog signaling pathway antagonist. Erivedge is approved for the treatment of advanced basal cell carcinoma (&#8220;BCC&#8221;).</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2015, the Company entered into an exclusive collaboration agreement with Aurigene Discovery Technologies Limited (&#8220;Aurigene&#8221;) for the discovery, development and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology, which was amended in September 2016 and February 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September 30, 2021, the Company had licensed <ix:nonFraction unitRef="program" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="cris:CollaborationAgreementNumberofProgramsLicensed" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zMS9mcmFnOjQxZmZhMTQyNzBkYTRkOGJiMzJmYTE4MjJiY2JlNmQyL3RleHRyZWdpb246NDFmZmExNDI3MGRhNGQ4YmIzMmZhMTgyMmJjYmU2ZDJfMjE5OTAyMzI2NTc1Mg_c2928448-3dc1-4a31-af5a-04f446c0a53a">four</ix:nonFraction> programs under the Aurigene collaboration.</span></div><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">IRAK4 Program - a precision oncology program of small molecule inhibitors of IRAK4. The development candidate is CA-4948, an orally available small molecule inhibitor of IRAK4.</span></div><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PD1/VISTA Program - an immuno-oncology program of small molecule antagonists of PD1 and VISTA immune checkpoint pathways. The development candidate is CA-170, an orally available small molecule antagonist of VISTA and PDL1.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><ix:continuation id="i11e7e685a9274461a7f2753be89e27ad"><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PD1/TIM3 Program - an immuno-oncology program of small molecule antagonists of PD1 and TIM3 immune checkpoint pathways. The development candidate is CA-327, an orally available small molecule antagonist of PDL1 and TIM3.</span></div><div style="margin-top:9pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company exercised its option to license a fourth program, which is an immuno-oncology program. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The COVID-19 pandemic has had and may continue to have an adverse effect on the Company&#8217;s business, financial condition, results of operations, and prospects. With respect to ongoing clinical trials, the anticipated timing of enrollment and the overall timelines of the trials have experienced delays and could be further delayed to the extent the Company experiences further delays in enrollment due to the COVID-19 pandemic. The Company&#8217;s ability to collect patient data in a timely fashion may also be impacted. The Company experienced delays in closing down its clinical trial sites related to its fimepinostat and CA-170 trials due to restrictions on non-essential workers imposed at those sites in response to COVID-19, which delayed the winding down of these trials.  In addition, the Company and its collaborators, third-party contract manufacturers, contract research organizations and clinical sites could experience delays or disruptions in supply and release of product candidates and/or procuring items that are essential for the Company's research and development activities, including, for example, raw materials used in the manufacturing of its product candidates, basic medical and laboratory supplies used in its clinical trials or preclinical studies, or animals that are used for preclinical testing, in each case, for which there may be shortages or supply chain disruptions as a result of the pandemic. The Company cannot be certain what the overall impact of the COVID-19 pandemic will be on its business.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry as well as risks that are specific to the Company&#8217;s business, including, but not limited to: the Company&#8217;s ability to obtain adequate financing to fund its operations; the Company&#8217;s ability to advance and expand its research and development programs; the impacts of the COVID-19 pandemic and responsive actions related thereto; the Company&#8217;s relationship with Aurigene to support development of drug candidates under the parties&#8217; collaboration agreement; the Company&#8217;s reliance on Roche and Genentech to successfully commercialize Erivedge in the approved indication of advanced BCC and to progress its clinical development in indications other than BCC; the ability of the Company and its wholly owned subsidiary, Curis Royalty, LLC (&#8220;Curis Royalty&#8221;) to satisfy the terms of the royalty interest purchase agreement (the &#8220;Oberland Purchase Agreement&#8221;) with TPC Investments I LP and TPC Investments II LP (the &#8220;Purchasers&#8221;) each of which is a Delaware limited partnership managed by Oberland Capital Management, LLC, and Lind SA LLC (the &#8220;Agent&#8221;) a Delaware limited liability company managed by Oberland Capital Management, LLC, as collateral agent for the Purchasers; the Company&#8217;s ability to obtain and maintain necessary intellectual property protection; development by the Company&#8217;s competitors of new or better technological innovations; the Company's dependence on key personnel; the Company&#8217;s ability to comply with regulatory requirements; the Company's ability to obtain and maintain applicable regulatory approvals and commercialize any approved product candidates; the Company&#8217;s ability to execute on its overall business strategies; and the Company&#8217;s ability to maintain its listing on the Nasdaq Global Market.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s future operating results will largely depend on the progress of drug candidates currently in its development pipeline and the magnitude of payments that it may receive and make under its current and potential future collaborations. The results of the Company&#8217;s operations have varied and will likely continue to vary significantly from year to year and quarter to quarter and depend on a number of factors, including, but not limited to: the timing, outcome and cost of the Company&#8217;s preclinical studies and clinical trials for its drug candidates; Aurigene&#8217;s ability to support advancement of development candidates  under the Company&#8217;s collaboration with Aurigene, as well as the Company&#8217;s ability to further develop programs under this collaboration; and Roche and Genentech&#8217;s ability to successfully commercialize Erivedge.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will require substantial funds to maintain research and development programs and support operations. The Company has incurred net losses and negative cash flows from operations since its inception. As of September 30, 2021, the Company had an accumulated deficit of approximately $<ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-8" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zMS9mcmFnOjQxZmZhMTQyNzBkYTRkOGJiMzJmYTE4MjJiY2JlNmQyL3RleHRyZWdpb246NDFmZmExNDI3MGRhNGQ4YmIzMmZhMTgyMmJjYmU2ZDJfODk5NQ_d3ee4a98-fbde-4c0f-a2f3-e7b216d5d326">1.1</ix:nonFraction> billion, and for the nine months ended September 30, 2021, the Company incurred a net loss of $<ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zMS9mcmFnOjQxZmZhMTQyNzBkYTRkOGJiMzJmYTE4MjJiY2JlNmQyL3RleHRyZWdpb246NDFmZmExNDI3MGRhNGQ4YmIzMmZhMTgyMmJjYmU2ZDJfOTA3NA_edd12791-9e04-4bea-af1e-5fc0ba3e1898">31.8</ix:nonFraction> million and used $<ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zMS9mcmFnOjQxZmZhMTQyNzBkYTRkOGJiMzJmYTE4MjJiY2JlNmQyL3RleHRyZWdpb246NDFmZmExNDI3MGRhNGQ4YmIzMmZhMTgyMmJjYmU2ZDJfOTA5NA_4bd733f7-230f-4b71-bbed-e3c92fa62fe9">29.4</ix:nonFraction> million of cash in operations. The Company expects to continue to generate operating losses in the foreseeable future. The Company anticipates that its $<ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zMS9mcmFnOjQxZmZhMTQyNzBkYTRkOGJiMzJmYTE4MjJiY2JlNmQyL3RleHRyZWdpb246NDFmZmExNDI3MGRhNGQ4YmIzMmZhMTgyMmJjYmU2ZDJfOTI0OQ_b5357a77-8b68-4ab9-bd81-0ca4843db65f">149.8</ix:nonFraction> million of existing cash, cash equivalents and investments at September 30, 2021 will be sufficient to fund operations for at least 12 months from the date of filing this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to raise additional funds will depend, among other factors, on financial, economic and market conditions, many of which are outside of its control and it may be unable to raise financing when needed, or on terms favorable to the Company. If necessary funds are not available, the Company will have to delay, reduce the scope of, or eliminate some of its development programs, potentially delaying the time to market for or preventing the marketing of any of its product candidates.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i90810bc68d594941912c6cfda631781c_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMTYyNzU_d5bd623a-686a-49b9-8719-a5e0e02e6f39" continuedAt="ia5481a7b4368490ea14d5d709333879d" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ia5481a7b4368490ea14d5d709333879d" continuedAt="i39368b65aac1416ea9a813c704c4d154"><div style="margin-top:10pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.84pt"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMTYyODU_e201d091-e41d-4604-b01c-a067ab1babbe" continuedAt="idcaa31c6ed174d8787141a5eb296127b" escape="true">Basis of Presentation and Principles of Consolidation</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idcaa31c6ed174d8787141a5eb296127b">The accompanying Condensed Consolidated Financial Statements have been prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. These statements, however, are condensed and do not include all disclosures required by accounting principles generally accepted in the U.S. (&#8220;GAAP&#8221;), for complete financial statements and should be read in conjunction with the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;), on March&#160;16, 2021</ix:continuation>.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of the management of the Company, the unaudited financial statements contain all adjustments (all of which were considered normal and recurring) necessary for a fair statement of the Company&#8217;s financial position at September 30, 2021; the results of operations for the three and nine-month periods ended September 30, 2021 and 2020; stockholders' equity (deficit) for the three and nine-month periods ended September 30, 2021 and 2020; and the cash flows for the nine-month periods ended September 30, 2021 and 2020. The Condensed Consolidated Balance Sheet at December 31, 2020 was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts within the statement of cash flows have been reclassified to conform to the current period presentation.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.84pt"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMTYyNzc_52d752bf-564a-4843-9e0b-2b8818b1c7fe" continuedAt="i46cbf008557540759454c569068cd863" escape="true">Use of Estimates and Assumptions</ix:nonNumeric></span></div><ix:continuation id="i46cbf008557540759454c569068cd863"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosure of certain assets and liabilities at the balance sheet date. Such estimates include the performance obligations under the Company&#8217;s collaboration agreements; the estimated repayment term of the Company&#8217;s debt and related short- and long-term classification; the collectability of receivables; the carrying value of property and equipment and goodwill; and the assumptions used in the Company&#8217;s valuation of stock-based compensation and the value of certain investments and liabilities. Actual results may differ from such estimates.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These interim results are not necessarily indicative of results to be expected for a full year or subsequent interim periods.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 has had and may continue to have impacts on the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of the COVID-19 pandemic, the extent to which it has impacted and may continue to impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business responses to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of September 30, 2021 and through the date of this report. The Company&#8217;s future assessment of the magnitude and duration of the COVID-19 pandemic, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div></ix:continuation><div style="margin-top:10pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.41pt"> <ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMTYyODc_a03f966b-4e98-4d64-b568-354289040b4a" continuedAt="i6a09b4858b7a42ebb5b0658057b251b5" escape="true">Cash Equivalents, Restricted Cash, and Investments</ix:nonNumeric></span></div><ix:continuation id="i6a09b4858b7a42ebb5b0658057b251b5"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments purchased with original maturities of three months or less. All other liquid investments are classified as marketable securities. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classified $<ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMjc0ODc3OTA4NTc1Ng_467da416-7f15-45bb-800f-b79709239258">0.7</ix:nonFraction>&#160;million of its cash as restricted cash as of September 30, 2021 and $<ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMjc0ODc3OTA4NTk4NQ_83d64c07-1860-49ca-8c65-6e7c10738a3a">0.8</ix:nonFraction>&#160;million as of December 31, 2020. This amount represents the security deposit delivered to the landlord of the Company's current Massachusetts headquarters. The restricted cash balance was reduced as of September 30, 2021 in accordance with the lease agreement.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's combined cash and restricted cash balances were $<ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMzc5NQ_e21cadc1-421e-4471-b00f-44bf1e327ab3">53.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i115d55a1156e4c969b9b8083b7760eb1_I20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMzgwMg_b0f5e743-47ef-45fd-815b-ebfc61446bfe">24.4</ix:nonFraction>&#160;million as of September 30, 2021 and September 30, 2020, respectively, as presented on the Company's Condensed Consolidated Statements of Cash Flows. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s short-term investments are marketable debt securities with original maturities of greater than three months from the date of purchase, but less than twelve months from the balance sheet date, and long-term investments are marketable debt securities with original maturities of greater than twelve months from the balance sheet date. Marketable securities consist of commercial paper, corporate bonds and notes, and/or government obligations. All of the Company&#8217;s investments have been designated available-for-sale and are stated at fair value. Unrealized gains and temporary losses on investments are included in accumulated other comprehensive income (loss) as a separate component of stockholders&#8217; equity (deficit). Realized gains and losses, dividends and interest income are included in other income (expense) in the period during which the securities are sold. Any premium or discount arising at purchase is amortized and/or accreted to interest income.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><ix:continuation id="i39368b65aac1416ea9a813c704c4d154" continuedAt="ibfafcd023e9d45eeb901bb44026016c4"><div style="margin-top:10pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.84pt"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMTYyODI_410a9e7d-9d11-4811-9aa1-2ac800349418" continuedAt="ib2ca384071a84adf9ce8f61f6873a862" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="ib2ca384071a84adf9ce8f61f6873a862" continuedAt="i8e93943105ed4b52987f1a769c6d860e"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at contract inception. Operating lease assets represent the Company's right to use an underlying asset for the lease term and operating lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of the Company's leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate, which is based on rates that would be incurred to borrow on a collateralized basis over a term equal to the lease payments in a similar economic environment, in determining the present value of lease payments.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The lease payment used to determine the operating lease asset may include lease incentives, stated rent increases and was recognized as an operating lease right-of-use asset in the Condensed Consolidated Balance Sheets. The Company's lease agreements may include both lease and non-lease components, which are accounted for as a single lease component when the payments are fixed. Variable payments included in the lease agreement are expensed as incurred. </span></div></ix:continuation><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8e93943105ed4b52987f1a769c6d860e">The Company's operating lease is reflected in operating lease right-of-use asset and operating lease liability in the Condensed Consolidated Balance Sheets. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</ix:continuation> </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.41pt"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMTYyODg_c690e651-d10c-4ec8-baac-bed5571cd751" continuedAt="iafb6ec4d0a0e41c380f65e02e790fbbd" escape="true">Revenue Recognition</ix:nonNumeric></span></div><ix:continuation id="iafb6ec4d0a0e41c380f65e02e790fbbd" continuedAt="i65d9c918b1504e0f80a6587dbae8f3d7"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business strategy includes entering into collaborative license and development agreements with biotechnology and pharmaceutical companies for the development and commercialization of the Company&#8217;s drug candidates. The terms of the agreements typically include non-refundable license fees, funding of research and development, payments based upon achievement of clinical development and regulatory objectives, and royalties on product sales. </span></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">License Fees and Multiple Element Arrangements</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to its intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, up-front fees allocated to the license at such time as the license is transferred to the licensee and the licensee is able to use, and benefit from, the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, will adjust the measure of performance and related revenue recognition. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company is involved in a steering committee as part of a multiple element arrangement, the Company assesses whether its involvement constitutes a performance obligation or a right to participate. Steering committee services that are not determined to be distinct performance obligations are combined with other research services or performance obligations required under an arrangement, if any, in determining the level of effort required in an arrangement and the period over which the Company expects to complete its aggregate performance obligations.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Appropriate methods of measuring progress include output methods and input methods. In determining the appropriate method for measuring progress, the Company considers the nature of service that it promises to transfer to the customer. When the Company decides on a method of measurement, the Company will apply that single method of measuring progress for each performance obligation satisfied over time and will apply that method consistently to similar performance obligations and in similar circumstances. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company cannot reasonably measure its progress toward complete satisfaction of a performance obligation because the Company lacks reliable information that would be required to apply an appropriate method of measuring progress, but it can reasonably estimate when the performance ceases or the remaining obligations become inconsequential and perfunctory, then revenue is not recognized until the Company can reasonably estimate when the performance obligation ceases or becomes inconsequential. Revenue is then recognized over the remaining estimated period of performance.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><ix:continuation id="ibfafcd023e9d45eeb901bb44026016c4" continuedAt="ifba5ce4196ff42f88dcdbb7415dc3c5a"><ix:continuation id="i65d9c918b1504e0f80a6587dbae8f3d7"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Contingent Research Milestone Payments</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Codification ("ASC") 606 constrains the amount of variable consideration included in the transaction price in that either all, or a portion, of an amount of variable consideration should be included in the transaction price. The variable consideration amount should be included only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The assessment of whether variable consideration should be constrained is largely a qualitative one that has two elements: the likelihood of a change in estimate, and the magnitude thereof. Variable consideration is not constrained if the potential reversal of cumulative revenue recognized is not significant, for example. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the consideration in a contract includes a variable amount, a company will estimate the amount of consideration in exchange for transfer of promised goods or services. The consideration also can vary if a company&#8217;s entitlement to the consideration is contingent on the occurrence or nonoccurrence of a future event. The Company considers contingent research milestone payments to fall under the scope of variable consideration, which should be estimated for revenue recognition purposes at the inception of the contract and reassessed ongoing at the end of each reporting period. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether contingent research milestones should be considered variable consideration that should be constrained and thus not part of the transaction price. This includes an assessment of the probability that all or some of the milestone revenues could be reversed when the uncertainty around whether or not the achievement of each milestone is resolved, and the amount of reversal could be significant. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP provides factors to consider when assessing whether variable consideration should be constrained. All of the factors should be considered, and no factor is determinative. The Company considers all relevant factors. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Reimbursement of Costs</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement of research and development costs by third-party collaborators is recognized as revenue over time provided the Company has determined that it transfers control (i.e. performs the services) of a service over time and, therefore, satisfies a performance obligation according to the provisions outlined in ASC 606-10-25-27, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Royalty Revenue</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes royalty revenues related to Genentech&#8217;s and Roche&#8217;s sales of Erivedge. For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and where the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). The Company expects to continue recognizing royalty revenue from Genentech&#8217;s sales of Erivedge in the U.S. and in other markets where Genentech and Roche successfully obtain marketing approval, if any (see Note&#160;9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Collaborations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). However, a portion of potential Erivedge royalties will be paid to the Purchasers pursuant to the Oberland Purchase Agreement (see Note 8, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liability Related to the Sale of Future Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Contra Revenue, Net</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contra revenue, net represents shared costs, primarily related to intellectual property, with the Company's collaboration partners, and reserves for potential royalty reductions.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to each of the foregoing areas of revenue recognition, the Company exercises significant judgment in determining whether an arrangement contains multiple elements, and, if so, how much revenue is allocable to each element. In addition, the Company exercises its judgment in determining when its significant obligations have been met under such agreements and the specific time periods over which the Company recognized revenue, such as non-refundable, up-front license fees. To the extent that actual facts and circumstances differ from the Company's initial judgments, its revenue recognition with respect to such transactions would change accordingly and any such change could affect the Company's reported financial results.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Summary</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2021, total gross revenues were <ix:nonFraction unitRef="number" contextRef="i36015b0cc9094033ad0afc16178a75cf_D20210101-20210930" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMTQ0Njc_54e85fa6-cace-432f-bc83-fb7f188107f1"><ix:nonFraction unitRef="number" contextRef="i2a46a72b07d94f83a96cc1ed91d2c92c_D20210701-20210930" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMTQ0Njc_62b5e185-8add-4776-89df-b751ffae091e">99</ix:nonFraction></ix:nonFraction>% from the Company&#8217;s collaboration with Genentech. During the three and nine months ended September 30, 2020 total gross revenues were <ix:nonFraction unitRef="number" contextRef="i8e17706f12e14935b7a015a9bceda833_D20200701-20200930" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMTQ1NzU_c9859596-1a12-4f06-9333-ab02a1eca3af">100</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i262850aa677c403ba7f59d77493f79af_D20200101-20200930" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMTQ1ODI_e1669ed7-805f-42f8-b709-347a2b54620e">97</ix:nonFraction>%, respectively, from the Company&#8217;s collaboration with Genentech. In addition to the revenues received from Genentech, the Company received a milestone payment from a previously out-licensed technology in the first quarter of 2020 that was recorded in other revenues. There were no such revenues recorded during the three and nine months ended September 30, 2021. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><ix:continuation id="ifba5ce4196ff42f88dcdbb7415dc3c5a"><div style="margin-top:10pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.07pt"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMTYyNzg_597284bb-58da-411c-99b8-9e259a407a67" continuedAt="ifeae90557e5e404186cac92e4be0c84f" escape="true">Segment Reporting</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifeae90557e5e404186cac92e4be0c84f">The Company operates in a single reportable segment, which is the research and development of innovative cancer therapeutics.</ix:continuation> </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.84pt"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMTYyODM_98bcecfb-3e6e-4cee-9dec-73298e28d29f" continuedAt="ic83d59abc4f6434798a392a5549a2723" escape="true">New Accounting Pronouncements</ix:nonNumeric></span></div><ix:continuation id="ic83d59abc4f6434798a392a5549a2723"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This standard requires that for most financial assets, losses be based on an expected loss approach which includes estimates of losses over the life of exposure that considers historical, current and forecasted information. Expanded disclosures related to the methods used to estimate the losses as well as a specific disaggregation of balances for financial assets are also required. The targeted transition relief standard allows filers an option to irrevocably elect the fair value option of ASC 825-10, Financial Instruments-Overall, applied on an instrument-by-instrument basis for eligible instruments. In November 2019 the effective date for smaller reporting companies was extended to January 1, 2023 with the issuance of ASU 2019-10 Financial Instruments-Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates. The Company adopted ASU 2016-13 as of January 1, 2021 and the adoption did not have a material impact on the Consolidated Financial Statements.</span></div></ix:continuation></ix:continuation><div id="i90810bc68d594941912c6cfda631781c_40"></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RleHRyZWdpb246MjkyNDJiMTVkYWU1NDZlOGEzODRlZWFhNDE4NjA3ZmNfMTUzOA_8cb93ac8-3bde-4dbc-966c-004b624f43be" continuedAt="i710b71d9e65241549800cf8a8eac96d0" escape="true"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RleHRyZWdpb246MjkyNDJiMTVkYWU1NDZlOGEzODRlZWFhNDE4NjA3ZmNfMTUzOQ_b4c9898b-21ba-46e5-8ee0-97bb5afc6c57" continuedAt="i701747d004cc4b84a97af2959f33aa43" escape="true">Fair Value of Financial Instruments</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i710b71d9e65241549800cf8a8eac96d0" continuedAt="i2fe7953126a84d6094ee04fc2fd675eb"><ix:continuation id="i701747d004cc4b84a97af2959f33aa43"><div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has adopted the provisions of the FASB Codification Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;Topic 820&#8221;) for its financial assets and liabilities that are re-measured and reported at fair value each reporting period and the non-financial assets and liabilities that are re-measured and reported at fair value on a non-recurring basis. Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it would transact and consider assumptions that market participants would use when pricing the asset or liability. Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. Financial assets and liabilities are categorized within the valuation hierarchy based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:</span></div><div style="margin-top:6pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quoted prices in active markets for identical assets or liabilities.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RleHRyZWdpb246MjkyNDJiMTVkYWU1NDZlOGEzODRlZWFhNDE4NjA3ZmNfMTUzNw_96624c53-c6b8-48da-a1c7-60ca3116adf6" continuedAt="ia0536cc9bc5b48c0941ec4939c270c56" escape="true"><div style="margin-bottom:6pt;margin-top:1pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the fair value hierarchy, the following table shows the fair value as of September 30, 2021 and December 31, 2020 of those financial assets and liabilities that are measured at fair value on a recurring basis, according to the valuation techniques the Company used to determine their fair value. No financial assets or liabilities are measured at fair value on a nonrecurring basis at September 30, 2021 and December 31, 2020.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:42.448%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in<br/>Active Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other&#160;Observable<br/>Inputs&#160;(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable<br/>Inputs&#160;(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2021:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3df875ea96bc4acbbb5cb6759aaf23a8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfMy0xLTEtMS0x_5d5d1f10-cfb7-4488-8e7b-adff001e12a3">49,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i752919577506410ea7bba33998b02ae8_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfMy0zLTEtMS0x_38fe302f-28cd-432e-a16d-93408e839efe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cdf5782b2f94b21b2601d416cac0370_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfMy01LTEtMS0x_5751abf2-d0ad-4697-87ef-c4a360799632">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43a2dff08c424d20b371f99c387f9552_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfMy03LTEtMS0x_969b4b6e-2921-4167-8965-1e1c10a9f4a4">49,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate commercial paper, bonds and notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad40040d3fdb4825b2d3d57150804fd8_I20210930" decimals="-3" format="ixt:fixed-zero" name="cris:ShortTermInvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfNS0xLTEtMS0x_071a6e78-cdfd-4bb8-a3c0-fa143a175d68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2274a8be63ab428c82beb8aa7d63ef65_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="cris:ShortTermInvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfNS0zLTEtMS0x_779a1fc8-e8dd-4b48-83f3-53190a0f76c7">75,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if877b50a8b61448bab75f25dec242c52_I20210930" decimals="-3" format="ixt:fixed-zero" name="cris:ShortTermInvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfNS01LTEtMS0x_51e56abd-5cb1-4857-a470-64a7a67c7896">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba7a650ba3e471bad9894814e905a1f_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="cris:ShortTermInvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfNS03LTEtMS0x_b7cfe1e6-de67-4a69-a479-929c03225556">75,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term  investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate commercial paper, bonds and notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad40040d3fdb4825b2d3d57150804fd8_I20210930" decimals="-3" format="ixt:fixed-zero" name="cris:LongTermInvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfNy0xLTEtMS0x_20fbbdc5-0c34-411c-8971-b8587f3436af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2274a8be63ab428c82beb8aa7d63ef65_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="cris:LongTermInvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfNy0zLTEtMS0x_f0f8b6cb-39dc-4066-89e6-799b4e98e64e">20,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if877b50a8b61448bab75f25dec242c52_I20210930" decimals="-3" format="ixt:fixed-zero" name="cris:LongTermInvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfNy01LTEtMS0x_b538a725-7330-4c8b-b7b9-e79842d6dd99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba7a650ba3e471bad9894814e905a1f_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="cris:LongTermInvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfNy03LTEtMS0x_dc952054-6784-49c8-894a-fac043e91a8f">20,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91bffd463f9a491d809bd7007380675e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfOC0xLTEtMS0x_8e82873b-342d-4436-868d-bad3d1f21053">49,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48c7eb38239442ad99050fe29f702ff5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfOC0zLTEtMS0x_b6851876-8881-4718-8203-d786d59f80b1">96,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f14473beda6447099b0a6cd272baf6a_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfOC01LTEtMS0x_54229271-1185-423b-aff3-f6d27f7b1188">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifadf6a4b0d22481ba0be83763d78d4c5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfOC03LTEtMS0x_619be368-5a0a-4736-83bd-117657f77378">145,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div><ix:continuation id="i2fe7953126a84d6094ee04fc2fd675eb"><ix:continuation id="ia0536cc9bc5b48c0941ec4939c270c56"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:42.448%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in<br/>Active Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other&#160;Observable<br/>Inputs&#160;(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unobservable<br/>Inputs&#160;(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90b3b70b1ebe49e3b4887be14abc4f66_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfMy0xLTEtMS0x_3f807cf7-75f9-48f1-b79f-de64411a89c1">115,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b067bfcfb3e48039d044d6458bfd391_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfMy0zLTEtMS0x_e9b55c3a-92a3-4a47-b998-180017eb8bca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadb4da6453d243de9db7f2235495b30b_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfMy01LTEtMS0x_99fb23ea-cc3e-4bda-8331-ba2e378e4557">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6ed47efff4d435ca7a150ad517661c2_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfMy03LTEtMS0x_1d6d0ec2-6402-405c-968b-4eedcc145b7f">115,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate commercial paper, bonds and notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e4fd250bac14a99a97209435af04856_I20201231" decimals="-3" format="ixt:fixed-zero" name="cris:ShortTermInvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfNS0xLTEtMS0x_6694cbfb-bc05-42c1-b511-8a87c5c83f94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6695b4c7cf4241ad83f88137c23fe102_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="cris:ShortTermInvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfNS0zLTEtMS0x_e1fc4aa0-3709-4c17-8bc3-27de41563caf">38,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id80a7c2a02984bf79a96da6df2e5a2b6_I20201231" decimals="-3" format="ixt:fixed-zero" name="cris:ShortTermInvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfNS01LTEtMS0x_a8d15ced-42a1-4e4c-afef-e5df79f08be2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52426bd73b8d4aea9d57fb272e80b022_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="cris:ShortTermInvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfNS03LTEtMS0x_ed4662a2-383b-499a-84f9-83717f4b8a8f">38,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term  investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate commercial paper, bonds and notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e4fd250bac14a99a97209435af04856_I20201231" decimals="-3" format="ixt:fixed-zero" name="cris:LongTermInvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfNy0xLTEtMS0x_eef61adb-2912-44fd-890d-c647b075fbca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6695b4c7cf4241ad83f88137c23fe102_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="cris:LongTermInvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfNy0zLTEtMS0x_a0ab3358-41b2-4eee-9cf5-c3191654c68b">14,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id80a7c2a02984bf79a96da6df2e5a2b6_I20201231" decimals="-3" format="ixt:fixed-zero" name="cris:LongTermInvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfNy01LTEtMS0x_e0db5697-edcb-4fd9-abc2-c42a3dd92384">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52426bd73b8d4aea9d57fb272e80b022_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="cris:LongTermInvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfNy03LTEtMS0x_f8079b2d-1ca9-408c-a2d0-54a454b903a0">14,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c228f3130b24ff3970c7f263b1d41aa_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfOC0xLTEtMS0x_f9aa6794-a4c8-4c2e-9987-c1397eb8ba3f">115,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b1c769aefa947ec9c248070d8b405b2_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfOC0zLTEtMS0x_edd47f98-911c-4955-8203-3a4ee532c980">53,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51d5333ea5724b6b9ff7023272b24535_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfOC01LTEtMS0x_5b05b695-f25d-48b2-9e23-2571a911e580">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4fdd2d8901b4eaca49139aa5b83e7bb_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfOC03LTEtMS0x_639b44c1-f6ef-47b1-822c-c04814596796">168,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div id="i90810bc68d594941912c6cfda631781c_43"></div><div style="margin-top:10pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RleHRyZWdpb246NDRkZTEwMzQzNmIyNDYwYThkZGRiZmU2ZDExMjM4OGNfMTM3Mg_a9aed63c-93d1-43ef-904d-f9d3848b8a49" continuedAt="idd0d5c07d7bf4949958d20cc7a269ff8" escape="true">Investments</ix:nonNumeric></span></div><ix:continuation id="idd0d5c07d7bf4949958d20cc7a269ff8" continuedAt="iae2712c6f12c4ed3aab677dc48a690b1"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RleHRyZWdpb246NDRkZTEwMzQzNmIyNDYwYThkZGRiZmU2ZDExMjM4OGNfMTM3MA_2365d988-f6a5-4435-9a50-5fad4d43f2d1" continuedAt="i9148515dec89411a804dbe5c24f79396" escape="true"><div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, unrealized gains and losses and fair value of investments available-for-sale as of September 30, 2021 are as follows:</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gain</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds and notes&#8212;short-term</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4abc2d093e574952b5b7a754de257c3a_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOmZmOGViOWRjZGRlZjRiMzE4ODE1MWQ5ZWM1Y2ZhNzhlL3RhYmxlcmFuZ2U6ZmY4ZWI5ZGNkZGVmNGIzMTg4MTUxZDllYzVjZmE3OGVfMS0xLTEtMS0x_c6ca4e6b-5ea1-4baa-879e-2abbb50b5b04">75,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4abc2d093e574952b5b7a754de257c3a_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOmZmOGViOWRjZGRlZjRiMzE4ODE1MWQ5ZWM1Y2ZhNzhlL3RhYmxlcmFuZ2U6ZmY4ZWI5ZGNkZGVmNGIzMTg4MTUxZDllYzVjZmE3OGVfMS0zLTEtMS0x_aec10d56-636f-420a-ae84-30d35001029a">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4abc2d093e574952b5b7a754de257c3a_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOmZmOGViOWRjZGRlZjRiMzE4ODE1MWQ5ZWM1Y2ZhNzhlL3RhYmxlcmFuZ2U6ZmY4ZWI5ZGNkZGVmNGIzMTg4MTUxZDllYzVjZmE3OGVfMS01LTEtMS0x_a4a6c81b-d029-4c99-baa5-fc10cebcba89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4abc2d093e574952b5b7a754de257c3a_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOmZmOGViOWRjZGRlZjRiMzE4ODE1MWQ5ZWM1Y2ZhNzhlL3RhYmxlcmFuZ2U6ZmY4ZWI5ZGNkZGVmNGIzMTg4MTUxZDllYzVjZmE3OGVfMS03LTEtMS0x_ef0aab9c-9847-4106-a010-08e4291351c0">75,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds and notes&#8212;long-term</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb8359146f7d40bdae64e9071788d92a_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOmZmOGViOWRjZGRlZjRiMzE4ODE1MWQ5ZWM1Y2ZhNzhlL3RhYmxlcmFuZ2U6ZmY4ZWI5ZGNkZGVmNGIzMTg4MTUxZDllYzVjZmE3OGVfMi0xLTEtMS0x_d9adb295-ff92-42cb-9cae-b7fee95513b4">20,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb8359146f7d40bdae64e9071788d92a_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOmZmOGViOWRjZGRlZjRiMzE4ODE1MWQ5ZWM1Y2ZhNzhlL3RhYmxlcmFuZ2U6ZmY4ZWI5ZGNkZGVmNGIzMTg4MTUxZDllYzVjZmE3OGVfMi0zLTEtMS0x_da02afd6-2d27-4b37-be9f-8c4d67969ff2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb8359146f7d40bdae64e9071788d92a_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOmZmOGViOWRjZGRlZjRiMzE4ODE1MWQ5ZWM1Y2ZhNzhlL3RhYmxlcmFuZ2U6ZmY4ZWI5ZGNkZGVmNGIzMTg4MTUxZDllYzVjZmE3OGVfMi01LTEtMS0x_a36af993-b57f-4b38-b5d0-5c78e0dcd11f">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb8359146f7d40bdae64e9071788d92a_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOmZmOGViOWRjZGRlZjRiMzE4ODE1MWQ5ZWM1Y2ZhNzhlL3RhYmxlcmFuZ2U6ZmY4ZWI5ZGNkZGVmNGIzMTg4MTUxZDllYzVjZmE3OGVfMi03LTEtMS0x_f7f78271-6681-468b-9594-741bb8f040d6">20,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOmZmOGViOWRjZGRlZjRiMzE4ODE1MWQ5ZWM1Y2ZhNzhlL3RhYmxlcmFuZ2U6ZmY4ZWI5ZGNkZGVmNGIzMTg4MTUxZDllYzVjZmE3OGVfMy0xLTEtMS0x_599b583d-94ce-4e45-bbae-c74b92ba5c48">96,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOmZmOGViOWRjZGRlZjRiMzE4ODE1MWQ5ZWM1Y2ZhNzhlL3RhYmxlcmFuZ2U6ZmY4ZWI5ZGNkZGVmNGIzMTg4MTUxZDllYzVjZmE3OGVfMy0zLTEtMS0x_8f4dfeaf-4ca1-4278-a727-20ccf08f0b6b">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOmZmOGViOWRjZGRlZjRiMzE4ODE1MWQ5ZWM1Y2ZhNzhlL3RhYmxlcmFuZ2U6ZmY4ZWI5ZGNkZGVmNGIzMTg4MTUxZDllYzVjZmE3OGVfMy01LTEtMS0x_73c7121f-c37d-47a3-9fce-0a59d3867390">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOmZmOGViOWRjZGRlZjRiMzE4ODE1MWQ5ZWM1Y2ZhNzhlL3RhYmxlcmFuZ2U6ZmY4ZWI5ZGNkZGVmNGIzMTg4MTUxZDllYzVjZmE3OGVfMy03LTEtMS0x_f2cd5135-ba1a-471c-be51-23e5764748d6">96,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments have maturities ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RleHRyZWdpb246NDRkZTEwMzQzNmIyNDYwYThkZGRiZmU2ZDExMjM4OGNfMTk3_cb80bf15-17b4-45da-ba01-4fb8b0381751">one</span> to <ix:nonNumeric contextRef="i0d85f4c8792a4a81a3945294a14918cf_D20210101-20210930" format="ixt-sec:durwordsen" name="cris:AvailableForSaleSecuritiesDateRange" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RleHRyZWdpb246NDRkZTEwMzQzNmIyNDYwYThkZGRiZmU2ZDExMjM4OGNfMTM3Nw_2e1220f2-9b78-474f-8cbd-017a29db9f8e">twelve months</ix:nonNumeric> with a weighted-average maturity of <ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" format="ixt-sec:duryear" name="cris:AvailableForSaleSecuritiesWeightedAverageMaturity" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RleHRyZWdpb246NDRkZTEwMzQzNmIyNDYwYThkZGRiZmU2ZDExMjM4OGNfMjQ5_e1a43117-8d22-4834-8faa-e5bb8c49a093">0.6</ix:nonNumeric> years at September 30, 2021. The weighted average maturity of long-term investments was <ix:nonNumeric contextRef="i9957a5ac4bf142e78afb996c95c0ac64_D20210101-20210930" format="ixt-sec:duryear" name="cris:AvailableForSaleSecuritiesWeightedAverageMaturity" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RleHRyZWdpb246NDRkZTEwMzQzNmIyNDYwYThkZGRiZmU2ZDExMjM4OGNfMzE4_770ed622-c96d-44a7-8811-4584daaedb16">1.6</ix:nonNumeric> years at September 30, 2021. </span></div><ix:continuation id="i9148515dec89411a804dbe5c24f79396"><div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, unrealized gains and losses and fair value of investments available-for-sale as of December 31, 2020 are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gain</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds and notes&#8212;short-term</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d10b233f290481a9f06412946f6a2ce_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOjg3ZDViY2EyMjYwYzRlZDJhMjYwMGZlODM2ZGZjMWIwL3RhYmxlcmFuZ2U6ODdkNWJjYTIyNjBjNGVkMmEyNjAwZmU4MzZkZmMxYjBfMS0xLTEtMS0x_ff743afc-93c8-48be-be85-dc71a783c165">38,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d10b233f290481a9f06412946f6a2ce_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOjg3ZDViY2EyMjYwYzRlZDJhMjYwMGZlODM2ZGZjMWIwL3RhYmxlcmFuZ2U6ODdkNWJjYTIyNjBjNGVkMmEyNjAwZmU4MzZkZmMxYjBfMS0zLTEtMS0x_c3b76db6-809a-46a7-9d20-d84bff8152ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d10b233f290481a9f06412946f6a2ce_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOjg3ZDViY2EyMjYwYzRlZDJhMjYwMGZlODM2ZGZjMWIwL3RhYmxlcmFuZ2U6ODdkNWJjYTIyNjBjNGVkMmEyNjAwZmU4MzZkZmMxYjBfMS01LTEtMS0x_5b8892b2-1e07-4825-b638-9f526eaa7796">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d10b233f290481a9f06412946f6a2ce_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOjg3ZDViY2EyMjYwYzRlZDJhMjYwMGZlODM2ZGZjMWIwL3RhYmxlcmFuZ2U6ODdkNWJjYTIyNjBjNGVkMmEyNjAwZmU4MzZkZmMxYjBfMS03LTEtMS0x_5e519e5b-506b-4dcf-8075-ff3d4a9a8e20">38,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds and notes&#8212;long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa1a4b9cd2ed47249f51596f460164a4_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOjg3ZDViY2EyMjYwYzRlZDJhMjYwMGZlODM2ZGZjMWIwL3RhYmxlcmFuZ2U6ODdkNWJjYTIyNjBjNGVkMmEyNjAwZmU4MzZkZmMxYjBfMi0xLTEtMS0x_76a1ddd1-2d9a-454d-8604-14e94cbd1307">14,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa1a4b9cd2ed47249f51596f460164a4_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOjg3ZDViY2EyMjYwYzRlZDJhMjYwMGZlODM2ZGZjMWIwL3RhYmxlcmFuZ2U6ODdkNWJjYTIyNjBjNGVkMmEyNjAwZmU4MzZkZmMxYjBfMi0zLTEtMS0x_41ef1e13-8a4f-4e03-a17b-03a35da19307">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa1a4b9cd2ed47249f51596f460164a4_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOjg3ZDViY2EyMjYwYzRlZDJhMjYwMGZlODM2ZGZjMWIwL3RhYmxlcmFuZ2U6ODdkNWJjYTIyNjBjNGVkMmEyNjAwZmU4MzZkZmMxYjBfMi01LTEtMS0x_b655a20a-95b4-48c3-be30-0dd67baf466c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa1a4b9cd2ed47249f51596f460164a4_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOjg3ZDViY2EyMjYwYzRlZDJhMjYwMGZlODM2ZGZjMWIwL3RhYmxlcmFuZ2U6ODdkNWJjYTIyNjBjNGVkMmEyNjAwZmU4MzZkZmMxYjBfMi03LTEtMS0x_5f8abf8b-04c3-42e1-9151-298edb0f40a6">14,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOjg3ZDViY2EyMjYwYzRlZDJhMjYwMGZlODM2ZGZjMWIwL3RhYmxlcmFuZ2U6ODdkNWJjYTIyNjBjNGVkMmEyNjAwZmU4MzZkZmMxYjBfMy0xLTEtMS0x_3c4d0f8b-8bf2-40a3-b421-9fc68405390d">53,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOjg3ZDViY2EyMjYwYzRlZDJhMjYwMGZlODM2ZGZjMWIwL3RhYmxlcmFuZ2U6ODdkNWJjYTIyNjBjNGVkMmEyNjAwZmU4MzZkZmMxYjBfMy0zLTEtMS0x_0f99bf49-be97-4846-b3b2-bb7e958b89ba">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOjg3ZDViY2EyMjYwYzRlZDJhMjYwMGZlODM2ZGZjMWIwL3RhYmxlcmFuZ2U6ODdkNWJjYTIyNjBjNGVkMmEyNjAwZmU4MzZkZmMxYjBfMy01LTEtMS0x_5565f3fb-5fc8-4927-bbea-6a6fb8c6c31c">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOjg3ZDViY2EyMjYwYzRlZDJhMjYwMGZlODM2ZGZjMWIwL3RhYmxlcmFuZ2U6ODdkNWJjYTIyNjBjNGVkMmEyNjAwZmU4MzZkZmMxYjBfMy03LTEtMS0x_21ec8fba-2a1d-41fd-82c0-22e03eb9971f">53,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments have maturities ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RleHRyZWdpb246NDRkZTEwMzQzNmIyNDYwYThkZGRiZmU2ZDExMjM4OGNfNTEx_4f659141-f01a-4310-9378-77affc0e77d5">one</span> to <ix:nonNumeric contextRef="i5de88db29d3e498087f6e6443e27c84c_D20200101-20201231" format="ixt-sec:durwordsen" name="cris:AvailableForSaleSecuritiesDateRange" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RleHRyZWdpb246NDRkZTEwMzQzNmIyNDYwYThkZGRiZmU2ZDExMjM4OGNfMTM3OQ_73c02764-32e3-4c0e-b8a5-20b3527960ef">twelve months</ix:nonNumeric> with a weighted-average maturity of <ix:nonNumeric contextRef="i8e5764c869674f6eaf807f9f08528150_D20200101-20201231" format="ixt-sec:duryear" name="cris:AvailableForSaleSecuritiesWeightedAverageMaturity" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RleHRyZWdpb246NDRkZTEwMzQzNmIyNDYwYThkZGRiZmU2ZDExMjM4OGNfNTYz_7a8070db-ca0f-4e32-87dc-231b8214586b">0.6</ix:nonNumeric> years at December 31, 2020. The weighted average maturity of long-term investments was <ix:nonNumeric contextRef="i2f243344a43a416aa68d31546bb3c8b8_D20200101-20201231" format="ixt-sec:duryear" name="cris:AvailableForSaleSecuritiesWeightedAverageMaturity" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RleHRyZWdpb246NDRkZTEwMzQzNmIyNDYwYThkZGRiZmU2ZDExMjM4OGNfNjM4_b170489c-e3ab-41d6-8a86-459fb79f900b">1.5</ix:nonNumeric> years at December 31, 2020. </span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No credit losses on available-for-sale securities were recognized during the three and nine months ended September 30, 2021 or September 30, 2020. In its evaluation to determine expected credit losses, management considered all available historical and current information, expectations of future economic conditions, the type of security, the credit rating of the security, and the size of the loss position, as well as other relevant information. The Company does not intend to sell, and is unlikely to be required to sell, any of these available-for-sale investments before their effective maturity or market price recovery.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:4pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iae2712c6f12c4ed3aab677dc48a690b1">As of September 30, 2021 and December 31, 2020, the Company held no investments that have been in a continuous unrealized loss position for 12 months or longer.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i90810bc68d594941912c6cfda631781c_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180Ni9mcmFnOjQxYTZjMTUwYTQwMDQ1OGY5OGVlZWQ4MWZhMWRmNzQzL3RleHRyZWdpb246NDFhNmMxNTBhNDAwNDU4Zjk4ZWVlZDgxZmExZGY3NDNfNzk_6f3c039b-7782-4c02-be1e-1fd9c145a767" continuedAt="i88a9e904a3bb4c57abdb0e26aafefe15" escape="true">Accrued Liabilities</ix:nonNumeric></span></div><ix:continuation id="i88a9e904a3bb4c57abdb0e26aafefe15"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180Ni9mcmFnOjQxYTZjMTUwYTQwMDQ1OGY5OGVlZWQ4MWZhMWRmNzQzL3RleHRyZWdpb246NDFhNmMxNTBhNDAwNDU4Zjk4ZWVlZDgxZmExZGY3NDNfNzg_31f6bc7a-75b8-44bc-a79f-704e5b7dab39" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following:</span></div><div style="margin-bottom:7pt;margin-top:11pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedSalariesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180Ni9mcmFnOjQxYTZjMTUwYTQwMDQ1OGY5OGVlZWQ4MWZhMWRmNzQzL3RhYmxlOmViZTI5MDFhOGZkZTRhZWE5MmVmMzJhYjVkNzBiOTU4L3RhYmxlcmFuZ2U6ZWJlMjkwMWE4ZmRlNGFlYTkyZWYzMmFiNWQ3MGI5NThfMS0xLTEtMS0x_d44f8134-0d54-4560-91fe-8bd0a4269a64">2,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedSalariesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180Ni9mcmFnOjQxYTZjMTUwYTQwMDQ1OGY5OGVlZWQ4MWZhMWRmNzQzL3RhYmxlOmViZTI5MDFhOGZkZTRhZWE5MmVmMzJhYjVkNzBiOTU4L3RhYmxlcmFuZ2U6ZWJlMjkwMWE4ZmRlNGFlYTkyZWYzMmFiNWQ3MGI5NThfMS0zLTEtMS0x_00f24462-27d9-4ca0-8778-3843aeafb918">2,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chemistry, manufacturing and controls costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="cris:ChemistryManufacturingAndControlsCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180Ni9mcmFnOjQxYTZjMTUwYTQwMDQ1OGY5OGVlZWQ4MWZhMWRmNzQzL3RhYmxlOmViZTI5MDFhOGZkZTRhZWE5MmVmMzJhYjVkNzBiOTU4L3RhYmxlcmFuZ2U6ZWJlMjkwMWE4ZmRlNGFlYTkyZWYzMmFiNWQ3MGI5NThfMi0xLTEtMS0x_a976763e-f8bd-40bc-b268-297785d47e12">1,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" format="ixt:fixed-zero" name="cris:ChemistryManufacturingAndControlsCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180Ni9mcmFnOjQxYTZjMTUwYTQwMDQ1OGY5OGVlZWQ4MWZhMWRmNzQzL3RhYmxlOmViZTI5MDFhOGZkZTRhZWE5MmVmMzJhYjVkNzBiOTU4L3RhYmxlcmFuZ2U6ZWJlMjkwMWE4ZmRlNGFlYTkyZWYzMmFiNWQ3MGI5NThfMi0zLTEtMS0x_6dced8e6-4fbc-48f9-8c44-b770a788b2eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional and legal fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180Ni9mcmFnOjQxYTZjMTUwYTQwMDQ1OGY5OGVlZWQ4MWZhMWRmNzQzL3RhYmxlOmViZTI5MDFhOGZkZTRhZWE5MmVmMzJhYjVkNzBiOTU4L3RhYmxlcmFuZ2U6ZWJlMjkwMWE4ZmRlNGFlYTkyZWYzMmFiNWQ3MGI5NThfMy0xLTEtMS0x_698ded33-2cd9-4759-9f59-2a908e50013b">541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180Ni9mcmFnOjQxYTZjMTUwYTQwMDQ1OGY5OGVlZWQ4MWZhMWRmNzQzL3RhYmxlOmViZTI5MDFhOGZkZTRhZWE5MmVmMzJhYjVkNzBiOTU4L3RhYmxlcmFuZ2U6ZWJlMjkwMWE4ZmRlNGFlYTkyZWYzMmFiNWQ3MGI5NThfMy0zLTEtMS0x_e8bde673-6f46-462d-b03d-3d5a401a73be">307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" name="cris:LicenseFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180Ni9mcmFnOjQxYTZjMTUwYTQwMDQ1OGY5OGVlZWQ4MWZhMWRmNzQzL3RhYmxlOmViZTI5MDFhOGZkZTRhZWE5MmVmMzJhYjVkNzBiOTU4L3RhYmxlcmFuZ2U6ZWJlMjkwMWE4ZmRlNGFlYTkyZWYzMmFiNWQ3MGI5NThfNC0xLTEtMS0x_846dc0fa-865e-40c3-a26a-d8a898e2ae2c">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" name="cris:LicenseFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180Ni9mcmFnOjQxYTZjMTUwYTQwMDQ1OGY5OGVlZWQ4MWZhMWRmNzQzL3RhYmxlOmViZTI5MDFhOGZkZTRhZWE5MmVmMzJhYjVkNzBiOTU4L3RhYmxlcmFuZ2U6ZWJlMjkwMWE4ZmRlNGFlYTkyZWYzMmFiNWQ3MGI5NThfNC0zLTEtMS0x_1fa7fe71-063d-4d33-ba15-f0fde6663659">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180Ni9mcmFnOjQxYTZjMTUwYTQwMDQ1OGY5OGVlZWQ4MWZhMWRmNzQzL3RhYmxlOmViZTI5MDFhOGZkZTRhZWE5MmVmMzJhYjVkNzBiOTU4L3RhYmxlcmFuZ2U6ZWJlMjkwMWE4ZmRlNGFlYTkyZWYzMmFiNWQ3MGI5NThfNS0xLTEtMS0x_2aa670c4-e436-4285-b6fa-9a3f16a99138">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180Ni9mcmFnOjQxYTZjMTUwYTQwMDQ1OGY5OGVlZWQ4MWZhMWRmNzQzL3RhYmxlOmViZTI5MDFhOGZkZTRhZWE5MmVmMzJhYjVkNzBiOTU4L3RhYmxlcmFuZ2U6ZWJlMjkwMWE4ZmRlNGFlYTkyZWYzMmFiNWQ3MGI5NThfNS0zLTEtMS0x_1b22bf43-bf12-40e4-b593-1c06833d77bf">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180Ni9mcmFnOjQxYTZjMTUwYTQwMDQ1OGY5OGVlZWQ4MWZhMWRmNzQzL3RhYmxlOmViZTI5MDFhOGZkZTRhZWE5MmVmMzJhYjVkNzBiOTU4L3RhYmxlcmFuZ2U6ZWJlMjkwMWE4ZmRlNGFlYTkyZWYzMmFiNWQ3MGI5NThfNi0xLTEtMS0x_ba813040-c898-4d0d-ad08-080c4ccbb447">5,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180Ni9mcmFnOjQxYTZjMTUwYTQwMDQ1OGY5OGVlZWQ4MWZhMWRmNzQzL3RhYmxlOmViZTI5MDFhOGZkZTRhZWE5MmVmMzJhYjVkNzBiOTU4L3RhYmxlcmFuZ2U6ZWJlMjkwMWE4ZmRlNGFlYTkyZWYzMmFiNWQ3MGI5NThfNi0zLTEtMS0x_81b25b93-8ef4-4b6d-a1b5-f9fd0daffa2e">3,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i90810bc68d594941912c6cfda631781c_49"></div><div style="margin-top:10pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180OS9mcmFnOmU2OTAwMWZkNzdlNDQ2NzQ5YjMwM2RkMjQ5Yzg1NzMyL3RleHRyZWdpb246ZTY5MDAxZmQ3N2U0NDY3NDliMzAzZGQyNDljODU3MzJfMTA3OA_956c5d9b-2028-4400-ab45-68a9031e9373" continuedAt="ic3f6e496fef047f4bed6cbadb582f1d7" escape="true">Debt</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic3f6e496fef047f4bed6cbadb582f1d7">In April 2020, the Company entered into a promissory note evidencing an unsecured $<ix:nonFraction unitRef="usd" contextRef="i27e768c412c64fadbdb2a523fde1e521_I20200430" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180OS9mcmFnOmU2OTAwMWZkNzdlNDQ2NzQ5YjMwM2RkMjQ5Yzg1NzMyL3RleHRyZWdpb246ZTY5MDAxZmQ3N2U0NDY3NDliMzAzZGQyNDljODU3MzJfOTY_92110e3d-afd0-4995-afd3-43cad9172ee2">0.9</ix:nonFraction>&#160;million loan (the &#8220;PPP Loan&#8221;) under the Paycheck Protection Program (&#8220;PPP&#8221;), of the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) as administered by the U.S. Small Business Administration (the "SBA"). The PPP Loan was made by Silicon Valley Bank and had a term of <ix:nonNumeric contextRef="i0d950297b01b4b72ae513d1a9aba345e_I20200430" format="ixt-sec:durmonth" name="us-gaap:LongTermDebtTerm" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180OS9mcmFnOmU2OTAwMWZkNzdlNDQ2NzQ5YjMwM2RkMjQ5Yzg1NzMyL3RleHRyZWdpb246ZTY5MDAxZmQ3N2U0NDY3NDliMzAzZGQyNDljODU3MzJfMzc0_0b2d95f5-8d35-4b5a-8b7b-232de3e94778">24</ix:nonNumeric>-months and an interest rate of <ix:nonFraction unitRef="number" contextRef="i0d950297b01b4b72ae513d1a9aba345e_I20200430" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180OS9mcmFnOmU2OTAwMWZkNzdlNDQ2NzQ5YjMwM2RkMjQ5Yzg1NzMyL3RleHRyZWdpb246ZTY5MDAxZmQ3N2U0NDY3NDliMzAzZGQyNDljODU3MzJfNDA4_a51672a8-e87f-43bd-b5bc-91c74fb8d219">1</ix:nonFraction>%. Under the terms of the CARES Act and the Paycheck Protection Program Flexibility Act of 2020, PPP Loan recipients can apply for and be granted forgiveness for all or a portion of loans granted under the PPP. The Company applied for such forgiveness in 2020 and received notification in June 2021 that the SBA had forgiven the PPP Loan in full, including interest accrued on the PPP Loan. During the nine months ended September 30, 2021, the Company recorded a gain of $<ix:nonFraction unitRef="usd" contextRef="icb1c5fdb8979488fbe5bdf7ab44b6d01_D20210101-20210930" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180OS9mcmFnOmU2OTAwMWZkNzdlNDQ2NzQ5YjMwM2RkMjQ5Yzg1NzMyL3RleHRyZWdpb246ZTY5MDAxZmQ3N2U0NDY3NDliMzAzZGQyNDljODU3MzJfODc2_92e33741-5960-4242-8c59-f71d047e71e9">0.9</ix:nonFraction> million to Other income (expense), net for extinguishment of the debt. As of December 31, 2020, the Company recorded short- and long-term debt related to the PPP Loan of $<ix:nonFraction unitRef="usd" contextRef="i8446755412e84406a49c98064e52b988_I20201231" decimals="-5" name="us-gaap:ShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180OS9mcmFnOmU2OTAwMWZkNzdlNDQ2NzQ5YjMwM2RkMjQ5Yzg1NzMyL3RleHRyZWdpb246ZTY5MDAxZmQ3N2U0NDY3NDliMzAzZGQyNDljODU3MzJfMTAzNA_03204cdc-75fb-40c7-bdf2-0b2c0e741e6b">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8446755412e84406a49c98064e52b988_I20201231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180OS9mcmFnOmU2OTAwMWZkNzdlNDQ2NzQ5YjMwM2RkMjQ5Yzg1NzMyL3RleHRyZWdpb246ZTY5MDAxZmQ3N2U0NDY3NDliMzAzZGQyNDljODU3MzJfMTA0OQ_09a61bff-2af2-400d-b4c9-0f94c5fb1841">0.3</ix:nonFraction> million, respectively.</ix:continuation> </span></div><div id="i90810bc68d594941912c6cfda631781c_52"></div><div style="margin-top:10pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfMTQwOQ_747fc23c-a89e-4f7b-9cd2-fcd0fc81eb60" continuedAt="i9444b62641a747a0a2358ca441ffc87f" escape="true">Lease</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9444b62641a747a0a2358ca441ffc87f" continuedAt="i7a26d185c9674f3dbde0b4bb19c839b3">The Company has a single lease for real estate, including laboratory and office space, and certain equipment. The lease at 128 Spring Street in Lexington, Massachusetts commenced on May 1, 2020 which is the date when the property became available for use to the Company. In accordance with the accounting requirements under ASC 842, the lease obligation was not recorded until its commencement. The discount rate associated with the Company's right-of-use asset is <ix:nonFraction unitRef="number" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfNDgw_4596d477-9589-4444-8cc1-ab90e24dc1be">9.95</ix:nonFraction>%. </ix:continuation></span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7a26d185c9674f3dbde0b4bb19c839b3">As of September 30, 2021, the Company had an operating lease liability of $<ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfNTQz_c49dddbc-6726-40dc-943c-bad5f8813aad">5.2</ix:nonFraction> million and related right-of-use asset of $<ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfNTg5_9fbc9c75-22f6-4c93-bd23-3a43305fce15">6.0</ix:nonFraction> million related to its operating lease. As of December 31, 2020, the Company had an operating lease liability of $<ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfNjkw_39ef8acb-4e17-4765-94ab-09380cf05910">6.8</ix:nonFraction> million and related right-of-use asset of $<ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfNzM1_6b9ec0f5-67c0-483c-bcd2-e9dedd079e8a">6.6</ix:nonFraction> million related to its operating lease. The Company recorded a lease cost of $<ix:nonFraction unitRef="usd" contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfMTA5OTUxMTYyOTE4OQ_5eb0b8c6-12ab-41c8-9f3b-88cf59f52377">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfODMx_8d39068e-b145-4ee6-a42c-c78f48878a7e">1.0</ix:nonFraction> million for the three and nine months ended September 30, 2021, respectively. The Company recorded a lease cost of $<ix:nonFraction unitRef="usd" contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfOTI4_4af640f6-86bd-4fa9-8dcb-27dd2aea9c0b">0.4</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfOTM1_e404d608-b25a-4828-be65-6ffc3f9af7ee">1.0</ix:nonFraction> million for the three and nine months ended September 30, 2020, respectively. The total cash obligation over the <ix:nonNumeric contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfMTQxMA_4e8d263b-c9de-4577-b634-1de246eca479">seven year</ix:nonNumeric> term of this lease is approximately $<ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfMTA3NA_67649360-3ae3-4f53-ba74-dc428fd3cd5c">9.3</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfMTA5OTUxMTYyOTE5NA_2171fe29-d5a2-4a1e-a617-0dd0ce32df3a">0.3</ix:nonFraction> million was paid during the three months ended September 30, 2021 and $<ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfMTE0OQ_72731cab-4a3f-4784-984e-1ebc7b26b125">2.0</ix:nonFraction> million was paid during the nine months ended September 30, 2021. The payments included a payment of $<ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-5" name="cris:OperatingLeaseOneTimePaymentTenantImprovements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfMTI0NA_9872ce06-4c3d-4b32-b9e7-cee31ef5c227">1.1</ix:nonFraction> million for tenant improvements. The Company did <ix:nonFraction unitRef="usd" contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:OperatingLeasePayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfMTI5Ng_8b83b08b-7077-4cc1-a16b-c81572e0ec66">no</ix:nonFraction>t make cash payments during the three months ended September 30, 2020. The Company paid $<ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfMTM2Nw_ea56012f-8295-4274-84f7-62d1c7230655">0.2</ix:nonFraction> million during the nine months ended September 30, 2020</ix:continuation>. </span></div><div id="i90810bc68d594941912c6cfda631781c_55"></div><div style="margin-top:12pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="us-gaap:NonmonetaryTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RleHRyZWdpb246NmY3NDZhZDk4ODlkNDMwYWE0YjIyMTQxNGM0NjFkOTVfNDIyMw_39759fe2-4f1d-4f20-9d5b-88da907efed7" continuedAt="i7311746008b44a259289f92464276253" escape="true">Liability Related to the Sale of Future Royalties</ix:nonNumeric></span></div><ix:continuation id="i7311746008b44a259289f92464276253" continuedAt="id74268ee9eb24ac3a0796ea9fd8200fa"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, the Company and Curis Royalty entered into the royalty interest purchase agreement (&#8220;Oberland Purchase Agreement&#8221;) with entities managed by Oberland Capital Management, LLC (the &#8220;Purchasers&#8221;). The Company sold to the Purchasers a portion of its rights to receive royalties from Genentech on potential net sales of Erivedge. Concurrently with the closing of the Oberland Purchase Agreement, Curis Royalty used a portion of the proceeds to terminate and repay the then existing loan with HealthCare Royalty Partners, III, L.P..</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As upfront consideration for the purchase of the royalty rights, at closing the Purchasers paid to Curis Royalty $<ix:nonFraction unitRef="usd" contextRef="ie5375dfdc8ee412588936e837f459f29_D20190301-20190331" decimals="-5" name="cris:ProceedsFromRoyaltyPurchaseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RleHRyZWdpb246NmY3NDZhZDk4ODlkNDMwYWE0YjIyMTQxNGM0NjFkOTVfNzEy_497c44b6-5426-4782-8d64-080f70c30950">65.0</ix:nonFraction> million less certain transaction expenses. Curis Royalty will also be entitled to receive up to approximately $<ix:nonFraction unitRef="usd" contextRef="ie5375dfdc8ee412588936e837f459f29_D20190301-20190331" decimals="-5" name="cris:RoyaltyPurchaseAgreementContingentConsiderationCashProceeds" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RleHRyZWdpb246NmY3NDZhZDk4ODlkNDMwYWE0YjIyMTQxNGM0NjFkOTVfODI1_97de9425-8786-4f86-a259-588437271bf0">70.7</ix:nonFraction> million in milestone payments based on sales of Erivedge as follows: (i) $<ix:nonFraction unitRef="usd" contextRef="iffa498edbc73462ba0ffcf6335f33a3b_D20190301-20190331" decimals="-5" name="cris:RoyaltyPurchaseAgreementContingentConsiderationCashProceeds" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RleHRyZWdpb246NmY3NDZhZDk4ODlkNDMwYWE0YjIyMTQxNGM0NjFkOTVfOTAx_1878f1ce-8bb4-4e71-bb2e-bdb971dc6459">17.2</ix:nonFraction> million if the Purchasers and Curis Royalty receive aggregate royalty payments pursuant to the Oberland Purchase Agreement in excess of $<ix:nonFraction unitRef="usd" contextRef="iffa498edbc73462ba0ffcf6335f33a3b_D20190301-20190331" decimals="-5" name="cris:RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RleHRyZWdpb246NmY3NDZhZDk4ODlkNDMwYWE0YjIyMTQxNGM0NjFkOTVfMTA0MA_f6fa5328-4a66-4e6b-b60b-29224a2ff71a">18.0</ix:nonFraction> million during the calendar year 2021, subject to certain exceptions and (ii) $<ix:nonFraction unitRef="usd" contextRef="ib033bd6eec734cf1826c9d37348e3df6_D20190301-20190331" decimals="-5" name="cris:RoyaltyPurchaseAgreementContingentConsiderationCashProceeds" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RleHRyZWdpb246NmY3NDZhZDk4ODlkNDMwYWE0YjIyMTQxNGM0NjFkOTVfMTEyMQ_50f5fbf7-b479-4301-aa86-f9b6ae4b01fa">53.5</ix:nonFraction> million if the Purchasers receive payments pursuant to the Oberland Purchase Agreement in excess of $<ix:nonFraction unitRef="usd" contextRef="ib033bd6eec734cf1826c9d37348e3df6_D20190301-20190331" decimals="-5" name="cris:RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RleHRyZWdpb246NmY3NDZhZDk4ODlkNDMwYWE0YjIyMTQxNGM0NjFkOTVfMTIyNA_d0d13ddd-a0b4-4272-9931-b420a28fb130">117.0</ix:nonFraction> million on or prior to December 31, 2026.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Oberland Purchase Agreement provides that after the occurrence of an event of default as defined under the security agreement by Curis Royalty, the Purchasers shall have the option, for a period of <ix:nonNumeric contextRef="i1df2f708d5694cd7803b3b1cdb822461_D20210101-20210930" format="ixt-sec:durday" name="cris:RoyaltyPurchaseAgreementTermsPurchaserDefaultOptionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RleHRyZWdpb246NmY3NDZhZDk4ODlkNDMwYWE0YjIyMTQxNGM0NjFkOTVfMTQ3MQ_3d90b047-7ead-4f4a-a80e-d062a84d3d09">180</ix:nonNumeric> days, to require Curis Royalty to repurchase a portion of certain royalty and royalty related payments, excluding a portion of non U.S. royalties retained by Curis Royalty (the &#8220;Purchased Receivables&#8221;), at a price (the &#8220;Put/Call Price&#8221;), equal to a percentage, beginning at a low triple digit </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><ix:continuation id="id74268ee9eb24ac3a0796ea9fd8200fa"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">percentage and increasing over time up to a low mid triple digit percentage of the sum of the upfront purchase price and any portion of the milestone payments paid in a lump sum by the Purchasers, if any, minus certain payments previously received by the Purchasers with respect to the Purchased Receivables. Additionally, Curis Royalty shall have the option at any time to repurchase the Purchased Receivables at the Put/Call Price as of the date of such repurchase. No events of default existed as of September 30, 2021.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the obligation to pay future royalties to Oberland, the Company recorded the proceeds from this transaction as a liability on its Consolidated Balance Sheet that will be accounted for using the interest method over the estimated life of the Oberland Purchase Agreement. As a result, the Company imputes interest on the transaction and records imputed interest expense at the estimated interest rate. The Company's estimate of the interest rate under the agreement is based on the amount of royalty payments expected to be received by Oberland over the life of the arrangement. The projected amount of royalty payments expected to be paid to Oberland involves the use of significant estimates and assumptions with respect to the revenue growth rate in the Company's projections of sales of Erivedge. The Company periodically assesses the expected royalty payments to Curis Royalty from Genentech using a combination of historical results and forecasts from market data sources. To the extent such payments are greater or less than its initial estimates or the timing of such payments is materially different than its original estimates, the Company will adjust the amortization of the liability. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the fair value of the liability related to the sale of future royalties at the time of the Oberland Purchase Agreement to be $<ix:nonFraction unitRef="usd" contextRef="ie5375dfdc8ee412588936e837f459f29_D20190301-20190331" decimals="-5" name="cris:ProceedsFromRoyaltyPurchaseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RleHRyZWdpb246NmY3NDZhZDk4ODlkNDMwYWE0YjIyMTQxNGM0NjFkOTVfMzYyOA_8fced041-e0cf-4743-afa6-3eb7297a1999">65.0</ix:nonFraction> million, with a current effective annual imputed interest rate of <ix:nonFraction unitRef="number" contextRef="if6e3f1f585a2476fb48ab5c48b4b4c0c_D20190301-20190331" decimals="3" name="cris:RoyaltyPurchaseAgreementInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RleHRyZWdpb246NmY3NDZhZDk4ODlkNDMwYWE0YjIyMTQxNGM0NjFkOTVfMzY5Nw_35585a6c-ba1b-4da9-bfe7-cd5ceebcd24f">7.6</ix:nonFraction>%. The Company incurred $<ix:nonFraction unitRef="usd" contextRef="if6e3f1f585a2476fb48ab5c48b4b4c0c_D20190301-20190331" decimals="-5" name="cris:RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RleHRyZWdpb246NmY3NDZhZDk4ODlkNDMwYWE0YjIyMTQxNGM0NjFkOTVfMzcyMg_bfdc87fd-9b60-42f3-8d2e-fa8776a7fedd">0.6</ix:nonFraction> million of transaction costs in connection with the agreement. These transaction costs are amortized to imputed interest expense over the estimated term of the Oberland Purchase Agreement. The Company determined that the fair value assessment of the liability related to the sale of future royalties is a Level 3 assessment within the valuation hierarchy. </span></div><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="us-gaap:ScheduleOfOtherSignificantNoncashTransactionsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RleHRyZWdpb246NmY3NDZhZDk4ODlkNDMwYWE0YjIyMTQxNGM0NjFkOTVfNDIyNQ_1567163e-1b81-4945-811a-f35b22024c42" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity with respect to the liability related to the sale of future royalties during the nine months ended September 30, 2021.</span></div><div style="margin-top:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:81.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying value of liability related to the sale of future royalties at January 1, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="cris:RoyaltyPurchaseAgreementLiabilityCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RhYmxlOjU2NzUzZDI4MzFhODRjYzJiNzFmNTlkNDVlYjcwNzExL3RhYmxlcmFuZ2U6NTY3NTNkMjgzMWE4NGNjMmI3MWY1OWQ0NWViNzA3MTFfMS0xLTEtMS0x_f80bc189-e460-4892-b83b-8b72f0b967a4">58,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of capitalized issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" name="cris:RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RhYmxlOjU2NzUzZDI4MzFhODRjYzJiNzFmNTlkNDVlYjcwNzExL3RhYmxlcmFuZ2U6NTY3NTNkMjgzMWE4NGNjMmI3MWY1OWQ0NWViNzA3MTFfMi0xLTEtMS0x_62e34b0b-e3c5-4556-bb5f-42863269e05a">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imputed interest expense recognized for the nine months ending September 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="cris:RoyaltyPurchaseAgreementAccretionExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RhYmxlOjU2NzUzZDI4MzFhODRjYzJiNzFmNTlkNDVlYjcwNzExL3RhYmxlcmFuZ2U6NTY3NTNkMjgzMWE4NGNjMmI3MWY1OWQ0NWViNzA3MTFfMy0xLTEtMS0x_95e04801-1101-4cd8-9d18-b7205098e472">3,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: payments to Oberland Capital, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="cris:PaymentsOfFutureRoyaltyLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RhYmxlOjU2NzUzZDI4MzFhODRjYzJiNzFmNTlkNDVlYjcwNzExL3RhYmxlcmFuZ2U6NTY3NTNkMjgzMWE4NGNjMmI3MWY1OWQ0NWViNzA3MTFfNC0xLTEtMS0x_7659cd3f-ee32-4193-9a2f-0f45cc35d241">6,434</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying value of liability related to the sale of future royalties at September 30, 2021</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="cris:RoyaltyPurchaseAgreementLiabilityCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RhYmxlOjU2NzUzZDI4MzFhODRjYzJiNzFmNTlkNDVlYjcwNzExL3RhYmxlcmFuZ2U6NTY3NTNkMjgzMWE4NGNjMmI3MWY1OWQ0NWViNzA3MTFfNS0xLTEtMS0x_d0341fc7-149c-435b-a0ba-d041bbb0f9c1">55,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i90810bc68d594941912c6cfda631781c_58"></div><div style="margin-top:18pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfOTI0Mw_404ba629-d4af-4b67-993d-5e16edb860b4" continuedAt="ida143da8c01f4b0dbb98c61c80acd9c4" escape="true">Research and Development Collaborations</ix:nonNumeric></span></div><ix:continuation id="ida143da8c01f4b0dbb98c61c80acd9c4" continuedAt="iaaef1192a3474e99bf2a7ae461e42a95"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.91pt">Genentech</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2003, the Company licensed its proprietary Hedgehog pathway antagonist technologies to Genentech for human therapeutic use. The primary focus of the collaborative research plan has been to develop molecules that inhibit the Hedgehog pathway for the treatment of various cancers. The collaboration is currently focused on the development of Erivedge, which is being commercialized by Genentech in the U.S. and by Genentech&#8217;s parent company, Roche, in several other countries for the treatment of advanced BCC. Pursuant to the agreement, the Company is eligible to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i6a3b34007b0a4945b84b16df5abc4a37_I20030630" decimals="-5" name="cris:CollaborationAgreementContingentConsiderationPotentialCashPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfNjYz_9aae107f-7929-46f4-aa4a-41907a479cf5">115.0</ix:nonFraction> million in contingent cash milestone payments, exclusive of royalty payments, in connection with the development of Erivedge or another small molecule Hedgehog pathway inhibitor, assuming the successful achievement by Genentech and Roche of specified clinical development and regulatory objectives. Of this amount, the Company has received $<ix:nonFraction unitRef="usd" contextRef="id3a04e3a472f4d30b82d08fe43d2c0b7_I20210930" decimals="-5" name="cris:CollaborationAgreementContingentConsiderationReceivedFromPartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMTAwNg_583711c2-d78e-4113-8625-a770d6d81f04">59.0</ix:nonFraction> million in cash milestone payments as of September 30, 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to these payments and pursuant to the collaboration agreement, the Company is entitled to a royalty on net sales of Erivedge that ranges from <ix:nonFraction unitRef="number" contextRef="i481f7ee4adb0442a9066ccee54707fa3_D20030601-20030630" decimals="INF" name="cris:PercentageOfRoyaltyOnNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMTIwOA_d5e05f35-160b-4d30-a655-db0b70338166">5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i1554d4e73abd4dabac3fe396586aa6c2_D20030601-20030630" decimals="INF" name="cris:PercentageOfRoyaltyOnNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMTIxNA_45209173-a348-49fd-ae79-cf173bd24e45">7.5</ix:nonFraction>%. The royalty rate applicable to Erivedge may be decreased by <ix:nonFraction unitRef="number" contextRef="ic26067fcb23449e68eba5cd92cb0a49e_D20030601-20030630" decimals="INF" name="cris:ReducedRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMTI3OA_7adb0cb5-1c7a-43e6-8b86-14fc7442cd1a">2</ix:nonFraction>% on a country-by-country basis in certain specified circumstances.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $<ix:nonFraction unitRef="usd" contextRef="ia877710393f94f3f8c7e7cd08300f3eb_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMTM3MA_b4b8b059-d554-4fca-b254-77b0237abfc9">3.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ied01dcd8f0fb415ba2f14add0c9df964_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMTM4NQ_9c303bf0-b621-4baf-8dde-a95148173b1e">2.7</ix:nonFraction> million in royalty revenue under the Genentech collaboration during the three months ended September 30, 2021 and 2020, respectively. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i6bffc8f5f047450b936f6e0e45ee38ee_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMTUyNA_f8254152-2384-4b2d-8c75-39dca34cfc86">7.6</ix:nonFraction> million in royalty revenue under the Genentech collaboration during the nine months ended September 30, 2021 and $<ix:nonFraction unitRef="usd" contextRef="i867de25d3dc74fc8a9604601d285b12c_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMTYyMg_07bfa0d9-866b-4d62-b18e-c820e822cab8">7.7</ix:nonFraction> million during the nine months ended September 30, 2020. The Company also recorded costs of royalty revenues within the costs and expenses section of its Condensed Consolidated Statements of Operations and Comprehensive Loss of $<ix:nonFraction unitRef="usd" contextRef="i6f251344683f457e89a14215c76f8256_D20210701-20210930" decimals="-5" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMTgzNg_02dd88ee-2b63-4a1a-bbad-417aac60b1d7">0.2</ix:nonFraction> million during the three months ended September 30, 2021 and $<ix:nonFraction unitRef="usd" contextRef="if18f2dacb57041919fa0284b6d6a3fd4_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMjE5OTAyMzI2NzE2Nw_3b14ead0-9ef7-481e-85b8-09385a48c811">0.1</ix:nonFraction>&#160;million during the three months ended September 30, 2020. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="i46169f75ca7f4f9db86ac1e7a209d5bf_D20210101-20210930" decimals="-5" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMTkwNg_a06cd634-564f-4943-a666-56dade36472a"><ix:nonFraction unitRef="usd" contextRef="i79ee3f9f0f4d480d8caee067d86e3ca8_D20200101-20200930" decimals="-5" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMTkwNg_ec8c15f7-4ddb-479a-8f35-b2e00c9d71f7">0.4</ix:nonFraction></ix:nonFraction> million of costs of royalty revenues during the nine months ended September 30, 2021 and 2020. Cost of royalty revenues comprises <ix:nonFraction unitRef="number" contextRef="if99565915c7247d696c1777c7a44e409_I20200930" decimals="2" name="cris:RoyaltyRatePercentageOfSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMjAxOQ_a7b55434-f4ca-4be7-83f6-038b34924d64">5</ix:nonFraction>% of the royalty payments that Curis Royalty receives from Genentech, through February 2022, which the Company is obligated to pay to university licensors. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:22.5pt"><span><br/></span></div><ix:continuation id="iaaef1192a3474e99bf2a7ae461e42a95" continuedAt="ic25611ca064e4f4d8a4a38e3a7dfb64a"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded receivables from Genentech under this collaboration, comprised primarily of Erivedge royalties earned in the first half of 2021 and 2020. The receivable recorded in the Company's current assets section of its Condensed Consolidated Balance Sheets amounted to $<ix:nonFraction unitRef="usd" contextRef="id3a04e3a472f4d30b82d08fe43d2c0b7_I20210930" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMjg5OA_43d4bcf8-d1ca-434a-b074-c8d9d90ee804"><ix:nonFraction unitRef="usd" contextRef="i5a557708fb604f12961074aec6ae2ddc_I20201231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMjg5OA_f7c9e651-21f7-4012-8019-9dd385ee6c82">3.0</ix:nonFraction></ix:nonFraction> million as of September 30, 2021 and December 31, 2020, respectively. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed in Note 8, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liability Related to the Sale of Future Royalties,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a portion of royalty revenues received from Genentech on net sales of Erivedge will be paid to the Purchasers pursuant to the Oberland Purchase Agreement.</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.34pt">Aurigene</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2015, the Company entered into an exclusive collaboration agreement with Aurigene for the discovery, development and commercialization of small molecule compounds in the areas of immuno-oncology and selected precision oncology targets, which was amended in September 2016. Under the collaboration agreement, Aurigene granted the Company an option to obtain exclusive, royalty-bearing licenses to relevant Aurigene technology to develop, manufacture and commercialize products containing certain of such compounds anywhere in the world, except for India and Russia, which are territories retained by Aurigene. In February 2020, the collaboration agreement was further amended whereby Aurigene received rights to develop and commercialize CA-170 in Asia in addition to its existing rights in India and Russia, and the Company became entitled to receive royalty payments on potential future sales of CA-170 in Asia at percentage rates ranging from the high single digits up to <ix:nonFraction unitRef="number" contextRef="ia3409ba719834a2f9e98876189a4ceb1_I20200229" decimals="INF" name="cris:CollaborationAgreementTermsPercentageOfRoyaltyFeesReceivable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfNDIwNA_cb643c4c-dc60-4b6f-8e19-a49aad2b1240">10</ix:nonFraction>% subject to specified reductions.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, the Company has exercised its option to license the following <ix:nonFraction unitRef="program" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="cris:CollaborationAgreementNumberofProgramsLicensed" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfNDMxMg_eff6dcd9-54eb-4422-8125-fea59043e94d">four</ix:nonFraction> programs under the collaboration:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">IRAK4 Program - a precision oncology program of small molecule inhibitors of IRAK4. The development candidate is CA-4948, an orally available small molecule inhibitor of IRAK4.</span></div><div style="padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">PD1/VISTA Program - an immuno-oncology program of small molecule antagonists of PD1 and VISTA immune checkpoint pathways. The development candidate is CA-170, an orally available small molecule antagonist of VISTA and PDL1.</span></div><div style="padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">PD1/TIM3 Program - an immuno-oncology program of small molecule antagonists of PD1 and TIM3 immune checkpoint pathways. The development candidate is CA-327, an orally available small molecule antagonist of PDL1 and TIM3.</span></div><div style="padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">In March 2018, the Company exercised its option to license a fourth program, which is an immuno-oncology program.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since January 2015, the Company has paid $<ix:nonFraction unitRef="usd" contextRef="i4bcee2e8132f40f29d06994aa69d5c75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="cris:PaymentsforCollaborativeArrangementstoDate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfNTEyNw_3eb86b75-16d1-4d81-8596-cd4b7aa2ebf8">14.5</ix:nonFraction>&#160;million in research payments and Aurigene has waived $<ix:nonFraction unitRef="usd" contextRef="i460702ed242d4892b13fa83e2f82d10c_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="cris:MilestonePaymentsWaivedToDate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfNTE3NQ_b05a2a9b-ac1f-4beb-9539-a141e1fa088b">19.5</ix:nonFraction>&#160;million in milestone payments. For each of the IRAK4, PD1/VISTA, and PD1/TIM3 programs, and the fourth immuno-oncology program: the Company has remaining unpaid or unwaived payment obligations of $<ix:nonFraction unitRef="usd" contextRef="i55779509759a4442aa49e025489ef439_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfNTM2Ng_7f8d57a9-bd14-4e7a-8249-6eb077c12104">42.5</ix:nonFraction>&#160;million per program, related to regulatory approval and commercial sales milestones, plus specified additional payments for approvals for additional indications, if any. The Company is further obligated to pay Aurigene tiered royalties on the Company's and its affiliates' annual net sales of products at percentage rates ranging from the high single digits up to <ix:nonFraction unitRef="number" contextRef="ia3409ba719834a2f9e98876189a4ceb1_I20200229" decimals="INF" name="cris:CollaborationAgreementTermsPercentageOfRoyaltyFeesReceivable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfNTcyNQ_d5b40a80-1077-4eab-9a0d-2d7d6c35cf8f">10</ix:nonFraction>%, subject to specified reductions. In addition, the Company agreed to make certain payments to Aurigene upon its entry into sublicense agreements on any program(s).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the collaboration agreement, the Company has entered into a master development and manufacturing agreement with Aurigene for the supply of drug substance and drug product. Under this agreement, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="i1b4c90b7e43448599c53fc40d6662bc3_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="cris:CollaborativeArrangementPaymentsAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMjc0ODc3OTA3OTA4NA_de279dfa-bc5a-4a6d-916d-31ec787aa4be">0.5</ix:nonFraction>&#160;million in research and development expense during the three months ended September 30, 2021 and $<ix:nonFraction unitRef="usd" contextRef="ib8625a7feacd4c3f8ea2bbf25583364c_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="cris:CollaborativeArrangementPaymentsAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMjc0ODc3OTA3OTA2NQ_efa2f44c-f132-4113-8139-133873876ffd">1.2</ix:nonFraction>&#160;million during the nine months ended September 30, 2021. The Company recorded less than $<ix:nonFraction unitRef="usd" contextRef="if724acf7f886498f936922f1b813133c_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMjc0ODc3OTA3OTA0Ng_c72fcc1e-a24a-4ad7-90ee-9df3bfd87754">0.1</ix:nonFraction>&#160;million in prepaid expenses and $<ix:nonFraction unitRef="usd" contextRef="if724acf7f886498f936922f1b813133c_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMjc0ODc3OTA3OTE1MA_192c521d-8515-40d6-b3c2-7087821f843f">0.9</ix:nonFraction>&#160;million in accrued expenses as of September 30, 2021 associated with this agreement.  The Company expensed $<ix:nonFraction unitRef="usd" contextRef="i1233820bbb0f46f1ae495b371f0da3a3_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="cris:CollaborationAgreementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMjc0ODc3OTA3ODk5Ng_9550a1ac-d945-48f3-8d81-ea2e47180ff4">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0c0e449c262a4c9fb7ac84a67ca508ed_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="cris:CollaborationAgreementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMjc0ODc3OTA3OTAxMA_fc617641-6392-4ee0-a1be-2f1a77884ecf">0.8</ix:nonFraction>&#160;million related to Aurigene for the three and nine month periods ended September 30, 2020, respectively. </span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.91pt">ImmuNext</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into an option and license agreement with ImmuNext (the &#8220;ImmuNext Agreement&#8221;). Under the terms of the ImmuNext Agreement, the Company agreed to engage in a collaborative effort with ImmuNext, and to conduct a Phase 1 clinical trial of CI-8993. In exchange, ImmuNext granted the Company an exclusive option, exercisable until the earlier of January 2024 or (b) 90 days after database lock for the first Phase 1 trial in which the endpoints are satisfied (the &#8220;Option Period&#8221;), to obtain an exclusive, worldwide license to develop and commercialize certain VISTA antagonizing compounds and products containing these compounds in the field of oncology.  </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the Option Period, the Company is obligated to pay a semi-annual fee of $<ix:nonFraction unitRef="usd" contextRef="i2553b5bece3047dca87c108aef6cfd51_I20210930" decimals="-5" name="cris:CollaborationArrangementSemiAnnualMaintenanceFeePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfNzE5Mw_e3f740e2-8346-40dd-83f2-2bfbbf2106a5">0.4</ix:nonFraction> million to ImmuNext and will conduct the Phase 1 trial, and ImmuNext will conduct certain agreed upon non-clinical research activities to support the Phase 1 trial. Additionally, the Company will assign to ImmuNext all right, title and interest in and to, inventions made by the Company alone or jointly with ImmuNext in conducting clinical and non-clinical activities under the ImmuNext Agreement and any </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><ix:continuation id="ic25611ca064e4f4d8a4a38e3a7dfb64a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patent rights covering those inventions. If the option is exercised, ImmuNext will assign to the Company (i) all such inventions that were made solely by the Company and any patent rights covering those inventions that were assigned by the Company to ImmuNext during the Option Period and (ii) a joint ownership interest in all such inventions that were made jointly by the Company and ImmuNext and patent rights covering those inventions that were assigned by the Company to ImmuNext during the Option Period, except for any of those inventions that relates to certain compounds to which ImmuNext has retained exclusive rights. In addition, the Company has agreed to reimburse ImmuNext for certain documented external costs and expenses incurred by ImmuNext in carrying out non-clinical research activities approved by the joint steering committee, up to $<ix:nonFraction unitRef="usd" contextRef="iae8e02ce92e14a61a403e503c35b7dd3_I20210930" decimals="-5" name="cris:CollaborationArrangementContingentConsiderationReimbursableExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfODQ1OA_e565f10d-025c-4206-9685-8d72b9378d1d">0.3</ix:nonFraction> million per calendar year, unless otherwise agreed to by both parties in writing. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company elects to exercise the option, the Company has agreed to pay to ImmuNext an option exercise fee of $<ix:nonFraction unitRef="usd" contextRef="iae8e02ce92e14a61a403e503c35b7dd3_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="cris:CollaborationArrangementContingentConsiderationOptionExerciseFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMTA5OTUxMTYzOTI2OA_d28bae55-f638-42fa-8d03-26c95f709996">20.0</ix:nonFraction>&#160;million. ImmuNext will be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="iae8e02ce92e14a61a403e503c35b7dd3_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="cris:CollaborationArrangementContingentConsiderationDevelopmentMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfODU4Nw_ca2a67b5-7906-4d04-b526-e075384545f2">4.6</ix:nonFraction>&#160;million in potential development milestones, up to $<ix:nonFraction unitRef="usd" contextRef="iae8e02ce92e14a61a403e503c35b7dd3_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="cris:CollaborationArrangementContingentConsiderationRegulatoryApprovalMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfODYzMw_db473a59-1e07-4e13-b066-e34880db1fa4">84.3</ix:nonFraction>&#160;million in potential regulatory approval milestones, and up to $<ix:nonFraction unitRef="usd" contextRef="iae8e02ce92e14a61a403e503c35b7dd3_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="cris:CollaborationArrangementContingentConsiderationSalesMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfODY5MQ_5050f6da-f5ab-4f59-9e3d-272f44a0a597">125.0</ix:nonFraction>&#160;million in potential sales milestone payments from us. ImmuNext is also eligible to receive tiered royalties on annual net sales on a product-by-product and country-by-country basis, at percentage rates ranging from high single digits to low double digits, subject to specified adjustments. In addition, the Company has agreed to pay ImmuNext a low double-digit percentage of sublicense revenue received by the Company or its affiliates.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:22.5pt"><span><br/></span></div><div id="i90810bc68d594941912c6cfda631781c_61"></div><div style="margin-top:10pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNzgwMQ_dc64daea-24f6-4959-8d99-9086aa7a9db6" continuedAt="i6df04965b98d46b7893575692ffa1034" escape="true">Common Stock</ix:nonNumeric></span></div><ix:continuation id="i6df04965b98d46b7893575692ffa1034" continuedAt="iab942c274b0741dd890b2f90a62fb612"><div style="margin-top:6pt;padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.84pt">Charter Amendments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2020, the Company's stockholders approved an increase to the number of authorized shares of its common stock from <ix:nonFraction unitRef="shares" contextRef="i6e2324829cfe492bb1ce3a18540cabae_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMTY2_3468e8ca-bee8-4053-a373-043130aa3498">101,250,000</ix:nonFraction> shares to <ix:nonFraction unitRef="shares" contextRef="i5e926263e5b843dba11e03bf2ac934c5_I20210531" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMTA5OTUxMTYzNTU4OA_3246de2e-9dbb-4766-9769-42360b4d90e1">151,875,000</ix:nonFraction> shares. The Company filed an amendment to its certificate of incorporation in June 2020 to effect such increase.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company's stockholders approved an increase to the number of authorized shares of its common stock from <ix:nonFraction unitRef="shares" contextRef="i5e926263e5b843dba11e03bf2ac934c5_I20210531" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNDE2_0c7a8022-2bff-42b5-b3e9-9f4582be2c37">151,875,000</ix:nonFraction> shares to <ix:nonFraction unitRef="shares" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNDI5_dd59d4c0-0e85-4b47-88fb-d1bafb55e3f3">227,812,500</ix:nonFraction> shares. The Company filed an amendment to its certificate of incorporation in May 2021 to effect such increase.</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.84pt">2021 Sales Agreement with Cantor Fitzgerald &amp; Co. and JonesTrading Institutional Services LLC</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company entered into a sales agreement (the &#8220;2021 Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co., or Cantor, and JonesTrading Institutional Services LLC , or JonesTrading, to sell from time to time up to $<ix:nonFraction unitRef="usd" contextRef="i389b853ef28c48bfb67d977144cea2be_I20210331" decimals="INF" format="ixt:num-dot-decimal" name="cris:StockSaleAgreementAuthorizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfODYx_dc94ee37-342b-4a30-921f-4a36d07237e3">100.0</ix:nonFraction>&#160;million of the Company&#8217;s common stock through an &#8220;at the market offering&#8221; program under which Cantor and JonesTrading act as sales agents. Subject to the terms and conditions of the 2021 Sales Agreement, Cantor and JonesTrading can sell the common stock by any method deemed to be an &#8220;at-the-market&#8221; offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the 2021 Sales Agreement, the aggregate compensation payable to each of Cantor and JonesTrading is <ix:nonFraction unitRef="number" contextRef="i13cd005f3b784a00a03427270ff13a4e_I20210316" decimals="2" name="cris:StockSaleAgreementCompensationFeePercentageOfGrossProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMTM5NA_8f971f49-4319-4492-a177-e67081aa92e0">3</ix:nonFraction>% of the gross proceeds from sales of the common stock sold by Cantor or JonesTrading, as applicable. Each party agreed in the 2021 Sales Agreement to provide indemnification and contribution against certain liabilities, including liabilities under the Securities Act, subject to the terms of the 2021 Sales Agreement. To date, the Company has not made any sales of common stock pursuant to the 2021 Sales Agreement.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The securities in this transaction were offered pursuant to an automatic shelf registration statement on Form S-3ASR (File No. 333-254362) that was filed with the SEC on March 16, 2021.</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.41pt">2020 Public Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company completed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="i1d46809b9cf44e11972741a203406eb1_D20201201-20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMjA5NQ_f8c2a95c-2fb2-4b51-bb6e-70c04502a0f1">29,500,000</ix:nonFraction> shares of the Company's common stock, including <ix:nonFraction unitRef="shares" contextRef="ib2634e1ed79549308ba035250ef761a1_D20201201-20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMjE0Ng_0017ce37-abf8-4179-acb1-5ac583282c7d">3,847,826</ix:nonFraction> shares issued and sold to the underwriters upon the exercise in full of their option to purchase additional shares, at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i005697a4b0824bddb4df769ee739b32c_I20201231" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMjI3OQ_cfb81304-2e1f-4f07-81dd-b46a9162214c">5.75</ix:nonFraction> per share, for aggregate gross proceeds of  $<ix:nonFraction unitRef="usd" contextRef="i531d173b436149d0977c73c89cfa4e0b_D20201201-20201231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMjMyNg_9c7e2027-1c81-4554-82e6-4f450644bb9b">169.6</ix:nonFraction>  million, before deducting underwriting discounts and commissions and other offering expenses of $<ix:nonFraction unitRef="usd" contextRef="i531d173b436149d0977c73c89cfa4e0b_D20201201-20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMjQyNg_76b59f1d-d43e-49c2-a070-5f1c2d5f956e">10.2</ix:nonFraction>&#160;million. The securities in this transaction were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-224627) that was filed with the SEC on May 3, 2018 and declared effective by the SEC on May 17, 2018 and an additional registration statement on Form S-3 (File No. 333-251211) filed pursuant to Rule 462(b) which became automatically effective on December 9, 2020.</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.84pt">2020 Registered Direct Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><ix:continuation id="iab942c274b0741dd890b2f90a62fb612" continuedAt="i9198112c8dfb416f9bbf05bf0d4daffb"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into a securities purchase agreement with certain institutional investors, pursuant to which the Company issued and sold, in a registered direct offering, an aggregate of <ix:nonFraction unitRef="shares" contextRef="i0104cbc441b344aa8d7670c779cd19fc_D20200601-20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMzA0OQ_e7501006-7154-4347-bb7e-d96446f41811">14,000,000</ix:nonFraction> shares of the Company's common stock at a purchase price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="if2e46877fa284075af8f8cd02a331c87_I20200630" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMzEyMg_a00c3f42-1bac-4964-910c-df450250c1f7">1.25</ix:nonFraction>, for aggregate gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="ia64c5dfac95a49f2be056702512a4950_D20200601-20200630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMzE1OA_07567581-7926-46e4-8b48-bdf3ef28ee54">17.5</ix:nonFraction>&#160;million, before deducting fees of approximately $<ix:nonFraction unitRef="usd" contextRef="ia64c5dfac95a49f2be056702512a4950_D20200601-20200630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMzIwMQ_9cff5a69-cfa9-44ed-a4b6-fe65c47f56b8">1.0</ix:nonFraction>&#160;million paid to the placement agent and other estimated offering expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="ia64c5dfac95a49f2be056702512a4950_D20200601-20200630" decimals="-5" format="ixt:num-dot-decimal" name="cris:SaleOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMzI4Nw_1230d2fd-01f4-4884-80e2-e4b7e0875d7a">0.5</ix:nonFraction>&#160;million paid by the Company. JonesTrading acted as the exclusive placement agent for the transaction, and the shares were offered by the Company pursuant to its universal shelf registration statement on Form S-3, which was filed with the SEC on May 3, 2018 and declared effective by the SEC on May 17, 2018 (File No. 333-224627), and a prospectus supplement thereunder. </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.41pt">2020 Sales Agreement with JonesTrading Institutional Services LLC</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Company entered into a Capital on Demand&#8482; Sales Agreement (the &#8220;Sales Agreement&#8221;) with JonesTrading to sell from time to time up to $<ix:nonFraction unitRef="usd" contextRef="ic9dc8759604c4487a95552d9277d2945_I20200331" decimals="INF" format="ixt:num-dot-decimal" name="cris:StockSaleAgreementAuthorizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMzg3MA_b881a25d-d7bf-47cd-8412-874ead3a0c0a">30.0</ix:nonFraction> million of the Company&#8217;s common stock through an &#8220;at-the-market&#8221; equity offering program under which JonesTrading acted as sales agent. Subject to the terms and conditions of the Sales Agreement, JonesTrading could sell the common stock by any method deemed to be an &#8220;at-the-market&#8221; offering as defined in Rule 415 promulgated under the Securities Act, including sales made directly on the Nasdaq Global Market, on any other existing trading market for the common stock or to or through a market maker other than on an exchange. In addition, with the Company&#8217;s prior written approval, JonesTrading could also sell the common stock by any other method permitted by law, including in privately negotiated transactions. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Sales Agreement, the aggregate compensation payable to JonesTrading was <ix:nonFraction unitRef="number" contextRef="ib4c44bc6307042429eb5deaab3627f34_I20200304" decimals="INF" name="cris:StockSaleAgreementCompensationFeePercentageOfGrossProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNDY4NA_49ecf27b-bec5-4b0c-b281-d3810c1344f1">3</ix:nonFraction>% of the gross proceeds from sales of the common stock sold by JonesTrading pursuant to the Sales Agreement. Each party agreed in the Sales Agreement to provide indemnification and contribution against certain liabilities, including liabilities under the Securities Act, subject to the terms of the Sales Agreement.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company terminated this sales agreement effective as of December 9, 2020. The Company did not incur any termination penalties as a result of the termination. As of the effective date of the termination of the Sales Agreement, the Company had sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="ia614167954ff4147a511fd404c79e22a_D20201209-20201209" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNTI2OA_7c3f0d33-1fea-4c69-a98c-5f0c3447e59e">6,298,648</ix:nonFraction> shares of common stock under the sales agreement for aggregate gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="ia614167954ff4147a511fd404c79e22a_D20201209-20201209" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNTM1Mg_17baff2d-acd4-4ca9-8ce6-99c606f5787e">8.3</ix:nonFraction>&#160;million and net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ia614167954ff4147a511fd404c79e22a_D20201209-20201209" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNTM3NQ_77d42805-b29f-4f28-894a-d60abe04fe64">7.9</ix:nonFraction>&#160;million after deducting commissions and offering expenses. The $<ix:nonFraction unitRef="usd" contextRef="i4f43d279bfc346499189eea5974d7564_I20201209" decimals="-5" format="ixt:num-dot-decimal" name="cris:StockPurchaseProgramRemainingAuthorizedPurchaseAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNTQzMw_a0877f74-824f-4408-9cdc-fb8551272e3b">21.7</ix:nonFraction> million of common stock that remained unsold at the time of termination is no longer available.</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.07pt">Aspire Capital Fund LLC</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the Company entered into a common stock purchase agreement (the &#8220;Agreement&#8221;) with Aspire Capital Fund, LLC (&#8220;Aspire Capital&#8221;) for the sale of up to $<ix:nonFraction unitRef="usd" contextRef="i59313702068b4ee9a458942cc6de5f0a_I20200229" decimals="INF" format="ixt:num-dot-decimal" name="cris:StockPurchaseProgramAuthorizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNTcxNA_567cabf0-fb56-42a8-90c2-189d27a84a76">30.0</ix:nonFraction> million of the Company's common stock. Under the terms of the Agreement, Aspire Capital has committed to purchase such shares of the Company's common stock at the Company&#8217;s request, from time to time during a <ix:nonNumeric contextRef="ia4d61c5f1c1a4c7b8b490d4990b8c9a1_D20200201-20200229" format="ixt-sec:durmonth" name="cris:StockPurchaseProgramPricePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNTkxOA_58a03e0e-1f37-4b2a-a5a0-df80be4307d3">30</ix:nonNumeric>-month period at prices based on the market price at the time of each sale, subject to specified terms and limitations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aspire Capital made an initial investment of $<ix:nonFraction unitRef="usd" contextRef="i7e2fb16ab10247c7bb59f0e0bb3f5e91_D20200226-20200226" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNjA4NQ_c101d218-b59e-447a-a04f-b786ec039118">3.0</ix:nonFraction> million through the purchase of <ix:nonFraction unitRef="shares" contextRef="i7e2fb16ab10247c7bb59f0e0bb3f5e91_D20200226-20200226" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNjExMg_8b82d137-1e0c-4190-a843-b051c2eb00ab">2,693,965</ix:nonFraction> shares of the Company's common stock.  In 2020, Aspire Capital subsequently purchased an additional <ix:nonFraction unitRef="shares" contextRef="i509ac601c8cb4988976c395f2c180da2_D20200101-20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNjIxNQ_efef643f-a72e-4562-9015-7db6d38cdc9f">4,650,000</ix:nonFraction> shares of the Company's common stock for $<ix:nonFraction unitRef="usd" contextRef="i3e79259145d846dfb9168818ded77f22_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNjI1OQ_6373e28a-e24a-4ba4-ae6b-bebe84d4d165">5.4</ix:nonFraction> million.  In addition, as consideration for Aspire Capital&#8217;s obligation under the Agreement, the Company issued <ix:nonFraction unitRef="shares" contextRef="i6e1d7b28e07045f8b69914b45905559b_I20200226" decimals="INF" format="ixt:num-dot-decimal" name="cris:StockPurchaseProgramCommitmentFeeShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNjM2Ng_4a9f1d52-14ba-4688-b0ef-4b9920845579">646,551</ix:nonFraction> shares of common stock to Aspire Capital as a commitment fee.  As of September 30, 2021 and December 31, 2020, a total of $<ix:nonFraction unitRef="usd" contextRef="icd185c48c5a14633a53cc897fedfc27f_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="cris:StockSaleAgreementRemainingAuthorizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNjQ2MA_54f2ca5a-7585-4401-8d1a-306019a58678"><ix:nonFraction unitRef="usd" contextRef="ic667076e7a4a430c82568988e947ba95_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="cris:StockSaleAgreementRemainingAuthorizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNjQ2MA_c9984850-c970-4525-80c6-b038c28835f6">21.6</ix:nonFraction></ix:nonFraction>&#160;million remained available under the Agreement. The Company did not sell shares of common stock under the Agreement during the three and nine months ended September 30, 2021. For the three months ended September 30, 2020, <ix:nonFraction unitRef="shares" contextRef="i298a95e35ee2477b900f65f112daddfd_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMjc0ODc3OTA3Nzg2OA_735e8ccb-97e7-47c2-88cd-c7e549829b01">3,600,000</ix:nonFraction> shares were sold representing net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i298a95e35ee2477b900f65f112daddfd_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMjc0ODc3OTA3Nzg3OQ_878468c7-78b5-4baa-bb17-20e17c5365f7">4.2</ix:nonFraction>&#160;million. For the nine months ended September 30, 2020, <ix:nonFraction unitRef="shares" contextRef="i8feff43f83394d56b56b4cc6fe8050aa_D20200101-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMjc0ODc3OTA3NzkwNw_ff4f212b-889a-4498-9b65-b5a5bd7d3f6a">6,293,965</ix:nonFraction> shares were sold representing net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i8feff43f83394d56b56b4cc6fe8050aa_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMjc0ODc3OTA3Nzg5Mw_a693ea9a-6014-4d0c-8127-aaa9eecc49e6">6.8</ix:nonFraction>&#160;million. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Agreement, the Company has the right to sell up to <ix:nonFraction unitRef="shares" contextRef="icd185c48c5a14633a53cc897fedfc27f_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="cris:StockPurchaseProgramTermsSharesAuthorizedPerDay" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNjgxMA_6377aaff-b2e2-4247-acba-0bb8531b12ec">150,000</ix:nonFraction> shares of common stock per day to Aspire Capital, which total may be increased by mutual agreement up to an additional <ix:nonFraction unitRef="shares" contextRef="icd185c48c5a14633a53cc897fedfc27f_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="cris:StockPurchaseProgramTermsSharesAuthorizedPerDayAfterMutualAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNjkzMg_d5100c3f-f708-4776-bdc3-c43f2cb43394">2,000,000</ix:nonFraction> shares per day. The extent to which the Company relies on Aspire Capital as a source of funding will depend on a number of factors, including the prevailing market price of its common stock and the extent to which it is able to secure working capital from other sources.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no warrants, derivatives, or other share classes associated with this Agreement. The Company will control the timing and amount of the further sale of its common stock to Aspire Capital. There are no restrictions on future financings and there are no financial covenants, participation rights, rights of first refusal, or penalties in the Agreement. The Company has the right to terminate the Agreement at any time without any additional cost or penalty.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9198112c8dfb416f9bbf05bf0d4daffb">The Company also entered into a Registration Rights Agreement with Aspire Capital in connection with its entry into the Agreement.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i90810bc68d594941912c6cfda631781c_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNjU2OA_0b3b6c1a-16a6-4364-bedb-879424593329" continuedAt="i0be2bd05fbd845779a599d2ab4178cbb" escape="true">Stock Plans and Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i0be2bd05fbd845779a599d2ab4178cbb" continuedAt="ie047e6ec060f440f972cb753e74e3382"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, the Company had <ix:nonFraction unitRef="plan" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="cris:ShareBasedCompensationPlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNzc_7edb5c10-30db-42ad-93c5-6f2a42bb339d">two</ix:nonFraction> shareholder-approved, stock-based compensation plans: (i) the Amended and Restated 2010 Employee Stock Purchase Plan (&#8220;ESPP&#8221;), adopted by the Board of Directors in April 2017 and approved by shareholders in June 2017, and (ii)&#160;the Fourth Amended and Restated 2010 Stock Incentive Plan (&#8220;2010 Plan&#8221;). New employees are typically issued options as an inducement equity award under Nasdaq Listing Rule 5635(c)(4) outside of the 2010 Plan.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Fourth Amended and Restated 2010 Stock Incentive Plan</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2010 Plan permits the granting of incentive and non-qualified stock options and stock awards to employees, officers, directors, and consultants of the Company and its subsidiaries at prices determined by the Company&#8217;s Board of Directors.  In May 2021, the Company's shareholders approved the Company's Fourth Amended and Restated 2010 Stock Incentive Plan to reserve an additional <ix:nonFraction unitRef="shares" contextRef="id1737ae1a00346e48a3f3c4d2b81c90d_D20210501-20210531" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfOTU5_d1ce1c0f-e33d-4497-9df6-ef65be086e9e">11,000,000</ix:nonFraction> shares of common stock for issuance under the 2010 Plan. The Company can issue up to <ix:nonFraction unitRef="shares" contextRef="i8f5c7a7ab0a4454988d74c383e8d95c1_I20210531" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMTA0Nw_330e6da1-728f-4297-ae8e-fd514eca09b5">23,190,000</ix:nonFraction> shares of its common stock pursuant to awards granted under the 2010 Plan. Options become exercisable as determined by the Board of Directors and expire up to <ix:nonNumeric contextRef="iec9ed577995e4041bf1893f19ed4df11_D20210501-20210531" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMTIwOQ_157dd6a2-70f0-4f4c-8fca-7782f88f10d9">ten years</ix:nonNumeric> from the date of grant. The 2010 Plan uses a &#8220;fungible share&#8221; concept under which each share of stock subject to awards granted as options and stock appreciation rights (&#8220;SARs&#8221;), will cause <ix:nonFraction unitRef="usdPerShare" contextRef="iec9ed577995e4041bf1893f19ed4df11_D20210501-20210531" decimals="INF" format="ixt-sec:numwordsen" name="cris:SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMTQwMg_f16a1497-9470-4472-b820-0903660acd4f">one</ix:nonFraction> share per share under the award to be removed from the available share pool, while each share of stock subject to awards granted as restricted stock, restricted stock units, other stock-based awards or performance awards where the price charged for the award is less than <ix:nonFraction unitRef="number" contextRef="i5d9cc7f517654e6a955f1150754f9212_D20210501-20210531" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMTY3Nw_12ee6bc3-a97a-4c42-8426-3927bfc2002d">100</ix:nonFraction>% of the fair market value of the Company&#8217;s common stock will cause <ix:nonFraction unitRef="usdPerShare" contextRef="i5d9cc7f517654e6a955f1150754f9212_D20210501-20210531" decimals="1" name="cris:SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMTc0Ng_a796e436-c3c1-4a32-be0a-4190b30c9ee9">1.3</ix:nonFraction> shares per share under the award to be removed from the available share pool. As of September 30, 2021 the Company has only granted options to purchase shares of the Company&#8217;s common stock with an exercise price equal to the closing market price of the Company&#8217;s common stock on the Nasdaq Global Market on the grant date. As of September 30, 2021, <ix:nonFraction unitRef="shares" contextRef="i9f1f0ba40401473facc35d4c0efc7dbc_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="cris:NumberOfSharesAwardedUnderStockValueLessThanSpecificPercentageOfFairMarketValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMjA2Ng_34927b51-2fec-442a-832a-2740119576e6">13,595,840</ix:nonFraction> shares remained available for grant under the 2010 Plan.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, the Company&#8217;s board of directors granted options to purchase <ix:nonFraction unitRef="shares" contextRef="i1219b3d01e7b42a58ca53018ecff778b_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMjIzMg_fb1f1660-8622-49d9-8b50-c08cc4068976">1,086,000</ix:nonFraction> shares of the Company&#8217;s common stock to the officers and employees of the Company, under the 2010 Plan. Shares granted to officers and employees vest as to <ix:nonFraction unitRef="number" contextRef="ib8de22fdc1364771a9ce096bd4828f96_D20210101-20210930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMjM5MQ_53d1865c-4298-4fed-adad-8c0126b7a9c4">25</ix:nonFraction>% of the shares underlying the award on the first anniversary of the grant date and as to an additional <ix:nonFraction unitRef="number" contextRef="ic13e507f88684f5ca74c1614332fef14_D20210101-20210930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMjQ5Ng_e36f825c-53e5-4a38-881c-3a6f7867d2d2">6.25</ix:nonFraction>% of the shares underlying the award at the end of each subsequent quarter, based upon continued employment over a <ix:nonNumeric contextRef="i07e1ce19861a4ae59be352c43fd153c5_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNjU1NA_4f807826-1b9d-4e6e-a616-43e3431ae79b">four year</ix:nonNumeric> period, and are exercisable at a price equal to the closing price of the Company&#8217;s common stock on the Nasdaq Global Market on the grant date. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2021, the Company&#8217;s board of directors granted options to its non-employee directors to purchase <ix:nonFraction unitRef="shares" contextRef="i9e4ba76c11bd4f45b6687b17d856c8d6_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMjg5MA_fe00b2f7-0f94-4e8f-b4d8-e3e3a90b7a4f">132,000</ix:nonFraction> shares of common stock under the 2010 Plan, which will vest and become exercisable <ix:nonNumeric contextRef="i9e4ba76c11bd4f45b6687b17d856c8d6_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNjU0OA_5cfd8271-ad4c-44f2-83dc-2ce8e74489e7">one year</ix:nonNumeric> from the grant date. There were <ix:nonFraction unitRef="shares" contextRef="i8b2ded813e3c47c0b1ea5d0064b18933_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMzAxNg_402726cd-c67a-4fec-a20b-f6525152d567">no</ix:nonFraction> additional non-employee grants made in the three months ended September 30, 2021. In addition, during the nine months ended September 30, 2021 the Company's board of directors issued options to newly-hired employees as an inducement equity award under Nasdaq Listing Rule 5635(c)(4) outside of the 2010 Plan to purchase <ix:nonFraction unitRef="shares" contextRef="i5d000460f02348d9a57c3b6ac2c6626a_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMzMwMg_fb33fd53-9e4e-4abb-8ffa-ed7b29f529a9">613,850</ix:nonFraction> shares of common stock. These options will vest as to <ix:nonFraction unitRef="number" contextRef="ib8de22fdc1364771a9ce096bd4828f96_D20210101-20210930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMzM2MA_53d1865c-4298-4fed-adad-8c0126b7a9c4">25</ix:nonFraction>% of the shares underlying the option on the first anniversary of the grant date, and as to an additional <ix:nonFraction unitRef="number" contextRef="ic13e507f88684f5ca74c1614332fef14_D20210101-20210930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMzQ2Nw_e36f825c-53e5-4a38-881c-3a6f7867d2d2">6.25</ix:nonFraction>% of the shares underlying the option on each successive three-month period thereafter. All option awards are exercisable at a price equal to the closing price of the Company&#8217;s common stock on the Nasdaq Global Market on the grant dates.</span></div><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNjU1MA_ec59f1e9-fde0-40d1-a281-3341443474c1" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity under the 2010 Plan and inducement awards are summarized as follows:</span></div><div style="margin-top:6pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.818%"><tr><td style="width:1.0%"></td><td style="width:48.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.995%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.000%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price&#160;per<br/>Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining Contractual Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfMS0xLTEtMS0x_5e78b93b-b111-4297-8492-da810cb342ae">8,668,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfMS0zLTEtMS0x_5b911f14-3342-49a2-9091-41fc9cf76241">2.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8e5764c869674f6eaf807f9f08528150_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfMS01LTEtMS0x_1fa0a9fe-8c54-43e6-bb00-00a2f2e20bd7">7.98</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfMi0xLTEtMS0x_1d161600-e421-4dee-b46c-f4e1b0997691">1,831,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfMi0zLTEtMS0x_ebb8c72b-5d52-49ca-94b0-9a3c40f4db4c">9.21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfMy0xLTEtMS0x_d1ee8081-9bc2-40a9-8d0e-1bb9789e15d4">85,751</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfMy0zLTEtMS0x_b8341fe8-4a38-44b7-a9a3-0f3336877ea2">1.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled/Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfNC0xLTEtMS0x_67a3a671-3931-4384-99c8-0eaa035c3689">115,825</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfNC0zLTEtMS0x_c16660d2-244e-4487-b646-6f717b361fe3">11.76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding, September 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfNS0xLTEtMS0x_32fa7324-a24c-4e17-b7e4-c4e7e047471f">10,298,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfNS0zLTEtMS0x_db51689a-5c60-49ec-8df0-ba63f3bd8550">3.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfNS01LTEtMS0x_aea7a0d8-45c6-40f1-a154-9215ccf52ceb">7.59</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfNS03LTEtMS0x_8b44e3fe-759a-4b12-a8e3-1d9efa6143ed">47,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at September 30, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfNi0xLTEtMS0x_8647c434-7874-4694-9c81-bb71adf078b5">5,689,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfNi0zLTEtMS0x_5c2b3d5a-24b8-4193-a236-181ea04b389d">3.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfNi01LTEtMS0x_d09c8ad4-73dc-4865-88d4-5813fbde8d00">6.96</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfNi03LTEtMS0x_c49c8ecd-9661-4f21-a525-5dec173c97ce">29,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and unvested expected to vest at September 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfNy0xLTEtMS0x_dbce5ecf-a1db-4a7c-bc39-651e36475b42">9,963,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfNy0zLTEtMS0x_4692b514-5297-46b7-afec-4303f280e751">3.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfNy01LTEtMS0x_1c7c9d42-9a69-4fdb-9a05-4d35f91b5046">7.56</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfNy03LTEtMS0x_c865ae4a-d6e7-4f9c-a0df-16b3ae5c7d6d">46,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><ix:continuation id="ie047e6ec060f440f972cb753e74e3382" continuedAt="i7fe8210a72b9470db9414f4d1037a542"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNjU2MQ_20477119-40fa-4257-9103-277095c51e51" escape="true"><div style="margin-bottom:6pt;margin-top:4pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair values of the stock options granted during the nine months ended September 30, 2021 and 2020 were $<ix:nonFraction unitRef="usdPerShare" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMzkyNw_e4139256-0142-43f2-8de4-d455539a260b">9.21</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMzkzNA_f75954cc-b976-421d-93e9-6092ca353b23">0.75</ix:nonFraction>, respectively, and were calculated using the following estimated assumptions:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (years) </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOjZhOThhMjc0YmJjYzRlMDg5NGJiZTY5YjIyYjVlYzU1L3RhYmxlcmFuZ2U6NmE5OGEyNzRiYmNjNGUwODk0YmJlNjliMjJiNWVjNTVfMi0xLTEtMS0x_0a51b489-2e04-414b-a35d-12482170e475">5.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOjZhOThhMjc0YmJjYzRlMDg5NGJiZTY5YjIyYjVlYzU1L3RhYmxlcmFuZ2U6NmE5OGEyNzRiYmNjNGUwODk0YmJlNjliMjJiNWVjNTVfMi0zLTEtMS0x_27db3540-ed3d-4842-a6b6-1c45570bebab">5.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOjZhOThhMjc0YmJjYzRlMDg5NGJiZTY5YjIyYjVlYzU1L3RhYmxlcmFuZ2U6NmE5OGEyNzRiYmNjNGUwODk0YmJlNjliMjJiNWVjNTVfNS0xLTEtMS0xL3RleHRyZWdpb246NWUxNWJlYzk4ZTUxNDk5NDg2Y2U1ZjMzODRjNmYxNWZfNA_d8f352f8-bc31-4ce2-bee7-278ee3b57922">0.4</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOjZhOThhMjc0YmJjYzRlMDg5NGJiZTY5YjIyYjVlYzU1L3RhYmxlcmFuZ2U6NmE5OGEyNzRiYmNjNGUwODk0YmJlNjliMjJiNWVjNTVfNS0xLTEtMS0xL3RleHRyZWdpb246NWUxNWJlYzk4ZTUxNDk5NDg2Y2U1ZjMzODRjNmYxNWZfNw_04019e69-6700-4bff-bfd7-17a74b127af8">1.4</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOjZhOThhMjc0YmJjYzRlMDg5NGJiZTY5YjIyYjVlYzU1L3RhYmxlcmFuZ2U6NmE5OGEyNzRiYmNjNGUwODk0YmJlNjliMjJiNWVjNTVfNS0zLTEtMS0xL3RleHRyZWdpb246NDNlNWNkN2U5MTJiNDY0NTgwZDU4Yjg3MWQwYjVhZjBfNA_145fc917-28da-48ba-bfcc-19cd354ad606">0.4</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOjZhOThhMjc0YmJjYzRlMDg5NGJiZTY5YjIyYjVlYzU1L3RhYmxlcmFuZ2U6NmE5OGEyNzRiYmNjNGUwODk0YmJlNjliMjJiNWVjNTVfNS0zLTEtMS0xL3RleHRyZWdpb246NDNlNWNkN2U5MTJiNDY0NTgwZDU4Yjg3MWQwYjVhZjBfNw_93d13c7b-16fe-4071-8b14-6427cb066d72">1.7</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOjZhOThhMjc0YmJjYzRlMDg5NGJiZTY5YjIyYjVlYzU1L3RhYmxlcmFuZ2U6NmE5OGEyNzRiYmNjNGUwODk0YmJlNjliMjJiNWVjNTVfNi0xLTEtMS0x_90c9eb38-c1ef-462a-96bd-90e2392bc86f">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOjZhOThhMjc0YmJjYzRlMDg5NGJiZTY5YjIyYjVlYzU1L3RhYmxlcmFuZ2U6NmE5OGEyNzRiYmNjNGUwODk0YmJlNjliMjJiNWVjNTVfNi0zLTEtMS0x_14bf8a05-cb09-42a7-af44-eb47e97b3c0d">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected Dividends</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">None</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:1pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of September 30, 2021, there was approximately $<ix:nonFraction unitRef="usd" contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNDA1Mg_7fd81a41-dd6c-4f36-a697-5aafd55990ed">11.4</ix:nonFraction> million of unrecognized compensation cost related to unvested employee stock option awards outstanding, net of the impact of estimated forfeitures that is expected to be recognized as expense over a weighted average period of <ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNDI4MQ_6cac1816-7164-449c-96c2-fc8ff42bf723">2.27</ix:nonNumeric> years. The intrinsic value of employee stock options exercised during the nine months ended September 30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNDM4MQ_9d73ab53-9918-4134-8591-b38c9867fcc9">0.5</ix:nonFraction>&#160;million. The intrinsic value of employee stock options exercised during the nine months ended September 30, 2020 was not material.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNjU2Mw_078d84fa-78a3-4f08-8ae8-a26df273833b" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of unvested restricted stock awards (&#8220;RSAs&#8221;) under the 2010 Plan as of September 30, 2021:</span></div><div style="margin-bottom:7pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.575%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested, December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if92fd01d600549e3966881e1346c980d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmRlOWJlMDNjMDNmMjQyYzRhOTYyMmFiNGU0MjQ2NDQ1L3RhYmxlcmFuZ2U6ZGU5YmUwM2MwM2YyNDJjNGE5NjIyYWI0ZTQyNDY0NDVfMS0xLTEtMS0x_f503c79d-84ed-4c9b-bf7d-57f7410d0c3c">20,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if92fd01d600549e3966881e1346c980d_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmRlOWJlMDNjMDNmMjQyYzRhOTYyMmFiNGU0MjQ2NDQ1L3RhYmxlcmFuZ2U6ZGU5YmUwM2MwM2YyNDJjNGE5NjIyYWI0ZTQyNDY0NDVfMS0zLTEtMS0x_874e4ec9-40c0-4d0b-b6af-4f01a2effd5a">3.45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07e1ce19861a4ae59be352c43fd153c5_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmRlOWJlMDNjMDNmMjQyYzRhOTYyMmFiNGU0MjQ2NDQ1L3RhYmxlcmFuZ2U6ZGU5YmUwM2MwM2YyNDJjNGE5NjIyYWI0ZTQyNDY0NDVfMi0xLTEtMS0x_12d20038-e456-4fba-ad1d-5453ab888c19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i07e1ce19861a4ae59be352c43fd153c5_D20210101-20210930" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmRlOWJlMDNjMDNmMjQyYzRhOTYyMmFiNGU0MjQ2NDQ1L3RhYmxlcmFuZ2U6ZGU5YmUwM2MwM2YyNDJjNGE5NjIyYWI0ZTQyNDY0NDVfMi0zLTEtMS0x_adfa9cea-f5ab-4ba3-a226-7e0a1cb1640b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i07e1ce19861a4ae59be352c43fd153c5_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmRlOWJlMDNjMDNmMjQyYzRhOTYyMmFiNGU0MjQ2NDQ1L3RhYmxlcmFuZ2U6ZGU5YmUwM2MwM2YyNDJjNGE5NjIyYWI0ZTQyNDY0NDVfMy0xLTEtMS0x_28515ee2-8e21-44ef-9fd6-34e47c5e267b">10,312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i07e1ce19861a4ae59be352c43fd153c5_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmRlOWJlMDNjMDNmMjQyYzRhOTYyMmFiNGU0MjQ2NDQ1L3RhYmxlcmFuZ2U6ZGU5YmUwM2MwM2YyNDJjNGE5NjIyYWI0ZTQyNDY0NDVfMy0zLTEtMS0x_efbafc65-c7fa-4cbc-b57d-2487f84e1b14">3.45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07e1ce19861a4ae59be352c43fd153c5_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmRlOWJlMDNjMDNmMjQyYzRhOTYyMmFiNGU0MjQ2NDQ1L3RhYmxlcmFuZ2U6ZGU5YmUwM2MwM2YyNDJjNGE5NjIyYWI0ZTQyNDY0NDVfNC0xLTEtMS0x_84b5f31a-8a71-4b3d-8de5-4330589dc0e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i07e1ce19861a4ae59be352c43fd153c5_D20210101-20210930" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmRlOWJlMDNjMDNmMjQyYzRhOTYyMmFiNGU0MjQ2NDQ1L3RhYmxlcmFuZ2U6ZGU5YmUwM2MwM2YyNDJjNGE5NjIyYWI0ZTQyNDY0NDVfNC0zLTEtMS0x_66c2c97e-22d4-44d6-9671-e2d5e8468b22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested, September 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82ceafb1c6a24cca84ef9a0241a19879_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmRlOWJlMDNjMDNmMjQyYzRhOTYyMmFiNGU0MjQ2NDQ1L3RhYmxlcmFuZ2U6ZGU5YmUwM2MwM2YyNDJjNGE5NjIyYWI0ZTQyNDY0NDVfNS0xLTEtMS0x_d4f3e9d3-c388-4c3f-9d6f-459e57173a3b">10,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i82ceafb1c6a24cca84ef9a0241a19879_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmRlOWJlMDNjMDNmMjQyYzRhOTYyMmFiNGU0MjQ2NDQ1L3RhYmxlcmFuZ2U6ZGU5YmUwM2MwM2YyNDJjNGE5NjIyYWI0ZTQyNDY0NDVfNS0zLTEtMS0x_9b381967-0e8a-4a87-abfb-d7b0abd724c6">3.45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:1pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i82ceafb1c6a24cca84ef9a0241a19879_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNDY1MA_9108281a-a179-4b84-bfb8-50fe221c4c82">10,312</ix:nonFraction> shares outstanding covered by RSAs that are expected to vest. The weighted average grant date fair value of these shares of restricted stock was $<ix:nonFraction unitRef="usdPerShare" contextRef="i07e1ce19861a4ae59be352c43fd153c5_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNDc5OQ_efbafc65-c7fa-4cbc-b57d-2487f84e1b14">3.45</ix:nonFraction> per share and the aggregate fair value of these shares of restricted stock was $<ix:nonFraction unitRef="usd" contextRef="i07e1ce19861a4ae59be352c43fd153c5_D20210101-20210930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNDg4MQ_ac6d3e39-2525-443d-9732-8f361c507e8c">0.1</ix:nonFraction> million. As of September 30, 2021, there was less than $<ix:nonFraction unitRef="usd" contextRef="i19989054788e4da19d8b3a02d19f3af8_I20210930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNDkyMw_24d021f6-71a4-4cf4-a5b8-2e8a6d6abad2">0.1</ix:nonFraction> million of unrecognized compensation costs, net of estimated forfeitures, related to RSAs granted to officers, which are expected to be recognized as expense over a remaining weighted average period of <ix:nonNumeric contextRef="iab7e84e85b8043f69c8eee23b3053c8a_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNTEyOA_35145192-5f32-4970-bc98-469ca34a8fbc">0.31</ix:nonNumeric> years.</span></div><div style="margin-top:8.8pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amended and Restated 2010 Employee Stock Purchase Plan</span></div><div style="margin-top:8.8pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reserved <ix:nonFraction unitRef="shares" contextRef="i20919e06b4f743a294203290cd8726b2_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNTIxOA_5d59550d-09c7-4891-9c87-5f7f5de693a2">2,000,000</ix:nonFraction> shares of common stock for issuance under the ESPP. Eligible employees may purchase shares of the Company&#8217;s common stock at <ix:nonFraction unitRef="number" contextRef="ibb5cbdbb686f429fb1f8c8cc33874d76_D20210101-20210930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNTM0NQ_b4e71700-c695-4d0e-a1a4-46f0a8a7ec04">85</ix:nonFraction>% of the lower closing market price of the common stock at the beginning of the enrollment period or ending date of the purchase period within a <ix:nonNumeric contextRef="ibb5cbdbb686f429fb1f8c8cc33874d76_D20210101-20210930" format="ixt-sec:durwordsen" name="cris:EmployeeStockPurchasePlanEnrollmentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNjU1OQ_9d817b4d-0bee-41f8-9ab0-52db8f98148b">two-year</ix:nonNumeric> enrollment period, as defined. The Company has <ix:nonFraction unitRef="purchase_period" contextRef="ibb5cbdbb686f429fb1f8c8cc33874d76_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="cris:NumberOfPurchasePeriodsPerEnrollmentPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNTU0Ng_ea2a66dc-15e8-4714-9b8e-3c5af13f0769">four</ix:nonFraction> <ix:nonNumeric contextRef="ibb5cbdbb686f429fb1f8c8cc33874d76_D20210101-20210930" format="ixt-sec:durwordsen" name="cris:SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNjU2Ng_d3f7b392-df6f-4ba6-92e7-6dee29b83bd5">six-month</ix:nonNumeric> purchase periods per each <ix:nonNumeric contextRef="ibb5cbdbb686f429fb1f8c8cc33874d76_D20210101-20210930" format="ixt-sec:durwordsen" name="cris:EmployeeStockPurchasePlanEnrollmentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNjU3MQ_7fcfc07e-8381-448a-886e-f3f724b5543d">two-year</ix:nonNumeric> enrollment period. If, within any one of the <ix:nonFraction unitRef="purchase_period" contextRef="ibb5cbdbb686f429fb1f8c8cc33874d76_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="cris:NumberOfPurchasePeriodsPerEnrollmentPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNTYzNw_ea2a66dc-15e8-4714-9b8e-3c5af13f0769">four</ix:nonFraction> purchase periods in an enrollment period, the purchase period ending stock price is lower than the stock price at the beginning of the enrollment period, the <ix:nonNumeric contextRef="ibb5cbdbb686f429fb1f8c8cc33874d76_D20210101-20210930" format="ixt-sec:durwordsen" name="cris:EmployeeStockPurchasePlanEnrollmentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNjU2NA_569c17ad-79cd-4b26-8d79-d39fceaf4281">two-year</ix:nonNumeric> enrollment resets at the new lower stock price. This aspect of the plan was amended in 2017. Prior to 2017, the plan included <ix:nonFraction unitRef="purchase_period" contextRef="iace147228c5946e7856c18ea03d6b20c_D20160101-20161231" decimals="INF" format="ixt-sec:numwordsen" name="cris:NumberOfPurchasePeriodsPerEnrollmentPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNTkzMg_ef4f995b-507a-4a18-bcbf-3a9fc3b7ebee">two</ix:nonFraction> <ix:nonNumeric contextRef="iace147228c5946e7856c18ea03d6b20c_D20160101-20161231" format="ixt-sec:durwordsen" name="cris:SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNjU2MA_9fc71b6e-3e9f-42ad-b105-ce4f1af987f2">six-month</ix:nonNumeric> purchase periods per year with no defined enrollment period. During the three  months ended September 30, 2021, <ix:nonFraction unitRef="shares" contextRef="idb9ad9cc9e894c4a8591a01bc5b0e7a3_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMjc0ODc3OTA3NjEzMw_594c7d83-5e11-45ce-84b1-ee7dcf41c773">no</ix:nonFraction> shares were issued under the ESPP. During the nine months ended September 30, 2021, <ix:nonFraction unitRef="shares" contextRef="i2bcecdf0c0fb4a72b6e837d5f3fe2504_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMTA5OTUxMTYzNDQxNA_c39dcd9f-f16b-43df-9a79-6f678e4917d9">20,791</ix:nonFraction> shares were issued under the ESPP. As of September 30, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i20919e06b4f743a294203290cd8726b2_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="cris:StockAvailableForFuturePurchaseUnderEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNjEwMg_0302e99a-c9f3-497b-8ddf-c4d970f0f171">1,576,599</ix:nonFraction> shares available for future purchase under the ESPP. </span></div><div style="margin-top:8.8pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ESPP compensation expense for the three and nine months ended September 30, 2021 and 2020 was not material. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><ix:continuation id="i7fe8210a72b9470db9414f4d1037a542"><div style="margin-top:8.8pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNjU1Mg_d3fa2431-a003-41d2-b948-c1058f1e5106" escape="true"><div style="margin-top:8.8pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021 and 2020, the Company recorded stock-based compensation expense to the following line items in its costs and expenses section of the Condensed Consolidated Statements of Operations and Comprehensive Loss, including expense related to its ESPP:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7e33ac900a448798f0a8d5fac3e7c9a_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmVhMDZlNmFiMDIzZDQ4YWNhZWQwYzMxYjVhYTQ1NGQ4L3RhYmxlcmFuZ2U6ZWEwNmU2YWIwMjNkNDhhY2FlZDBjMzFiNWFhNDU0ZDhfMi0xLTEtMS0x_6a5b154d-b054-4daf-b7d4-c5eff758fb47">553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e0e7bd086684b51905901766d082679_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmVhMDZlNmFiMDIzZDQ4YWNhZWQwYzMxYjVhYTQ1NGQ4L3RhYmxlcmFuZ2U6ZWEwNmU2YWIwMjNkNDhhY2FlZDBjMzFiNWFhNDU0ZDhfMi0zLTEtMS0x_51a41efd-6da4-4405-b741-f20eab8bc931">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ed4bd4d72e5471aae94ac0a3df1cd55_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmVhMDZlNmFiMDIzZDQ4YWNhZWQwYzMxYjVhYTQ1NGQ4L3RhYmxlcmFuZ2U6ZWEwNmU2YWIwMjNkNDhhY2FlZDBjMzFiNWFhNDU0ZDhfMi01LTEtMS0x_8a6ed898-9e04-40bc-9fc3-425bec5d85b2">1,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9179bb8d8abc4e7a966aa44e418032fa_D20200101-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmVhMDZlNmFiMDIzZDQ4YWNhZWQwYzMxYjVhYTQ1NGQ4L3RhYmxlcmFuZ2U6ZWEwNmU2YWIwMjNkNDhhY2FlZDBjMzFiNWFhNDU0ZDhfMi03LTEtMS0x_f8bbb5cc-e75c-4c6e-9ba9-acccdc6e60a5">548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d1e27447c134e8b8836cf1c2b82cc83_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmVhMDZlNmFiMDIzZDQ4YWNhZWQwYzMxYjVhYTQ1NGQ4L3RhYmxlcmFuZ2U6ZWEwNmU2YWIwMjNkNDhhY2FlZDBjMzFiNWFhNDU0ZDhfMy0xLTEtMS0x_0403226f-0c3a-469e-9e7c-38003d302789">911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19eea75f02854b849783be2ececc8962_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmVhMDZlNmFiMDIzZDQ4YWNhZWQwYzMxYjVhYTQ1NGQ4L3RhYmxlcmFuZ2U6ZWEwNmU2YWIwMjNkNDhhY2FlZDBjMzFiNWFhNDU0ZDhfMy0zLTEtMS0x_dd3df1c9-945f-4363-acb4-082cc8bb527b">431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1569ff1a3c7e4c1a828aa4de4ce7b739_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmVhMDZlNmFiMDIzZDQ4YWNhZWQwYzMxYjVhYTQ1NGQ4L3RhYmxlcmFuZ2U6ZWEwNmU2YWIwMjNkNDhhY2FlZDBjMzFiNWFhNDU0ZDhfMy01LTEtMS0x_9f07a549-bbd2-4ef4-a881-fd10cc0660c8">2,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb8cdae355c147d78b1f92ad1395fbb7_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmVhMDZlNmFiMDIzZDQ4YWNhZWQwYzMxYjVhYTQ1NGQ4L3RhYmxlcmFuZ2U6ZWEwNmU2YWIwMjNkNDhhY2FlZDBjMzFiNWFhNDU0ZDhfMy03LTEtMS0x_b7ace800-4661-42cf-94af-ef1120584b6d">1,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmVhMDZlNmFiMDIzZDQ4YWNhZWQwYzMxYjVhYTQ1NGQ4L3RhYmxlcmFuZ2U6ZWEwNmU2YWIwMjNkNDhhY2FlZDBjMzFiNWFhNDU0ZDhfNC0xLTEtMS0x_37a18c5b-be3e-446c-90df-d6878b4b3441">1,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmVhMDZlNmFiMDIzZDQ4YWNhZWQwYzMxYjVhYTQ1NGQ4L3RhYmxlcmFuZ2U6ZWEwNmU2YWIwMjNkNDhhY2FlZDBjMzFiNWFhNDU0ZDhfNC0zLTEtMS0x_eb165043-99fb-4be3-be04-d1e20e3221e3">624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmVhMDZlNmFiMDIzZDQ4YWNhZWQwYzMxYjVhYTQ1NGQ4L3RhYmxlcmFuZ2U6ZWEwNmU2YWIwMjNkNDhhY2FlZDBjMzFiNWFhNDU0ZDhfNC01LTEtMS0x_abe7e977-b6ff-4771-ba68-93a196e657b7">3,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmVhMDZlNmFiMDIzZDQ4YWNhZWQwYzMxYjVhYTQ1NGQ4L3RhYmxlcmFuZ2U6ZWEwNmU2YWIwMjNkNDhhY2FlZDBjMzFiNWFhNDU0ZDhfNC03LTEtMS0x_3594cedc-16c1-4303-8427-154faf96facc">1,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i90810bc68d594941912c6cfda631781c_67"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182Ny9mcmFnOjg1OTk3NzU2Y2FmZTRjMzZhMTM0OWQzMThmODMwMDlhL3RleHRyZWdpb246ODU5OTc3NTZjYWZlNGMzNmExMzQ5ZDMxOGY4MzAwOWFfNTgx_34c4107f-91b1-47f8-a08d-83ba357f82b5" continuedAt="i5c52dfa35bf645bb864bd76a98078480" escape="true">Loss Per Common Share</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5c52dfa35bf645bb864bd76a98078480">Basic and diluted loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is the same as basic net loss per common share for the three and nine months ended September 30, 2021 and 2020, because the effect of the potential common stock equivalents would be antidilutive due to the Company&#8217;s net loss position for these periods. Antidilutive securities consist of stock options outstanding of <ix:nonFraction unitRef="shares" contextRef="id1569a19d3534733a5351d7321844968_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182Ny9mcmFnOjg1OTk3NzU2Y2FmZTRjMzZhMTM0OWQzMThmODMwMDlhL3RleHRyZWdpb246ODU5OTc3NTZjYWZlNGMzNmExMzQ5ZDMxOGY4MzAwOWFfNTQx_6b14f8ff-5e17-4e52-ae92-5cda00a9a136">10,298,279</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i85ee1298708f4cd9b83af95152514d48_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182Ny9mcmFnOjg1OTk3NzU2Y2FmZTRjMzZhMTM0OWQzMThmODMwMDlhL3RleHRyZWdpb246ODU5OTc3NTZjYWZlNGMzNmExMzQ5ZDMxOGY4MzAwOWFfNTQ4_08b6d272-bf0e-4ec7-a983-59c7ff5826e9">9,128,896</ix:nonFraction> as of September 30, 2021 and 2020, respectively.</ix:continuation></span></div><div id="i90810bc68d594941912c6cfda631781c_70"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY183MC9mcmFnOjhlYTBkYmQzNDkxNjQyMmM5OTQzNGNjMGU4YzI3NDlmL3RleHRyZWdpb246OGVhMGRiZDM0OTE2NDIyYzk5NDM0Y2MwZThjMjc0OWZfMTcxNA_8189da0f-d2a7-4bba-85ca-92a5eb157c26" continuedAt="i2035bd39bfbb4a6c937bc2541ceeef56" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="i2035bd39bfbb4a6c937bc2541ceeef56" continuedAt="i3064d1e473b045b496d84361e5c798d2"><div style="margin-top:6pt;padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.41pt">Agreement with Head of Research and Development - Robert E. Martell, M.D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Ph.D.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an exclusive option and license agreement with Epi-Cure Pharmaceuticals, Inc., (&#8220;Epi-Cure&#8221;) a privately held early stage biotechnology company. Robert E. Martell, M.D., Ph.D., the Company&#8217;s Head of Research and Development and a former director of the Company, is a founder of Epi-Cure, was formerly an officer and director of Epi-Cure, and is currently a holder of a convertible promissory note to Epi-Cure. Under the terms of the option and license agreement, Epi-Cure granted Curis an exclusive option to certain program compounds that may arise during the initial research and development period, and any extension thereof. Upon execution of the option and license agreement, the Company paid Epi-Cure an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i10387d0e7a2b43aea7787dd2ecda9786_D20181018-20181018" decimals="-5" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY183MC9mcmFnOjhlYTBkYmQzNDkxNjQyMmM5OTQzNGNjMGU4YzI3NDlmL3RleHRyZWdpb246OGVhMGRiZDM0OTE2NDIyYzk5NDM0Y2MwZThjMjc0OWZfODg5_ac449c22-eebe-4d8f-ad8d-9cc04942c5f1">0.1</ix:nonFraction> million for legal and consulting costs incurred by Epi-Cure in connection with the transaction. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Epi-Cure had primary responsibility for conducting research and development activities and Curis was responsible for funding up to $<ix:nonFraction unitRef="usd" contextRef="i272602d3cc7643438ce9826f03bb4e8d_D20210101-20210930" decimals="-5" name="cris:RelatedPartyTransactionMaximumFundingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY183MC9mcmFnOjhlYTBkYmQzNDkxNjQyMmM5OTQzNGNjMGU4YzI3NDlmL3RleHRyZWdpb246OGVhMGRiZDM0OTE2NDIyYzk5NDM0Y2MwZThjMjc0OWZfMTE1NA_354db0ac-42ce-4387-8e7d-c3deb1b71a83">0.5</ix:nonFraction> million of the research and development program costs and expenses during the initial research and development period. After the end of the research and development period, which ended in April 2020, Curis had <ix:nonFraction unitRef="day" contextRef="i272602d3cc7643438ce9826f03bb4e8d_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="cris:RelatedPartyTransactionTermsAndMannerOfSettlementMinimumDaysNoticeToTerminatePriorToWrittenNotice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY183MC9mcmFnOjhlYTBkYmQzNDkxNjQyMmM5OTQzNGNjMGU4YzI3NDlmL3RleHRyZWdpb246OGVhMGRiZDM0OTE2NDIyYzk5NDM0Y2MwZThjMjc0OWZfMTM2Nw_c49a6a6f-eded-43ed-94a7-da2f23ee0e3c">sixty</ix:nonFraction> days to elect to exercise its option to license the program compounds. In June 2020, the Company decided not to exercise its option to license the program compounds, and the agreement expired.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3064d1e473b045b496d84361e5c798d2">In 2020, the Company expensed $<ix:nonFraction unitRef="usd" contextRef="i1b869695d75c4d90a845094790292154_D20200101-20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY183MC9mcmFnOjhlYTBkYmQzNDkxNjQyMmM5OTQzNGNjMGU4YzI3NDlmL3RleHRyZWdpb246OGVhMGRiZDM0OTE2NDIyYzk5NDM0Y2MwZThjMjc0OWZfMTU5Mw_40024e25-4953-4cc8-a22a-f221b89d11ab">0.1</ix:nonFraction>&#160;million of fees related to this agreement. <ix:nonFraction unitRef="usd" contextRef="i476e1229fc4b40faa3024587e5c8cf5c_D20200601-20200630" decimals="INF" format="ixt:fixed-zero" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY183MC9mcmFnOjhlYTBkYmQzNDkxNjQyMmM5OTQzNGNjMGU4YzI3NDlmL3RleHRyZWdpb246OGVhMGRiZDM0OTE2NDIyYzk5NDM0Y2MwZThjMjc0OWZfMTYzMQ_56aa6eb4-6020-4e43-8fbc-4bf22a3e15a2">No</ix:nonFraction> expense has been incurred following the expiration of the agreement in June 2020</ix:continuation>.</span></div><div id="i90810bc68d594941912c6cfda631781c_79"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations should be read in conjunction with the Condensed Consolidated Financial Statements and the related notes appearing elsewhere in this report. Some of the information contained in this discussion and analysis and set forth elsewhere in this report, including information with respect to our plans and strategy for our business, includes forward-looking statements, based on current expectations and related to future events and our future financial and operational performance, that involve risks and uncertainties. You should review the  discussion above under the heading &#8220;Risk Factor Summary,&#8221; the risk factors detailed further in Item 1A, "Risk Factors" of Part I of our Annual Report on Form 10-K for the year ended December 31, 2020, and, if applicable, those included under Part II, Item 1A of this Quarterly Report on Form 10-Q, for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. As used throughout this report, the terms &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to the business of Curis, Inc. and its wholly owned subsidiaries, except where the context otherwise requires, and the term &#8220;Curis&#8221; refers to Curis, Inc.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i90810bc68d594941912c6cfda631781c_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a biotechnology company focused on the development of first-in-class and innovative therapeutics for the treatment of cancer. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct our research and development programs both internally and through strategic collaborations. Our clinical stage drug candidates are:</span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:8.52pt">CA-4948, an orally-available small molecule inhibitor of Interleukin-1 receptor-associated kinase 4, or IRAK4, which is currently undergoing testing in a Phase 1/2 open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas, including those with Myeloid Differentiation Primary Response Protein 88, or MYD88 alterations. We reported preliminary clinical data from the study in December 2020. The trial was amended to include a combination study of CA-4948 and ibrutinib, a BTK inhibitor, in patients with non-Hodgkin lymphomas for which we enrolled the first patient in February 2021. We expect to provide initial data from the combination study in the first half of 2022. We are also conducting a separate Phase 1/2 open-label, single arm dose escalating and expansion trial in patients with acute myeloid leukemia, or AML, and myelodysplastic syndromes, or MDS, and announced preliminary clinical data from this study in December 2020. The study was amended in April 2021 to include dose escalation cohorts of CA-4948 in combination with azacitidine or venetoclax. In April 2021, CA-4948 was granted Orphan Drug Designation for the treatment of AML and MDS by the U.S. Food and Drug Administration, or FDA. In June 2021, we reported updated preliminary clinical data from the Phase 1/2 study in patients with AML or MDS and announced the recommended Phase 2 dose for monotherapy dose expansion.</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation, or VISTA signaling pathway. In June 2020, we announced the FDA had cleared our Investigational New Drug, or IND, application for CI-8993. In September 2020, we began enrollment in our Phase 1 trial of CI-8993 in patients with solid tumors. We have an option to license CI-8993 from ImmuNext, Inc., or ImmuNext.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pipeline also includes the following:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Fimepinostat, a small molecule that potently inhibits the activity of histone deacetylase, or HDAC, and phosphotidyl-inositol 3 kinase, or PI3 kinase enzymes, which has been granted Orphan Drug Designation and Fast Track Designation for the treatment of diffuse large B-cell lymphoma, or DLBCL, and nuclear protein in testis (NUT) midline carcinoma by the FDA. In 2019, we began enrollment in a Phase 1 combination study with venetoclax in DLBCL patients, including patients with translocations in both MYC and the BCL2 gene, also referred to as double-hit lymphoma, or high-grade B-cell lymphoma, or HGBL. We reported preliminary clinical data from this combination study in December 2019. In March 2020, we announced that although we observed no significant drug-drug interaction in our Phase 1 study of fimepinostat in combination with venetoclax, we did not see an efficacy signal that would warrant continuation of the study. Accordingly, no further patients will be enrolled in this study. We are currently evaluating future studies for fimepinostat.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">CA-170, a small molecule antagonist of VISTA and PDL1, for which we announced initial data from a clinical study in patients with mesothelioma in conjunction with the Society of Immunotherapy of Cancer conference in November 2019. Based on this data, no further patients will be enrolled in the study. We are currently evaluating future studies for CA-170.</span></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">CA-327, a small molecule antagonist of PDL1 and TIM3, which is a pre-IND stage oncology drug candidate. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to a collaboration with Genentech Inc., or Genentech, a member of the Roche Group, under which F. Hoffmann-La Roche Ltd, or Roche, and Genentech are commercializing Erivedge</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vismodegib), a first-in-class orally administered small molecule Hedgehog signaling pathway antagonist. Erivedge is approved for the treatment of advanced basal cell carcinoma, or BCC. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2015, we entered into an exclusive collaboration agreement focused on immuno-oncology and selected precision oncology targets with Aurigene Discovery Technologies Limited, or Aurigene, which was amended in September 2016 and February 2020. As of September 30, 2021, we have licensed four programs under the Aurigene collaboration: </span></div><div style="margin-top:5pt"><span><br/></span></div><div style="padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">IRAK4 Program - a precision oncology program of small molecule inhibitors of IRAK4. The development candidate is CA-4948.</span></div><div style="padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">PD1/VISTA Program - an immuno-oncology program of small molecule antagonists of PD1 and VISTA immune checkpoint pathways. The development candidate is CA-170.</span></div><div style="padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">PD1/TIM3 Program - an immuno-oncology program of small molecule antagonists of PD1 and TIM3 immune checkpoint pathways. The development candidate is CA-327.</span></div><div style="padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">In March 2018, we exercised our option to license a fourth program, which is an immuno-oncology program. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:8pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are party to an option and license agreement with ImmuNext. Pursuant to the terms of the option and license agreement, we have an option, exercisable for a specified period as set forth in the option and license agreement, to obtain an exclusive license to develop and commercialize certain VISTA antagonizing compounds, including ImmuNext's lead compound, CI-8993, and products containing these compounds in the field of oncology.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our clinical development plans for our pipeline, we intend to predominantly focus our available resources on the continued development of CA-4948, in collaboration with Aurigene, and CI-8993, in collaboration with ImmuNext, in the near term. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Liquidity</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have funded our operations primarily through private and public placements of our equity securities, license fees, contingent cash payments, research and development funding from our corporate collaborators, debt financings and the monetization of certain royalty rights. We have never been profitable on an annual basis and have an accumulated deficit of $1.1 billion as of September 30, 2021. For the nine months ended September 30, 2021, we&#160;incurred a net loss of $31.8 million and used $29.4 million of cash in operations. We expect that our $149.8 million cash, cash equivalents and investments as of September 30, 2021 should enable us to maintain our planned operations into 2024. We have based this assessment on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect.  </span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to generate significant revenues to achieve profitability, and do not expect to achieve profitability in the foreseeable future, if at all.  If sufficient funds are not available, we will have to delay, reduce the scope of, or eliminate some of our research and development programs, including related clinical trials and operating expenses, potentially delaying the time to market for or preventing the marketing of any of our product candidates, which could adversely affect our business prospects and our ability to continue our operations, and would have a negative impact on our financial condition and ability to pursue our business strategies. In addition, we may seek to engage in one or more strategic alternatives, such as a strategic partnership with one or more parties, the licensing, sale or divestiture of some of our assets or proprietary technologies or the sale of our company, but there can be no assurance that we would be able to enter into such a transaction or transactions on a timely basis or on terms favorable to us, or at all.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has caused many governments to implement measures to slow the spread of the pandemic through quarantines, strict travel restrictions, heightened border scrutiny, and other measures. The pandemic and government measures taken in response have had a significant impact, both direct and indirect, on businesses and commerce. While the COVID-19 pandemic has had adverse effects on our business and we expect the pandemic to have an adverse effect on our business, financial conditions and results of operations in the future, we are unable to predict the extent or nature of the future progression of the COVID-19 pandemic or its effects on our business and operations at this time.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have enrolled, and will seek to enroll, cancer patients in clinical trials at sites located both in the United States and internationally. Many of our clinical trial sites have imposed restrictions as a result of the COVID-19 pandemic, which have had and may continue to have a negative impact on our ability to conduct our clinical trials. We have encountered and may continue to face difficulties recruiting and retaining patients in our ongoing and planned clinical trials to the extent patients are affected by the virus or are fearful of visiting or traveling to our clinical trial sites because of the pandemic. In addition, we do not currently know the duration or to what degree medical facilities, including our clinical trial sites, will continue to be impacted by the pandemic. For example, all of our clinical trial sites for our ongoing Phase 1/2 clinical trial for CA-4948 in patients with non-Hodgkin lymphomas, including those with MYD88 alterations, are at large academic research hospitals that have imposed restrictions on entry which have in some instances prohibited, and in other instances may potentially prohibit in the future, clinical trial monitors and patients from entering the trial sites. We are actively working with our clinical trial sites to follow FDA guidelines for conducting clinical trials during the COVID-19 pandemic, including performing remote monitoring to the extent possible and arranging for the shipment of medicine directly from the clinical trial site to patients who are enrolled in our trials, if required; however, there is no assurance such arrangements will be successful. As a result, further enrollment in our ongoing clinical trial for CA-4948 in patients with non-Hodgkin lymphomas, including those with MYD88 alterations, has been delayed and may continue to be delayed and patients currently enrolled in the trial may cease treatment due to the restrictions described above or fear of visiting or inability to visit our trial sites. As a result, enrollment in this trial has been slower than expected and the timeline of this trial has been delayed and may continue to be delayed. In addition, in July 2020, we commenced enrollment in our Phase 1 clinical trial of CA-4948 in patients with AML and MDS. Clinical trial sites for this study have also imposed and may continue to impose restrictions similar to those described above. As a result, we may not be able to enroll this trial on our planned timeline, which would cause a delay in the overall timeline for this trial. Similarly, enrollment in and the overall timeline of our combination study of CA-4948 and ibrutinib, for which we commenced enrollment </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in February 2021, and our Phase 1 clinical trial for CI-8993, for which we commenced enrollment in September 2020, have been delayed and may continue to be delayed due to the factors discussed above. To the extent clinical trial sites are slowed down or closed to enrollment in our ongoing and planned clinical trials, this could also have a material adverse impact on our clinical trial plans and timelines. These restrictions may also impact our ability to collect patient data in a timely fashion. In addition, we do not know whether and to what extent potential exposure to COVID-19 of patients in our clinical trials could impact the efficacy of CA-4948 or CI-8993. The response to the COVID-19 pandemic may redirect resources of regulators in a way that would adversely impact our ability to progress regulatory approvals. In addition, we may face impediments to regulatory meetings and approvals relating to our clinical trials due to measures intended to limit in-person interactions.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We and our collaborators, third-party contract manufacturers, contract research organizations and clinical sites may experience delays or disruptions in supply and release of product candidates and/or procuring items that are essential for our research and development activities, including, for example, raw materials used in the manufacturing of our product candidates, basic medical and laboratory supplies used in our clinical trials or preclinical studies or animals that are used for preclinical testing, in each case, for which there may be shortages or supply chain disruptions as a result of the pandemic. While we believe that we currently have sufficient supply of our product candidates to continue our ongoing clinical trials, shortages and global supply chain disruptions could make it difficult to obtain, or cause us to be delayed in obtaining, some of our product candidates, or materials contained therein, especially when such materials come from facilities located in areas particularly impacted by COVID-19. In addition, any disruptions could impact the supply, manufacturing or distribution of Erivedge, and sales of Erivedge may be negatively impacted by a decrease in new prescriptions as a result of a decline in patient medical visits due to the COVID-19 pandemic, which has had and could continue to have a negative impact on the amount and timing of any royalty revenue we may receive from Genentech related to Erivedge. There is no guarantee that the COVID-19 pandemic, or any potential future outbreak, would not impact our supply chain, which could have a material adverse impact on our clinical trial plans and business operations.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We experienced delays in closing down our clinical trial sites related to our fimepinostat and CA-170 trials due to restrictions on non-essential workers imposed at those sites in response to COVID-19, which delayed the winding down of these trials.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any negative impact that the COVID-19 pandemic has on the ability of our suppliers to provide materials for our product candidates or on recruiting or retaining patients in our clinical trials could cause costly delays to clinical trial activities, which could adversely affect our ability to obtain regulatory approval for and to commercialize our product candidates, increase our operating expenses, and have a material adverse effect on our financial results. Additionally, the pandemic has already caused significant disruptions in the financial markets, and may continue to cause such disruptions, which could impact our ability to raise additional funds and has also impacted, and may continue to impact, the volatility of our stock price and trading in our stock. Moreover, the pandemic has significantly impacted economies worldwide, which could result in adverse effects on our business and operations. We cannot be certain what the overall impact of the COVID-19 pandemic will be on our business and it has had and may continue to have an adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div id="i90810bc68d594941912c6cfda631781c_85"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Drivers</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that near term key drivers to our success will include:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully plan, finance and complete current and planned clinical trials for CA-4948 and CI-8993, as well as for such clinical trials to generate favorable data; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise additional financing, when required, to fund operations.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the longer term, a key driver to our success will be our ability, and the ability of any current or future collaborator or licensee, to successfully develop and commercialize drug candidates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Collaborations and License Agreements</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information regarding our collaboration and license agreements, refer to Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Collaborations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the accompanying Notes to the Condensed Consolidated Financial Statements included in Item 1 of Part I of this Quarterly Report on Form 10-Q and Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Collaborations,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Item 8 of our Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission, or SEC, on March&#160;16, 2021.</span></div><div id="i90810bc68d594941912c6cfda631781c_88"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future operating results will largely depend on the progress of drug candidates currently in our research and development pipeline. The results of our operations will vary significantly from year to year and quarter to quarter and depend on, among other factors, the cost and outcome of any preclinical development or clinical trials then being conducted. For a discussion of our liquidity and funding requirements, see &#8220;Liquidity&#8221; and &#8220;Liquidity and Capital Resources - Funding Requirements&#8221;. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liability Related to the Sale of Future Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In connection with the termination and repayment in full of our prior loan with HealthCare Royalty Partners, III, L.P., or HealthCare Royalty, we and Curis Royalty entered into the royalty interest purchase agreement, or Oberland Purchase Agreement, with entities managed by Oberland Capital Management, LLC, or the Purchasers. Upon closing of the Oberland Purchase Agreement, Curis Royalty received an upfront purchase price of $65.0 million from the Purchasers, approximately $33.8 million of which was used to pay off the remaining loan principal to HealthCare Royalty, and $3.7 million of which was used to pay transaction costs, including $3.4 million to HealthCare Royalty in accrued and unpaid interest and prepayment fees under the loan, resulting in net proceeds of $27.5 million. Curis Royalty will also be entitled to receive milestone payments of (i) $17.2 million if the Purchasers and Curis Royalty receive aggregate royalty payments pursuant to the Oberland Purchase Agreement in excess of $18.0 million during the calendar year 2021, subject to certain exceptions, and (ii) $53.5 million if the Purchasers receive payments pursuant to the Oberland Purchase Agreement in excess of $117.0 million on or prior to December 31, 2026, which milestone payments may each be paid, at the option of the Purchasers, in a lump sum in cash or out of the Purchaser&#8217;s portion of future payments under the Oberland Purchase Agreement. For a discussion of the Oberland Purchase Agreement, see &#8220;Liquidity and Capital Resources &#8211; Royalty Interest Purchase Agreement&#8221;. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to generate any revenues from our direct sale of products for several years, if ever. Substantially all of our revenues to date have been derived from license fees, research and development payments, and other amounts that we have received from our strategic collaborators and licensees, including royalty payments. Since the first quarter of 2012, we have recognized royalty revenues related to Genentech&#8217;s sales of Erivedge and we expect to continue to recognize royalty revenue in future quarters from Genentech&#8217;s sales of Erivedge in the U.S. and Roche&#8217;s sales of Erivedge outside of the U.S. However, a portion of our royalty and royalty-related revenues under our collaboration with Genentech will be paid to the Purchasers, pursuant to the Oberland Purchase Agreement. The Oberland Purchase Agreement will terminate upon the earlier to occur of (i) the date on which Curis Royalty&#8217;s rights to receive the Purchased Receivables owed by Genentech under the Genentech collaboration agreement have terminated in their entirety and (ii) the date on which payment in full of the put/call price is received by the Purchasers pursuant to the Purchasers&#8217; exercise of their put option or Curis Royalty&#8217;s exercise of its call right. For additional information regarding the terms and termination provisions of this agreement, see Note 8,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Liability Related to the Sale of Future Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the accompanying Notes to the Condensed Consolidated Financial Statements included in Item 1 of Part I of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could receive additional milestone payments from Genentech, provided that contractually specified development and regulatory objectives are met. Also, we could receive milestone payments from the Purchasers, provided that contractually specified royalty payment amounts are met within applicable time periods. Our only source of revenues and/or cash flows from operations for the foreseeable future will be royalty payments that are contingent upon the continued commercialization of Erivedge under our collaboration with Genentech, and contingent cash payments for the achievement of clinical, development and regulatory objectives, if any, that are met, under our collaboration with Genentech. Our receipt of additional payments under our collaboration with Genentech cannot be assured, nor can we predict the timing of any such payments, as the case may be.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Royalty Revenues. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of royalty revenues consists of all expenses incurred that are associated with royalty revenues that we record as revenues in our Condensed Consolidated Statements of Operations and Comprehensive Loss. These costs currently consist of payments we are obligated to make to university licensors on royalties that Curis Royalty receives from Genentech on net sales of Erivedge. In all territories other than Australia, our obligation is equal to 5% of the royalty payments that we receive from Genentech for a period of 10 years from the first commercial sale of Erivedge, which occurred in February 2012 in the U.S.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists of costs incurred to develop our drug candidates. These expenses consist primarily of: </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.75pt">salaries and related expenses for personnel, including stock-based compensation expense;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">costs of conducting clinical trials, including amounts paid to clinical centers, clinical research organizations and consultants, among others;</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.75pt"> other outside service costs including costs of contract manufacturing;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.75pt">sublicense payments; </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.75pt">the costs of supplies and reagents;</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.75pt">occupancy and depreciation charges; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">certain payments that we make under our collaboration agreements, including, for example, semi-annual payments, option exercise fees and milestone payments;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">payments that we are obligated to make to certain third-party university licensors upon our receipt of payments from Genentech related to the achievement of clinical development and regulatory objectives under our collaboration agreement; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">internal and external costs of complying with the requirements of the FDA or another regulatory authority.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. We are currently incurring research and development costs under our Hedgehog signaling pathway antagonist collaboration with Genentech related to the maintenance of third-party licenses to certain background technologies.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect that our research and development expenses will increase substantially over the next several years as we conduct our clinical trials of CA-4948 and CI-8993; prepare regulatory filings for our product candidates; continue to develop additional product candidates; and potentially advance our product candidates into later stages of clinical development. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development and commercialization of our product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any of our product candidates. This uncertainty is due to the numerous risks and uncertainties associated with product development and commercialization, including the uncertainty of:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully enroll our current and future clinical trials and our ability to initiate future clinical trials, which has been and may continue to be negatively impacted by the COVID-19 pandemic and responsive measures relating thereto;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, quality of data, rate of progress and cost of clinical trials and other research and development activities undertaken by us or our collaborators;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of future preclinical studies and clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of regulatory approvals and maintaining compliance with regulatory requirements;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of establishing sales, marketing and distribution capabilities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of establishing clinical and commercial supplies of our drug candidates and any products that we may develop;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and effectiveness of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any changes in the outcome of any of these variables with respect to the development of our product candidates could mean a significant change in the costs and timing associated with the development of these product candidates. For example, if the FDA or another regulatory authority were to delay our clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time to complete clinical development of that product candidate. We may never obtain regulatory approval for any of our product candidates. If we do obtain regulatory approval for our product candidates, drug commercialization will take several years and millions of dollars in development costs.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A further discussion of some of the risks and uncertainties associated with completing our research and development programs on schedule, or at all, and some consequences of failing to do so, are set forth under Item 1A, "Risk Factors" of Part I of our Annual Report on Form 10-K for the year ended December 31, 2020.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense consists primarily of salaries, stock-based compensation expense and other related costs for personnel in executive, finance, accounting, business development, legal, information technology, corporate communications and human resource functions. Other costs include facility costs not otherwise included </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in research and development expense, insurance, and professional fees for legal, patent and accounting services. Patent costs include certain patents covered under collaborations, a portion of which is reimbursed by collaborators and a portion of which is borne by us. </span></div><div id="i90810bc68d594941912c6cfda631781c_91"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements in conformity with accounting principles generally accepted in the United States requires that we make estimates and assumptions that affect the reported amounts and disclosure of certain assets and liabilities at our balance sheet date. Such estimates and judgments include the carrying value of property and equipment and intangible assets, revenue recognition, the value of certain liabilities, debt classification and stock-based compensation. We base our estimates on historical experience and on various other factors that we believe to be appropriate under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, there were no material changes to our critical accounting policies and estimates as reported in our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the SEC on March&#160;16, 2021.</span></div><div id="i90810bc68d594941912c6cfda631781c_94"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three and Nine Months Ended September 30, 2021 and September 30, 2020 </span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the&#160;three and nine months ended&#160;September 30, 2021&#160;and&#160;2020:</span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.702%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage<br/>Increase <br/>(Decrease)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage<br/>Increase<br/>(Decrease)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues, net:</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Costs and expenses: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of royalty revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,768&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,051)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,974)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,816)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,391)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Total revenues are summarized as follows:</span></div><div style="margin-top:6pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.848%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage<br/>Increase<br/>(Decrease)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage<br/>Increase<br/>(Decrease)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues, net:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalties</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contra revenue, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&lt;(100)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,039&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,514&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,811&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Total revenues, net of $3.0 million increased by 11% for the three months ended September 30, 2021 as compared to the same period in 2020. The increase is driven by increased royalty revenues arising from Genentech and Roche&#8217;s net sales of Erivedge during the current year period as compared to the prior year period. </span></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues, net of $7.5 million decreased by 4% for the nine months ended September 30, 2021 as compared to the same period in 2020. The decrease was primarily due to the inclusion of a milestone payment from an out-licensed technology that occurred in the first quarter of 2020 for which there was no such amount in 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Royalty Revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cost of royalty revenues increased by 12% for the three months ended September 30, 2021 as compared to the same period in 2020, which is consistent with the increase in royalty revenue. Cost of royalty revenues decreased by 2% for the nine months ended September 30, 2021 as compared to the same period in 2020, which is consistent with the decrease in royalty revenue. We are obligated to make payments to two university licensors on royalties that Curis Royalty earns from Genentech on net sales of Erivedge.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The following table summarizes our research and development expenses incurred during the periods indicated:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.702%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage<br/>Increase<br/>(Decrease)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage<br/>Increase<br/>(Decrease)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Direct research and development expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee related expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,672&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,339&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;100 %</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,523&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,496&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Facilities, depreciation and other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,602&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,705&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,112&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,459&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $8.6 million for the three months ended September 30, 2021 as compared to $4.7 million in the same period in 2020, an increase of approximately $3.9 million, or 83%. Direct research and development expenses increased by $1.6 million for the three months ended September 30, 2021 as compared to the same period in 2020. The increase in direct research and development expenses for the quarter is primarily attributable to increased clinical and manufacturing costs for our programs. Additionally, employee related costs increased by $2.3 million, primarily attributable to increased stock compensation and personnel costs as a result of additional headcount.</span></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $24.1 million for the nine months ended September 30, 2021 as compared to $17.5 million in the same period in 2020, an increase of approximately $6.7 million, or 38%. Direct research and development expenses increased by $2.7 million for the nine months ended September 30, 2021 as compared to the same period in 2020. The increase in direct research and development expenses for the quarter is primarily attributable to increased clinical and manufacturing costs for our programs. The increase in costs is offset by the upfront license fee expense from our option and license agreement with ImmuNext that occurred during the first quarter of 2020. Additionally, employee related costs increased by $4.0 million, primarily attributable to increased stock compensation and personnel costs as a result of additional headcount.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that a majority of our research and development expenses for the foreseeable future will be incurred in connection with our efforts to advance our programs, including clinical and preclinical development costs, manufacturing, option exercise fees, and potential milestone payments upon achievement of certain milestones.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> General and administrative expenses are summarized as follows:</span></div><div style="margin-top:12pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.702%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage<br/>Increase<br/>(Decrease)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage<br/>Increase<br/>(Decrease)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Personnel</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Occupancy and depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Legal services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional and consulting services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;100 %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Insurance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;100 %</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;100 %</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total general and administrative expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,334&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,613&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,524&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,593&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $4.3 million for the three months ended September 30, 2021, as compared to $2.6 million in the same period in 2020, an increase of $1.7 million, or 66%. The increase in general administrative expense was driven primarily by higher costs for stock-based compensation, personnel, and professional and consulting services during the three months ended September 30, 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $12.5 million for the nine months ended September 30, 2021, as compared to $8.6 million in the same period in 2020, an increase of $3.9 million, or 46%. The increase in general administrative expense was driven primarily by higher costs for stock-based compensation, personnel, and professional and consulting services costs during the nine months ended September 30, 2021.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Expense.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other expense decreased by $0.3 million, or 21% for the three months ended September 30, 2021 as compared to the same period in 2020 primarily due to decreased imputed interest expense related to future royalty payments.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense decreased by $1.5 million, or 38% for the nine months ended September 30, 2021 as compared to the same period in 2020 primarily due to the forgiveness of the PPP Loan in June 2021. See "Liquidity and Capital Resources - Debt Financing" for further discussion. The remaining net other expense for the nine months ended September 30, 2021 and September 30, 2020 primarily consisted of imputed interest expense related to future royalty payments.</span></div><div id="i90810bc68d594941912c6cfda631781c_97"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have financed our operations primarily through private and public placements of our equity securities, license fees, contingent cash payments and research and development funding from our corporate collaborators, debt financings, and the monetization of certain royalty rights. See &#8220;Funding Requirements&#8221; and Note 1 to the Condensed Consolidated Financial Statements appearing in this Quarterly Report on Form 10-Q for a further discussion of our liquidity.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021, our principal sources of liquidity consisted of cash, cash equivalents and investments of $149.8 million, excluding our restricted cash of $0.7 million. Our cash and cash equivalents are highly liquid investments with a maturity of three months or less at date of purchase. Our short and long-term investments primarily include commercial paper and securities. We maintain cash balances with financial institutions in excess of insured limits.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock Purchase Agreement </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we entered into a common stock purchase agreement, or the Agreement, with Aspire Capital Fund, LLC, or Aspire Capital, for the sale of up to $30.0 million of our common stock. Under the terms of the Agreement, Aspire Capital has committed to purchase such shares of our common stock at our request, from time to time during a 30-month period at prices based on the market price at the time of each sale, subject to specified terms and limitations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aspire Capital made an initial investment of $3.0 million through the purchase of 2,693,965 shares of our common stock.  In 2020, Aspire Capital subsequently purchased an additional 4,650,000 shares of our common stock for $5.4 million.  In addition, as consideration for Aspire Capital&#8217;s obligation under the Agreement, we issued 646,551 shares of common stock to Aspire Capital as a commitment fee. We also entered into a registration rights agreement with Aspire Capital in connection with our entry into the Agreement in which we agreed to file with the SEC one or more registration statements, as necessary, and to the extent permissible and subject to certain exceptions, to register under the Securities Act, the sale of the shares of our common stock that have been and may be issued to Aspire Capital under the Agreement. As of September 30, 2021 and December 31, 2020, a total of $21.6 million remained available under the Agreement. The Company did not sell shares of common stock under the Agreement during the three and nine months ended September 30, 2021. For the three months ended September 30, 2020, 3,600,000 shares were sold representing net proceeds of $4.2 million. For the nine months ended September 30, 2020, 6,293,965 shares were sold representing net proceeds of $6.8 million. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Agreement, we have the right to sell up to 150,000 shares of common stock per day to Aspire Capital, which total may be increased by mutual agreement up to an additional 2,000,000 shares per day. The extent to which we rely on Aspire Capital as a source of funding will depend on a number of factors, including the prevailing market price of our common stock and the extent to which we are able to secure working capital from other sources. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Agreement, we will control the timing and amount of the further sale of our common stock to Aspire Capital. We plan to use the proceeds for general corporate purposes, including research and development, clinical trial activity and working capital. There are no restrictions on future financings and there are no financial covenants, participation rights, rights of first refusal, or penalties in the Agreement. We have the right to terminate the Agreement at any time without any additional cost or penalty. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Offerings</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we entered into a Capital on Demand&#8482; Sales Agreement with JonesTrading Institutional Services LLC, or JonesTrading, to sell from time to time up to $30.0 million of our common stock through an &#8220;at the market offering&#8221; program under which JonesTrading acted as sales agent. We terminated this sales agreement effective as of December 9, 2020. We did not incur any termination penalties as a result of the termination. As of the effective date of the termination of this sales agreement, we had sold an aggregate of 6,298,648 shares of common stock under the sales agreement for aggregate gross </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceeds of $8.3 million and net proceeds of $7.9 million, after deducting commissions and offering expenses. The $21.7 million of common stock that remained unsold under this sales agreement at the time of termination is no longer available.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2020, we entered into a securities purchase agreement with certain institutional investors, pursuant to which we issued and sold, in a registered direct offering, an aggregate of 14,000,000 shares of our common stock at a purchase price per share of $1.25, for aggregate gross proceeds of $17.5&#160;million, before deducting fees of approximately $1.0&#160;million paid to the placement agent and other offering expenses of approximately $0.5&#160;million  paid by us. JonesTrading acted as the exclusive placement agent for the transaction, and we offered the shares pursuant to our universal shelf registration statement on Form S-3, or the 2018 Shelf, which was filed with the SEC on May 3, 2018 and declared effective by the SEC on May 17, 2018 (File No. 333-224627), and a prospectus supplement thereunder. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2020, we completed an underwritten public offering of 29,500,000 shares of our common stock, including 3,847,826 shares issued and sold upon the exercise in full of the underwriters&#8217; option to purchase additional shares, at a public offering price of $5.75 per share, for aggregate gross proceeds of $169.6 million before deducting underwriting discounts and commissions and other offering expenses of $10.2 million. The securities in this transaction were offered pursuant to the 2018 Shelf and an additional registration statement on Form S-3 (File No. 333-251211) filed pursuant to Rule 462(b) which became automatically effective on December 9, 2020, and a prospectus supplement thereunder.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2021, we entered into a Sales Agreement with Cantor Fitzgerald &amp; Co., or Cantor, and JonesTrading to sell from time to time up to $100.0 million of our common stock through an &#8220;at the market offering&#8221; program under which Cantor and JonesTrading act as sales agents. To date, we have not made any sales of common stock pursuant to the sales agreement. The securities in this transaction were offered pursuant to an automatic shelf registration statement of securities on  Form S-3ASR (File No. 333-254362) that was filed with the SEC on March 16, 2021.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Debt Financing</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, we entered into a promissory note evidencing an unsecured $0.9 million loan, or the PPP Loan, under the Paycheck Protection Program, or PPP, of the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act as administered by the U.S. Small Business Administration, or the SBA. The PPP Loan was made by Silicon Valley Bank and had a term of 24-months and an interest rate of 1%. Under the terms of the CARES Act and the Paycheck Protection Program Flexibility Act of 2020, PPP Loan recipients can apply for and be granted forgiveness for all or a portion of loans granted under the PPP. We applied for such forgiveness in 2020 and received notification in June 2021 that the SBA had forgiven the PPP Loan in full, including interest accrued on the PPP Loan. During the nine months ended September 30, 2021, the Company recorded a gain of $0.9 million to Other income (expense), net for extinguishment of the debt. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Royalty Interest Purchase Agreement </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, we and Curis Royalty entered into the Oberland Purchase Agreement with the Purchasers. We sold to the Purchasers a portion of our rights to receive royalties from Genentech on potential net sales of Erivedge. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As upfront consideration for the purchase of the royalty rights, at closing the Purchasers paid to Curis Royalty $65.0 million less certain transaction expenses. Curis Royalty will also be entitled to receive up to approximately $70.7 million in milestone payments based on sales of Erivedge as follows: (i) $17.2 million if the Purchasers and Curis Royalty receive aggregate royalty payments pursuant to the Oberland Purchase Agreement in excess of $18.0 million during the calendar year 2021, subject to certain exceptions and (ii) $53.5 million if the Purchasers receive payments pursuant to the Oberland Purchase Agreement in excess of $117.0 million on or prior to December 31, 2026. For further discussion please refer to Note 8, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Liability Related to the Sale of Future Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, in the accompanying Notes to the Condensed Consolidated Financial Statements included in Item 1 of Part I of this Quarterly Report on Form 10-Q. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments and Monetization of Royalty Rights</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received aggregate milestone payments totaling $59.0 million under our collaboration with Genentech since 2012. In addition, we began receiving royalty revenues in 2012 in connection with Genentech&#8217;s sales of Erivedge in the U.S. and Roche&#8217;s sales of Erivedge outside of the U.S. Erivedge royalty revenues received after December 2012 have been used to repay Curis Royalty&#8217;s outstanding principal and interest under the loans due to BioPharma-II and HealthCare Royalty. A portion of Erivedge royalty and royalty-related revenue payments will be paid to the Purchasers pursuant to the Oberland Purchase Agreement. We also remain entitled to receive any contingent payments upon achievement of clinical development objectives and royalty payments related to sales of Erivedge pursuant to our collaboration agreement with Genentech and certain contingent payments upon achievement of contractually specified royalty revenue payment amounts related to sales of Erivedge pursuant to the Oberland Purchase Agreement. Upon receipt of any such payments, as well as on royalties received in any territory other than Australia, we are required to make payments to certain university licensors totaling 5% of these amounts. In addition, for royalties that Curis Royalty receives from Roche&#8217;s sales of Erivedge in Australia, we were obligated to make payments to university licensors of 2% of Roche&#8217;s direct net sales in Australia until the expiration of the patent in April 2019. After April 2019, the amount we are obligated to pay in Australia decreased to 5% of the royalty payments that Curis Royalty receives from Genentech.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows for operations have primarily been used for salaries and wages for our employees, facility and facility-related costs for our office and laboratory, fees paid in connection with preclinical and clinical studies, laboratory supplies, consulting fees and legal fees. We expect that costs associated with clinical studies will increase in future periods.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities of $29.4 million during the nine months ended September 30, 2021 was primarily the result of our net loss for the period of $31.8 million, offset by non-cash charges consisting of stock-based compensation, loan forgiveness, non-cash lease expense, depreciation, and non-cash imputed interest totaling $4.7 million. Accounts payable, accrued expenses and operating lease liability decreased by $0.6 million and prepaid expenses and other assets increased by $1.9 million. These changes increased cash utilization. Accounts receivable decreased $0.1 million and reduced cash utilization. We recognized a gain of $0.9 million on the forgiveness of the PPP Loan. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities of $20.0 million during the nine months ended September 30, 2020 was primarily the result of our net loss for the period of $22.4 million, offset by non-cash charges consisting of stock-based compensation, amortization of debt issuance costs, non-cash lease expense, depreciation, and non-cash imputed interest totaling $2.5 million. Accounts payable and accrued and other liabilities increased $0.7 million, and accounts receivable decreased $0.5 million related to a decrease in Erivedge royalties. Prepaid expenses and other assets decreased $0.9 million.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to use cash in operations as we seek to advance our drug candidates and our programs under our collaboration agreements with Aurigene and ImmuNext. In addition, in the future we may owe royalties and other contingent payments to our licensors based on the achievement of developmental milestones, product sales and other specified objectives.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing activities used cash of $44.4 million and provided cash of $4.4 million for the nine months ended September 30, 2021 and 2020, respectively, resulting primarily from net investment activity from purchases and sales or maturities of investments for the respective periods. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing activities used cash of $2.9 million for the nine months ended September 30, 2021, primarily due to the payment of our liability under the Oberland Purchase Agreement.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing activities provided cash of $23.6 million for the nine months ended September 30, 2020, as a result of the proceeds from our registered direct offering in June 2020, our sales to Aspire Capital pursuant to our common stock purchase agreement, our at-the-market sales pursuant to our Sales Agreement with JonesTrading, and our PPP Loan, partially offset by the payment of our liability under the Oberland Purchase Agreement.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">We have historically derived a portion of our operating cash flow from our receipt of milestone payments under collaboration agreements with third parties. However, we cannot predict whether we will receive additional milestone payments under existing or future collaborations.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Funding Requirements </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant losses since our inception. As of September 30, 2021, we had an accumulated deficit of approximately $1.1 billion. We will require substantial funds to continue our research and development programs and to fulfill our planned operating goals. Our planned operating and capital requirements currently include the support of our current and future research and development activities for CA-4948 and CI-8993 as well as development candidates we have and continue to license under our collaborations with Aurigene and ImmuNext. We will require substantial additional capital to fund the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">further development of these programs, as well as to fund our general and administrative costs and expenses. Moreover, our agreements with collaborators impose significant potential financial obligations on us. For example, under our collaboration, license and option agreement with Aurigene, we are required to make milestone, royalty and option fee payments for discovery, research and preclinical development programs that will be performed by Aurigene, which impose significant potential financial obligations on us. In addition, if we choose to exercise our option under the option and license agreement with ImmuNext, or the ImmuNext Agreement, we will be required to make milestone, royalty, and option fee payments in connection with the development of CI-8993.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon our current operating plan, we believe that our existing cash, cash equivalents and investments of $149.8 million as of September 30, 2021, should enable us to fund our operating expenses and capital expenditure requirements into 2024.  We have based this assessment on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. We will need to raise additional capital or incur indebtedness to continue to fund our operations in the future. Our ability to raise additional funds will depend on financial, economic and market conditions, many of which are outside of our control, and we may be unable to raise financing when needed, or on terms favorable to us. If necessary funds are not available, we may have to delay, reduce the scope of, or eliminate some of our development programs, potentially delaying the time to market for, or preventing the marketing of, any of our product candidates, which could adversely affect our business prospects, and we may be unable to continue our operations.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, there are a number of factors that may affect our future capital requirements and further accelerate our need for additional working capital, many of which are outside our control, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated costs in our research and development programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and cost of obtaining regulatory approvals for our drug candidates and maintaining compliance with regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">payments due to licensors, including Aurigene and ImmuNext if we exercise our option under the ImmuNext Agreement, for patent rights and technology used in our drug development programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of commercialization activities for any of our drug candidates that receive marketing approval, to the extent such costs are our responsibility, including the costs and timing of establishing drug sales, marketing, distribution and manufacturing capabilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unplanned costs to prepare, file, prosecute, defend and enforce patent claims and other patent-related costs, including litigation costs and technology license fees; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected losses in our cash investments or an inability to otherwise liquidate our cash investments due to unfavorable conditions in the capital markets; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impacts resulting from the COVID-19 pandemic and responsive actions relating thereto.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To become and remain profitable, we, either alone or with collaborators, must develop and eventually commercialize one or more drug candidates with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our drug candidates, obtaining marketing approval for these drug candidates, manufacturing, marketing and selling those drugs for which we may obtain marketing approval and satisfying any post marketing requirements. We may never succeed in these activities and, even if we do, may never generate revenues that are significant or large enough to achieve profitability. Other than Erivedge, which is being commercialized by Genentech and Roche, our most advanced drug candidates are currently only in early clinical testing.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the foreseeable future, we will need to spend significant capital in an effort to develop and commercialize products and we expect to incur substantial operating losses. Our failure to become and remain profitable would, among other things, depress the market price of our common stock and could impair our ability to raise capital, expand our business, diversify our research and development programs or continue our operations.</span></div><div id="i90810bc68d594941912c6cfda631781c_100"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For detailed information regarding&#160;recently issued accounting pronouncements&#160;and the expected impact on our Condensed Consolidated Financial Statements, see Note 2g, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the accompanying Notes to Condensed Consolidated Financial Statements included in Item 1 of Part I of this Form 10-Q.</span></div><div id="i90810bc68d594941912c6cfda631781c_103"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our contractual obligations set forth under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Contractual Obligations&#8221; in our Annual Report on Form&#160;10-K for the year ended December 31, 2020.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i90810bc68d594941912c6cfda631781c_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no off-balance sheet arrangements as of September 30, 2021.</span></div><div id="i90810bc68d594941912c6cfda631781c_109"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not required.</span></div><div id="i90810bc68d594941912c6cfda631781c_112"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of Disclosure Controls&#160;&amp; Procedures</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2021. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2021, our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the three months ended September 30, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i90810bc68d594941912c6cfda631781c_115"></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i90810bc68d594941912c6cfda631781c_118"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to a number of risks that could materially and adversely affect our business, financial condition, and results of operations and future prospects, including those identified in Item 1A., &#8220;Risk Factors&#8221; of Part I of our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the SEC on March 16, 2021.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i90810bc68d594941912c6cfda631781c_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.332%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cris-9302021x10qexx31.htm">Restated Certificate of Incorporation of Curis, Inc., as amended</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cris-9302021x10qexx31.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1 *</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cris-9302021x10qexx311.htm">Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Exchange Act</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2 *</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cris-9302021x10qexx312.htm">Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Exchange Act</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1 *</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cris-9302021x10qexx321.htm">Certification of the Chief Executive Officer pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section&#160;1350</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2 *</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cris-9302021x10qexx322.htm">Certification of the Principal Financial Officer pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section&#160;1350</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS *</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">InLine XBRL Instance Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH *</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">InLine XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL *</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">InLine XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF *</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">InLine XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB *</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">InLine XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE *</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">InLine XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*  Filed herewith </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i90810bc68d594941912c6cfda631781c_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i90810bc68d594941912c6cfda631781c_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.850%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CURIS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ JAMES E. DENTZER</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">James E. Dentzer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CURIS, INC.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ WILLIAM STEINKRAUSS</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">William Steinkrauss</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>cris-9302021x10qexx31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i509178fc35f54af4955a7da9837fe7fa_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EXHIBIT 3.1</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">RESTATED CERTIFICATE OF INCORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CURIS, INC.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CURIS, INC. (the &#8220;Corporation&#8221;), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the &#8220;General Corporation Law&#8221;), hereby certifies as follows&#58;</font></div><div style="margin-top:6.6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The name of the Corporation is Curis, Inc. A Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on February&#160;14, 2000.</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Restated Certificate of Incorporation restates and integrates and further amends the Certificate of Incorporation of the Corporation, was duly adopted by the Board of Directors of the Corporation in accordance with the provisions of Sections 141 and 245 of the Delaware General Corporation Law, and was approved by written consent of the stockholders of the Corporation given in accordance with the provisions of Section&#160;228 and Section&#160;242 of the Delaware General Corporation Law (prompt notice of such action having been given to those stockholders who did not consent in writing).</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The text of the Certificate of Incorporation of the Corporation is hereby restated and amended to read in its entirety as follows&#58;</font></div><div style="margin-top:6.6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">FIRST</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The name of this corporation (the &#8220;Corporation&#8221;) is Curis, Inc.</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">SECOND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The address of the registered office of the Corporation in the State of Delaware is 1209 Orange Street, Wilmington, Delaware 19801, County of New Castle, and the name of its registered agent at such address is The Corporation Trust Company.</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">THIRD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The purpose for which the Corporation is organized is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware.</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">FOURTH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Corporation is authorized to issue two classes of capital stock, one of which is designated as common stock, $.01 par value per share (&#8220;Common Stock&#8221;), and the other of which is designated as preferred stock, $.01 par value per share (&#8220;Preferred Stock&#8221;). The total number of shares of both classes of capital stock that the Corporation shall have authority to issue is 130,000,000 shares, consisting of 125,000,000 shares of Common Stock and 5,000,000 shares of Preferred Stock. The Preferred Stock may be issued from time to time in one or more series as set forth in Section (b)&#160;of this Article FOURTH. The following is a statement of the designations and the powers, preferences and rights of, and the qualifications, limitations or restrictions applicable to, each class of capital stock of the Corporation.</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.84pt">Common Stock</font></div><div style="margin-top:6.6pt;padding-left:4.5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> General.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The voting, dividend and liquidation rights of holders of Common Stock are subject to and qualified by the rights of holders of Preferred Stock of any series as may be designated in any resolution or resolutions providing for the issue of such series as may be adopted by the board of directors as hereinafter provided.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.918%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">STATE OF DELAWARE<br>SECRETARY OF STATE<br>DIVISION OF CORPORATIONS<br>FILED 01&#58;30 PM 06&#47;19&#47;2000<br>001309790 - 3152050</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="padding-left:4.5pt;text-indent:22.5pt"><font><br></font></div><div style="padding-left:4.5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Voting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Holders of Common Stock are entitled to one vote for each share held at all meetings of stockholders. The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the capital stock of the Corporation entitled to vote, irrespective of the provisions of Section&#160;242(b)(2) of the General Corporation Law of the State of Delaware.</font></div><div style="margin-top:6.6pt;padding-left:4.5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Dividends.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Dividends may be declared and paid on Common Stock from funds lawfully available therefor, as and when determined by the board of directors and subject to any preferential dividend rights of any series of Preferred Stock then outstanding.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6.6pt;padding-left:4.5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Liquidation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Upon the dissolution or liquidation of the Corporation, whether voluntary or involuntary, holders of Common Stock will be entitled to receive all assets of the Corporation available for distribution to stockholders of the Corporation, subject to any preferential rights of any series of Preferred Stock then outstanding.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.28pt">Preferred Stock</font></div><div style="margin-top:6.6pt;padding-left:4.5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Issuance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Preferred Stock may be issued from time to time in one or more series, each of which series shall have such terms as are set forth herein and in any resolution or resolutions providing for the issue of such series as may be adopted by the board of directors as hereinafter provided. Any shares of Preferred Stock that may be redeemed, purchased or acquired by the Corporation may be reissued except as otherwise expressly provided in this Certificate of Incorporation or provided by law. Different series of Preferred Stock shall not be construed to constitute different classes of capital stock for the purposes of voting by classes unless expressly provided.</font></div><div style="margin-top:6.6pt;padding-left:4.5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Authority of Board.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Authority is hereby expressly granted to the board of directors to provide for the issuance of Preferred Stock from time to time in one or more series, and in connection with the creation of any such series, to determine and fix such voting powers, full or limited, or no voting powers, and such designations, preferences and relative participating, optional or other special rights thereof, and qualifications, limitations or restrictions applicable thereto, as shall be stated and expressed in such resolutions, all to the full extent now or hereafter permitted by the General Corporation Law of the State of Delaware. Without limiting the generality of the foregoing, a resolution or resolutions providing for issuance of any series of Preferred Stock may provide for dividend rights, conversion rights, redemption privileges and liquidation preferences applicable to such series and may provide that such series shall rank superior, equal or junior to the Preferred Stock of any other series, in each case except as otherwise expressly provided in this Certificate of Incorporation or as provided by law. Except as otherwise provided in this Certificate of Incorporation, no vote of holders of Common Stock or holders of Preferred Stock shall be a prerequisite to the designation or issuance of any shares of any series of Preferred Stock authorized by and complying with the conditions of this Certificate of Incorporation.</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">FIFTH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Special meetings of stockholders may be called at any time by the Chairman of the Board, the Chief Executive Officer (or if there is no Chief Executive Officer, the President) or the board of directors. Business transacted at any special meeting of stockholders shall be limited to matters relating to the purpose or purposes stated in the notice of the general meeting. From and after the effective date of the Form 8-A Registration Statement under the Securities Exchange Act of 1934, as amended, the stockholders of the Corporation shall not be permitted to take any action otherwise required to be taken at any annual meeting or special meeting of the stockholders of the Corporation by a consent in writing in lieu of any such meeting.</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">SIXTH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No director shall be personally liable to the Corporation or to any of its stockholders for monetary damages arising out of such director&#8217;s breach of fiduciary duty as a director of the Corporation, except to the extent that the elimination or limitation of such liability is not permitted by the General Corporation Law of the State of Delaware, as the same exists or may hereafter be amended. No amendment to or repeal of the provisions of this Article SIXTH shall deprive any director of the Corporation of the benefit of the provisions of this Article SIXTH with respect to any act or failure to act of any director occurring prior to such amendment or repeal.</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">SEVENTH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In furtherance of and not in limitation of powers conferred by statute, it is further provided that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.84pt">Amendment of By-Laws</font></div><div style="margin-top:6.6pt;padding-left:4.5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the limitations and exceptions, if any, contained in the by-laws of the Corporation, the by-laws may be adopted, amended or repealed by the board of directors.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.28pt">Election of Directors</font></div><div style="margin-top:6.6pt;padding-left:4.5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elections of directors need not be by written ballot unless otherwise provided in the by-laws of the Corporation.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.41pt">Location of Corporate Books</font></div><div style="margin-top:6.6pt;padding-left:4.5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to any applicable requirements of the General Corporation Law of the State of Delaware, the books of the Corporation may be kept outside the State of Delaware at such location or locations as may be designated from time to time by the board of directors or in the by-laws of the Corporation.</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">EIGHTH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Corporation shall indemnify each person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Corporation), by reason of the fact that such person is or was, or has agreed to become, a </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:13.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">director or officer of the Corporation, or is or was serving or has agreed to serve, at the request of the Corporation, as a director, officer or trustee of, or in a similar capacity with, another corporation (including any partially or wholly owned subsidiary of the Corporation), partnership, joint venture, trust or other enterprise (including any employee benefit plan), against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with any such action, suit or proceeding to the maximum extent permitted by the General Corporation Law of Delaware. The foregoing right of indemnification shall in no way be exclusive of any other rights of indemnification to which any such director or officer may be entitled, under any by-law, agreement, vote of directors or stockholders or otherwise. No amendment to or repeal of the provisions of this paragraph shall deprive a person of the benefit of this paragraph with respect to any act or failure to act of such person occurring prior to such amendment or repeal.</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">NINTH&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Whenever a compromise or arrangement is proposed between the Corporation and its creditors or any class of them or between the Corporation and its stockholders or any class of them, any court of equitable jurisdiction within the State of Delaware may, on the application in a summary way of the Corporation or of any creditor or stockholder thereof or on the application of any receiver or receivers appointed for the Corporation under Section&#160;291 of Title 8 of the Delaware Code or on the application of trustees in dissolution or of any receiver or receivers appointed for the Corporation under Section&#160;279 of Title 8 of the Delaware Code, order a meeting of the creditors or class of creditors, and&#47;or of the stockholders or class of stockholders of the Corporation, as the case my be, to be summoned in such manner as the said court directs. If a majority in number representing three-fourths in value of the creditors or class of creditors, and&#47;or of the stockholders or class of stockholders of the Corporation, as the case may be, agree to any compromise or arrangement and to any reorganization of the Corporation as a consequence of such compromise or arrangement, the said compromise or arrangement and the said reorganization shall, if sanctioned by the court to which the said application has been made, be binding on all the creditors or class of creditors, and&#47;or on all the stockholders or class of stockholders, of the Corporation, as the case may be, and also on the Corporation.</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">TENTH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Corporation reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation in the manner now or hereafter prescribed by the General Corporation Law of the State of Delaware and this Certificate of Incorporation, and all rights conferred upon stockholders herein are granted subject to this reservation. Notwithstanding any provision of law, any other provision of this Certificate of Incorporation or any provision of the by-laws of the Corporation, the affirmative vote of the holders of three-fourths of the shares of capital stock of the Corporation issued and outstanding and entitled to vote shall be required to amend or repeal, or to adopt any provision inconsistent with, any provision of Article FIFTH or this Article TENTH.</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">ELEVENTH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The name of the sole incorporator of the Corporation is Jonathan H. Hulbert and his mailing address is c&#47;o Foley, Hoag&#160;&#38; Eliot LLP, One Post Office Square, Boston, Massachusetts 02109.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Corporation has caused this Restated Certificate of Incorporation to be executed by the undersigned as of the 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  day June, 2000.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.836%"><tr><td style="width:1.0%"></td><td style="width:8.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.336%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.908%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CURIS, INC.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Doros Platika</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Doros Platika<br>President and Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:186.75pt;padding-right:186.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State of Delaware</font></div><div style="padding-left:186.75pt;padding-right:186.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Secretary of State</font></div><div style="padding-left:186.75pt;padding-right:186.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Division of Corporations</font></div><div style="padding-left:186.75pt;padding-right:186.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Delivered 02&#58;45 PM 05&#47;30&#47;2013</font></div><div style="padding-left:186.75pt;padding-right:186.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FILED 02&#58;36 PM 05&#47;30&#47;2013</font></div><div style="padding-left:186.75pt;padding-right:186.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SRV 130697723 - 3152050 FILE</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:13.2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATE OF AMENDMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESTATED CERTIFICATE OF INCORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURIS, INC.</font></div><div style="margin-top:6.6pt;text-indent:22.5pt"><font><br></font></div><div style="margin-top:6.6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Curis, 1nc. (the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> &#34;Corporation&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify&#58;</font></div><div style="margin-top:6.6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FIRST&#58; That the Board of Directors of the Corporation has duly adopted resolutions authorizing and approving an amendment to the Restated Certificate of Incorporation of the Corporation to (i)&#160;increase the number of authorized shares of capital stock of the Corporation and (ii)&#160;increase the number of authorized shares of Common Stock of the Corporation.</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECOND&#58; That the amendment to the Restated Certificate of Incorporation of the Corporation set forth in this Certificate of Amendment was duly adopted in accordance with the provisions of Section&#160;242 of the General Corporation Law of Delaware by the Board of Directors and holders of a majority of the outstanding stock of the Corporation entitled to vote thereon.</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">THIRD&#58; That upon the effectiveness of this Certificate of Amendment, the first paragraph of Article FOURTH of the Restated Certificate of Incorporation is hereby amended and restated as follows&#58;</font></div><div style="margin-top:6.6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOURTH&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Corporation is authorized to issue two classes of capital stock, one of which is designated as common stock, $.01 par value per share (&#8220;Common Stock&#8221;), and the other of which is designated as preferred stock, $.01 par value per share (&#8220;Preferred Stock&#8221;). The total number of shares of both classes of capital stock that the Corporation shall have authority to issue is 230,000,000 shares, consisting of 225,000,000 shares of Common Stock and 5,000,000 shares of Preferred Stock. The Preferred Stock may be issued from time to time in one or more series as set forth in Section (b)&#160;of this Article FOURTH. The following is a statement of the designations and the powers, preferences and rights of, and the qualifications, limitations or restrictions applicable to, each class of capital stock of the Corporation.&#8221;</font></div><div style="margin-top:6.6pt;text-align:center;text-indent:22.5pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* * *</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:20.25pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, this Certificate of Amendment of Restated Certificate of Incorporation has been executed by a duly authorized officer of the Corporation on this 30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  day of May, 2013.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:11.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.982%"><tr><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.677%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Dan Passeri</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dan Passeri<br>Title&#58; Chief Executive Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:173.25pt;padding-right:173.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State of Delaware</font></div><div style="padding-left:173.25pt;padding-right:173.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Secretary of State</font></div><div style="padding-left:173.25pt;padding-right:173.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Division of Corporations</font></div><div style="padding-left:173.25pt;padding-right:173.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Delivered  10&#58;46 AM 05&#47;15&#47;2018 </font></div><div style="padding-left:173.25pt;padding-right:173.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FILED 10&#58;46 AM 05&#47;15&#47;2018</font></div><div style="padding-left:173.25pt;padding-right:173.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SR 20183757772 - File Number 3152050</font></div><div style="padding-left:351pt"><font><br></font></div><div style="margin-top:13.2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATE OF AMENDMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESTATED CERTIFICATE OF INCORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURIS, INC.</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Curis, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify&#58;</font></div><div style="padding-left:4.5pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FIRST&#58;&#160;&#160;&#160;&#160;That the Board of Directors of the Corporation has duly adopted resolutions authorizing and approving an amendment to the Restated Certificate of Incorporation of the Corporation to (i) increase the number of authorized shares of capital stock of the Corporation and (ii) increase the number of authorized shares of Common Stock  of the Corporation.</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECOND&#58; That the amendment to the Restated Certificate of Incorporation of the Corporation set forth in this Certificate of Amendment was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of Delaware by the Board of Directors and holders of a majority of the outstanding stock of the Corporation entitled to vote thereon.</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">THIRD&#58;&#160;&#160;&#160;&#160;That upon the effectiveness of this Certificate of Amendment, the first paragraph of Article FOURTH of the Restated Certificate of 1ncorporation is hereby amended and restated as follows&#58;</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#34;FOURTH&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporation is authorized to issue two classes of capital stock, one of which is designated as common stock, $.01 par value per share (&#34;Common Stock&#34;), and the other of which is designated as preferred stock, $.01 par value per share (&#34;Preferred Stock&#34;). The total number of shares of both classes of capital stock that the Corporation shall have authority to issue is 342,500,000 shares, consisting of 337,500,000 shares of Common Stock and 5,000,000 shares of Preferred Stock. The Preferred Stock may be issued from time to time in one or more series as set forth in Section (b) of this Article FOURTH. The following is a statement of the designations and the powers, preferences and rights of, and the qualifications, limitations or restrictions applicable to, each class of capital stock of the Corporation.&#34;</font></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:20.25pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, this Certificate of Amendment of Restated Certificate of Incorporation has been executed by a duly authorized officer of the Corporation on this 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  day of May, 2018.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.298%"><tr><td style="width:1.0%"></td><td style="width:11.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Ali Fattaey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ali Fattaey, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">                    State of Delaware</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">                     Secretary of State</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">               Division of Corporations</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">        Delivered  08&#58;05 AM 0512912018</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">          FILED  08&#58;05 AM 0512912018</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SR 20184453936 - File Number 3152050</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:351pt"><font><br></font></div><div style="margin-top:13.2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATE OF AMENDMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESTATED CERTIFICATE OF INCORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURIS, INC.</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Curis, 1nc. (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#34;Corporation&#34;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify&#58;</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FIRST&#58;&#160;&#160;&#160;&#160;That the Board of Directors of the Corporation has duly adopted resolutions authorizing and approving an amendment to the Restated Certificate of Incorporation of the Corporation.</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECOND&#58; That the amendment to the Restated Certificate of Incorporation  of the Corporation set forth in this Certificate of Amendment was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of Delaware by the Board of Directors and holders of a majority of the outstanding stock of the Corporation entitled to vote thereon.</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">THIRD&#58;&#160;&#160;&#160;&#160;That upon the effectiveness of this Certificate of Amendment, Article FOURTH of the Restated Certificate of Incorporation is hereby amended by adding the following two paragraphs as the first two paragraphs in lieu of the existing first paragraph of such Article FOURTH&#58;</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Effective at 5&#58;00 p.m., Eastern Time, on the date of filing of this Certificate of Amendment to the Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the &#34;Effective Time&#34;),  a one-for-five reverse stock split of the Corporation's common stock, $0.01 par  value per share (the &#34;Common Stock&#34;), shall become effective, pursuant to which each five shares of Common Stock issued or outstanding (including treasury shares) immediately prior to the Effective Time shall be reclassified  and combined into one validly issued, fully paid and nonassessable share of Common Stock automatically and without any action by the holder thereof upon the Effective Time and shall represent one share of Common Stock from and after the Effective Time (such reclassification and combination of shares, the &#34;Reverse Stock Split&#34;). The par value of the Common Stock following the Reverse Stock Split shall remain at $0.01 par value per share. No fractional shares of Common Stock shall be issued as a result of the Reverse Stock Split and, in lieu thereof, upon surrender after the Effective Time of a certificate which formerly represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time, any person who would otherwise be entitled to a fractional share of Common Stock as a result of the Reverse Stock Split, following the Effective Time, shall be entitled to receive a cash payment equal to the fraction of a share of Common Stock to which such holder would otherwise be entitled multiplied by the fair value per share of the Common Stock immediately prior to the Effective Time as determined by the Board of Directors of the Corporation.</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each stock certificate that, immediately prior to the Effective Time, represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall, from and after the Effective Time, automatically and without the necessity of presenting the same for exchange, represent that number of whole shares of Common Stock after the Effective Time into which the shares formerly represented by such certificate have been reclassified (as well as the right to receive cash in lieu of fractional shares of Common Stock after the Effective Time)&#59; provided, however, that each person of record holding a certificate that represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall receive, upon surrender of such certificate, a new certificate evidencing and representing the number of whole shares of Common Stock after the Effective Time into which the shares of Common Stock formerly represented by such certificate shall have been reclassified. The Corporation is authorized to issue two classes of capital stock, one of which is designated as Common Stock, and the other of which is designated as preferred stock, $.01 par value per share (&#34;Preferred Stock&#34;). The total number of shares of both classes of capital stock that the Corporation shall have authority to issue is 72,500,000 shares, consisting of 67,500,000 shares of Common Stock and 5,000,000 shares of Preferred Stock. The Preferred Stock may be issued from time to time in one or more series as set forth in Section (b) of this Article FOURTH. The following is a statement of the </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:13.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">designations and the powers, preferences and rights of, and the qualifications, limitations or restrictions applicable to, each class of capital stock of the Corporation.&#34;</font></div><div style="margin-top:13.2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*   *   *</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:20.25pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, this Certificate of Amendment of Restated Certificate of Incorporation has been executed by a duly authorized officer of the Corporation on this 29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  day of May, 2018.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.298%"><tr><td style="width:1.0%"></td><td style="width:11.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Ali Fattaey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ali Fattaey, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">   &#160;&#160;&#160;&#160;       State of Delaware</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">                     Secretary of State</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">               Division of Corporations</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">        Delivered  02&#58;54 Pi&#92;I 05123&#47;2019</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">          FILED  02&#58;54 Pi&#92;! 05123&#47;2019</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SR 20194444435 - File Number 3152050</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:351pt"><font><br></font></div><div style="margin-top:13.2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATE OF AMENDMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESTATED CERTIFICATE OF INCORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURIS, INC.</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Curis, Inc. (the &#34;Corporation&#34;), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify&#58;</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FIRST&#58;&#160;&#160;&#160;&#160;That the Board of Directors of the Corporation has duly adopted resolutions authorizing and approving an amendment to the Restated Certificate of Incorporation of the Corporation to (i) increase the number of authorized shares of capital stock of the Corporation and (ii) increase the number of authorized shares of Common Stock of the Corporation.</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECOND&#58; &#160;&#160;&#160;&#160;That the amendment to the Restated Certificate of Incorporation of the Corporation set forth in this Certificate of Amendment was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of Delaware by the Board of Directors and holders of a majority of the outstanding stock of the Corporation entitled to vote thereon.</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">THIRD&#58;&#160;&#160;&#160;&#160;That upon the effectiveness of this Certificate of Amendment, the first two paragraphs of Article FOURTH of the Restated Certificate of Incorporation are hereby amended and restated as follows&#58;</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOURTH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; The Corporation is authorized to issue two classes of capital stock, one of which is designated as common stock, $.01 par value per share (&#34;Common Stock&#34;), and the other of which is designated as preferred stock, $.01 par value per share (&#34;Preferred Stock&#34;). The total number of shares of both classes of capital stock that the Corporation shall have authority to issue is 106,250,000 shares, consisting of 101,250,000 shares of Common Stock and 5,000,000 shares of Preferred Stock. The Preferred Stock may be issued from time to time in one or more series as set forth in Section (b) of this Article FOURTH. The following is a statement of the designations and the powers, preferences and rights of, and the qualifications, limitations or restrictions applicable to, each class of capital stock of the Corporation.&#34;</font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font><br></font></div><div style="margin-top:13.2pt;text-align:center"><font><br></font></div><div style="margin-top:13.2pt;text-indent:22.5pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:20.25pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, this Certificate of Amendment of Restated Certificate of Incorporation has been executed by a duly authorized officer of the Corporation on this 23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  day of May, 2019.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.298%"><tr><td style="width:1.0%"></td><td style="width:11.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; James E. Dentzer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James E. Dentzer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">                     State of Delaware </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">                     Secretary of State </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">              Division of Corporations</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">       Delivered 04&#58;32 PM 06&#47;04&#47;2020 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">          FILED 04&#58;32 PM 06&#47;04&#47;2020</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SR 20205507455 - File Number 3152050</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:11.05pt;padding-left:3.37pt;padding-right:3.37pt;text-align:center;text-indent:36pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATE OF AMENDMENT </font></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center;text-indent:36pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF</font></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center;text-indent:36pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESTATED CERTIFICATE OF INCORPORATION </font></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center;text-indent:36pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF</font></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center;text-indent:36pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURIS, INC.</font></div><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center;text-indent:36pt"><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:36pt;padding-right:6.75pt;text-indent:36pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Curis, Inc. (the </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#34;Corporation&#34;), </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify&#58;</font></div><div style="margin-top:4.55pt;padding-left:36pt;padding-right:6.75pt;text-indent:36pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:36pt;padding-right:6.75pt;text-indent:36pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FIRST&#58; That the Board of Directors of the Corporation has duly adopted resolutions authorizing and approving an amendment to the Restated Certificate of Incorporation of the Corporation to (i) increase the number of authorized shares of capital stock of the Corporation and (ii) increase the number of authorized shares of Common Stock of the Corporation.</font></div><div style="margin-top:4.55pt;padding-left:36pt;padding-right:6.75pt;text-indent:36pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:36pt;padding-right:6.75pt;text-indent:36pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECOND&#58; That the amendment to the Restated Certificate of Incorporation of the Corporation set faith in this Certificate of Amendment was duly adopted in</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accordance with the provisions of Section 242 of the General Corporation Law of Delaware by the Board of Directors and holders of a majority of the outstanding stock of the Corporation entitled to vote thereon.</font></div><div style="margin-top:4.55pt;padding-left:36pt;padding-right:6.75pt;text-indent:36pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:36pt;padding-right:6.75pt;text-indent:36pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">THIRD&#58; That upon the effectiveness of this Certificate of Amendment, the first paragraph of Article FOURTH of the Restated Certificate of Incorporation is hereby amended and restated as follows&#58;</font></div><div style="margin-top:4.55pt;padding-left:36pt;padding-right:6.75pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:36pt;padding-right:6.75pt;text-indent:36pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#34;FOURTH&#58; </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporation is authorized to issue two classes of capital stock, one of which is designated as common stock, $.01 par value per share (&#34;Common Stock&#34;), and the other of which is designated as preferred stock, $.01 par value per share (&#34;Preferred Stock&#34;). The total number of shares of both classes of capital stock that the Corporation shall have authority to issue is 156,875,000 shares, consisting of 151,875,000 shares of Common Stock and 5,000,000 shares of Preferred Stock. The Preferred Stock may be issued from time to time in one or more series as set forth in Section (b) of this Article FOURTH. The following is a statement of the designations and the powers, preferences and rights of, and the qualifications, limitations or restrictions applicable to, each class of capital stock of the Corporation.&#34;</font></div><div style="margin-top:4.55pt;padding-left:36pt;padding-right:6.75pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, this Certificate of Amendment of Restated Certificate of Incorporation has been executed by a duly authorized officer of the Corporation on this 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day of June, 2020.</font></div><div style="margin-top:4.55pt;padding-left:36pt;padding-right:6.75pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:36pt;padding-right:6.75pt;text-align:justify;text-indent:36pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.859%"><tr><td style="width:1.0%"></td><td style="width:14.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; James E. Dentzer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;<br>Title&#58;   </font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James E. Dentzer<br>President and Chief Executive Officer</font></td></tr></table></div><div style="padding-left:245.25pt;padding-right:245.25pt;text-align:center"><font><br></font></div><div style="padding-left:249.75pt;padding-right:249.75pt;text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">      &#160;&#160;&#160;&#160;       State of Delaware </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">                     Secretary of State </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">              Division of Corporations</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">       Delivered 08&#58;28 PM 05&#47;28&#47;2021 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">          FILED 08&#58;28 PM 05&#47;28&#47;2021</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SR 20212231164 - File Number 3152050</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATE OF AMENDMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESTATED CERTIFICATE OF INCORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURIS, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Curis, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FIRST&#58;            That the Board of Directors of the Corporation has duly adopted resolutions authorizing and approving an amendment to the Restated Certificate of Incorporation of the Corporation to (i) increase the number of authorized shares of capital stock of the Corporation and (ii) increase the number of authorized shares of Common Stock of the Corporation.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECOND&#58;       That the amendment to the Restated Certificate of Incorporation of the Corporation set forth in this Certificate of Amendment was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of Delaware by the Board of Directors and holders of a majority of the outstanding stock of  the Corporation entitled to vote thereon.  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">THIRD&#58;           That upon the effectiveness of this Certificate of Amendment, the first paragraph of Article FOURTH of the Restated Certificate of Incorporation is hereby amended and restated as follows&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOURTH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; The Corporation is authorized to issue two classes of capital stock, one of which is designated as common stock, $.01 par value per share (&#8220;Common Stock&#8221;), and the other of which is designated as preferred stock, $.01 par value per share (&#8220;Preferred Stock&#8221;). The total number of shares of both classes of capital stock that the Corporation shall have authority to issue is 232,812,500 shares, consisting of 227,812,500 shares of Common Stock and 5,000,000 shares of Preferred Stock. The Preferred Stock may be issued from time to time in one or more series as set forth in Section (b) of this Article FOURTH. The following is a statement of the designations and the powers, preferences and rights of, and the qualifications, limitations or restrictions applicable to, each class of capital stock of the Corporation.&#8221;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, this Certificate of Amendment of Restated Certificate of Incorporation has been executed by a duly authorized officer of the Corporation on this 28th day of May, 2021.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.859%"><tr><td style="width:1.0%"></td><td style="width:14.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; James E. Dentzer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;<br>Title&#58;   </font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James E. Dentzer<br>President and Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>cris-9302021x10qexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iec02b8e48ba1423a9c0256fc409df1f0_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13a-14(a) OF THE EXCHANGE ACT </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James E. Dentzer, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form 10-Q of Curis, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:4.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.492%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; JAMES E. DENTZER</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James E. Dentzer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>cris-9302021x10qexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i9e2c4aaac2df49ac8825fe3a6d452398_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13a-14(a) OF THE EXCHANGE ACT </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, William Steinkrauss, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form 10-Q of Curis, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:4.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.492%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; WILLIAM STEINKRAUSS</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William Steinkrauss</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>cris-9302021x10qexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="if3f56653df7c4264aa079fdd32344210_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13a-14(b) OF THE EXCHANGE ACT AND 18 U.S.C. SECTION 1350</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Curis, Inc. (the &#8220;Company&#8221;) for the period ended September 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, James E. Dentzer, President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:4.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.492%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; JAMES E. DENTZER</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James E. Dentzer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>cris-9302021x10qexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="id54446e3b67d436880aa1b729738e677_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13a-14(b) OF THE EXCHANGE ACT AND 18 U.S.C. SECTION 1350</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Curis, Inc. (the &#8220;Company&#8221;) for the period ended September 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, William Steinkrauss, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:4.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.492%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; WILLIAM STEINKRAUSS</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William Steinkrauss</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>cris-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:67cd88cd-4961-40fd-b7ee-f0e04fb032e1,g:de03038a-bcb1-460d-82b7-20721bd560b4-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cris="http://www.curis.com/20210930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.curis.com/20210930">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cris-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cris-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cris-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cris-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.curis.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" roleURI="http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusiness" roleURI="http://www.curis.com/role/NatureofBusiness">
        <link:definition>2101101 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessDetails" roleURI="http://www.curis.com/role/NatureofBusinessDetails">
        <link:definition>2402401 - Disclosure - Nature of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.curis.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.curis.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.curis.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2405402 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstruments" roleURI="http://www.curis.com/role/FairValueofFinancialInstruments">
        <link:definition>2106103 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsTables" roleURI="http://www.curis.com/role/FairValueofFinancialInstrumentsTables">
        <link:definition>2307301 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsSummaryDetails" roleURI="http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails">
        <link:definition>2408403 - Disclosure - Fair Value of Financial Instruments - Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.curis.com/role/Investments">
        <link:definition>2109104 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.curis.com/role/InvestmentsTables">
        <link:definition>2310302 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails" roleURI="http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails">
        <link:definition>2411404 - Disclosure - Investments - Amortized Cost of Unrealized Gains and Losses and Fair Value of Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilities" roleURI="http://www.curis.com/role/AccruedLiabilities">
        <link:definition>2112105 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesTables" roleURI="http://www.curis.com/role/AccruedLiabilitiesTables">
        <link:definition>2313303 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesSummaryDetails" roleURI="http://www.curis.com/role/AccruedLiabilitiesSummaryDetails">
        <link:definition>2414405 - Disclosure - Accrued Liabilities - Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.curis.com/role/Debt">
        <link:definition>2115106 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtDetails" roleURI="http://www.curis.com/role/DebtDetails">
        <link:definition>2416406 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Lease" roleURI="http://www.curis.com/role/Lease">
        <link:definition>2117107 - Disclosure - Lease</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDetails" roleURI="http://www.curis.com/role/LeasesDetails">
        <link:definition>2418407 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheSaleofFutureRoyalties" roleURI="http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyalties">
        <link:definition>2119108 - Disclosure - Liability Related to the Sale of Future Royalties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheSaleofFutureRoyaltiesTables" roleURI="http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables">
        <link:definition>2320304 - Disclosure - Liability Related to the Sale of Future Royalties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails" roleURI="http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails">
        <link:definition>2421408 - Disclosure - Liability Related to the Sale of Future Royalties - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheSaleofFutureRoyaltiesLiabilityDuetoNonCashTransactionDetails" roleURI="http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesLiabilityDuetoNonCashTransactionDetails">
        <link:definition>2422409 - Disclosure - Liability Related to the Sale of Future Royalties - Liability Due to Non-Cash Transaction (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchandDevelopmentCollaborations" roleURI="http://www.curis.com/role/ResearchandDevelopmentCollaborations">
        <link:definition>2123109 - Disclosure - Research and Development Collaborations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchandDevelopmentCollaborationsDetails" roleURI="http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails">
        <link:definition>2424410 - Disclosure - Research and Development Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStock" roleURI="http://www.curis.com/role/CommonStock">
        <link:definition>2125110 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockDetails" roleURI="http://www.curis.com/role/CommonStockDetails">
        <link:definition>2426411 - Disclosure - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlansandStockBasedCompensation" roleURI="http://www.curis.com/role/StockPlansandStockBasedCompensation">
        <link:definition>2127111 - Disclosure - Stock Plans and Stock Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlansandStockBasedCompensationTables" roleURI="http://www.curis.com/role/StockPlansandStockBasedCompensationTables">
        <link:definition>2328305 - Disclosure - Stock Plans and Stock Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlansandStockBasedCompensationNarrativeDetails" roleURI="http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails">
        <link:definition>2429412 - Disclosure - Stock Plans and Stock Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlansandStockBasedCompensationStockOptionActivityDetails" roleURI="http://www.curis.com/role/StockPlansandStockBasedCompensationStockOptionActivityDetails">
        <link:definition>2430413 - Disclosure - Stock Plans and Stock Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlansandStockBasedCompensationKeyAssumptionsDetails" roleURI="http://www.curis.com/role/StockPlansandStockBasedCompensationKeyAssumptionsDetails">
        <link:definition>2431414 - Disclosure - Stock Plans and Stock Based Compensation - Key Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlansandStockBasedCompensationRestrictedStockAwardActivityDetails" roleURI="http://www.curis.com/role/StockPlansandStockBasedCompensationRestrictedStockAwardActivityDetails">
        <link:definition>2432415 - Disclosure - Stock Plans and Stock Based Compensation - Restricted Stock Award Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlansandStockBasedCompensationStockbasedCompensationExpenseDetails" roleURI="http://www.curis.com/role/StockPlansandStockBasedCompensationStockbasedCompensationExpenseDetails">
        <link:definition>2433416 - Disclosure - Stock Plans and Stock Based Compensation - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShare" roleURI="http://www.curis.com/role/LossPerCommonShare">
        <link:definition>2134112 - Disclosure - Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareDetails" roleURI="http://www.curis.com/role/LossPerCommonShareDetails">
        <link:definition>2435417 - Disclosure - Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.curis.com/role/RelatedPartyTransactions">
        <link:definition>2136113 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.curis.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2437418 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cris_CollaborationAgreementTermsPercentageOfRoyaltyFeesReceivable" abstract="false" name="CollaborationAgreementTermsPercentageOfRoyaltyFeesReceivable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cris_RoyaltyAmountsIn2021Member" abstract="true" name="RoyaltyAmountsIn2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cris_StockPurchaseProgramTermsSharesAuthorizedPerDay" abstract="false" name="StockPurchaseProgramTermsSharesAuthorizedPerDay" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cris_SiliconValleyBankMember" abstract="true" name="SiliconValleyBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cris_SaleOfStockIssuanceCosts" abstract="false" name="SaleOfStockIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue" abstract="false" name="NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_CollaborationArrangementContingentConsiderationDevelopmentMilestonePayments" abstract="false" name="CollaborationArrangementContingentConsiderationDevelopmentMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_NonmonetaryTransactionRollForward" abstract="true" name="NonmonetaryTransactionRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cris_GrossRoyaltyRevenueMember" abstract="true" name="GrossRoyaltyRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cris_IRAK4PD1VISTAPD1TIM3ProgramMember" abstract="true" name="IRAK4PD1VISTAPD1TIM3ProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cris_ContingentPaymentBenchmarkAxis" abstract="true" name="ContingentPaymentBenchmarkAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cris_RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold" abstract="false" name="RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_StockAvailableForFuturePurchaseUnderEmployeeStockPurchasePlans" abstract="false" name="StockAvailableForFuturePurchaseUnderEmployeeStockPurchasePlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cris_PaymentsforCollaborativeArrangementstoDate" abstract="false" name="PaymentsforCollaborativeArrangementstoDate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_RoyaltyPurchaseAgreementAccretionExpense" abstract="false" name="RoyaltyPurchaseAgreementAccretionExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_GenentechIncMember" abstract="true" name="GenentechIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cris_OperatingLeaseOneTimePaymentTenantImprovements" abstract="false" name="OperatingLeaseOneTimePaymentTenantImprovements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_ContraRevenueMember" abstract="true" name="ContraRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cris_PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest" abstract="false" name="PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="cris_ProceedsFromRoyaltyPurchaseAgreement" abstract="false" name="ProceedsFromRoyaltyPurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_IncreaseDecreaseOperatingLeaseLiability" abstract="false" name="IncreaseDecreaseOperatingLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_ChemistryManufacturingAndControlsCosts" abstract="false" name="ChemistryManufacturingAndControlsCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_RelatedPartyTransactionTermsAndMannerOfSettlementMinimumDaysNoticeToTerminatePriorToWrittenNotice" abstract="false" name="RelatedPartyTransactionTermsAndMannerOfSettlementMinimumDaysNoticeToTerminatePriorToWrittenNotice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cris_CollaborationArrangementContingentConsiderationOptionExerciseFee" abstract="false" name="CollaborationArrangementContingentConsiderationOptionExerciseFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cris_OberlandCapitalMember" abstract="true" name="OberlandCapitalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cris_StockPurchaseProgramRemainingAuthorizedPurchaseAmount" abstract="false" name="StockPurchaseProgramRemainingAuthorizedPurchaseAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_RoyaltyGuaranteesCommitmentsAmountNoncurrent" abstract="false" name="RoyaltyGuaranteesCommitmentsAmountNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_NumberOfPurchasePeriodsPerEnrollmentPeriod" abstract="false" name="NumberOfPurchasePeriodsPerEnrollmentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cris_RoyaltyPurchaseAgreementInterestRate" abstract="false" name="RoyaltyPurchaseAgreementInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cris_NonCashImputedInterestExpenseNetOfImputedInterest" abstract="false" name="NonCashImputedInterestExpenseNetOfImputedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cris_ShortTermInvestmentsFairValueDisclosure" abstract="false" name="ShortTermInvestmentsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_RoyaltyRatePercentageOfSales" abstract="false" name="RoyaltyRatePercentageOfSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cris_LongTermInvestmentsFairValueDisclosure" abstract="false" name="LongTermInvestmentsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_ContingentPaymentBenchmarkDomain" abstract="true" name="ContingentPaymentBenchmarkDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cris_AgreementWithHeadOfResearchAndDevelopmentMember" abstract="true" name="AgreementWithHeadOfResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cris_RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts" abstract="false" name="RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts" abstract="false" name="ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_MilestonePaymentsWaivedToDate" abstract="false" name="MilestonePaymentsWaivedToDate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_CollaborationAgreementContingentConsiderationPotentialCashPayment" abstract="false" name="CollaborationAgreementContingentConsiderationPotentialCashPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_CaresActPPPLoanMember" abstract="true" name="CaresActPPPLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cris_StockPurchaseProgramAuthorizedAmount" abstract="false" name="StockPurchaseProgramAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_EpiCurePharmaceuticalsInc.Member" abstract="true" name="EpiCurePharmaceuticalsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cris_RoyaltyPurchaseAgreementTermsPurchaserDefaultOptionPeriod" abstract="false" name="RoyaltyPurchaseAgreementTermsPurchaserDefaultOptionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cris_CollaborativeArrangementPaymentsAgreement" abstract="false" name="CollaborativeArrangementPaymentsAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_CollaborationAgreementNumberofProgramsLicensed" abstract="false" name="CollaborationAgreementNumberofProgramsLicensed" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cris_CollaborationAgreementContingentConsiderationReceivedFromPartner" abstract="false" name="CollaborationAgreementContingentConsiderationReceivedFromPartner" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_CollaborationArrangementContingentConsiderationReimbursableExpenses" abstract="false" name="CollaborationArrangementContingentConsiderationReimbursableExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_OfficersAndNonEmployeeDirectorsMember" abstract="true" name="OfficersAndNonEmployeeDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cris_StockPurchaseProgramCommitmentFeeShares" abstract="false" name="StockPurchaseProgramCommitmentFeeShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cris_StockSaleAgreementCompensationFeePercentageOfGrossProceeds" abstract="false" name="StockSaleAgreementCompensationFeePercentageOfGrossProceeds" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cris_CollaborationArrangementContingentConsiderationRegulatoryApprovalMilestonePayments" abstract="false" name="CollaborationArrangementContingentConsiderationRegulatoryApprovalMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_RoyaltyPurchaseAgreementContingentConsiderationCashProceeds" abstract="false" name="RoyaltyPurchaseAgreementContingentConsiderationCashProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_RestrictedStockRSUsOtherStockBasedAwardsOrPerformanceAwardsMember" abstract="true" name="RestrictedStockRSUsOtherStockBasedAwardsOrPerformanceAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cris_PaymentsOfFutureRoyaltyLiability" abstract="false" name="PaymentsOfFutureRoyaltyLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_AvailableForSaleSecuritiesWeightedAverageMaturity" abstract="false" name="AvailableForSaleSecuritiesWeightedAverageMaturity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cris_AurigeneDiscoveryTechnologiesLtdMember" abstract="true" name="AurigeneDiscoveryTechnologiesLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cris_EmployeeStockPurchasePlanEnrollmentPeriod" abstract="false" name="EmployeeStockPurchasePlanEnrollmentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cris_NonCashLeaseExpense" abstract="false" name="NonCashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_CollaborationArrangementSemiAnnualMaintenanceFeePayment" abstract="false" name="CollaborationArrangementSemiAnnualMaintenanceFeePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_StockSaleAgreementRemainingAuthorizedAmount" abstract="false" name="StockSaleAgreementRemainingAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_ReducedRoyaltyRate" abstract="false" name="ReducedRoyaltyRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cris_AggregateNetRoyaltiesPriorTo2027Member" abstract="true" name="AggregateNetRoyaltiesPriorTo2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cris_DemandSalesAgreementMember" abstract="true" name="DemandSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cris_StockSaleAgreementAuthorizedAmount" abstract="false" name="StockSaleAgreementAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_LicenseFees" abstract="false" name="LicenseFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_AvailableForSaleSecuritiesDateRange" abstract="false" name="AvailableForSaleSecuritiesDateRange" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cris_CollaborationAgreementExpense" abstract="false" name="CollaborationAgreementExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_AmendedAndRestatedTwoThousandTenStockIncentivePlanMember" abstract="true" name="AmendedAndRestatedTwoThousandTenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cris_RoyaltyPurchaseAgreementLiabilityCarryingValue" abstract="false" name="RoyaltyPurchaseAgreementLiabilityCarryingValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_AspireCapitalFundLLCMember" abstract="true" name="AspireCapitalFundLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cris_RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization" abstract="false" name="RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_CorporateCommercialPaperStockBondsAndNotesMember" abstract="true" name="CorporateCommercialPaperStockBondsAndNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cris_StockOptionsorStockAppreciationRightsMember" abstract="true" name="StockOptionsorStockAppreciationRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cris_PercentageOfRoyaltyOnNetSales" abstract="false" name="PercentageOfRoyaltyOnNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cris_CollaborationArrangementContingentConsiderationSalesMilestonePayments" abstract="false" name="CollaborationArrangementContingentConsiderationSalesMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_MasterDevelopmentAndManufacturingAgreementMember" abstract="true" name="MasterDevelopmentAndManufacturingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cris_NonEmployeeDirectorsMember" abstract="true" name="NonEmployeeDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cris_ImmuNextMember" abstract="true" name="ImmuNextMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cris_TwoThousandAndTenPlanMember" abstract="true" name="TwoThousandAndTenPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cris_StockPurchaseProgramTermsSharesAuthorizedPerDayAfterMutualAgreement" abstract="false" name="StockPurchaseProgramTermsSharesAuthorizedPerDayAfterMutualAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cris_NumberOfSharesAwardedUnderStockValueLessThanSpecificPercentageOfFairMarketValue" abstract="false" name="NumberOfSharesAwardedUnderStockValueLessThanSpecificPercentageOfFairMarketValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cris_ShareBasedCompensationPlans" abstract="false" name="ShareBasedCompensationPlans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cris_StockPurchaseProgramPricePeriod" abstract="false" name="StockPurchaseProgramPricePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cris_ThirdandFourthProgramsMember" abstract="true" name="ThirdandFourthProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cris_DirectPlacementMember" abstract="true" name="DirectPlacementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cris_RelatedPartyTransactionMaximumFundingAmount" abstract="false" name="RelatedPartyTransactionMaximumFundingAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cris_OtherRevenueMember" abstract="true" name="OtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cris_NonCashImputedInterestExpense" abstract="false" name="NonCashImputedInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>cris-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:67cd88cd-4961-40fd-b7ee-f0e04fb032e1,g:de03038a-bcb1-460d-82b7-20721bd560b4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="cris-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7df95dbb-9ea6-44b1-8e26-7e85654688bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_279e821e-1ba3-4bee-9d88-e2940350fbf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7df95dbb-9ea6-44b1-8e26-7e85654688bf" xlink:to="loc_us-gaap_AccountsPayableCurrent_279e821e-1ba3-4bee-9d88-e2940350fbf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ce194086-5806-45e7-b305-4f88f68e2d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7df95dbb-9ea6-44b1-8e26-7e85654688bf" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ce194086-5806-45e7-b305-4f88f68e2d0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_dd063f7c-169b-4fe2-9408-89ccded48c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7df95dbb-9ea6-44b1-8e26-7e85654688bf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_dd063f7c-169b-4fe2-9408-89ccded48c1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_9adc7c96-6d9a-488e-b9e4-b6fc3c9a7204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7df95dbb-9ea6-44b1-8e26-7e85654688bf" xlink:to="loc_us-gaap_LongTermDebtCurrent_9adc7c96-6d9a-488e-b9e4-b6fc3c9a7204" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_114f5db3-1eed-4339-8a29-1bc1fd0a2a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1f59d303-0a6d-42fb-aefb-0ede5e99591b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_114f5db3-1eed-4339-8a29-1bc1fd0a2a9e" xlink:to="loc_us-gaap_AssetsCurrent_1f59d303-0a6d-42fb-aefb-0ede5e99591b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a3e60c4f-9534-4959-b1ba-af0fc92448d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_114f5db3-1eed-4339-8a29-1bc1fd0a2a9e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a3e60c4f-9534-4959-b1ba-af0fc92448d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_5be82b60-b0ba-4e12-9448-805f20dd1dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_114f5db3-1eed-4339-8a29-1bc1fd0a2a9e" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_5be82b60-b0ba-4e12-9448-805f20dd1dff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_eb09ed66-463e-4ea9-b16a-6bc2fd625899" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_114f5db3-1eed-4339-8a29-1bc1fd0a2a9e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_eb09ed66-463e-4ea9-b16a-6bc2fd625899" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_acf58e5d-76ad-4dcb-aecf-774aeb1c6404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_114f5db3-1eed-4339-8a29-1bc1fd0a2a9e" xlink:to="loc_us-gaap_Goodwill_acf58e5d-76ad-4dcb-aecf-774aeb1c6404" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b7aa185e-8f06-4743-a9ba-872582e34ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_114f5db3-1eed-4339-8a29-1bc1fd0a2a9e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b7aa185e-8f06-4743-a9ba-872582e34ae1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_85b744d4-9b36-48ec-b232-69812eaa86f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_114f5db3-1eed-4339-8a29-1bc1fd0a2a9e" xlink:to="loc_us-gaap_LongTermInvestments_85b744d4-9b36-48ec-b232-69812eaa86f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9777eaf5-6fce-4b45-be29-73aa94ad2929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_86a557b1-70c3-4669-9047-442f292a0832" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9777eaf5-6fce-4b45-be29-73aa94ad2929" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_86a557b1-70c3-4669-9047-442f292a0832" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_26b7b369-d35a-4d7a-8ff7-852bfaf41d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9777eaf5-6fce-4b45-be29-73aa94ad2929" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_26b7b369-d35a-4d7a-8ff7-852bfaf41d23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_529a3a14-992a-4cf5-bab2-d9eb4ba096bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9777eaf5-6fce-4b45-be29-73aa94ad2929" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_529a3a14-992a-4cf5-bab2-d9eb4ba096bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d7037ca8-5b9d-4d84-b639-065f13fc4979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9777eaf5-6fce-4b45-be29-73aa94ad2929" xlink:to="loc_us-gaap_CommonStockValue_d7037ca8-5b9d-4d84-b639-065f13fc4979" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1097a251-33e5-49d3-9153-f97bce2b70ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2e698d5c-1e3b-49c9-9496-79f6757f3fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1097a251-33e5-49d3-9153-f97bce2b70ba" xlink:to="loc_us-gaap_LiabilitiesCurrent_2e698d5c-1e3b-49c9-9496-79f6757f3fa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cde294dd-8ea5-4262-900c-9fcc0833788d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1097a251-33e5-49d3-9153-f97bce2b70ba" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cde294dd-8ea5-4262-900c-9fcc0833788d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyGuaranteesCommitmentsAmountNoncurrent_43c9ae65-48e8-49b2-bbe5-aad80509ffff" xlink:href="cris-20210930.xsd#cris_RoyaltyGuaranteesCommitmentsAmountNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1097a251-33e5-49d3-9153-f97bce2b70ba" xlink:to="loc_cris_RoyaltyGuaranteesCommitmentsAmountNoncurrent_43c9ae65-48e8-49b2-bbe5-aad80509ffff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3dff30f1-ba9a-4bde-bc0b-2097f9b8c1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1097a251-33e5-49d3-9153-f97bce2b70ba" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3dff30f1-ba9a-4bde-bc0b-2097f9b8c1f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_01cfd842-c19a-4731-b861-b677fa6bd271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8f810c1a-6d09-45cd-afd8-6b5eee87bace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_01cfd842-c19a-4731-b861-b677fa6bd271" xlink:to="loc_us-gaap_Liabilities_8f810c1a-6d09-45cd-afd8-6b5eee87bace" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_231bec45-1fc8-40e0-b4db-f4ba794e1547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_01cfd842-c19a-4731-b861-b677fa6bd271" xlink:to="loc_us-gaap_StockholdersEquity_231bec45-1fc8-40e0-b4db-f4ba794e1547" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_67170eb4-ee00-4432-b565-013aae8ee6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ded1648c-045e-4fe1-a532-3994eac48f52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67170eb4-ee00-4432-b565-013aae8ee6b8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ded1648c-045e-4fe1-a532-3994eac48f52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2120856e-9dd2-4393-82b7-3dd37a1c6c51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67170eb4-ee00-4432-b565-013aae8ee6b8" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2120856e-9dd2-4393-82b7-3dd37a1c6c51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a330e4a9-9f7d-40fb-8016-ab3e1c9c48fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67170eb4-ee00-4432-b565-013aae8ee6b8" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a330e4a9-9f7d-40fb-8016-ab3e1c9c48fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_cced6db6-b9bb-4bed-b9d1-03f346f1c295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67170eb4-ee00-4432-b565-013aae8ee6b8" xlink:to="loc_us-gaap_ShortTermInvestments_cced6db6-b9bb-4bed-b9d1-03f346f1c295" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="cris-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_afca03b4-287f-4ab6-b1d6-bc0cc1f0e3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ebafe44e-f1cd-44d6-aea9-0ecffbd8b496" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_afca03b4-287f-4ab6-b1d6-bc0cc1f0e3ba" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ebafe44e-f1cd-44d6-aea9-0ecffbd8b496" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b3338ced-12f7-4c6f-9841-7aa26cd62341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_afca03b4-287f-4ab6-b1d6-bc0cc1f0e3ba" xlink:to="loc_us-gaap_CostsAndExpenses_b3338ced-12f7-4c6f-9841-7aa26cd62341" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2be2ee40-e5f2-4c7e-b06b-cd9b16971194" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_64a344f3-8462-4924-b18a-499fad3db44b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2be2ee40-e5f2-4c7e-b06b-cd9b16971194" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_64a344f3-8462-4924-b18a-499fad3db44b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e7066295-6b00-4b5a-b92a-b02c2f19aa7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2be2ee40-e5f2-4c7e-b06b-cd9b16971194" xlink:to="loc_us-gaap_NetIncomeLoss_e7066295-6b00-4b5a-b92a-b02c2f19aa7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e5623f3b-551c-4685-9bd7-b274525b8aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_b28760b3-dc08-42ef-adba-f2377d12eff4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_e5623f3b-551c-4685-9bd7-b274525b8aba" xlink:to="loc_us-gaap_InvestmentIncomeInterest_b28760b3-dc08-42ef-adba-f2377d12eff4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_NonCashImputedInterestExpense_e9d3122d-d938-4a4b-8715-b0c10334d9df" xlink:href="cris-20210930.xsd#cris_NonCashImputedInterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_e5623f3b-551c-4685-9bd7-b274525b8aba" xlink:to="loc_cris_NonCashImputedInterestExpense_e9d3122d-d938-4a4b-8715-b0c10334d9df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_db1d78ea-7dc1-4b04-b2dd-ec0d63ea909e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_e5623f3b-551c-4685-9bd7-b274525b8aba" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_db1d78ea-7dc1-4b04-b2dd-ec0d63ea909e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_487a5e5a-f1db-49cc-b5b9-fa7ea257159d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_16b0ffe7-e19e-4fad-82ba-9fa7084bb782" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_487a5e5a-f1db-49cc-b5b9-fa7ea257159d" xlink:to="loc_us-gaap_RoyaltyExpense_16b0ffe7-e19e-4fad-82ba-9fa7084bb782" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ab10749b-0aa3-4702-a923-ecc9b27e1b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_487a5e5a-f1db-49cc-b5b9-fa7ea257159d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ab10749b-0aa3-4702-a923-ecc9b27e1b1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5b9770fa-a654-4533-815e-d8dc5a566dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_487a5e5a-f1db-49cc-b5b9-fa7ea257159d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5b9770fa-a654-4533-815e-d8dc5a566dbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_00989ef3-4b6f-47d2-b445-c17bfe4dc3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_35f85223-ceb7-4449-b39d-6a8bad27857d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_00989ef3-4b6f-47d2-b445-c17bfe4dc3ae" xlink:to="loc_us-gaap_OperatingIncomeLoss_35f85223-ceb7-4449-b39d-6a8bad27857d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_abdc9ae6-b5d4-49a9-98fe-ac9ddb3c2be1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_00989ef3-4b6f-47d2-b445-c17bfe4dc3ae" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_abdc9ae6-b5d4-49a9-98fe-ac9ddb3c2be1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="cris-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dc732b9e-89f3-4652-9290-ebc331b9f927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_deceba91-7425-49bf-9268-7cd67e0f6cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dc732b9e-89f3-4652-9290-ebc331b9f927" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_deceba91-7425-49bf-9268-7cd67e0f6cc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bc444063-38bd-4ad6-8013-08a3fc9dfd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dc732b9e-89f3-4652-9290-ebc331b9f927" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bc444063-38bd-4ad6-8013-08a3fc9dfd3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c2bda67e-58f5-4d7e-a7fb-56b2883076ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dc732b9e-89f3-4652-9290-ebc331b9f927" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c2bda67e-58f5-4d7e-a7fb-56b2883076ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_417b5ad8-fb6f-4d98-9ca0-ae42d61e0897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f8bfa9fd-555d-4921-8466-3df591cfa13c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_417b5ad8-fb6f-4d98-9ca0-ae42d61e0897" xlink:to="loc_us-gaap_NetIncomeLoss_f8bfa9fd-555d-4921-8466-3df591cfa13c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_309cca69-6e3d-4314-adf4-fabe61f4b8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_417b5ad8-fb6f-4d98-9ca0-ae42d61e0897" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_309cca69-6e3d-4314-adf4-fabe61f4b8c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_b1bb3b57-7462-4aa3-8e43-77e3866af31a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_f6007b1d-6bbc-4b38-b44d-43bd0a368fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_b1bb3b57-7462-4aa3-8e43-77e3866af31a" xlink:to="loc_us-gaap_DepreciationAndAmortization_f6007b1d-6bbc-4b38-b44d-43bd0a368fa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_NonCashLeaseExpense_bb6ee51b-7b53-49dc-94e4-110a03cde388" xlink:href="cris-20210930.xsd#cris_NonCashLeaseExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_b1bb3b57-7462-4aa3-8e43-77e3866af31a" xlink:to="loc_cris_NonCashLeaseExpense_bb6ee51b-7b53-49dc-94e4-110a03cde388" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4ebed0db-dd51-47c2-b523-f5e2e1a33a83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_b1bb3b57-7462-4aa3-8e43-77e3866af31a" xlink:to="loc_us-gaap_ShareBasedCompensation_4ebed0db-dd51-47c2-b523-f5e2e1a33a83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_NonCashImputedInterestExpenseNetOfImputedInterest_262a1110-de00-471b-91a9-048aed3b1b3b" xlink:href="cris-20210930.xsd#cris_NonCashImputedInterestExpenseNetOfImputedInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_b1bb3b57-7462-4aa3-8e43-77e3866af31a" xlink:to="loc_cris_NonCashImputedInterestExpenseNetOfImputedInterest_262a1110-de00-471b-91a9-048aed3b1b3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4ed5ae6d-d7be-468f-bc65-5aa7466d02ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_b1bb3b57-7462-4aa3-8e43-77e3866af31a" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4ed5ae6d-d7be-468f-bc65-5aa7466d02ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3c18f538-13db-4b2a-899c-d737e25e6ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_b1bb3b57-7462-4aa3-8e43-77e3866af31a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3c18f538-13db-4b2a-899c-d737e25e6ae5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3e95bd15-321a-4051-b50a-08e1e4659fae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_b1bb3b57-7462-4aa3-8e43-77e3866af31a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3e95bd15-321a-4051-b50a-08e1e4659fae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_a38c3a31-b0ff-46f0-ad63-af03a480df68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_b1bb3b57-7462-4aa3-8e43-77e3866af31a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_a38c3a31-b0ff-46f0-ad63-af03a480df68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_IncreaseDecreaseOperatingLeaseLiability_452f4674-5c54-45ba-925f-28f3e44e9278" xlink:href="cris-20210930.xsd#cris_IncreaseDecreaseOperatingLeaseLiability"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_b1bb3b57-7462-4aa3-8e43-77e3866af31a" xlink:to="loc_cris_IncreaseDecreaseOperatingLeaseLiability_452f4674-5c54-45ba-925f-28f3e44e9278" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5f81df39-045b-4950-be61-0c11efda68a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_b1bb3b57-7462-4aa3-8e43-77e3866af31a" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5f81df39-045b-4950-be61-0c11efda68a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5cff2501-c70c-4ddf-b49c-f10ea2a5dc64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_80d64792-1ce7-49f5-b4bb-0bc13e4bf802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5cff2501-c70c-4ddf-b49c-f10ea2a5dc64" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_80d64792-1ce7-49f5-b4bb-0bc13e4bf802" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_e1e62e7b-0d82-4e59-9998-4da01a5f06bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5cff2501-c70c-4ddf-b49c-f10ea2a5dc64" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_e1e62e7b-0d82-4e59-9998-4da01a5f06bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest_871afbe6-b54e-44dc-af62-aabdddfd2d5c" xlink:href="cris-20210930.xsd#cris_PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5cff2501-c70c-4ddf-b49c-f10ea2a5dc64" xlink:to="loc_cris_PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest_871afbe6-b54e-44dc-af62-aabdddfd2d5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_db8344bd-529c-41ca-8131-ec0760fac2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5cff2501-c70c-4ddf-b49c-f10ea2a5dc64" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_db8344bd-529c-41ca-8131-ec0760fac2ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts_f79c0741-e55c-42c1-88f5-3a074c9f5a8f" xlink:href="cris-20210930.xsd#cris_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5cff2501-c70c-4ddf-b49c-f10ea2a5dc64" xlink:to="loc_cris_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts_f79c0741-e55c-42c1-88f5-3a074c9f5a8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_72d22a3f-b76a-4d89-8ce8-31a962f421b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5cff2501-c70c-4ddf-b49c-f10ea2a5dc64" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_72d22a3f-b76a-4d89-8ce8-31a962f421b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b940f88e-6470-4707-abb4-5a84f8ca559c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_8a1fb948-9146-4479-bb05-e3f586e172bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b940f88e-6470-4707-abb4-5a84f8ca559c" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_8a1fb948-9146-4479-bb05-e3f586e172bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_883bc6f5-8062-4ed9-82c9-9b4b74e86f00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b940f88e-6470-4707-abb4-5a84f8ca559c" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_883bc6f5-8062-4ed9-82c9-9b4b74e86f00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4df2c695-a617-47fe-ad8c-a12095ee7c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b940f88e-6470-4707-abb4-5a84f8ca559c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4df2c695-a617-47fe-ad8c-a12095ee7c6b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#FairValueofFinancialInstrumentsSummaryDetails"/>
  <link:calculationLink xlink:role="http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ced7ebfe-5b39-4f82-b5ce-c7624cf1f20d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8c35d423-df93-4ca8-8ba0-ffd2a6aec0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_ced7ebfe-5b39-4f82-b5ce-c7624cf1f20d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8c35d423-df93-4ca8-8ba0-ffd2a6aec0f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_LongTermInvestmentsFairValueDisclosure_e38fbf6f-ffa6-4f8f-93fd-ddd598a620d2" xlink:href="cris-20210930.xsd#cris_LongTermInvestmentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_ced7ebfe-5b39-4f82-b5ce-c7624cf1f20d" xlink:to="loc_cris_LongTermInvestmentsFairValueDisclosure_e38fbf6f-ffa6-4f8f-93fd-ddd598a620d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ShortTermInvestmentsFairValueDisclosure_678a7e7d-1723-46d5-b5a9-2e0049987681" xlink:href="cris-20210930.xsd#cris_ShortTermInvestmentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_ced7ebfe-5b39-4f82-b5ce-c7624cf1f20d" xlink:to="loc_cris_ShortTermInvestmentsFairValueDisclosure_678a7e7d-1723-46d5-b5a9-2e0049987681" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fac54362-b52d-4bda-805e-4e6850b4a075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9096e943-04ce-4bf8-85e5-fb621c7ee0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fac54362-b52d-4bda-805e-4e6850b4a075" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9096e943-04ce-4bf8-85e5-fb621c7ee0dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d00a5c8e-780d-4bd0-a85b-603122dbffa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fac54362-b52d-4bda-805e-4e6850b4a075" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d00a5c8e-780d-4bd0-a85b-603122dbffa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_675bddd0-9b42-47f9-b0d9-4151ccbbdbb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fac54362-b52d-4bda-805e-4e6850b4a075" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_675bddd0-9b42-47f9-b0d9-4151ccbbdbb8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.curis.com/role/AccruedLiabilitiesSummaryDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#AccruedLiabilitiesSummaryDetails"/>
  <link:calculationLink xlink:role="http://www.curis.com/role/AccruedLiabilitiesSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0eaf35f4-de18-4a07-8eef-c9d471c80290" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_ca9274a1-4ded-42f5-a052-599a0d98f526" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0eaf35f4-de18-4a07-8eef-c9d471c80290" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_ca9274a1-4ded-42f5-a052-599a0d98f526" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fb52d44d-c87a-4e49-9e98-1f53b20053d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0eaf35f4-de18-4a07-8eef-c9d471c80290" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fb52d44d-c87a-4e49-9e98-1f53b20053d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_2d8e772b-4860-4f6d-88c5-d98d300d89f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0eaf35f4-de18-4a07-8eef-c9d471c80290" xlink:to="loc_us-gaap_AccruedSalariesCurrent_2d8e772b-4860-4f6d-88c5-d98d300d89f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_LicenseFees_242872d5-d83d-42bf-a0be-9d1b90e0d9ea" xlink:href="cris-20210930.xsd#cris_LicenseFees"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0eaf35f4-de18-4a07-8eef-c9d471c80290" xlink:to="loc_cris_LicenseFees_242872d5-d83d-42bf-a0be-9d1b90e0d9ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ChemistryManufacturingAndControlsCosts_b7c36fbc-12e4-4288-a9ef-8732dbef8b40" xlink:href="cris-20210930.xsd#cris_ChemistryManufacturingAndControlsCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0eaf35f4-de18-4a07-8eef-c9d471c80290" xlink:to="loc_cris_ChemistryManufacturingAndControlsCosts_b7c36fbc-12e4-4288-a9ef-8732dbef8b40" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>cris-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:67cd88cd-4961-40fd-b7ee-f0e04fb032e1,g:de03038a-bcb1-460d-82b7-20721bd560b4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="cris-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended" id="ic1ce276795344d1c861a2e5371d07a82_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_913084be-37d9-432c-98bf-2c21b81fdc28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_c406788a-cf3d-443a-ab43-76f297f40017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_913084be-37d9-432c-98bf-2c21b81fdc28" xlink:to="loc_us-gaap_RevenuesAbstract_c406788a-cf3d-443a-ab43-76f297f40017" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_300f9dea-50c1-4300-a78d-bd020b6f741f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_c406788a-cf3d-443a-ab43-76f297f40017" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_300f9dea-50c1-4300-a78d-bd020b6f741f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_658e693f-9117-4e2b-9826-bd47fa4fc6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_913084be-37d9-432c-98bf-2c21b81fdc28" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_658e693f-9117-4e2b-9826-bd47fa4fc6a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_236a0da0-9b8e-4f4f-a6c6-90af8804c742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_658e693f-9117-4e2b-9826-bd47fa4fc6a6" xlink:to="loc_us-gaap_RoyaltyExpense_236a0da0-9b8e-4f4f-a6c6-90af8804c742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_30694a01-276d-48ad-b1c7-f7ddf1312b46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_658e693f-9117-4e2b-9826-bd47fa4fc6a6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_30694a01-276d-48ad-b1c7-f7ddf1312b46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_e5562066-92d1-4b31-a0c8-f266a52da727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_658e693f-9117-4e2b-9826-bd47fa4fc6a6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_e5562066-92d1-4b31-a0c8-f266a52da727" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_290600e0-838b-4f30-a4d8-3426bf3e5e20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_658e693f-9117-4e2b-9826-bd47fa4fc6a6" xlink:to="loc_us-gaap_CostsAndExpenses_290600e0-838b-4f30-a4d8-3426bf3e5e20" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8268448b-4af9-4dd9-9943-c97d9fd73162" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_913084be-37d9-432c-98bf-2c21b81fdc28" xlink:to="loc_us-gaap_OperatingIncomeLoss_8268448b-4af9-4dd9-9943-c97d9fd73162" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dc78cf09-3022-4619-a78d-5a0e8935a13b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_913084be-37d9-432c-98bf-2c21b81fdc28" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dc78cf09-3022-4619-a78d-5a0e8935a13b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_865d06a5-79c7-4cf5-bd05-fd6eb96baecc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dc78cf09-3022-4619-a78d-5a0e8935a13b" xlink:to="loc_us-gaap_InvestmentIncomeInterest_865d06a5-79c7-4cf5-bd05-fd6eb96baecc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_NonCashImputedInterestExpense_20b8357b-a668-4fab-9a1f-e2aa6bedaab5" xlink:href="cris-20210930.xsd#cris_NonCashImputedInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dc78cf09-3022-4619-a78d-5a0e8935a13b" xlink:to="loc_cris_NonCashImputedInterestExpense_20b8357b-a668-4fab-9a1f-e2aa6bedaab5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d5139d14-f7c2-4918-8a0e-5db1aca5d9cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dc78cf09-3022-4619-a78d-5a0e8935a13b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d5139d14-f7c2-4918-8a0e-5db1aca5d9cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_248f0f2e-6ab4-4dd1-875c-63ed84fa7c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dc78cf09-3022-4619-a78d-5a0e8935a13b" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_248f0f2e-6ab4-4dd1-875c-63ed84fa7c0a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6511dd59-98e6-43ad-9d8c-9abf98e941b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_913084be-37d9-432c-98bf-2c21b81fdc28" xlink:to="loc_us-gaap_NetIncomeLoss_6511dd59-98e6-43ad-9d8c-9abf98e941b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b2916844-0f33-4c59-9723-c793e65fa366" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_913084be-37d9-432c-98bf-2c21b81fdc28" xlink:to="loc_us-gaap_EarningsPerShareBasic_b2916844-0f33-4c59-9723-c793e65fa366" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3b9a7dca-320c-4be8-b6c2-d6924bfd3fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_913084be-37d9-432c-98bf-2c21b81fdc28" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3b9a7dca-320c-4be8-b6c2-d6924bfd3fd0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e0a5e624-9e69-43b6-be94-499e568b613a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_913084be-37d9-432c-98bf-2c21b81fdc28" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e0a5e624-9e69-43b6-be94-499e568b613a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ada7edc3-50fa-442f-ad47-a1a863601124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_913084be-37d9-432c-98bf-2c21b81fdc28" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ada7edc3-50fa-442f-ad47-a1a863601124" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_92fc1864-0ec9-4a93-96e3-535b625cd2d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9d148b0c-6af2-403a-8e2c-49e6b37f85c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_913084be-37d9-432c-98bf-2c21b81fdc28" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9d148b0c-6af2-403a-8e2c-49e6b37f85c4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0954055b-0546-406b-ad56-6e48002e0d50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9d148b0c-6af2-403a-8e2c-49e6b37f85c4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0954055b-0546-406b-ad56-6e48002e0d50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b8c1dc1a-b9ef-4d2e-94c9-db9053bb3b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9d148b0c-6af2-403a-8e2c-49e6b37f85c4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_b8c1dc1a-b9ef-4d2e-94c9-db9053bb3b4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8a14d3e3-1244-47a2-9a72-9f971361313e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_913084be-37d9-432c-98bf-2c21b81fdc28" xlink:to="loc_us-gaap_StatementTable_8a14d3e3-1244-47a2-9a72-9f971361313e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_90326587-7ac7-4bb6-a62b-80a27390ae0a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8a14d3e3-1244-47a2-9a72-9f971361313e" xlink:to="loc_srt_ProductOrServiceAxis_90326587-7ac7-4bb6-a62b-80a27390ae0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_90326587-7ac7-4bb6-a62b-80a27390ae0a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_90326587-7ac7-4bb6-a62b-80a27390ae0a" xlink:to="loc_srt_ProductsAndServicesDomain_90326587-7ac7-4bb6-a62b-80a27390ae0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dbfd043f-63a7-4146-adaf-fd02e1c9955b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_90326587-7ac7-4bb6-a62b-80a27390ae0a" xlink:to="loc_srt_ProductsAndServicesDomain_dbfd043f-63a7-4146-adaf-fd02e1c9955b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_GrossRoyaltyRevenueMember_538f5f5f-48cf-4c9a-ae00-5781e4aebabf" xlink:href="cris-20210930.xsd#cris_GrossRoyaltyRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dbfd043f-63a7-4146-adaf-fd02e1c9955b" xlink:to="loc_cris_GrossRoyaltyRevenueMember_538f5f5f-48cf-4c9a-ae00-5781e4aebabf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_OtherRevenueMember_1db9a3db-eb07-453e-9d83-3c92417f517a" xlink:href="cris-20210930.xsd#cris_OtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dbfd043f-63a7-4146-adaf-fd02e1c9955b" xlink:to="loc_cris_OtherRevenueMember_1db9a3db-eb07-453e-9d83-3c92417f517a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ContraRevenueMember_fd951ac3-ac25-43bd-ae35-b871bc68d5d1" xlink:href="cris-20210930.xsd#cris_ContraRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dbfd043f-63a7-4146-adaf-fd02e1c9955b" xlink:to="loc_cris_ContraRevenueMember_fd951ac3-ac25-43bd-ae35-b871bc68d5d1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="cris-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:definitionLink xlink:role="http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended" id="i54a1db70b11c421d94a24117d1f3b4fd_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_eef0d087-c564-4f35-ae07-c468469a5e46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eef0d087-c564-4f35-ae07-c468469a5e46" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4598a53f-50d3-4b8c-aead-4886a3aa0b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_CommonStockSharesIssued_4598a53f-50d3-4b8c-aead-4886a3aa0b2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0fdaa7c6-de61-426f-97d9-3a2feb4d4eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_StockholdersEquity_0fdaa7c6-de61-426f-97d9-3a2feb4d4eda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_93728ced-2d00-47c9-b024-8239724d8866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_93728ced-2d00-47c9-b024-8239724d8866" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_eb6c556b-32ff-4119-a9f7-7f988104d6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_eb6c556b-32ff-4119-a9f7-7f988104d6ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_b593bdb6-29aa-4d21-adb8-f11726431654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_b593bdb6-29aa-4d21-adb8-f11726431654" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a7e0a619-1e9a-4a64-aadf-cc752fb2bfc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a7e0a619-1e9a-4a64-aadf-cc752fb2bfc4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a22c992c-2f1d-4d28-9e55-dd7f6fc3b5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a22c992c-2f1d-4d28-9e55-dd7f6fc3b5c0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_103c336c-3ed4-46eb-9a89-0205845f7bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_103c336c-3ed4-46eb-9a89-0205845f7bfa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_d1f1fa78-fa71-42f1-a27e-ac36a94cd8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_d1f1fa78-fa71-42f1-a27e-ac36a94cd8b8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_348a450f-a359-4e46-ab2f-70ea45965bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_348a450f-a359-4e46-ab2f-70ea45965bb8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2b5b4b84-6cca-4108-a8d8-692fb1eecea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2b5b4b84-6cca-4108-a8d8-692fb1eecea3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_63bc47c0-46d6-48e8-824a-978d07abf684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_63bc47c0-46d6-48e8-824a-978d07abf684" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_9108f42d-2ba8-40d0-8830-5782bfcb04b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_9108f42d-2ba8-40d0-8830-5782bfcb04b5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1feb0ee6-2715-4da5-b016-0b85916d2896" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_NetIncomeLoss_1feb0ee6-2715-4da5-b016-0b85916d2896" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_46e63e02-d076-4bc0-93c7-a4d0763f749c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7f6b897e-0f24-4a6a-b94c-dee873b62310" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f9ded707-5d97-4a07-8079-322a9d1839d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_eef0d087-c564-4f35-ae07-c468469a5e46" xlink:to="loc_us-gaap_StatementTable_f9ded707-5d97-4a07-8079-322a9d1839d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fb1dc74b-9227-4168-90bb-eff1c2ec58c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f9ded707-5d97-4a07-8079-322a9d1839d7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fb1dc74b-9227-4168-90bb-eff1c2ec58c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fb1dc74b-9227-4168-90bb-eff1c2ec58c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fb1dc74b-9227-4168-90bb-eff1c2ec58c3" xlink:to="loc_us-gaap_EquityComponentDomain_fb1dc74b-9227-4168-90bb-eff1c2ec58c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b846968d-92d9-4a1c-9a64-2f7096437048" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fb1dc74b-9227-4168-90bb-eff1c2ec58c3" xlink:to="loc_us-gaap_EquityComponentDomain_b846968d-92d9-4a1c-9a64-2f7096437048" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_68bcc3ce-ef8c-4f46-9a4e-66f20e711734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b846968d-92d9-4a1c-9a64-2f7096437048" xlink:to="loc_us-gaap_CommonStockMember_68bcc3ce-ef8c-4f46-9a4e-66f20e711734" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_199381f7-5c17-497c-b747-5325a9e7ab42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b846968d-92d9-4a1c-9a64-2f7096437048" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_199381f7-5c17-497c-b747-5325a9e7ab42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_46231028-2eb2-4a4a-acf9-79020a1c3e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b846968d-92d9-4a1c-9a64-2f7096437048" xlink:to="loc_us-gaap_RetainedEarningsMember_46231028-2eb2-4a4a-acf9-79020a1c3e77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6c3e227e-9d39-44d5-9071-cb5a51ddd715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b846968d-92d9-4a1c-9a64-2f7096437048" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6c3e227e-9d39-44d5-9071-cb5a51ddd715" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a36c58aa-e802-4456-9598-42be07904820" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f9ded707-5d97-4a07-8079-322a9d1839d7" xlink:to="loc_srt_CounterpartyNameAxis_a36c58aa-e802-4456-9598-42be07904820" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a36c58aa-e802-4456-9598-42be07904820_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a36c58aa-e802-4456-9598-42be07904820" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a36c58aa-e802-4456-9598-42be07904820_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b69f070d-9b10-41b0-be1b-b2c51eac6402" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a36c58aa-e802-4456-9598-42be07904820" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b69f070d-9b10-41b0-be1b-b2c51eac6402" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_AspireCapitalFundLLCMember_41c20ef7-887a-4c16-a994-6a054392185d" xlink:href="cris-20210930.xsd#cris_AspireCapitalFundLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b69f070d-9b10-41b0-be1b-b2c51eac6402" xlink:to="loc_cris_AspireCapitalFundLLCMember_41c20ef7-887a-4c16-a994-6a054392185d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_DemandSalesAgreementMember_853c9f76-019d-4c21-a742-b975bb500655" xlink:href="cris-20210930.xsd#cris_DemandSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b69f070d-9b10-41b0-be1b-b2c51eac6402" xlink:to="loc_cris_DemandSalesAgreementMember_853c9f76-019d-4c21-a742-b975bb500655" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_57b19fef-7ad3-45e6-98c0-1ac89570ce98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f9ded707-5d97-4a07-8079-322a9d1839d7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_57b19fef-7ad3-45e6-98c0-1ac89570ce98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_57b19fef-7ad3-45e6-98c0-1ac89570ce98_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_57b19fef-7ad3-45e6-98c0-1ac89570ce98" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_57b19fef-7ad3-45e6-98c0-1ac89570ce98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_df7499d4-f926-4048-aaa5-7e163d189264" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_57b19fef-7ad3-45e6-98c0-1ac89570ce98" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_df7499d4-f926-4048-aaa5-7e163d189264" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_08989560-4907-4c78-9281-28a6cd4a906a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_df7499d4-f926-4048-aaa5-7e163d189264" xlink:to="loc_us-gaap_PrivatePlacementMember_08989560-4907-4c78-9281-28a6cd4a906a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="cris-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="i25332b42faf5417b8d0217724aabebc6_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cdcfa7ae-851e-45f0-8761-c87a95213597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fe03bc0e-a461-4231-bf04-23ecd65be372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cdcfa7ae-851e-45f0-8761-c87a95213597" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fe03bc0e-a461-4231-bf04-23ecd65be372" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a67a88f1-a1d9-4891-b035-e0be19cf9398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fe03bc0e-a461-4231-bf04-23ecd65be372" xlink:to="loc_us-gaap_NetIncomeLoss_a67a88f1-a1d9-4891-b035-e0be19cf9398" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_802ab1c4-e844-4617-8ede-f5dcb1fb7e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fe03bc0e-a461-4231-bf04-23ecd65be372" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_802ab1c4-e844-4617-8ede-f5dcb1fb7e1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_dadc9237-f188-4dbb-8849-9c13a07eda2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_802ab1c4-e844-4617-8ede-f5dcb1fb7e1d" xlink:to="loc_us-gaap_DepreciationAndAmortization_dadc9237-f188-4dbb-8849-9c13a07eda2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_NonCashLeaseExpense_3de441a7-0297-4ce9-abdb-52f803759aec" xlink:href="cris-20210930.xsd#cris_NonCashLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_802ab1c4-e844-4617-8ede-f5dcb1fb7e1d" xlink:to="loc_cris_NonCashLeaseExpense_3de441a7-0297-4ce9-abdb-52f803759aec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2e0f1475-f753-4b23-9c73-15c32dc17184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_802ab1c4-e844-4617-8ede-f5dcb1fb7e1d" xlink:to="loc_us-gaap_ShareBasedCompensation_2e0f1475-f753-4b23-9c73-15c32dc17184" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_NonCashImputedInterestExpenseNetOfImputedInterest_2a7e76b4-2f6a-4f33-9d77-427d1cfbcb91" xlink:href="cris-20210930.xsd#cris_NonCashImputedInterestExpenseNetOfImputedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_802ab1c4-e844-4617-8ede-f5dcb1fb7e1d" xlink:to="loc_cris_NonCashImputedInterestExpenseNetOfImputedInterest_2a7e76b4-2f6a-4f33-9d77-427d1cfbcb91" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4f3f8ea5-9f19-4d1c-ad56-9d680d385333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_802ab1c4-e844-4617-8ede-f5dcb1fb7e1d" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4f3f8ea5-9f19-4d1c-ad56-9d680d385333" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6dc12adc-01a3-413b-a739-3fece94ba102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_802ab1c4-e844-4617-8ede-f5dcb1fb7e1d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6dc12adc-01a3-413b-a739-3fece94ba102" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_46086fd5-f3a5-4d0c-84e5-d4817c6f4698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_802ab1c4-e844-4617-8ede-f5dcb1fb7e1d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_46086fd5-f3a5-4d0c-84e5-d4817c6f4698" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6b6d46a4-2610-4d07-988b-6239f5b04f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_46086fd5-f3a5-4d0c-84e5-d4817c6f4698" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6b6d46a4-2610-4d07-988b-6239f5b04f7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_75065981-eb83-4f9d-b78c-7351474e6e91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_46086fd5-f3a5-4d0c-84e5-d4817c6f4698" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_75065981-eb83-4f9d-b78c-7351474e6e91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_914c8cce-b637-4034-a0c4-8785dc40ca8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_46086fd5-f3a5-4d0c-84e5-d4817c6f4698" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_914c8cce-b637-4034-a0c4-8785dc40ca8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_IncreaseDecreaseOperatingLeaseLiability_44bbd174-10e5-4e6f-82ce-c29e435ac555" xlink:href="cris-20210930.xsd#cris_IncreaseDecreaseOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_46086fd5-f3a5-4d0c-84e5-d4817c6f4698" xlink:to="loc_cris_IncreaseDecreaseOperatingLeaseLiability_44bbd174-10e5-4e6f-82ce-c29e435ac555" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_4b96cb49-a4af-4db9-b497-15ee5bccecc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_802ab1c4-e844-4617-8ede-f5dcb1fb7e1d" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_4b96cb49-a4af-4db9-b497-15ee5bccecc9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb23a6eb-75bf-47a6-b994-87108472e4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fe03bc0e-a461-4231-bf04-23ecd65be372" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb23a6eb-75bf-47a6-b994-87108472e4c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e2910c12-30e4-4c85-a3ba-48ee19025e05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cdcfa7ae-851e-45f0-8761-c87a95213597" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e2910c12-30e4-4c85-a3ba-48ee19025e05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_58bfeda5-94c1-4f80-873d-153d492f4c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e2910c12-30e4-4c85-a3ba-48ee19025e05" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_58bfeda5-94c1-4f80-873d-153d492f4c35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_df2d30cb-86a2-45ca-af6e-a54c5f80ceb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e2910c12-30e4-4c85-a3ba-48ee19025e05" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_df2d30cb-86a2-45ca-af6e-a54c5f80ceb1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_dc6af2fd-ac88-4096-97a3-9b873e165bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e2910c12-30e4-4c85-a3ba-48ee19025e05" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_dc6af2fd-ac88-4096-97a3-9b873e165bbc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c3afbb57-1d8b-4ff4-ad31-5686023b7259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e2910c12-30e4-4c85-a3ba-48ee19025e05" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c3afbb57-1d8b-4ff4-ad31-5686023b7259" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1e5064b5-80f1-4f37-ad35-ef9d6bddd6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cdcfa7ae-851e-45f0-8761-c87a95213597" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1e5064b5-80f1-4f37-ad35-ef9d6bddd6f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_256a5994-bc93-42a9-be7c-642d0a88e91f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1e5064b5-80f1-4f37-ad35-ef9d6bddd6f6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_256a5994-bc93-42a9-be7c-642d0a88e91f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e7d4a934-3550-4204-8dcf-588af6e3844b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1e5064b5-80f1-4f37-ad35-ef9d6bddd6f6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e7d4a934-3550-4204-8dcf-588af6e3844b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts_b6e0ac98-33a3-4967-a3e0-ff335c6c62da" xlink:href="cris-20210930.xsd#cris_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1e5064b5-80f1-4f37-ad35-ef9d6bddd6f6" xlink:to="loc_cris_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts_b6e0ac98-33a3-4967-a3e0-ff335c6c62da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_cc0dbfb1-1c05-439e-b50e-f1126e0e3934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1e5064b5-80f1-4f37-ad35-ef9d6bddd6f6" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_cc0dbfb1-1c05-439e-b50e-f1126e0e3934" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_2efb92e6-4eef-4ca6-85c3-c4e3b6b17da7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1e5064b5-80f1-4f37-ad35-ef9d6bddd6f6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_2efb92e6-4eef-4ca6-85c3-c4e3b6b17da7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest_b1323fc0-e892-4eec-8a48-3ac7aa846ea0" xlink:href="cris-20210930.xsd#cris_PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1e5064b5-80f1-4f37-ad35-ef9d6bddd6f6" xlink:to="loc_cris_PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest_b1323fc0-e892-4eec-8a48-3ac7aa846ea0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1bd3fcfa-599b-40ee-8423-12c05b27a3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1e5064b5-80f1-4f37-ad35-ef9d6bddd6f6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1bd3fcfa-599b-40ee-8423-12c05b27a3e5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_23229276-8037-405a-9b3c-00a4a6b105ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cdcfa7ae-851e-45f0-8761-c87a95213597" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_23229276-8037-405a-9b3c-00a4a6b105ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_42bded9c-13c2-4d0d-ad1c-41f296e0efee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cdcfa7ae-851e-45f0-8761-c87a95213597" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_42bded9c-13c2-4d0d-ad1c-41f296e0efee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c6416855-1a19-4bd5-b464-328756e83d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_abb07b90-8f48-400a-826d-2d44d7a96e59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cdcfa7ae-851e-45f0-8761-c87a95213597" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_abb07b90-8f48-400a-826d-2d44d7a96e59" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_b163848b-9ced-465e-9c60-759a9905a92f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_abb07b90-8f48-400a-826d-2d44d7a96e59" xlink:to="loc_us-gaap_InterestPaidNet_b163848b-9ced-465e-9c60-759a9905a92f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue_f026e669-7058-44d2-9e30-ed9849aa1857" xlink:href="cris-20210930.xsd#cris_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_abb07b90-8f48-400a-826d-2d44d7a96e59" xlink:to="loc_cris_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue_f026e669-7058-44d2-9e30-ed9849aa1857" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_fbb1f3ad-de02-4ed4-a615-59b57ec73377" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_abb07b90-8f48-400a-826d-2d44d7a96e59" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_fbb1f3ad-de02-4ed4-a615-59b57ec73377" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_df3cb406-3bcb-4c4e-857f-9bd4003febd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_cdcfa7ae-851e-45f0-8761-c87a95213597" xlink:to="loc_us-gaap_StatementTable_df3cb406-3bcb-4c4e-857f-9bd4003febd6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3699dfe1-62cc-4bc3-9564-e4373a73ac1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_df3cb406-3bcb-4c4e-857f-9bd4003febd6" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3699dfe1-62cc-4bc3-9564-e4373a73ac1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3699dfe1-62cc-4bc3-9564-e4373a73ac1b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3699dfe1-62cc-4bc3-9564-e4373a73ac1b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3699dfe1-62cc-4bc3-9564-e4373a73ac1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b7a37cc-8f74-4dcc-ae13-75967823d147" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3699dfe1-62cc-4bc3-9564-e4373a73ac1b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b7a37cc-8f74-4dcc-ae13-75967823d147" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_AspireCapitalFundLLCMember_edda0921-ffaa-4da4-9b9d-99f4ddf917b8" xlink:href="cris-20210930.xsd#cris_AspireCapitalFundLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b7a37cc-8f74-4dcc-ae13-75967823d147" xlink:to="loc_cris_AspireCapitalFundLLCMember_edda0921-ffaa-4da4-9b9d-99f4ddf917b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_DirectPlacementMember_ac4c7159-342a-41e2-b460-b1d126adc49c" xlink:href="cris-20210930.xsd#cris_DirectPlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b7a37cc-8f74-4dcc-ae13-75967823d147" xlink:to="loc_cris_DirectPlacementMember_ac4c7159-342a-41e2-b460-b1d126adc49c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_DemandSalesAgreementMember_454d35a5-d715-40af-b5dc-ad5027fdafbc" xlink:href="cris-20210930.xsd#cris_DemandSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b7a37cc-8f74-4dcc-ae13-75967823d147" xlink:to="loc_cris_DemandSalesAgreementMember_454d35a5-d715-40af-b5dc-ad5027fdafbc" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.curis.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.curis.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="i5cf58b03cdd54fb8b47e8f1f21a99d8c_SummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_d7c3da8f-3c8a-43d0-8778-ed3661307ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_029f47c9-41f8-4207-9714-deb1c9abf996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_d7c3da8f-3c8a-43d0-8778-ed3661307ebf" xlink:to="loc_us-gaap_RestrictedCash_029f47c9-41f8-4207-9714-deb1c9abf996" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e69480f1-6341-49eb-8e99-ae32235678be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_d7c3da8f-3c8a-43d0-8778-ed3661307ebf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e69480f1-6341-49eb-8e99-ae32235678be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a5b70958-73b0-4892-857b-371856e487a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_d7c3da8f-3c8a-43d0-8778-ed3661307ebf" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a5b70958-73b0-4892-857b-371856e487a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_dc9ec9fb-7688-46d3-839f-225672231f21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_d7c3da8f-3c8a-43d0-8778-ed3661307ebf" xlink:to="loc_us-gaap_NumberOfReportableSegments_dc9ec9fb-7688-46d3-839f-225672231f21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1c9a5b0a-7772-425c-a164-e8e9ab0190de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_d7c3da8f-3c8a-43d0-8778-ed3661307ebf" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1c9a5b0a-7772-425c-a164-e8e9ab0190de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_66bbaeb6-7a43-401e-9061-3c8758087ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1c9a5b0a-7772-425c-a164-e8e9ab0190de" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_66bbaeb6-7a43-401e-9061-3c8758087ba1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_66bbaeb6-7a43-401e-9061-3c8758087ba1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_66bbaeb6-7a43-401e-9061-3c8758087ba1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_66bbaeb6-7a43-401e-9061-3c8758087ba1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b50488a3-dacd-49eb-9233-89ea8c942466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_66bbaeb6-7a43-401e-9061-3c8758087ba1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b50488a3-dacd-49eb-9233-89ea8c942466" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_f8aad0f0-9e6f-45ac-8ec9-990fc1e90bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_b50488a3-dacd-49eb-9233-89ea8c942466" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_f8aad0f0-9e6f-45ac-8ec9-990fc1e90bfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_fbe34378-3c4b-4da8-ae66-e4ff1fe46fdf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1c9a5b0a-7772-425c-a164-e8e9ab0190de" xlink:to="loc_srt_MajorCustomersAxis_fbe34378-3c4b-4da8-ae66-e4ff1fe46fdf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_fbe34378-3c4b-4da8-ae66-e4ff1fe46fdf_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_fbe34378-3c4b-4da8-ae66-e4ff1fe46fdf" xlink:to="loc_srt_NameOfMajorCustomerDomain_fbe34378-3c4b-4da8-ae66-e4ff1fe46fdf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_18f3a7a7-58f5-4743-808f-fb12acd160dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_fbe34378-3c4b-4da8-ae66-e4ff1fe46fdf" xlink:to="loc_srt_NameOfMajorCustomerDomain_18f3a7a7-58f5-4743-808f-fb12acd160dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_GenentechIncMember_28d62471-cc98-4539-912e-8b76011a2b4b" xlink:href="cris-20210930.xsd#cris_GenentechIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_18f3a7a7-58f5-4743-808f-fb12acd160dd" xlink:to="loc_cris_GenentechIncMember_28d62471-cc98-4539-912e-8b76011a2b4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cbe7670e-aced-43e4-9db7-757f203729ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1c9a5b0a-7772-425c-a164-e8e9ab0190de" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cbe7670e-aced-43e4-9db7-757f203729ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cbe7670e-aced-43e4-9db7-757f203729ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cbe7670e-aced-43e4-9db7-757f203729ff" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cbe7670e-aced-43e4-9db7-757f203729ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_07386a15-8954-4bd6-8e39-2556286d4b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cbe7670e-aced-43e4-9db7-757f203729ff" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_07386a15-8954-4bd6-8e39-2556286d4b3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_dddeca58-c440-4346-9446-020ed9106f91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_07386a15-8954-4bd6-8e39-2556286d4b3f" xlink:to="loc_us-gaap_SalesRevenueNetMember_dddeca58-c440-4346-9446-020ed9106f91" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#FairValueofFinancialInstrumentsSummaryDetails"/>
  <link:definitionLink xlink:role="http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails" xlink:type="extended" id="i02743136e0fe445f936afa38064fe27e_FairValueofFinancialInstrumentsSummaryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eadd2edb-e83d-45f1-98d5-07289530b226" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_44a30ac9-8aaa-4720-b670-26621eec88f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eadd2edb-e83d-45f1-98d5-07289530b226" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_44a30ac9-8aaa-4720-b670-26621eec88f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c6dbd5cb-5987-41ef-bfb6-81604ef422c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_44a30ac9-8aaa-4720-b670-26621eec88f2" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c6dbd5cb-5987-41ef-bfb6-81604ef422c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_279ba855-7ba1-4c34-9519-e672bc331905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eadd2edb-e83d-45f1-98d5-07289530b226" xlink:to="loc_us-gaap_ShortTermInvestmentsAbstract_279ba855-7ba1-4c34-9519-e672bc331905" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ShortTermInvestmentsFairValueDisclosure_a8915ed0-c61d-4dd1-9c87-3abe2e50804e" xlink:href="cris-20210930.xsd#cris_ShortTermInvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_279ba855-7ba1-4c34-9519-e672bc331905" xlink:to="loc_cris_ShortTermInvestmentsFairValueDisclosure_a8915ed0-c61d-4dd1-9c87-3abe2e50804e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosureAbstract_a13dbea8-cdd0-425b-9180-7c074acd29b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eadd2edb-e83d-45f1-98d5-07289530b226" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosureAbstract_a13dbea8-cdd0-425b-9180-7c074acd29b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_LongTermInvestmentsFairValueDisclosure_087cb7ab-6e69-4be5-b6b3-f20583627fee" xlink:href="cris-20210930.xsd#cris_LongTermInvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosureAbstract_a13dbea8-cdd0-425b-9180-7c074acd29b6" xlink:to="loc_cris_LongTermInvestmentsFairValueDisclosure_087cb7ab-6e69-4be5-b6b3-f20583627fee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4fbeaea5-2e6f-4ffa-b994-ed50dd7dd9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eadd2edb-e83d-45f1-98d5-07289530b226" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_4fbeaea5-2e6f-4ffa-b994-ed50dd7dd9a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_72e9d0d3-a0c6-4718-a8d8-e4e9f7128727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eadd2edb-e83d-45f1-98d5-07289530b226" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_72e9d0d3-a0c6-4718-a8d8-e4e9f7128727" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1b6b94dd-a933-4cc9-a4a2-77b63eb31234" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_72e9d0d3-a0c6-4718-a8d8-e4e9f7128727" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1b6b94dd-a933-4cc9-a4a2-77b63eb31234" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1b6b94dd-a933-4cc9-a4a2-77b63eb31234_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1b6b94dd-a933-4cc9-a4a2-77b63eb31234" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1b6b94dd-a933-4cc9-a4a2-77b63eb31234_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_15e40cf2-0ccb-48dc-b579-8cd0185ca343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1b6b94dd-a933-4cc9-a4a2-77b63eb31234" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_15e40cf2-0ccb-48dc-b579-8cd0185ca343" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9c084417-d9e2-4ea4-afa8-f9137464e3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_15e40cf2-0ccb-48dc-b579-8cd0185ca343" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9c084417-d9e2-4ea4-afa8-f9137464e3ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a9ab1c0-603c-460f-b5c8-69b9d18b696e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_72e9d0d3-a0c6-4718-a8d8-e4e9f7128727" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a9ab1c0-603c-460f-b5c8-69b9d18b696e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a9ab1c0-603c-460f-b5c8-69b9d18b696e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a9ab1c0-603c-460f-b5c8-69b9d18b696e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a9ab1c0-603c-460f-b5c8-69b9d18b696e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78331ee2-7b50-40df-9015-eb18f40a397e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a9ab1c0-603c-460f-b5c8-69b9d18b696e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78331ee2-7b50-40df-9015-eb18f40a397e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8f69de67-9032-46e5-869d-6e2706ffff93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78331ee2-7b50-40df-9015-eb18f40a397e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8f69de67-9032-46e5-869d-6e2706ffff93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ccdc7607-cb3d-491a-a767-49dd7b028a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78331ee2-7b50-40df-9015-eb18f40a397e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ccdc7607-cb3d-491a-a767-49dd7b028a09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8b341d34-abb0-4913-8225-a38e5c898568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78331ee2-7b50-40df-9015-eb18f40a397e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8b341d34-abb0-4913-8225-a38e5c898568" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_4a2522e2-680a-4ca0-9b8b-8951d23e66bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_72e9d0d3-a0c6-4718-a8d8-e4e9f7128727" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_4a2522e2-680a-4ca0-9b8b-8951d23e66bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4a2522e2-680a-4ca0-9b8b-8951d23e66bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_4a2522e2-680a-4ca0-9b8b-8951d23e66bb" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4a2522e2-680a-4ca0-9b8b-8951d23e66bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b698d9fe-ce46-411c-99a0-6c3ea99d888a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_4a2522e2-680a-4ca0-9b8b-8951d23e66bb" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b698d9fe-ce46-411c-99a0-6c3ea99d888a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8aceae16-c411-407d-99db-8ad219f7b507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b698d9fe-ce46-411c-99a0-6c3ea99d888a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8aceae16-c411-407d-99db-8ad219f7b507" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0a75a261-0d34-4eef-bdf8-5aef810e68e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_72e9d0d3-a0c6-4718-a8d8-e4e9f7128727" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0a75a261-0d34-4eef-bdf8-5aef810e68e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a75a261-0d34-4eef-bdf8-5aef810e68e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0a75a261-0d34-4eef-bdf8-5aef810e68e5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a75a261-0d34-4eef-bdf8-5aef810e68e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f14ea4e4-aa52-41d6-9e61-32cba3c48ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0a75a261-0d34-4eef-bdf8-5aef810e68e5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f14ea4e4-aa52-41d6-9e61-32cba3c48ca5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CorporateCommercialPaperStockBondsAndNotesMember_1ff17494-709c-42d4-8806-309cf81afc5d" xlink:href="cris-20210930.xsd#cris_CorporateCommercialPaperStockBondsAndNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f14ea4e4-aa52-41d6-9e61-32cba3c48ca5" xlink:to="loc_cris_CorporateCommercialPaperStockBondsAndNotesMember_1ff17494-709c-42d4-8806-309cf81afc5d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails" xlink:type="extended" id="i684730f2fea34e509a5cec7363d32ca9_InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05610094-31e8-471b-9da4-69723cc64283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c8dc25ed-5c50-4f41-9a84-3baa74d27b15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05610094-31e8-471b-9da4-69723cc64283" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c8dc25ed-5c50-4f41-9a84-3baa74d27b15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e4eb0ba7-5ac8-419b-84f3-c3cb699c5e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05610094-31e8-471b-9da4-69723cc64283" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e4eb0ba7-5ac8-419b-84f3-c3cb699c5e4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_363ebbd8-52d5-484c-86b8-9e324eb7c01e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05610094-31e8-471b-9da4-69723cc64283" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_363ebbd8-52d5-484c-86b8-9e324eb7c01e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f8b58bc7-ec9e-4b44-bbbd-0f390fc0a670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05610094-31e8-471b-9da4-69723cc64283" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f8b58bc7-ec9e-4b44-bbbd-0f390fc0a670" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_AvailableForSaleSecuritiesDateRange_19738650-6c2b-43bf-9d09-890c2099a7b4" xlink:href="cris-20210930.xsd#cris_AvailableForSaleSecuritiesDateRange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05610094-31e8-471b-9da4-69723cc64283" xlink:to="loc_cris_AvailableForSaleSecuritiesDateRange_19738650-6c2b-43bf-9d09-890c2099a7b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_AvailableForSaleSecuritiesWeightedAverageMaturity_fd8eb12e-bee8-4d3c-aac2-e1f98164cf83" xlink:href="cris-20210930.xsd#cris_AvailableForSaleSecuritiesWeightedAverageMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05610094-31e8-471b-9da4-69723cc64283" xlink:to="loc_cris_AvailableForSaleSecuritiesWeightedAverageMaturity_fd8eb12e-bee8-4d3c-aac2-e1f98164cf83" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ff7ce023-184b-4098-8c19-c9ae3f1ef640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05610094-31e8-471b-9da4-69723cc64283" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ff7ce023-184b-4098-8c19-c9ae3f1ef640" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b8a5a7b8-9541-4560-af00-452f4e7561c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ff7ce023-184b-4098-8c19-c9ae3f1ef640" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b8a5a7b8-9541-4560-af00-452f4e7561c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b8a5a7b8-9541-4560-af00-452f4e7561c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b8a5a7b8-9541-4560-af00-452f4e7561c9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b8a5a7b8-9541-4560-af00-452f4e7561c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5b441a8c-ee0c-4b20-9817-ceed7d5e619f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b8a5a7b8-9541-4560-af00-452f4e7561c9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5b441a8c-ee0c-4b20-9817-ceed7d5e619f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b76d528e-40c2-46f1-948c-c37550fd9be3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5b441a8c-ee0c-4b20-9817-ceed7d5e619f" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b76d528e-40c2-46f1-948c-c37550fd9be3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_ea5aaf45-4d71-4cd8-8b00-0f606faad16a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ff7ce023-184b-4098-8c19-c9ae3f1ef640" xlink:to="loc_us-gaap_InvestmentTypeAxis_ea5aaf45-4d71-4cd8-8b00-0f606faad16a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_ea5aaf45-4d71-4cd8-8b00-0f606faad16a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_ea5aaf45-4d71-4cd8-8b00-0f606faad16a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_ea5aaf45-4d71-4cd8-8b00-0f606faad16a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_259957d0-f033-4d66-9bde-d9b0c5e25e68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_ea5aaf45-4d71-4cd8-8b00-0f606faad16a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_259957d0-f033-4d66-9bde-d9b0c5e25e68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_1caa29dd-5cde-4c25-a0e7-7945a20a1b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_259957d0-f033-4d66-9bde-d9b0c5e25e68" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_1caa29dd-5cde-4c25-a0e7-7945a20a1b0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestmentsMember_3206b505-66a0-4541-b3a1-9c49eb13a670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_259957d0-f033-4d66-9bde-d9b0c5e25e68" xlink:to="loc_us-gaap_OtherLongTermInvestmentsMember_3206b505-66a0-4541-b3a1-9c49eb13a670" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_abcf5229-52d8-457b-b6a8-9f05dafb566f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ff7ce023-184b-4098-8c19-c9ae3f1ef640" xlink:to="loc_srt_RangeAxis_abcf5229-52d8-457b-b6a8-9f05dafb566f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_abcf5229-52d8-457b-b6a8-9f05dafb566f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_abcf5229-52d8-457b-b6a8-9f05dafb566f" xlink:to="loc_srt_RangeMember_abcf5229-52d8-457b-b6a8-9f05dafb566f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_557fb475-0246-41ca-9e75-08b16f260b39" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_abcf5229-52d8-457b-b6a8-9f05dafb566f" xlink:to="loc_srt_RangeMember_557fb475-0246-41ca-9e75-08b16f260b39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5f642b7d-3c12-48c0-afdb-42fcc4307476" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_557fb475-0246-41ca-9e75-08b16f260b39" xlink:to="loc_srt_MinimumMember_5f642b7d-3c12-48c0-afdb-42fcc4307476" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b794e8da-bed8-45dd-a913-efc81a495c4c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_557fb475-0246-41ca-9e75-08b16f260b39" xlink:to="loc_srt_MaximumMember_b794e8da-bed8-45dd-a913-efc81a495c4c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.curis.com/role/DebtDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#DebtDetails"/>
  <link:definitionLink xlink:role="http://www.curis.com/role/DebtDetails" xlink:type="extended" id="i73b85284fedc44fcbabc1aa4d4d98024_DebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8a8d47d0-9660-4bfb-b23b-77f132e8ee58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_320d700e-af6a-41f5-86c5-65c68817a2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a8d47d0-9660-4bfb-b23b-77f132e8ee58" xlink:to="loc_us-gaap_LongTermDebt_320d700e-af6a-41f5-86c5-65c68817a2ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTerm_083b9279-e3b7-48ee-9f95-fb53a4b2e705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a8d47d0-9660-4bfb-b23b-77f132e8ee58" xlink:to="loc_us-gaap_LongTermDebtTerm_083b9279-e3b7-48ee-9f95-fb53a4b2e705" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b2a7944d-f0b0-4148-bd6d-9823d1ce869d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a8d47d0-9660-4bfb-b23b-77f132e8ee58" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b2a7944d-f0b0-4148-bd6d-9823d1ce869d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f0a27935-f2d3-44e4-ad73-2edbc1308ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a8d47d0-9660-4bfb-b23b-77f132e8ee58" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f0a27935-f2d3-44e4-ad73-2edbc1308ceb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_dc08bd49-fa5e-43be-8457-9200b895f714" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a8d47d0-9660-4bfb-b23b-77f132e8ee58" xlink:to="loc_us-gaap_ShortTermBorrowings_dc08bd49-fa5e-43be-8457-9200b895f714" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_fde16da1-d216-4543-8eff-0d389c96b307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a8d47d0-9660-4bfb-b23b-77f132e8ee58" xlink:to="loc_us-gaap_DebtInstrumentTable_fde16da1-d216-4543-8eff-0d389c96b307" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e262b2f5-9996-4648-a703-59549b24d875" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fde16da1-d216-4543-8eff-0d389c96b307" xlink:to="loc_srt_CounterpartyNameAxis_e262b2f5-9996-4648-a703-59549b24d875" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e262b2f5-9996-4648-a703-59549b24d875_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e262b2f5-9996-4648-a703-59549b24d875" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e262b2f5-9996-4648-a703-59549b24d875_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17cc8610-907f-4107-a7d8-3e9b43212377" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e262b2f5-9996-4648-a703-59549b24d875" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17cc8610-907f-4107-a7d8-3e9b43212377" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_SiliconValleyBankMember_edeb0560-f336-4f26-b149-bc12e6e37a5a" xlink:href="cris-20210930.xsd#cris_SiliconValleyBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17cc8610-907f-4107-a7d8-3e9b43212377" xlink:to="loc_cris_SiliconValleyBankMember_edeb0560-f336-4f26-b149-bc12e6e37a5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_861af58d-27e7-44e9-af85-65edadb994c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fde16da1-d216-4543-8eff-0d389c96b307" xlink:to="loc_us-gaap_DebtInstrumentAxis_861af58d-27e7-44e9-af85-65edadb994c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_861af58d-27e7-44e9-af85-65edadb994c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_861af58d-27e7-44e9-af85-65edadb994c4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_861af58d-27e7-44e9-af85-65edadb994c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_61a124d8-00ac-4f28-8dbd-8e1673a6bad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_861af58d-27e7-44e9-af85-65edadb994c4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_61a124d8-00ac-4f28-8dbd-8e1673a6bad7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CaresActPPPLoanMember_b796e11b-1590-4035-9536-f7fe9c4dc819" xlink:href="cris-20210930.xsd#cris_CaresActPPPLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_61a124d8-00ac-4f28-8dbd-8e1673a6bad7" xlink:to="loc_cris_CaresActPPPLoanMember_b796e11b-1590-4035-9536-f7fe9c4dc819" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a9c378ca-e6bc-4b38-b9a1-94fcb3a6e354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fde16da1-d216-4543-8eff-0d389c96b307" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a9c378ca-e6bc-4b38-b9a1-94fcb3a6e354" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a9c378ca-e6bc-4b38-b9a1-94fcb3a6e354_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a9c378ca-e6bc-4b38-b9a1-94fcb3a6e354" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a9c378ca-e6bc-4b38-b9a1-94fcb3a6e354_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3e7143f0-1633-4a97-815b-6b7bc71e70a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a9c378ca-e6bc-4b38-b9a1-94fcb3a6e354" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3e7143f0-1633-4a97-815b-6b7bc71e70a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_fd99049f-fd7e-433a-a504-45d8ea0827aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3e7143f0-1633-4a97-815b-6b7bc71e70a5" xlink:to="loc_us-gaap_CommercialPaperMember_fd99049f-fd7e-433a-a504-45d8ea0827aa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails" xlink:type="extended" id="ie9b2e0714c33454d90e5233b7b325ccf_LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionLineItems_a107d004-a078-4ad7-bbbc-d1442232d241" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ProceedsFromRoyaltyPurchaseAgreement_d1888d29-e4cb-405d-b85d-b3d58d667ce5" xlink:href="cris-20210930.xsd#cris_ProceedsFromRoyaltyPurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonmonetaryTransactionLineItems_a107d004-a078-4ad7-bbbc-d1442232d241" xlink:to="loc_cris_ProceedsFromRoyaltyPurchaseAgreement_d1888d29-e4cb-405d-b85d-b3d58d667ce5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyPurchaseAgreementContingentConsiderationCashProceeds_b4bbeb15-f325-432c-a16f-2c444a608642" xlink:href="cris-20210930.xsd#cris_RoyaltyPurchaseAgreementContingentConsiderationCashProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonmonetaryTransactionLineItems_a107d004-a078-4ad7-bbbc-d1442232d241" xlink:to="loc_cris_RoyaltyPurchaseAgreementContingentConsiderationCashProceeds_b4bbeb15-f325-432c-a16f-2c444a608642" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold_d5c6c5e7-5624-4d75-8004-54ad612a6b44" xlink:href="cris-20210930.xsd#cris_RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonmonetaryTransactionLineItems_a107d004-a078-4ad7-bbbc-d1442232d241" xlink:to="loc_cris_RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold_d5c6c5e7-5624-4d75-8004-54ad612a6b44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyPurchaseAgreementTermsPurchaserDefaultOptionPeriod_400e7be4-0d34-4f2f-9186-d6735b5f0c50" xlink:href="cris-20210930.xsd#cris_RoyaltyPurchaseAgreementTermsPurchaserDefaultOptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonmonetaryTransactionLineItems_a107d004-a078-4ad7-bbbc-d1442232d241" xlink:to="loc_cris_RoyaltyPurchaseAgreementTermsPurchaserDefaultOptionPeriod_400e7be4-0d34-4f2f-9186-d6735b5f0c50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyPurchaseAgreementInterestRate_8fa6238f-3857-4971-a07e-100e5a464ac4" xlink:href="cris-20210930.xsd#cris_RoyaltyPurchaseAgreementInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonmonetaryTransactionLineItems_a107d004-a078-4ad7-bbbc-d1442232d241" xlink:to="loc_cris_RoyaltyPurchaseAgreementInterestRate_8fa6238f-3857-4971-a07e-100e5a464ac4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts_1770e256-f3a6-4bea-975c-fd5e81e57d88" xlink:href="cris-20210930.xsd#cris_RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonmonetaryTransactionLineItems_a107d004-a078-4ad7-bbbc-d1442232d241" xlink:to="loc_cris_RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts_1770e256-f3a6-4bea-975c-fd5e81e57d88" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionByTypeTable_086ba914-8ec8-41e5-a0a3-4cd84e104a75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionByTypeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NonmonetaryTransactionLineItems_a107d004-a078-4ad7-bbbc-d1442232d241" xlink:to="loc_us-gaap_NonmonetaryTransactionByTypeTable_086ba914-8ec8-41e5-a0a3-4cd84e104a75" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a94e7633-2fc8-4c79-8c9d-a4f1324ed03e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NonmonetaryTransactionByTypeTable_086ba914-8ec8-41e5-a0a3-4cd84e104a75" xlink:to="loc_srt_CounterpartyNameAxis_a94e7633-2fc8-4c79-8c9d-a4f1324ed03e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a94e7633-2fc8-4c79-8c9d-a4f1324ed03e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a94e7633-2fc8-4c79-8c9d-a4f1324ed03e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a94e7633-2fc8-4c79-8c9d-a4f1324ed03e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f96add02-a084-409f-afbb-39280fc2b65d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a94e7633-2fc8-4c79-8c9d-a4f1324ed03e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f96add02-a084-409f-afbb-39280fc2b65d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_OberlandCapitalMember_bf8d0a9e-4f51-4182-b91b-1c298e6d1cf4" xlink:href="cris-20210930.xsd#cris_OberlandCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f96add02-a084-409f-afbb-39280fc2b65d" xlink:to="loc_cris_OberlandCapitalMember_bf8d0a9e-4f51-4182-b91b-1c298e6d1cf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ContingentPaymentBenchmarkAxis_3e6a801e-3aac-4ca2-b79c-694e5f33808c" xlink:href="cris-20210930.xsd#cris_ContingentPaymentBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NonmonetaryTransactionByTypeTable_086ba914-8ec8-41e5-a0a3-4cd84e104a75" xlink:to="loc_cris_ContingentPaymentBenchmarkAxis_3e6a801e-3aac-4ca2-b79c-694e5f33808c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ContingentPaymentBenchmarkDomain_3e6a801e-3aac-4ca2-b79c-694e5f33808c_default" xlink:href="cris-20210930.xsd#cris_ContingentPaymentBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cris_ContingentPaymentBenchmarkAxis_3e6a801e-3aac-4ca2-b79c-694e5f33808c" xlink:to="loc_cris_ContingentPaymentBenchmarkDomain_3e6a801e-3aac-4ca2-b79c-694e5f33808c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ContingentPaymentBenchmarkDomain_2bda238e-f63e-417a-9556-e89cd95f79b7" xlink:href="cris-20210930.xsd#cris_ContingentPaymentBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cris_ContingentPaymentBenchmarkAxis_3e6a801e-3aac-4ca2-b79c-694e5f33808c" xlink:to="loc_cris_ContingentPaymentBenchmarkDomain_2bda238e-f63e-417a-9556-e89cd95f79b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyAmountsIn2021Member_e8977323-d249-4f47-8419-073192bc75c6" xlink:href="cris-20210930.xsd#cris_RoyaltyAmountsIn2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cris_ContingentPaymentBenchmarkDomain_2bda238e-f63e-417a-9556-e89cd95f79b7" xlink:to="loc_cris_RoyaltyAmountsIn2021Member_e8977323-d249-4f47-8419-073192bc75c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_AggregateNetRoyaltiesPriorTo2027Member_26e3c7b6-ea88-4bec-b2af-ef3da4326ca6" xlink:href="cris-20210930.xsd#cris_AggregateNetRoyaltiesPriorTo2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cris_ContingentPaymentBenchmarkDomain_2bda238e-f63e-417a-9556-e89cd95f79b7" xlink:to="loc_cris_AggregateNetRoyaltiesPriorTo2027Member_26e3c7b6-ea88-4bec-b2af-ef3da4326ca6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#ResearchandDevelopmentCollaborationsDetails"/>
  <link:definitionLink xlink:role="http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails" xlink:type="extended" id="i7e29766fb4b541df9113248d45078019_ResearchandDevelopmentCollaborationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment_4ff42dbd-5e53-4748-805a-130d9df1f0d3" xlink:href="cris-20210930.xsd#cris_CollaborationAgreementContingentConsiderationPotentialCashPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment_4ff42dbd-5e53-4748-805a-130d9df1f0d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner_39c7212d-a050-401c-8451-2cd589063383" xlink:href="cris-20210930.xsd#cris_CollaborationAgreementContingentConsiderationReceivedFromPartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner_39c7212d-a050-401c-8451-2cd589063383" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_PercentageOfRoyaltyOnNetSales_4e1817d2-22d0-4bc1-80f2-2fd2450f2897" xlink:href="cris-20210930.xsd#cris_PercentageOfRoyaltyOnNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_PercentageOfRoyaltyOnNetSales_4e1817d2-22d0-4bc1-80f2-2fd2450f2897" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ReducedRoyaltyRate_15d0d309-e9c3-46f9-b96a-48cfa8385ff2" xlink:href="cris-20210930.xsd#cris_ReducedRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_ReducedRoyaltyRate_15d0d309-e9c3-46f9-b96a-48cfa8385ff2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2875386d-65ae-420e-a5bd-e282e2657818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2875386d-65ae-420e-a5bd-e282e2657818" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_7edd4d88-9c6f-4fda-9a3c-b9c11ce66eac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_us-gaap_RoyaltyExpense_7edd4d88-9c6f-4fda-9a3c-b9c11ce66eac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyRatePercentageOfSales_0a93dded-5b98-4630-a023-3431812cbbef" xlink:href="cris-20210930.xsd#cris_RoyaltyRatePercentageOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_RoyaltyRatePercentageOfSales_0a93dded-5b98-4630-a023-3431812cbbef" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_87e71c26-59b0-43c8-8896-26e951bcb17d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_87e71c26-59b0-43c8-8896-26e951bcb17d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationAgreementTermsPercentageOfRoyaltyFeesReceivable_7f96ea0d-e84b-46b6-8888-a8b572b7d997" xlink:href="cris-20210930.xsd#cris_CollaborationAgreementTermsPercentageOfRoyaltyFeesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_CollaborationAgreementTermsPercentageOfRoyaltyFeesReceivable_7f96ea0d-e84b-46b6-8888-a8b572b7d997" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationAgreementNumberofProgramsLicensed_96037e74-8de0-4d8f-a930-a31a96506d87" xlink:href="cris-20210930.xsd#cris_CollaborationAgreementNumberofProgramsLicensed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_CollaborationAgreementNumberofProgramsLicensed_96037e74-8de0-4d8f-a930-a31a96506d87" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_PaymentsforCollaborativeArrangementstoDate_64450ac7-e993-4630-92ed-6ac7fe9d454e" xlink:href="cris-20210930.xsd#cris_PaymentsforCollaborativeArrangementstoDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_PaymentsforCollaborativeArrangementstoDate_64450ac7-e993-4630-92ed-6ac7fe9d454e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_MilestonePaymentsWaivedToDate_25c1a712-1680-4180-a46c-20981955fa89" xlink:href="cris-20210930.xsd#cris_MilestonePaymentsWaivedToDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_MilestonePaymentsWaivedToDate_25c1a712-1680-4180-a46c-20981955fa89" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1_ecf564c4-71ce-4801-8919-4a8cbedbf691" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1_ecf564c4-71ce-4801-8919-4a8cbedbf691" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborativeArrangementPaymentsAgreement_37b017ee-52ff-4c44-b6cf-dddee7944d3c" xlink:href="cris-20210930.xsd#cris_CollaborativeArrangementPaymentsAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_CollaborativeArrangementPaymentsAgreement_37b017ee-52ff-4c44-b6cf-dddee7944d3c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_9a5fcf62-b201-49ed-b9e8-c9b4e5df61fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_9a5fcf62-b201-49ed-b9e8-c9b4e5df61fc" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_7d890a3d-075d-455c-a8d0-d9d2d2591f04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_7d890a3d-075d-455c-a8d0-d9d2d2591f04" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationAgreementExpense_cda9da50-dc90-496b-a440-c99dc0880020" xlink:href="cris-20210930.xsd#cris_CollaborationAgreementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_CollaborationAgreementExpense_cda9da50-dc90-496b-a440-c99dc0880020" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationArrangementSemiAnnualMaintenanceFeePayment_69f37d14-7446-492c-bdcc-c8af327f0272" xlink:href="cris-20210930.xsd#cris_CollaborationArrangementSemiAnnualMaintenanceFeePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_CollaborationArrangementSemiAnnualMaintenanceFeePayment_69f37d14-7446-492c-bdcc-c8af327f0272" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationArrangementContingentConsiderationReimbursableExpenses_7ef7a98d-c8dc-40e4-8f6a-d952fd96ff8b" xlink:href="cris-20210930.xsd#cris_CollaborationArrangementContingentConsiderationReimbursableExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_CollaborationArrangementContingentConsiderationReimbursableExpenses_7ef7a98d-c8dc-40e4-8f6a-d952fd96ff8b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationArrangementContingentConsiderationOptionExerciseFee_8dda9268-63a2-4074-8759-9d10a499bab4" xlink:href="cris-20210930.xsd#cris_CollaborationArrangementContingentConsiderationOptionExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_CollaborationArrangementContingentConsiderationOptionExerciseFee_8dda9268-63a2-4074-8759-9d10a499bab4" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationArrangementContingentConsiderationDevelopmentMilestonePayments_35da596c-b0d5-43f6-a934-4c9b4f43776f" xlink:href="cris-20210930.xsd#cris_CollaborationArrangementContingentConsiderationDevelopmentMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_CollaborationArrangementContingentConsiderationDevelopmentMilestonePayments_35da596c-b0d5-43f6-a934-4c9b4f43776f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationArrangementContingentConsiderationRegulatoryApprovalMilestonePayments_8850d616-683a-4e31-9bbe-9a95f7a011ec" xlink:href="cris-20210930.xsd#cris_CollaborationArrangementContingentConsiderationRegulatoryApprovalMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_CollaborationArrangementContingentConsiderationRegulatoryApprovalMilestonePayments_8850d616-683a-4e31-9bbe-9a95f7a011ec" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationArrangementContingentConsiderationSalesMilestonePayments_945317f8-75e4-4e35-9f0d-3d90b0fa9d30" xlink:href="cris-20210930.xsd#cris_CollaborationArrangementContingentConsiderationSalesMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_CollaborationArrangementContingentConsiderationSalesMilestonePayments_945317f8-75e4-4e35-9f0d-3d90b0fa9d30" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_31b4de96-640e-4194-837c-8cdd4bf53e48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_31b4de96-640e-4194-837c-8cdd4bf53e48" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8364d545-36ef-437d-865b-7c926b398ba8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_31b4de96-640e-4194-837c-8cdd4bf53e48" xlink:to="loc_srt_CounterpartyNameAxis_8364d545-36ef-437d-865b-7c926b398ba8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8364d545-36ef-437d-865b-7c926b398ba8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8364d545-36ef-437d-865b-7c926b398ba8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8364d545-36ef-437d-865b-7c926b398ba8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d368d6a3-d683-47da-b732-8cbd9c378fc1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8364d545-36ef-437d-865b-7c926b398ba8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d368d6a3-d683-47da-b732-8cbd9c378fc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_GenentechIncMember_2a550922-457a-4ce3-9315-810f2a343cf5" xlink:href="cris-20210930.xsd#cris_GenentechIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d368d6a3-d683-47da-b732-8cbd9c378fc1" xlink:to="loc_cris_GenentechIncMember_2a550922-457a-4ce3-9315-810f2a343cf5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_AurigeneDiscoveryTechnologiesLtdMember_a256da48-ca25-40e7-96bc-81f4513c8d63" xlink:href="cris-20210930.xsd#cris_AurigeneDiscoveryTechnologiesLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d368d6a3-d683-47da-b732-8cbd9c378fc1" xlink:to="loc_cris_AurigeneDiscoveryTechnologiesLtdMember_a256da48-ca25-40e7-96bc-81f4513c8d63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ImmuNextMember_b6bd76da-71d8-4968-87d5-19fcfac4ce71" xlink:href="cris-20210930.xsd#cris_ImmuNextMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d368d6a3-d683-47da-b732-8cbd9c378fc1" xlink:to="loc_cris_ImmuNextMember_b6bd76da-71d8-4968-87d5-19fcfac4ce71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_41b610c1-d5dd-4ebd-bf87-03dd66c6c9ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_31b4de96-640e-4194-837c-8cdd4bf53e48" xlink:to="loc_srt_RangeAxis_41b610c1-d5dd-4ebd-bf87-03dd66c6c9ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_41b610c1-d5dd-4ebd-bf87-03dd66c6c9ab_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_41b610c1-d5dd-4ebd-bf87-03dd66c6c9ab" xlink:to="loc_srt_RangeMember_41b610c1-d5dd-4ebd-bf87-03dd66c6c9ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c6b90435-d00c-45dd-8c66-99b25aa478dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_41b610c1-d5dd-4ebd-bf87-03dd66c6c9ab" xlink:to="loc_srt_RangeMember_c6b90435-d00c-45dd-8c66-99b25aa478dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c596a7fa-6eca-4add-b3e6-18a5883271c4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c6b90435-d00c-45dd-8c66-99b25aa478dd" xlink:to="loc_srt_MaximumMember_c596a7fa-6eca-4add-b3e6-18a5883271c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5a4a96a1-36e3-4116-ac0f-58d04d5f9746" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c6b90435-d00c-45dd-8c66-99b25aa478dd" xlink:to="loc_srt_MinimumMember_5a4a96a1-36e3-4116-ac0f-58d04d5f9746" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9249b0f3-2e3c-4922-8934-3a51e6c8426e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_31b4de96-640e-4194-837c-8cdd4bf53e48" xlink:to="loc_srt_ProductOrServiceAxis_9249b0f3-2e3c-4922-8934-3a51e6c8426e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9249b0f3-2e3c-4922-8934-3a51e6c8426e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9249b0f3-2e3c-4922-8934-3a51e6c8426e" xlink:to="loc_srt_ProductsAndServicesDomain_9249b0f3-2e3c-4922-8934-3a51e6c8426e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6a0109e6-ac73-43cc-84aa-eaeffd8cd878" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9249b0f3-2e3c-4922-8934-3a51e6c8426e" xlink:to="loc_srt_ProductsAndServicesDomain_6a0109e6-ac73-43cc-84aa-eaeffd8cd878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_GrossRoyaltyRevenueMember_4f00bac2-39e6-43f7-9105-65004b33d962" xlink:href="cris-20210930.xsd#cris_GrossRoyaltyRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6a0109e6-ac73-43cc-84aa-eaeffd8cd878" xlink:to="loc_cris_GrossRoyaltyRevenueMember_4f00bac2-39e6-43f7-9105-65004b33d962" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b4bbde35-5bf3-4fc0-b691-223a4c76d413" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_31b4de96-640e-4194-837c-8cdd4bf53e48" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b4bbde35-5bf3-4fc0-b691-223a4c76d413" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b4bbde35-5bf3-4fc0-b691-223a4c76d413_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b4bbde35-5bf3-4fc0-b691-223a4c76d413" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b4bbde35-5bf3-4fc0-b691-223a4c76d413_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f6f822fe-c257-4a8f-94c6-20a9a090414a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b4bbde35-5bf3-4fc0-b691-223a4c76d413" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f6f822fe-c257-4a8f-94c6-20a9a090414a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ThirdandFourthProgramsMember_1ed72298-7069-4d43-8910-68978fca961b" xlink:href="cris-20210930.xsd#cris_ThirdandFourthProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f6f822fe-c257-4a8f-94c6-20a9a090414a" xlink:to="loc_cris_ThirdandFourthProgramsMember_1ed72298-7069-4d43-8910-68978fca961b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_IRAK4PD1VISTAPD1TIM3ProgramMember_9ff81ae4-b0a0-4fd3-8237-557ff63aaf66" xlink:href="cris-20210930.xsd#cris_IRAK4PD1VISTAPD1TIM3ProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f6f822fe-c257-4a8f-94c6-20a9a090414a" xlink:to="loc_cris_IRAK4PD1VISTAPD1TIM3ProgramMember_9ff81ae4-b0a0-4fd3-8237-557ff63aaf66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_MasterDevelopmentAndManufacturingAgreementMember_a8514192-1ebe-451e-ba5c-4c94842f94ab" xlink:href="cris-20210930.xsd#cris_MasterDevelopmentAndManufacturingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f6f822fe-c257-4a8f-94c6-20a9a090414a" xlink:to="loc_cris_MasterDevelopmentAndManufacturingAgreementMember_a8514192-1ebe-451e-ba5c-4c94842f94ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8f411771-117b-4c8c-9629-427265910450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_31b4de96-640e-4194-837c-8cdd4bf53e48" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8f411771-117b-4c8c-9629-427265910450" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8f411771-117b-4c8c-9629-427265910450_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8f411771-117b-4c8c-9629-427265910450" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8f411771-117b-4c8c-9629-427265910450_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_50ffde00-73da-4b9b-acfb-608177d54e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8f411771-117b-4c8c-9629-427265910450" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_50ffde00-73da-4b9b-acfb-608177d54e40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d29204f6-5dc6-4efc-91ae-ba6fd87c1bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_50ffde00-73da-4b9b-acfb-608177d54e40" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d29204f6-5dc6-4efc-91ae-ba6fd87c1bdc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.curis.com/role/CommonStockDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#CommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.curis.com/role/CommonStockDetails" xlink:type="extended" id="i104cd70fa00745f0a8c38ffd1cf2e918_CommonStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6c79b206-6615-4915-a246-75cfafd1dfdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6c79b206-6615-4915-a246-75cfafd1dfdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockSaleAgreementAuthorizedAmount_8573f09e-a05b-47ce-b712-1c82c2b961f7" xlink:href="cris-20210930.xsd#cris_StockSaleAgreementAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_cris_StockSaleAgreementAuthorizedAmount_8573f09e-a05b-47ce-b712-1c82c2b961f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockSaleAgreementCompensationFeePercentageOfGrossProceeds_4799343d-6869-4115-bedf-52213178d4ed" xlink:href="cris-20210930.xsd#cris_StockSaleAgreementCompensationFeePercentageOfGrossProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_cris_StockSaleAgreementCompensationFeePercentageOfGrossProceeds_4799343d-6869-4115-bedf-52213178d4ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ee159aed-b3b9-43ec-a06c-d171bdfb6724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ee159aed-b3b9-43ec-a06c-d171bdfb6724" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_abe2c0e3-92f7-4c6b-a7ae-60ea6d69fc97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_abe2c0e3-92f7-4c6b-a7ae-60ea6d69fc97" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_2c3fdacb-5f52-4212-8813-f456579fd73f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_2c3fdacb-5f52-4212-8813-f456579fd73f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_8ed51a0a-9d6d-4900-b215-c1c0364a3931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_8ed51a0a-9d6d-4900-b215-c1c0364a3931" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_4728acf5-8821-4689-8094-c9cf18a13c95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_us-gaap_ProfessionalFees_4728acf5-8821-4689-8094-c9cf18a13c95" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_SaleOfStockIssuanceCosts_90a334e7-cc2d-42de-a151-fd843be24206" xlink:href="cris-20210930.xsd#cris_SaleOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_cris_SaleOfStockIssuanceCosts_90a334e7-cc2d-42de-a151-fd843be24206" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_aa5a8838-f643-4f63-884e-579e7cc12862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_aa5a8838-f643-4f63-884e-579e7cc12862" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockPurchaseProgramRemainingAuthorizedPurchaseAmount_d1a9a804-ba4b-41cc-8b3a-f7da8078bdcc" xlink:href="cris-20210930.xsd#cris_StockPurchaseProgramRemainingAuthorizedPurchaseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_cris_StockPurchaseProgramRemainingAuthorizedPurchaseAmount_d1a9a804-ba4b-41cc-8b3a-f7da8078bdcc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockPurchaseProgramAuthorizedAmount_d6aecb8d-a257-4fb4-a257-467ade603463" xlink:href="cris-20210930.xsd#cris_StockPurchaseProgramAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_cris_StockPurchaseProgramAuthorizedAmount_d6aecb8d-a257-4fb4-a257-467ade603463" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockPurchaseProgramPricePeriod_d9f126a0-cba4-4788-a57e-966ae9c57330" xlink:href="cris-20210930.xsd#cris_StockPurchaseProgramPricePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_cris_StockPurchaseProgramPricePeriod_d9f126a0-cba4-4788-a57e-966ae9c57330" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3be6a7e2-6e5d-4bd1-b6fc-c74c47f48309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3be6a7e2-6e5d-4bd1-b6fc-c74c47f48309" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_96352325-90a6-494a-8dff-2d57a527cf55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_us-gaap_CommonStockValue_96352325-90a6-494a-8dff-2d57a527cf55" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockPurchaseProgramCommitmentFeeShares_deca351f-3c08-4a3a-aad4-25f540c39f3b" xlink:href="cris-20210930.xsd#cris_StockPurchaseProgramCommitmentFeeShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_cris_StockPurchaseProgramCommitmentFeeShares_deca351f-3c08-4a3a-aad4-25f540c39f3b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockSaleAgreementRemainingAuthorizedAmount_b7817400-6f1d-4130-ac96-a76626761d78" xlink:href="cris-20210930.xsd#cris_StockSaleAgreementRemainingAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_cris_StockSaleAgreementRemainingAuthorizedAmount_b7817400-6f1d-4130-ac96-a76626761d78" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_88dfa6fe-564c-4d0b-a054-dab26a02e7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_88dfa6fe-564c-4d0b-a054-dab26a02e7b5" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockPurchaseProgramTermsSharesAuthorizedPerDay_0648c854-0214-47c2-8e4b-6b4342dbd761" xlink:href="cris-20210930.xsd#cris_StockPurchaseProgramTermsSharesAuthorizedPerDay"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_cris_StockPurchaseProgramTermsSharesAuthorizedPerDay_0648c854-0214-47c2-8e4b-6b4342dbd761" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockPurchaseProgramTermsSharesAuthorizedPerDayAfterMutualAgreement_42590257-e3e9-42fc-93ab-db0e345b4d83" xlink:href="cris-20210930.xsd#cris_StockPurchaseProgramTermsSharesAuthorizedPerDayAfterMutualAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_cris_StockPurchaseProgramTermsSharesAuthorizedPerDayAfterMutualAgreement_42590257-e3e9-42fc-93ab-db0e345b4d83" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_b95eaa89-c7df-4164-98b5-12d51b2de152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_b95eaa89-c7df-4164-98b5-12d51b2de152" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_380433de-1f58-4b47-998f-da5d71181b84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b95eaa89-c7df-4164-98b5-12d51b2de152" xlink:to="loc_us-gaap_AwardTypeAxis_380433de-1f58-4b47-998f-da5d71181b84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_380433de-1f58-4b47-998f-da5d71181b84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_380433de-1f58-4b47-998f-da5d71181b84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_380433de-1f58-4b47-998f-da5d71181b84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec829d91-9777-405b-80ff-ae80aba6e220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_380433de-1f58-4b47-998f-da5d71181b84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec829d91-9777-405b-80ff-ae80aba6e220" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c2345861-1ae9-4c1a-a8b1-704ccb1683d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec829d91-9777-405b-80ff-ae80aba6e220" xlink:to="loc_us-gaap_CommonStockMember_c2345861-1ae9-4c1a-a8b1-704ccb1683d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_635f174b-b3ce-45c9-a6de-c19a9e20f984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b95eaa89-c7df-4164-98b5-12d51b2de152" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_635f174b-b3ce-45c9-a6de-c19a9e20f984" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_635f174b-b3ce-45c9-a6de-c19a9e20f984_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_635f174b-b3ce-45c9-a6de-c19a9e20f984" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_635f174b-b3ce-45c9-a6de-c19a9e20f984_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c90a6aae-9886-42ec-a659-44357d6826ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_635f174b-b3ce-45c9-a6de-c19a9e20f984" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c90a6aae-9886-42ec-a659-44357d6826ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_53e85c6e-2ceb-4b93-91a7-db724c7fbff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c90a6aae-9886-42ec-a659-44357d6826ec" xlink:to="loc_us-gaap_PrivatePlacementMember_53e85c6e-2ceb-4b93-91a7-db724c7fbff2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_0a77c893-e0af-4f26-aa0a-6f5c9270d084" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c90a6aae-9886-42ec-a659-44357d6826ec" xlink:to="loc_us-gaap_OverAllotmentOptionMember_0a77c893-e0af-4f26-aa0a-6f5c9270d084" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_444bbc0a-f494-4afb-9547-fdc942be7bd9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b95eaa89-c7df-4164-98b5-12d51b2de152" xlink:to="loc_srt_CounterpartyNameAxis_444bbc0a-f494-4afb-9547-fdc942be7bd9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_444bbc0a-f494-4afb-9547-fdc942be7bd9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_444bbc0a-f494-4afb-9547-fdc942be7bd9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_444bbc0a-f494-4afb-9547-fdc942be7bd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efaa3f91-8e40-4b11-a9f6-0fd8a5dbba27" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_444bbc0a-f494-4afb-9547-fdc942be7bd9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efaa3f91-8e40-4b11-a9f6-0fd8a5dbba27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_DemandSalesAgreementMember_e8e4ab3d-159f-42d3-a644-ebefe9c97ec0" xlink:href="cris-20210930.xsd#cris_DemandSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efaa3f91-8e40-4b11-a9f6-0fd8a5dbba27" xlink:to="loc_cris_DemandSalesAgreementMember_e8e4ab3d-159f-42d3-a644-ebefe9c97ec0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_AspireCapitalFundLLCMember_2ef9dcce-3b06-407d-858c-f14c15264d71" xlink:href="cris-20210930.xsd#cris_AspireCapitalFundLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efaa3f91-8e40-4b11-a9f6-0fd8a5dbba27" xlink:to="loc_cris_AspireCapitalFundLLCMember_2ef9dcce-3b06-407d-858c-f14c15264d71" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#StockPlansandStockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails" xlink:type="extended" id="i237f5d05ebe3458b9513ebd9babe009e_StockPlansandStockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ShareBasedCompensationPlans_83982924-d4fd-4762-babd-84f53cb73ceb" xlink:href="cris-20210930.xsd#cris_ShareBasedCompensationPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_cris_ShareBasedCompensationPlans_83982924-d4fd-4762-babd-84f53cb73ceb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_2f3c1a0d-db34-42f8-b987-4d5578e0ca7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_2f3c1a0d-db34-42f8-b987-4d5578e0ca7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_04ad02c5-60d6-469a-89f8-0518c5a3af1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_04ad02c5-60d6-469a-89f8-0518c5a3af1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_962d40a3-fb9d-4a4e-bfad-2ab6e0d4fd6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_962d40a3-fb9d-4a4e-bfad-2ab6e0d4fd6c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare_905eb097-dbc6-478a-be6e-bace1eddc2bd" xlink:href="cris-20210930.xsd#cris_SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare_905eb097-dbc6-478a-be6e-bace1eddc2bd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_345b3887-3665-43b7-a812-55c6483656e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_345b3887-3665-43b7-a812-55c6483656e3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_NumberOfSharesAwardedUnderStockValueLessThanSpecificPercentageOfFairMarketValue_982d2305-f011-49f1-aa8d-87e62dd5ac92" xlink:href="cris-20210930.xsd#cris_NumberOfSharesAwardedUnderStockValueLessThanSpecificPercentageOfFairMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_cris_NumberOfSharesAwardedUnderStockValueLessThanSpecificPercentageOfFairMarketValue_982d2305-f011-49f1-aa8d-87e62dd5ac92" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e1c6a23c-5b5a-47a4-935f-c778a5fabcf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e1c6a23c-5b5a-47a4-935f-c778a5fabcf8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_6d0b3e89-024f-448e-90a2-96197e1f9a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_6d0b3e89-024f-448e-90a2-96197e1f9a4e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2317d649-bf1c-496e-9906-e27dccbf6620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2317d649-bf1c-496e-9906-e27dccbf6620" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4bc8bbe8-1cf1-4e60-84ee-81548674c1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4bc8bbe8-1cf1-4e60-84ee-81548674c1d3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2e0628d4-7ba2-412c-b29a-f65ec88070e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2e0628d4-7ba2-412c-b29a-f65ec88070e4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_aa62d8a4-d3fb-4f85-bf3a-b3ae300de4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_aa62d8a4-d3fb-4f85-bf3a-b3ae300de4f1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f6b2fb62-9dca-4c18-a472-386ae5be0676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f6b2fb62-9dca-4c18-a472-386ae5be0676" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0e4c2a6a-2819-4857-9680-067a78a30111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0e4c2a6a-2819-4857-9680-067a78a30111" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1e796c8d-c702-4190-ad37-f49e9b47cfcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1e796c8d-c702-4190-ad37-f49e9b47cfcb" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_65d2875d-807a-43a8-9cfc-0322df639f04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_65d2875d-807a-43a8-9cfc-0322df639f04" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_EmployeeStockPurchasePlanEnrollmentPeriod_0ac84483-d876-4690-a24f-4083e5f5541b" xlink:href="cris-20210930.xsd#cris_EmployeeStockPurchasePlanEnrollmentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_cris_EmployeeStockPurchasePlanEnrollmentPeriod_0ac84483-d876-4690-a24f-4083e5f5541b" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_NumberOfPurchasePeriodsPerEnrollmentPeriod_f4aca2ee-3cc1-468a-8122-4ab94e962f33" xlink:href="cris-20210930.xsd#cris_NumberOfPurchasePeriodsPerEnrollmentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_cris_NumberOfPurchasePeriodsPerEnrollmentPeriod_f4aca2ee-3cc1-468a-8122-4ab94e962f33" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod_fa8cd4c2-d7ab-4994-9e1b-7fadc46c4db9" xlink:href="cris-20210930.xsd#cris_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod_fa8cd4c2-d7ab-4994-9e1b-7fadc46c4db9" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_20efb321-427b-48b7-b832-c91188c7a2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_20efb321-427b-48b7-b832-c91188c7a2c8" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockAvailableForFuturePurchaseUnderEmployeeStockPurchasePlans_32e065c9-95df-4dd4-821c-e84f437ec6e9" xlink:href="cris-20210930.xsd#cris_StockAvailableForFuturePurchaseUnderEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_cris_StockAvailableForFuturePurchaseUnderEmployeeStockPurchasePlans_32e065c9-95df-4dd4-821c-e84f437ec6e9" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_7ef84679-acdb-4d1e-91c7-8d019b81cb5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_7ef84679-acdb-4d1e-91c7-8d019b81cb5b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4d79ef96-a858-427d-b9f2-d4478f5b029d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_7ef84679-acdb-4d1e-91c7-8d019b81cb5b" xlink:to="loc_us-gaap_PlanNameAxis_4d79ef96-a858-427d-b9f2-d4478f5b029d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4d79ef96-a858-427d-b9f2-d4478f5b029d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_4d79ef96-a858-427d-b9f2-d4478f5b029d" xlink:to="loc_us-gaap_PlanNameDomain_4d79ef96-a858-427d-b9f2-d4478f5b029d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ee185a6c-7224-442b-b0ba-68d2c5e9218d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_4d79ef96-a858-427d-b9f2-d4478f5b029d" xlink:to="loc_us-gaap_PlanNameDomain_ee185a6c-7224-442b-b0ba-68d2c5e9218d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_AmendedAndRestatedTwoThousandTenStockIncentivePlanMember_fc37c8f8-c5de-483e-b29f-59ce5f15575a" xlink:href="cris-20210930.xsd#cris_AmendedAndRestatedTwoThousandTenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ee185a6c-7224-442b-b0ba-68d2c5e9218d" xlink:to="loc_cris_AmendedAndRestatedTwoThousandTenStockIncentivePlanMember_fc37c8f8-c5de-483e-b29f-59ce5f15575a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_TwoThousandAndTenPlanMember_fdc5d2f3-8a76-475b-883f-9a241f2b1a6d" xlink:href="cris-20210930.xsd#cris_TwoThousandAndTenPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ee185a6c-7224-442b-b0ba-68d2c5e9218d" xlink:to="loc_cris_TwoThousandAndTenPlanMember_fdc5d2f3-8a76-475b-883f-9a241f2b1a6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_EmployeeStockPurchasePlanMember_fe6786ed-6c7c-47b7-b885-f0bf076e8672" xlink:href="cris-20210930.xsd#cris_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ee185a6c-7224-442b-b0ba-68d2c5e9218d" xlink:to="loc_cris_EmployeeStockPurchasePlanMember_fe6786ed-6c7c-47b7-b885-f0bf076e8672" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_58445745-a6f2-4ac1-8e7f-c262355cd724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_7ef84679-acdb-4d1e-91c7-8d019b81cb5b" xlink:to="loc_us-gaap_AwardTypeAxis_58445745-a6f2-4ac1-8e7f-c262355cd724" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58445745-a6f2-4ac1-8e7f-c262355cd724_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_58445745-a6f2-4ac1-8e7f-c262355cd724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58445745-a6f2-4ac1-8e7f-c262355cd724_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d11bc07-f930-497a-9dcd-c9b3f1dcde43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_58445745-a6f2-4ac1-8e7f-c262355cd724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d11bc07-f930-497a-9dcd-c9b3f1dcde43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_aa148856-0841-4014-a504-0002c3b30d66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d11bc07-f930-497a-9dcd-c9b3f1dcde43" xlink:to="loc_us-gaap_EmployeeStockMember_aa148856-0841-4014-a504-0002c3b30d66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockOptionsorStockAppreciationRightsMember_790b830a-0e25-45ee-b22f-d3dc9056492e" xlink:href="cris-20210930.xsd#cris_StockOptionsorStockAppreciationRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d11bc07-f930-497a-9dcd-c9b3f1dcde43" xlink:to="loc_cris_StockOptionsorStockAppreciationRightsMember_790b830a-0e25-45ee-b22f-d3dc9056492e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RestrictedStockRSUsOtherStockBasedAwardsOrPerformanceAwardsMember_570e7873-a029-4d14-aefd-6796bba10046" xlink:href="cris-20210930.xsd#cris_RestrictedStockRSUsOtherStockBasedAwardsOrPerformanceAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d11bc07-f930-497a-9dcd-c9b3f1dcde43" xlink:to="loc_cris_RestrictedStockRSUsOtherStockBasedAwardsOrPerformanceAwardsMember_570e7873-a029-4d14-aefd-6796bba10046" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_bc8d9b67-6728-49f4-b280-f55d4d54155b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d11bc07-f930-497a-9dcd-c9b3f1dcde43" xlink:to="loc_us-gaap_RestrictedStockMember_bc8d9b67-6728-49f4-b280-f55d4d54155b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_d2956a1c-676b-49ce-be02-c0d6f27e9457" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_7ef84679-acdb-4d1e-91c7-8d019b81cb5b" xlink:to="loc_us-gaap_VestingAxis_d2956a1c-676b-49ce-be02-c0d6f27e9457" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_d2956a1c-676b-49ce-be02-c0d6f27e9457_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_d2956a1c-676b-49ce-be02-c0d6f27e9457" xlink:to="loc_us-gaap_VestingDomain_d2956a1c-676b-49ce-be02-c0d6f27e9457_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_84d4b342-3c63-41ca-92b3-4bad927a2328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_d2956a1c-676b-49ce-be02-c0d6f27e9457" xlink:to="loc_us-gaap_VestingDomain_84d4b342-3c63-41ca-92b3-4bad927a2328" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_9e89c51f-28f4-4747-aab1-05ac14117a15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_84d4b342-3c63-41ca-92b3-4bad927a2328" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_9e89c51f-28f4-4747-aab1-05ac14117a15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_4a72f9bc-3393-4e60-a7ed-41e9391a92d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_84d4b342-3c63-41ca-92b3-4bad927a2328" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_4a72f9bc-3393-4e60-a7ed-41e9391a92d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_2f673139-319b-4de7-a0bd-e74b2466d258" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_7ef84679-acdb-4d1e-91c7-8d019b81cb5b" xlink:to="loc_srt_TitleOfIndividualAxis_2f673139-319b-4de7-a0bd-e74b2466d258" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2f673139-319b-4de7-a0bd-e74b2466d258_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_2f673139-319b-4de7-a0bd-e74b2466d258" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2f673139-319b-4de7-a0bd-e74b2466d258_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8ddbb288-6e7c-4403-8389-5f09652a72dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_2f673139-319b-4de7-a0bd-e74b2466d258" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8ddbb288-6e7c-4403-8389-5f09652a72dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_NonEmployeeDirectorsMember_cd444c08-12f5-46dd-9153-d7c23a2e4dac" xlink:href="cris-20210930.xsd#cris_NonEmployeeDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8ddbb288-6e7c-4403-8389-5f09652a72dd" xlink:to="loc_cris_NonEmployeeDirectorsMember_cd444c08-12f5-46dd-9153-d7c23a2e4dac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficerMember_2adac523-0958-4f82-bf25-a3d9d2544980" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8ddbb288-6e7c-4403-8389-5f09652a72dd" xlink:to="loc_srt_OfficerMember_2adac523-0958-4f82-bf25-a3d9d2544980" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_OfficersAndNonEmployeeDirectorsMember_dbb5c44b-7196-4b59-bda5-afab7ae86df6" xlink:href="cris-20210930.xsd#cris_OfficersAndNonEmployeeDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8ddbb288-6e7c-4403-8389-5f09652a72dd" xlink:to="loc_cris_OfficersAndNonEmployeeDirectorsMember_dbb5c44b-7196-4b59-bda5-afab7ae86df6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.curis.com/role/StockPlansandStockBasedCompensationRestrictedStockAwardActivityDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#StockPlansandStockBasedCompensationRestrictedStockAwardActivityDetails"/>
  <link:definitionLink xlink:role="http://www.curis.com/role/StockPlansandStockBasedCompensationRestrictedStockAwardActivityDetails" xlink:type="extended" id="i3cbfaf4e72fc4cf5971876db96b5b25c_StockPlansandStockBasedCompensationRestrictedStockAwardActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21285a8e-69f1-4bd0-a235-9e9a61411a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea421126-16ec-4cf0-88ed-17ce97522c93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21285a8e-69f1-4bd0-a235-9e9a61411a6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea421126-16ec-4cf0-88ed-17ce97522c93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bb4d286a-20b2-4e2d-a8ed-7a350611c1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea421126-16ec-4cf0-88ed-17ce97522c93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bb4d286a-20b2-4e2d-a8ed-7a350611c1e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_65d5ed3c-71c2-4c96-88f8-c0927ab49c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea421126-16ec-4cf0-88ed-17ce97522c93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_65d5ed3c-71c2-4c96-88f8-c0927ab49c5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e79425c0-5bcd-4f07-af68-f87d10d4c943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea421126-16ec-4cf0-88ed-17ce97522c93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e79425c0-5bcd-4f07-af68-f87d10d4c943" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_76f3f797-b2ad-42f9-9658-37690c1234d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea421126-16ec-4cf0-88ed-17ce97522c93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_76f3f797-b2ad-42f9-9658-37690c1234d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3ac1c4f4-9856-4632-b36d-53f550c1f04f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c412a4fa-9d29-450e-80ae-8f006b02e924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21285a8e-69f1-4bd0-a235-9e9a61411a6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c412a4fa-9d29-450e-80ae-8f006b02e924" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_871b9be8-0894-46bc-9415-c72e35a74e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c412a4fa-9d29-450e-80ae-8f006b02e924" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_871b9be8-0894-46bc-9415-c72e35a74e02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_05fff384-dc24-4ab1-9707-687840087d79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c412a4fa-9d29-450e-80ae-8f006b02e924" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_05fff384-dc24-4ab1-9707-687840087d79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_62f86f42-8a9a-43b9-9d50-20280eebe281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c412a4fa-9d29-450e-80ae-8f006b02e924" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_62f86f42-8a9a-43b9-9d50-20280eebe281" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_034b93c8-707e-41fe-81b8-1555dfe11975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c412a4fa-9d29-450e-80ae-8f006b02e924" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_034b93c8-707e-41fe-81b8-1555dfe11975" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_217146f9-ae5e-4e2e-97b2-9b8606db4025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_756da598-7fb0-4dda-b116-8f491590bc03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21285a8e-69f1-4bd0-a235-9e9a61411a6c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_756da598-7fb0-4dda-b116-8f491590bc03" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a98384ab-a927-4a1b-9df6-96e2d0173e25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_756da598-7fb0-4dda-b116-8f491590bc03" xlink:to="loc_us-gaap_AwardTypeAxis_a98384ab-a927-4a1b-9df6-96e2d0173e25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a98384ab-a927-4a1b-9df6-96e2d0173e25_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a98384ab-a927-4a1b-9df6-96e2d0173e25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a98384ab-a927-4a1b-9df6-96e2d0173e25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eb99a882-3eb7-40b5-b648-c6b653642cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a98384ab-a927-4a1b-9df6-96e2d0173e25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eb99a882-3eb7-40b5-b648-c6b653642cbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_2a56acb7-fc53-4ec3-aba2-dd13d60facd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eb99a882-3eb7-40b5-b648-c6b653642cbb" xlink:to="loc_us-gaap_RestrictedStockMember_2a56acb7-fc53-4ec3-aba2-dd13d60facd5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.curis.com/role/StockPlansandStockBasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#StockPlansandStockBasedCompensationStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.curis.com/role/StockPlansandStockBasedCompensationStockbasedCompensationExpenseDetails" xlink:type="extended" id="iff896eb5843f4f39b97647d750bd53a0_StockPlansandStockBasedCompensationStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_a73fd485-3336-4f18-b74d-68828d49e09f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1b8e648f-111d-44db-a770-eae956369df3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_a73fd485-3336-4f18-b74d-68828d49e09f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1b8e648f-111d-44db-a770-eae956369df3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_27c590d3-53f1-4177-b3fe-eeb251570412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_a73fd485-3336-4f18-b74d-68828d49e09f" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_27c590d3-53f1-4177-b3fe-eeb251570412" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c8a55c5a-3811-4d6b-9115-78f37faa7a61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_27c590d3-53f1-4177-b3fe-eeb251570412" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c8a55c5a-3811-4d6b-9115-78f37faa7a61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c8a55c5a-3811-4d6b-9115-78f37faa7a61_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c8a55c5a-3811-4d6b-9115-78f37faa7a61" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c8a55c5a-3811-4d6b-9115-78f37faa7a61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6f2ca47f-0455-4b50-b063-93ce2c8c4094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c8a55c5a-3811-4d6b-9115-78f37faa7a61" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6f2ca47f-0455-4b50-b063-93ce2c8c4094" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d17d5cb9-90ba-4c17-989d-18c638324a53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6f2ca47f-0455-4b50-b063-93ce2c8c4094" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d17d5cb9-90ba-4c17-989d-18c638324a53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1ef716e2-25cf-41ee-9c31-171ae64c0e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6f2ca47f-0455-4b50-b063-93ce2c8c4094" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1ef716e2-25cf-41ee-9c31-171ae64c0e9b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.curis.com/role/LossPerCommonShareDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#LossPerCommonShareDetails"/>
  <link:definitionLink xlink:role="http://www.curis.com/role/LossPerCommonShareDetails" xlink:type="extended" id="i9384ba4d238648f09150f09fb4207cce_LossPerCommonShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_955d7cbf-b126-48aa-b5e4-0cc6c104848c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_adfef240-5c37-40e6-b7c2-3df5980c78eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_955d7cbf-b126-48aa-b5e4-0cc6c104848c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_adfef240-5c37-40e6-b7c2-3df5980c78eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d19d19cf-625a-463a-a2f6-f9cdbc35cd37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_955d7cbf-b126-48aa-b5e4-0cc6c104848c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d19d19cf-625a-463a-a2f6-f9cdbc35cd37" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1f785d64-702f-42b1-ab75-abcac94028bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d19d19cf-625a-463a-a2f6-f9cdbc35cd37" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1f785d64-702f-42b1-ab75-abcac94028bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1f785d64-702f-42b1-ab75-abcac94028bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1f785d64-702f-42b1-ab75-abcac94028bb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1f785d64-702f-42b1-ab75-abcac94028bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_feb7546d-722e-4354-8336-e1c45ab1acb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1f785d64-702f-42b1-ab75-abcac94028bb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_feb7546d-722e-4354-8336-e1c45ab1acb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0a611229-5af2-428a-a8ca-296f5b6b505d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_feb7546d-722e-4354-8336-e1c45ab1acb7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0a611229-5af2-428a-a8ca-296f5b6b505d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.curis.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.curis.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="i8a3fefca20864943b2e1a4bac48cfdf1_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_10523215-7c20-4e9c-bfb6-b29e348b58c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_6bf9bf52-7fe0-4e59-b2cb-4f69f2340bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_10523215-7c20-4e9c-bfb6-b29e348b58c2" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_6bf9bf52-7fe0-4e59-b2cb-4f69f2340bdc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RelatedPartyTransactionMaximumFundingAmount_c228d487-f97c-4788-9f6e-44f57cbe1071" xlink:href="cris-20210930.xsd#cris_RelatedPartyTransactionMaximumFundingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_10523215-7c20-4e9c-bfb6-b29e348b58c2" xlink:to="loc_cris_RelatedPartyTransactionMaximumFundingAmount_c228d487-f97c-4788-9f6e-44f57cbe1071" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RelatedPartyTransactionTermsAndMannerOfSettlementMinimumDaysNoticeToTerminatePriorToWrittenNotice_2118b507-b4c7-47c2-8c62-8165ecbc11fd" xlink:href="cris-20210930.xsd#cris_RelatedPartyTransactionTermsAndMannerOfSettlementMinimumDaysNoticeToTerminatePriorToWrittenNotice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_10523215-7c20-4e9c-bfb6-b29e348b58c2" xlink:to="loc_cris_RelatedPartyTransactionTermsAndMannerOfSettlementMinimumDaysNoticeToTerminatePriorToWrittenNotice_2118b507-b4c7-47c2-8c62-8165ecbc11fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_ec58debf-3203-4dbe-b8b6-61c21d30a559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_10523215-7c20-4e9c-bfb6-b29e348b58c2" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_ec58debf-3203-4dbe-b8b6-61c21d30a559" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_523672fc-fa70-494a-8e4c-ac51edfc4a60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_10523215-7c20-4e9c-bfb6-b29e348b58c2" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_523672fc-fa70-494a-8e4c-ac51edfc4a60" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_21d56c4f-a306-4903-910b-3c460ea1e872" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_523672fc-fa70-494a-8e4c-ac51edfc4a60" xlink:to="loc_srt_CounterpartyNameAxis_21d56c4f-a306-4903-910b-3c460ea1e872" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_21d56c4f-a306-4903-910b-3c460ea1e872_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_21d56c4f-a306-4903-910b-3c460ea1e872" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_21d56c4f-a306-4903-910b-3c460ea1e872_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7fa9774b-b374-4bc5-8414-476ba3aa11d3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_21d56c4f-a306-4903-910b-3c460ea1e872" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7fa9774b-b374-4bc5-8414-476ba3aa11d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_EpiCurePharmaceuticalsInc.Member_366c09eb-c7b2-46cb-b40f-5c9b0cfd26c5" xlink:href="cris-20210930.xsd#cris_EpiCurePharmaceuticalsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7fa9774b-b374-4bc5-8414-476ba3aa11d3" xlink:to="loc_cris_EpiCurePharmaceuticalsInc.Member_366c09eb-c7b2-46cb-b40f-5c9b0cfd26c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d1b61467-55c5-4152-b9ec-0689e4c4132f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_523672fc-fa70-494a-8e4c-ac51edfc4a60" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d1b61467-55c5-4152-b9ec-0689e4c4132f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d1b61467-55c5-4152-b9ec-0689e4c4132f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d1b61467-55c5-4152-b9ec-0689e4c4132f" xlink:to="loc_us-gaap_RelatedPartyDomain_d1b61467-55c5-4152-b9ec-0689e4c4132f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5b2ea7c7-9112-485e-88cd-8f5203ac3042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d1b61467-55c5-4152-b9ec-0689e4c4132f" xlink:to="loc_us-gaap_RelatedPartyDomain_5b2ea7c7-9112-485e-88cd-8f5203ac3042" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_1ffd39c3-3704-4d8d-962d-96c311b9bfd1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5b2ea7c7-9112-485e-88cd-8f5203ac3042" xlink:to="loc_srt_AffiliatedEntityMember_1ffd39c3-3704-4d8d-962d-96c311b9bfd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_f83aee88-aa81-4af8-bb7d-440e4c3f9305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_523672fc-fa70-494a-8e4c-ac51edfc4a60" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_f83aee88-aa81-4af8-bb7d-440e4c3f9305" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_f83aee88-aa81-4af8-bb7d-440e4c3f9305_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_f83aee88-aa81-4af8-bb7d-440e4c3f9305" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_f83aee88-aa81-4af8-bb7d-440e4c3f9305_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_64a16283-8a9d-432e-b40e-7db006211fba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_f83aee88-aa81-4af8-bb7d-440e4c3f9305" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_64a16283-8a9d-432e-b40e-7db006211fba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_AgreementWithHeadOfResearchAndDevelopmentMember_d65e719a-e03f-4a23-987a-30d0818f5aef" xlink:href="cris-20210930.xsd#cris_AgreementWithHeadOfResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_64a16283-8a9d-432e-b40e-7db006211fba" xlink:to="loc_cris_AgreementWithHeadOfResearchAndDevelopmentMember_d65e719a-e03f-4a23-987a-30d0818f5aef" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>cris-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:67cd88cd-4961-40fd-b7ee-f0e04fb032e1,g:de03038a-bcb1-460d-82b7-20721bd560b4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_cris_IncreaseDecreaseOperatingLeaseLiability_a156598d-4c8c-4f2a-a375-a484d3421463_terseLabel_en-US" xlink:label="lab_cris_IncreaseDecreaseOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_cris_IncreaseDecreaseOperatingLeaseLiability_label_en-US" xlink:label="lab_cris_IncreaseDecreaseOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Operating Lease Liability</link:label>
    <link:label id="lab_cris_IncreaseDecreaseOperatingLeaseLiability_documentation_en-US" xlink:label="lab_cris_IncreaseDecreaseOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_IncreaseDecreaseOperatingLeaseLiability" xlink:href="cris-20210930.xsd#cris_IncreaseDecreaseOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_IncreaseDecreaseOperatingLeaseLiability" xlink:to="lab_cris_IncreaseDecreaseOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_aec05da4-d752-40ba-8c5e-ca1268e8f0a6_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow data:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_8c6e7f09-8076-4058-82ae-62b9448b218f_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_87c1e6f6-9cdf-46d0-a8fe-b101f75cdc80_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a6959e37-8777-4477-bd18-f118d9fd9601_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_6b42224c-e798-4bc0-b486-dbacc4719082_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_866aa877-ef6b-4245-a6af-ab475768191c_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_4d34e806-3f5c-4827-acb1-a1213aafc6ce_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_0bc52f59-f210-4f29-b92b-77595934add1_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_ac6dd849-20aa-48e3-b59a-fef5867ed312_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_64fe294a-4b94-4a45-a171-549912e994f9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_CollaborativeArrangementPaymentsAgreement_9ca556a2-f46a-4cb7-ac6e-63d86ea391b6_terseLabel_en-US" xlink:label="lab_cris_CollaborativeArrangementPaymentsAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement payments agreement</link:label>
    <link:label id="lab_cris_CollaborativeArrangementPaymentsAgreement_label_en-US" xlink:label="lab_cris_CollaborativeArrangementPaymentsAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Payments Agreement</link:label>
    <link:label id="lab_cris_CollaborativeArrangementPaymentsAgreement_documentation_en-US" xlink:label="lab_cris_CollaborativeArrangementPaymentsAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Payments Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborativeArrangementPaymentsAgreement" xlink:href="cris-20210930.xsd#cris_CollaborativeArrangementPaymentsAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborativeArrangementPaymentsAgreement" xlink:to="lab_cris_CollaborativeArrangementPaymentsAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_7747f5e4-995d-4066-89c1-c04a487b513e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_055b0318-26e0-407d-af6b-9448a58d27e8_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_324629b3-c815-472d-83d9-7f54edeaaf18_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_aed1a988-d199-4bf9-aa48-1bfa95948de4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_41bd5ac7-c8b7-48d3-ae16-bb676acc3310_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_AurigeneDiscoveryTechnologiesLtdMember_e9e6bcff-9928-464a-a008-49df6fb00ad4_terseLabel_en-US" xlink:label="lab_cris_AurigeneDiscoveryTechnologiesLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aurigene</link:label>
    <link:label id="lab_cris_AurigeneDiscoveryTechnologiesLtdMember_label_en-US" xlink:label="lab_cris_AurigeneDiscoveryTechnologiesLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aurigene Discovery Technologies Ltd [Member]</link:label>
    <link:label id="lab_cris_AurigeneDiscoveryTechnologiesLtdMember_documentation_en-US" xlink:label="lab_cris_AurigeneDiscoveryTechnologiesLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aurigene Discovery Technologies Ltd [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_AurigeneDiscoveryTechnologiesLtdMember" xlink:href="cris-20210930.xsd#cris_AurigeneDiscoveryTechnologiesLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_AurigeneDiscoveryTechnologiesLtdMember" xlink:to="lab_cris_AurigeneDiscoveryTechnologiesLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_GenentechIncMember_9e4cfb5d-3ad7-4367-bf13-e3ea6348f36d_terseLabel_en-US" xlink:label="lab_cris_GenentechIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech, Inc.</link:label>
    <link:label id="lab_cris_GenentechIncMember_label_en-US" xlink:label="lab_cris_GenentechIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech Inc [Member]</link:label>
    <link:label id="lab_cris_GenentechIncMember_documentation_en-US" xlink:label="lab_cris_GenentechIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_GenentechIncMember" xlink:href="cris-20210930.xsd#cris_GenentechIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_GenentechIncMember" xlink:to="lab_cris_GenentechIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0d749ae1-bb97-414a-be56-0a4be19bdde2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonmonetaryTransactionsDisclosureTextBlock_362f314f-13ae-41ee-9ca5-d8f9a1acce59_terseLabel_en-US" xlink:label="lab_us-gaap_NonmonetaryTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to the Sale of Future Royalties</link:label>
    <link:label id="lab_us-gaap_NonmonetaryTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_NonmonetaryTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonmonetary Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonmonetaryTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_NonmonetaryTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_97acc6cd-2872-42ef-9816-90e94cfe8a05_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_6524673d-571b-42fc-ba73-f54092bc7a3f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_530ceb3e-3f63-4de6-9c8d-296b3e5ddf76_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled/Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_a3bed2ef-f4c0-404b-a498-63598bbf35a1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6b8cbe50-bace-4ae7-b668-27a7fc6fe8ee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_DirectPlacementMember_2f68441b-4d97-416f-b7fe-fb00fba80ddc_terseLabel_en-US" xlink:label="lab_cris_DirectPlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct Placement</link:label>
    <link:label id="lab_cris_DirectPlacementMember_label_en-US" xlink:label="lab_cris_DirectPlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct Placement [Member]</link:label>
    <link:label id="lab_cris_DirectPlacementMember_documentation_en-US" xlink:label="lab_cris_DirectPlacementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_DirectPlacementMember" xlink:href="cris-20210930.xsd#cris_DirectPlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_DirectPlacementMember" xlink:to="lab_cris_DirectPlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_RoyaltyPurchaseAgreementAccretionExpense_6a8c5bc7-c203-44ea-8544-0c152ed47922_terseLabel_en-US" xlink:label="lab_cris_RoyaltyPurchaseAgreementAccretionExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed interest expense recognized</link:label>
    <link:label id="lab_cris_RoyaltyPurchaseAgreementAccretionExpense_label_en-US" xlink:label="lab_cris_RoyaltyPurchaseAgreementAccretionExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Accretion Expense</link:label>
    <link:label id="lab_cris_RoyaltyPurchaseAgreementAccretionExpense_documentation_en-US" xlink:label="lab_cris_RoyaltyPurchaseAgreementAccretionExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Accretion Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyPurchaseAgreementAccretionExpense" xlink:href="cris-20210930.xsd#cris_RoyaltyPurchaseAgreementAccretionExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_RoyaltyPurchaseAgreementAccretionExpense" xlink:to="lab_cris_RoyaltyPurchaseAgreementAccretionExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_46dc43b8-14e7-40b6-a32c-76114c6e37e3_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_42164723-7975-4360-b274-fb0c225e6d99_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7217fd78-44e1-4c3e-9647-77a2ccd2c222_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e7282ddb-a06f-43cf-b4d7-fc449eb6c6f0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic values of employee stock options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_8d0dd45d-4927-4b09-8a64-cba0107eee0d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_NonEmployeeDirectorsMember_94799072-fbb0-4de4-9feb-1a2de517ff27_terseLabel_en-US" xlink:label="lab_cris_NonEmployeeDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Employee Directors</link:label>
    <link:label id="lab_cris_NonEmployeeDirectorsMember_label_en-US" xlink:label="lab_cris_NonEmployeeDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee Directors [Member]</link:label>
    <link:label id="lab_cris_NonEmployeeDirectorsMember_documentation_en-US" xlink:label="lab_cris_NonEmployeeDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-employee directors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_NonEmployeeDirectorsMember" xlink:href="cris-20210930.xsd#cris_NonEmployeeDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_NonEmployeeDirectorsMember" xlink:to="lab_cris_NonEmployeeDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_8c6ad8f3-90f0-4788-bef5-271d8ac2997e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Share-based Payments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Share-based Payments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a2c1f880-457e-4426-a5a9-742e5f55fcd7_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_070e82df-8473-41b7-b24d-7a61fe4cf538_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c61c7e02-e84e-43cb-93af-c0942d2803a8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_203e0dff-6839-4ab2-af33-37328928e045_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_020532c0-aed3-4599-b4d9-e1522294e92c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_725b3151-2ef0-421e-9494-8edf671c598d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Ownership Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_355a0695-5868-441a-b388-310ee17d4ea3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_OtherRevenueMember_68a6ba65-5274-4964-8a30-1917b8205a93_terseLabel_en-US" xlink:label="lab_cris_OtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_cris_OtherRevenueMember_label_en-US" xlink:label="lab_cris_OtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenue [Member]</link:label>
    <link:label id="lab_cris_OtherRevenueMember_documentation_en-US" xlink:label="lab_cris_OtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_OtherRevenueMember" xlink:href="cris-20210930.xsd#cris_OtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_OtherRevenueMember" xlink:to="lab_cris_OtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_8c2e13c9-a3f5-4408-a56d-8c614d51a2fc_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Restricted Cash, and Investments</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_9d8101a0-53b2-41fa-ba31-031dc415836e_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e3d38c99-d9c0-4017-83b7-b614679690f1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_8e518e12-e0a8-4e80-b714-9033f5435400_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_ad144ac3-a483-46ca-a622-1fccd2039d60_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_CollaborationArrangementContingentConsiderationRegulatoryApprovalMilestonePayments_405c1182-dd73-4c5f-aab6-2de5a1300e81_terseLabel_en-US" xlink:label="lab_cris_CollaborationArrangementContingentConsiderationRegulatoryApprovalMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory approval milestone payments</link:label>
    <link:label id="lab_cris_CollaborationArrangementContingentConsiderationRegulatoryApprovalMilestonePayments_label_en-US" xlink:label="lab_cris_CollaborationArrangementContingentConsiderationRegulatoryApprovalMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Contingent Consideration, Regulatory Approval Milestone Payments</link:label>
    <link:label id="lab_cris_CollaborationArrangementContingentConsiderationRegulatoryApprovalMilestonePayments_documentation_en-US" xlink:label="lab_cris_CollaborationArrangementContingentConsiderationRegulatoryApprovalMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Contingent Consideration, Regulatory Approval Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationArrangementContingentConsiderationRegulatoryApprovalMilestonePayments" xlink:href="cris-20210930.xsd#cris_CollaborationArrangementContingentConsiderationRegulatoryApprovalMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborationArrangementContingentConsiderationRegulatoryApprovalMilestonePayments" xlink:to="lab_cris_CollaborationArrangementContingentConsiderationRegulatoryApprovalMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fbf6c8b7-c049-4104-a8f6-e2d760fc6115_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_722d59b3-c37e-4ace-9c30-109023b8da9e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_807d2371-7610-496c-a29f-af4597129e43_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a3a47e65-3dd5-48e5-8497-a94b6e089d76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2e7c1d06-055d-425b-b28a-cd99e11e6e57_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_ebe7585d-49b0-4d65-8f94-8e55ab6719f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTerm_f3560df5-454c-4475-8e07-96eb82302353_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured loan term</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTerm_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTerm" xlink:to="lab_us-gaap_LongTermDebtTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment_341e87a8-8873-4037-ac22-8260d4f831f0_terseLabel_en-US" xlink:label="lab_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible to receive contingent cash payment for specified clinical development and regulatory objectives (up to)</link:label>
    <link:label id="lab_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment_label_en-US" xlink:label="lab_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Contingent Consideration Potential Cash Payment</link:label>
    <link:label id="lab_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment_documentation_en-US" xlink:label="lab_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement contingent consideration potential cash payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment" xlink:href="cris-20210930.xsd#cris_CollaborationAgreementContingentConsiderationPotentialCashPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment" xlink:to="lab_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_GrossRoyaltyRevenueMember_4047c1b7-696d-4cba-a2c9-2ca1075c4ebc_terseLabel_en-US" xlink:label="lab_cris_GrossRoyaltyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_cris_GrossRoyaltyRevenueMember_label_en-US" xlink:label="lab_cris_GrossRoyaltyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Royalty Revenue [Member]</link:label>
    <link:label id="lab_cris_GrossRoyaltyRevenueMember_documentation_en-US" xlink:label="lab_cris_GrossRoyaltyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Royalty Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_GrossRoyaltyRevenueMember" xlink:href="cris-20210930.xsd#cris_GrossRoyaltyRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_GrossRoyaltyRevenueMember" xlink:to="lab_cris_GrossRoyaltyRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0f4fe4aa-23ca-4d98-aa12-c910289c6092_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonmonetaryTransactionLineItems_4abbe910-a0a2-4d47-ab00-a5459ddab68f_terseLabel_en-US" xlink:label="lab_us-gaap_NonmonetaryTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonmonetary Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_NonmonetaryTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_NonmonetaryTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonmonetary Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonmonetaryTransactionLineItems" xlink:to="lab_us-gaap_NonmonetaryTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_96e18c5c-e8f7-4268-979f-4c02e76bc614_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_3259190e-6604-4ed0-bc65-19ceddcf6093_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_ShareBasedCompensationPlans_809f0d1d-701d-470a-b890-f9c65e0a01a3_terseLabel_en-US" xlink:label="lab_cris_ShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shareholder-approved, share-based compensation plans</link:label>
    <link:label id="lab_cris_ShareBasedCompensationPlans_label_en-US" xlink:label="lab_cris_ShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Plans</link:label>
    <link:label id="lab_cris_ShareBasedCompensationPlans_documentation_en-US" xlink:label="lab_cris_ShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, number of plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ShareBasedCompensationPlans" xlink:href="cris-20210930.xsd#cris_ShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_ShareBasedCompensationPlans" xlink:to="lab_cris_ShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_StockPurchaseProgramRemainingAuthorizedPurchaseAmount_dfe80b8d-a6af-4d0d-84ad-0f5e2a44ced1_terseLabel_en-US" xlink:label="lab_cris_StockPurchaseProgramRemainingAuthorizedPurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining authorized stock purchase amount</link:label>
    <link:label id="lab_cris_StockPurchaseProgramRemainingAuthorizedPurchaseAmount_label_en-US" xlink:label="lab_cris_StockPurchaseProgramRemainingAuthorizedPurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Program, Remaining Authorized Purchase Amount</link:label>
    <link:label id="lab_cris_StockPurchaseProgramRemainingAuthorizedPurchaseAmount_documentation_en-US" xlink:label="lab_cris_StockPurchaseProgramRemainingAuthorizedPurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Program, Remaining Authorized Purchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockPurchaseProgramRemainingAuthorizedPurchaseAmount" xlink:href="cris-20210930.xsd#cris_StockPurchaseProgramRemainingAuthorizedPurchaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_StockPurchaseProgramRemainingAuthorizedPurchaseAmount" xlink:to="lab_cris_StockPurchaseProgramRemainingAuthorizedPurchaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_462b9092-b855-431b-ab80-840417ebb508_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0bf7a0ba-584a-4fea-b85a-e2d7f504b42e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d0c40c3c-8c57-4c10-888d-34a275bb65b8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_d1505ffd-07e2-4800-8356-255a1916d9f6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_352b1ec9-d30d-487d-9c4e-7e6b19a026d2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_31de6742-96df-4c62-9ec6-94b1b0dd984f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_80ae459e-e2a1-4af3-af6f-09cf0b0133f7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_RoyaltyPurchaseAgreementInterestRate_91767dec-c06e-45c6-a7d8-3931b2922ec2_terseLabel_en-US" xlink:label="lab_cris_RoyaltyPurchaseAgreementInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest rate</link:label>
    <link:label id="lab_cris_RoyaltyPurchaseAgreementInterestRate_label_en-US" xlink:label="lab_cris_RoyaltyPurchaseAgreementInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Interest Rate</link:label>
    <link:label id="lab_cris_RoyaltyPurchaseAgreementInterestRate_documentation_en-US" xlink:label="lab_cris_RoyaltyPurchaseAgreementInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyPurchaseAgreementInterestRate" xlink:href="cris-20210930.xsd#cris_RoyaltyPurchaseAgreementInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_RoyaltyPurchaseAgreementInterestRate" xlink:to="lab_cris_RoyaltyPurchaseAgreementInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_LicenseFees_5c06d9b4-e8ef-4ee6-921a-b2a8022d353b_terseLabel_en-US" xlink:label="lab_cris_LicenseFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fees</link:label>
    <link:label id="lab_cris_LicenseFees_label_en-US" xlink:label="lab_cris_LicenseFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees</link:label>
    <link:label id="lab_cris_LicenseFees_documentation_en-US" xlink:label="lab_cris_LicenseFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_LicenseFees" xlink:href="cris-20210930.xsd#cris_LicenseFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_LicenseFees" xlink:to="lab_cris_LicenseFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f083e313-f456-440a-acf5-d2d49b84df18_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f5030afa-f9ea-4cb7-8046-d0200c804693_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6eb7b882-8b3b-4ddf-9cf3-d8b0dd08c756_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_4cef9002-06bf-4ecc-89e1-eb99c65a5532_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_NonCashLeaseExpense_e3483768-c971-44c4-9751-904c1770fa79_terseLabel_en-US" xlink:label="lab_cris_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_cris_NonCashLeaseExpense_label_en-US" xlink:label="lab_cris_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Lease Expense</link:label>
    <link:label id="lab_cris_NonCashLeaseExpense_documentation_en-US" xlink:label="lab_cris_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_NonCashLeaseExpense" xlink:href="cris-20210930.xsd#cris_NonCashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_NonCashLeaseExpense" xlink:to="lab_cris_NonCashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_d1049579-944e-4097-b0ed-1554e1b72eee_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of vested shares which are exercisable under stock option</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1_f6137531-c8a5-4d55-903e-01d379a49751_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Waived payment of milestone and other payments (up to)</link:label>
    <link:label id="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1_label_en-US" xlink:label="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Significant Noncash Transaction, Value of Consideration Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1" xlink:to="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermInvestmentsMember_167d4caf-63bd-40d9-9e08-b7bb151937aa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds and notes&#8212;long-term</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestmentsMember" xlink:to="lab_us-gaap_OtherLongTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_8041f1d5-f1ea-4452-af46-f1e3fbc81476_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_dfd2f2ba-1443-4caa-88ea-28694e3a2e4c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share (basic ) (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_79326464-66ed-4078-8dfe-87847db3880a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_07345295-a205-4356-95c7-95b01442cd0f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under the Company's share-based compensation plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_ThirdandFourthProgramsMember_eacc6881-8df5-4a61-a91f-ddca9a9d7724_terseLabel_en-US" xlink:label="lab_cris_ThirdandFourthProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Programs Three and Four</link:label>
    <link:label id="lab_cris_ThirdandFourthProgramsMember_label_en-US" xlink:label="lab_cris_ThirdandFourthProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third and Fourth Programs [Member]</link:label>
    <link:label id="lab_cris_ThirdandFourthProgramsMember_documentation_en-US" xlink:label="lab_cris_ThirdandFourthProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third and Fourth Programs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ThirdandFourthProgramsMember" xlink:href="cris-20210930.xsd#cris_ThirdandFourthProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_ThirdandFourthProgramsMember" xlink:to="lab_cris_ThirdandFourthProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_235b58a8-9fab-453d-9ded-30847a7637d5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_002c05a2-97b3-453a-af78-63c82dc8b285_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_681eac6f-5a9a-44c5-a8fc-a2130de50126_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_0505017b-8f0d-4442-8691-b8e13d3770d4_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_baac0885-a42e-4ea8-95f3-7b8fe8d379b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts_e4bcbddd-1545-4ce2-9987-9bd5de1e1865_terseLabel_en-US" xlink:label="lab_cris_RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction fees</link:label>
    <link:label id="lab_cris_RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts_label_en-US" xlink:label="lab_cris_RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Transaction Fees And Closing Costs</link:label>
    <link:label id="lab_cris_RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts_documentation_en-US" xlink:label="lab_cris_RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Transaction Fees And Closing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts" xlink:href="cris-20210930.xsd#cris_RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts" xlink:to="lab_cris_RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_2646a3a1-394e-415d-8bc1-81bfe24511d2_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_CollaborationArrangementContingentConsiderationReimbursableExpenses_25e6e1e5-e020-411c-a03f-3a1c7a7d9f47_terseLabel_en-US" xlink:label="lab_cris_CollaborationArrangementContingentConsiderationReimbursableExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum reimbursable expenses</link:label>
    <link:label id="lab_cris_CollaborationArrangementContingentConsiderationReimbursableExpenses_label_en-US" xlink:label="lab_cris_CollaborationArrangementContingentConsiderationReimbursableExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Contingent Consideration, Reimbursable Expenses</link:label>
    <link:label id="lab_cris_CollaborationArrangementContingentConsiderationReimbursableExpenses_documentation_en-US" xlink:label="lab_cris_CollaborationArrangementContingentConsiderationReimbursableExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Contingent Consideration, Reimbursable Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationArrangementContingentConsiderationReimbursableExpenses" xlink:href="cris-20210930.xsd#cris_CollaborationArrangementContingentConsiderationReimbursableExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborationArrangementContingentConsiderationReimbursableExpenses" xlink:to="lab_cris_CollaborationArrangementContingentConsiderationReimbursableExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_6dd888ef-c70f-41c1-bc5a-b21f57ebb17b_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7453db9a-16f2-453d-940b-2a7b6887ca45_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_1e3aa805-b235-4291-a7f2-7acf51de9e25_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_NonmonetaryTransactionRollForward_df6f93e6-67a9-4032-b18b-6926fdec9df9_terseLabel_en-US" xlink:label="lab_cris_NonmonetaryTransactionRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonmonetary Transaction [Roll Forward]</link:label>
    <link:label id="lab_cris_NonmonetaryTransactionRollForward_label_en-US" xlink:label="lab_cris_NonmonetaryTransactionRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonmonetary Transaction [Roll Forward]</link:label>
    <link:label id="lab_cris_NonmonetaryTransactionRollForward_documentation_en-US" xlink:label="lab_cris_NonmonetaryTransactionRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonmonetary Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_NonmonetaryTransactionRollForward" xlink:href="cris-20210930.xsd#cris_NonmonetaryTransactionRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_NonmonetaryTransactionRollForward" xlink:to="lab_cris_NonmonetaryTransactionRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_164bbe12-8cae-4225-91a9-ff0154bb773e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_5bd9fd2b-092f-4b39-8b88-bd545b61f503_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured loan</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent_19fa2e63-6e21-4b93-943d-759e18c2eefd_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid balance</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_384f0b2d-bdf6-432f-8940-e45d72a4f60f_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherSignificantNoncashTransactionsTextBlock_d3d7214c-6eff-4664-b071-12f34a32f7eb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherSignificantNoncashTransactionsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability Due to Non-Cash Transaction</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherSignificantNoncashTransactionsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherSignificantNoncashTransactionsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Significant Noncash Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherSignificantNoncashTransactionsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherSignificantNoncashTransactionsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherSignificantNoncashTransactionsTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherSignificantNoncashTransactionsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_8cf93167-5d1f-4e0d-9f46-826092081b36_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted&#160;Prices&#160;in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_803e9999-da33-491c-b206-d488fc33ca71_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_a5e3d35e-54a0-4876-ae57-e64dad16080e_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_RoyaltyPurchaseAgreementLiabilityCarryingValue_4cc2b1ba-847e-4ea2-afc8-39a8a74517ad_periodStartLabel_en-US" xlink:label="lab_cris_RoyaltyPurchaseAgreementLiabilityCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of liability related to the sale of future royalties beginning balance</link:label>
    <link:label id="lab_cris_RoyaltyPurchaseAgreementLiabilityCarryingValue_59045632-8258-4665-9328-2489af22c99f_periodEndLabel_en-US" xlink:label="lab_cris_RoyaltyPurchaseAgreementLiabilityCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of liability related to the sale of future royalties ending balance</link:label>
    <link:label id="lab_cris_RoyaltyPurchaseAgreementLiabilityCarryingValue_label_en-US" xlink:label="lab_cris_RoyaltyPurchaseAgreementLiabilityCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Liability, Carrying Value</link:label>
    <link:label id="lab_cris_RoyaltyPurchaseAgreementLiabilityCarryingValue_documentation_en-US" xlink:label="lab_cris_RoyaltyPurchaseAgreementLiabilityCarryingValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Liability, Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyPurchaseAgreementLiabilityCarryingValue" xlink:href="cris-20210930.xsd#cris_RoyaltyPurchaseAgreementLiabilityCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_RoyaltyPurchaseAgreementLiabilityCarryingValue" xlink:to="lab_cris_RoyaltyPurchaseAgreementLiabilityCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_ccf6f1ab-420d-429f-bf9a-287d348f7318_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_5b4dea75-91cc-4223-bbb3-cc00406ec578_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_80a46dea-4c7e-4a41-8cc6-58d5cb785749_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_NonCashImputedInterestExpense_ee5b63ea-ebaf-40a5-b850-efb27dd6f085_negatedTerseLabel_en-US" xlink:label="lab_cris_NonCashImputedInterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed interest expense related to the sale of future royalties</link:label>
    <link:label id="lab_cris_NonCashImputedInterestExpense_label_en-US" xlink:label="lab_cris_NonCashImputedInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Imputed Interest Expense</link:label>
    <link:label id="lab_cris_NonCashImputedInterestExpense_documentation_en-US" xlink:label="lab_cris_NonCashImputedInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Imputed Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_NonCashImputedInterestExpense" xlink:href="cris-20210930.xsd#cris_NonCashImputedInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_NonCashImputedInterestExpense" xlink:to="lab_cris_NonCashImputedInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a75ed5a7-ae6e-4c6f-9616-c1b5c3cd18b3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e869b200-2f2a-4512-a062-59d061697694_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_21950782-7a63-4a56-b796-f8edfc8f7382_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_StockSaleAgreementRemainingAuthorizedAmount_7ea0046f-170b-4643-a379-2ede82fcbd8a_terseLabel_en-US" xlink:label="lab_cris_StockSaleAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock remaining authorized amount</link:label>
    <link:label id="lab_cris_StockSaleAgreementRemainingAuthorizedAmount_label_en-US" xlink:label="lab_cris_StockSaleAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Remaining Authorized Amount</link:label>
    <link:label id="lab_cris_StockSaleAgreementRemainingAuthorizedAmount_documentation_en-US" xlink:label="lab_cris_StockSaleAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Remaining Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockSaleAgreementRemainingAuthorizedAmount" xlink:href="cris-20210930.xsd#cris_StockSaleAgreementRemainingAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_StockSaleAgreementRemainingAuthorizedAmount" xlink:to="lab_cris_StockSaleAgreementRemainingAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_RelatedPartyTransactionTermsAndMannerOfSettlementMinimumDaysNoticeToTerminatePriorToWrittenNotice_5d9f5fac-a3bd-4038-8aa6-be6570e460a3_terseLabel_en-US" xlink:label="lab_cris_RelatedPartyTransactionTermsAndMannerOfSettlementMinimumDaysNoticeToTerminatePriorToWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum days notice to terminate prior to written notice</link:label>
    <link:label id="lab_cris_RelatedPartyTransactionTermsAndMannerOfSettlementMinimumDaysNoticeToTerminatePriorToWrittenNotice_label_en-US" xlink:label="lab_cris_RelatedPartyTransactionTermsAndMannerOfSettlementMinimumDaysNoticeToTerminatePriorToWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Terms And Manner Of Settlement, Minimum Days Notice To Terminate Prior To Written Notice</link:label>
    <link:label id="lab_cris_RelatedPartyTransactionTermsAndMannerOfSettlementMinimumDaysNoticeToTerminatePriorToWrittenNotice_documentation_en-US" xlink:label="lab_cris_RelatedPartyTransactionTermsAndMannerOfSettlementMinimumDaysNoticeToTerminatePriorToWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Terms And Manner Of Settlement, Minimum Days Notice To Terminate Prior To Written Notice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RelatedPartyTransactionTermsAndMannerOfSettlementMinimumDaysNoticeToTerminatePriorToWrittenNotice" xlink:href="cris-20210930.xsd#cris_RelatedPartyTransactionTermsAndMannerOfSettlementMinimumDaysNoticeToTerminatePriorToWrittenNotice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_RelatedPartyTransactionTermsAndMannerOfSettlementMinimumDaysNoticeToTerminatePriorToWrittenNotice" xlink:to="lab_cris_RelatedPartyTransactionTermsAndMannerOfSettlementMinimumDaysNoticeToTerminatePriorToWrittenNotice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9bf7d466-d097-470f-ae6a-0c1e42f9bafb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_89c63891-9ba6-403f-bfcd-496d5de0bd3e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_RelatedPartyTransactionMaximumFundingAmount_bf40e611-e6f5-4500-bd1d-569f8ad08a73_terseLabel_en-US" xlink:label="lab_cris_RelatedPartyTransactionMaximumFundingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum funding amount</link:label>
    <link:label id="lab_cris_RelatedPartyTransactionMaximumFundingAmount_label_en-US" xlink:label="lab_cris_RelatedPartyTransactionMaximumFundingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Maximum Funding Amount</link:label>
    <link:label id="lab_cris_RelatedPartyTransactionMaximumFundingAmount_documentation_en-US" xlink:label="lab_cris_RelatedPartyTransactionMaximumFundingAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Maximum Funding Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RelatedPartyTransactionMaximumFundingAmount" xlink:href="cris-20210930.xsd#cris_RelatedPartyTransactionMaximumFundingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_RelatedPartyTransactionMaximumFundingAmount" xlink:to="lab_cris_RelatedPartyTransactionMaximumFundingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bfa656b0-2c21-462d-a0b5-92158dd14a1c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_70955bce-6877-4e84-9e4c-cecfe7668771_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_c562b846-ff6a-4cf3-8a1b-489afc88ad72_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_c0633f3e-b499-41ed-a99e-0fdb4f20458c_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_c52e8955-4089-4f93-b75d-def0bf393f52_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_StockSaleAgreementCompensationFeePercentageOfGrossProceeds_d16bd8c4-4685-4e70-a8c1-32f55304fdc4_terseLabel_en-US" xlink:label="lab_cris_StockSaleAgreementCompensationFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation fee</link:label>
    <link:label id="lab_cris_StockSaleAgreementCompensationFeePercentageOfGrossProceeds_label_en-US" xlink:label="lab_cris_StockSaleAgreementCompensationFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Compensation Fee, Percentage Of Gross Proceeds</link:label>
    <link:label id="lab_cris_StockSaleAgreementCompensationFeePercentageOfGrossProceeds_documentation_en-US" xlink:label="lab_cris_StockSaleAgreementCompensationFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Compensation Fee, Percentage Of Gross Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockSaleAgreementCompensationFeePercentageOfGrossProceeds" xlink:href="cris-20210930.xsd#cris_StockSaleAgreementCompensationFeePercentageOfGrossProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_StockSaleAgreementCompensationFeePercentageOfGrossProceeds" xlink:to="lab_cris_StockSaleAgreementCompensationFeePercentageOfGrossProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0ed94433-fc34-4b4a-bb90-94a5d5a7240f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e069c69b-804c-44f8-b006-193834541f0b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_e1ec4f48-7060-40c1-af03-996bf986fa14_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_f0a253e7-785a-4877-84ca-491ccc77c692_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_3fc4ab93-5bdb-41e6-a2cf-3bed23243add_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_ec3926e9-0919-47a7-af24-0bce0be0cae8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8e3a83ce-96b3-4189-97f6-b87d532f9c32_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8fddb4b1-bcf4-47ce-bde7-abe18746a4ae_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Plans and Stock Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_808ede46-0248-42f6-9334-8f08a70dd918_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unobservable Inputs&#160;(Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_a97b5855-7cc9-4653-be97-021aba3d3319_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_CaresActPPPLoanMember_2df812f4-8cb8-4aa9-ad1b-fbd4ec23686e_terseLabel_en-US" xlink:label="lab_cris_CaresActPPPLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cares Act PPP Loan</link:label>
    <link:label id="lab_cris_CaresActPPPLoanMember_label_en-US" xlink:label="lab_cris_CaresActPPPLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cares Act PPP Loan [Member]</link:label>
    <link:label id="lab_cris_CaresActPPPLoanMember_documentation_en-US" xlink:label="lab_cris_CaresActPPPLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cares Act PPP Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CaresActPPPLoanMember" xlink:href="cris-20210930.xsd#cris_CaresActPPPLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CaresActPPPLoanMember" xlink:to="lab_cris_CaresActPPPLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5fdcda10-a292-4825-9a29-119aedc48fc4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_a50adc2c-40ff-4c28-9176-8b3b84663038_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f15e3e14-d515-48ff-8e5b-47dced6a3c58_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_904a27e9-169e-4e84-965e-1762b4cb457e_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_ea0f8416-3d2e-4a9c-9ec4-2ec6e29e7e50_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_77497489-13c1-41a7-b39d-8525c1da92d5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional and legal fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_StockAvailableForFuturePurchaseUnderEmployeeStockPurchasePlans_0b086340-7a26-4e94-88a3-52de64061001_terseLabel_en-US" xlink:label="lab_cris_StockAvailableForFuturePurchaseUnderEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock available under ESPPs (in shares)</link:label>
    <link:label id="lab_cris_StockAvailableForFuturePurchaseUnderEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_cris_StockAvailableForFuturePurchaseUnderEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Available For Future Purchase Under Employee Stock Purchase Plans</link:label>
    <link:label id="lab_cris_StockAvailableForFuturePurchaseUnderEmployeeStockPurchasePlans_documentation_en-US" xlink:label="lab_cris_StockAvailableForFuturePurchaseUnderEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock available for future purchase under employee stock purchase plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockAvailableForFuturePurchaseUnderEmployeeStockPurchasePlans" xlink:href="cris-20210930.xsd#cris_StockAvailableForFuturePurchaseUnderEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_StockAvailableForFuturePurchaseUnderEmployeeStockPurchasePlans" xlink:to="lab_cris_StockAvailableForFuturePurchaseUnderEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_OperatingLeaseOneTimePaymentTenantImprovements_41944968-8260-4cc9-8c96-f741ef4c5fce_terseLabel_en-US" xlink:label="lab_cris_OperatingLeaseOneTimePaymentTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One time payment, tenant improvements</link:label>
    <link:label id="lab_cris_OperatingLeaseOneTimePaymentTenantImprovements_label_en-US" xlink:label="lab_cris_OperatingLeaseOneTimePaymentTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, One Time Payment, Tenant Improvements</link:label>
    <link:label id="lab_cris_OperatingLeaseOneTimePaymentTenantImprovements_documentation_en-US" xlink:label="lab_cris_OperatingLeaseOneTimePaymentTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, One Time Payment, Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_OperatingLeaseOneTimePaymentTenantImprovements" xlink:href="cris-20210930.xsd#cris_OperatingLeaseOneTimePaymentTenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_OperatingLeaseOneTimePaymentTenantImprovements" xlink:to="lab_cris_OperatingLeaseOneTimePaymentTenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_e1631080-f281-4d8d-9ff1-37fecc7c9ed9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_PercentageOfRoyaltyOnNetSales_41450c4c-e923-4062-ab86-6e1dc53bb218_terseLabel_en-US" xlink:label="lab_cris_PercentageOfRoyaltyOnNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of royalty on net sales</link:label>
    <link:label id="lab_cris_PercentageOfRoyaltyOnNetSales_label_en-US" xlink:label="lab_cris_PercentageOfRoyaltyOnNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Royalty On Net Sales</link:label>
    <link:label id="lab_cris_PercentageOfRoyaltyOnNetSales_documentation_en-US" xlink:label="lab_cris_PercentageOfRoyaltyOnNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of royalty on net sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_PercentageOfRoyaltyOnNetSales" xlink:href="cris-20210930.xsd#cris_PercentageOfRoyaltyOnNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_PercentageOfRoyaltyOnNetSales" xlink:to="lab_cris_PercentageOfRoyaltyOnNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_AvailableForSaleSecuritiesWeightedAverageMaturity_7951110a-91e3-43ec-b7b2-90af119f7650_terseLabel_en-US" xlink:label="lab_cris_AvailableForSaleSecuritiesWeightedAverageMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average maturity of short-term investments</link:label>
    <link:label id="lab_cris_AvailableForSaleSecuritiesWeightedAverageMaturity_label_en-US" xlink:label="lab_cris_AvailableForSaleSecuritiesWeightedAverageMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Weighted Average Maturity</link:label>
    <link:label id="lab_cris_AvailableForSaleSecuritiesWeightedAverageMaturity_documentation_en-US" xlink:label="lab_cris_AvailableForSaleSecuritiesWeightedAverageMaturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities weighted average maturity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_AvailableForSaleSecuritiesWeightedAverageMaturity" xlink:href="cris-20210930.xsd#cris_AvailableForSaleSecuritiesWeightedAverageMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_AvailableForSaleSecuritiesWeightedAverageMaturity" xlink:to="lab_cris_AvailableForSaleSecuritiesWeightedAverageMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_db7661a7-480c-4036-9e1c-97a7ffc268e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_f09a7021-b613-4598-bbbd-71256619572b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value&#8212;227,812,500 shares authorized; 91,609,165 shares issued and outstanding at September 30, 2021; 151,875,000 shares authorized; 91,502,461 shares issued and outstanding at December 31, 2020</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_a46461d4-80ef-4fcf-9665-ebfb37e8a555_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares of common stock issued</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_233353e4-dfca-4cc6-94fc-414f4421af85_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expense</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_93dfeeed-659a-444b-b9fe-67baf8dae9c1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost, weighted average period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3c5dbcb8-bda1-4a97-b811-af5c1b561f2e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4d87e5f8-c1bf-47a5-a94d-4996e3353e12_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_84e14957-3195-4f2f-97da-1d09e98161a1_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1b600388-136a-445f-8772-1a666a3ac7e5_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_StockPurchaseProgramTermsSharesAuthorizedPerDayAfterMutualAgreement_9b027f50-1b09-45d3-b008-c9c98ccabd6f_terseLabel_en-US" xlink:label="lab_cris_StockPurchaseProgramTermsSharesAuthorizedPerDayAfterMutualAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase program, authorized per day, after mutual agreement (in shares)</link:label>
    <link:label id="lab_cris_StockPurchaseProgramTermsSharesAuthorizedPerDayAfterMutualAgreement_label_en-US" xlink:label="lab_cris_StockPurchaseProgramTermsSharesAuthorizedPerDayAfterMutualAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Program, Terms, Shares Authorized Per Day, After Mutual Agreement</link:label>
    <link:label id="lab_cris_StockPurchaseProgramTermsSharesAuthorizedPerDayAfterMutualAgreement_documentation_en-US" xlink:label="lab_cris_StockPurchaseProgramTermsSharesAuthorizedPerDayAfterMutualAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Program, Terms, Shares Authorized Per Day, After Mutual Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockPurchaseProgramTermsSharesAuthorizedPerDayAfterMutualAgreement" xlink:href="cris-20210930.xsd#cris_StockPurchaseProgramTermsSharesAuthorizedPerDayAfterMutualAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_StockPurchaseProgramTermsSharesAuthorizedPerDayAfterMutualAgreement" xlink:to="lab_cris_StockPurchaseProgramTermsSharesAuthorizedPerDayAfterMutualAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_fc7e2b34-654e-452a-9680-d99243641f86_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d0f7025f-3bca-4562-b17c-6f2d50785ebe_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_a54f46c9-d568-4895-800c-5226736d8de7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_bc764533-0769-460c-afd5-ca10ba10e69d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Key Assumptions for Options Awarded</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_31c69694-aea6-4c26-a7b1-06d0dec369c0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from PPP Loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_55a35033-803f-4709-a553-b465ec005827_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_7dd1a01a-b907-474c-b62b-0ba9282a9e26_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_e775f030-57d8-43a6-8a93-e1ed62c3183f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_9baeebfb-1946-4e31-947f-defe0eaa6876_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_196ac12c-ef76-4c4c-88bb-ae54da0a6f87_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of royalties</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_11e0014b-0c83-44cf-a77e-74b081f1b048_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_14265e04-8426-4cc9-8ac3-119f0bc9f1fd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amortized Cost of Unrealized Gains and Losses and Fair Value of Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrealized Loss on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_373af67d-211f-4e4a-b0fe-7214298c7157_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b7df4a22-f6d7-47f8-92f2-69577c8d1657_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, consideration received</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_SaleOfStockIssuanceCosts_61fa3ce7-736a-4d44-91b9-e9f77b0625fe_terseLabel_en-US" xlink:label="lab_cris_SaleOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other estimated offering expenses payable expense</link:label>
    <link:label id="lab_cris_SaleOfStockIssuanceCosts_label_en-US" xlink:label="lab_cris_SaleOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Issuance Costs</link:label>
    <link:label id="lab_cris_SaleOfStockIssuanceCosts_documentation_en-US" xlink:label="lab_cris_SaleOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_SaleOfStockIssuanceCosts" xlink:href="cris-20210930.xsd#cris_SaleOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_SaleOfStockIssuanceCosts" xlink:to="lab_cris_SaleOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_adc129f7-7be5-45c1-8581-8e5de3cdcba4_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_58480dd7-0793-4035-b1f4-67fa9f0c1b64_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_ad174643-2b4b-4d29-ad59-53251461f6c4_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_64deb832-d65d-4d89-a6a8-99b4406f23f0_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4674fcc8-0c17-49ad-a4a3-ab745583542b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues, net</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_MilestonePaymentsWaivedToDate_01005fd4-3b00-4df9-90a0-3a9dc367d5d4_terseLabel_en-US" xlink:label="lab_cris_MilestonePaymentsWaivedToDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments waived to date</link:label>
    <link:label id="lab_cris_MilestonePaymentsWaivedToDate_label_en-US" xlink:label="lab_cris_MilestonePaymentsWaivedToDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Waived To Date</link:label>
    <link:label id="lab_cris_MilestonePaymentsWaivedToDate_documentation_en-US" xlink:label="lab_cris_MilestonePaymentsWaivedToDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Waived To Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_MilestonePaymentsWaivedToDate" xlink:href="cris-20210930.xsd#cris_MilestonePaymentsWaivedToDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_MilestonePaymentsWaivedToDate" xlink:to="lab_cris_MilestonePaymentsWaivedToDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_f26db9f3-063c-4b87-a444-05f00aa93672_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from direct offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue_233b23e8-27e8-4494-a74b-fc73f552e8a4_terseLabel_en-US" xlink:label="lab_cris_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash commitment shares issued to Aspire Capital</link:label>
    <link:label id="lab_cris_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue_label_en-US" xlink:label="lab_cris_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Or Part Noncash Acquisition, Noncash Financial Or Equity Instrument Consideration, Shares Issued, Value</link:label>
    <link:label id="lab_cris_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue_documentation_en-US" xlink:label="lab_cris_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Or Part Noncash Acquisition, Noncash Financial Or Equity Instrument Consideration, Shares Issued, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue" xlink:href="cris-20210930.xsd#cris_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue" xlink:to="lab_cris_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_4db48497-e6ef-48bb-a328-296167939bf3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Outstanding</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_d377819c-2e78-488c-b0b3-7b980218fe74_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fees for issuance of shares in connection with Capital on Demand&#8482; Sales Agreement</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_fdf5bbd5-e865-4da5-bfe6-284f2f76bcf9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_CollaborationArrangementSemiAnnualMaintenanceFeePayment_908397b8-73e6-43fe-a0b2-5dcb28c3de9d_terseLabel_en-US" xlink:label="lab_cris_CollaborationArrangementSemiAnnualMaintenanceFeePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Semi-annual maintenance fee payments</link:label>
    <link:label id="lab_cris_CollaborationArrangementSemiAnnualMaintenanceFeePayment_label_en-US" xlink:label="lab_cris_CollaborationArrangementSemiAnnualMaintenanceFeePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Semi-Annual Maintenance Fee Payment</link:label>
    <link:label id="lab_cris_CollaborationArrangementSemiAnnualMaintenanceFeePayment_documentation_en-US" xlink:label="lab_cris_CollaborationArrangementSemiAnnualMaintenanceFeePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Semi-Annual Maintenance Fee Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationArrangementSemiAnnualMaintenanceFeePayment" xlink:href="cris-20210930.xsd#cris_CollaborationArrangementSemiAnnualMaintenanceFeePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborationArrangementSemiAnnualMaintenanceFeePayment" xlink:to="lab_cris_CollaborationArrangementSemiAnnualMaintenanceFeePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_041b7024-cf92-45bb-9194-b136b282fe35_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold_bfc4ea27-0f26-4acc-b6e5-379116ee326d_terseLabel_en-US" xlink:label="lab_cris_RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty amount threshold</link:label>
    <link:label id="lab_cris_RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold_label_en-US" xlink:label="lab_cris_RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Terms, Royalty Amount Threshold</link:label>
    <link:label id="lab_cris_RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold_documentation_en-US" xlink:label="lab_cris_RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Terms, Royalty Amount Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold" xlink:href="cris-20210930.xsd#cris_RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold" xlink:to="lab_cris_RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_b8508a08-63f5-4b0b-91af-721f58c761d0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_27cf69c2-6231-4d29-a6cd-37a045b6c452_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfessionalFees_2e4a81a2-2b03-4726-a5b2-64c4decac3e2_terseLabel_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fees payable expenses</link:label>
    <link:label id="lab_us-gaap_ProfessionalFees_label_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees" xlink:to="lab_us-gaap_ProfessionalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_f494fecc-2677-42da-894d-ea20f211da25_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_AggregateNetRoyaltiesPriorTo2027Member_042fb58b-2bc4-43b4-88c9-9ab0a271eb8d_terseLabel_en-US" xlink:label="lab_cris_AggregateNetRoyaltiesPriorTo2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Net Royalties Prior to 2027</link:label>
    <link:label id="lab_cris_AggregateNetRoyaltiesPriorTo2027Member_label_en-US" xlink:label="lab_cris_AggregateNetRoyaltiesPriorTo2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Net Royalties Prior To 2027 [Member]</link:label>
    <link:label id="lab_cris_AggregateNetRoyaltiesPriorTo2027Member_documentation_en-US" xlink:label="lab_cris_AggregateNetRoyaltiesPriorTo2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Net Royalties Prior To 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_AggregateNetRoyaltiesPriorTo2027Member" xlink:href="cris-20210930.xsd#cris_AggregateNetRoyaltiesPriorTo2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_AggregateNetRoyaltiesPriorTo2027Member" xlink:to="lab_cris_AggregateNetRoyaltiesPriorTo2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_288b8b9b-eaf7-4d59-aae4-de71dff28796_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_11cf1dd2-805a-4929-a6fe-3dd30a3ffbf0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_18f7f513-ba7a-43e9-9b76-2ec886e88004_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_c2ce79e8-c389-477c-b5f1-56e389ef1650_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Collaborations</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e1e5e91-d940-4e47-8c2f-f2570a788772_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest_1ad921b4-a622-4fbe-9fce-2ed39fb91b0b_negatedTerseLabel_en-US" xlink:label="lab_cris_PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of liability of future royalties, net of imputed interest</link:label>
    <link:label id="lab_cris_PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest_label_en-US" xlink:label="lab_cris_PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Future Royalty Liability, Net Of Imputed Interest</link:label>
    <link:label id="lab_cris_PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest_documentation_en-US" xlink:label="lab_cris_PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Future Royalty Liability, Net Of Imputed Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest" xlink:href="cris-20210930.xsd#cris_PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest" xlink:to="lab_cris_PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_6d535450-876f-4c50-aeaf-68b98c873385_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_38a2c351-ed4f-4366-8d1e-f30937c03c3f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_30e84e44-6db8-4c19-a399-44f854a3d87f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsAbstract_0ee8926f-5a1b-447a-b680-c4a14803feec_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments:</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract" xlink:to="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_c16c5f29-db99-4c76-82b3-19c574887026_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount paid for transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_96b5115c-a383-4a53-8de2-4d18e4d3049c_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_4eb2892a-55c4-4fcd-9c00-490cc45b96b6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6b520774-905f-4665-b5e3-ff00d7b98024_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_bfe988c2-7df8-4ea4-b70b-4c099f61f4e0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Award Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_eeb221f9-e3fa-4b45-aa96-64550d7c1e90_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_ShortTermInvestmentsFairValueDisclosure_7692b372-321e-4bea-a1e1-bf98142d820f_terseLabel_en-US" xlink:label="lab_cris_ShortTermInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate commercial paper, bonds and notes</link:label>
    <link:label id="lab_cris_ShortTermInvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_cris_ShortTermInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Investments, Fair Value Disclosure</link:label>
    <link:label id="lab_cris_ShortTermInvestmentsFairValueDisclosure_documentation_en-US" xlink:label="lab_cris_ShortTermInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ShortTermInvestmentsFairValueDisclosure" xlink:href="cris-20210930.xsd#cris_ShortTermInvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_ShortTermInvestmentsFairValueDisclosure" xlink:to="lab_cris_ShortTermInvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_IRAK4PD1VISTAPD1TIM3ProgramMember_c222833d-688d-4e21-abce-044ae81a2032_terseLabel_en-US" xlink:label="lab_cris_IRAK4PD1VISTAPD1TIM3ProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IRAK4, PD1/VISTA, and PD1/TIM3 Programs</link:label>
    <link:label id="lab_cris_IRAK4PD1VISTAPD1TIM3ProgramMember_label_en-US" xlink:label="lab_cris_IRAK4PD1VISTAPD1TIM3ProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IRAK4, PD1/VISTA,PD1/TIM3 Program [Member]</link:label>
    <link:label id="lab_cris_IRAK4PD1VISTAPD1TIM3ProgramMember_documentation_en-US" xlink:label="lab_cris_IRAK4PD1VISTAPD1TIM3ProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IRAK4, PD1/VISTA,PD1/TIM3 Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_IRAK4PD1VISTAPD1TIM3ProgramMember" xlink:href="cris-20210930.xsd#cris_IRAK4PD1VISTAPD1TIM3ProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_IRAK4PD1VISTAPD1TIM3ProgramMember" xlink:to="lab_cris_IRAK4PD1VISTAPD1TIM3ProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bfbe487a-c26d-4df5-869a-3eae50758e0d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_StockPurchaseProgramCommitmentFeeShares_d9b4eea2-898d-47c2-96b6-6fb574545ac4_terseLabel_en-US" xlink:label="lab_cris_StockPurchaseProgramCommitmentFeeShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee (in shares)</link:label>
    <link:label id="lab_cris_StockPurchaseProgramCommitmentFeeShares_label_en-US" xlink:label="lab_cris_StockPurchaseProgramCommitmentFeeShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Program, Commitment Fee, Shares</link:label>
    <link:label id="lab_cris_StockPurchaseProgramCommitmentFeeShares_documentation_en-US" xlink:label="lab_cris_StockPurchaseProgramCommitmentFeeShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Program, Commitment Fee, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockPurchaseProgramCommitmentFeeShares" xlink:href="cris-20210930.xsd#cris_StockPurchaseProgramCommitmentFeeShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_StockPurchaseProgramCommitmentFeeShares" xlink:to="lab_cris_StockPurchaseProgramCommitmentFeeShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_d710aa01-2bbf-4ce6-9844-4443fc56d3ac_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_fb77b5eb-0ed7-4245-aec1-bd67645dbfe5_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0c4e47f-0c6d-4f58-ac0a-0bfa1d5113b1_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_CollaborationAgreementExpense_355a3157-eb44-4a4e-947e-0c0b4f66d01d_terseLabel_en-US" xlink:label="lab_cris_CollaborationAgreementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, expense</link:label>
    <link:label id="lab_cris_CollaborationAgreementExpense_label_en-US" xlink:label="lab_cris_CollaborationAgreementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Expense</link:label>
    <link:label id="lab_cris_CollaborationAgreementExpense_documentation_en-US" xlink:label="lab_cris_CollaborationAgreementExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationAgreementExpense" xlink:href="cris-20210930.xsd#cris_CollaborationAgreementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborationAgreementExpense" xlink:to="lab_cris_CollaborationAgreementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_0e9b1216-bcdb-4fab-8b9b-4387bf98402a_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_CollaborationAgreementNumberofProgramsLicensed_8edc64e8-27b6-4ad2-bc4f-79d86a53293f_terseLabel_en-US" xlink:label="lab_cris_CollaborationAgreementNumberofProgramsLicensed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of program licensed</link:label>
    <link:label id="lab_cris_CollaborationAgreementNumberofProgramsLicensed_label_en-US" xlink:label="lab_cris_CollaborationAgreementNumberofProgramsLicensed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Number of Programs Licensed</link:label>
    <link:label id="lab_cris_CollaborationAgreementNumberofProgramsLicensed_documentation_en-US" xlink:label="lab_cris_CollaborationAgreementNumberofProgramsLicensed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Number of Programs Licensed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationAgreementNumberofProgramsLicensed" xlink:href="cris-20210930.xsd#cris_CollaborationAgreementNumberofProgramsLicensed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborationAgreementNumberofProgramsLicensed" xlink:to="lab_cris_CollaborationAgreementNumberofProgramsLicensed" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_ContingentPaymentBenchmarkAxis_981b4782-b27c-452d-9a0f-3849c2fd1a1a_terseLabel_en-US" xlink:label="lab_cris_ContingentPaymentBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Payment, Benchmark [Axis]</link:label>
    <link:label id="lab_cris_ContingentPaymentBenchmarkAxis_label_en-US" xlink:label="lab_cris_ContingentPaymentBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Payment, Benchmark [Axis]</link:label>
    <link:label id="lab_cris_ContingentPaymentBenchmarkAxis_documentation_en-US" xlink:label="lab_cris_ContingentPaymentBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Payment, Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ContingentPaymentBenchmarkAxis" xlink:href="cris-20210930.xsd#cris_ContingentPaymentBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_ContingentPaymentBenchmarkAxis" xlink:to="lab_cris_ContingentPaymentBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_98a1aa1f-d762-4792-9641-f3507a251f32_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_c9d73a98-3696-4293-ae10-109d04cd907b_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosureAbstract_1eeaf3ee-f4a8-4ea8-bcc9-662549cd779f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments:</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14203ca4-5cd5-49f2-8a1d-179856f58738_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e3dd53e4-1722-4217-9046-1a04351b30e6_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6bde7355-d391-4752-a560-d65da50bcaba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_17eaec09-7cb0-47c9-90a5-0c15cab290b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and unvested expected to vest at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_LongTermInvestmentsFairValueDisclosure_c3575e9f-fdb0-402d-9b01-7ff3e874d58a_verboseLabel_en-US" xlink:label="lab_cris_LongTermInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate commercial paper, bonds and notes</link:label>
    <link:label id="lab_cris_LongTermInvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_cris_LongTermInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investments, Fair Value Disclosure</link:label>
    <link:label id="lab_cris_LongTermInvestmentsFairValueDisclosure_documentation_en-US" xlink:label="lab_cris_LongTermInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_LongTermInvestmentsFairValueDisclosure" xlink:href="cris-20210930.xsd#cris_LongTermInvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_LongTermInvestmentsFairValueDisclosure" xlink:to="lab_cris_LongTermInvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_d295f102-644a-49fa-83e4-25b4366b46a7_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_18ff9b36-d821-4b24-8116-b2bc729502ac_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ed31e77e-7327-48b4-a9a6-2cb2ccf73450_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5cfaa757-3c63-4781-9ffc-eda0a27ba922_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_36f27313-727e-48a7-b9b4-17d311dd1ba1_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_a6e97035-d4f4-453f-aff9-0cf3d66c9458_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_a0bbfd40-d0fe-450a-9151-eb892f929037_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ca63c591-0660-412f-af07-740cf9cce24a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonmonetaryTransactionByTypeTable_12930657-8cd5-47de-a5bf-76347ab8c51f_terseLabel_en-US" xlink:label="lab_us-gaap_NonmonetaryTransactionByTypeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonmonetary Transaction, by Type [Table]</link:label>
    <link:label id="lab_us-gaap_NonmonetaryTransactionByTypeTable_label_en-US" xlink:label="lab_us-gaap_NonmonetaryTransactionByTypeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonmonetary Transaction, by Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionByTypeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionByTypeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonmonetaryTransactionByTypeTable" xlink:to="lab_us-gaap_NonmonetaryTransactionByTypeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod_9fcdf152-74ed-46e8-aa89-c2aa97cff5a0_terseLabel_en-US" xlink:label="lab_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock plan offering period</link:label>
    <link:label id="lab_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod_label_en-US" xlink:label="lab_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period</link:label>
    <link:label id="lab_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod_documentation_en-US" xlink:label="lab_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod" xlink:href="cris-20210930.xsd#cris_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod" xlink:to="lab_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_ContingentPaymentBenchmarkDomain_c5f1e73a-a479-4237-88ee-c54c5afe0ab5_terseLabel_en-US" xlink:label="lab_cris_ContingentPaymentBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Payment, Benchmark [Domain]</link:label>
    <link:label id="lab_cris_ContingentPaymentBenchmarkDomain_label_en-US" xlink:label="lab_cris_ContingentPaymentBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Payment, Benchmark [Domain]</link:label>
    <link:label id="lab_cris_ContingentPaymentBenchmarkDomain_documentation_en-US" xlink:label="lab_cris_ContingentPaymentBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Contingent Payment, Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ContingentPaymentBenchmarkDomain" xlink:href="cris-20210930.xsd#cris_ContingentPaymentBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_ContingentPaymentBenchmarkDomain" xlink:to="lab_cris_ContingentPaymentBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_d9e94050-4edf-4293-84f6-b8913ee5e499_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on forgiveness of PPP Loan</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_99eca30f-ba22-40c6-b284-291a218b5d9f_verboseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_d1639457-e588-4b40-95ae-e4e4508a1447_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_22d0f35e-3938-47b8-bb9e-4eb48ec386d9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk -free Interest rate (minimum)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_adaf952e-e4f3-4738-9787-aeca34e7d4a7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_b0c3eb8a-ca3e-4513-9bc7-32b38523f49c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_StockOptionsorStockAppreciationRightsMember_7b98d025-2678-4771-9697-bb9c0b22284d_terseLabel_en-US" xlink:label="lab_cris_StockOptionsorStockAppreciationRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, or Stock Appreciation Rights</link:label>
    <link:label id="lab_cris_StockOptionsorStockAppreciationRightsMember_label_en-US" xlink:label="lab_cris_StockOptionsorStockAppreciationRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, or Stock Appreciation Rights [Member]</link:label>
    <link:label id="lab_cris_StockOptionsorStockAppreciationRightsMember_documentation_en-US" xlink:label="lab_cris_StockOptionsorStockAppreciationRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, or Stock Appreciation Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockOptionsorStockAppreciationRightsMember" xlink:href="cris-20210930.xsd#cris_StockOptionsorStockAppreciationRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_StockOptionsorStockAppreciationRightsMember" xlink:to="lab_cris_StockOptionsorStockAppreciationRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c1dc4d68-0075-4429-bdcf-97632d53663b_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_cd4c23f5-4507-4b26-9f2c-53ca08ec743a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_aac6016b-656f-4656-9ba3-e5b18344a38f_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_11683d6b-f027-49fd-a5af-2472c33f746b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_bb3436a2-24d6-49fa-af1a-06706aba2b70_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5a40cc0d-3412-43e2-bd45-ba511613961a_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under Employee Stock Purchase Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_de631bb0-7951-45db-9875-69496c66af74_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued under employee stock purchase plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_00c154f0-8046-44c9-88fe-0d8b218f2f93_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_3f7f0a09-db7b-42ac-b101-b2b19b64f97e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_cb5d4cb5-30a3-4831-95c8-00c70cbd2dd9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d9bcc8fe-bcff-4ff2-9ebe-5dfb73fc4c78_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_SiliconValleyBankMember_1311b922-15a6-40c9-a5aa-b2a214f5a1f9_terseLabel_en-US" xlink:label="lab_cris_SiliconValleyBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Silicon Valley Bank</link:label>
    <link:label id="lab_cris_SiliconValleyBankMember_label_en-US" xlink:label="lab_cris_SiliconValleyBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Silicon Valley Bank [Member]</link:label>
    <link:label id="lab_cris_SiliconValleyBankMember_documentation_en-US" xlink:label="lab_cris_SiliconValleyBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Silicon Valley Bank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_SiliconValleyBankMember" xlink:href="cris-20210930.xsd#cris_SiliconValleyBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_SiliconValleyBankMember" xlink:to="lab_cris_SiliconValleyBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_RoyaltyAmountsIn2021Member_56b87ab4-3b8d-4757-b290-8dcdac18418f_terseLabel_en-US" xlink:label="lab_cris_RoyaltyAmountsIn2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Amounts in 2021</link:label>
    <link:label id="lab_cris_RoyaltyAmountsIn2021Member_label_en-US" xlink:label="lab_cris_RoyaltyAmountsIn2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Amounts In 2021 [Member]</link:label>
    <link:label id="lab_cris_RoyaltyAmountsIn2021Member_documentation_en-US" xlink:label="lab_cris_RoyaltyAmountsIn2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Amounts In 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyAmountsIn2021Member" xlink:href="cris-20210930.xsd#cris_RoyaltyAmountsIn2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_RoyaltyAmountsIn2021Member" xlink:to="lab_cris_RoyaltyAmountsIn2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_fd0e42ee-9c4e-4472-a075-213587288eef_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_28b5b75c-1222-47a1-af01-3b1fe82ee6ee_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7219f605-692c-4bd3-9d17-71658d0c9c06_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled/Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_EmployeeStockPurchasePlanMember_1603f05b-65c6-4df5-bcfc-b2fd60977b68_terseLabel_en-US" xlink:label="lab_cris_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_cris_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_cris_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_cris_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_cris_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_EmployeeStockPurchasePlanMember" xlink:href="cris-20210930.xsd#cris_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_EmployeeStockPurchasePlanMember" xlink:to="lab_cris_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_4680b5c2-77fb-4996-8c8e-fa140e949880_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_17202667-1ffd-4172-a123-f290bc7fc328_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_9987b792-0627-4899-bdcc-9499ac10e97c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7dd8b1de-b1d1-49c2-899d-c5ef8e3e338a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_656dd8e4-d83f-4180-aa89-49e2ce8d8106_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_f450ecac-879e-4648-9d89-6e74c95c533d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_986e9612-b117-45cd-9195-84316c2278ae_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease obligations</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_205e29e7-f4a2-457e-8972-d833136a566e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_3d0129ef-14b3-403b-8f3e-f67c3be02b30_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e2f6a8bc-f5c2-4268-a8eb-9e03292cc6f6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_cf98fb70-1621-40d7-9e04-d3955a9c11b5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b9a0d2fd-dd86-4b06-9f82-2eb5bb29c48f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0e60f54e-4ff5-41a3-9a2c-c88d63e7ce7d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_965a192d-bec3-42c3-a1e7-dfb9f080cb07_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0944796f-78c0-4c90-91c7-4e8cd91c625a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_4a15d36f-ceef-4e90-ad26-0a4e7a3a2f9c_totalLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total adjustments</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_7c36380d-95b1-494d-be48-35625ff76dc3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_1e5ff934-a473-42f4-9d60-e29edfd92ba6_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_0b2f25d5-1a1a-43e6-9cef-31d7119d4c2f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_fe19aee3-f388-471b-bf8e-5922a2cc245f_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_2a16a949-ab0c-4f3b-9bc5-374a1e34bc15_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_573619c3-53ee-4551-a65e-98c660984721_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair values of stock options (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_f2bc1895-6380-4a42-8807-7672b82503b1_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_ProceedsFromRoyaltyPurchaseAgreement_9b04179a-94d2-4507-a6eb-39bffda37bbf_terseLabel_en-US" xlink:label="lab_cris_ProceedsFromRoyaltyPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from royalty interest purchase agreement with Oberland Capital Management, LLC</link:label>
    <link:label id="lab_cris_ProceedsFromRoyaltyPurchaseAgreement_label_en-US" xlink:label="lab_cris_ProceedsFromRoyaltyPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Royalty Purchase Agreement</link:label>
    <link:label id="lab_cris_ProceedsFromRoyaltyPurchaseAgreement_documentation_en-US" xlink:label="lab_cris_ProceedsFromRoyaltyPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Royalty Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ProceedsFromRoyaltyPurchaseAgreement" xlink:href="cris-20210930.xsd#cris_ProceedsFromRoyaltyPurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_ProceedsFromRoyaltyPurchaseAgreement" xlink:to="lab_cris_ProceedsFromRoyaltyPurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_AspireCapitalFundLLCMember_8429c36e-1790-4159-b7f7-e811b59e4743_terseLabel_en-US" xlink:label="lab_cris_AspireCapitalFundLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aspire Capital Fund, LLC</link:label>
    <link:label id="lab_cris_AspireCapitalFundLLCMember_a90142f1-d56b-4fc3-b41f-3c79c5338ad5_verboseLabel_en-US" xlink:label="lab_cris_AspireCapitalFundLLCMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aspire Capital Fund, LLC</link:label>
    <link:label id="lab_cris_AspireCapitalFundLLCMember_label_en-US" xlink:label="lab_cris_AspireCapitalFundLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aspire Capital Fund, LLC [Member]</link:label>
    <link:label id="lab_cris_AspireCapitalFundLLCMember_documentation_en-US" xlink:label="lab_cris_AspireCapitalFundLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aspire Capital Fund, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_AspireCapitalFundLLCMember" xlink:href="cris-20210930.xsd#cris_AspireCapitalFundLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_AspireCapitalFundLLCMember" xlink:to="lab_cris_AspireCapitalFundLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_RoyaltyGuaranteesCommitmentsAmountNoncurrent_38e1ed05-5779-47fd-ac62-403de62807b8_terseLabel_en-US" xlink:label="lab_cris_RoyaltyGuaranteesCommitmentsAmountNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to the sale of future royalties, net</link:label>
    <link:label id="lab_cris_RoyaltyGuaranteesCommitmentsAmountNoncurrent_label_en-US" xlink:label="lab_cris_RoyaltyGuaranteesCommitmentsAmountNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Guarantees, Commitments, Amount, Noncurrent</link:label>
    <link:label id="lab_cris_RoyaltyGuaranteesCommitmentsAmountNoncurrent_documentation_en-US" xlink:label="lab_cris_RoyaltyGuaranteesCommitmentsAmountNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Guarantees, Commitments, Amount, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyGuaranteesCommitmentsAmountNoncurrent" xlink:href="cris-20210930.xsd#cris_RoyaltyGuaranteesCommitmentsAmountNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_RoyaltyGuaranteesCommitmentsAmountNoncurrent" xlink:to="lab_cris_RoyaltyGuaranteesCommitmentsAmountNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_1a856ac6-0036-4685-884c-4af48dfbfcb7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_c7017bdd-e0e1-402d-98d4-a9552235a9bf_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash, long-term</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e0d350ca-e90d-4145-9899-fb552b461851_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price&#160;per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_7f1006dc-065d-4093-8498-bff25e4e8996_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_077d6865-76de-4b9c-a226-a3abbbe8c52d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases from related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Purchases from Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_RoyaltyRatePercentageOfSales_822da85d-63b9-444d-9b2d-5d24496e3fbb_terseLabel_en-US" xlink:label="lab_cris_RoyaltyRatePercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty rate, percentage of sales (percent)</link:label>
    <link:label id="lab_cris_RoyaltyRatePercentageOfSales_label_en-US" xlink:label="lab_cris_RoyaltyRatePercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Rate, Percentage Of Sales</link:label>
    <link:label id="lab_cris_RoyaltyRatePercentageOfSales_documentation_en-US" xlink:label="lab_cris_RoyaltyRatePercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Rate, Percentage Of Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyRatePercentageOfSales" xlink:href="cris-20210930.xsd#cris_RoyaltyRatePercentageOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_RoyaltyRatePercentageOfSales" xlink:to="lab_cris_RoyaltyRatePercentageOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c3003663-95d4-47d4-87ba-77fb7dd6c8c4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_fd977153-40af-486e-8461-5cd6d797bf46_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds and notes&#8212;short-term</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_6d1ba811-8fbb-4383-9424-5982d923e48a_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_cfe8a3eb-48cb-4638-9f19-38daf115c26d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_CollaborationArrangementContingentConsiderationSalesMilestonePayments_55454ac5-ac60-413a-aef8-3040e709bef1_terseLabel_en-US" xlink:label="lab_cris_CollaborationArrangementContingentConsiderationSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone payments</link:label>
    <link:label id="lab_cris_CollaborationArrangementContingentConsiderationSalesMilestonePayments_label_en-US" xlink:label="lab_cris_CollaborationArrangementContingentConsiderationSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Contingent Consideration, Sales Milestone Payments</link:label>
    <link:label id="lab_cris_CollaborationArrangementContingentConsiderationSalesMilestonePayments_documentation_en-US" xlink:label="lab_cris_CollaborationArrangementContingentConsiderationSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Contingent Consideration, Sales Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationArrangementContingentConsiderationSalesMilestonePayments" xlink:href="cris-20210930.xsd#cris_CollaborationArrangementContingentConsiderationSalesMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborationArrangementContingentConsiderationSalesMilestonePayments" xlink:to="lab_cris_CollaborationArrangementContingentConsiderationSalesMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_e68e35a5-92a5-49bf-ac0b-602a8288af0b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_dee31164-aad9-469f-be05-538ae74ae6d3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_6071e140-cb0d-4594-accf-b1b659104336_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_94975334-bd31-427b-98e3-38e0b631e97c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_b03747c2-f73e-45f4-af4d-fcdaaffd2e20_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#160;Observable Inputs&#160;(Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_RoyaltyPurchaseAgreementContingentConsiderationCashProceeds_e0fb9b8a-df36-4175-82b4-48f6cf7f9298_terseLabel_en-US" xlink:label="lab_cris_RoyaltyPurchaseAgreementContingentConsiderationCashProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash proceeds from royalty purchase agreement</link:label>
    <link:label id="lab_cris_RoyaltyPurchaseAgreementContingentConsiderationCashProceeds_label_en-US" xlink:label="lab_cris_RoyaltyPurchaseAgreementContingentConsiderationCashProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Contingent Consideration, Cash Proceeds</link:label>
    <link:label id="lab_cris_RoyaltyPurchaseAgreementContingentConsiderationCashProceeds_documentation_en-US" xlink:label="lab_cris_RoyaltyPurchaseAgreementContingentConsiderationCashProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Contingent Consideration, Cash Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyPurchaseAgreementContingentConsiderationCashProceeds" xlink:href="cris-20210930.xsd#cris_RoyaltyPurchaseAgreementContingentConsiderationCashProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_RoyaltyPurchaseAgreementContingentConsiderationCashProceeds" xlink:to="lab_cris_RoyaltyPurchaseAgreementContingentConsiderationCashProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_CollaborationAgreementTermsPercentageOfRoyaltyFeesReceivable_8515972f-cd86-43ec-9339-83dbee95920c_terseLabel_en-US" xlink:label="lab_cris_CollaborationAgreementTermsPercentageOfRoyaltyFeesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty fees receivable (as a percent)</link:label>
    <link:label id="lab_cris_CollaborationAgreementTermsPercentageOfRoyaltyFeesReceivable_label_en-US" xlink:label="lab_cris_CollaborationAgreementTermsPercentageOfRoyaltyFeesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Terms, Percentage Of Royalty Fees Receivable</link:label>
    <link:label id="lab_cris_CollaborationAgreementTermsPercentageOfRoyaltyFeesReceivable_documentation_en-US" xlink:label="lab_cris_CollaborationAgreementTermsPercentageOfRoyaltyFeesReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Terms, Percentage Of Royalty Fees Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationAgreementTermsPercentageOfRoyaltyFeesReceivable" xlink:href="cris-20210930.xsd#cris_CollaborationAgreementTermsPercentageOfRoyaltyFeesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborationAgreementTermsPercentageOfRoyaltyFeesReceivable" xlink:to="lab_cris_CollaborationAgreementTermsPercentageOfRoyaltyFeesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bc22097d-e16e-4027-b377-3c0293ab830f_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_StockPurchaseProgramTermsSharesAuthorizedPerDay_f80c66a3-9aa5-4b99-82d9-b9d6235a556c_terseLabel_en-US" xlink:label="lab_cris_StockPurchaseProgramTermsSharesAuthorizedPerDay" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase program, authorized per day (in shares)</link:label>
    <link:label id="lab_cris_StockPurchaseProgramTermsSharesAuthorizedPerDay_label_en-US" xlink:label="lab_cris_StockPurchaseProgramTermsSharesAuthorizedPerDay" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Program, Terms, Shares Authorized Per Day</link:label>
    <link:label id="lab_cris_StockPurchaseProgramTermsSharesAuthorizedPerDay_documentation_en-US" xlink:label="lab_cris_StockPurchaseProgramTermsSharesAuthorizedPerDay" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Program, Terms, Shares Authorized Per Day</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockPurchaseProgramTermsSharesAuthorizedPerDay" xlink:href="cris-20210930.xsd#cris_StockPurchaseProgramTermsSharesAuthorizedPerDay"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_StockPurchaseProgramTermsSharesAuthorizedPerDay" xlink:to="lab_cris_StockPurchaseProgramTermsSharesAuthorizedPerDay" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_375c9189-c308-478a-a432-07bd75163de7_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_9efa98f6-fc1e-4c3e-b500-4113fecbcb3c_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates and Assumptions</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_272baf9d-e9ca-4893-835d-93bd666b53ce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bf705995-2cd5-4c63-b870-408662a069fd_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_c12a1c08-24e1-4de6-9d0b-f02a69c97d4d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_dc8644fb-a0ac-43af-9bd2-0156e1cbe7a6_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7851f49c-af88-42ed-b99d-405603cd44ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_5fddfe7b-2f78-4742-9773-2399af5af611_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_b2905fe9-1d43-4978-920a-7a7d0b824dce_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds of Aspire Capital Agreement, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_79061988-d171-4d07-85cf-e729ce27f83e_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds of aspire capital agreement, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_b50efd00-3d5c-482a-a40e-6dfadc2abe75_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_7b7cd5ce-9230-4f6c-9e85-2aab1d1e4f00_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_e424dcb8-edf3-43fc-b3f9-acafc61cdc49_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_f7326f74-6313-4d9a-858c-f7c1dab1456d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_EmployeeStockPurchasePlanEnrollmentPeriod_f57585e0-eb95-4bdc-bc3a-ddce0bc97905_terseLabel_en-US" xlink:label="lab_cris_EmployeeStockPurchasePlanEnrollmentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enrollment period</link:label>
    <link:label id="lab_cris_EmployeeStockPurchasePlanEnrollmentPeriod_label_en-US" xlink:label="lab_cris_EmployeeStockPurchasePlanEnrollmentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Enrollment Period</link:label>
    <link:label id="lab_cris_EmployeeStockPurchasePlanEnrollmentPeriod_documentation_en-US" xlink:label="lab_cris_EmployeeStockPurchasePlanEnrollmentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Enrollment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_EmployeeStockPurchasePlanEnrollmentPeriod" xlink:href="cris-20210930.xsd#cris_EmployeeStockPurchasePlanEnrollmentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_EmployeeStockPurchasePlanEnrollmentPeriod" xlink:to="lab_cris_EmployeeStockPurchasePlanEnrollmentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_6e730514-da1e-4af3-bc4d-bd8ae4d806aa_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_b2fb10c4-0027-4c82-b332-8ec22904721a_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_cd6652bd-4581-41a9-a577-6f5ca622e255_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_df42ab44-04f6-43b7-9221-a372ce8cb3b0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured loan interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_TwoThousandAndTenPlanMember_dec2c4f3-fad0-4e09-b41f-444e6b6f7540_terseLabel_en-US" xlink:label="lab_cris_TwoThousandAndTenPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2010 Plan</link:label>
    <link:label id="lab_cris_TwoThousandAndTenPlanMember_label_en-US" xlink:label="lab_cris_TwoThousandAndTenPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Ten Plan [Member]</link:label>
    <link:label id="lab_cris_TwoThousandAndTenPlanMember_documentation_en-US" xlink:label="lab_cris_TwoThousandAndTenPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Ten Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_TwoThousandAndTenPlanMember" xlink:href="cris-20210930.xsd#cris_TwoThousandAndTenPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_TwoThousandAndTenPlanMember" xlink:to="lab_cris_TwoThousandAndTenPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e70dd09-36fa-4054-be14-a27ac1e8ac3a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_5e19cad6-b1f0-4563-a370-b10db3150180_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_70a692c6-7f1b-4e17-8d8b-477c42448d35_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_cf8ae8f9-d2fc-41aa-af3d-775ee37f1e46_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_b442f9ce-6865-4015-8dac-5c356f724fff_negatedLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_OberlandCapitalMember_fea30041-9be9-4a32-9c86-5a48e75636bf_terseLabel_en-US" xlink:label="lab_cris_OberlandCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oberland Capital</link:label>
    <link:label id="lab_cris_OberlandCapitalMember_label_en-US" xlink:label="lab_cris_OberlandCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oberland Capital [Member]</link:label>
    <link:label id="lab_cris_OberlandCapitalMember_documentation_en-US" xlink:label="lab_cris_OberlandCapitalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oberland Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_OberlandCapitalMember" xlink:href="cris-20210930.xsd#cris_OberlandCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_OberlandCapitalMember" xlink:to="lab_cris_OberlandCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_03f63651-6b90-4f94-9de0-0529c18fc13d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_44713320-4aa6-432a-919a-fe452166771e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_7eb3ef60-fb49-43d3-b66f-281cdde52e66_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts_77b4d719-b5a7-4ea6-acb8-ca3846525cdf_terseLabel_en-US" xlink:label="lab_cris_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds of direct placement</link:label>
    <link:label id="lab_cris_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts_label_en-US" xlink:label="lab_cris_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Private Placement, Net Of Issuance Costs</link:label>
    <link:label id="lab_cris_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_cris_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Private Placement, Net Of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts" xlink:href="cris-20210930.xsd#cris_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts" xlink:to="lab_cris_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3609aa70-7957-4737-a181-e96ad721a66f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares (basic) (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_661ab7d4-e618-4197-b662-95bb7de45eeb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share (diluted) (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_05d271c1-36c1-4cb9-8b7d-9f82d8d9b162_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_24ecd65d-2a78-47b1-9dd2-9a62b0d6e600_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_MasterDevelopmentAndManufacturingAgreementMember_1455c587-28f5-495a-addd-44eed952cc46_terseLabel_en-US" xlink:label="lab_cris_MasterDevelopmentAndManufacturingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Master Development and Manufacturing Agreement</link:label>
    <link:label id="lab_cris_MasterDevelopmentAndManufacturingAgreementMember_label_en-US" xlink:label="lab_cris_MasterDevelopmentAndManufacturingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Master Development And Manufacturing Agreement [Member]</link:label>
    <link:label id="lab_cris_MasterDevelopmentAndManufacturingAgreementMember_documentation_en-US" xlink:label="lab_cris_MasterDevelopmentAndManufacturingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Master Development And Manufacturing Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_MasterDevelopmentAndManufacturingAgreementMember" xlink:href="cris-20210930.xsd#cris_MasterDevelopmentAndManufacturingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_MasterDevelopmentAndManufacturingAgreementMember" xlink:to="lab_cris_MasterDevelopmentAndManufacturingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_1d9df3f3-a56c-4a55-a9f4-eff0fac6549d_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d4e23738-bf27-4df1-8e84-815f44287c8c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_2f9200d1-aada-42e7-8829-a85ab5e6e4d4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_5f2008db-6c22-40e0-965f-889fcbb67beb_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_93af738c-53ed-49a4-8531-a6d859414c0e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_ReducedRoyaltyRate_30ad9dd0-54d3-4d16-bde9-605bc5559b75_terseLabel_en-US" xlink:label="lab_cris_ReducedRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of royalty rate decrease</link:label>
    <link:label id="lab_cris_ReducedRoyaltyRate_label_en-US" xlink:label="lab_cris_ReducedRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduced Royalty Rate</link:label>
    <link:label id="lab_cris_ReducedRoyaltyRate_documentation_en-US" xlink:label="lab_cris_ReducedRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduced Royalty Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ReducedRoyaltyRate" xlink:href="cris-20210930.xsd#cris_ReducedRoyaltyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_ReducedRoyaltyRate" xlink:to="lab_cris_ReducedRoyaltyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_0a12b217-bb7c-4b18-8d96-14ab955a856b_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_8e579f18-4ba4-4ff3-ad0c-2309c5c895b0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_f5c99142-6153-468b-aed4-fc68bd626b77_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_4946f456-54c9-4520-823c-88552f9d8b7b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and related costs</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_CorporateCommercialPaperStockBondsAndNotesMember_ab8ff76c-e2b6-4910-becf-fe9d4830a219_terseLabel_en-US" xlink:label="lab_cris_CorporateCommercialPaperStockBondsAndNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate commercial paper, bonds and notes</link:label>
    <link:label id="lab_cris_CorporateCommercialPaperStockBondsAndNotesMember_label_en-US" xlink:label="lab_cris_CorporateCommercialPaperStockBondsAndNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Commercial Paper, Stock, Bonds And Notes [Member]</link:label>
    <link:label id="lab_cris_CorporateCommercialPaperStockBondsAndNotesMember_documentation_en-US" xlink:label="lab_cris_CorporateCommercialPaperStockBondsAndNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Commercial Paper, Stock, Bonds And Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CorporateCommercialPaperStockBondsAndNotesMember" xlink:href="cris-20210930.xsd#cris_CorporateCommercialPaperStockBondsAndNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CorporateCommercialPaperStockBondsAndNotesMember" xlink:to="lab_cris_CorporateCommercialPaperStockBondsAndNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_894b5b22-0a74-4271-8522-1dbe734180da_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Assets or Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_914be215-7f4c-4008-8497-bdb767bcf574_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_ChemistryManufacturingAndControlsCosts_8ad3a992-67c8-4024-bc7c-6359c3b0ec92_terseLabel_en-US" xlink:label="lab_cris_ChemistryManufacturingAndControlsCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chemistry, manufacturing and controls costs</link:label>
    <link:label id="lab_cris_ChemistryManufacturingAndControlsCosts_label_en-US" xlink:label="lab_cris_ChemistryManufacturingAndControlsCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chemistry Manufacturing And Controls Costs</link:label>
    <link:label id="lab_cris_ChemistryManufacturingAndControlsCosts_documentation_en-US" xlink:label="lab_cris_ChemistryManufacturingAndControlsCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chemistry Manufacturing And Controls Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ChemistryManufacturingAndControlsCosts" xlink:href="cris-20210930.xsd#cris_ChemistryManufacturingAndControlsCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_ChemistryManufacturingAndControlsCosts" xlink:to="lab_cris_ChemistryManufacturingAndControlsCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6ef12203-284a-4c52-9646-88efa7b3f8d4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_2bab8f5f-53aa-4830-8f53-366cb542cece_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_806cd504-afa3-41e7-8577-b7fe5b4e59a3_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_CollaborationArrangementContingentConsiderationDevelopmentMilestonePayments_96247dde-2e42-44dd-8d81-1fbb53dfdfc7_terseLabel_en-US" xlink:label="lab_cris_CollaborationArrangementContingentConsiderationDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestone payments</link:label>
    <link:label id="lab_cris_CollaborationArrangementContingentConsiderationDevelopmentMilestonePayments_label_en-US" xlink:label="lab_cris_CollaborationArrangementContingentConsiderationDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Contingent Consideration, Development Milestone Payments</link:label>
    <link:label id="lab_cris_CollaborationArrangementContingentConsiderationDevelopmentMilestonePayments_documentation_en-US" xlink:label="lab_cris_CollaborationArrangementContingentConsiderationDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Contingent Consideration, Development Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationArrangementContingentConsiderationDevelopmentMilestonePayments" xlink:href="cris-20210930.xsd#cris_CollaborationArrangementContingentConsiderationDevelopmentMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborationArrangementContingentConsiderationDevelopmentMilestonePayments" xlink:to="lab_cris_CollaborationArrangementContingentConsiderationDevelopmentMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_5e0e61ce-4ee3-4754-a019-e222f44ea315_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, net:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_199facc2-478e-4b49-ae9b-a9ff04170fd2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7ace5ad0-dae7-4e49-8192-39724d078899_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_997bb4a9-1ded-4108-9f21-dc44b853c264_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7722e76a-4570-40f2-a7b2-f9c9edde66a4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_NumberOfPurchasePeriodsPerEnrollmentPeriod_86ee59fd-c878-42cd-b450-2fa34dccc67c_terseLabel_en-US" xlink:label="lab_cris_NumberOfPurchasePeriodsPerEnrollmentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of purchase periods per year</link:label>
    <link:label id="lab_cris_NumberOfPurchasePeriodsPerEnrollmentPeriod_label_en-US" xlink:label="lab_cris_NumberOfPurchasePeriodsPerEnrollmentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Purchase Periods Per Enrollment Period</link:label>
    <link:label id="lab_cris_NumberOfPurchasePeriodsPerEnrollmentPeriod_documentation_en-US" xlink:label="lab_cris_NumberOfPurchasePeriodsPerEnrollmentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of purchase periods per enrollment period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_NumberOfPurchasePeriodsPerEnrollmentPeriod" xlink:href="cris-20210930.xsd#cris_NumberOfPurchasePeriodsPerEnrollmentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_NumberOfPurchasePeriodsPerEnrollmentPeriod" xlink:to="lab_cris_NumberOfPurchasePeriodsPerEnrollmentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_4d1f0189-59df-4ce9-95d9-d6f35331e057_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_7fb5663e-bdf7-4f20-9e82-189f0200b68b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_914b7c55-6667-4ccb-b186-e5f021720f4f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_674feaf3-750f-409d-bd1d-1a1b13e91b3a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_StockSaleAgreementAuthorizedAmount_6704f0be-5f9a-408f-8f29-b435877d63c8_terseLabel_en-US" xlink:label="lab_cris_StockSaleAgreementAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized</link:label>
    <link:label id="lab_cris_StockSaleAgreementAuthorizedAmount_label_en-US" xlink:label="lab_cris_StockSaleAgreementAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Authorized Amount</link:label>
    <link:label id="lab_cris_StockSaleAgreementAuthorizedAmount_documentation_en-US" xlink:label="lab_cris_StockSaleAgreementAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockSaleAgreementAuthorizedAmount" xlink:href="cris-20210930.xsd#cris_StockSaleAgreementAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_StockSaleAgreementAuthorizedAmount" xlink:to="lab_cris_StockSaleAgreementAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_abab2e2e-53ef-4bbe-a7df-2d9fc3c5372e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_fa8f9e6e-0042-450e-acb1-bd4e403daf6a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_558dc9a1-883b-4488-ba65-4ca50084cb80_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_AvailableForSaleSecuritiesDateRange_168fecad-5365-4e49-98af-7b583c3f2e4a_terseLabel_en-US" xlink:label="lab_cris_AvailableForSaleSecuritiesDateRange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of maturities</link:label>
    <link:label id="lab_cris_AvailableForSaleSecuritiesDateRange_label_en-US" xlink:label="lab_cris_AvailableForSaleSecuritiesDateRange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Date Range</link:label>
    <link:label id="lab_cris_AvailableForSaleSecuritiesDateRange_documentation_en-US" xlink:label="lab_cris_AvailableForSaleSecuritiesDateRange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale securities date range.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_AvailableForSaleSecuritiesDateRange" xlink:href="cris-20210930.xsd#cris_AvailableForSaleSecuritiesDateRange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_AvailableForSaleSecuritiesDateRange" xlink:to="lab_cris_AvailableForSaleSecuritiesDateRange" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_333ea03e-5695-413d-96ea-9d9d9b440343_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f98c2e77-be07-49e1-9612-f632ed7269b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and unvested expected to vest at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_039fcf26-77f2-47ce-9b5c-aa00960dff27_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9225f2f7-4d32-4a27-8991-30f0a195e458_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_029fbf08-a140-4d70-9d9c-f5841c198b9a_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_12aa2229-f7e8-42b8-b502-f4c68d9c2838_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare_badb807d-139c-46b6-9f1a-9110934ba770_terseLabel_en-US" xlink:label="lab_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares removed from pool (in shares per share)</link:label>
    <link:label id="lab_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare_label_en-US" xlink:label="lab_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Shares Removed From Available Share Pool, Per Share</link:label>
    <link:label id="lab_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare_documentation_en-US" xlink:label="lab_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Shares Removed From Available Share Pool, Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare" xlink:href="cris-20210930.xsd#cris_SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare" xlink:to="lab_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_f5eb679b-2cd8-4298-b284-7d4bae3e9a26_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d1cacda3-a841-4fe7-a5dc-c2bc9adbc09e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_d8f6cf9c-4a7b-4cb6-84db-567a75db9350_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4b2043bb-ea37-4000-b7a5-9caf540129ad_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_df531f68-e57e-4071-941f-5103bb89eb45_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_b4273561-5546-409e-b3c5-b55a83550e27_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_CollaborationArrangementContingentConsiderationOptionExerciseFee_21a3d752-a1f0-4abc-9525-c428de560aee_terseLabel_en-US" xlink:label="lab_cris_CollaborationArrangementContingentConsiderationOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option exercise fee</link:label>
    <link:label id="lab_cris_CollaborationArrangementContingentConsiderationOptionExerciseFee_label_en-US" xlink:label="lab_cris_CollaborationArrangementContingentConsiderationOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Contingent Consideration, Option Exercise Fee</link:label>
    <link:label id="lab_cris_CollaborationArrangementContingentConsiderationOptionExerciseFee_documentation_en-US" xlink:label="lab_cris_CollaborationArrangementContingentConsiderationOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Contingent Consideration, Option Exercise Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationArrangementContingentConsiderationOptionExerciseFee" xlink:href="cris-20210930.xsd#cris_CollaborationArrangementContingentConsiderationOptionExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborationArrangementContingentConsiderationOptionExerciseFee" xlink:to="lab_cris_CollaborationArrangementContingentConsiderationOptionExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_74deb568-01e8-4309-98ea-1a55d9c1b2c1_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_ad3987be-bff2-4ce7-9f05-3848e1ee3af5_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amortization of premiums and discounts on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_f703b8ed-9fbb-44f9-b6ea-ea71f3caab60_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_5bbac153-8f95-49b9-afb8-64e3e798eb66_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_e7091ad5-bf11-4819-ad17-e429737b5d0a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under Employee Stock Purchase Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0a258c89-fce4-4080-be14-7461c82f2b4a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_77ad5f2a-7edf-44ac-bcd8-d5fc73b61a5f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5e574aa4-a5e3-48eb-a2fa-0910749177e5_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, restricted cash and restricted cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_630813e3-9e40-4e76-bfe6-18f5b1e3d257_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_c2d29a8b-45a9-43d4-b219-f03ae9635b3d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_ContraRevenueMember_0c3126f3-8ae0-4460-9d13-cdb6c3500d8a_terseLabel_en-US" xlink:label="lab_cris_ContraRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contra revenue, net</link:label>
    <link:label id="lab_cris_ContraRevenueMember_label_en-US" xlink:label="lab_cris_ContraRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contra Revenue [Member]</link:label>
    <link:label id="lab_cris_ContraRevenueMember_documentation_en-US" xlink:label="lab_cris_ContraRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contra Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ContraRevenueMember" xlink:href="cris-20210930.xsd#cris_ContraRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_ContraRevenueMember" xlink:to="lab_cris_ContraRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_6a695f21-ad84-46c3-94cf-0e5c21080190_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk -free Interest rate (maximum)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_5d9f900b-e616-4dbd-951d-ee31bee16039_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_3076a333-9245-4e38-9ed3-f7d88d43f793_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_2d85164d-614a-41ae-9e14-35527ac582a8_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c72e6f68-e48c-4ea4-b477-d3638aa68ff9_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_837936a2-e0a2-45e4-aa06-fd1eb7c78af3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_04905a28-6935-4a32-ab7c-14d899e507ba_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_db1b5e33-a3a3-4759-afbd-eae72f022d21_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_cab8032c-0768-4cd0-af09-8bbb1a218112_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5d04c67b-6405-4bdf-9cc1-96943b455d2a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares (diluted) (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_5e59c1a5-80ca-47d9-8494-1d60b1d863ac_terseLabel_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Corrections and Prior Period Adjustments Restatement [Line Items]</link:label>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_label_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Corrections and Prior Period Adjustments Restatement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_0b03ba89-ce8f-4001-8498-6747c7ebd9c0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_AgreementWithHeadOfResearchAndDevelopmentMember_85c7aadd-175c-4f7a-acd6-5799aabd6257_terseLabel_en-US" xlink:label="lab_cris_AgreementWithHeadOfResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement With Head of Research and Development</link:label>
    <link:label id="lab_cris_AgreementWithHeadOfResearchAndDevelopmentMember_label_en-US" xlink:label="lab_cris_AgreementWithHeadOfResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement With Head Of Research And Development [Member]</link:label>
    <link:label id="lab_cris_AgreementWithHeadOfResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_cris_AgreementWithHeadOfResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement With Head Of Research And Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_AgreementWithHeadOfResearchAndDevelopmentMember" xlink:href="cris-20210930.xsd#cris_AgreementWithHeadOfResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_AgreementWithHeadOfResearchAndDevelopmentMember" xlink:to="lab_cris_AgreementWithHeadOfResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_5e7588be-ec37-4d6d-bff9-b798301c5166_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_DemandSalesAgreementMember_ec0c2203-6c91-4156-918e-3786a297fce0_terseLabel_en-US" xlink:label="lab_cris_DemandSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Demand Sales Agreement</link:label>
    <link:label id="lab_cris_DemandSalesAgreementMember_label_en-US" xlink:label="lab_cris_DemandSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Demand Sales Agreement [Member]</link:label>
    <link:label id="lab_cris_DemandSalesAgreementMember_documentation_en-US" xlink:label="lab_cris_DemandSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Demand Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_DemandSalesAgreementMember" xlink:href="cris-20210930.xsd#cris_DemandSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_DemandSalesAgreementMember" xlink:to="lab_cris_DemandSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_1a897b34-3a4d-4bd6-81b7-e4e52bf32c56_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_e40c5d8b-412e-45d6-b9b5-613785d403a2_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_709a4fce-5b86-4e53-a121-32d479ee82e8_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_5bbf9972-a7b6-4cfc-8536-7beb601487da_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_AmendedAndRestatedTwoThousandTenStockIncentivePlanMember_3b1bec3b-f45a-494b-8f7d-73aee7e50836_terseLabel_en-US" xlink:label="lab_cris_AmendedAndRestatedTwoThousandTenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated 2010 Stock Incentive Plan</link:label>
    <link:label id="lab_cris_AmendedAndRestatedTwoThousandTenStockIncentivePlanMember_label_en-US" xlink:label="lab_cris_AmendedAndRestatedTwoThousandTenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated Two Thousand Ten Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_cris_AmendedAndRestatedTwoThousandTenStockIncentivePlanMember_documentation_en-US" xlink:label="lab_cris_AmendedAndRestatedTwoThousandTenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and restated two thousand ten stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_AmendedAndRestatedTwoThousandTenStockIncentivePlanMember" xlink:href="cris-20210930.xsd#cris_AmendedAndRestatedTwoThousandTenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_AmendedAndRestatedTwoThousandTenStockIncentivePlanMember" xlink:to="lab_cris_AmendedAndRestatedTwoThousandTenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_17cfd6bd-9c51-4387-8a06-87db38b9d03c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_PaymentsforCollaborativeArrangementstoDate_f0246f5b-5e4f-4399-8605-399f41489184_terseLabel_en-US" xlink:label="lab_cris_PaymentsforCollaborativeArrangementstoDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments made under collaboration arrangements</link:label>
    <link:label id="lab_cris_PaymentsforCollaborativeArrangementstoDate_label_en-US" xlink:label="lab_cris_PaymentsforCollaborativeArrangementstoDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Collaborative Arrangements to Date</link:label>
    <link:label id="lab_cris_PaymentsforCollaborativeArrangementstoDate_documentation_en-US" xlink:label="lab_cris_PaymentsforCollaborativeArrangementstoDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments made under collaborative arrangements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_PaymentsforCollaborativeArrangementstoDate" xlink:href="cris-20210930.xsd#cris_PaymentsforCollaborativeArrangementstoDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_PaymentsforCollaborativeArrangementstoDate" xlink:to="lab_cris_PaymentsforCollaborativeArrangementstoDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_62e00c79-c946-4919-92df-265cf57e6139_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner_49c75a90-381b-4e67-a2f0-0517a78119f9_terseLabel_en-US" xlink:label="lab_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount received for specified clinical development and regulatory objectives</link:label>
    <link:label id="lab_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner_label_en-US" xlink:label="lab_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Contingent Consideration Received From Partner</link:label>
    <link:label id="lab_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner_documentation_en-US" xlink:label="lab_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement contingent consideration received from partner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner" xlink:href="cris-20210930.xsd#cris_CollaborationAgreementContingentConsiderationReceivedFromPartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner" xlink:to="lab_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OfficerMember_93cc6213-fa78-4b1e-88c4-8cc5ebcdf0fd_terseLabel_en-US" xlink:label="lab_srt_OfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Officer</link:label>
    <link:label id="lab_srt_OfficerMember_label_en-US" xlink:label="lab_srt_OfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OfficerMember" xlink:to="lab_srt_OfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_b6787151-b033-4b8c-b3cf-7e4244af717d_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_068c2556-760c-4027-83b7-f05d7c6f3c89_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_da8f515a-fcff-4ce1-8268-24ff6a3bd8cf_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_46026f51-521e-4946-bc0a-b9fe8cfa60e3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4b7170ea-387e-46ca-b5ea-7ae896b6108d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1a4ac98e-33bd-49ae-80f0-9afbe1f70f6a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_75590d0d-036a-432b-8e84-fb8e5126f5b4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonmonetaryTransactionsAbstract_a851c935-147c-4071-908a-cd8fc0c7d143_terseLabel_en-US" xlink:label="lab_us-gaap_NonmonetaryTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonmonetary Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_NonmonetaryTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_NonmonetaryTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonmonetary Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonmonetaryTransactionsAbstract" xlink:to="lab_us-gaap_NonmonetaryTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4eca70fe-18bf-4c5b-a944-7d9cf6b3719e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f2507c0d-1e0c-4f10-8f18-7acf4cfcb0b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_443130a7-33ba-4bb7-b50e-260f6a08c22b_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_PaymentsOfFutureRoyaltyLiability_546cb9a5-4dbe-4c38-8eb1-f3fc32828b68_negatedLabel_en-US" xlink:label="lab_cris_PaymentsOfFutureRoyaltyLiability" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: payments to Oberland Capital, LLC</link:label>
    <link:label id="lab_cris_PaymentsOfFutureRoyaltyLiability_label_en-US" xlink:label="lab_cris_PaymentsOfFutureRoyaltyLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Future Royalty Liability</link:label>
    <link:label id="lab_cris_PaymentsOfFutureRoyaltyLiability_documentation_en-US" xlink:label="lab_cris_PaymentsOfFutureRoyaltyLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Future Royalty Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_PaymentsOfFutureRoyaltyLiability" xlink:href="cris-20210930.xsd#cris_PaymentsOfFutureRoyaltyLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_PaymentsOfFutureRoyaltyLiability" xlink:to="lab_cris_PaymentsOfFutureRoyaltyLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_25caaf81-1641-493c-8709-dc1a6f5fac44_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e6487045-29d6-447e-a8dd-e3983610e43b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_db201d51-c5bb-437f-9303-f453e7f5a08b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_RoyaltyPurchaseAgreementTermsPurchaserDefaultOptionPeriod_6221d703-d608-4f5c-ab1c-417fec880dca_terseLabel_en-US" xlink:label="lab_cris_RoyaltyPurchaseAgreementTermsPurchaserDefaultOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchaser default option period</link:label>
    <link:label id="lab_cris_RoyaltyPurchaseAgreementTermsPurchaserDefaultOptionPeriod_label_en-US" xlink:label="lab_cris_RoyaltyPurchaseAgreementTermsPurchaserDefaultOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Terms, Purchaser Default Option Period</link:label>
    <link:label id="lab_cris_RoyaltyPurchaseAgreementTermsPurchaserDefaultOptionPeriod_documentation_en-US" xlink:label="lab_cris_RoyaltyPurchaseAgreementTermsPurchaserDefaultOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Terms, Purchaser Default Option Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyPurchaseAgreementTermsPurchaserDefaultOptionPeriod" xlink:href="cris-20210930.xsd#cris_RoyaltyPurchaseAgreementTermsPurchaserDefaultOptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_RoyaltyPurchaseAgreementTermsPurchaserDefaultOptionPeriod" xlink:to="lab_cris_RoyaltyPurchaseAgreementTermsPurchaserDefaultOptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_f8cfdb00-cf53-4d33-9b03-df2b7b10e6b0_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_e2bfe499-7318-48d9-8a35-241a66a47369_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and unvested expected to vest at end of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_bba14043-8fa1-4f48-bfd3-a15eb8d431a7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_NonCashImputedInterestExpenseNetOfImputedInterest_0dad7265-3863-495c-98ff-6faacb0e77df_terseLabel_en-US" xlink:label="lab_cris_NonCashImputedInterestExpenseNetOfImputedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash imputed interest expense related to the sale of future royalties</link:label>
    <link:label id="lab_cris_NonCashImputedInterestExpenseNetOfImputedInterest_label_en-US" xlink:label="lab_cris_NonCashImputedInterestExpenseNetOfImputedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Imputed Interest Expense, Net Of Imputed Interest</link:label>
    <link:label id="lab_cris_NonCashImputedInterestExpenseNetOfImputedInterest_documentation_en-US" xlink:label="lab_cris_NonCashImputedInterestExpenseNetOfImputedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Imputed Interest Expense, Net Of Imputed Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_NonCashImputedInterestExpenseNetOfImputedInterest" xlink:href="cris-20210930.xsd#cris_NonCashImputedInterestExpenseNetOfImputedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_NonCashImputedInterestExpenseNetOfImputedInterest" xlink:to="lab_cris_NonCashImputedInterestExpenseNetOfImputedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_a13ec430-8999-426e-8042-493a06f63314_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2bab3dd1-8692-44d9-a19e-4de9ff134bc1_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_StockPurchaseProgramAuthorizedAmount_8eea7b62-9536-42c3-9352-094d80c24f91_terseLabel_en-US" xlink:label="lab_cris_StockPurchaseProgramAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized amount of stock repurchase</link:label>
    <link:label id="lab_cris_StockPurchaseProgramAuthorizedAmount_label_en-US" xlink:label="lab_cris_StockPurchaseProgramAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Program, Authorized Amount</link:label>
    <link:label id="lab_cris_StockPurchaseProgramAuthorizedAmount_documentation_en-US" xlink:label="lab_cris_StockPurchaseProgramAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockPurchaseProgramAuthorizedAmount" xlink:href="cris-20210930.xsd#cris_StockPurchaseProgramAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_StockPurchaseProgramAuthorizedAmount" xlink:to="lab_cris_StockPurchaseProgramAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_StockPurchaseProgramPricePeriod_ca634d95-2f21-4c85-b8d5-838ae20e5b4c_terseLabel_en-US" xlink:label="lab_cris_StockPurchaseProgramPricePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase program price, period</link:label>
    <link:label id="lab_cris_StockPurchaseProgramPricePeriod_label_en-US" xlink:label="lab_cris_StockPurchaseProgramPricePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Program Price, Period</link:label>
    <link:label id="lab_cris_StockPurchaseProgramPricePeriod_documentation_en-US" xlink:label="lab_cris_StockPurchaseProgramPricePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Program Price, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockPurchaseProgramPricePeriod" xlink:href="cris-20210930.xsd#cris_StockPurchaseProgramPricePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_StockPurchaseProgramPricePeriod" xlink:to="lab_cris_StockPurchaseProgramPricePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_d2d64fd0-edcb-4390-9712-2ff3633663c0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_OfficersAndNonEmployeeDirectorsMember_588d2027-58fd-42a2-86f6-cfc721570408_terseLabel_en-US" xlink:label="lab_cris_OfficersAndNonEmployeeDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Officers and Non-Employee Directors</link:label>
    <link:label id="lab_cris_OfficersAndNonEmployeeDirectorsMember_label_en-US" xlink:label="lab_cris_OfficersAndNonEmployeeDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Officers And Non Employee Directors [Member]</link:label>
    <link:label id="lab_cris_OfficersAndNonEmployeeDirectorsMember_documentation_en-US" xlink:label="lab_cris_OfficersAndNonEmployeeDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Officers And Non Employee Directors [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_OfficersAndNonEmployeeDirectorsMember" xlink:href="cris-20210930.xsd#cris_OfficersAndNonEmployeeDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_OfficersAndNonEmployeeDirectorsMember" xlink:to="lab_cris_OfficersAndNonEmployeeDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_918e8c2c-7ea5-4d1f-8614-4e7502af93a1_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_EpiCurePharmaceuticalsInc.Member_89545e09-0cbb-4510-9b1a-f79a6739d3b2_terseLabel_en-US" xlink:label="lab_cris_EpiCurePharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epi-Cure Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_cris_EpiCurePharmaceuticalsInc.Member_label_en-US" xlink:label="lab_cris_EpiCurePharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epi-Cure Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_cris_EpiCurePharmaceuticalsInc.Member_documentation_en-US" xlink:label="lab_cris_EpiCurePharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epi-Cure Pharmaceuticals, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_EpiCurePharmaceuticalsInc.Member" xlink:href="cris-20210930.xsd#cris_EpiCurePharmaceuticalsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_EpiCurePharmaceuticalsInc.Member" xlink:to="lab_cris_EpiCurePharmaceuticalsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b58a866e-1c43-4e53-9519-e115b33b1abd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a19c80ff-9e37-4be8-aeae-42d6b0b54aaa_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2bfb098f-0487-4911-8580-23e9722823bf_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost, net of estimated forfeitures</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_68836c80-7c69-4ed9-8e27-8831b7a3b332_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_NumberOfSharesAwardedUnderStockValueLessThanSpecificPercentageOfFairMarketValue_e2e7e103-bbbb-4858-812a-dd07f07f2bf1_terseLabel_en-US" xlink:label="lab_cris_NumberOfSharesAwardedUnderStockValueLessThanSpecificPercentageOfFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares awarded under plan (in shares)</link:label>
    <link:label id="lab_cris_NumberOfSharesAwardedUnderStockValueLessThanSpecificPercentageOfFairMarketValue_label_en-US" xlink:label="lab_cris_NumberOfSharesAwardedUnderStockValueLessThanSpecificPercentageOfFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Awarded Under Stock Value Less Than Specific Percentage Of Fair Market Value</link:label>
    <link:label id="lab_cris_NumberOfSharesAwardedUnderStockValueLessThanSpecificPercentageOfFairMarketValue_documentation_en-US" xlink:label="lab_cris_NumberOfSharesAwardedUnderStockValueLessThanSpecificPercentageOfFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares awarded per share under stock value less than specific percentage of fair market value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_NumberOfSharesAwardedUnderStockValueLessThanSpecificPercentageOfFairMarketValue" xlink:href="cris-20210930.xsd#cris_NumberOfSharesAwardedUnderStockValueLessThanSpecificPercentageOfFairMarketValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_NumberOfSharesAwardedUnderStockValueLessThanSpecificPercentageOfFairMarketValue" xlink:to="lab_cris_NumberOfSharesAwardedUnderStockValueLessThanSpecificPercentageOfFairMarketValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_1849f214-7835-48ee-a389-ba7975a3467e_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_ImmuNextMember_26365ed0-e18c-45a0-b2c8-ba1b1ce52671_terseLabel_en-US" xlink:label="lab_cris_ImmuNextMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ImmuNext</link:label>
    <link:label id="lab_cris_ImmuNextMember_label_en-US" xlink:label="lab_cris_ImmuNextMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ImmuNext [Member]</link:label>
    <link:label id="lab_cris_ImmuNextMember_documentation_en-US" xlink:label="lab_cris_ImmuNextMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ImmuNext [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ImmuNextMember" xlink:href="cris-20210930.xsd#cris_ImmuNextMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_ImmuNextMember" xlink:to="lab_cris_ImmuNextMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_06a927ec-74d4-4ee7-8534-97cd4a359c73_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3ca4d48e-af1f-455d-940f-5c104e064716_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_eac318ca-fda9-4fbf-b4ba-1a21a3f210df_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_286ecf5f-212a-4031-b6c2-f8305a57a5ae_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_a824abf6-474b-4fc3-a7a1-365bf3262604_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization_bc7778d1-feea-4f3d-8fe2-8042a5eb0ec0_terseLabel_en-US" xlink:label="lab_cris_RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of capitalized issuance costs</link:label>
    <link:label id="lab_cris_RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization_label_en-US" xlink:label="lab_cris_RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Issuance Costs Capitalized, Amortization</link:label>
    <link:label id="lab_cris_RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization_documentation_en-US" xlink:label="lab_cris_RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Issuance Costs Capitalized, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization" xlink:href="cris-20210930.xsd#cris_RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization" xlink:to="lab_cris_RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2e061d6f-4d9c-446f-a3c1-0e4868b92c0f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cris_RestrictedStockRSUsOtherStockBasedAwardsOrPerformanceAwardsMember_41bebe41-9ca4-4459-82fc-510cf0578b4b_terseLabel_en-US" xlink:label="lab_cris_RestrictedStockRSUsOtherStockBasedAwardsOrPerformanceAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock, RSUs, Other Stock-Based Awards, or Performance Awards</link:label>
    <link:label id="lab_cris_RestrictedStockRSUsOtherStockBasedAwardsOrPerformanceAwardsMember_label_en-US" xlink:label="lab_cris_RestrictedStockRSUsOtherStockBasedAwardsOrPerformanceAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock, RSUs, Other Stock-Based Awards, Or Performance Awards [Member]</link:label>
    <link:label id="lab_cris_RestrictedStockRSUsOtherStockBasedAwardsOrPerformanceAwardsMember_documentation_en-US" xlink:label="lab_cris_RestrictedStockRSUsOtherStockBasedAwardsOrPerformanceAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock, RSUs, Other Stock-Based Awards, Or Performance Awards [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RestrictedStockRSUsOtherStockBasedAwardsOrPerformanceAwardsMember" xlink:href="cris-20210930.xsd#cris_RestrictedStockRSUsOtherStockBasedAwardsOrPerformanceAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_RestrictedStockRSUsOtherStockBasedAwardsOrPerformanceAwardsMember" xlink:to="lab_cris_RestrictedStockRSUsOtherStockBasedAwardsOrPerformanceAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_f9b527cf-5bc8-4506-a86a-ce5fc4149444_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and unvested expected to vest at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>cris-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:67cd88cd-4961-40fd-b7ee-f0e04fb032e1,g:de03038a-bcb1-460d-82b7-20721bd560b4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.curis.com/role/Cover" xlink:type="simple" xlink:href="cris-20210930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_15708572-e7d1-4b88-bd97-5fe1bf0ae411" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_DocumentType_15708572-e7d1-4b88-bd97-5fe1bf0ae411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_06d2fbe2-b1ab-4e4d-b244-df316f45f32f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_DocumentQuarterlyReport_06d2fbe2-b1ab-4e4d-b244-df316f45f32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ada82682-2fba-4086-8c86-dff12ff9fde8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_DocumentPeriodEndDate_ada82682-2fba-4086-8c86-dff12ff9fde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_d5e06776-0276-41c1-919a-00d650a2e8be" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_DocumentTransitionReport_d5e06776-0276-41c1-919a-00d650a2e8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_895583e6-d8be-43e7-9409-be31f0a77779" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_EntityFileNumber_895583e6-d8be-43e7-9409-be31f0a77779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_88c756e5-e9a7-43ce-9b23-c6ee2e9b940a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_EntityRegistrantName_88c756e5-e9a7-43ce-9b23-c6ee2e9b940a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b1788ea9-5da5-4478-ab30-fa1593b61a55" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b1788ea9-5da5-4478-ab30-fa1593b61a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_2ef7e7a6-fa62-46b6-bd4d-31c2aae328d9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_EntityTaxIdentificationNumber_2ef7e7a6-fa62-46b6-bd4d-31c2aae328d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3adc3607-3b6b-4498-ac5c-1c655414e7e8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_EntityAddressAddressLine1_3adc3607-3b6b-4498-ac5c-1c655414e7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_9e3272c5-1d22-45d9-b05c-92dc2509e515" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_EntityAddressAddressLine2_9e3272c5-1d22-45d9-b05c-92dc2509e515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_7b63ef50-30d5-4b3d-92b7-c1a57c12fa5d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_EntityAddressCityOrTown_7b63ef50-30d5-4b3d-92b7-c1a57c12fa5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_061df172-bd2a-4eff-91d9-4548dc45abf3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_EntityAddressStateOrProvince_061df172-bd2a-4eff-91d9-4548dc45abf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_fd830050-c31e-4c2c-81cf-282d56b3dafa" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_EntityAddressPostalZipCode_fd830050-c31e-4c2c-81cf-282d56b3dafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_cfa6e960-e828-42ef-8525-47be8edecbac" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_CityAreaCode_cfa6e960-e828-42ef-8525-47be8edecbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_6eb2e3c6-e2c7-4e1c-bc26-8c7a28269614" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_LocalPhoneNumber_6eb2e3c6-e2c7-4e1c-bc26-8c7a28269614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_0c2c8d45-5f71-4a4f-ae65-cfad75ba263c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_Security12bTitle_0c2c8d45-5f71-4a4f-ae65-cfad75ba263c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3518a623-66bc-4450-8037-1d58d18cc3ee" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_TradingSymbol_3518a623-66bc-4450-8037-1d58d18cc3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_455617c4-1ae5-440b-8eb2-81ccca07c156" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_SecurityExchangeName_455617c4-1ae5-440b-8eb2-81ccca07c156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_cc302b2f-6160-4dcd-931c-a4def7321978" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_EntityCurrentReportingStatus_cc302b2f-6160-4dcd-931c-a4def7321978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_af4fc3e8-bf66-41b6-8916-0dc7cde6f6ff" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_EntityInteractiveDataCurrent_af4fc3e8-bf66-41b6-8916-0dc7cde6f6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_40abde0b-12e7-4af0-b778-97d852744e95" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_EntityFilerCategory_40abde0b-12e7-4af0-b778-97d852744e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_d5bb34d1-f3d8-4bcf-afdb-b77bf779b1a1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_EntitySmallBusiness_d5bb34d1-f3d8-4bcf-afdb-b77bf779b1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_308d9117-ac1d-4f99-b849-a842e89e43c8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_EntityEmergingGrowthCompany_308d9117-ac1d-4f99-b849-a842e89e43c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_6529d857-e6fd-47d6-8f0a-f393edb1bd3a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_EntityShellCompany_6529d857-e6fd-47d6-8f0a-f393edb1bd3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_5fe969e7-4792-47e3-9531-036ab3b4be15" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_5fe969e7-4792-47e3-9531-036ab3b4be15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3cead1ea-c8ca-4294-900e-e044a1683914" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_AmendmentFlag_3cead1ea-c8ca-4294-900e-e044a1683914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_277f9bc9-093d-428c-bebd-ece333434065" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_DocumentFiscalYearFocus_277f9bc9-093d-428c-bebd-ece333434065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_81cb1941-3051-4f0b-ac1f-0a49e49e1365" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_DocumentFiscalPeriodFocus_81cb1941-3051-4f0b-ac1f-0a49e49e1365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_503a71ac-8d4f-4c55-b4f2-6421c3cf6176" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_EntityCentralIndexKey_503a71ac-8d4f-4c55-b4f2-6421c3cf6176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_193f4e47-22c1-4051-aa8b-e15c4b6b5dd9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6c5dd36-a864-47eb-8c4f-6e3bc9756f6b" xlink:to="loc_dei_CurrentFiscalYearEndDate_193f4e47-22c1-4051-aa8b-e15c4b6b5dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="cris-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_77c512c4-7fc6-4635-8ce2-e6b3997d5bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_dbfc5073-1c63-4ebf-98ee-68f57f5e1490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_77c512c4-7fc6-4635-8ce2-e6b3997d5bc0" xlink:to="loc_us-gaap_AssetsAbstract_dbfc5073-1c63-4ebf-98ee-68f57f5e1490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_08f4a1f7-4980-4625-bdcb-b377bd71963c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dbfc5073-1c63-4ebf-98ee-68f57f5e1490" xlink:to="loc_us-gaap_AssetsCurrentAbstract_08f4a1f7-4980-4625-bdcb-b377bd71963c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4e15aea9-f389-421f-ae41-8664a89a91d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08f4a1f7-4980-4625-bdcb-b377bd71963c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4e15aea9-f389-421f-ae41-8664a89a91d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_b9fcaeef-54f8-4473-a9f4-be954bdd34c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08f4a1f7-4980-4625-bdcb-b377bd71963c" xlink:to="loc_us-gaap_ShortTermInvestments_b9fcaeef-54f8-4473-a9f4-be954bdd34c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_89d2b32a-4203-4872-9c00-3d4c89d1f197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08f4a1f7-4980-4625-bdcb-b377bd71963c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_89d2b32a-4203-4872-9c00-3d4c89d1f197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d2459fb4-7d48-4ffd-b1aa-dded7b99c2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08f4a1f7-4980-4625-bdcb-b377bd71963c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d2459fb4-7d48-4ffd-b1aa-dded7b99c2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_00671168-7357-434b-85da-44fd6b01564c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08f4a1f7-4980-4625-bdcb-b377bd71963c" xlink:to="loc_us-gaap_AssetsCurrent_00671168-7357-434b-85da-44fd6b01564c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_37e1e45d-cd5a-4b90-a8da-e70ac02b34a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dbfc5073-1c63-4ebf-98ee-68f57f5e1490" xlink:to="loc_us-gaap_LongTermInvestments_37e1e45d-cd5a-4b90-a8da-e70ac02b34a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c60d70f5-a345-4279-a8c6-2436b53e9c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dbfc5073-1c63-4ebf-98ee-68f57f5e1490" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c60d70f5-a345-4279-a8c6-2436b53e9c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_c52ee959-6ab8-4dce-ab47-8ebb0e1bf31c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dbfc5073-1c63-4ebf-98ee-68f57f5e1490" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_c52ee959-6ab8-4dce-ab47-8ebb0e1bf31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5a83cc73-e4cd-44ec-bbed-d6c94e5dc6f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dbfc5073-1c63-4ebf-98ee-68f57f5e1490" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5a83cc73-e4cd-44ec-bbed-d6c94e5dc6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1e067c3e-0523-4caf-909b-0eb28498b085" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dbfc5073-1c63-4ebf-98ee-68f57f5e1490" xlink:to="loc_us-gaap_Goodwill_1e067c3e-0523-4caf-909b-0eb28498b085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_21946f23-b60c-4d8a-a634-675141d5cd87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dbfc5073-1c63-4ebf-98ee-68f57f5e1490" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_21946f23-b60c-4d8a-a634-675141d5cd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3043257e-161b-4fb4-8d88-b96dd6f8a47f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dbfc5073-1c63-4ebf-98ee-68f57f5e1490" xlink:to="loc_us-gaap_Assets_3043257e-161b-4fb4-8d88-b96dd6f8a47f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f627188c-a08d-49fc-be83-adef98fd4afd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_77c512c4-7fc6-4635-8ce2-e6b3997d5bc0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f627188c-a08d-49fc-be83-adef98fd4afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_fb8ee05a-4091-47ea-a3da-0ab3f850e026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f627188c-a08d-49fc-be83-adef98fd4afd" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_fb8ee05a-4091-47ea-a3da-0ab3f850e026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f8115b72-26c6-4c8b-96c0-a4409dbbcde2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fb8ee05a-4091-47ea-a3da-0ab3f850e026" xlink:to="loc_us-gaap_AccountsPayableCurrent_f8115b72-26c6-4c8b-96c0-a4409dbbcde2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_fc99b029-f839-4765-8807-4d6925ba9b30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fb8ee05a-4091-47ea-a3da-0ab3f850e026" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_fc99b029-f839-4765-8807-4d6925ba9b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5806528a-39a1-4cd6-bf21-99303415d566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fb8ee05a-4091-47ea-a3da-0ab3f850e026" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5806528a-39a1-4cd6-bf21-99303415d566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_790ee444-9e91-4be5-8953-3fad8c497335" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fb8ee05a-4091-47ea-a3da-0ab3f850e026" xlink:to="loc_us-gaap_LongTermDebtCurrent_790ee444-9e91-4be5-8953-3fad8c497335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5b2271e7-8622-4544-8253-00dadbf66b08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fb8ee05a-4091-47ea-a3da-0ab3f850e026" xlink:to="loc_us-gaap_LiabilitiesCurrent_5b2271e7-8622-4544-8253-00dadbf66b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d2ffd0c9-cbe0-4ae0-a5e3-2c5700d14723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f627188c-a08d-49fc-be83-adef98fd4afd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d2ffd0c9-cbe0-4ae0-a5e3-2c5700d14723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyGuaranteesCommitmentsAmountNoncurrent_97180c5b-9313-45da-a807-23d67320683d" xlink:href="cris-20210930.xsd#cris_RoyaltyGuaranteesCommitmentsAmountNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f627188c-a08d-49fc-be83-adef98fd4afd" xlink:to="loc_cris_RoyaltyGuaranteesCommitmentsAmountNoncurrent_97180c5b-9313-45da-a807-23d67320683d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d8168032-983b-4ac1-ba89-6f6c29d95b23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f627188c-a08d-49fc-be83-adef98fd4afd" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d8168032-983b-4ac1-ba89-6f6c29d95b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_57786ed4-bfd1-4683-b2db-2ae6ef2aafe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f627188c-a08d-49fc-be83-adef98fd4afd" xlink:to="loc_us-gaap_Liabilities_57786ed4-bfd1-4683-b2db-2ae6ef2aafe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_7485ed59-ced0-41ec-96e8-acda36556dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f627188c-a08d-49fc-be83-adef98fd4afd" xlink:to="loc_us-gaap_StockholdersEquityAbstract_7485ed59-ced0-41ec-96e8-acda36556dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_25f69dd4-5c47-44e6-939e-4df694c5581e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7485ed59-ced0-41ec-96e8-acda36556dfe" xlink:to="loc_us-gaap_CommonStockValue_25f69dd4-5c47-44e6-939e-4df694c5581e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f4986050-0e18-4694-bb1b-f949f08e3902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7485ed59-ced0-41ec-96e8-acda36556dfe" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f4986050-0e18-4694-bb1b-f949f08e3902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0f3eceb3-da64-4311-bd59-dd6aa0f958af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7485ed59-ced0-41ec-96e8-acda36556dfe" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0f3eceb3-da64-4311-bd59-dd6aa0f958af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_617ee3fe-e916-4e45-877a-bda0f918ada6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7485ed59-ced0-41ec-96e8-acda36556dfe" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_617ee3fe-e916-4e45-877a-bda0f918ada6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ab34ba7c-4dbc-4f93-8024-973cfdbe6965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7485ed59-ced0-41ec-96e8-acda36556dfe" xlink:to="loc_us-gaap_StockholdersEquity_ab34ba7c-4dbc-4f93-8024-973cfdbe6965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b73b5d9a-49b8-4802-9d27-5071a43d884e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f627188c-a08d-49fc-be83-adef98fd4afd" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_b73b5d9a-49b8-4802-9d27-5071a43d884e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="cris-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d6071175-23c2-47dd-8637-d00cde8cba91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_88ce5044-5bac-4187-bbc5-cb19eee9e705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d6071175-23c2-47dd-8637-d00cde8cba91" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_88ce5044-5bac-4187-bbc5-cb19eee9e705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e4a32302-cf3e-480f-b675-742e8776c9d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d6071175-23c2-47dd-8637-d00cde8cba91" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e4a32302-cf3e-480f-b675-742e8776c9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c2998a40-6daf-446d-8fe8-0066e963389c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d6071175-23c2-47dd-8637-d00cde8cba91" xlink:to="loc_us-gaap_CommonStockSharesIssued_c2998a40-6daf-446d-8fe8-0066e963389c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d2a93a96-7fcc-4ec9-9a20-04e59cef43db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d6071175-23c2-47dd-8637-d00cde8cba91" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d2a93a96-7fcc-4ec9-9a20-04e59cef43db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="cris-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_5bd756ea-b797-42f4-9dfc-53560dba6161" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8a14d3e3-1244-47a2-9a72-9f971361313e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5bd756ea-b797-42f4-9dfc-53560dba6161" xlink:to="loc_us-gaap_StatementTable_8a14d3e3-1244-47a2-9a72-9f971361313e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_90326587-7ac7-4bb6-a62b-80a27390ae0a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8a14d3e3-1244-47a2-9a72-9f971361313e" xlink:to="loc_srt_ProductOrServiceAxis_90326587-7ac7-4bb6-a62b-80a27390ae0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dbfd043f-63a7-4146-adaf-fd02e1c9955b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_90326587-7ac7-4bb6-a62b-80a27390ae0a" xlink:to="loc_srt_ProductsAndServicesDomain_dbfd043f-63a7-4146-adaf-fd02e1c9955b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_GrossRoyaltyRevenueMember_538f5f5f-48cf-4c9a-ae00-5781e4aebabf" xlink:href="cris-20210930.xsd#cris_GrossRoyaltyRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dbfd043f-63a7-4146-adaf-fd02e1c9955b" xlink:to="loc_cris_GrossRoyaltyRevenueMember_538f5f5f-48cf-4c9a-ae00-5781e4aebabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_OtherRevenueMember_1db9a3db-eb07-453e-9d83-3c92417f517a" xlink:href="cris-20210930.xsd#cris_OtherRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dbfd043f-63a7-4146-adaf-fd02e1c9955b" xlink:to="loc_cris_OtherRevenueMember_1db9a3db-eb07-453e-9d83-3c92417f517a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ContraRevenueMember_fd951ac3-ac25-43bd-ae35-b871bc68d5d1" xlink:href="cris-20210930.xsd#cris_ContraRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dbfd043f-63a7-4146-adaf-fd02e1c9955b" xlink:to="loc_cris_ContraRevenueMember_fd951ac3-ac25-43bd-ae35-b871bc68d5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_913084be-37d9-432c-98bf-2c21b81fdc28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8a14d3e3-1244-47a2-9a72-9f971361313e" xlink:to="loc_us-gaap_StatementLineItems_913084be-37d9-432c-98bf-2c21b81fdc28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_c406788a-cf3d-443a-ab43-76f297f40017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_913084be-37d9-432c-98bf-2c21b81fdc28" xlink:to="loc_us-gaap_RevenuesAbstract_c406788a-cf3d-443a-ab43-76f297f40017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_300f9dea-50c1-4300-a78d-bd020b6f741f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_c406788a-cf3d-443a-ab43-76f297f40017" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_300f9dea-50c1-4300-a78d-bd020b6f741f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_658e693f-9117-4e2b-9826-bd47fa4fc6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_913084be-37d9-432c-98bf-2c21b81fdc28" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_658e693f-9117-4e2b-9826-bd47fa4fc6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_236a0da0-9b8e-4f4f-a6c6-90af8804c742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_658e693f-9117-4e2b-9826-bd47fa4fc6a6" xlink:to="loc_us-gaap_RoyaltyExpense_236a0da0-9b8e-4f4f-a6c6-90af8804c742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_30694a01-276d-48ad-b1c7-f7ddf1312b46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_658e693f-9117-4e2b-9826-bd47fa4fc6a6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_30694a01-276d-48ad-b1c7-f7ddf1312b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_e5562066-92d1-4b31-a0c8-f266a52da727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_658e693f-9117-4e2b-9826-bd47fa4fc6a6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_e5562066-92d1-4b31-a0c8-f266a52da727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_290600e0-838b-4f30-a4d8-3426bf3e5e20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_658e693f-9117-4e2b-9826-bd47fa4fc6a6" xlink:to="loc_us-gaap_CostsAndExpenses_290600e0-838b-4f30-a4d8-3426bf3e5e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8268448b-4af9-4dd9-9943-c97d9fd73162" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_913084be-37d9-432c-98bf-2c21b81fdc28" xlink:to="loc_us-gaap_OperatingIncomeLoss_8268448b-4af9-4dd9-9943-c97d9fd73162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dc78cf09-3022-4619-a78d-5a0e8935a13b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_913084be-37d9-432c-98bf-2c21b81fdc28" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dc78cf09-3022-4619-a78d-5a0e8935a13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_865d06a5-79c7-4cf5-bd05-fd6eb96baecc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dc78cf09-3022-4619-a78d-5a0e8935a13b" xlink:to="loc_us-gaap_InvestmentIncomeInterest_865d06a5-79c7-4cf5-bd05-fd6eb96baecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_NonCashImputedInterestExpense_20b8357b-a668-4fab-9a1f-e2aa6bedaab5" xlink:href="cris-20210930.xsd#cris_NonCashImputedInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dc78cf09-3022-4619-a78d-5a0e8935a13b" xlink:to="loc_cris_NonCashImputedInterestExpense_20b8357b-a668-4fab-9a1f-e2aa6bedaab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d5139d14-f7c2-4918-8a0e-5db1aca5d9cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dc78cf09-3022-4619-a78d-5a0e8935a13b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d5139d14-f7c2-4918-8a0e-5db1aca5d9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_248f0f2e-6ab4-4dd1-875c-63ed84fa7c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dc78cf09-3022-4619-a78d-5a0e8935a13b" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_248f0f2e-6ab4-4dd1-875c-63ed84fa7c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6511dd59-98e6-43ad-9d8c-9abf98e941b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_913084be-37d9-432c-98bf-2c21b81fdc28" xlink:to="loc_us-gaap_NetIncomeLoss_6511dd59-98e6-43ad-9d8c-9abf98e941b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b2916844-0f33-4c59-9723-c793e65fa366" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_913084be-37d9-432c-98bf-2c21b81fdc28" xlink:to="loc_us-gaap_EarningsPerShareBasic_b2916844-0f33-4c59-9723-c793e65fa366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3b9a7dca-320c-4be8-b6c2-d6924bfd3fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_913084be-37d9-432c-98bf-2c21b81fdc28" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3b9a7dca-320c-4be8-b6c2-d6924bfd3fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e0a5e624-9e69-43b6-be94-499e568b613a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_913084be-37d9-432c-98bf-2c21b81fdc28" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e0a5e624-9e69-43b6-be94-499e568b613a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ada7edc3-50fa-442f-ad47-a1a863601124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_913084be-37d9-432c-98bf-2c21b81fdc28" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ada7edc3-50fa-442f-ad47-a1a863601124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_92fc1864-0ec9-4a93-96e3-535b625cd2d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_913084be-37d9-432c-98bf-2c21b81fdc28" xlink:to="loc_us-gaap_NetIncomeLoss_92fc1864-0ec9-4a93-96e3-535b625cd2d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9d148b0c-6af2-403a-8e2c-49e6b37f85c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_913084be-37d9-432c-98bf-2c21b81fdc28" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9d148b0c-6af2-403a-8e2c-49e6b37f85c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0954055b-0546-406b-ad56-6e48002e0d50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9d148b0c-6af2-403a-8e2c-49e6b37f85c4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0954055b-0546-406b-ad56-6e48002e0d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b8c1dc1a-b9ef-4d2e-94c9-db9053bb3b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9d148b0c-6af2-403a-8e2c-49e6b37f85c4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_b8c1dc1a-b9ef-4d2e-94c9-db9053bb3b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="cris-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_1a70cb45-a028-4ab2-b845-375a9613dcc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f9ded707-5d97-4a07-8079-322a9d1839d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_1a70cb45-a028-4ab2-b845-375a9613dcc1" xlink:to="loc_us-gaap_StatementTable_f9ded707-5d97-4a07-8079-322a9d1839d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fb1dc74b-9227-4168-90bb-eff1c2ec58c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f9ded707-5d97-4a07-8079-322a9d1839d7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fb1dc74b-9227-4168-90bb-eff1c2ec58c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b846968d-92d9-4a1c-9a64-2f7096437048" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fb1dc74b-9227-4168-90bb-eff1c2ec58c3" xlink:to="loc_us-gaap_EquityComponentDomain_b846968d-92d9-4a1c-9a64-2f7096437048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_68bcc3ce-ef8c-4f46-9a4e-66f20e711734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b846968d-92d9-4a1c-9a64-2f7096437048" xlink:to="loc_us-gaap_CommonStockMember_68bcc3ce-ef8c-4f46-9a4e-66f20e711734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_199381f7-5c17-497c-b747-5325a9e7ab42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b846968d-92d9-4a1c-9a64-2f7096437048" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_199381f7-5c17-497c-b747-5325a9e7ab42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_46231028-2eb2-4a4a-acf9-79020a1c3e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b846968d-92d9-4a1c-9a64-2f7096437048" xlink:to="loc_us-gaap_RetainedEarningsMember_46231028-2eb2-4a4a-acf9-79020a1c3e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6c3e227e-9d39-44d5-9071-cb5a51ddd715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b846968d-92d9-4a1c-9a64-2f7096437048" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6c3e227e-9d39-44d5-9071-cb5a51ddd715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a36c58aa-e802-4456-9598-42be07904820" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f9ded707-5d97-4a07-8079-322a9d1839d7" xlink:to="loc_srt_CounterpartyNameAxis_a36c58aa-e802-4456-9598-42be07904820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b69f070d-9b10-41b0-be1b-b2c51eac6402" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a36c58aa-e802-4456-9598-42be07904820" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b69f070d-9b10-41b0-be1b-b2c51eac6402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_AspireCapitalFundLLCMember_41c20ef7-887a-4c16-a994-6a054392185d" xlink:href="cris-20210930.xsd#cris_AspireCapitalFundLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b69f070d-9b10-41b0-be1b-b2c51eac6402" xlink:to="loc_cris_AspireCapitalFundLLCMember_41c20ef7-887a-4c16-a994-6a054392185d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_DemandSalesAgreementMember_853c9f76-019d-4c21-a742-b975bb500655" xlink:href="cris-20210930.xsd#cris_DemandSalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b69f070d-9b10-41b0-be1b-b2c51eac6402" xlink:to="loc_cris_DemandSalesAgreementMember_853c9f76-019d-4c21-a742-b975bb500655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_57b19fef-7ad3-45e6-98c0-1ac89570ce98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f9ded707-5d97-4a07-8079-322a9d1839d7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_57b19fef-7ad3-45e6-98c0-1ac89570ce98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_df7499d4-f926-4048-aaa5-7e163d189264" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_57b19fef-7ad3-45e6-98c0-1ac89570ce98" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_df7499d4-f926-4048-aaa5-7e163d189264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_08989560-4907-4c78-9281-28a6cd4a906a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_df7499d4-f926-4048-aaa5-7e163d189264" xlink:to="loc_us-gaap_PrivatePlacementMember_08989560-4907-4c78-9281-28a6cd4a906a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_eef0d087-c564-4f35-ae07-c468469a5e46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f9ded707-5d97-4a07-8079-322a9d1839d7" xlink:to="loc_us-gaap_StatementLineItems_eef0d087-c564-4f35-ae07-c468469a5e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eef0d087-c564-4f35-ae07-c468469a5e46" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4598a53f-50d3-4b8c-aead-4886a3aa0b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_CommonStockSharesIssued_4598a53f-50d3-4b8c-aead-4886a3aa0b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0fdaa7c6-de61-426f-97d9-3a2feb4d4eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_StockholdersEquity_0fdaa7c6-de61-426f-97d9-3a2feb4d4eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_93728ced-2d00-47c9-b024-8239724d8866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_93728ced-2d00-47c9-b024-8239724d8866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_eb6c556b-32ff-4119-a9f7-7f988104d6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_eb6c556b-32ff-4119-a9f7-7f988104d6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_b593bdb6-29aa-4d21-adb8-f11726431654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_b593bdb6-29aa-4d21-adb8-f11726431654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a7e0a619-1e9a-4a64-aadf-cc752fb2bfc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a7e0a619-1e9a-4a64-aadf-cc752fb2bfc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a22c992c-2f1d-4d28-9e55-dd7f6fc3b5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a22c992c-2f1d-4d28-9e55-dd7f6fc3b5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_103c336c-3ed4-46eb-9a89-0205845f7bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_103c336c-3ed4-46eb-9a89-0205845f7bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_d1f1fa78-fa71-42f1-a27e-ac36a94cd8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_d1f1fa78-fa71-42f1-a27e-ac36a94cd8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_348a450f-a359-4e46-ab2f-70ea45965bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_348a450f-a359-4e46-ab2f-70ea45965bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2b5b4b84-6cca-4108-a8d8-692fb1eecea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2b5b4b84-6cca-4108-a8d8-692fb1eecea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_63bc47c0-46d6-48e8-824a-978d07abf684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_63bc47c0-46d6-48e8-824a-978d07abf684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_9108f42d-2ba8-40d0-8830-5782bfcb04b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_9108f42d-2ba8-40d0-8830-5782bfcb04b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1feb0ee6-2715-4da5-b016-0b85916d2896" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_NetIncomeLoss_1feb0ee6-2715-4da5-b016-0b85916d2896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_46e63e02-d076-4bc0-93c7-a4d0763f749c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_CommonStockSharesIssued_46e63e02-d076-4bc0-93c7-a4d0763f749c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7f6b897e-0f24-4a6a-b94c-dee873b62310" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76cd7182-1566-4fc3-8630-b65b6d5de8ae" xlink:to="loc_us-gaap_StockholdersEquity_7f6b897e-0f24-4a6a-b94c-dee873b62310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="cris-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_bcbaa4c4-5759-470e-be26-37bd7a96e731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_df3cb406-3bcb-4c4e-857f-9bd4003febd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bcbaa4c4-5759-470e-be26-37bd7a96e731" xlink:to="loc_us-gaap_StatementTable_df3cb406-3bcb-4c4e-857f-9bd4003febd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3699dfe1-62cc-4bc3-9564-e4373a73ac1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_df3cb406-3bcb-4c4e-857f-9bd4003febd6" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3699dfe1-62cc-4bc3-9564-e4373a73ac1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b7a37cc-8f74-4dcc-ae13-75967823d147" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3699dfe1-62cc-4bc3-9564-e4373a73ac1b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b7a37cc-8f74-4dcc-ae13-75967823d147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_AspireCapitalFundLLCMember_edda0921-ffaa-4da4-9b9d-99f4ddf917b8" xlink:href="cris-20210930.xsd#cris_AspireCapitalFundLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b7a37cc-8f74-4dcc-ae13-75967823d147" xlink:to="loc_cris_AspireCapitalFundLLCMember_edda0921-ffaa-4da4-9b9d-99f4ddf917b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_DirectPlacementMember_ac4c7159-342a-41e2-b460-b1d126adc49c" xlink:href="cris-20210930.xsd#cris_DirectPlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b7a37cc-8f74-4dcc-ae13-75967823d147" xlink:to="loc_cris_DirectPlacementMember_ac4c7159-342a-41e2-b460-b1d126adc49c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_DemandSalesAgreementMember_454d35a5-d715-40af-b5dc-ad5027fdafbc" xlink:href="cris-20210930.xsd#cris_DemandSalesAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b7a37cc-8f74-4dcc-ae13-75967823d147" xlink:to="loc_cris_DemandSalesAgreementMember_454d35a5-d715-40af-b5dc-ad5027fdafbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cdcfa7ae-851e-45f0-8761-c87a95213597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_df3cb406-3bcb-4c4e-857f-9bd4003febd6" xlink:to="loc_us-gaap_StatementLineItems_cdcfa7ae-851e-45f0-8761-c87a95213597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fe03bc0e-a461-4231-bf04-23ecd65be372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cdcfa7ae-851e-45f0-8761-c87a95213597" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fe03bc0e-a461-4231-bf04-23ecd65be372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a67a88f1-a1d9-4891-b035-e0be19cf9398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fe03bc0e-a461-4231-bf04-23ecd65be372" xlink:to="loc_us-gaap_NetIncomeLoss_a67a88f1-a1d9-4891-b035-e0be19cf9398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_802ab1c4-e844-4617-8ede-f5dcb1fb7e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fe03bc0e-a461-4231-bf04-23ecd65be372" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_802ab1c4-e844-4617-8ede-f5dcb1fb7e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_dadc9237-f188-4dbb-8849-9c13a07eda2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_802ab1c4-e844-4617-8ede-f5dcb1fb7e1d" xlink:to="loc_us-gaap_DepreciationAndAmortization_dadc9237-f188-4dbb-8849-9c13a07eda2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_NonCashLeaseExpense_3de441a7-0297-4ce9-abdb-52f803759aec" xlink:href="cris-20210930.xsd#cris_NonCashLeaseExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_802ab1c4-e844-4617-8ede-f5dcb1fb7e1d" xlink:to="loc_cris_NonCashLeaseExpense_3de441a7-0297-4ce9-abdb-52f803759aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2e0f1475-f753-4b23-9c73-15c32dc17184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_802ab1c4-e844-4617-8ede-f5dcb1fb7e1d" xlink:to="loc_us-gaap_ShareBasedCompensation_2e0f1475-f753-4b23-9c73-15c32dc17184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_NonCashImputedInterestExpenseNetOfImputedInterest_2a7e76b4-2f6a-4f33-9d77-427d1cfbcb91" xlink:href="cris-20210930.xsd#cris_NonCashImputedInterestExpenseNetOfImputedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_802ab1c4-e844-4617-8ede-f5dcb1fb7e1d" xlink:to="loc_cris_NonCashImputedInterestExpenseNetOfImputedInterest_2a7e76b4-2f6a-4f33-9d77-427d1cfbcb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4f3f8ea5-9f19-4d1c-ad56-9d680d385333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_802ab1c4-e844-4617-8ede-f5dcb1fb7e1d" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4f3f8ea5-9f19-4d1c-ad56-9d680d385333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6dc12adc-01a3-413b-a739-3fece94ba102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_802ab1c4-e844-4617-8ede-f5dcb1fb7e1d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6dc12adc-01a3-413b-a739-3fece94ba102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_46086fd5-f3a5-4d0c-84e5-d4817c6f4698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_802ab1c4-e844-4617-8ede-f5dcb1fb7e1d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_46086fd5-f3a5-4d0c-84e5-d4817c6f4698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6b6d46a4-2610-4d07-988b-6239f5b04f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_46086fd5-f3a5-4d0c-84e5-d4817c6f4698" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6b6d46a4-2610-4d07-988b-6239f5b04f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_75065981-eb83-4f9d-b78c-7351474e6e91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_46086fd5-f3a5-4d0c-84e5-d4817c6f4698" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_75065981-eb83-4f9d-b78c-7351474e6e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_914c8cce-b637-4034-a0c4-8785dc40ca8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_46086fd5-f3a5-4d0c-84e5-d4817c6f4698" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_914c8cce-b637-4034-a0c4-8785dc40ca8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_IncreaseDecreaseOperatingLeaseLiability_44bbd174-10e5-4e6f-82ce-c29e435ac555" xlink:href="cris-20210930.xsd#cris_IncreaseDecreaseOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_46086fd5-f3a5-4d0c-84e5-d4817c6f4698" xlink:to="loc_cris_IncreaseDecreaseOperatingLeaseLiability_44bbd174-10e5-4e6f-82ce-c29e435ac555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_4b96cb49-a4af-4db9-b497-15ee5bccecc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_802ab1c4-e844-4617-8ede-f5dcb1fb7e1d" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_4b96cb49-a4af-4db9-b497-15ee5bccecc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb23a6eb-75bf-47a6-b994-87108472e4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fe03bc0e-a461-4231-bf04-23ecd65be372" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb23a6eb-75bf-47a6-b994-87108472e4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e2910c12-30e4-4c85-a3ba-48ee19025e05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cdcfa7ae-851e-45f0-8761-c87a95213597" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e2910c12-30e4-4c85-a3ba-48ee19025e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_58bfeda5-94c1-4f80-873d-153d492f4c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e2910c12-30e4-4c85-a3ba-48ee19025e05" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_58bfeda5-94c1-4f80-873d-153d492f4c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_df2d30cb-86a2-45ca-af6e-a54c5f80ceb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e2910c12-30e4-4c85-a3ba-48ee19025e05" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_df2d30cb-86a2-45ca-af6e-a54c5f80ceb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_dc6af2fd-ac88-4096-97a3-9b873e165bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e2910c12-30e4-4c85-a3ba-48ee19025e05" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_dc6af2fd-ac88-4096-97a3-9b873e165bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c3afbb57-1d8b-4ff4-ad31-5686023b7259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e2910c12-30e4-4c85-a3ba-48ee19025e05" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c3afbb57-1d8b-4ff4-ad31-5686023b7259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1e5064b5-80f1-4f37-ad35-ef9d6bddd6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cdcfa7ae-851e-45f0-8761-c87a95213597" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1e5064b5-80f1-4f37-ad35-ef9d6bddd6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_256a5994-bc93-42a9-be7c-642d0a88e91f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1e5064b5-80f1-4f37-ad35-ef9d6bddd6f6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_256a5994-bc93-42a9-be7c-642d0a88e91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e7d4a934-3550-4204-8dcf-588af6e3844b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1e5064b5-80f1-4f37-ad35-ef9d6bddd6f6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e7d4a934-3550-4204-8dcf-588af6e3844b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts_b6e0ac98-33a3-4967-a3e0-ff335c6c62da" xlink:href="cris-20210930.xsd#cris_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1e5064b5-80f1-4f37-ad35-ef9d6bddd6f6" xlink:to="loc_cris_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts_b6e0ac98-33a3-4967-a3e0-ff335c6c62da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_cc0dbfb1-1c05-439e-b50e-f1126e0e3934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1e5064b5-80f1-4f37-ad35-ef9d6bddd6f6" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_cc0dbfb1-1c05-439e-b50e-f1126e0e3934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_2efb92e6-4eef-4ca6-85c3-c4e3b6b17da7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1e5064b5-80f1-4f37-ad35-ef9d6bddd6f6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_2efb92e6-4eef-4ca6-85c3-c4e3b6b17da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest_b1323fc0-e892-4eec-8a48-3ac7aa846ea0" xlink:href="cris-20210930.xsd#cris_PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1e5064b5-80f1-4f37-ad35-ef9d6bddd6f6" xlink:to="loc_cris_PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest_b1323fc0-e892-4eec-8a48-3ac7aa846ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1bd3fcfa-599b-40ee-8423-12c05b27a3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1e5064b5-80f1-4f37-ad35-ef9d6bddd6f6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1bd3fcfa-599b-40ee-8423-12c05b27a3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_23229276-8037-405a-9b3c-00a4a6b105ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cdcfa7ae-851e-45f0-8761-c87a95213597" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_23229276-8037-405a-9b3c-00a4a6b105ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_42bded9c-13c2-4d0d-ad1c-41f296e0efee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cdcfa7ae-851e-45f0-8761-c87a95213597" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_42bded9c-13c2-4d0d-ad1c-41f296e0efee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c6416855-1a19-4bd5-b464-328756e83d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cdcfa7ae-851e-45f0-8761-c87a95213597" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c6416855-1a19-4bd5-b464-328756e83d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_abb07b90-8f48-400a-826d-2d44d7a96e59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cdcfa7ae-851e-45f0-8761-c87a95213597" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_abb07b90-8f48-400a-826d-2d44d7a96e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_b163848b-9ced-465e-9c60-759a9905a92f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_abb07b90-8f48-400a-826d-2d44d7a96e59" xlink:to="loc_us-gaap_InterestPaidNet_b163848b-9ced-465e-9c60-759a9905a92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue_f026e669-7058-44d2-9e30-ed9849aa1857" xlink:href="cris-20210930.xsd#cris_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_abb07b90-8f48-400a-826d-2d44d7a96e59" xlink:to="loc_cris_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue_f026e669-7058-44d2-9e30-ed9849aa1857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_fbb1f3ad-de02-4ed4-a615-59b57ec73377" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_abb07b90-8f48-400a-826d-2d44d7a96e59" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_fbb1f3ad-de02-4ed4-a615-59b57ec73377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/NatureofBusiness" xlink:type="simple" xlink:href="cris-20210930.xsd#NatureofBusiness"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/NatureofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2465bf42-68b8-433b-8427-7b325f1bc968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_cbf9994f-ed73-4d86-b47e-ff9adb4d1d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2465bf42-68b8-433b-8427-7b325f1bc968" xlink:to="loc_us-gaap_NatureOfOperations_cbf9994f-ed73-4d86-b47e-ff9adb4d1d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/NatureofBusinessDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#NatureofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/NatureofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0644bb6b-17d3-4a59-9b80-f50c429f6794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationAgreementNumberofProgramsLicensed_6d1eca28-16c0-4886-bf21-319fb9817dff" xlink:href="cris-20210930.xsd#cris_CollaborationAgreementNumberofProgramsLicensed"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0644bb6b-17d3-4a59-9b80-f50c429f6794" xlink:to="loc_cris_CollaborationAgreementNumberofProgramsLicensed_6d1eca28-16c0-4886-bf21-319fb9817dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_dca76d70-f616-4b67-abd5-04c0bbf2f9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0644bb6b-17d3-4a59-9b80-f50c429f6794" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_dca76d70-f616-4b67-abd5-04c0bbf2f9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f5a9f3dd-ee30-4424-9d22-76e5ebd8e0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0644bb6b-17d3-4a59-9b80-f50c429f6794" xlink:to="loc_us-gaap_NetIncomeLoss_f5a9f3dd-ee30-4424-9d22-76e5ebd8e0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63818329-9626-42fb-89c4-9c965c0c879b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0644bb6b-17d3-4a59-9b80-f50c429f6794" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63818329-9626-42fb-89c4-9c965c0c879b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_651ea771-85cc-4623-83de-4b654302a3cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0644bb6b-17d3-4a59-9b80-f50c429f6794" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_651ea771-85cc-4623-83de-4b654302a3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="cris-20210930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cec806f9-4ebb-4526-b981-f0ad8215e5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_91315d38-aef8-4b11-9fd4-22d1146e5dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cec806f9-4ebb-4526-b981-f0ad8215e5a2" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_91315d38-aef8-4b11-9fd4-22d1146e5dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cris-20210930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b00b086-79b0-4b71-b0a5-4fdbf029efeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f7c2aacb-3a68-4004-8345-c2e622bad176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b00b086-79b0-4b71-b0a5-4fdbf029efeb" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f7c2aacb-3a68-4004-8345-c2e622bad176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_341949d6-1aa7-4bc5-8967-bd4d568a5171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b00b086-79b0-4b71-b0a5-4fdbf029efeb" xlink:to="loc_us-gaap_UseOfEstimates_341949d6-1aa7-4bc5-8967-bd4d568a5171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_e3110ff0-7f99-4f92-ab46-8fd67f307fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b00b086-79b0-4b71-b0a5-4fdbf029efeb" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_e3110ff0-7f99-4f92-ab46-8fd67f307fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_6bfd5810-bd98-4046-97e8-4470819d440f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b00b086-79b0-4b71-b0a5-4fdbf029efeb" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_6bfd5810-bd98-4046-97e8-4470819d440f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_a5fbbaeb-a586-40c1-b2a5-e8a35133b80b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b00b086-79b0-4b71-b0a5-4fdbf029efeb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_a5fbbaeb-a586-40c1-b2a5-e8a35133b80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_13185c21-bb99-4498-b976-74a42abec540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b00b086-79b0-4b71-b0a5-4fdbf029efeb" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_13185c21-bb99-4498-b976-74a42abec540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7222484c-42c7-4ccf-b592-accac82a88a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b00b086-79b0-4b71-b0a5-4fdbf029efeb" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7222484c-42c7-4ccf-b592-accac82a88a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_52376b1b-0a54-4535-9150-5c594fbb56c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b00b086-79b0-4b71-b0a5-4fdbf029efeb" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_52376b1b-0a54-4535-9150-5c594fbb56c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c4e3afd5-1925-45ee-86b4-774a189008e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1c9a5b0a-7772-425c-a164-e8e9ab0190de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c4e3afd5-1925-45ee-86b4-774a189008e7" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1c9a5b0a-7772-425c-a164-e8e9ab0190de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_66bbaeb6-7a43-401e-9061-3c8758087ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1c9a5b0a-7772-425c-a164-e8e9ab0190de" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_66bbaeb6-7a43-401e-9061-3c8758087ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b50488a3-dacd-49eb-9233-89ea8c942466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_66bbaeb6-7a43-401e-9061-3c8758087ba1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b50488a3-dacd-49eb-9233-89ea8c942466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_f8aad0f0-9e6f-45ac-8ec9-990fc1e90bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_b50488a3-dacd-49eb-9233-89ea8c942466" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_f8aad0f0-9e6f-45ac-8ec9-990fc1e90bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_fbe34378-3c4b-4da8-ae66-e4ff1fe46fdf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1c9a5b0a-7772-425c-a164-e8e9ab0190de" xlink:to="loc_srt_MajorCustomersAxis_fbe34378-3c4b-4da8-ae66-e4ff1fe46fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_18f3a7a7-58f5-4743-808f-fb12acd160dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_fbe34378-3c4b-4da8-ae66-e4ff1fe46fdf" xlink:to="loc_srt_NameOfMajorCustomerDomain_18f3a7a7-58f5-4743-808f-fb12acd160dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_GenentechIncMember_28d62471-cc98-4539-912e-8b76011a2b4b" xlink:href="cris-20210930.xsd#cris_GenentechIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_18f3a7a7-58f5-4743-808f-fb12acd160dd" xlink:to="loc_cris_GenentechIncMember_28d62471-cc98-4539-912e-8b76011a2b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cbe7670e-aced-43e4-9db7-757f203729ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1c9a5b0a-7772-425c-a164-e8e9ab0190de" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cbe7670e-aced-43e4-9db7-757f203729ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_07386a15-8954-4bd6-8e39-2556286d4b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cbe7670e-aced-43e4-9db7-757f203729ff" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_07386a15-8954-4bd6-8e39-2556286d4b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_dddeca58-c440-4346-9446-020ed9106f91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_07386a15-8954-4bd6-8e39-2556286d4b3f" xlink:to="loc_us-gaap_SalesRevenueNetMember_dddeca58-c440-4346-9446-020ed9106f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_d7c3da8f-3c8a-43d0-8778-ed3661307ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1c9a5b0a-7772-425c-a164-e8e9ab0190de" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_d7c3da8f-3c8a-43d0-8778-ed3661307ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_029f47c9-41f8-4207-9714-deb1c9abf996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_d7c3da8f-3c8a-43d0-8778-ed3661307ebf" xlink:to="loc_us-gaap_RestrictedCash_029f47c9-41f8-4207-9714-deb1c9abf996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e69480f1-6341-49eb-8e99-ae32235678be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_d7c3da8f-3c8a-43d0-8778-ed3661307ebf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e69480f1-6341-49eb-8e99-ae32235678be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a5b70958-73b0-4892-857b-371856e487a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_d7c3da8f-3c8a-43d0-8778-ed3661307ebf" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a5b70958-73b0-4892-857b-371856e487a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_dc9ec9fb-7688-46d3-839f-225672231f21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_d7c3da8f-3c8a-43d0-8778-ed3661307ebf" xlink:to="loc_us-gaap_NumberOfReportableSegments_dc9ec9fb-7688-46d3-839f-225672231f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="cris-20210930.xsd#FairValueofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/FairValueofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_89bb1048-36af-460d-815f-58bd39a8f280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_bb1254bd-5381-4c9b-9909-4a8a4f0c3e45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_89bb1048-36af-460d-815f-58bd39a8f280" xlink:to="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_bb1254bd-5381-4c9b-9909-4a8a4f0c3e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="cris-20210930.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b78b229b-c59c-4cf1-90e9-f2bda37428a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_fc9a79be-7627-4a9f-98e9-442f8736569b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b78b229b-c59c-4cf1-90e9-f2bda37428a0" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_fc9a79be-7627-4a9f-98e9-442f8736569b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#FairValueofFinancialInstrumentsSummaryDetails"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0e788cc6-4626-4efd-abf1-3b3ca4acebfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_72e9d0d3-a0c6-4718-a8d8-e4e9f7128727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0e788cc6-4626-4efd-abf1-3b3ca4acebfb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_72e9d0d3-a0c6-4718-a8d8-e4e9f7128727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1b6b94dd-a933-4cc9-a4a2-77b63eb31234" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_72e9d0d3-a0c6-4718-a8d8-e4e9f7128727" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1b6b94dd-a933-4cc9-a4a2-77b63eb31234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_15e40cf2-0ccb-48dc-b579-8cd0185ca343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1b6b94dd-a933-4cc9-a4a2-77b63eb31234" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_15e40cf2-0ccb-48dc-b579-8cd0185ca343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9c084417-d9e2-4ea4-afa8-f9137464e3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_15e40cf2-0ccb-48dc-b579-8cd0185ca343" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9c084417-d9e2-4ea4-afa8-f9137464e3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a9ab1c0-603c-460f-b5c8-69b9d18b696e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_72e9d0d3-a0c6-4718-a8d8-e4e9f7128727" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a9ab1c0-603c-460f-b5c8-69b9d18b696e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78331ee2-7b50-40df-9015-eb18f40a397e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a9ab1c0-603c-460f-b5c8-69b9d18b696e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78331ee2-7b50-40df-9015-eb18f40a397e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8f69de67-9032-46e5-869d-6e2706ffff93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78331ee2-7b50-40df-9015-eb18f40a397e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8f69de67-9032-46e5-869d-6e2706ffff93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ccdc7607-cb3d-491a-a767-49dd7b028a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78331ee2-7b50-40df-9015-eb18f40a397e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ccdc7607-cb3d-491a-a767-49dd7b028a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8b341d34-abb0-4913-8225-a38e5c898568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78331ee2-7b50-40df-9015-eb18f40a397e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8b341d34-abb0-4913-8225-a38e5c898568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_4a2522e2-680a-4ca0-9b8b-8951d23e66bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_72e9d0d3-a0c6-4718-a8d8-e4e9f7128727" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_4a2522e2-680a-4ca0-9b8b-8951d23e66bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b698d9fe-ce46-411c-99a0-6c3ea99d888a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_4a2522e2-680a-4ca0-9b8b-8951d23e66bb" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b698d9fe-ce46-411c-99a0-6c3ea99d888a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8aceae16-c411-407d-99db-8ad219f7b507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b698d9fe-ce46-411c-99a0-6c3ea99d888a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8aceae16-c411-407d-99db-8ad219f7b507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0a75a261-0d34-4eef-bdf8-5aef810e68e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_72e9d0d3-a0c6-4718-a8d8-e4e9f7128727" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0a75a261-0d34-4eef-bdf8-5aef810e68e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f14ea4e4-aa52-41d6-9e61-32cba3c48ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0a75a261-0d34-4eef-bdf8-5aef810e68e5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f14ea4e4-aa52-41d6-9e61-32cba3c48ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CorporateCommercialPaperStockBondsAndNotesMember_1ff17494-709c-42d4-8806-309cf81afc5d" xlink:href="cris-20210930.xsd#cris_CorporateCommercialPaperStockBondsAndNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f14ea4e4-aa52-41d6-9e61-32cba3c48ca5" xlink:to="loc_cris_CorporateCommercialPaperStockBondsAndNotesMember_1ff17494-709c-42d4-8806-309cf81afc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eadd2edb-e83d-45f1-98d5-07289530b226" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_72e9d0d3-a0c6-4718-a8d8-e4e9f7128727" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eadd2edb-e83d-45f1-98d5-07289530b226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_44a30ac9-8aaa-4720-b670-26621eec88f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eadd2edb-e83d-45f1-98d5-07289530b226" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_44a30ac9-8aaa-4720-b670-26621eec88f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c6dbd5cb-5987-41ef-bfb6-81604ef422c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_44a30ac9-8aaa-4720-b670-26621eec88f2" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c6dbd5cb-5987-41ef-bfb6-81604ef422c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_279ba855-7ba1-4c34-9519-e672bc331905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eadd2edb-e83d-45f1-98d5-07289530b226" xlink:to="loc_us-gaap_ShortTermInvestmentsAbstract_279ba855-7ba1-4c34-9519-e672bc331905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ShortTermInvestmentsFairValueDisclosure_a8915ed0-c61d-4dd1-9c87-3abe2e50804e" xlink:href="cris-20210930.xsd#cris_ShortTermInvestmentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_279ba855-7ba1-4c34-9519-e672bc331905" xlink:to="loc_cris_ShortTermInvestmentsFairValueDisclosure_a8915ed0-c61d-4dd1-9c87-3abe2e50804e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosureAbstract_a13dbea8-cdd0-425b-9180-7c074acd29b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosureAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eadd2edb-e83d-45f1-98d5-07289530b226" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosureAbstract_a13dbea8-cdd0-425b-9180-7c074acd29b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_LongTermInvestmentsFairValueDisclosure_087cb7ab-6e69-4be5-b6b3-f20583627fee" xlink:href="cris-20210930.xsd#cris_LongTermInvestmentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosureAbstract_a13dbea8-cdd0-425b-9180-7c074acd29b6" xlink:to="loc_cris_LongTermInvestmentsFairValueDisclosure_087cb7ab-6e69-4be5-b6b3-f20583627fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4fbeaea5-2e6f-4ffa-b994-ed50dd7dd9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eadd2edb-e83d-45f1-98d5-07289530b226" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_4fbeaea5-2e6f-4ffa-b994-ed50dd7dd9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/Investments" xlink:type="simple" xlink:href="cris-20210930.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7af7540e-70ef-4f5d-8db2-eb62b0e1b4de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_40b10d26-82c7-4671-b158-8c058112f4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7af7540e-70ef-4f5d-8db2-eb62b0e1b4de" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_40b10d26-82c7-4671-b158-8c058112f4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/InvestmentsTables" xlink:type="simple" xlink:href="cris-20210930.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_06854ab9-92c3-4952-ba9a-e5b16e12161f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_ab281e21-77a6-4c3a-834a-88ee6efcfba6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_06854ab9-92c3-4952-ba9a-e5b16e12161f" xlink:to="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_ab281e21-77a6-4c3a-834a-88ee6efcfba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1a32557f-c1df-4922-bcd0-650b64631d41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ff7ce023-184b-4098-8c19-c9ae3f1ef640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1a32557f-c1df-4922-bcd0-650b64631d41" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ff7ce023-184b-4098-8c19-c9ae3f1ef640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b8a5a7b8-9541-4560-af00-452f4e7561c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ff7ce023-184b-4098-8c19-c9ae3f1ef640" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b8a5a7b8-9541-4560-af00-452f4e7561c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5b441a8c-ee0c-4b20-9817-ceed7d5e619f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b8a5a7b8-9541-4560-af00-452f4e7561c9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5b441a8c-ee0c-4b20-9817-ceed7d5e619f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b76d528e-40c2-46f1-948c-c37550fd9be3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5b441a8c-ee0c-4b20-9817-ceed7d5e619f" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b76d528e-40c2-46f1-948c-c37550fd9be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_ea5aaf45-4d71-4cd8-8b00-0f606faad16a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ff7ce023-184b-4098-8c19-c9ae3f1ef640" xlink:to="loc_us-gaap_InvestmentTypeAxis_ea5aaf45-4d71-4cd8-8b00-0f606faad16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_259957d0-f033-4d66-9bde-d9b0c5e25e68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_ea5aaf45-4d71-4cd8-8b00-0f606faad16a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_259957d0-f033-4d66-9bde-d9b0c5e25e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_1caa29dd-5cde-4c25-a0e7-7945a20a1b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_259957d0-f033-4d66-9bde-d9b0c5e25e68" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_1caa29dd-5cde-4c25-a0e7-7945a20a1b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestmentsMember_3206b505-66a0-4541-b3a1-9c49eb13a670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_259957d0-f033-4d66-9bde-d9b0c5e25e68" xlink:to="loc_us-gaap_OtherLongTermInvestmentsMember_3206b505-66a0-4541-b3a1-9c49eb13a670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_abcf5229-52d8-457b-b6a8-9f05dafb566f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ff7ce023-184b-4098-8c19-c9ae3f1ef640" xlink:to="loc_srt_RangeAxis_abcf5229-52d8-457b-b6a8-9f05dafb566f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_557fb475-0246-41ca-9e75-08b16f260b39" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_abcf5229-52d8-457b-b6a8-9f05dafb566f" xlink:to="loc_srt_RangeMember_557fb475-0246-41ca-9e75-08b16f260b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5f642b7d-3c12-48c0-afdb-42fcc4307476" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_557fb475-0246-41ca-9e75-08b16f260b39" xlink:to="loc_srt_MinimumMember_5f642b7d-3c12-48c0-afdb-42fcc4307476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b794e8da-bed8-45dd-a913-efc81a495c4c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_557fb475-0246-41ca-9e75-08b16f260b39" xlink:to="loc_srt_MaximumMember_b794e8da-bed8-45dd-a913-efc81a495c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05610094-31e8-471b-9da4-69723cc64283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ff7ce023-184b-4098-8c19-c9ae3f1ef640" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05610094-31e8-471b-9da4-69723cc64283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c8dc25ed-5c50-4f41-9a84-3baa74d27b15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05610094-31e8-471b-9da4-69723cc64283" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c8dc25ed-5c50-4f41-9a84-3baa74d27b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e4eb0ba7-5ac8-419b-84f3-c3cb699c5e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05610094-31e8-471b-9da4-69723cc64283" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e4eb0ba7-5ac8-419b-84f3-c3cb699c5e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_363ebbd8-52d5-484c-86b8-9e324eb7c01e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05610094-31e8-471b-9da4-69723cc64283" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_363ebbd8-52d5-484c-86b8-9e324eb7c01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f8b58bc7-ec9e-4b44-bbbd-0f390fc0a670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05610094-31e8-471b-9da4-69723cc64283" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f8b58bc7-ec9e-4b44-bbbd-0f390fc0a670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_AvailableForSaleSecuritiesDateRange_19738650-6c2b-43bf-9d09-890c2099a7b4" xlink:href="cris-20210930.xsd#cris_AvailableForSaleSecuritiesDateRange"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05610094-31e8-471b-9da4-69723cc64283" xlink:to="loc_cris_AvailableForSaleSecuritiesDateRange_19738650-6c2b-43bf-9d09-890c2099a7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_AvailableForSaleSecuritiesWeightedAverageMaturity_fd8eb12e-bee8-4d3c-aac2-e1f98164cf83" xlink:href="cris-20210930.xsd#cris_AvailableForSaleSecuritiesWeightedAverageMaturity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05610094-31e8-471b-9da4-69723cc64283" xlink:to="loc_cris_AvailableForSaleSecuritiesWeightedAverageMaturity_fd8eb12e-bee8-4d3c-aac2-e1f98164cf83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/AccruedLiabilities" xlink:type="simple" xlink:href="cris-20210930.xsd#AccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/AccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_43989cd7-85bf-4327-b270-2344861bdc5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_82d3dee0-3f55-4b3f-acee-335aee4f31f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_43989cd7-85bf-4327-b270-2344861bdc5e" xlink:to="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_82d3dee0-3f55-4b3f-acee-335aee4f31f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/AccruedLiabilitiesTables" xlink:type="simple" xlink:href="cris-20210930.xsd#AccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/AccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_8e531da5-a823-4e79-bfbf-d1d6f439e3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_34b8cee2-f55a-46e3-aaf4-5465c82bb6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_8e531da5-a823-4e79-bfbf-d1d6f439e3b4" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_34b8cee2-f55a-46e3-aaf4-5465c82bb6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/AccruedLiabilitiesSummaryDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#AccruedLiabilitiesSummaryDetails"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/AccruedLiabilitiesSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_997f92b7-b98c-4b54-b90b-7d0871a144e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_2b9d87e5-223f-447f-975f-642577058889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_997f92b7-b98c-4b54-b90b-7d0871a144e9" xlink:to="loc_us-gaap_AccruedSalariesCurrent_2b9d87e5-223f-447f-975f-642577058889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ChemistryManufacturingAndControlsCosts_5fb14d2a-45bc-479b-a191-54e113b41fee" xlink:href="cris-20210930.xsd#cris_ChemistryManufacturingAndControlsCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_997f92b7-b98c-4b54-b90b-7d0871a144e9" xlink:to="loc_cris_ChemistryManufacturingAndControlsCosts_5fb14d2a-45bc-479b-a191-54e113b41fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_cdfaed8d-b2ff-4197-9d96-ec4556c003c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_997f92b7-b98c-4b54-b90b-7d0871a144e9" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_cdfaed8d-b2ff-4197-9d96-ec4556c003c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_LicenseFees_ef1b56d7-e9aa-4c03-9dc0-d344edf9c220" xlink:href="cris-20210930.xsd#cris_LicenseFees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_997f92b7-b98c-4b54-b90b-7d0871a144e9" xlink:to="loc_cris_LicenseFees_ef1b56d7-e9aa-4c03-9dc0-d344edf9c220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6ba4175e-a6d3-436a-bfaa-e29be4a6480d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_997f92b7-b98c-4b54-b90b-7d0871a144e9" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6ba4175e-a6d3-436a-bfaa-e29be4a6480d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3ab6dae1-de5a-4779-aead-4eb202a419d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_997f92b7-b98c-4b54-b90b-7d0871a144e9" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3ab6dae1-de5a-4779-aead-4eb202a419d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/Debt" xlink:type="simple" xlink:href="cris-20210930.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c5c6843c-d4bd-43a5-8fd1-b3eeb8df8237" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_ecdffcee-829d-41b3-94c8-9387c33971da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c5c6843c-d4bd-43a5-8fd1-b3eeb8df8237" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_ecdffcee-829d-41b3-94c8-9387c33971da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/DebtDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#DebtDetails"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/DebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_58bf0e29-943e-44e4-8d31-aa61956a3643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_fde16da1-d216-4543-8eff-0d389c96b307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_58bf0e29-943e-44e4-8d31-aa61956a3643" xlink:to="loc_us-gaap_DebtInstrumentTable_fde16da1-d216-4543-8eff-0d389c96b307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e262b2f5-9996-4648-a703-59549b24d875" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fde16da1-d216-4543-8eff-0d389c96b307" xlink:to="loc_srt_CounterpartyNameAxis_e262b2f5-9996-4648-a703-59549b24d875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17cc8610-907f-4107-a7d8-3e9b43212377" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e262b2f5-9996-4648-a703-59549b24d875" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17cc8610-907f-4107-a7d8-3e9b43212377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_SiliconValleyBankMember_edeb0560-f336-4f26-b149-bc12e6e37a5a" xlink:href="cris-20210930.xsd#cris_SiliconValleyBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17cc8610-907f-4107-a7d8-3e9b43212377" xlink:to="loc_cris_SiliconValleyBankMember_edeb0560-f336-4f26-b149-bc12e6e37a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_861af58d-27e7-44e9-af85-65edadb994c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fde16da1-d216-4543-8eff-0d389c96b307" xlink:to="loc_us-gaap_DebtInstrumentAxis_861af58d-27e7-44e9-af85-65edadb994c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_61a124d8-00ac-4f28-8dbd-8e1673a6bad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_861af58d-27e7-44e9-af85-65edadb994c4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_61a124d8-00ac-4f28-8dbd-8e1673a6bad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CaresActPPPLoanMember_b796e11b-1590-4035-9536-f7fe9c4dc819" xlink:href="cris-20210930.xsd#cris_CaresActPPPLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_61a124d8-00ac-4f28-8dbd-8e1673a6bad7" xlink:to="loc_cris_CaresActPPPLoanMember_b796e11b-1590-4035-9536-f7fe9c4dc819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a9c378ca-e6bc-4b38-b9a1-94fcb3a6e354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fde16da1-d216-4543-8eff-0d389c96b307" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a9c378ca-e6bc-4b38-b9a1-94fcb3a6e354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3e7143f0-1633-4a97-815b-6b7bc71e70a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a9c378ca-e6bc-4b38-b9a1-94fcb3a6e354" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3e7143f0-1633-4a97-815b-6b7bc71e70a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_fd99049f-fd7e-433a-a504-45d8ea0827aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3e7143f0-1633-4a97-815b-6b7bc71e70a5" xlink:to="loc_us-gaap_CommercialPaperMember_fd99049f-fd7e-433a-a504-45d8ea0827aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8a8d47d0-9660-4bfb-b23b-77f132e8ee58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fde16da1-d216-4543-8eff-0d389c96b307" xlink:to="loc_us-gaap_DebtInstrumentLineItems_8a8d47d0-9660-4bfb-b23b-77f132e8ee58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_320d700e-af6a-41f5-86c5-65c68817a2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a8d47d0-9660-4bfb-b23b-77f132e8ee58" xlink:to="loc_us-gaap_LongTermDebt_320d700e-af6a-41f5-86c5-65c68817a2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTerm_083b9279-e3b7-48ee-9f95-fb53a4b2e705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a8d47d0-9660-4bfb-b23b-77f132e8ee58" xlink:to="loc_us-gaap_LongTermDebtTerm_083b9279-e3b7-48ee-9f95-fb53a4b2e705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b2a7944d-f0b0-4148-bd6d-9823d1ce869d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a8d47d0-9660-4bfb-b23b-77f132e8ee58" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b2a7944d-f0b0-4148-bd6d-9823d1ce869d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f0a27935-f2d3-44e4-ad73-2edbc1308ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a8d47d0-9660-4bfb-b23b-77f132e8ee58" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f0a27935-f2d3-44e4-ad73-2edbc1308ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_dc08bd49-fa5e-43be-8457-9200b895f714" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a8d47d0-9660-4bfb-b23b-77f132e8ee58" xlink:to="loc_us-gaap_ShortTermBorrowings_dc08bd49-fa5e-43be-8457-9200b895f714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/Lease" xlink:type="simple" xlink:href="cris-20210930.xsd#Lease"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/Lease" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9b6dd2b4-57d6-40ce-800d-2abf018634d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_fa50f6c8-def2-4526-a6a0-0cf565dea1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9b6dd2b4-57d6-40ce-800d-2abf018634d6" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_fa50f6c8-def2-4526-a6a0-0cf565dea1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/LeasesDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#LeasesDetails"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/LeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2560e188-5d01-42c4-ac82-2842fbd0e60c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6b649ba4-ecf5-451e-9916-8849c8bb61fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2560e188-5d01-42c4-ac82-2842fbd0e60c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6b649ba4-ecf5-451e-9916-8849c8bb61fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7d8dad41-e75d-4d7b-8b7f-14131a0ee00e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2560e188-5d01-42c4-ac82-2842fbd0e60c" xlink:to="loc_us-gaap_OperatingLeaseLiability_7d8dad41-e75d-4d7b-8b7f-14131a0ee00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_be2f4c52-ed98-45c6-ba40-7fa1290527d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2560e188-5d01-42c4-ac82-2842fbd0e60c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_be2f4c52-ed98-45c6-ba40-7fa1290527d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_39881dc2-9c7f-4df2-9be5-25aab1aa8782" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2560e188-5d01-42c4-ac82-2842fbd0e60c" xlink:to="loc_us-gaap_OperatingLeaseExpense_39881dc2-9c7f-4df2-9be5-25aab1aa8782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_5fff4ee0-4ac5-4cd4-b300-35a899e74b35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2560e188-5d01-42c4-ac82-2842fbd0e60c" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_5fff4ee0-4ac5-4cd4-b300-35a899e74b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5311161f-4a64-4fa0-9343-1722e5d1da6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2560e188-5d01-42c4-ac82-2842fbd0e60c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5311161f-4a64-4fa0-9343-1722e5d1da6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_4e009efc-fafe-4fc5-aba9-22a7e2bffd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2560e188-5d01-42c4-ac82-2842fbd0e60c" xlink:to="loc_us-gaap_OperatingLeasePayments_4e009efc-fafe-4fc5-aba9-22a7e2bffd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_OperatingLeaseOneTimePaymentTenantImprovements_2af7d253-7251-47c0-8e57-88acb5c4d7e1" xlink:href="cris-20210930.xsd#cris_OperatingLeaseOneTimePaymentTenantImprovements"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2560e188-5d01-42c4-ac82-2842fbd0e60c" xlink:to="loc_cris_OperatingLeaseOneTimePaymentTenantImprovements_2af7d253-7251-47c0-8e57-88acb5c4d7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyalties" xlink:type="simple" xlink:href="cris-20210930.xsd#LiabilityRelatedtotheSaleofFutureRoyalties"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyalties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionsAbstract_b721e98d-ee20-47cd-b58e-02b6059283a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionsDisclosureTextBlock_a109948c-3553-45c7-ada6-a5e01465a8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonmonetaryTransactionsAbstract_b721e98d-ee20-47cd-b58e-02b6059283a1" xlink:to="loc_us-gaap_NonmonetaryTransactionsDisclosureTextBlock_a109948c-3553-45c7-ada6-a5e01465a8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables" xlink:type="simple" xlink:href="cris-20210930.xsd#LiabilityRelatedtotheSaleofFutureRoyaltiesTables"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionsAbstract_222daa45-f437-48b3-9f1f-752f84be4804" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherSignificantNoncashTransactionsTextBlock_9a1bba30-bace-4a8c-8132-aaea3f7161f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherSignificantNoncashTransactionsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonmonetaryTransactionsAbstract_222daa45-f437-48b3-9f1f-752f84be4804" xlink:to="loc_us-gaap_ScheduleOfOtherSignificantNoncashTransactionsTextBlock_9a1bba30-bace-4a8c-8132-aaea3f7161f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionsAbstract_0c23ac43-9869-48c0-89dd-5620d9911b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionByTypeTable_086ba914-8ec8-41e5-a0a3-4cd84e104a75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionByTypeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonmonetaryTransactionsAbstract_0c23ac43-9869-48c0-89dd-5620d9911b3e" xlink:to="loc_us-gaap_NonmonetaryTransactionByTypeTable_086ba914-8ec8-41e5-a0a3-4cd84e104a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a94e7633-2fc8-4c79-8c9d-a4f1324ed03e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonmonetaryTransactionByTypeTable_086ba914-8ec8-41e5-a0a3-4cd84e104a75" xlink:to="loc_srt_CounterpartyNameAxis_a94e7633-2fc8-4c79-8c9d-a4f1324ed03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f96add02-a084-409f-afbb-39280fc2b65d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a94e7633-2fc8-4c79-8c9d-a4f1324ed03e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f96add02-a084-409f-afbb-39280fc2b65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_OberlandCapitalMember_bf8d0a9e-4f51-4182-b91b-1c298e6d1cf4" xlink:href="cris-20210930.xsd#cris_OberlandCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f96add02-a084-409f-afbb-39280fc2b65d" xlink:to="loc_cris_OberlandCapitalMember_bf8d0a9e-4f51-4182-b91b-1c298e6d1cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ContingentPaymentBenchmarkAxis_3e6a801e-3aac-4ca2-b79c-694e5f33808c" xlink:href="cris-20210930.xsd#cris_ContingentPaymentBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonmonetaryTransactionByTypeTable_086ba914-8ec8-41e5-a0a3-4cd84e104a75" xlink:to="loc_cris_ContingentPaymentBenchmarkAxis_3e6a801e-3aac-4ca2-b79c-694e5f33808c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ContingentPaymentBenchmarkDomain_2bda238e-f63e-417a-9556-e89cd95f79b7" xlink:href="cris-20210930.xsd#cris_ContingentPaymentBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cris_ContingentPaymentBenchmarkAxis_3e6a801e-3aac-4ca2-b79c-694e5f33808c" xlink:to="loc_cris_ContingentPaymentBenchmarkDomain_2bda238e-f63e-417a-9556-e89cd95f79b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyAmountsIn2021Member_e8977323-d249-4f47-8419-073192bc75c6" xlink:href="cris-20210930.xsd#cris_RoyaltyAmountsIn2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cris_ContingentPaymentBenchmarkDomain_2bda238e-f63e-417a-9556-e89cd95f79b7" xlink:to="loc_cris_RoyaltyAmountsIn2021Member_e8977323-d249-4f47-8419-073192bc75c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_AggregateNetRoyaltiesPriorTo2027Member_26e3c7b6-ea88-4bec-b2af-ef3da4326ca6" xlink:href="cris-20210930.xsd#cris_AggregateNetRoyaltiesPriorTo2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cris_ContingentPaymentBenchmarkDomain_2bda238e-f63e-417a-9556-e89cd95f79b7" xlink:to="loc_cris_AggregateNetRoyaltiesPriorTo2027Member_26e3c7b6-ea88-4bec-b2af-ef3da4326ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionLineItems_a107d004-a078-4ad7-bbbc-d1442232d241" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonmonetaryTransactionByTypeTable_086ba914-8ec8-41e5-a0a3-4cd84e104a75" xlink:to="loc_us-gaap_NonmonetaryTransactionLineItems_a107d004-a078-4ad7-bbbc-d1442232d241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ProceedsFromRoyaltyPurchaseAgreement_d1888d29-e4cb-405d-b85d-b3d58d667ce5" xlink:href="cris-20210930.xsd#cris_ProceedsFromRoyaltyPurchaseAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonmonetaryTransactionLineItems_a107d004-a078-4ad7-bbbc-d1442232d241" xlink:to="loc_cris_ProceedsFromRoyaltyPurchaseAgreement_d1888d29-e4cb-405d-b85d-b3d58d667ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyPurchaseAgreementContingentConsiderationCashProceeds_b4bbeb15-f325-432c-a16f-2c444a608642" xlink:href="cris-20210930.xsd#cris_RoyaltyPurchaseAgreementContingentConsiderationCashProceeds"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonmonetaryTransactionLineItems_a107d004-a078-4ad7-bbbc-d1442232d241" xlink:to="loc_cris_RoyaltyPurchaseAgreementContingentConsiderationCashProceeds_b4bbeb15-f325-432c-a16f-2c444a608642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold_d5c6c5e7-5624-4d75-8004-54ad612a6b44" xlink:href="cris-20210930.xsd#cris_RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonmonetaryTransactionLineItems_a107d004-a078-4ad7-bbbc-d1442232d241" xlink:to="loc_cris_RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold_d5c6c5e7-5624-4d75-8004-54ad612a6b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyPurchaseAgreementTermsPurchaserDefaultOptionPeriod_400e7be4-0d34-4f2f-9186-d6735b5f0c50" xlink:href="cris-20210930.xsd#cris_RoyaltyPurchaseAgreementTermsPurchaserDefaultOptionPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonmonetaryTransactionLineItems_a107d004-a078-4ad7-bbbc-d1442232d241" xlink:to="loc_cris_RoyaltyPurchaseAgreementTermsPurchaserDefaultOptionPeriod_400e7be4-0d34-4f2f-9186-d6735b5f0c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyPurchaseAgreementInterestRate_8fa6238f-3857-4971-a07e-100e5a464ac4" xlink:href="cris-20210930.xsd#cris_RoyaltyPurchaseAgreementInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonmonetaryTransactionLineItems_a107d004-a078-4ad7-bbbc-d1442232d241" xlink:to="loc_cris_RoyaltyPurchaseAgreementInterestRate_8fa6238f-3857-4971-a07e-100e5a464ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts_1770e256-f3a6-4bea-975c-fd5e81e57d88" xlink:href="cris-20210930.xsd#cris_RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonmonetaryTransactionLineItems_a107d004-a078-4ad7-bbbc-d1442232d241" xlink:to="loc_cris_RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts_1770e256-f3a6-4bea-975c-fd5e81e57d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesLiabilityDuetoNonCashTransactionDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#LiabilityRelatedtotheSaleofFutureRoyaltiesLiabilityDuetoNonCashTransactionDetails"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesLiabilityDuetoNonCashTransactionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionsAbstract_8589b17a-d8cf-4198-b6f5-8926cafd50cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_NonmonetaryTransactionRollForward_320f2e2d-b7d0-4fa8-9e9b-402c66c178cd" xlink:href="cris-20210930.xsd#cris_NonmonetaryTransactionRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonmonetaryTransactionsAbstract_8589b17a-d8cf-4198-b6f5-8926cafd50cd" xlink:to="loc_cris_NonmonetaryTransactionRollForward_320f2e2d-b7d0-4fa8-9e9b-402c66c178cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyPurchaseAgreementLiabilityCarryingValue_398bbe29-951f-4266-aaa5-2d29282a901c" xlink:href="cris-20210930.xsd#cris_RoyaltyPurchaseAgreementLiabilityCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cris_NonmonetaryTransactionRollForward_320f2e2d-b7d0-4fa8-9e9b-402c66c178cd" xlink:to="loc_cris_RoyaltyPurchaseAgreementLiabilityCarryingValue_398bbe29-951f-4266-aaa5-2d29282a901c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization_1eb71a1a-1b4c-4e5c-85f4-99a779c56f91" xlink:href="cris-20210930.xsd#cris_RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cris_NonmonetaryTransactionRollForward_320f2e2d-b7d0-4fa8-9e9b-402c66c178cd" xlink:to="loc_cris_RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization_1eb71a1a-1b4c-4e5c-85f4-99a779c56f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyPurchaseAgreementAccretionExpense_53ef2aa8-d0e2-417d-808a-34cc2b106336" xlink:href="cris-20210930.xsd#cris_RoyaltyPurchaseAgreementAccretionExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cris_NonmonetaryTransactionRollForward_320f2e2d-b7d0-4fa8-9e9b-402c66c178cd" xlink:to="loc_cris_RoyaltyPurchaseAgreementAccretionExpense_53ef2aa8-d0e2-417d-808a-34cc2b106336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_PaymentsOfFutureRoyaltyLiability_adbc8d56-b44f-4716-8d2b-790ff4ec9f3e" xlink:href="cris-20210930.xsd#cris_PaymentsOfFutureRoyaltyLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cris_NonmonetaryTransactionRollForward_320f2e2d-b7d0-4fa8-9e9b-402c66c178cd" xlink:to="loc_cris_PaymentsOfFutureRoyaltyLiability_adbc8d56-b44f-4716-8d2b-790ff4ec9f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyPurchaseAgreementLiabilityCarryingValue_89900b2f-8db7-458d-8e21-040c78b290b1" xlink:href="cris-20210930.xsd#cris_RoyaltyPurchaseAgreementLiabilityCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cris_NonmonetaryTransactionRollForward_320f2e2d-b7d0-4fa8-9e9b-402c66c178cd" xlink:to="loc_cris_RoyaltyPurchaseAgreementLiabilityCarryingValue_89900b2f-8db7-458d-8e21-040c78b290b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/ResearchandDevelopmentCollaborations" xlink:type="simple" xlink:href="cris-20210930.xsd#ResearchandDevelopmentCollaborations"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/ResearchandDevelopmentCollaborations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_105cd7c1-a2e9-4325-a30d-1565aa99a481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_b1a60533-29c4-4522-b478-d0f5a558ebaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_105cd7c1-a2e9-4325-a30d-1565aa99a481" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_b1a60533-29c4-4522-b478-d0f5a558ebaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#ResearchandDevelopmentCollaborationsDetails"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_74df8ecb-a559-47aa-8b62-71cf31e70bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_31b4de96-640e-4194-837c-8cdd4bf53e48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_74df8ecb-a559-47aa-8b62-71cf31e70bd4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_31b4de96-640e-4194-837c-8cdd4bf53e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8364d545-36ef-437d-865b-7c926b398ba8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_31b4de96-640e-4194-837c-8cdd4bf53e48" xlink:to="loc_srt_CounterpartyNameAxis_8364d545-36ef-437d-865b-7c926b398ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d368d6a3-d683-47da-b732-8cbd9c378fc1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8364d545-36ef-437d-865b-7c926b398ba8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d368d6a3-d683-47da-b732-8cbd9c378fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_GenentechIncMember_2a550922-457a-4ce3-9315-810f2a343cf5" xlink:href="cris-20210930.xsd#cris_GenentechIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d368d6a3-d683-47da-b732-8cbd9c378fc1" xlink:to="loc_cris_GenentechIncMember_2a550922-457a-4ce3-9315-810f2a343cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_AurigeneDiscoveryTechnologiesLtdMember_a256da48-ca25-40e7-96bc-81f4513c8d63" xlink:href="cris-20210930.xsd#cris_AurigeneDiscoveryTechnologiesLtdMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d368d6a3-d683-47da-b732-8cbd9c378fc1" xlink:to="loc_cris_AurigeneDiscoveryTechnologiesLtdMember_a256da48-ca25-40e7-96bc-81f4513c8d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ImmuNextMember_b6bd76da-71d8-4968-87d5-19fcfac4ce71" xlink:href="cris-20210930.xsd#cris_ImmuNextMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d368d6a3-d683-47da-b732-8cbd9c378fc1" xlink:to="loc_cris_ImmuNextMember_b6bd76da-71d8-4968-87d5-19fcfac4ce71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_41b610c1-d5dd-4ebd-bf87-03dd66c6c9ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_31b4de96-640e-4194-837c-8cdd4bf53e48" xlink:to="loc_srt_RangeAxis_41b610c1-d5dd-4ebd-bf87-03dd66c6c9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c6b90435-d00c-45dd-8c66-99b25aa478dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_41b610c1-d5dd-4ebd-bf87-03dd66c6c9ab" xlink:to="loc_srt_RangeMember_c6b90435-d00c-45dd-8c66-99b25aa478dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c596a7fa-6eca-4add-b3e6-18a5883271c4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c6b90435-d00c-45dd-8c66-99b25aa478dd" xlink:to="loc_srt_MaximumMember_c596a7fa-6eca-4add-b3e6-18a5883271c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5a4a96a1-36e3-4116-ac0f-58d04d5f9746" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c6b90435-d00c-45dd-8c66-99b25aa478dd" xlink:to="loc_srt_MinimumMember_5a4a96a1-36e3-4116-ac0f-58d04d5f9746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9249b0f3-2e3c-4922-8934-3a51e6c8426e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_31b4de96-640e-4194-837c-8cdd4bf53e48" xlink:to="loc_srt_ProductOrServiceAxis_9249b0f3-2e3c-4922-8934-3a51e6c8426e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6a0109e6-ac73-43cc-84aa-eaeffd8cd878" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9249b0f3-2e3c-4922-8934-3a51e6c8426e" xlink:to="loc_srt_ProductsAndServicesDomain_6a0109e6-ac73-43cc-84aa-eaeffd8cd878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_GrossRoyaltyRevenueMember_4f00bac2-39e6-43f7-9105-65004b33d962" xlink:href="cris-20210930.xsd#cris_GrossRoyaltyRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6a0109e6-ac73-43cc-84aa-eaeffd8cd878" xlink:to="loc_cris_GrossRoyaltyRevenueMember_4f00bac2-39e6-43f7-9105-65004b33d962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b4bbde35-5bf3-4fc0-b691-223a4c76d413" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_31b4de96-640e-4194-837c-8cdd4bf53e48" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b4bbde35-5bf3-4fc0-b691-223a4c76d413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f6f822fe-c257-4a8f-94c6-20a9a090414a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b4bbde35-5bf3-4fc0-b691-223a4c76d413" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f6f822fe-c257-4a8f-94c6-20a9a090414a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ThirdandFourthProgramsMember_1ed72298-7069-4d43-8910-68978fca961b" xlink:href="cris-20210930.xsd#cris_ThirdandFourthProgramsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f6f822fe-c257-4a8f-94c6-20a9a090414a" xlink:to="loc_cris_ThirdandFourthProgramsMember_1ed72298-7069-4d43-8910-68978fca961b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_IRAK4PD1VISTAPD1TIM3ProgramMember_9ff81ae4-b0a0-4fd3-8237-557ff63aaf66" xlink:href="cris-20210930.xsd#cris_IRAK4PD1VISTAPD1TIM3ProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f6f822fe-c257-4a8f-94c6-20a9a090414a" xlink:to="loc_cris_IRAK4PD1VISTAPD1TIM3ProgramMember_9ff81ae4-b0a0-4fd3-8237-557ff63aaf66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_MasterDevelopmentAndManufacturingAgreementMember_a8514192-1ebe-451e-ba5c-4c94842f94ab" xlink:href="cris-20210930.xsd#cris_MasterDevelopmentAndManufacturingAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f6f822fe-c257-4a8f-94c6-20a9a090414a" xlink:to="loc_cris_MasterDevelopmentAndManufacturingAgreementMember_a8514192-1ebe-451e-ba5c-4c94842f94ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8f411771-117b-4c8c-9629-427265910450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_31b4de96-640e-4194-837c-8cdd4bf53e48" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8f411771-117b-4c8c-9629-427265910450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_50ffde00-73da-4b9b-acfb-608177d54e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8f411771-117b-4c8c-9629-427265910450" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_50ffde00-73da-4b9b-acfb-608177d54e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d29204f6-5dc6-4efc-91ae-ba6fd87c1bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_50ffde00-73da-4b9b-acfb-608177d54e40" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d29204f6-5dc6-4efc-91ae-ba6fd87c1bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_31b4de96-640e-4194-837c-8cdd4bf53e48" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment_4ff42dbd-5e53-4748-805a-130d9df1f0d3" xlink:href="cris-20210930.xsd#cris_CollaborationAgreementContingentConsiderationPotentialCashPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment_4ff42dbd-5e53-4748-805a-130d9df1f0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner_39c7212d-a050-401c-8451-2cd589063383" xlink:href="cris-20210930.xsd#cris_CollaborationAgreementContingentConsiderationReceivedFromPartner"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner_39c7212d-a050-401c-8451-2cd589063383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_PercentageOfRoyaltyOnNetSales_4e1817d2-22d0-4bc1-80f2-2fd2450f2897" xlink:href="cris-20210930.xsd#cris_PercentageOfRoyaltyOnNetSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_PercentageOfRoyaltyOnNetSales_4e1817d2-22d0-4bc1-80f2-2fd2450f2897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ReducedRoyaltyRate_15d0d309-e9c3-46f9-b96a-48cfa8385ff2" xlink:href="cris-20210930.xsd#cris_ReducedRoyaltyRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_ReducedRoyaltyRate_15d0d309-e9c3-46f9-b96a-48cfa8385ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2875386d-65ae-420e-a5bd-e282e2657818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2875386d-65ae-420e-a5bd-e282e2657818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_7edd4d88-9c6f-4fda-9a3c-b9c11ce66eac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_us-gaap_RoyaltyExpense_7edd4d88-9c6f-4fda-9a3c-b9c11ce66eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RoyaltyRatePercentageOfSales_0a93dded-5b98-4630-a023-3431812cbbef" xlink:href="cris-20210930.xsd#cris_RoyaltyRatePercentageOfSales"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_RoyaltyRatePercentageOfSales_0a93dded-5b98-4630-a023-3431812cbbef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_87e71c26-59b0-43c8-8896-26e951bcb17d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_87e71c26-59b0-43c8-8896-26e951bcb17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationAgreementTermsPercentageOfRoyaltyFeesReceivable_7f96ea0d-e84b-46b6-8888-a8b572b7d997" xlink:href="cris-20210930.xsd#cris_CollaborationAgreementTermsPercentageOfRoyaltyFeesReceivable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_CollaborationAgreementTermsPercentageOfRoyaltyFeesReceivable_7f96ea0d-e84b-46b6-8888-a8b572b7d997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationAgreementNumberofProgramsLicensed_96037e74-8de0-4d8f-a930-a31a96506d87" xlink:href="cris-20210930.xsd#cris_CollaborationAgreementNumberofProgramsLicensed"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_CollaborationAgreementNumberofProgramsLicensed_96037e74-8de0-4d8f-a930-a31a96506d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_PaymentsforCollaborativeArrangementstoDate_64450ac7-e993-4630-92ed-6ac7fe9d454e" xlink:href="cris-20210930.xsd#cris_PaymentsforCollaborativeArrangementstoDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_PaymentsforCollaborativeArrangementstoDate_64450ac7-e993-4630-92ed-6ac7fe9d454e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_MilestonePaymentsWaivedToDate_25c1a712-1680-4180-a46c-20981955fa89" xlink:href="cris-20210930.xsd#cris_MilestonePaymentsWaivedToDate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_MilestonePaymentsWaivedToDate_25c1a712-1680-4180-a46c-20981955fa89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1_ecf564c4-71ce-4801-8919-4a8cbedbf691" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1_ecf564c4-71ce-4801-8919-4a8cbedbf691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborativeArrangementPaymentsAgreement_37b017ee-52ff-4c44-b6cf-dddee7944d3c" xlink:href="cris-20210930.xsd#cris_CollaborativeArrangementPaymentsAgreement"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_CollaborativeArrangementPaymentsAgreement_37b017ee-52ff-4c44-b6cf-dddee7944d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_9a5fcf62-b201-49ed-b9e8-c9b4e5df61fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_9a5fcf62-b201-49ed-b9e8-c9b4e5df61fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_7d890a3d-075d-455c-a8d0-d9d2d2591f04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_7d890a3d-075d-455c-a8d0-d9d2d2591f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationAgreementExpense_cda9da50-dc90-496b-a440-c99dc0880020" xlink:href="cris-20210930.xsd#cris_CollaborationAgreementExpense"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_CollaborationAgreementExpense_cda9da50-dc90-496b-a440-c99dc0880020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationArrangementSemiAnnualMaintenanceFeePayment_69f37d14-7446-492c-bdcc-c8af327f0272" xlink:href="cris-20210930.xsd#cris_CollaborationArrangementSemiAnnualMaintenanceFeePayment"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_CollaborationArrangementSemiAnnualMaintenanceFeePayment_69f37d14-7446-492c-bdcc-c8af327f0272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationArrangementContingentConsiderationReimbursableExpenses_7ef7a98d-c8dc-40e4-8f6a-d952fd96ff8b" xlink:href="cris-20210930.xsd#cris_CollaborationArrangementContingentConsiderationReimbursableExpenses"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_CollaborationArrangementContingentConsiderationReimbursableExpenses_7ef7a98d-c8dc-40e4-8f6a-d952fd96ff8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationArrangementContingentConsiderationOptionExerciseFee_8dda9268-63a2-4074-8759-9d10a499bab4" xlink:href="cris-20210930.xsd#cris_CollaborationArrangementContingentConsiderationOptionExerciseFee"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_CollaborationArrangementContingentConsiderationOptionExerciseFee_8dda9268-63a2-4074-8759-9d10a499bab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationArrangementContingentConsiderationDevelopmentMilestonePayments_35da596c-b0d5-43f6-a934-4c9b4f43776f" xlink:href="cris-20210930.xsd#cris_CollaborationArrangementContingentConsiderationDevelopmentMilestonePayments"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_CollaborationArrangementContingentConsiderationDevelopmentMilestonePayments_35da596c-b0d5-43f6-a934-4c9b4f43776f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationArrangementContingentConsiderationRegulatoryApprovalMilestonePayments_8850d616-683a-4e31-9bbe-9a95f7a011ec" xlink:href="cris-20210930.xsd#cris_CollaborationArrangementContingentConsiderationRegulatoryApprovalMilestonePayments"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_CollaborationArrangementContingentConsiderationRegulatoryApprovalMilestonePayments_8850d616-683a-4e31-9bbe-9a95f7a011ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_CollaborationArrangementContingentConsiderationSalesMilestonePayments_945317f8-75e4-4e35-9f0d-3d90b0fa9d30" xlink:href="cris-20210930.xsd#cris_CollaborationArrangementContingentConsiderationSalesMilestonePayments"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b7b50dcd-4f9a-4ba5-9e4d-edb0cb14d765" xlink:to="loc_cris_CollaborationArrangementContingentConsiderationSalesMilestonePayments_945317f8-75e4-4e35-9f0d-3d90b0fa9d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/CommonStock" xlink:type="simple" xlink:href="cris-20210930.xsd#CommonStock"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/CommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7b7e7223-0025-4948-8138-d0a2a8564fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d328404d-b2ee-4993-8e19-cd1a31aec2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7b7e7223-0025-4948-8138-d0a2a8564fcc" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d328404d-b2ee-4993-8e19-cd1a31aec2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/CommonStockDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#CommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/CommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c7cdd9f3-d864-4c03-aa87-8d397e67e25d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_b95eaa89-c7df-4164-98b5-12d51b2de152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c7cdd9f3-d864-4c03-aa87-8d397e67e25d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_b95eaa89-c7df-4164-98b5-12d51b2de152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_380433de-1f58-4b47-998f-da5d71181b84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b95eaa89-c7df-4164-98b5-12d51b2de152" xlink:to="loc_us-gaap_AwardTypeAxis_380433de-1f58-4b47-998f-da5d71181b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec829d91-9777-405b-80ff-ae80aba6e220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_380433de-1f58-4b47-998f-da5d71181b84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec829d91-9777-405b-80ff-ae80aba6e220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c2345861-1ae9-4c1a-a8b1-704ccb1683d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec829d91-9777-405b-80ff-ae80aba6e220" xlink:to="loc_us-gaap_CommonStockMember_c2345861-1ae9-4c1a-a8b1-704ccb1683d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_635f174b-b3ce-45c9-a6de-c19a9e20f984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b95eaa89-c7df-4164-98b5-12d51b2de152" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_635f174b-b3ce-45c9-a6de-c19a9e20f984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c90a6aae-9886-42ec-a659-44357d6826ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_635f174b-b3ce-45c9-a6de-c19a9e20f984" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c90a6aae-9886-42ec-a659-44357d6826ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_53e85c6e-2ceb-4b93-91a7-db724c7fbff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c90a6aae-9886-42ec-a659-44357d6826ec" xlink:to="loc_us-gaap_PrivatePlacementMember_53e85c6e-2ceb-4b93-91a7-db724c7fbff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_0a77c893-e0af-4f26-aa0a-6f5c9270d084" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c90a6aae-9886-42ec-a659-44357d6826ec" xlink:to="loc_us-gaap_OverAllotmentOptionMember_0a77c893-e0af-4f26-aa0a-6f5c9270d084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_444bbc0a-f494-4afb-9547-fdc942be7bd9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b95eaa89-c7df-4164-98b5-12d51b2de152" xlink:to="loc_srt_CounterpartyNameAxis_444bbc0a-f494-4afb-9547-fdc942be7bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efaa3f91-8e40-4b11-a9f6-0fd8a5dbba27" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_444bbc0a-f494-4afb-9547-fdc942be7bd9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efaa3f91-8e40-4b11-a9f6-0fd8a5dbba27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_DemandSalesAgreementMember_e8e4ab3d-159f-42d3-a644-ebefe9c97ec0" xlink:href="cris-20210930.xsd#cris_DemandSalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efaa3f91-8e40-4b11-a9f6-0fd8a5dbba27" xlink:to="loc_cris_DemandSalesAgreementMember_e8e4ab3d-159f-42d3-a644-ebefe9c97ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_AspireCapitalFundLLCMember_2ef9dcce-3b06-407d-858c-f14c15264d71" xlink:href="cris-20210930.xsd#cris_AspireCapitalFundLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efaa3f91-8e40-4b11-a9f6-0fd8a5dbba27" xlink:to="loc_cris_AspireCapitalFundLLCMember_2ef9dcce-3b06-407d-858c-f14c15264d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b95eaa89-c7df-4164-98b5-12d51b2de152" xlink:to="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6c79b206-6615-4915-a246-75cfafd1dfdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6c79b206-6615-4915-a246-75cfafd1dfdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockSaleAgreementAuthorizedAmount_8573f09e-a05b-47ce-b712-1c82c2b961f7" xlink:href="cris-20210930.xsd#cris_StockSaleAgreementAuthorizedAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_cris_StockSaleAgreementAuthorizedAmount_8573f09e-a05b-47ce-b712-1c82c2b961f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockSaleAgreementCompensationFeePercentageOfGrossProceeds_4799343d-6869-4115-bedf-52213178d4ed" xlink:href="cris-20210930.xsd#cris_StockSaleAgreementCompensationFeePercentageOfGrossProceeds"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_cris_StockSaleAgreementCompensationFeePercentageOfGrossProceeds_4799343d-6869-4115-bedf-52213178d4ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ee159aed-b3b9-43ec-a06c-d171bdfb6724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ee159aed-b3b9-43ec-a06c-d171bdfb6724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_abe2c0e3-92f7-4c6b-a7ae-60ea6d69fc97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_abe2c0e3-92f7-4c6b-a7ae-60ea6d69fc97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_2c3fdacb-5f52-4212-8813-f456579fd73f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_2c3fdacb-5f52-4212-8813-f456579fd73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_8ed51a0a-9d6d-4900-b215-c1c0364a3931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_8ed51a0a-9d6d-4900-b215-c1c0364a3931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_4728acf5-8821-4689-8094-c9cf18a13c95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_us-gaap_ProfessionalFees_4728acf5-8821-4689-8094-c9cf18a13c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_SaleOfStockIssuanceCosts_90a334e7-cc2d-42de-a151-fd843be24206" xlink:href="cris-20210930.xsd#cris_SaleOfStockIssuanceCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_cris_SaleOfStockIssuanceCosts_90a334e7-cc2d-42de-a151-fd843be24206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_aa5a8838-f643-4f63-884e-579e7cc12862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_aa5a8838-f643-4f63-884e-579e7cc12862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockPurchaseProgramRemainingAuthorizedPurchaseAmount_d1a9a804-ba4b-41cc-8b3a-f7da8078bdcc" xlink:href="cris-20210930.xsd#cris_StockPurchaseProgramRemainingAuthorizedPurchaseAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_cris_StockPurchaseProgramRemainingAuthorizedPurchaseAmount_d1a9a804-ba4b-41cc-8b3a-f7da8078bdcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockPurchaseProgramAuthorizedAmount_d6aecb8d-a257-4fb4-a257-467ade603463" xlink:href="cris-20210930.xsd#cris_StockPurchaseProgramAuthorizedAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_cris_StockPurchaseProgramAuthorizedAmount_d6aecb8d-a257-4fb4-a257-467ade603463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockPurchaseProgramPricePeriod_d9f126a0-cba4-4788-a57e-966ae9c57330" xlink:href="cris-20210930.xsd#cris_StockPurchaseProgramPricePeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_cris_StockPurchaseProgramPricePeriod_d9f126a0-cba4-4788-a57e-966ae9c57330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3be6a7e2-6e5d-4bd1-b6fc-c74c47f48309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3be6a7e2-6e5d-4bd1-b6fc-c74c47f48309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_96352325-90a6-494a-8dff-2d57a527cf55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_us-gaap_CommonStockValue_96352325-90a6-494a-8dff-2d57a527cf55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockPurchaseProgramCommitmentFeeShares_deca351f-3c08-4a3a-aad4-25f540c39f3b" xlink:href="cris-20210930.xsd#cris_StockPurchaseProgramCommitmentFeeShares"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_cris_StockPurchaseProgramCommitmentFeeShares_deca351f-3c08-4a3a-aad4-25f540c39f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockSaleAgreementRemainingAuthorizedAmount_b7817400-6f1d-4130-ac96-a76626761d78" xlink:href="cris-20210930.xsd#cris_StockSaleAgreementRemainingAuthorizedAmount"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_cris_StockSaleAgreementRemainingAuthorizedAmount_b7817400-6f1d-4130-ac96-a76626761d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_88dfa6fe-564c-4d0b-a054-dab26a02e7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_88dfa6fe-564c-4d0b-a054-dab26a02e7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockPurchaseProgramTermsSharesAuthorizedPerDay_0648c854-0214-47c2-8e4b-6b4342dbd761" xlink:href="cris-20210930.xsd#cris_StockPurchaseProgramTermsSharesAuthorizedPerDay"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_cris_StockPurchaseProgramTermsSharesAuthorizedPerDay_0648c854-0214-47c2-8e4b-6b4342dbd761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockPurchaseProgramTermsSharesAuthorizedPerDayAfterMutualAgreement_42590257-e3e9-42fc-93ab-db0e345b4d83" xlink:href="cris-20210930.xsd#cris_StockPurchaseProgramTermsSharesAuthorizedPerDayAfterMutualAgreement"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f2c8a64-2167-4817-ba53-2bb27b0c641c" xlink:to="loc_cris_StockPurchaseProgramTermsSharesAuthorizedPerDayAfterMutualAgreement_42590257-e3e9-42fc-93ab-db0e345b4d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/StockPlansandStockBasedCompensation" xlink:type="simple" xlink:href="cris-20210930.xsd#StockPlansandStockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/StockPlansandStockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5ff2ea11-b77c-41e2-96b9-eb5a995856c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_bffd5234-5666-4ad0-b2ce-bc88e85c1573" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5ff2ea11-b77c-41e2-96b9-eb5a995856c8" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_bffd5234-5666-4ad0-b2ce-bc88e85c1573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/StockPlansandStockBasedCompensationTables" xlink:type="simple" xlink:href="cris-20210930.xsd#StockPlansandStockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/StockPlansandStockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_baac809d-0975-4269-8a29-759a393a0e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_816f4a3a-d82b-4737-a426-00d664daf5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_baac809d-0975-4269-8a29-759a393a0e4b" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_816f4a3a-d82b-4737-a426-00d664daf5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2860b5c6-db06-4078-943f-cc4af25163d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_baac809d-0975-4269-8a29-759a393a0e4b" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2860b5c6-db06-4078-943f-cc4af25163d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_bda4260f-d98c-4efd-91e7-2d7aedcf593c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_baac809d-0975-4269-8a29-759a393a0e4b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_bda4260f-d98c-4efd-91e7-2d7aedcf593c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c5017063-ab74-43cf-a9c7-ed78138793c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_baac809d-0975-4269-8a29-759a393a0e4b" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c5017063-ab74-43cf-a9c7-ed78138793c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#StockPlansandStockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ea87eefc-b741-449a-9bc7-503986acf545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_7ef84679-acdb-4d1e-91c7-8d019b81cb5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ea87eefc-b741-449a-9bc7-503986acf545" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_7ef84679-acdb-4d1e-91c7-8d019b81cb5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4d79ef96-a858-427d-b9f2-d4478f5b029d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_7ef84679-acdb-4d1e-91c7-8d019b81cb5b" xlink:to="loc_us-gaap_PlanNameAxis_4d79ef96-a858-427d-b9f2-d4478f5b029d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ee185a6c-7224-442b-b0ba-68d2c5e9218d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4d79ef96-a858-427d-b9f2-d4478f5b029d" xlink:to="loc_us-gaap_PlanNameDomain_ee185a6c-7224-442b-b0ba-68d2c5e9218d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_AmendedAndRestatedTwoThousandTenStockIncentivePlanMember_fc37c8f8-c5de-483e-b29f-59ce5f15575a" xlink:href="cris-20210930.xsd#cris_AmendedAndRestatedTwoThousandTenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ee185a6c-7224-442b-b0ba-68d2c5e9218d" xlink:to="loc_cris_AmendedAndRestatedTwoThousandTenStockIncentivePlanMember_fc37c8f8-c5de-483e-b29f-59ce5f15575a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_TwoThousandAndTenPlanMember_fdc5d2f3-8a76-475b-883f-9a241f2b1a6d" xlink:href="cris-20210930.xsd#cris_TwoThousandAndTenPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ee185a6c-7224-442b-b0ba-68d2c5e9218d" xlink:to="loc_cris_TwoThousandAndTenPlanMember_fdc5d2f3-8a76-475b-883f-9a241f2b1a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_EmployeeStockPurchasePlanMember_fe6786ed-6c7c-47b7-b885-f0bf076e8672" xlink:href="cris-20210930.xsd#cris_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ee185a6c-7224-442b-b0ba-68d2c5e9218d" xlink:to="loc_cris_EmployeeStockPurchasePlanMember_fe6786ed-6c7c-47b7-b885-f0bf076e8672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_58445745-a6f2-4ac1-8e7f-c262355cd724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_7ef84679-acdb-4d1e-91c7-8d019b81cb5b" xlink:to="loc_us-gaap_AwardTypeAxis_58445745-a6f2-4ac1-8e7f-c262355cd724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d11bc07-f930-497a-9dcd-c9b3f1dcde43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_58445745-a6f2-4ac1-8e7f-c262355cd724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d11bc07-f930-497a-9dcd-c9b3f1dcde43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_aa148856-0841-4014-a504-0002c3b30d66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d11bc07-f930-497a-9dcd-c9b3f1dcde43" xlink:to="loc_us-gaap_EmployeeStockMember_aa148856-0841-4014-a504-0002c3b30d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockOptionsorStockAppreciationRightsMember_790b830a-0e25-45ee-b22f-d3dc9056492e" xlink:href="cris-20210930.xsd#cris_StockOptionsorStockAppreciationRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d11bc07-f930-497a-9dcd-c9b3f1dcde43" xlink:to="loc_cris_StockOptionsorStockAppreciationRightsMember_790b830a-0e25-45ee-b22f-d3dc9056492e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RestrictedStockRSUsOtherStockBasedAwardsOrPerformanceAwardsMember_570e7873-a029-4d14-aefd-6796bba10046" xlink:href="cris-20210930.xsd#cris_RestrictedStockRSUsOtherStockBasedAwardsOrPerformanceAwardsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d11bc07-f930-497a-9dcd-c9b3f1dcde43" xlink:to="loc_cris_RestrictedStockRSUsOtherStockBasedAwardsOrPerformanceAwardsMember_570e7873-a029-4d14-aefd-6796bba10046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_bc8d9b67-6728-49f4-b280-f55d4d54155b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d11bc07-f930-497a-9dcd-c9b3f1dcde43" xlink:to="loc_us-gaap_RestrictedStockMember_bc8d9b67-6728-49f4-b280-f55d4d54155b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_d2956a1c-676b-49ce-be02-c0d6f27e9457" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_7ef84679-acdb-4d1e-91c7-8d019b81cb5b" xlink:to="loc_us-gaap_VestingAxis_d2956a1c-676b-49ce-be02-c0d6f27e9457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_84d4b342-3c63-41ca-92b3-4bad927a2328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_d2956a1c-676b-49ce-be02-c0d6f27e9457" xlink:to="loc_us-gaap_VestingDomain_84d4b342-3c63-41ca-92b3-4bad927a2328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_9e89c51f-28f4-4747-aab1-05ac14117a15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_84d4b342-3c63-41ca-92b3-4bad927a2328" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_9e89c51f-28f4-4747-aab1-05ac14117a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_4a72f9bc-3393-4e60-a7ed-41e9391a92d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_84d4b342-3c63-41ca-92b3-4bad927a2328" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_4a72f9bc-3393-4e60-a7ed-41e9391a92d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_2f673139-319b-4de7-a0bd-e74b2466d258" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_7ef84679-acdb-4d1e-91c7-8d019b81cb5b" xlink:to="loc_srt_TitleOfIndividualAxis_2f673139-319b-4de7-a0bd-e74b2466d258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8ddbb288-6e7c-4403-8389-5f09652a72dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_2f673139-319b-4de7-a0bd-e74b2466d258" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8ddbb288-6e7c-4403-8389-5f09652a72dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_NonEmployeeDirectorsMember_cd444c08-12f5-46dd-9153-d7c23a2e4dac" xlink:href="cris-20210930.xsd#cris_NonEmployeeDirectorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8ddbb288-6e7c-4403-8389-5f09652a72dd" xlink:to="loc_cris_NonEmployeeDirectorsMember_cd444c08-12f5-46dd-9153-d7c23a2e4dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficerMember_2adac523-0958-4f82-bf25-a3d9d2544980" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OfficerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8ddbb288-6e7c-4403-8389-5f09652a72dd" xlink:to="loc_srt_OfficerMember_2adac523-0958-4f82-bf25-a3d9d2544980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_OfficersAndNonEmployeeDirectorsMember_dbb5c44b-7196-4b59-bda5-afab7ae86df6" xlink:href="cris-20210930.xsd#cris_OfficersAndNonEmployeeDirectorsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8ddbb288-6e7c-4403-8389-5f09652a72dd" xlink:to="loc_cris_OfficersAndNonEmployeeDirectorsMember_dbb5c44b-7196-4b59-bda5-afab7ae86df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_7ef84679-acdb-4d1e-91c7-8d019b81cb5b" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_ShareBasedCompensationPlans_83982924-d4fd-4762-babd-84f53cb73ceb" xlink:href="cris-20210930.xsd#cris_ShareBasedCompensationPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_cris_ShareBasedCompensationPlans_83982924-d4fd-4762-babd-84f53cb73ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_2f3c1a0d-db34-42f8-b987-4d5578e0ca7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_2f3c1a0d-db34-42f8-b987-4d5578e0ca7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_04ad02c5-60d6-469a-89f8-0518c5a3af1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_04ad02c5-60d6-469a-89f8-0518c5a3af1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_962d40a3-fb9d-4a4e-bfad-2ab6e0d4fd6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_962d40a3-fb9d-4a4e-bfad-2ab6e0d4fd6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare_905eb097-dbc6-478a-be6e-bace1eddc2bd" xlink:href="cris-20210930.xsd#cris_SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare_905eb097-dbc6-478a-be6e-bace1eddc2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_345b3887-3665-43b7-a812-55c6483656e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_345b3887-3665-43b7-a812-55c6483656e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_NumberOfSharesAwardedUnderStockValueLessThanSpecificPercentageOfFairMarketValue_982d2305-f011-49f1-aa8d-87e62dd5ac92" xlink:href="cris-20210930.xsd#cris_NumberOfSharesAwardedUnderStockValueLessThanSpecificPercentageOfFairMarketValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_cris_NumberOfSharesAwardedUnderStockValueLessThanSpecificPercentageOfFairMarketValue_982d2305-f011-49f1-aa8d-87e62dd5ac92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e1c6a23c-5b5a-47a4-935f-c778a5fabcf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e1c6a23c-5b5a-47a4-935f-c778a5fabcf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_6d0b3e89-024f-448e-90a2-96197e1f9a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_6d0b3e89-024f-448e-90a2-96197e1f9a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2317d649-bf1c-496e-9906-e27dccbf6620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2317d649-bf1c-496e-9906-e27dccbf6620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4bc8bbe8-1cf1-4e60-84ee-81548674c1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4bc8bbe8-1cf1-4e60-84ee-81548674c1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2e0628d4-7ba2-412c-b29a-f65ec88070e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2e0628d4-7ba2-412c-b29a-f65ec88070e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_aa62d8a4-d3fb-4f85-bf3a-b3ae300de4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_aa62d8a4-d3fb-4f85-bf3a-b3ae300de4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f6b2fb62-9dca-4c18-a472-386ae5be0676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f6b2fb62-9dca-4c18-a472-386ae5be0676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0e4c2a6a-2819-4857-9680-067a78a30111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0e4c2a6a-2819-4857-9680-067a78a30111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1e796c8d-c702-4190-ad37-f49e9b47cfcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1e796c8d-c702-4190-ad37-f49e9b47cfcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_65d2875d-807a-43a8-9cfc-0322df639f04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_65d2875d-807a-43a8-9cfc-0322df639f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_EmployeeStockPurchasePlanEnrollmentPeriod_0ac84483-d876-4690-a24f-4083e5f5541b" xlink:href="cris-20210930.xsd#cris_EmployeeStockPurchasePlanEnrollmentPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_cris_EmployeeStockPurchasePlanEnrollmentPeriod_0ac84483-d876-4690-a24f-4083e5f5541b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_NumberOfPurchasePeriodsPerEnrollmentPeriod_f4aca2ee-3cc1-468a-8122-4ab94e962f33" xlink:href="cris-20210930.xsd#cris_NumberOfPurchasePeriodsPerEnrollmentPeriod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_cris_NumberOfPurchasePeriodsPerEnrollmentPeriod_f4aca2ee-3cc1-468a-8122-4ab94e962f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod_fa8cd4c2-d7ab-4994-9e1b-7fadc46c4db9" xlink:href="cris-20210930.xsd#cris_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod_fa8cd4c2-d7ab-4994-9e1b-7fadc46c4db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_20efb321-427b-48b7-b832-c91188c7a2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_20efb321-427b-48b7-b832-c91188c7a2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_StockAvailableForFuturePurchaseUnderEmployeeStockPurchasePlans_32e065c9-95df-4dd4-821c-e84f437ec6e9" xlink:href="cris-20210930.xsd#cris_StockAvailableForFuturePurchaseUnderEmployeeStockPurchasePlans"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_055fc656-eb4a-443c-8e28-b6219677d2e9" xlink:to="loc_cris_StockAvailableForFuturePurchaseUnderEmployeeStockPurchasePlans_32e065c9-95df-4dd4-821c-e84f437ec6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/StockPlansandStockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#StockPlansandStockBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/StockPlansandStockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6e3d6e94-6861-4377-b42a-afbe1055ea25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9f35ed71-82f1-424a-a748-151c4973bd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6e3d6e94-6861-4377-b42a-afbe1055ea25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9f35ed71-82f1-424a-a748-151c4973bd7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b3994239-b06b-4ebc-b930-07df7f1f4469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9f35ed71-82f1-424a-a748-151c4973bd7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b3994239-b06b-4ebc-b930-07df7f1f4469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_29a8eb7b-21fa-4e7a-aa47-8f7db2652568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9f35ed71-82f1-424a-a748-151c4973bd7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_29a8eb7b-21fa-4e7a-aa47-8f7db2652568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ddd14b79-4d08-4d13-8134-9b38528a7f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9f35ed71-82f1-424a-a748-151c4973bd7e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ddd14b79-4d08-4d13-8134-9b38528a7f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_949467ae-2af3-4032-bf79-3cbafcaadb3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9f35ed71-82f1-424a-a748-151c4973bd7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_949467ae-2af3-4032-bf79-3cbafcaadb3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5535605c-40cb-4412-ad98-6f636a4d6a24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9f35ed71-82f1-424a-a748-151c4973bd7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5535605c-40cb-4412-ad98-6f636a4d6a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_fbbc7eda-eb74-40c5-bc44-60b7dbad2f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6e3d6e94-6861-4377-b42a-afbe1055ea25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_fbbc7eda-eb74-40c5-bc44-60b7dbad2f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_52af8c7f-0c82-44a1-9763-ff09599c2664" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6e3d6e94-6861-4377-b42a-afbe1055ea25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_52af8c7f-0c82-44a1-9763-ff09599c2664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2adaece5-f744-41e0-afb9-f659804fd3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6e3d6e94-6861-4377-b42a-afbe1055ea25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2adaece5-f744-41e0-afb9-f659804fd3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e199eb9c-da2e-482d-8136-47c4391a7cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2adaece5-f744-41e0-afb9-f659804fd3a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e199eb9c-da2e-482d-8136-47c4391a7cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cfac3c43-042e-406a-a21e-c947bf8a9d16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2adaece5-f744-41e0-afb9-f659804fd3a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cfac3c43-042e-406a-a21e-c947bf8a9d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ce0365f1-32c2-4806-a8a4-58cb839cbd1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2adaece5-f744-41e0-afb9-f659804fd3a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ce0365f1-32c2-4806-a8a4-58cb839cbd1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f0bcdc9e-c178-47e3-b7ed-5ff831c0b874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2adaece5-f744-41e0-afb9-f659804fd3a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f0bcdc9e-c178-47e3-b7ed-5ff831c0b874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_dfd295b8-3386-479f-a3b6-93a1cdbeeab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2adaece5-f744-41e0-afb9-f659804fd3a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_dfd295b8-3386-479f-a3b6-93a1cdbeeab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_55a39f15-26f8-436a-80ef-70a216299447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6e3d6e94-6861-4377-b42a-afbe1055ea25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_55a39f15-26f8-436a-80ef-70a216299447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_9a688d7d-e86c-4642-bd82-fd7b6af43193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6e3d6e94-6861-4377-b42a-afbe1055ea25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_9a688d7d-e86c-4642-bd82-fd7b6af43193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5c5383eb-67dc-4449-8e7b-e3cc44feda70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6e3d6e94-6861-4377-b42a-afbe1055ea25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5c5383eb-67dc-4449-8e7b-e3cc44feda70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e0e0c622-7c0b-4235-971e-1486131c0f77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5c5383eb-67dc-4449-8e7b-e3cc44feda70" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e0e0c622-7c0b-4235-971e-1486131c0f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f139d552-7e5b-4f25-89c3-759433bbb234" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5c5383eb-67dc-4449-8e7b-e3cc44feda70" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f139d552-7e5b-4f25-89c3-759433bbb234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_84aa8ed7-e1ae-4cd7-9236-874d3fab5e37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5c5383eb-67dc-4449-8e7b-e3cc44feda70" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_84aa8ed7-e1ae-4cd7-9236-874d3fab5e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_356d74b8-5c5f-4aba-b0dc-cd7d230510f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6e3d6e94-6861-4377-b42a-afbe1055ea25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_356d74b8-5c5f-4aba-b0dc-cd7d230510f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_df130ab8-08c5-4202-87c8-2e4ccc5f8003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_356d74b8-5c5f-4aba-b0dc-cd7d230510f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_df130ab8-08c5-4202-87c8-2e4ccc5f8003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b73703b5-7695-48a8-9854-41ef5a847268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_356d74b8-5c5f-4aba-b0dc-cd7d230510f4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b73703b5-7695-48a8-9854-41ef5a847268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_cf52808b-971f-4996-ab3b-5a9880df35fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_356d74b8-5c5f-4aba-b0dc-cd7d230510f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_cf52808b-971f-4996-ab3b-5a9880df35fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/StockPlansandStockBasedCompensationKeyAssumptionsDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#StockPlansandStockBasedCompensationKeyAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/StockPlansandStockBasedCompensationKeyAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_244e9756-b3bc-45ec-9fe9-cdb13994b0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_612860f0-d0ca-498d-8bfa-56e46430dd42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_244e9756-b3bc-45ec-9fe9-cdb13994b0c0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_612860f0-d0ca-498d-8bfa-56e46430dd42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b8523853-58a4-4f7d-892c-dae755c31bea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_244e9756-b3bc-45ec-9fe9-cdb13994b0c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b8523853-58a4-4f7d-892c-dae755c31bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_61b06cf7-9545-4f2b-acdb-bfb5e977fe44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_244e9756-b3bc-45ec-9fe9-cdb13994b0c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_61b06cf7-9545-4f2b-acdb-bfb5e977fe44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ffcf5180-4091-4a92-8181-be0db2bdb20a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_244e9756-b3bc-45ec-9fe9-cdb13994b0c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ffcf5180-4091-4a92-8181-be0db2bdb20a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/StockPlansandStockBasedCompensationRestrictedStockAwardActivityDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#StockPlansandStockBasedCompensationRestrictedStockAwardActivityDetails"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/StockPlansandStockBasedCompensationRestrictedStockAwardActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b7aada20-e5ae-48f9-8bae-9da9f8907499" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_756da598-7fb0-4dda-b116-8f491590bc03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b7aada20-e5ae-48f9-8bae-9da9f8907499" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_756da598-7fb0-4dda-b116-8f491590bc03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a98384ab-a927-4a1b-9df6-96e2d0173e25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_756da598-7fb0-4dda-b116-8f491590bc03" xlink:to="loc_us-gaap_AwardTypeAxis_a98384ab-a927-4a1b-9df6-96e2d0173e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eb99a882-3eb7-40b5-b648-c6b653642cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a98384ab-a927-4a1b-9df6-96e2d0173e25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eb99a882-3eb7-40b5-b648-c6b653642cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_2a56acb7-fc53-4ec3-aba2-dd13d60facd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eb99a882-3eb7-40b5-b648-c6b653642cbb" xlink:to="loc_us-gaap_RestrictedStockMember_2a56acb7-fc53-4ec3-aba2-dd13d60facd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21285a8e-69f1-4bd0-a235-9e9a61411a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_756da598-7fb0-4dda-b116-8f491590bc03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21285a8e-69f1-4bd0-a235-9e9a61411a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea421126-16ec-4cf0-88ed-17ce97522c93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21285a8e-69f1-4bd0-a235-9e9a61411a6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea421126-16ec-4cf0-88ed-17ce97522c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bb4d286a-20b2-4e2d-a8ed-7a350611c1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea421126-16ec-4cf0-88ed-17ce97522c93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bb4d286a-20b2-4e2d-a8ed-7a350611c1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_65d5ed3c-71c2-4c96-88f8-c0927ab49c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea421126-16ec-4cf0-88ed-17ce97522c93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_65d5ed3c-71c2-4c96-88f8-c0927ab49c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e79425c0-5bcd-4f07-af68-f87d10d4c943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea421126-16ec-4cf0-88ed-17ce97522c93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e79425c0-5bcd-4f07-af68-f87d10d4c943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_76f3f797-b2ad-42f9-9658-37690c1234d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea421126-16ec-4cf0-88ed-17ce97522c93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_76f3f797-b2ad-42f9-9658-37690c1234d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3ac1c4f4-9856-4632-b36d-53f550c1f04f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea421126-16ec-4cf0-88ed-17ce97522c93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3ac1c4f4-9856-4632-b36d-53f550c1f04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c412a4fa-9d29-450e-80ae-8f006b02e924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21285a8e-69f1-4bd0-a235-9e9a61411a6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c412a4fa-9d29-450e-80ae-8f006b02e924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_871b9be8-0894-46bc-9415-c72e35a74e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c412a4fa-9d29-450e-80ae-8f006b02e924" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_871b9be8-0894-46bc-9415-c72e35a74e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_05fff384-dc24-4ab1-9707-687840087d79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c412a4fa-9d29-450e-80ae-8f006b02e924" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_05fff384-dc24-4ab1-9707-687840087d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_62f86f42-8a9a-43b9-9d50-20280eebe281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c412a4fa-9d29-450e-80ae-8f006b02e924" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_62f86f42-8a9a-43b9-9d50-20280eebe281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_034b93c8-707e-41fe-81b8-1555dfe11975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c412a4fa-9d29-450e-80ae-8f006b02e924" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_034b93c8-707e-41fe-81b8-1555dfe11975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_217146f9-ae5e-4e2e-97b2-9b8606db4025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c412a4fa-9d29-450e-80ae-8f006b02e924" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_217146f9-ae5e-4e2e-97b2-9b8606db4025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/StockPlansandStockBasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#StockPlansandStockBasedCompensationStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/StockPlansandStockBasedCompensationStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_39f11504-d226-4da6-aeb1-df1b7f1a9758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_27c590d3-53f1-4177-b3fe-eeb251570412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_39f11504-d226-4da6-aeb1-df1b7f1a9758" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_27c590d3-53f1-4177-b3fe-eeb251570412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c8a55c5a-3811-4d6b-9115-78f37faa7a61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_27c590d3-53f1-4177-b3fe-eeb251570412" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c8a55c5a-3811-4d6b-9115-78f37faa7a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6f2ca47f-0455-4b50-b063-93ce2c8c4094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c8a55c5a-3811-4d6b-9115-78f37faa7a61" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6f2ca47f-0455-4b50-b063-93ce2c8c4094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d17d5cb9-90ba-4c17-989d-18c638324a53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6f2ca47f-0455-4b50-b063-93ce2c8c4094" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d17d5cb9-90ba-4c17-989d-18c638324a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1ef716e2-25cf-41ee-9c31-171ae64c0e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6f2ca47f-0455-4b50-b063-93ce2c8c4094" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1ef716e2-25cf-41ee-9c31-171ae64c0e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_a73fd485-3336-4f18-b74d-68828d49e09f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_27c590d3-53f1-4177-b3fe-eeb251570412" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_a73fd485-3336-4f18-b74d-68828d49e09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1b8e648f-111d-44db-a770-eae956369df3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_a73fd485-3336-4f18-b74d-68828d49e09f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1b8e648f-111d-44db-a770-eae956369df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/LossPerCommonShare" xlink:type="simple" xlink:href="cris-20210930.xsd#LossPerCommonShare"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/LossPerCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a45839f3-f89f-44a4-85d3-845e474ee77b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_cd12d76b-d3d8-4f0e-bed6-8db46c873f33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a45839f3-f89f-44a4-85d3-845e474ee77b" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_cd12d76b-d3d8-4f0e-bed6-8db46c873f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/LossPerCommonShareDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#LossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/LossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_32818d4c-8f49-4307-992a-afee9d11ff36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d19d19cf-625a-463a-a2f6-f9cdbc35cd37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_32818d4c-8f49-4307-992a-afee9d11ff36" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d19d19cf-625a-463a-a2f6-f9cdbc35cd37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1f785d64-702f-42b1-ab75-abcac94028bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d19d19cf-625a-463a-a2f6-f9cdbc35cd37" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1f785d64-702f-42b1-ab75-abcac94028bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_feb7546d-722e-4354-8336-e1c45ab1acb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1f785d64-702f-42b1-ab75-abcac94028bb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_feb7546d-722e-4354-8336-e1c45ab1acb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0a611229-5af2-428a-a8ca-296f5b6b505d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_feb7546d-722e-4354-8336-e1c45ab1acb7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0a611229-5af2-428a-a8ca-296f5b6b505d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_955d7cbf-b126-48aa-b5e4-0cc6c104848c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d19d19cf-625a-463a-a2f6-f9cdbc35cd37" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_955d7cbf-b126-48aa-b5e4-0cc6c104848c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_adfef240-5c37-40e6-b7c2-3df5980c78eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_955d7cbf-b126-48aa-b5e4-0cc6c104848c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_adfef240-5c37-40e6-b7c2-3df5980c78eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="cris-20210930.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0172cb57-d7a9-4b7a-b6a1-2f6e2e4cec47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_02364434-6905-49f2-ac0e-3a347a474fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0172cb57-d7a9-4b7a-b6a1-2f6e2e4cec47" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_02364434-6905-49f2-ac0e-3a347a474fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.curis.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="cris-20210930.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.curis.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_980e2ac5-0f1d-4dc4-8fea-834f4f0062c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_523672fc-fa70-494a-8e4c-ac51edfc4a60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_980e2ac5-0f1d-4dc4-8fea-834f4f0062c9" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_523672fc-fa70-494a-8e4c-ac51edfc4a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_21d56c4f-a306-4903-910b-3c460ea1e872" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_523672fc-fa70-494a-8e4c-ac51edfc4a60" xlink:to="loc_srt_CounterpartyNameAxis_21d56c4f-a306-4903-910b-3c460ea1e872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7fa9774b-b374-4bc5-8414-476ba3aa11d3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_21d56c4f-a306-4903-910b-3c460ea1e872" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7fa9774b-b374-4bc5-8414-476ba3aa11d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_EpiCurePharmaceuticalsInc.Member_366c09eb-c7b2-46cb-b40f-5c9b0cfd26c5" xlink:href="cris-20210930.xsd#cris_EpiCurePharmaceuticalsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7fa9774b-b374-4bc5-8414-476ba3aa11d3" xlink:to="loc_cris_EpiCurePharmaceuticalsInc.Member_366c09eb-c7b2-46cb-b40f-5c9b0cfd26c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d1b61467-55c5-4152-b9ec-0689e4c4132f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_523672fc-fa70-494a-8e4c-ac51edfc4a60" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d1b61467-55c5-4152-b9ec-0689e4c4132f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5b2ea7c7-9112-485e-88cd-8f5203ac3042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d1b61467-55c5-4152-b9ec-0689e4c4132f" xlink:to="loc_us-gaap_RelatedPartyDomain_5b2ea7c7-9112-485e-88cd-8f5203ac3042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_1ffd39c3-3704-4d8d-962d-96c311b9bfd1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_5b2ea7c7-9112-485e-88cd-8f5203ac3042" xlink:to="loc_srt_AffiliatedEntityMember_1ffd39c3-3704-4d8d-962d-96c311b9bfd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_f83aee88-aa81-4af8-bb7d-440e4c3f9305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_523672fc-fa70-494a-8e4c-ac51edfc4a60" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_f83aee88-aa81-4af8-bb7d-440e4c3f9305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_64a16283-8a9d-432e-b40e-7db006211fba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_f83aee88-aa81-4af8-bb7d-440e4c3f9305" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_64a16283-8a9d-432e-b40e-7db006211fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_AgreementWithHeadOfResearchAndDevelopmentMember_d65e719a-e03f-4a23-987a-30d0818f5aef" xlink:href="cris-20210930.xsd#cris_AgreementWithHeadOfResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_64a16283-8a9d-432e-b40e-7db006211fba" xlink:to="loc_cris_AgreementWithHeadOfResearchAndDevelopmentMember_d65e719a-e03f-4a23-987a-30d0818f5aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_10523215-7c20-4e9c-bfb6-b29e348b58c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_523672fc-fa70-494a-8e4c-ac51edfc4a60" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_10523215-7c20-4e9c-bfb6-b29e348b58c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_6bf9bf52-7fe0-4e59-b2cb-4f69f2340bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_10523215-7c20-4e9c-bfb6-b29e348b58c2" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_6bf9bf52-7fe0-4e59-b2cb-4f69f2340bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RelatedPartyTransactionMaximumFundingAmount_c228d487-f97c-4788-9f6e-44f57cbe1071" xlink:href="cris-20210930.xsd#cris_RelatedPartyTransactionMaximumFundingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_10523215-7c20-4e9c-bfb6-b29e348b58c2" xlink:to="loc_cris_RelatedPartyTransactionMaximumFundingAmount_c228d487-f97c-4788-9f6e-44f57cbe1071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cris_RelatedPartyTransactionTermsAndMannerOfSettlementMinimumDaysNoticeToTerminatePriorToWrittenNotice_2118b507-b4c7-47c2-8c62-8165ecbc11fd" xlink:href="cris-20210930.xsd#cris_RelatedPartyTransactionTermsAndMannerOfSettlementMinimumDaysNoticeToTerminatePriorToWrittenNotice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_10523215-7c20-4e9c-bfb6-b29e348b58c2" xlink:to="loc_cris_RelatedPartyTransactionTermsAndMannerOfSettlementMinimumDaysNoticeToTerminatePriorToWrittenNotice_2118b507-b4c7-47c2-8c62-8165ecbc11fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_ec58debf-3203-4dbe-b8b6-61c21d30a559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_10523215-7c20-4e9c-bfb6-b29e348b58c2" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_ec58debf-3203-4dbe-b8b6-61c21d30a559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>cris-20210930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cris="http://www.curis.com/20210930"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cris-20210930.xsd" xlink:type="simple"/>
    <context id="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4622e98fdb9241eca259fdf1067c64c6_I20211102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
        </entity>
        <period>
            <instant>2021-11-02</instant>
        </period>
    </context>
    <context id="i11c1bbbe971845e8b341c2dce21185d6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id4ae33930dfd48de8c0c9dab2d240035_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i533a446c7b4c4bbd9762a2f0852c2191_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:GrossRoyaltyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8e6bc48882e74b6dbc7edc5bfb61e854_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:GrossRoyaltyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i430322671c674a2e9ecf19555642b870_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:GrossRoyaltyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifdd8513423b24617ae9145402fcccf5e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:GrossRoyaltyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7059a303d18b4097838037b575847c70_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i995dfcf8f34847c9b9eac02305265435_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia720d94f508f4eb2a4f3c307eedfe435_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8fe8f17e9bca46a08a36d1be114833e2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id4d63a2bfd9a446bb2f258585206efff_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:ContraRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2377a33c77ce4828b22b332828013bd7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:ContraRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic76462d861cb47cc9c192a17cca41dd6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:ContraRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iac7eb7aada544feeb409a3508f46d4a8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:ContraRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i67dd4d38bbfc42dcac4661194af3c1b4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0ca78b914bf041dc884674999397831a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i50c937c85a114412bbb18451d45b1f0b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifc7b92e171e5450db55aa4c462149d6d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i60293bf8d8b34ce2b686154bc0dc8870_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id12cf2f5b2304c4187ba46547f160ae5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if39a3310599b4dc48df4759fd2f23b75_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibfe15ac9fbdb4c41a9436d65053dd823_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6273ec08929c4042b363f75dc65c925f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5ad6fa8151644284ba6c19774592e6d0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id26880c55f3b45a6ad8a5ccba68564a1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifcd76ade8392457889758a7b96e60905_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3a966410bb90428a843d3f569be9b164_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia8d1462eadbb4aa1a9833bece5ae287b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id8fc6b4c7394423b8ec79ccd7eae0b2a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6d24421a8b204e50b645dcdee96de56f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib83f38159c0d47a39e7ba5f026425795_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7aab08630ed447578b4a6fabcff3af4a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i57052d63d35b413e91d2037ed469551b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8c2d8b06604949d8b1946a6b3626e498_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if008f4d0347f4f1e96cd9a5e2c5bc985_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ife718f47b62e4c3687c07aa35e307ce2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i373c682106604fba9c0c257203578939_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0a91365e4a5949bf9ba583bd68d30198_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1556c61df1fe4774856be3b37d7866b3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if16ae74c3f204c54a9fdb59324c1a8c1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib819b69ecf0d4a69af2a5cfdb3d3f29d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i496aa636a74449e6bb23b783bf1af401_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i59c5613ca42840cd90b239dfeb0d2776_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3c0d8228dd6c47dc8835400718fb7794_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id82880f87ee44511a970554ad14e0b2c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0c7dd4eefa794b288e0e2911576a70f1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i59d2a236085c4461b444f9e731b5d83a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i77cd53b4f6e44e56bc18efef6b6c48fe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iff6f88189e6c489fadca834518204877_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i60b1a5740938422195d69fe89e22dbc2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i74e73d5375984977b6347e5a763139d0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i773b93e5620347e1ab3d326166347a05_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib3df11fcc545447489bc72b8df5ec6a5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2b54cebb2076495ebc3a6534669720f4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i668eb741fed8462b9be0b59ca9b25135_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i00fcba8a8a6049a0b2dd2926f0f9f9d3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iaf69f9380ea04321ac14ce6785b41f7c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2c1929f827ff4826a126b14efa9ed807_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic5f6802b38e34cdca4064f21d5ed6f28_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iab83bec3cf434ed190d72f069b95e844_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i3398a93d47d24500ab8ab9d0d4a0aae0_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id3db7b202b9742b4ba2ad6c5070f5d3a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie7587529ce7947f8ba47ac622a4fc47e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5e195d3203824b3d9aab16f7ec0f0922_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i74f2b1fab46944cf9e3f63c1971776bf_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i160c6a5048d844c1bb83e8a5d34a79cb_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id4a6ffee772a437a8a6979d274823c5a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="idb5feb63bb884b278199f05efec2e882_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib1145ae8cfec46ea9d2ea1ff2a92e958_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5fdb43e2101b443f8adf0e0948bf2820_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i79eb58664af1462c86740522e97626dc_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i81c6a9cdd6304647889f68d7fc513971_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6e2324829cfe492bb1ce3a18540cabae_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5696cc43a1414c5eb951ffb14fe34541_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id551d22461aa42b4ac2f10c2d9ef6e0d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ied34bb1c61f14a14b532c5987fe42f4d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i68950601d26a41dca198d584853b5317_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:DemandSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic5d45aa56d6e4b4888724ffa54069f9a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:DemandSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i243b02ffde754d02a51ddcf82577ece7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:DemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6334c899a5394f309f5ba35f98753e11_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i84408fe3e0ed4336aa0f6ff3095dd860_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i484203a4a3aa47f5a945b8781929feb6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id7fc2a9a1f5c430ab65ea66663c830cd_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie1072f132f4d4820b9dfdf6759a5c275_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ice8c0d0a4a4c414b80040c8507090a61_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i115d55a1156e4c969b9b8083b7760eb1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia6b5f21400a142dd92d6458b6bc2b0f9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0585c12f68584892a486dd533b6667ce_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i37f437e27c6c449b80dcb3c731463e31_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cris:DirectPlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1a2d864386944501a52823fe60a6ac4a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cris:DirectPlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iae11a3b9f70d4d8b8470bb42b3f5c915_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cris:DemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ica18ded6bc544002a83550782ca17ceb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cris:DemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i36015b0cc9094033ad0afc16178a75cf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cris:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2a46a72b07d94f83a96cc1ed91d2c92c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cris:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8e17706f12e14935b7a015a9bceda833_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cris:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i262850aa677c403ba7f59d77493f79af_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cris:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3df875ea96bc4acbbb5cb6759aaf23a8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i752919577506410ea7bba33998b02ae8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5cdf5782b2f94b21b2601d416cac0370_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i43a2dff08c424d20b371f99c387f9552_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iad40040d3fdb4825b2d3d57150804fd8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cris:CorporateCommercialPaperStockBondsAndNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2274a8be63ab428c82beb8aa7d63ef65_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cris:CorporateCommercialPaperStockBondsAndNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if877b50a8b61448bab75f25dec242c52_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cris:CorporateCommercialPaperStockBondsAndNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibba7a650ba3e471bad9894814e905a1f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cris:CorporateCommercialPaperStockBondsAndNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i91bffd463f9a491d809bd7007380675e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i48c7eb38239442ad99050fe29f702ff5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6f14473beda6447099b0a6cd272baf6a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifadf6a4b0d22481ba0be83763d78d4c5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i90b3b70b1ebe49e3b4887be14abc4f66_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7b067bfcfb3e48039d044d6458bfd391_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iadb4da6453d243de9db7f2235495b30b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib6ed47efff4d435ca7a150ad517661c2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e4fd250bac14a99a97209435af04856_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cris:CorporateCommercialPaperStockBondsAndNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6695b4c7cf4241ad83f88137c23fe102_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cris:CorporateCommercialPaperStockBondsAndNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id80a7c2a02984bf79a96da6df2e5a2b6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cris:CorporateCommercialPaperStockBondsAndNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i52426bd73b8d4aea9d57fb272e80b022_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cris:CorporateCommercialPaperStockBondsAndNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1c228f3130b24ff3970c7f263b1d41aa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2b1c769aefa947ec9c248070d8b405b2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i51d5333ea5724b6b9ff7023272b24535_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic4fdd2d8901b4eaca49139aa5b83e7bb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4abc2d093e574952b5b7a754de257c3a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibb8359146f7d40bdae64e9071788d92a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibfc1f9ad461d4835b6ff18f84a6e7ea8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0d85f4c8792a4a81a3945294a14918cf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9957a5ac4bf142e78afb996c95c0ac64_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0d10b233f290481a9f06412946f6a2ce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifa1a4b9cd2ed47249f51596f460164a4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i06b66b7f05424af0a5f75ecabde108be_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5de88db29d3e498087f6e6443e27c84c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8e5764c869674f6eaf807f9f08528150_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2f243344a43a416aa68d31546bb3c8b8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i27e768c412c64fadbdb2a523fde1e521_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i0d950297b01b4b72ae513d1a9aba345e_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cris:CaresActPPPLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="icb1c5fdb8979488fbe5bdf7ab44b6d01_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cris:CaresActPPPLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8446755412e84406a49c98064e52b988_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cris:CaresActPPPLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie5375dfdc8ee412588936e837f459f29_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:OberlandCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="iffa498edbc73462ba0ffcf6335f33a3b_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:OberlandCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cris:ContingentPaymentBenchmarkAxis">cris:RoyaltyAmountsIn2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ib033bd6eec734cf1826c9d37348e3df6_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:OberlandCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cris:ContingentPaymentBenchmarkAxis">cris:AggregateNetRoyaltiesPriorTo2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i1df2f708d5694cd7803b3b1cdb822461_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:OberlandCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if6e3f1f585a2476fb48ab5c48b4b4c0c_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i6a3b34007b0a4945b84b16df5abc4a37_I20030630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2003-06-30</instant>
        </period>
    </context>
    <context id="id3a04e3a472f4d30b82d08fe43d2c0b7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i481f7ee4adb0442a9066ccee54707fa3_D20030601-20030630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2003-06-01</startDate>
            <endDate>2003-06-30</endDate>
        </period>
    </context>
    <context id="i1554d4e73abd4dabac3fe396586aa6c2_D20030601-20030630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2003-06-01</startDate>
            <endDate>2003-06-30</endDate>
        </period>
    </context>
    <context id="ic26067fcb23449e68eba5cd92cb0a49e_D20030601-20030630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2003-06-01</startDate>
            <endDate>2003-06-30</endDate>
        </period>
    </context>
    <context id="ia877710393f94f3f8c7e7cd08300f3eb_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:GrossRoyaltyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ied01dcd8f0fb415ba2f14add0c9df964_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:GrossRoyaltyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6bffc8f5f047450b936f6e0e45ee38ee_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:GrossRoyaltyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i867de25d3dc74fc8a9604601d285b12c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cris:GrossRoyaltyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6f251344683f457e89a14215c76f8256_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if18f2dacb57041919fa0284b6d6a3fd4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i46169f75ca7f4f9db86ac1e7a209d5bf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i79ee3f9f0f4d480d8caee067d86e3ca8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if99565915c7247d696c1777c7a44e409_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5a557708fb604f12961074aec6ae2ddc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia3409ba719834a2f9e98876189a4ceb1_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i4bcee2e8132f40f29d06994aa69d5c75_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:ThirdandFourthProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i460702ed242d4892b13fa83e2f82d10c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i55779509759a4442aa49e025489ef439_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:IRAK4PD1VISTAPD1TIM3ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1b4c90b7e43448599c53fc40d6662bc3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:MasterDevelopmentAndManufacturingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib8625a7feacd4c3f8ea2bbf25583364c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:MasterDevelopmentAndManufacturingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if724acf7f886498f936922f1b813133c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:MasterDevelopmentAndManufacturingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1233820bbb0f46f1ae495b371f0da3a3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0c0e449c262a4c9fb7ac84a67ca508ed_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2553b5bece3047dca87c108aef6cfd51_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:ImmuNextMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iae8e02ce92e14a61a403e503c35b7dd3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:ImmuNextMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5e926263e5b843dba11e03bf2ac934c5_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i389b853ef28c48bfb67d977144cea2be_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i13cd005f3b784a00a03427270ff13a4e_I20210316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-16</instant>
        </period>
    </context>
    <context id="i1d46809b9cf44e11972741a203406eb1_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib2634e1ed79549308ba035250ef761a1_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i005697a4b0824bddb4df769ee739b32c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i531d173b436149d0977c73c89cfa4e0b_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0104cbc441b344aa8d7670c779cd19fc_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if2e46877fa284075af8f8cd02a331c87_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia64c5dfac95a49f2be056702512a4950_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic9dc8759604c4487a95552d9277d2945_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:DemandSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ib4c44bc6307042429eb5deaab3627f34_I20200304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:DemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-04</instant>
        </period>
    </context>
    <context id="ia614167954ff4147a511fd404c79e22a_D20201209-20201209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:DemandSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-09</startDate>
            <endDate>2020-12-09</endDate>
        </period>
    </context>
    <context id="i4f43d279bfc346499189eea5974d7564_I20201209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:DemandSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-09</instant>
        </period>
    </context>
    <context id="i59313702068b4ee9a458942cc6de5f0a_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="ia4d61c5f1c1a4c7b8b490d4990b8c9a1_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i7e2fb16ab10247c7bb59f0e0bb3f5e91_D20200226-20200226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-26</startDate>
            <endDate>2020-02-26</endDate>
        </period>
    </context>
    <context id="i509ac601c8cb4988976c395f2c180da2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3e79259145d846dfb9168818ded77f22_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e1d7b28e07045f8b69914b45905559b_I20200226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-26</instant>
        </period>
    </context>
    <context id="icd185c48c5a14633a53cc897fedfc27f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic667076e7a4a430c82568988e947ba95_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i298a95e35ee2477b900f65f112daddfd_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8feff43f83394d56b56b4cc6fe8050aa_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:AspireCapitalFundLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id1737ae1a00346e48a3f3c4d2b81c90d_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:AmendedAndRestatedTwoThousandTenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i8f5c7a7ab0a4454988d74c383e8d95c1_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:AmendedAndRestatedTwoThousandTenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="iec9ed577995e4041bf1893f19ed4df11_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cris:StockOptionsorStockAppreciationRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:AmendedAndRestatedTwoThousandTenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i5d9cc7f517654e6a955f1150754f9212_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cris:RestrictedStockRSUsOtherStockBasedAwardsOrPerformanceAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:AmendedAndRestatedTwoThousandTenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i9f1f0ba40401473facc35d4c0efc7dbc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:AmendedAndRestatedTwoThousandTenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1219b3d01e7b42a58ca53018ecff778b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:TwoThousandAndTenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib8de22fdc1364771a9ce096bd4828f96_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:TwoThousandAndTenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic13e507f88684f5ca74c1614332fef14_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:TwoThousandAndTenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i07e1ce19861a4ae59be352c43fd153c5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9e4ba76c11bd4f45b6687b17d856c8d6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cris:NonEmployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:TwoThousandAndTenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8b2ded813e3c47c0b1ea5d0064b18933_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cris:NonEmployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:TwoThousandAndTenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5d000460f02348d9a57c3b6ac2c6626a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if92fd01d600549e3966881e1346c980d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i82ceafb1c6a24cca84ef9a0241a19879_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i19989054788e4da19d8b3a02d19f3af8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cris:OfficersAndNonEmployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iab7e84e85b8043f69c8eee23b3053c8a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cris:OfficersAndNonEmployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i20919e06b4f743a294203290cd8726b2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibb5cbdbb686f429fb1f8c8cc33874d76_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iace147228c5946e7856c18ea03d6b20c_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="idb9ad9cc9e894c4a8591a01bc5b0e7a3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2bcecdf0c0fb4a72b6e837d5f3fe2504_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id7e33ac900a448798f0a8d5fac3e7c9a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2e0e7bd086684b51905901766d082679_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3ed4bd4d72e5471aae94ac0a3df1cd55_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9179bb8d8abc4e7a966aa44e418032fa_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4d1e27447c134e8b8836cf1c2b82cc83_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i19eea75f02854b849783be2ececc8962_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1569ff1a3c7e4c1a828aa4de4ce7b739_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibb8cdae355c147d78b1f92ad1395fbb7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id1569a19d3534733a5351d7321844968_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i85ee1298708f4cd9b83af95152514d48_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i10387d0e7a2b43aea7787dd2ecda9786_D20181018-20181018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:EpiCurePharmaceuticalsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cris:AgreementWithHeadOfResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-18</startDate>
            <endDate>2018-10-18</endDate>
        </period>
    </context>
    <context id="i272602d3cc7643438ce9826f03bb4e8d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:EpiCurePharmaceuticalsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cris:AgreementWithHeadOfResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1b869695d75c4d90a845094790292154_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:EpiCurePharmaceuticalsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i476e1229fc4b40faa3024587e5c8cf5c_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001108205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cris:EpiCurePharmaceuticalsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="program">
        <measure>cris:program</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>cris:segment</measure>
    </unit>
    <unit id="plan">
        <measure>cris:plan</measure>
    </unit>
    <unit id="purchase_period">
        <measure>cris:purchase_period</measure>
    </unit>
    <unit id="day">
        <measure>cris:day</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180L2ZyYWc6ODRkNTRiNTY3Y2QwNDM4NmIxYTVkMWJmOGNjZDYyOTQvdGFibGU6MGU5MzRmNjA4OTBmNDMwNThjZDBiMDQxNDQxYWQ0ZjQvdGFibGVyYW5nZTowZTkzNGY2MDg5MGY0MzA1OGNkMGIwNDE0NDFhZDRmNF80LTEtMS0xLTE_eb3793de-e082-4f8e-a4d7-6693b85ce2fb">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180L2ZyYWc6ODRkNTRiNTY3Y2QwNDM4NmIxYTVkMWJmOGNjZDYyOTQvdGFibGU6MGU5MzRmNjA4OTBmNDMwNThjZDBiMDQxNDQxYWQ0ZjQvdGFibGVyYW5nZTowZTkzNGY2MDg5MGY0MzA1OGNkMGIwNDE0NDFhZDRmNF81LTEtMS0xLTE_74a00d1c-0299-4891-864e-42dedd52a511">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180L2ZyYWc6ODRkNTRiNTY3Y2QwNDM4NmIxYTVkMWJmOGNjZDYyOTQvdGFibGU6MGU5MzRmNjA4OTBmNDMwNThjZDBiMDQxNDQxYWQ0ZjQvdGFibGVyYW5nZTowZTkzNGY2MDg5MGY0MzA1OGNkMGIwNDE0NDFhZDRmNF82LTEtMS0xLTE_4162c52d-fc80-4b32-9609-51c99d99008f">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180L2ZyYWc6ODRkNTRiNTY3Y2QwNDM4NmIxYTVkMWJmOGNjZDYyOTQvdGFibGU6MGU5MzRmNjA4OTBmNDMwNThjZDBiMDQxNDQxYWQ0ZjQvdGFibGVyYW5nZTowZTkzNGY2MDg5MGY0MzA1OGNkMGIwNDE0NDFhZDRmNF83LTEtMS0xLTE_125de36d-3315-4949-863e-b68eeb0f3a00">0001108205</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180L2ZyYWc6ODRkNTRiNTY3Y2QwNDM4NmIxYTVkMWJmOGNjZDYyOTQvdGFibGU6MGU5MzRmNjA4OTBmNDMwNThjZDBiMDQxNDQxYWQ0ZjQvdGFibGVyYW5nZTowZTkzNGY2MDg5MGY0MzA1OGNkMGIwNDE0NDFhZDRmNF84LTEtMS0xLTE_5bf0634f-7d82-4532-aca9-eea9b8c1bdc4">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:NumberOfReportableSegments
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNy9mcmFnOmJiOTI1MGY5Nzc1NzQ2ZGU4NDY4NjljOGE3NTIxYTk5L3RhYmxlOjA2NmMwODE2ZjliYTRjNjc4YWQyZTA2MmIxOTJmNzJmL3RhYmxlcmFuZ2U6MDY2YzA4MTZmOWJhNGM2NzhhZDJlMDYyYjE5MmY3MmZfMi0xLTEtMS0x_2946d669-7a86-4afc-aa07-921c6b069d0a"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <cris:AvailableForSaleSecuritiesDateRange
      contextRef="ibfc1f9ad461d4835b6ff18f84a6e7ea8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RleHRyZWdpb246NDRkZTEwMzQzNmIyNDYwYThkZGRiZmU2ZDExMjM4OGNfMTk3_cb80bf15-17b4-45da-ba01-4fb8b0381751">P1M</cris:AvailableForSaleSecuritiesDateRange>
    <cris:AvailableForSaleSecuritiesDateRange
      contextRef="i06b66b7f05424af0a5f75ecabde108be_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RleHRyZWdpb246NDRkZTEwMzQzNmIyNDYwYThkZGRiZmU2ZDExMjM4OGNfNTEx_4f659141-f01a-4310-9378-77affc0e77d5">P1M</cris:AvailableForSaleSecuritiesDateRange>
    <dei:DocumentType
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGV4dHJlZ2lvbjoyZWUxYWNkYTI4ZWY0NWRjODVlMGUzNjg0ODA5ZjI3Zl8xOTg4_48ea47d7-2d1b-48b7-a08b-151bbfa301cd">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6ZTNiZWI0N2YxZTg3NDAxNTljZGViNTVhOThjYzkzZjEvdGFibGVyYW5nZTplM2JlYjQ3ZjFlODc0MDE1OWNkZWI1NWE5OGNjOTNmMV8wLTAtMS0xLTE_a1674305-716e-4856-91b5-0c7be8e4630a">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGV4dHJlZ2lvbjoyZWUxYWNkYTI4ZWY0NWRjODVlMGUzNjg0ODA5ZjI3Zl82NTk3MDY5NzY4Njk3_07e4b86d-f8d4-475c-a455-a99755394de0">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6YTE2MGUzM2NlMTI0NDM1N2EyNDY1ZWJkYmMwNmUzZDkvdGFibGVyYW5nZTphMTYwZTMzY2UxMjQ0MzU3YTI0NjVlYmRiYzA2ZTNkOV8wLTAtMS0xLTE_c4e8402f-5d39-40a2-9179-5e2e6952cbd7">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGV4dHJlZ2lvbjoyZWUxYWNkYTI4ZWY0NWRjODVlMGUzNjg0ODA5ZjI3Zl8xOTg5_cad2f032-eda0-4d2e-bcb3-929ef46eee6b">000-30347</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGV4dHJlZ2lvbjoyZWUxYWNkYTI4ZWY0NWRjODVlMGUzNjg0ODA5ZjI3Zl8xOTkw_b0f46d63-9b15-4733-a519-6a03d3d17627">CURIS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6ZTNhN2I0NDU5NjcwNDJhY2I2Y2FhYjJhM2IwYzljYjEvdGFibGVyYW5nZTplM2E3YjQ0NTk2NzA0MmFjYjZjYWFiMmEzYjBjOWNiMV8wLTAtMS0xLTE_3ab66f53-881e-45c7-8301-b4a4de749e2c">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6ZTNhN2I0NDU5NjcwNDJhY2I2Y2FhYjJhM2IwYzljYjEvdGFibGVyYW5nZTplM2E3YjQ0NTk2NzA0MmFjYjZjYWFiMmEzYjBjOWNiMV8wLTItMS0xLTE_a5e57da2-9f4b-4bfc-aab3-6f8298e87666">04-3505116</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6ZTNhN2I0NDU5NjcwNDJhY2I2Y2FhYjJhM2IwYzljYjEvdGFibGVyYW5nZTplM2E3YjQ0NTk2NzA0MmFjYjZjYWFiMmEzYjBjOWNiMV8zLTAtMS0xLTEvdGV4dHJlZ2lvbjoyOGEyYzQxMWEwZWM0YmYxYmNhYzc4NzYyYmExZWFkZV80_b1f27d8a-0500-47cb-8c04-76cfe61510d2">128 Spring Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6ZTNhN2I0NDU5NjcwNDJhY2I2Y2FhYjJhM2IwYzljYjEvdGFibGVyYW5nZTplM2E3YjQ0NTk2NzA0MmFjYjZjYWFiMmEzYjBjOWNiMV8zLTAtMS0xLTEvdGV4dHJlZ2lvbjoyOGEyYzQxMWEwZWM0YmYxYmNhYzc4NzYyYmExZWFkZV84_d96e81f5-b65f-458c-9685-e98c1c4b749b">Building C - Suite 500</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6ZTNhN2I0NDU5NjcwNDJhY2I2Y2FhYjJhM2IwYzljYjEvdGFibGVyYW5nZTplM2E3YjQ0NTk2NzA0MmFjYjZjYWFiMmEzYjBjOWNiMV8zLTAtMS0xLTEvdGV4dHJlZ2lvbjoyOGEyYzQxMWEwZWM0YmYxYmNhYzc4NzYyYmExZWFkZV8xMg_65d426e8-251c-42db-aaaf-ab9cddbbb3fb">Lexington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6ZTNhN2I0NDU5NjcwNDJhY2I2Y2FhYjJhM2IwYzljYjEvdGFibGVyYW5nZTplM2E3YjQ0NTk2NzA0MmFjYjZjYWFiMmEzYjBjOWNiMV8zLTAtMS0xLTEvdGV4dHJlZ2lvbjoyOGEyYzQxMWEwZWM0YmYxYmNhYzc4NzYyYmExZWFkZV8xNg_c05b95b2-6d7d-4237-9ade-a2463779d41f">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6ZTNhN2I0NDU5NjcwNDJhY2I2Y2FhYjJhM2IwYzljYjEvdGFibGVyYW5nZTplM2E3YjQ0NTk2NzA0MmFjYjZjYWFiMmEzYjBjOWNiMV8zLTAtMS0xLTEvdGV4dHJlZ2lvbjoyOGEyYzQxMWEwZWM0YmYxYmNhYzc4NzYyYmExZWFkZV8xOQ_e8a5bc39-23b6-4dfd-a212-f2e03175f3eb">02421</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGV4dHJlZ2lvbjoyZWUxYWNkYTI4ZWY0NWRjODVlMGUzNjg0ODA5ZjI3Zl8xOTkx_bbb2ddcb-c5ec-4479-b2f2-e4940a2bf9b4">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGV4dHJlZ2lvbjoyZWUxYWNkYTI4ZWY0NWRjODVlMGUzNjg0ODA5ZjI3Zl8xOTk3_3515f063-b620-4e06-a964-8878bbcb2241">503-6500</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6YTU1NGQ5YjQ5NWZmNGFjZWI4YjBkNjliNGI3ODA1ZWUvdGFibGVyYW5nZTphNTU0ZDliNDk1ZmY0YWNlYjhiMGQ2OWI0Yjc4MDVlZV8xLTAtMS0xLTE_652a179a-d889-4104-ba84-c85b66ebefa2">Common Stock, Par Value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6YTU1NGQ5YjQ5NWZmNGFjZWI4YjBkNjliNGI3ODA1ZWUvdGFibGVyYW5nZTphNTU0ZDliNDk1ZmY0YWNlYjhiMGQ2OWI0Yjc4MDVlZV8xLTItMS0xLTE_624980a7-3186-4523-aba9-afe7e43a7262">CRIS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6YTU1NGQ5YjQ5NWZmNGFjZWI4YjBkNjliNGI3ODA1ZWUvdGFibGVyYW5nZTphNTU0ZDliNDk1ZmY0YWNlYjhiMGQ2OWI0Yjc4MDVlZV8xLTQtMS0xLTE_c6b200d3-a146-4ce6-a689-ec3d141fecfe">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGV4dHJlZ2lvbjoyZWUxYWNkYTI4ZWY0NWRjODVlMGUzNjg0ODA5ZjI3Zl8xOTky_990da9bd-3883-43d0-9b2c-7d7ec63f49a6">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGV4dHJlZ2lvbjoyZWUxYWNkYTI4ZWY0NWRjODVlMGUzNjg0ODA5ZjI3Zl8xOTkz_2e231068-f2d9-49bc-a461-4963fc87206b">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6ZDFkZjI0MGVhMWE3NDkyYTk0NDRhNjVmZTg3ZDQzZjMvdGFibGVyYW5nZTpkMWRmMjQwZWExYTc0OTJhOTQ0NGE2NWZlODdkNDNmM18wLTItMS0xLTEvdGV4dHJlZ2lvbjo2NDgxOTcyYWYwNWY0MzdlYWI5MmMzOGQ5YzJmYzdmN180_506727d9-7d7f-48ae-b76b-58c7d0449e07">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6ZDFkZjI0MGVhMWE3NDkyYTk0NDRhNjVmZTg3ZDQzZjMvdGFibGVyYW5nZTpkMWRmMjQwZWExYTc0OTJhOTQ0NGE2NWZlODdkNDNmM18wLTMtMS0xLTEvdGV4dHJlZ2lvbjpjMDNlMWJiOWM4Mjg0YzdlYmVlNzIwNTJlZTkzNTlhM18zMw_8f1521b6-bd9b-42d5-ad9e-9eade9c26821">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGFibGU6ZDFkZjI0MGVhMWE3NDkyYTk0NDRhNjVmZTg3ZDQzZjMvdGFibGVyYW5nZTpkMWRmMjQwZWExYTc0OTJhOTQ0NGE2NWZlODdkNDNmM18xLTMtMS0xLTEvdGV4dHJlZ2lvbjpiNjg4NTA4YWM4MzQ0ZjM0YjE5NjBkYzBhYmI5OGE5NV8zMA_37ebf728-39cc-4697-a8e7-91e9a96a074a">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGV4dHJlZ2lvbjoyZWUxYWNkYTI4ZWY0NWRjODVlMGUzNjg0ODA5ZjI3Zl8xOTk0_9a831897-52b2-4868-9391-6cbfc6a77202">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i4622e98fdb9241eca259fdf1067c64c6_I20211102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xL2ZyYWc6MmVlMWFjZGEyOGVmNDVkYzg1ZTBlMzY4NDgwOWYyN2YvdGV4dHJlZ2lvbjoyZWUxYWNkYTI4ZWY0NWRjODVlMGUzNjg0ODA5ZjI3Zl8xMDk5NTExNjI5Nzk0_c20a7ae7-8a41-4844-baae-372aff65c734"
      unitRef="shares">91609165</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMy0xLTEtMS0x_f7a8fb85-ffea-4d1b-bc48-9f9fc8678e07"
      unitRef="usd">53020000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMy0zLTEtMS0x_5ac399b5-f6bc-4ed2-a200-1ca9192dcbee"
      unitRef="usd">129610000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfNS0xLTEtMS0x_f9549b9d-fa32-406b-8e44-5c38aa87ecc2"
      unitRef="usd">75884000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfNS0zLTEtMS0x_298a942e-a215-49e7-8406-30c22160a732"
      unitRef="usd">38884000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfNi0xLTEtMS0x_6ede449b-c863-48c2-b099-6127dceac2e5"
      unitRef="usd">2959000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfNi0zLTEtMS0x_83ab3699-18ba-4d86-9ecf-bb9e56f3f167"
      unitRef="usd">3043000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfNy0xLTEtMS0x_dc01fc9e-297d-4633-bed1-84c4e28c096e"
      unitRef="usd">3088000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfNy0zLTEtMS0x_e9269b87-a87b-4841-8acd-a2b5901fc112"
      unitRef="usd">1215000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfOC0xLTEtMS0x_0bb6645e-02ea-48ea-b621-1ff16e4df5ee"
      unitRef="usd">134951000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfOC0zLTEtMS0x_2c09340d-80c1-4431-9460-2c067dfd1a8d"
      unitRef="usd">172752000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfOS0xLTEtMS0x_2021d83e-ebf8-4de5-911b-c9e37e10cd2e"
      unitRef="usd">20922000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfOS0zLTEtMS0x_5294755c-6d15-439c-a160-43d6f6250b44"
      unitRef="usd">14564000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTAtMS0xLTEtMQ_bcd416ab-7d73-4358-9124-31b934e633c4"
      unitRef="usd">543000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTAtMy0xLTEtMQ_d0476770-5a6a-49ce-943d-7c618bd6abc8"
      unitRef="usd">663000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTEtMS0xLTEtMQ_f4c3fbdb-0fae-4436-b87b-2ce591d119f7"
      unitRef="usd">726000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTEtMy0xLTEtMQ_23ab8ce1-f887-4d8c-b569-5abd47c21d13"
      unitRef="usd">816000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTItMS0xLTEtMQ_959e52b0-30bd-44eb-81d5-980fc2af5253"
      unitRef="usd">5962000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTItMy0xLTEtMQ_4a260ff0-92d0-49b1-85c9-78253970281f"
      unitRef="usd">6578000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTMtMS0xLTEtMQ_ea294f73-7a07-4eb7-b095-b8ed8056d379"
      unitRef="usd">8982000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTMtMy0xLTEtMQ_aaa02bd9-46f4-495c-a825-1805d445e90c"
      unitRef="usd">8982000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTQtMS0xLTEtMQ_8352c01d-1dc6-4595-a5ee-6e532bec4790"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTQtMy0xLTEtMQ_ae7ae001-8b8e-4c26-8a23-9de2fe7c603d"
      unitRef="usd">3000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTUtMS0xLTEtMQ_4c78bfb8-3d98-4414-ba75-4703b3891bd9"
      unitRef="usd">172086000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTUtMy0xLTEtMQ_095c264c-a8b9-45a4-8c2b-de8110cc595b"
      unitRef="usd">204358000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTgtMS0xLTEtMQ_f03851be-5712-4036-b227-522564c8c628"
      unitRef="usd">3506000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTgtMy0xLTEtMQ_c994859c-9d65-4dd9-991f-70b8a9018f97"
      unitRef="usd">4166000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTktMS0xLTEtMQ_7101b87b-d6f6-4d34-a435-b84bdad5a4d9"
      unitRef="usd">5310000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMTktMy0xLTEtMQ_9bd66892-9f5d-4970-9e65-e659aea71d12"
      unitRef="usd">3625000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjAtMS0xLTEtMQ_7227175f-0baa-44cd-b010-ac9531039981"
      unitRef="usd">657000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjAtMy0xLTEtMQ_af675bbb-3799-4e06-873c-426242b10bf5"
      unitRef="usd">1731000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjEtMS0xLTEtMQ_739be440-d7d3-49a9-af57-bf5a61abd3e7"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjEtMy0xLTEtMQ_e9632cc5-83dd-495e-8605-cabb5e2417e1"
      unitRef="usd">557000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjItMS0xLTEtMQ_42313092-5107-4a21-810c-76edef873fee"
      unitRef="usd">9473000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjItMy0xLTEtMQ_539afb27-354d-4bbb-b207-9f3d8db97230"
      unitRef="usd">10079000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjMtMS0xLTEtMQ_36ced6aa-43eb-4992-9e6d-dfc2bd5d8a4b"
      unitRef="usd">4537000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjMtMy0xLTEtMQ_e64a5361-e0b1-4b1c-8aab-2e7c298722d0"
      unitRef="usd">5040000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <cris:RoyaltyGuaranteesCommitmentsAmountNoncurrent
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjQtMS0xLTEtMQ_d148339a-47fd-4846-b47d-d95d2516d1a7"
      unitRef="usd">55167000</cris:RoyaltyGuaranteesCommitmentsAmountNoncurrent>
    <cris:RoyaltyGuaranteesCommitmentsAmountNoncurrent
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjQtMy0xLTEtMQ_0bbc9daa-7909-4238-b4f9-02d7212dd878"
      unitRef="usd">58235000</cris:RoyaltyGuaranteesCommitmentsAmountNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjUtMS0xLTEtMQ_da9ac315-b57e-49b2-8f7d-ed758f935fa9"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjUtMy0xLTEtMQ_abb9ed97-efa9-4c75-824a-9e078ec2c2ae"
      unitRef="usd">334000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:Liabilities
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjYtMS0xLTEtMQ_897256d5-fc21-4911-a445-73b69051b65f"
      unitRef="usd">69177000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjYtMy0xLTEtMQ_78d79ca5-7521-48aa-ac86-7171c7fc78a1"
      unitRef="usd">73688000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOjMxMWMwNmMzMjQwZDQ1MDE4ODE0YmI0ZTk2YzFmZGQzXzE4_0f3a4caa-6dcc-47d5-b826-7894aac92919"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOjMxMWMwNmMzMjQwZDQ1MDE4ODE0YmI0ZTk2YzFmZGQzXzE4_2d149b57-a4d8-4cdf-b58c-0d70197a7532"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOjMxMWMwNmMzMjQwZDQ1MDE4ODE0YmI0ZTk2YzFmZGQzXzMx_73cdac74-8170-4f71-a166-34c3105f214f"
      unitRef="shares">227812500</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOjMxMWMwNmMzMjQwZDQ1MDE4ODE0YmI0ZTk2YzFmZGQzXzUz_371de6eb-d3c0-4af4-a5f1-666bc4fad68f"
      unitRef="shares">91609165</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOjMxMWMwNmMzMjQwZDQ1MDE4ODE0YmI0ZTk2YzFmZGQzXzUz_49b99050-8df2-431b-8d83-c20d95df91ed"
      unitRef="shares">91609165</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOjMxMWMwNmMzMjQwZDQ1MDE4ODE0YmI0ZTk2YzFmZGQzXzkz_ad6c0b8b-ab56-455a-a804-cc3d5e2bec93"
      unitRef="shares">151875000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOjMxMWMwNmMzMjQwZDQ1MDE4ODE0YmI0ZTk2YzFmZGQzXzExNg_1ae39130-1e82-42a5-a922-d5bd7a677574"
      unitRef="shares">91502461</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjgtMC0xLTEtMS90ZXh0cmVnaW9uOjMxMWMwNmMzMjQwZDQ1MDE4ODE0YmI0ZTk2YzFmZGQzXzExNg_adf7dee7-67bf-4404-8f15-397a4099dd71"
      unitRef="shares">91502461</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjgtMS0xLTEtMQ_765fc52d-21ed-4656-a338-ffc357f58414"
      unitRef="usd">916000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjgtMy0xLTEtMQ_60d61621-4f41-4bcc-ade9-52c0c99ad63d"
      unitRef="usd">915000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjktMS0xLTEtMQ_ee42f761-dd69-4568-94ba-1bb26c92f183"
      unitRef="usd">1180701000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMjktMy0xLTEtMQ_01a30a6f-a521-4dc9-b6fb-a4c44cc3c215"
      unitRef="usd">1176647000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMzAtMS0xLTEtMQ_4bdc5ab6-9a7d-4f2c-8296-c605b5efa1dc"
      unitRef="usd">-1078705000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMzAtMy0xLTEtMQ_758c1afc-3f74-470c-871e-ab5316b19c53"
      unitRef="usd">-1046889000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMzEtMS0xLTEtMQ_7885240a-5cca-4bfd-9a4a-4cdb76425b22"
      unitRef="usd">-3000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMzEtMy0xLTEtMQ_eb25793d-63d4-4db3-9fbf-a641ce7bb856"
      unitRef="usd">-3000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMzItMS0xLTEtMQ_8f70447d-ea1e-4ad4-a4fd-7cb713230973"
      unitRef="usd">102909000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMzItMy0xLTEtMQ_e0e4193f-2333-4032-b94f-d0f056608124"
      unitRef="usd">130670000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMzMtMS0xLTEtMQ_c69c0f30-a08e-48fc-b2a0-08c0581bc068"
      unitRef="usd">172086000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xNi9mcmFnOjdhNjRmN2NhM2E2MzRiMzlhNjM2MjE0ZDY0YzM3MmI3L3RhYmxlOmMxZmYyMWQwMTNkMjQzOGI4MWUwMDdhYzVlYjgxMGZkL3RhYmxlcmFuZ2U6YzFmZjIxZDAxM2QyNDM4YjgxZTAwN2FjNWViODEwZmRfMzMtMy0xLTEtMQ_c6b8b572-9e5a-43ae-ad43-7d7ee71c8581"
      unitRef="usd">204358000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i533a446c7b4c4bbd9762a2f0852c2191_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMy0xLTEtMS0x_1a5dddd0-26a1-46fc-97a7-958b1482693f"
      unitRef="usd">3058000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e6bc48882e74b6dbc7edc5bfb61e854_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMy0zLTEtMS0x_60e09de3-42ba-475e-85ba-f7714eb0dc97"
      unitRef="usd">2720000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i430322671c674a2e9ecf19555642b870_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMy01LTEtMS0x_66eb645c-d3a7-408d-b8df-e885ac86632b"
      unitRef="usd">7593000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifdd8513423b24617ae9145402fcccf5e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMy03LTEtMS0x_887a0df2-faf0-4a95-b395-c84c37e9e6ee"
      unitRef="usd">7681000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7059a303d18b4097838037b575847c70_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfNC0xLTEtMS0x_719969bf-65da-40f1-87db-9af5eb606c28"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i995dfcf8f34847c9b9eac02305265435_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfNC0zLTEtMS0x_8fca9709-614d-4b05-8cdc-1a4fd7bf0b30"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia720d94f508f4eb2a4f3c307eedfe435_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfNC01LTEtMS0x_f79d72af-8c4c-475d-805c-3ffac3c271d6"
      unitRef="usd">1000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fe8f17e9bca46a08a36d1be114833e2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfNC03LTEtMS0x_0c922229-7abf-4029-a0fe-3ff33b413046"
      unitRef="usd">211000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4d63a2bfd9a446bb2f258585206efff_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfNS0xLTEtMS0x_c523432a-9317-4d80-89e2-a1da898fb015"
      unitRef="usd">-19000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2377a33c77ce4828b22b332828013bd7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfNS0zLTEtMS0x_342a7d57-312b-4f39-958f-de3b496064aa"
      unitRef="usd">22000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic76462d861cb47cc9c192a17cca41dd6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfNS01LTEtMS0x_3ba71975-23b5-41a7-b8d6-db06f8888796"
      unitRef="usd">-80000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac7eb7aada544feeb409a3508f46d4a8_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfNS03LTEtMS0x_776ec87d-dfff-48ba-a2a9-b8d386dc94c0"
      unitRef="usd">-81000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfNi0xLTEtMS0x_58c41428-bbee-4833-b538-35dee5200c01"
      unitRef="usd">3039000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfNi0zLTEtMS0x_2d731600-2c0a-43e5-86e5-da75d63abe11"
      unitRef="usd">2742000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfNi01LTEtMS0x_d31511ed-66b5-4684-bac6-e7cb7325fbbb"
      unitRef="usd">7514000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfNi03LTEtMS0x_cda4ef74-4af0-4c30-a5e7-3ec6fa3c7288"
      unitRef="usd">7811000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RoyaltyExpense
      contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfOC0xLTEtMS0x_7b497f64-5f79-40b6-bc29-56133db6fae4"
      unitRef="usd">151000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfOC0zLTEtMS0x_4781b3af-7386-4fe1-b5d2-4ff795d3a1ac"
      unitRef="usd">135000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfOC01LTEtMS0x_005ec0e5-4508-45e9-875e-e5202ad18e71"
      unitRef="usd">376000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfOC03LTEtMS0x_d7881fd5-38af-47b5-b7a2-925f0b9ad2e4"
      unitRef="usd">382000</us-gaap:RoyaltyExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfOS0xLTEtMS0x_72da1a50-0d60-4d30-a6c9-850a097ee299"
      unitRef="usd">8602000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfOS0zLTEtMS0x_d4d4c6da-4347-4ab2-b32e-bf7ffcac1484"
      unitRef="usd">4705000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfOS01LTEtMS0x_eb2b3cc4-a9d5-444d-bd59-4593e240435b"
      unitRef="usd">24112000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfOS03LTEtMS0x_060d4ec9-ab81-464d-bdf5-e33332c78eb2"
      unitRef="usd">17459000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTAtMS0xLTEtMQ_9d6ba295-2234-4ed7-ad21-80000559f267"
      unitRef="usd">4334000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTAtMy0xLTEtMQ_e6f58e87-2ce5-4d05-a1bf-bdbdfe3d4c07"
      unitRef="usd">2613000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTAtNS0xLTEtMQ_9761cbaf-4208-41af-8b83-d9e69344e2db"
      unitRef="usd">12524000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTAtNy0xLTEtMQ_d0ba81c0-5dcd-4592-b074-5bc709259f5d"
      unitRef="usd">8593000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTEtMS0xLTEtMQ_3de959d7-4ca2-4d21-91d2-ff6419ea3bb8"
      unitRef="usd">13087000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTEtMy0xLTEtMQ_67ae12da-1451-48bb-9354-427d05de7d3c"
      unitRef="usd">7453000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTEtNS0xLTEtMQ_c2c4fd13-ea92-49f4-a886-3d65072959c1"
      unitRef="usd">37012000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTEtNy0xLTEtMQ_9cc7ad24-204c-4632-96a1-32a5b6953f73"
      unitRef="usd">26434000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTItMS0xLTEtMQ_6eb1528e-0c29-47b6-ad86-3046472bcec9"
      unitRef="usd">-10048000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTItMy0xLTEtMQ_31880012-8f34-468c-94d3-068699cab8be"
      unitRef="usd">-4711000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTItNS0xLTEtMQ_4f90b711-aa41-4981-b51b-2b5fedd82b4c"
      unitRef="usd">-29498000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTItNy0xLTEtMQ_002fbd01-5574-4414-90da-6b5e60134592"
      unitRef="usd">-18623000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTUtMS0xLTEtMQ_5b206c56-5ae6-4adf-9b92-b7cff0332866"
      unitRef="usd">54000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTUtMy0xLTEtMQ_e435ab4c-af61-4280-b4bf-211ff15f6a8c"
      unitRef="usd">3000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTUtNS0xLTEtMQ_a8591bc4-7021-4d68-a33c-910508790c7e"
      unitRef="usd">158000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTUtNy0xLTEtMQ_9972646c-a135-4769-a475-893fd7da056b"
      unitRef="usd">58000</us-gaap:InvestmentIncomeInterest>
    <cris:NonCashImputedInterestExpense
      contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTYtMS0xLTEtMQ_17fb27d6-440b-4979-9ac3-35e10ff699f6"
      unitRef="usd">1057000</cris:NonCashImputedInterestExpense>
    <cris:NonCashImputedInterestExpense
      contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTYtMy0xLTEtMQ_4fbd7f48-c92a-4882-8a2f-e4b2e1ab69b4"
      unitRef="usd">1266000</cris:NonCashImputedInterestExpense>
    <cris:NonCashImputedInterestExpense
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTYtNS0xLTEtMQ_bacc5402-cc3a-4ebf-ac5e-41d059bc34e0"
      unitRef="usd">3366000</cris:NonCashImputedInterestExpense>
    <cris:NonCashImputedInterestExpense
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTYtNy0xLTEtMQ_bcc17653-505e-4244-8f0d-00c38948b6c2"
      unitRef="usd">3848000</cris:NonCashImputedInterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTgtMS0xLTEtMQ_080edac3-6fbd-4500-ac80-e6c9aef83789"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTgtMy0xLTEtMQ_4e2450f9-3961-41db-b9e8-3f37501e2719"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTgtNS0xLTEtMQ_171557b9-0a86-400a-9339-c5883f153f13"
      unitRef="usd">890000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTgtNy0xLTEtMQ_39759f57-7dd0-45a1-9f64-164f27cd490d"
      unitRef="usd">22000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTktMS0xLTEtMQ_b8592d25-eae1-4d1d-b375-b3fd3b8e6c43"
      unitRef="usd">-1003000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTktMy0xLTEtMQ_6ce84aa3-080c-40f5-8df0-b6862e710779"
      unitRef="usd">-1263000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTktNS0xLTEtMQ_862d37d6-5985-4b13-959a-4b67832745ca"
      unitRef="usd">-2318000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMTktNy0xLTEtMQ_c8ed7974-225f-49c1-ad4c-f6cae945509c"
      unitRef="usd">-3768000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjAtMS0xLTEtMQ_abd02570-76d7-49b4-9fe7-ea6d138b20cb"
      unitRef="usd">-11051000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjAtMy0xLTEtMQ_572120dc-0bcb-4fcf-8b68-bc725ce41ad1"
      unitRef="usd">-5974000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjAtNS0xLTEtMQ_cd7b07c1-2b6a-4707-84a5-5f132320b985"
      unitRef="usd">-31816000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjAtNy0xLTEtMQ_6b44677d-a22f-4842-878f-cee9c7682dff"
      unitRef="usd">-22391000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjEtMS0xLTEtMQ_7c6cbfff-c096-44d9-9137-84dab33fca64"
      unitRef="usdPerShare">-0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjEtMS0xLTEtMQ_cad53d5e-2c55-4751-a497-37229a166723"
      unitRef="usdPerShare">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjEtMy0xLTEtMQ_49ea4a5f-cdbd-4471-925e-43ade6289321"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjEtMy0xLTEtMQ_9032a96d-81c9-4827-ae28-799a2bb10bf3"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjEtNS0xLTEtMQ_9f46e4dc-828d-412f-a5d7-6a37c8d9bb3f"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjEtNS0xLTEtMQ_f4d96ebb-c19b-4535-aca4-def9e6a4f818"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjEtNy0xLTEtMQ_8d79d997-215b-403f-8458-f19c61396ec0"
      unitRef="usdPerShare">-0.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjEtNy0xLTEtMQ_aaadeaa4-5a4c-4f4a-9245-0adbabd66388"
      unitRef="usdPerShare">-0.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjItMS0xLTEtMQ_d3da5b63-1970-4dde-b403-8ffd43b1965d"
      unitRef="shares">91601362</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjItMS0xLTEtMQ_dd19bf7b-ebe2-4da5-8f59-3c5147857876"
      unitRef="shares">91601362</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjItMy0xLTEtMQ_25605c8a-6152-4c04-95db-461d33770a10"
      unitRef="shares">54554129</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjItMy0xLTEtMQ_c2bb0358-6328-4698-bec8-72474e72bb20"
      unitRef="shares">54554129</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjItNS0xLTEtMQ_0143a8cb-54e5-48a4-be9e-324389a28cb7"
      unitRef="shares">91552433</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjItNS0xLTEtMQ_13b4c177-676c-491d-abcb-7944e75ae438"
      unitRef="shares">91552433</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjItNy0xLTEtMQ_0c5e2b20-ba1b-413e-9702-fe3830edeb97"
      unitRef="shares">42884201</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjItNy0xLTEtMQ_466f9453-57a5-448f-9d5d-14fc06a6f88d"
      unitRef="shares">42884201</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjMtMS0xLTEtMQ_bbfda567-30ee-4a1e-893b-2e657d55f932"
      unitRef="usd">-11051000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjMtMy0xLTEtMQ_b7af17d9-26b9-4d07-9ecc-ad6dda628c6c"
      unitRef="usd">-5974000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjMtNS0xLTEtMQ_1ee188ee-06f6-44e4-bc79-3c80983a1407"
      unitRef="usd">-31816000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjMtNy0xLTEtMQ_809bde1a-f0c5-44f8-978b-fa050c34c5d2"
      unitRef="usd">-22391000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjUtMS0xLTEtMQ_1165e9e1-b70c-4f9f-bfba-b576724435e2"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjUtMS0xLTEtMQ_3cd2fa83-cadd-473e-8cef-1982a23f0515"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjUtMy0xLTEtMQ_ebd11549-b1a6-4ec7-82d7-9da3364ccb1b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjUtNS0xLTEtMQ_783988be-2329-4473-9dd9-1a47978d2785"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjUtNy0xLTEtMQ_4ef329c1-6bf6-49b8-a2d7-33d5a3dd5bc8"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjYtMS0xLTEtMQ_04f30df2-5e3e-4719-a42c-d988dc6257f5"
      unitRef="usd">-11051000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjYtMy0xLTEtMQ_fa5cde1a-5b63-4589-a072-6941342ea86b"
      unitRef="usd">-5974000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjYtNS0xLTEtMQ_aff3ea17-0010-43f3-8f0b-8ff2485f35a7"
      unitRef="usd">-31816000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18xOS9mcmFnOmFkYzMxY2IzOTY0MDQxZWJiMTkxMDQzOTY1MzU5MGMwL3RhYmxlOjQ4OWNhNjg5ZmIyMTQxN2E5YzViOTgyMmExYWFiZDNkL3RhYmxlcmFuZ2U6NDg5Y2E2ODlmYjIxNDE3YTljNWI5ODIyYTFhYWJkM2RfMjYtNy0xLTEtMQ_a185a1ff-5518-42ba-bb9b-acc31d754d4b"
      unitRef="usd">-22391000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i67dd4d38bbfc42dcac4661194af3c1b4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMi0xLTEtMS0x_f71fd034-9d35-42ed-82a1-b89ea22f30f5"
      unitRef="shares">91502461</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i67dd4d38bbfc42dcac4661194af3c1b4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMi0zLTEtMS0x_a9021486-6557-47cd-ab9e-e2b96b6e7030"
      unitRef="usd">915000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0ca78b914bf041dc884674999397831a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMi01LTEtMS0x_9e08a794-4537-4f19-8f5b-ef3fa5dbb394"
      unitRef="usd">1176647000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i50c937c85a114412bbb18451d45b1f0b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMi05LTEtMS0x_fa675838-2fd6-4f1a-9b98-cd0136c0c183"
      unitRef="usd">-1046889000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifc7b92e171e5450db55aa4c462149d6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMi0xMS0xLTEtMQ_8c388e28-97cc-4000-959e-a0edac573033"
      unitRef="usd">-3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMi0xMy0xLTEtMQ_92c888f7-948e-4b11-bd36-52cde119e653"
      unitRef="usd">130670000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i60293bf8d8b34ce2b686154bc0dc8870_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMy01LTEtMS0x_660658f9-7b65-4d99-a1b3-e7dbbd5ce7c2"
      unitRef="usd">1099000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id12cf2f5b2304c4187ba46547f160ae5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMy0xMy0xLTEtMQ_03c6d208-3dad-4b32-844e-5c901f159b6d"
      unitRef="usd">1099000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if39a3310599b4dc48df4759fd2f23b75_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfNS0xLTEtMS0x_b6828ad9-59f4-4fb0-b626-1d8fd1a97f4d"
      unitRef="shares">31811</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if39a3310599b4dc48df4759fd2f23b75_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfNS0zLTEtMS0x_7e61601d-8bdb-45f9-bee7-4ceef62077c2"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i60293bf8d8b34ce2b686154bc0dc8870_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfNS01LTEtMS0x_e380dbec-6600-42b0-8ad1-cf994637b6a6"
      unitRef="usd">78000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id12cf2f5b2304c4187ba46547f160ae5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfNS0xMy0xLTEtMQ_762e1eac-4318-4e37-a3ec-09e7a6168538"
      unitRef="usd">79000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="ibfe15ac9fbdb4c41a9436d65053dd823_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfNi0xMS0xLTEtMQ_a035d22c-ccda-4377-858f-fed89aa93d52"
      unitRef="usd">-6000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="ibfe15ac9fbdb4c41a9436d65053dd823_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfNi0xMS0xLTEtMQ_a6967f0f-c7a2-4c99-a2f6-29592c9258e6"
      unitRef="usd">-6000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="id12cf2f5b2304c4187ba46547f160ae5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfNi0xMy0xLTEtMQ_2f469768-cfd7-48a7-a64e-a8034cebc3ca"
      unitRef="usd">-6000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6273ec08929c4042b363f75dc65c925f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfNy05LTEtMS0x_d13481e3-eaf9-4144-8cb6-08415e5cd3d1"
      unitRef="usd">-9927000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id12cf2f5b2304c4187ba46547f160ae5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfNy0xMy0xLTEtMQ_ce1c4137-fb02-4fa0-886b-8bb983e934d3"
      unitRef="usd">-9927000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5ad6fa8151644284ba6c19774592e6d0_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfOC0xLTEtMS0x_fab203c4-9f04-4013-91c7-ae77b32b9a4f"
      unitRef="shares">91534272</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i5ad6fa8151644284ba6c19774592e6d0_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfOC0zLTEtMS0x_444b45d7-28e3-400c-8bb9-7d7d25949adb"
      unitRef="usd">916000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id26880c55f3b45a6ad8a5ccba68564a1_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfOC01LTEtMS0x_cf5e4392-2ddf-4d41-a0a8-c320d7ed4133"
      unitRef="usd">1177824000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifcd76ade8392457889758a7b96e60905_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfOC05LTEtMS0x_8c32eba0-04a1-4fd2-a57f-034c5bfa26c3"
      unitRef="usd">-1056816000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3a966410bb90428a843d3f569be9b164_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfOC0xMS0xLTEtMQ_20b4affb-e8a7-4989-be9e-e1495aa3e360"
      unitRef="usd">-9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia8d1462eadbb4aa1a9833bece5ae287b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfOC0xMy0xLTEtMQ_5e4a4c23-1139-434f-8f42-ee067f727f1e"
      unitRef="usd">121915000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id8fc6b4c7394423b8ec79ccd7eae0b2a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfOS01LTEtMS0x_917cd12d-d904-4b5b-b05c-5f5820472fe7"
      unitRef="usd">1275000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6d24421a8b204e50b645dcdee96de56f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfOS0xMy0xLTEtMQ_9c73c48d-3cf9-482c-9b1d-dc25146fc405"
      unitRef="usd">1275000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ib83f38159c0d47a39e7ba5f026425795_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTAtMS0xLTEtMQ_c126fdb1-082a-4a8c-83d2-f62d81ce9b00"
      unitRef="shares">20791</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="id8fc6b4c7394423b8ec79ccd7eae0b2a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTAtNS0xLTEtMQ_2a57e9e4-0c7e-4c15-b329-fcc1f8d374a2"
      unitRef="usd">68000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="i6d24421a8b204e50b645dcdee96de56f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTAtMTMtMS0xLTE_42f3a5e6-9456-409d-a4f5-ca012eb9469d"
      unitRef="usd">68000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ib83f38159c0d47a39e7ba5f026425795_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTEtMS0xLTEtMQ_1d6e3173-f476-4bdb-813f-1f785c5be796"
      unitRef="shares">41306</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id8fc6b4c7394423b8ec79ccd7eae0b2a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTEtNS0xLTEtMQ_1ef68075-4735-4d04-b17e-1b12e67f9c54"
      unitRef="usd">48000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6d24421a8b204e50b645dcdee96de56f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTEtMTMtMS0xLTE_63b1d1ae-e521-4eb3-bd54-64954bbbd9e6"
      unitRef="usd">48000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i7aab08630ed447578b4a6fabcff3af4a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTItMTEtMS0xLTE_667535f7-5d2b-417a-8c9e-8f3970e5a8d3"
      unitRef="usd">6000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i6d24421a8b204e50b645dcdee96de56f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTItMTMtMS0xLTE_93546e31-cc84-491d-a648-270032f8d97d"
      unitRef="usd">6000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i57052d63d35b413e91d2037ed469551b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTMtOS0xLTEtMQ_cf366dee-8606-491d-81bb-f3030ec2f167"
      unitRef="usd">-10838000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6d24421a8b204e50b645dcdee96de56f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTMtMTMtMS0xLTE_1252c9c2-f475-4203-95bd-0698b8811029"
      unitRef="usd">-10838000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8c2d8b06604949d8b1946a6b3626e498_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTQtMS0xLTEtMQ_814bff76-f548-47c3-a851-b771934bf2cd"
      unitRef="shares">91596369</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i8c2d8b06604949d8b1946a6b3626e498_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTQtMy0xLTEtMQ_2fe3fa72-c80f-4040-93f1-c49aa6a43c57"
      unitRef="usd">916000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if008f4d0347f4f1e96cd9a5e2c5bc985_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTQtNS0xLTEtMQ_4b186679-25fd-4276-845e-3cc8175e4ea9"
      unitRef="usd">1179215000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ife718f47b62e4c3687c07aa35e307ce2_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTQtOS0xLTEtMQ_53c502b6-9fd1-41b2-829a-ce3d25211c0a"
      unitRef="usd">-1067654000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i373c682106604fba9c0c257203578939_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTQtMTEtMS0xLTE_d62f10be-27fa-422c-b570-2a7b44ee1601"
      unitRef="usd">-3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0a91365e4a5949bf9ba583bd68d30198_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTQtMTMtMS0xLTE_50bbc24b-22ed-47d5-9f4e-40a26ed0d685"
      unitRef="usd">112474000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1556c61df1fe4774856be3b37d7866b3_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTUtNS0xLTEtMTMxMDA_6c2ed5ba-54e0-41af-b7dc-240df8ab66e7"
      unitRef="usd">1464000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTUtMTMtMS0xLTEzMTAz_d1372263-89aa-4dd1-be0a-ac6efc3e6f4d"
      unitRef="usd">1464000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if16ae74c3f204c54a9fdb59324c1a8c1_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTYtMS0xLTEtMTMxMDU_022f1e5b-52db-4ec5-9d27-da98ccbae7d9"
      unitRef="shares">12796</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1556c61df1fe4774856be3b37d7866b3_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTYtNS0xLTEtMTMxMDk_5fffb685-f3a3-4c05-b3b5-abb89ea9b4af"
      unitRef="usd">22000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTYtMTMtMS0xLTEzMTEx_924dddd0-f775-421d-9398-cc37a5ce7bad"
      unitRef="usd">22000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="ib819b69ecf0d4a69af2a5cfdb3d3f29d_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTctMTEtMS0xLTEzMTEz_2ccc5fe1-8316-419c-8460-d71747130a1f"
      unitRef="usd">0</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTctMTMtMS0xLTEzMTIz_8b43d1c2-6b72-4c3e-a759-edc75c63b048"
      unitRef="usd">0</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i496aa636a74449e6bb23b783bf1af401_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTgtOS0xLTEtMTM4MDg_28fefd93-6ff0-46d8-893d-911733fefed9"
      unitRef="usd">-11051000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTgtMTMtMS0xLTE0MDY1_91b93d7d-3ecd-41c2-ba3c-7651d70cfea9"
      unitRef="usd">-11051000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="i59c5613ca42840cd90b239dfeb0d2776_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTgtMS0xLTEtMTMxMjE_9ca93a86-8cdd-4640-934d-40fd1230c6b2"
      unitRef="shares">91609165</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i59c5613ca42840cd90b239dfeb0d2776_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTgtMy0xLTEtMTMxMTk_9e1dbe94-f751-48cf-b5c4-17283963fc34"
      unitRef="usd">916000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3c0d8228dd6c47dc8835400718fb7794_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTgtNS0xLTEtMTMxMTc_46132b07-3492-410f-82a7-1ed234c37566"
      unitRef="usd">1180701000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id82880f87ee44511a970554ad14e0b2c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTgtOS0xLTEtMTMxMTU_4f237f2a-030e-45f9-b674-9a1183f86f1c"
      unitRef="usd">-1078705000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0c7dd4eefa794b288e0e2911576a70f1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTgtMTEtMS0xLTEzMTEz_38943766-7359-486c-998c-84a46cbfe63a"
      unitRef="usd">-3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOjk1ODYxN2MxMjQzYTQ3ZmNiNzBkOWMyNTdiZmUzZDNlL3RhYmxlcmFuZ2U6OTU4NjE3YzEyNDNhNDdmY2I3MGQ5YzI1N2JmZTNkM2VfMTgtMTMtMS0xLTEzMTIz_f4e1e9f0-8ec9-4b5f-8501-a929c24ca49f"
      unitRef="usd">102909000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="i59d2a236085c4461b444f9e731b5d83a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMi0xLTEtMS0x_402de9ff-dd79-4566-9f5f-7fc64cb72ba8"
      unitRef="shares">33241793</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i59d2a236085c4461b444f9e731b5d83a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMi0zLTEtMS0x_4b18682a-714a-479b-aa4a-b5f506e1b5df"
      unitRef="usd">332000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i77cd53b4f6e44e56bc18efef6b6c48fe_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMi01LTEtMS0x_ae706281-c040-4cbc-affb-f8736df1c838"
      unitRef="usd">982738000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iff6f88189e6c489fadca834518204877_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMi05LTEtMS0x_99805ccc-b897-43b9-9d3f-5451cb1aedd4"
      unitRef="usd">-1016981000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i60b1a5740938422195d69fe89e22dbc2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMi0xMS0xLTEtMQ_a59dc1a5-594f-4821-a8c8-3757bbc725c9"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i74e73d5375984977b6347e5a763139d0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMi0xMy0xLTEtMQ_67e8ca0a-8faf-43c6-8dd0-7230a8d2cef4"
      unitRef="usd">-33911000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i773b93e5620347e1ab3d326166347a05_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMy01LTEtMS0x_acf062c2-d799-47d0-82f0-b1350a8aaf58"
      unitRef="usd">625000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib3df11fcc545447489bc72b8df5ec6a5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMy0xMy0xLTEtMQ_a8058031-f91b-4f3b-bc9c-0c6731dc94cf"
      unitRef="usd">625000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i2b54cebb2076495ebc3a6534669720f4_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNC0xLTEtMS0x_b502dd7e-7aff-4ce4-aee2-9857ef21c987"
      unitRef="shares">3340516</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2b54cebb2076495ebc3a6534669720f4_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNC0zLTEtMS0x_ad8eaeae-b51c-4e51-8d3b-e2c1549430cc"
      unitRef="usd">34000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i668eb741fed8462b9be0b59ca9b25135_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNC01LTEtMS0x_2b51cf1f-40e6-4c61-aa2b-1c783c961ab1"
      unitRef="usd">2692000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i00fcba8a8a6049a0b2dd2926f0f9f9d3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNC0xMy0xLTEtMQ_321e3602-90ec-4f5b-a5c5-cad74ce4f2c3"
      unitRef="usd">2726000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="iaf69f9380ea04321ac14ce6785b41f7c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNS05LTEtMS0x_39ebe2a6-8ea7-4f14-8103-1e0a6ee97346"
      unitRef="usd">-9709000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib3df11fcc545447489bc72b8df5ec6a5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNS0xMy0xLTEtMQ_7c2ad8fe-4d96-4e38-898a-6be4ed5fe0c1"
      unitRef="usd">-9709000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2c1929f827ff4826a126b14efa9ed807_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNi0xLTEtMS0x_f6bf93ab-f1b6-496e-960d-f7ccd3873968"
      unitRef="shares">36582309</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i2c1929f827ff4826a126b14efa9ed807_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNi0zLTEtMS0x_fd824020-da15-41ed-aa91-dcaa8df4de66"
      unitRef="usd">366000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic5f6802b38e34cdca4064f21d5ed6f28_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNi01LTEtMS0x_943bc33a-ae56-41cb-a757-3e6ded5e8f13"
      unitRef="usd">986055000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iab83bec3cf434ed190d72f069b95e844_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNi05LTEtMS0x_66e20a9f-f621-4140-a2c9-a56873a23a85"
      unitRef="usd">-1026690000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3398a93d47d24500ab8ab9d0d4a0aae0_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNi0xMS0xLTEtMQ_fb17ba1a-94d4-48af-8d80-4a3af57c5cd1"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id3db7b202b9742b4ba2ad6c5070f5d3a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNi0xMy0xLTEtMQ_934001c8-1a51-4ee8-95e4-086fe64303ae"
      unitRef="usd">-40269000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ie7587529ce7947f8ba47ac622a4fc47e_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNy0xLTEtMS0x_25b7faf7-b4cf-4f20-839b-5cad24a71209"
      unitRef="shares">14000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie7587529ce7947f8ba47ac622a4fc47e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNy0zLTEtMS0x_b29b5f06-f3a9-48de-b725-634aa646ed89"
      unitRef="usd">140000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5e195d3203824b3d9aab16f7ec0f0922_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNy01LTEtMS0x_0ab037ab-79f8-43aa-b819-e7c79edb9225"
      unitRef="usd">15825000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i74f2b1fab46944cf9e3f63c1971776bf_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfNy0xMy0xLTEtMQ_8a70f610-8698-4e8e-a406-64459d166691"
      unitRef="usd">15965000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i160c6a5048d844c1bb83e8a5d34a79cb_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfOC01LTEtMS0x_1bf4f013-06c8-4e5f-bb92-eaf0568977f2"
      unitRef="usd">585000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i74f2b1fab46944cf9e3f63c1971776bf_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfOC0xMy0xLTEtMQ_8717edff-6302-47d2-ba7b-f7731e4a21b5"
      unitRef="usd">585000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="id4a6ffee772a437a8a6979d274823c5a_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfOS0xLTEtMS0x_086a5135-9475-4536-9cb2-713645f0e2fa"
      unitRef="shares">41583</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i160c6a5048d844c1bb83e8a5d34a79cb_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfOS01LTEtMS0x_44d144db-dfa7-4e4a-8a29-7de32eb04336"
      unitRef="usd">29000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i74f2b1fab46944cf9e3f63c1971776bf_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfOS0xMy0xLTEtMQ_11a8de38-012f-419a-bd71-be92c82a8e27"
      unitRef="usd">29000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id4a6ffee772a437a8a6979d274823c5a_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTAtMS0xLTEtMQ_c5066ef1-60b9-47f9-acf5-d812c859f5a6"
      unitRef="shares">15156</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i160c6a5048d844c1bb83e8a5d34a79cb_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTAtNS0xLTEtMQ_94fbd24b-a0d4-4bfc-88ae-175d67007372"
      unitRef="usd">18000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i74f2b1fab46944cf9e3f63c1971776bf_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTAtMTMtMS0xLTE_e1e690fe-bd56-4cb4-bbd0-2cfee36f3a95"
      unitRef="usd">18000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="idb5feb63bb884b278199f05efec2e882_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTEtOS0xLTEtMQ_d69e9881-1c88-4a46-8e26-1a22e7e355de"
      unitRef="usd">-6708000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i74f2b1fab46944cf9e3f63c1971776bf_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTEtMTMtMS0xLTE_19e5200d-1108-4156-8601-5263de4bff54"
      unitRef="usd">-6708000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib1145ae8cfec46ea9d2ea1ff2a92e958_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTItMS0xLTEtMQ_801b3deb-9121-4d93-b3e4-90c38fde8970"
      unitRef="shares">50639048</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ib1145ae8cfec46ea9d2ea1ff2a92e958_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTItMy0xLTEtMQ_1181a579-c14e-4dee-9e45-83e713756f2a"
      unitRef="usd">506000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5fdb43e2101b443f8adf0e0948bf2820_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTItNS0xLTEtMQ_7c9eea90-503c-45fb-9d50-5564282dd202"
      unitRef="usd">1002512000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i79eb58664af1462c86740522e97626dc_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTItOS0xLTEtMQ_905029b3-be7b-4b23-9ace-284b6f6c4f72"
      unitRef="usd">-1033398000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i81c6a9cdd6304647889f68d7fc513971_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTItMTEtMS0xLTE_fdede2d9-484b-4368-bd4d-e92ad5228e8f"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6e2324829cfe492bb1ce3a18540cabae_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTItMTMtMS0xLTE_26a89107-1e71-47ad-9ac2-fcfe2d116341"
      unitRef="usd">-30380000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i5696cc43a1414c5eb951ffb14fe34541_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTMtMS0xLTEtMTMxMjU_0ffa63b8-2fe8-4e34-9828-1d5a06225850"
      unitRef="shares">3600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5696cc43a1414c5eb951ffb14fe34541_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTMtMy0xLTEtMTMxMzI_387258a1-5f5e-4b29-ab79-9922951b78a6"
      unitRef="usd">36000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id551d22461aa42b4ac2f10c2d9ef6e0d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTMtNS0xLTEtMTMxMzQ_8036ccae-bfb7-4298-ab31-31720139b4d5"
      unitRef="usd">4119000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ied34bb1c61f14a14b532c5987fe42f4d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTMtMTMtMS0xLTEzMTM2_09647e65-085e-4cc8-8c56-b85152591528"
      unitRef="usd">4155000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i68950601d26a41dca198d584853b5317_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTQtMS0xLTEtMTMxMjU_2175b051-a637-43af-9bca-743d2913be95"
      unitRef="shares">2413837</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i68950601d26a41dca198d584853b5317_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTQtMy0xLTEtMTMxMzI_c6d03fd8-e858-463a-857f-2cb487d78598"
      unitRef="usd">24000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic5d45aa56d6e4b4888724ffa54069f9a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTQtNS0xLTEtMTMxMzQ_45cae60a-5002-4f1a-adea-47622afc0be2"
      unitRef="usd">3205000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i243b02ffde754d02a51ddcf82577ece7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTQtMTMtMS0xLTEzMTM2_361415e5-bede-46df-825c-8ce1ba8922b2"
      unitRef="usd">3229000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i6334c899a5394f309f5ba35f98753e11_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTUtNS0xLTEtMTMxMzQ_c57ab141-3ca7-4a85-b5bf-c6041977fe54"
      unitRef="usd">262000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTUtMTMtMS0xLTEzMTM2_13358417-9e31-4f80-9f50-e63e5e7b0b35"
      unitRef="usd">262000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6334c899a5394f309f5ba35f98753e11_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTYtNS0xLTEtMTMxMzQ_ad747adc-ffc6-4bf8-b316-005c99ed4cdb"
      unitRef="usd">624000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTYtMTMtMS0xLTEzMTM2_0d91ea61-b275-45a8-a9e3-3d082f34bbc4"
      unitRef="usd">624000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i84408fe3e0ed4336aa0f6ff3095dd860_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTctOS0xLTEtMTMxNDQ_caff020d-1edf-4535-b21a-a9b3a8c82bf0"
      unitRef="usd">-5974000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTctMTMtMS0xLTEzMTM2_cd193b2c-b13c-4565-942a-47f293097242"
      unitRef="usd">-5974000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="i484203a4a3aa47f5a945b8781929feb6_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTgtMS0xLTEtMTMxNDg_04e4cd23-83e1-438c-89e4-ba27afd7165a"
      unitRef="shares">56652885</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i484203a4a3aa47f5a945b8781929feb6_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTgtMy0xLTEtMTMxNDY_dc7dcc97-d50f-4455-a08d-b3fe814caf3b"
      unitRef="usd">566000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id7fc2a9a1f5c430ab65ea66663c830cd_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTgtNS0xLTEtMTMxNDI_0b120048-b5f8-4113-84a1-8b2c40c27b79"
      unitRef="usd">1010198000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie1072f132f4d4820b9dfdf6759a5c275_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTgtOS0xLTEtMTMxNDA_eb75bad2-4bc5-4487-988f-fe63561682c7"
      unitRef="usd">-1039372000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ice8c0d0a4a4c414b80040c8507090a61_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTgtMTEtMS0xLTEzMTM4_5dfd096e-aaff-4b9d-b4d1-8e99c133578f"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i115d55a1156e4c969b9b8083b7760eb1_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yMi9mcmFnOjY3MzRkZGMzYjc1ODQxZjdhMzUzZWM2OGI5NDg5ZTg0L3RhYmxlOmEyY2U3ZDY3ZjRjMzRiMDhiMzgyYjQzNTI1MzhjZTkzL3RhYmxlcmFuZ2U6YTJjZTdkNjdmNGMzNGIwOGIzODJiNDM1MjUzOGNlOTNfMTgtMTMtMS0xLTEzMTM2_15237eaf-8156-4790-b139-3c9355cebd59"
      unitRef="usd">-28608000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMy0xLTEtMS0x_a9c82b75-6783-4e9c-ac0e-6add4ed8ed63"
      unitRef="usd">-31816000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMy0zLTEtMS0x_7dc0ba1b-5263-4c3b-8d32-0ed9a3c172d7"
      unitRef="usd">-22391000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNS0xLTEtMS0x_d0f02373-9143-48f5-a0cc-967a443ffd3d"
      unitRef="usd">120000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNS0zLTEtMS0x_4cb32c90-9d45-4b3d-aa7c-f1ffe5dad370"
      unitRef="usd">116000</us-gaap:DepreciationAndAmortization>
    <cris:NonCashLeaseExpense
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNi0xLTEtMS0x_309c2586-6559-4971-9691-c29be66f9fa0"
      unitRef="usd">616000</cris:NonCashLeaseExpense>
    <cris:NonCashLeaseExpense
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNi0zLTEtMS0x_509cdb44-174e-400f-87f1-65266914b45f"
      unitRef="usd">431000</cris:NonCashLeaseExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfOC0xLTEtMS0x_1dfa9714-3bb4-41b0-8510-b5cc00abe858"
      unitRef="usd">3838000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfOC0zLTEtMS0x_df831e21-c972-4a2d-9ef5-4c12a9bdd6f8"
      unitRef="usd">1833000</us-gaap:ShareBasedCompensation>
    <cris:NonCashImputedInterestExpenseNetOfImputedInterest
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMTAtMS0xLTEtMQ_c6c5e976-4c5e-4b23-8ab5-4f35a2f42a22"
      unitRef="usd">9000</cris:NonCashImputedInterestExpenseNetOfImputedInterest>
    <cris:NonCashImputedInterestExpenseNetOfImputedInterest
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMTAtMy0xLTEtMQ_d9f69067-5f82-4842-b7a6-0e6b3262e4ea"
      unitRef="usd">35000</cris:NonCashImputedInterestExpenseNetOfImputedInterest>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMTEtMS0xLTEtMQ_4906fa24-2495-4421-a6f1-9fa98f86b75a"
      unitRef="usd">-1013000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMTEtMy0xLTEtMQ_28eb8d53-d526-4a93-a63d-3e770d2fce3f"
      unitRef="usd">-35000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMTItMS0xLTEtMQ_13dc9571-b5c2-454d-a6ce-aad71642716b"
      unitRef="usd">890000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMTItMy0xLTEtMQ_77caafb0-ac24-4c77-baba-c2958628172a"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMTctMS0xLTEtMQ_1972d2ee-47ac-4af3-a2c6-2dc26fdf5eaa"
      unitRef="usd">-84000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMTctMy0xLTEtMQ_e608bb19-3205-4dd6-ab29-01d3c8d36c55"
      unitRef="usd">-500000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMTgtMS0xLTEtMQ_42cbb44b-5763-41b6-a7fa-517179732890"
      unitRef="usd">1870000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMTgtMy0xLTEtMQ_25e5589e-e26c-499e-bbe3-9eedbebfe10c"
      unitRef="usd">940000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMTktMS0xLTEtMQ_770a61dd-0cf4-4bb1-bfb0-fa22e235bc9f"
      unitRef="usd">1025000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMTktMy0xLTEtMQ_0e9771fb-351f-4954-b3f2-7bfa8dca3ae4"
      unitRef="usd">684000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <cris:IncreaseDecreaseOperatingLeaseLiability
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjAtMS0xLTEtMQ_c52da20f-97ac-40bf-bc9b-390e6f7a4be7"
      unitRef="usd">-1577000</cris:IncreaseDecreaseOperatingLeaseLiability>
    <cris:IncreaseDecreaseOperatingLeaseLiability
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjAtMy0xLTEtMQ_3fccf853-044e-41e0-a462-b8262e092d6a"
      unitRef="usd">-327000</cris:IncreaseDecreaseOperatingLeaseLiability>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjEtMS0xLTEtMQ_2faa0017-96c5-4e57-b5c6-32a14a348200"
      unitRef="usd">2368000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjEtMy0xLTEtMQ_f90f91c8-391c-41c9-8465-27433ebd7eed"
      unitRef="usd">2367000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjItMS0xLTEtMQ_e088dc81-14fb-4aa3-bed6-28dea51d46ee"
      unitRef="usd">-29448000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjItMy0xLTEtMQ_6d81583e-e1ad-4eaf-a2c1-1e75d30e6602"
      unitRef="usd">-20024000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjQtMS0xLTEtMQ_6e6aa8fc-0710-4ff8-89e6-7f4f670be779"
      unitRef="usd">70977000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjQtMy0xLTEtMQ_005113b6-7ee3-426b-8837-9a9c0586a241"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjUtMS0xLTEtMQ_1a8932fe-1518-46ed-be1f-dafa70015b67"
      unitRef="usd">26605000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjUtMy0xLTEtMQ_52408dcd-db6f-4e15-b65b-d83dca2234df"
      unitRef="usd">5078000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjYtMS0xLTEtMQ_a3ae6a56-f87a-4765-a2ae-3cef32c366a3"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjYtMy0xLTEtMQ_ff3ad1a6-b240-4785-a1c6-227477836767"
      unitRef="usd">657000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjctMS0xLTEtMQ_3b28d406-391d-4adb-9c97-133f9a5b9eff"
      unitRef="usd">-44372000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjctMy0xLTEtMQ_221da1f2-ddee-4679-8335-496e3b9e44b7"
      unitRef="usd">4421000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjktMS0xLTEtMQ_617e1675-54ec-4754-befa-af186259cb27"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMjktMy0xLTEtMQ_27ceb1ce-df5e-4623-9ee7-8cb152c5037f"
      unitRef="usd">890000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ia6b5f21400a142dd92d6458b6bc2b0f9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMzAtMS0xLTEtMQ_91c9d7b0-c430-4bee-b73f-df0aeaf28238"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i0585c12f68584892a486dd533b6667ce_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMzAtMy0xLTEtMQ_1feec0d1-7d31-43a7-834c-ab038715d91a"
      unitRef="usd">6881000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cris:ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMzEtMS0xLTEtMQ_91151e14-88d5-4534-b732-3c9b3b3e23f3"
      unitRef="usd">0</cris:ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts>
    <cris:ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMzEtMy0xLTEtMQ_2d22d2f3-8b7d-40ce-9e11-6e94976fa209"
      unitRef="usd">17500000</cris:ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i37f437e27c6c449b80dcb3c731463e31_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMzItMS0xLTEtMQ_4b0da77b-4bf4-464b-8aa5-32cc163fb018"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i1a2d864386944501a52823fe60a6ac4a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMzItMy0xLTEtMQ_5463d56f-b050-4975-8062-f8a8d3ff4cfb"
      unitRef="usd">1535000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="iae11a3b9f70d4d8b8470bb42b3f5c915_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMzMtMS0xLTEtMQ_566e3327-ba56-4831-87f1-3c2d9bfbb26e"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ica18ded6bc544002a83550782ca17ceb_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMzMtMy0xLTEtMQ_03c330e8-2534-4f86-aea3-cb2ec62d85eb"
      unitRef="usd">3229000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="iae11a3b9f70d4d8b8470bb42b3f5c915_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMzQtMS0xLTEtMQ_b863964c-4f0c-4799-9fff-032845a5747b"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ica18ded6bc544002a83550782ca17ceb_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMzQtMy0xLTEtMQ_b70d610f-fc90-42eb-bfd6-0110e648a3c0"
      unitRef="usd">262000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMzctMS0xLTEtMQ_3e7ee391-bb15-4dcf-9582-f32c349fb1a9"
      unitRef="usd">217000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMzctMy0xLTEtMQ_18794500-020c-4d85-ab34-6102add3cc8a"
      unitRef="usd">47000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <cris:PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMzgtMS0xLTEtMQ_36516709-206c-4493-aa4d-a44ae6319fc8"
      unitRef="usd">3077000</cris:PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest>
    <cris:PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfMzgtMy0xLTEtMQ_15cc7e29-8ef7-49d8-8ae8-62f00923f669"
      unitRef="usd">3175000</cris:PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNDEtMS0xLTEtMQ_4955a435-c093-4946-a825-6c2ee1fc36bd"
      unitRef="usd">-2860000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNDEtMy0xLTEtMQ_8120f708-e659-4ce8-8d90-1db44d6ded50"
      unitRef="usd">23575000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNDItMS0xLTEtMQ_967f1ccb-b281-4ad3-a2ac-18a59f128303"
      unitRef="usd">-76680000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNDItMy0xLTEtMQ_b2d6ffb0-c020-4585-ae0e-222c675da55f"
      unitRef="usd">7972000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNDMtMS0xLTEtMQ_4567205d-cb6c-4424-819c-e1316330850b"
      unitRef="usd">130426000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i74e73d5375984977b6347e5a763139d0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNDMtMy0xLTEtMQ_568b13ec-7cf9-4fdb-9078-672b6179680a"
      unitRef="usd">16399000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNDQtMS0xLTEtMQ_0229d211-1ea4-4273-ba92-23bb6aa5273c"
      unitRef="usd">53746000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i115d55a1156e4c969b9b8083b7760eb1_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNDQtMy0xLTEtMQ_33dd2a2d-8147-42fc-9da8-3fff03505c55"
      unitRef="usd">24371000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNDgtMS0xLTEtMQ_a1c4a613-bfb7-4712-983c-8701c3aa46d4"
      unitRef="usd">3357000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNDgtMy0xLTEtMQ_4ce8b44b-c1c9-4673-b29a-71ae922e10bd"
      unitRef="usd">3824000</us-gaap:InterestPaidNet>
    <cris:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNDktMS0xLTEtMQ_bf94f9b2-7ee4-415a-9e38-79d418dc1795"
      unitRef="usd">0</cris:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue>
    <cris:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNDktMy0xLTEtMQ_225f89e3-252d-4ee4-b2ca-c82d3b86bb15"
      unitRef="usd">900000</cris:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNTAtMS0xLTEtMQ_7790bf2d-2fe9-4177-b9cc-f9e06673f17b"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18yNS9mcmFnOmU5N2Y5ZjE0MjQzNjQ2NGJiNTAzNTE4ZTJiYzczMmVkL3RhYmxlOjA5ZWFmYmRiNGZmZTQyNWE4YWU4OWRiMzg5NDM0NWNmL3RhYmxlcmFuZ2U6MDllYWZiZGI0ZmZlNDI1YThhZTg5ZGIzODk0MzQ1Y2ZfNTAtMy0xLTEtMQ_0e5838e1-e3ff-4b48-b875-cd0464ee6972"
      unitRef="usd">7029000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NatureOfOperations
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zMS9mcmFnOjQxZmZhMTQyNzBkYTRkOGJiMzJmYTE4MjJiY2JlNmQyL3RleHRyZWdpb246NDFmZmExNDI3MGRhNGQ4YmIzMmZhMTgyMmJjYmU2ZDJfOTk0Mg_84760732-13a9-45a5-9096-60deb1ed6a00">Nature of Business&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Curis, Inc. is a biotechnology company focused on the development of first-in-class and innovative therapeutics for the treatment of cancer. Throughout these Condensed Consolidated Financial Statements, Curis, Inc. and its wholly owned subsidiaries are collectively referred to as &#x201c;the Company&#x201d; or &#x201c;Curis.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company conducts its research and development programs both internally and through strategic collaborations. The Company&#x2019;s clinical stage drug candidates are:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;CA-4948, an orally available  small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 ("IRAK4"), which is currently undergoing testing in a Phase 1/2 open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas, including those with myeloid Differentiation Primary Response Protein 88 (&#x201c;MYD88&#x201d;) alterations. The trial was amended to include a combination study of CA-4948 and ibrutinib, a BTK inhibitor, in patients with non-Hodgkin lymphomas for which the Company enrolled the first patient in February 2021. The Company is also conducting a separate Phase 1/2 open-label, single arm dose escalating and expansion trial in patients with acute myeloid leukemia (&#x201c;AML&#x201d;) and myelodysplastic syndromes (&#x201c;MDS&#x201d;). The study was amended in April 2021 to include dose escalation cohorts of CA-4948 in combination with azacitidine or venetoclax. In April 2021, CA-4948 was granted Orphan Drug Designation for the treatment of AML and MDS by the U.S. Food and Drug Administration ("FDA"). In June 2021, we reported updated preliminary clinical data from the Phase 1/2 study in patients with AML or MDS and announced the recommended Phase 2 dose for monotherapy dose expansion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation (&#x201c;VISTA&#x201d;) signaling pathway. In June 2020, the Company announced that the FDA had cleared its Investigational New Drug (&#x201c;IND&#x201d;) application for CI-8993. In September 2020, enrollment for a Phase 1 trial in patients with solid tumors commenced. The Company has an option to license CI-8993 from ImmuNext, Inc. ("ImmuNext").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s pipeline also includes the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Fimepinostat, a small molecule that potently inhibits the activity of histone deacetylase and phosphotidyl-inositol 3 kinase enzymes, which has been granted Orphan Drug Designation and Fast Track Designation for the treatment of diffuse large B-cell lymphoma and nuclear protein in testis (NUT) midline carcinoma. The Company is currently evaluating future studies for fimepinostat.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;CA-170, a small molecule antagonist of VISTA and PDL1, for which the Company announced initial data from a clinical study in patients with mesothelioma, in conjunction with the Society of lmmunotherapy of Cancer conference in November 2019. Based on this data, no further patients will be enrolled in the study. The Company is currently evaluating future studies for CA-170.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;CA-327, a small molecule antagonist of TIM3 and PDL1, is a pre-IND stage oncology drug candidate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to a collaboration with Genentech Inc. (&#x201c;Genentech&#x201d;), a member of the Roche Group, under which Genentech and F. Hoffmann-La Roche Ltd (&#x201c;Roche&#x201d;) are commercializing Erivedge&#xae; (vismodegib), a first-in-class orally administered small molecule Hedgehog signaling pathway antagonist. Erivedge is approved for the treatment of advanced basal cell carcinoma (&#x201c;BCC&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2015, the Company entered into an exclusive collaboration agreement with Aurigene Discovery Technologies Limited (&#x201c;Aurigene&#x201d;) for the discovery, development and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology, which was amended in September 2016 and February 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of September 30, 2021, the Company had licensed four programs under the Aurigene collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;IRAK4 Program - a precision oncology program of small molecule inhibitors of IRAK4. The development candidate is CA-4948, an orally available small molecule inhibitor of IRAK4.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;PD1/VISTA Program - an immuno-oncology program of small molecule antagonists of PD1 and VISTA immune checkpoint pathways. The development candidate is CA-170, an orally available small molecule antagonist of VISTA and PDL1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;PD1/TIM3 Program - an immuno-oncology program of small molecule antagonists of PD1 and TIM3 immune checkpoint pathways. The development candidate is CA-327, an orally available small molecule antagonist of PDL1 and TIM3.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The Company exercised its option to license a fourth program, which is an immuno-oncology program. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The COVID-19 pandemic has had and may continue to have an adverse effect on the Company&#x2019;s business, financial condition, results of operations, and prospects. With respect to ongoing clinical trials, the anticipated timing of enrollment and the overall timelines of the trials have experienced delays and could be further delayed to the extent the Company experiences further delays in enrollment due to the COVID-19 pandemic. The Company&#x2019;s ability to collect patient data in a timely fashion may also be impacted. The Company experienced delays in closing down its clinical trial sites related to its fimepinostat and CA-170 trials due to restrictions on non-essential workers imposed at those sites in response to COVID-19, which delayed the winding down of these trials.  In addition, the Company and its collaborators, third-party contract manufacturers, contract research organizations and clinical sites could experience delays or disruptions in supply and release of product candidates and/or procuring items that are essential for the Company's research and development activities, including, for example, raw materials used in the manufacturing of its product candidates, basic medical and laboratory supplies used in its clinical trials or preclinical studies, or animals that are used for preclinical testing, in each case, for which there may be shortages or supply chain disruptions as a result of the pandemic. The Company cannot be certain what the overall impact of the COVID-19 pandemic will be on its business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks common to companies in the biotechnology industry as well as risks that are specific to the Company&#x2019;s business, including, but not limited to: the Company&#x2019;s ability to obtain adequate financing to fund its operations; the Company&#x2019;s ability to advance and expand its research and development programs; the impacts of the COVID-19 pandemic and responsive actions related thereto; the Company&#x2019;s relationship with Aurigene to support development of drug candidates under the parties&#x2019; collaboration agreement; the Company&#x2019;s reliance on Roche and Genentech to successfully commercialize Erivedge in the approved indication of advanced BCC and to progress its clinical development in indications other than BCC; the ability of the Company and its wholly owned subsidiary, Curis Royalty, LLC (&#x201c;Curis Royalty&#x201d;) to satisfy the terms of the royalty interest purchase agreement (the &#x201c;Oberland Purchase Agreement&#x201d;) with TPC Investments I LP and TPC Investments II LP (the &#x201c;Purchasers&#x201d;) each of which is a Delaware limited partnership managed by Oberland Capital Management, LLC, and Lind SA LLC (the &#x201c;Agent&#x201d;) a Delaware limited liability company managed by Oberland Capital Management, LLC, as collateral agent for the Purchasers; the Company&#x2019;s ability to obtain and maintain necessary intellectual property protection; development by the Company&#x2019;s competitors of new or better technological innovations; the Company's dependence on key personnel; the Company&#x2019;s ability to comply with regulatory requirements; the Company's ability to obtain and maintain applicable regulatory approvals and commercialize any approved product candidates; the Company&#x2019;s ability to execute on its overall business strategies; and the Company&#x2019;s ability to maintain its listing on the Nasdaq Global Market.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s future operating results will largely depend on the progress of drug candidates currently in its development pipeline and the magnitude of payments that it may receive and make under its current and potential future collaborations. The results of the Company&#x2019;s operations have varied and will likely continue to vary significantly from year to year and quarter to quarter and depend on a number of factors, including, but not limited to: the timing, outcome and cost of the Company&#x2019;s preclinical studies and clinical trials for its drug candidates; Aurigene&#x2019;s ability to support advancement of development candidates  under the Company&#x2019;s collaboration with Aurigene, as well as the Company&#x2019;s ability to further develop programs under this collaboration; and Roche and Genentech&#x2019;s ability to successfully commercialize Erivedge.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will require substantial funds to maintain research and development programs and support operations. The Company has incurred net losses and negative cash flows from operations since its inception. As of September 30, 2021, the Company had an accumulated deficit of approximately $1.1 billion, and for the nine months ended September 30, 2021, the Company incurred a net loss of $31.8 million and used $29.4 million of cash in operations. The Company expects to continue to generate operating losses in the foreseeable future. The Company anticipates that its $149.8 million of existing cash, cash equivalents and investments at September 30, 2021 will be sufficient to fund operations for at least 12 months from the date of filing this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to raise additional funds will depend, among other factors, on financial, economic and market conditions, many of which are outside of its control and it may be unable to raise financing when needed, or on terms favorable to the Company. If necessary funds are not available, the Company will have to delay, reduce the scope of, or eliminate some of its development programs, potentially delaying the time to market for or preventing the marketing of any of its product candidates.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <cris:CollaborationAgreementNumberofProgramsLicensed
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zMS9mcmFnOjQxZmZhMTQyNzBkYTRkOGJiMzJmYTE4MjJiY2JlNmQyL3RleHRyZWdpb246NDFmZmExNDI3MGRhNGQ4YmIzMmZhMTgyMmJjYmU2ZDJfMjE5OTAyMzI2NTc1Mg_c2928448-3dc1-4a31-af5a-04f446c0a53a"
      unitRef="program">4</cris:CollaborationAgreementNumberofProgramsLicensed>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zMS9mcmFnOjQxZmZhMTQyNzBkYTRkOGJiMzJmYTE4MjJiY2JlNmQyL3RleHRyZWdpb246NDFmZmExNDI3MGRhNGQ4YmIzMmZhMTgyMmJjYmU2ZDJfODk5NQ_d3ee4a98-fbde-4c0f-a2f3-e7b216d5d326"
      unitRef="usd">-1100000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zMS9mcmFnOjQxZmZhMTQyNzBkYTRkOGJiMzJmYTE4MjJiY2JlNmQyL3RleHRyZWdpb246NDFmZmExNDI3MGRhNGQ4YmIzMmZhMTgyMmJjYmU2ZDJfOTA3NA_edd12791-9e04-4bea-af1e-5fc0ba3e1898"
      unitRef="usd">-31800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zMS9mcmFnOjQxZmZhMTQyNzBkYTRkOGJiMzJmYTE4MjJiY2JlNmQyL3RleHRyZWdpb246NDFmZmExNDI3MGRhNGQ4YmIzMmZhMTgyMmJjYmU2ZDJfOTA5NA_4bd733f7-230f-4b71-bbed-e3c92fa62fe9"
      unitRef="usd">-29400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zMS9mcmFnOjQxZmZhMTQyNzBkYTRkOGJiMzJmYTE4MjJiY2JlNmQyL3RleHRyZWdpb246NDFmZmExNDI3MGRhNGQ4YmIzMmZhMTgyMmJjYmU2ZDJfOTI0OQ_b5357a77-8b68-4ab9-bd81-0ca4843db65f"
      unitRef="usd">149800000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMTYyNzU_d5bd623a-686a-49b9-8719-a5e0e02e6f39">Summary of Significant Accounting Policies&lt;div style="margin-top:10pt;padding-left:22.5pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.84pt"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements have been prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. These statements, however, are condensed and do not include all disclosures required by accounting principles generally accepted in the U.S. (&#x201c;GAAP&#x201d;), for complete financial statements and should be read in conjunction with the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;), on March&#160;16, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of the management of the Company, the unaudited financial statements contain all adjustments (all of which were considered normal and recurring) necessary for a fair statement of the Company&#x2019;s financial position at September 30, 2021; the results of operations for the three and nine-month periods ended September 30, 2021 and 2020; stockholders' equity (deficit) for the three and nine-month periods ended September 30, 2021 and 2020; and the cash flows for the nine-month periods ended September 30, 2021 and 2020. The Condensed Consolidated Balance Sheet at December 31, 2020 was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts within the statement of cash flows have been reclassified to conform to the current period presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:22.5pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.84pt"&gt;Use of Estimates and Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the Company&#x2019;s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosure of certain assets and liabilities at the balance sheet date. Such estimates include the performance obligations under the Company&#x2019;s collaboration agreements; the estimated repayment term of the Company&#x2019;s debt and related short- and long-term classification; the collectability of receivables; the carrying value of property and equipment and goodwill; and the assumptions used in the Company&#x2019;s valuation of stock-based compensation and the value of certain investments and liabilities. Actual results may differ from such estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These interim results are not necessarily indicative of results to be expected for a full year or subsequent interim periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent to which COVID-19 has had and may continue to have impacts on the Company&#x2019;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of the COVID-19 pandemic, the extent to which it has impacted and may continue to impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business responses to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of September 30, 2021 and through the date of this report. The Company&#x2019;s future assessment of the magnitude and duration of the COVID-19 pandemic, as well as other factors, could result in material impacts to the Company&#x2019;s consolidated financial statements in future reporting periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:22.5pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.41pt"&gt; Cash Equivalents, Restricted Cash, and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of highly liquid investments purchased with original maturities of three months or less. All other liquid investments are classified as marketable securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classified $0.7&#160;million of its cash as restricted cash as of September 30, 2021 and $0.8&#160;million as of December 31, 2020. This amount represents the security deposit delivered to the landlord of the Company's current Massachusetts headquarters. The restricted cash balance was reduced as of September 30, 2021 in accordance with the lease agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's combined cash and restricted cash balances were $53.7 million and $24.4&#160;million as of September 30, 2021 and September 30, 2020, respectively, as presented on the Company's Condensed Consolidated Statements of Cash Flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s short-term investments are marketable debt securities with original maturities of greater than three months from the date of purchase, but less than twelve months from the balance sheet date, and long-term investments are marketable debt securities with original maturities of greater than twelve months from the balance sheet date. Marketable securities consist of commercial paper, corporate bonds and notes, and/or government obligations. All of the Company&#x2019;s investments have been designated available-for-sale and are stated at fair value. Unrealized gains and temporary losses on investments are included in accumulated other comprehensive income (loss) as a separate component of stockholders&#x2019; equity (deficit). Realized gains and losses, dividends and interest income are included in other income (expense) in the period during which the securities are sold. Any premium or discount arising at purchase is amortized and/or accreted to interest income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:22.5pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.84pt"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at contract inception. Operating lease assets represent the Company's right to use an underlying asset for the lease term and operating lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of the Company's leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate, which is based on rates that would be incurred to borrow on a collateralized basis over a term equal to the lease payments in a similar economic environment, in determining the present value of lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The lease payment used to determine the operating lease asset may include lease incentives, stated rent increases and was recognized as an operating lease right-of-use asset in the Condensed Consolidated Balance Sheets. The Company's lease agreements may include both lease and non-lease components, which are accounted for as a single lease component when the payments are fixed. Variable payments included in the lease agreement are expensed as incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's operating lease is reflected in operating lease right-of-use asset and operating lease liability in the Condensed Consolidated Balance Sheets. Lease expense for lease payments is recognized on a straight-line basis over the lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:22.5pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.41pt"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s business strategy includes entering into collaborative license and development agreements with biotechnology and pharmaceutical companies for the development and commercialization of the Company&#x2019;s drug candidates. The terms of the agreements typically include non-refundable license fees, funding of research and development, payments based upon achievement of clinical development and regulatory objectives, and royalties on product sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:31.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;License Fees and Multiple Element Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a license to its intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, up-front fees allocated to the license at such time as the license is transferred to the licensee and the licensee is able to use, and benefit from, the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, will adjust the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company is involved in a steering committee as part of a multiple element arrangement, the Company assesses whether its involvement constitutes a performance obligation or a right to participate. Steering committee services that are not determined to be distinct performance obligations are combined with other research services or performance obligations required under an arrangement, if any, in determining the level of effort required in an arrangement and the period over which the Company expects to complete its aggregate performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Appropriate methods of measuring progress include output methods and input methods. In determining the appropriate method for measuring progress, the Company considers the nature of service that it promises to transfer to the customer. When the Company decides on a method of measurement, the Company will apply that single method of measuring progress for each performance obligation satisfied over time and will apply that method consistently to similar performance obligations and in similar circumstances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company cannot reasonably measure its progress toward complete satisfaction of a performance obligation because the Company lacks reliable information that would be required to apply an appropriate method of measuring progress, but it can reasonably estimate when the performance ceases or the remaining obligations become inconsequential and perfunctory, then revenue is not recognized until the Company can reasonably estimate when the performance obligation ceases or becomes inconsequential. Revenue is then recognized over the remaining estimated period of performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Contingent Research Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting Standards Codification ("ASC") 606 constrains the amount of variable consideration included in the transaction price in that either all, or a portion, of an amount of variable consideration should be included in the transaction price. The variable consideration amount should be included only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The assessment of whether variable consideration should be constrained is largely a qualitative one that has two elements: the likelihood of a change in estimate, and the magnitude thereof. Variable consideration is not constrained if the potential reversal of cumulative revenue recognized is not significant, for example. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the consideration in a contract includes a variable amount, a company will estimate the amount of consideration in exchange for transfer of promised goods or services. The consideration also can vary if a company&#x2019;s entitlement to the consideration is contingent on the occurrence or nonoccurrence of a future event. The Company considers contingent research milestone payments to fall under the scope of variable consideration, which should be estimated for revenue recognition purposes at the inception of the contract and reassessed ongoing at the end of each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses whether contingent research milestones should be considered variable consideration that should be constrained and thus not part of the transaction price. This includes an assessment of the probability that all or some of the milestone revenues could be reversed when the uncertainty around whether or not the achievement of each milestone is resolved, and the amount of reversal could be significant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GAAP provides factors to consider when assessing whether variable consideration should be constrained. All of the factors should be considered, and no factor is determinative. The Company considers all relevant factors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Reimbursement of Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reimbursement of research and development costs by third-party collaborators is recognized as revenue over time provided the Company has determined that it transfers control (i.e. performs the services) of a service over time and, therefore, satisfies a performance obligation according to the provisions outlined in ASC 606-10-25-27, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Royalty Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes royalty revenues related to Genentech&#x2019;s and Roche&#x2019;s sales of Erivedge. For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and where the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). The Company expects to continue recognizing royalty revenue from Genentech&#x2019;s sales of Erivedge in the U.S. and in other markets where Genentech and Roche successfully obtain marketing approval, if any (see Note&#160;9, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Collaborations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). However, a portion of potential Erivedge royalties will be paid to the Purchasers pursuant to the Oberland Purchase Agreement (see Note 8, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liability Related to the Sale of Future Royalties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Contra Revenue, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contra revenue, net represents shared costs, primarily related to intellectual property, with the Company's collaboration partners, and reserves for potential royalty reductions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to each of the foregoing areas of revenue recognition, the Company exercises significant judgment in determining whether an arrangement contains multiple elements, and, if so, how much revenue is allocable to each element. In addition, the Company exercises its judgment in determining when its significant obligations have been met under such agreements and the specific time periods over which the Company recognized revenue, such as non-refundable, up-front license fees. To the extent that actual facts and circumstances differ from the Company's initial judgments, its revenue recognition with respect to such transactions would change accordingly and any such change could affect the Company's reported financial results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Summary&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September 30, 2021, total gross revenues were 99% from the Company&#x2019;s collaboration with Genentech. During the three and nine months ended September 30, 2020 total gross revenues were 100% and 97%, respectively, from the Company&#x2019;s collaboration with Genentech. In addition to the revenues received from Genentech, the Company received a milestone payment from a previously out-licensed technology in the first quarter of 2020 that was recorded in other revenues. There were no such revenues recorded during the three and nine months ended September 30, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:22.5pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.07pt"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates in a single reportable segment, which is the research and development of innovative cancer therapeutics. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:22.5pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(g)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.84pt"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-13, Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This standard requires that for most financial assets, losses be based on an expected loss approach which includes estimates of losses over the life of exposure that considers historical, current and forecasted information. Expanded disclosures related to the methods used to estimate the losses as well as a specific disaggregation of balances for financial assets are also required. The targeted transition relief standard allows filers an option to irrevocably elect the fair value option of ASC 825-10, Financial Instruments-Overall, applied on an instrument-by-instrument basis for eligible instruments. In November 2019 the effective date for smaller reporting companies was extended to January 1, 2023 with the issuance of ASU 2019-10 Financial Instruments-Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates. The Company adopted ASU 2016-13 as of January 1, 2021 and the adoption did not have a material impact on the Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMTYyODU_e201d091-e41d-4604-b01c-a067ab1babbe">Basis of Presentation and Principles of ConsolidationThe accompanying Condensed Consolidated Financial Statements have been prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. These statements, however, are condensed and do not include all disclosures required by accounting principles generally accepted in the U.S. (&#x201c;GAAP&#x201d;), for complete financial statements and should be read in conjunction with the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;), on March&#160;16, 2021</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMTYyNzc_52d752bf-564a-4843-9e0b-2b8818b1c7fe">Use of Estimates and Assumptions&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the Company&#x2019;s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosure of certain assets and liabilities at the balance sheet date. Such estimates include the performance obligations under the Company&#x2019;s collaboration agreements; the estimated repayment term of the Company&#x2019;s debt and related short- and long-term classification; the collectability of receivables; the carrying value of property and equipment and goodwill; and the assumptions used in the Company&#x2019;s valuation of stock-based compensation and the value of certain investments and liabilities. Actual results may differ from such estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These interim results are not necessarily indicative of results to be expected for a full year or subsequent interim periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent to which COVID-19 has had and may continue to have impacts on the Company&#x2019;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of the COVID-19 pandemic, the extent to which it has impacted and may continue to impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business responses to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of September 30, 2021 and through the date of this report. The Company&#x2019;s future assessment of the magnitude and duration of the COVID-19 pandemic, as well as other factors, could result in material impacts to the Company&#x2019;s consolidated financial statements in future reporting periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMTYyODc_a03f966b-4e98-4d64-b568-354289040b4a">Cash Equivalents, Restricted Cash, and Investments&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of highly liquid investments purchased with original maturities of three months or less. All other liquid investments are classified as marketable securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classified $0.7&#160;million of its cash as restricted cash as of September 30, 2021 and $0.8&#160;million as of December 31, 2020. This amount represents the security deposit delivered to the landlord of the Company's current Massachusetts headquarters. The restricted cash balance was reduced as of September 30, 2021 in accordance with the lease agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's combined cash and restricted cash balances were $53.7 million and $24.4&#160;million as of September 30, 2021 and September 30, 2020, respectively, as presented on the Company's Condensed Consolidated Statements of Cash Flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s short-term investments are marketable debt securities with original maturities of greater than three months from the date of purchase, but less than twelve months from the balance sheet date, and long-term investments are marketable debt securities with original maturities of greater than twelve months from the balance sheet date. Marketable securities consist of commercial paper, corporate bonds and notes, and/or government obligations. All of the Company&#x2019;s investments have been designated available-for-sale and are stated at fair value. Unrealized gains and temporary losses on investments are included in accumulated other comprehensive income (loss) as a separate component of stockholders&#x2019; equity (deficit). Realized gains and losses, dividends and interest income are included in other income (expense) in the period during which the securities are sold. Any premium or discount arising at purchase is amortized and/or accreted to interest income.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCash
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMjc0ODc3OTA4NTc1Ng_467da416-7f15-45bb-800f-b79709239258"
      unitRef="usd">700000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMjc0ODc3OTA4NTk4NQ_83d64c07-1860-49ca-8c65-6e7c10738a3a"
      unitRef="usd">800000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMzc5NQ_e21cadc1-421e-4471-b00f-44bf1e327ab3"
      unitRef="usd">53700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i115d55a1156e4c969b9b8083b7760eb1_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMzgwMg_b0f5e743-47ef-45fd-815b-ebfc61446bfe"
      unitRef="usd">24400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMTYyODI_410a9e7d-9d11-4811-9aa1-2ac800349418">Leases&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at contract inception. Operating lease assets represent the Company's right to use an underlying asset for the lease term and operating lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of the Company's leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate, which is based on rates that would be incurred to borrow on a collateralized basis over a term equal to the lease payments in a similar economic environment, in determining the present value of lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The lease payment used to determine the operating lease asset may include lease incentives, stated rent increases and was recognized as an operating lease right-of-use asset in the Condensed Consolidated Balance Sheets. The Company's lease agreements may include both lease and non-lease components, which are accounted for as a single lease component when the payments are fixed. Variable payments included in the lease agreement are expensed as incurred. &lt;/span&gt;&lt;/div&gt;The Company's operating lease is reflected in operating lease right-of-use asset and operating lease liability in the Condensed Consolidated Balance Sheets. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMTYyODg_c690e651-d10c-4ec8-baac-bed5571cd751">Revenue Recognition&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s business strategy includes entering into collaborative license and development agreements with biotechnology and pharmaceutical companies for the development and commercialization of the Company&#x2019;s drug candidates. The terms of the agreements typically include non-refundable license fees, funding of research and development, payments based upon achievement of clinical development and regulatory objectives, and royalties on product sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:31.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;License Fees and Multiple Element Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a license to its intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, up-front fees allocated to the license at such time as the license is transferred to the licensee and the licensee is able to use, and benefit from, the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, will adjust the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company is involved in a steering committee as part of a multiple element arrangement, the Company assesses whether its involvement constitutes a performance obligation or a right to participate. Steering committee services that are not determined to be distinct performance obligations are combined with other research services or performance obligations required under an arrangement, if any, in determining the level of effort required in an arrangement and the period over which the Company expects to complete its aggregate performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Appropriate methods of measuring progress include output methods and input methods. In determining the appropriate method for measuring progress, the Company considers the nature of service that it promises to transfer to the customer. When the Company decides on a method of measurement, the Company will apply that single method of measuring progress for each performance obligation satisfied over time and will apply that method consistently to similar performance obligations and in similar circumstances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company cannot reasonably measure its progress toward complete satisfaction of a performance obligation because the Company lacks reliable information that would be required to apply an appropriate method of measuring progress, but it can reasonably estimate when the performance ceases or the remaining obligations become inconsequential and perfunctory, then revenue is not recognized until the Company can reasonably estimate when the performance obligation ceases or becomes inconsequential. Revenue is then recognized over the remaining estimated period of performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Contingent Research Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting Standards Codification ("ASC") 606 constrains the amount of variable consideration included in the transaction price in that either all, or a portion, of an amount of variable consideration should be included in the transaction price. The variable consideration amount should be included only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The assessment of whether variable consideration should be constrained is largely a qualitative one that has two elements: the likelihood of a change in estimate, and the magnitude thereof. Variable consideration is not constrained if the potential reversal of cumulative revenue recognized is not significant, for example. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the consideration in a contract includes a variable amount, a company will estimate the amount of consideration in exchange for transfer of promised goods or services. The consideration also can vary if a company&#x2019;s entitlement to the consideration is contingent on the occurrence or nonoccurrence of a future event. The Company considers contingent research milestone payments to fall under the scope of variable consideration, which should be estimated for revenue recognition purposes at the inception of the contract and reassessed ongoing at the end of each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses whether contingent research milestones should be considered variable consideration that should be constrained and thus not part of the transaction price. This includes an assessment of the probability that all or some of the milestone revenues could be reversed when the uncertainty around whether or not the achievement of each milestone is resolved, and the amount of reversal could be significant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GAAP provides factors to consider when assessing whether variable consideration should be constrained. All of the factors should be considered, and no factor is determinative. The Company considers all relevant factors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Reimbursement of Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reimbursement of research and development costs by third-party collaborators is recognized as revenue over time provided the Company has determined that it transfers control (i.e. performs the services) of a service over time and, therefore, satisfies a performance obligation according to the provisions outlined in ASC 606-10-25-27, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Royalty Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes royalty revenues related to Genentech&#x2019;s and Roche&#x2019;s sales of Erivedge. For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and where the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). The Company expects to continue recognizing royalty revenue from Genentech&#x2019;s sales of Erivedge in the U.S. and in other markets where Genentech and Roche successfully obtain marketing approval, if any (see Note&#160;9, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Collaborations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). However, a portion of potential Erivedge royalties will be paid to the Purchasers pursuant to the Oberland Purchase Agreement (see Note 8, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liability Related to the Sale of Future Royalties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Contra Revenue, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contra revenue, net represents shared costs, primarily related to intellectual property, with the Company's collaboration partners, and reserves for potential royalty reductions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to each of the foregoing areas of revenue recognition, the Company exercises significant judgment in determining whether an arrangement contains multiple elements, and, if so, how much revenue is allocable to each element. In addition, the Company exercises its judgment in determining when its significant obligations have been met under such agreements and the specific time periods over which the Company recognized revenue, such as non-refundable, up-front license fees. To the extent that actual facts and circumstances differ from the Company's initial judgments, its revenue recognition with respect to such transactions would change accordingly and any such change could affect the Company's reported financial results.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i36015b0cc9094033ad0afc16178a75cf_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMTQ0Njc_54e85fa6-cace-432f-bc83-fb7f188107f1"
      unitRef="number">0.99</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2a46a72b07d94f83a96cc1ed91d2c92c_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMTQ0Njc_62b5e185-8add-4776-89df-b751ffae091e"
      unitRef="number">0.99</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8e17706f12e14935b7a015a9bceda833_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMTQ1NzU_c9859596-1a12-4f06-9333-ab02a1eca3af"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i262850aa677c403ba7f59d77493f79af_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMTQ1ODI_e1669ed7-805f-42f8-b709-347a2b54620e"
      unitRef="number">0.97</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMTYyNzg_597284bb-58da-411c-99b8-9e259a407a67">Segment ReportingThe Company operates in a single reportable segment, which is the research and development of innovative cancer therapeutics.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY18zNC9mcmFnOjU4NWQ3YjRjZGViMjQ5Mzc5ZWE4ODMxOWJhNTlmZTZlL3RleHRyZWdpb246NTg1ZDdiNGNkZWIyNDkzNzllYTg4MzE5YmE1OWZlNmVfMTYyODM_98bcecfb-3e6e-4cee-9dec-73298e28d29f">New Accounting Pronouncements&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-13, Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This standard requires that for most financial assets, losses be based on an expected loss approach which includes estimates of losses over the life of exposure that considers historical, current and forecasted information. Expanded disclosures related to the methods used to estimate the losses as well as a specific disaggregation of balances for financial assets are also required. The targeted transition relief standard allows filers an option to irrevocably elect the fair value option of ASC 825-10, Financial Instruments-Overall, applied on an instrument-by-instrument basis for eligible instruments. In November 2019 the effective date for smaller reporting companies was extended to January 1, 2023 with the issuance of ASU 2019-10 Financial Instruments-Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates. The Company adopted ASU 2016-13 as of January 1, 2021 and the adoption did not have a material impact on the Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RleHRyZWdpb246MjkyNDJiMTVkYWU1NDZlOGEzODRlZWFhNDE4NjA3ZmNfMTUzOA_8cb93ac8-3bde-4dbc-966c-004b624f43be">Fair Value of Financial Instruments&lt;div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has adopted the provisions of the FASB Codification Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;Topic 820&#x201d;) for its financial assets and liabilities that are re-measured and reported at fair value each reporting period and the non-financial assets and liabilities that are re-measured and reported at fair value on a non-recurring basis. Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it would transact and consider assumptions that market participants would use when pricing the asset or liability. Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. Financial assets and liabilities are categorized within the valuation hierarchy based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the fair value hierarchy, the following table shows the fair value as of September 30, 2021 and December 31, 2020 of those financial assets and liabilities that are measured at fair value on a recurring basis, according to the valuation techniques the Company used to determine their fair value. No financial assets or liabilities are measured at fair value on a nonrecurring basis at September 30, 2021 and December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&lt;br/&gt;Active Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&#160;Observable&lt;br/&gt;Inputs&#160;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;br/&gt;Inputs&#160;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate commercial paper, bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term  investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate commercial paper, bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&lt;br/&gt;Active Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&#160;Observable&lt;br/&gt;Inputs&#160;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;br/&gt;Inputs&#160;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate commercial paper, bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term  investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate commercial paper, bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RleHRyZWdpb246MjkyNDJiMTVkYWU1NDZlOGEzODRlZWFhNDE4NjA3ZmNfMTUzOQ_b4c9898b-21ba-46e5-8ee0-97bb5afc6c57">Fair Value of Financial Instruments&lt;div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has adopted the provisions of the FASB Codification Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;Topic 820&#x201d;) for its financial assets and liabilities that are re-measured and reported at fair value each reporting period and the non-financial assets and liabilities that are re-measured and reported at fair value on a non-recurring basis. Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it would transact and consider assumptions that market participants would use when pricing the asset or liability. Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. Financial assets and liabilities are categorized within the valuation hierarchy based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RleHRyZWdpb246MjkyNDJiMTVkYWU1NDZlOGEzODRlZWFhNDE4NjA3ZmNfMTUzNw_96624c53-c6b8-48da-a1c7-60ca3116adf6">&lt;div style="margin-bottom:6pt;margin-top:1pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the fair value hierarchy, the following table shows the fair value as of September 30, 2021 and December 31, 2020 of those financial assets and liabilities that are measured at fair value on a recurring basis, according to the valuation techniques the Company used to determine their fair value. No financial assets or liabilities are measured at fair value on a nonrecurring basis at September 30, 2021 and December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&lt;br/&gt;Active Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&#160;Observable&lt;br/&gt;Inputs&#160;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;br/&gt;Inputs&#160;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate commercial paper, bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term  investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate commercial paper, bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&lt;br/&gt;Active Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&#160;Observable&lt;br/&gt;Inputs&#160;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;br/&gt;Inputs&#160;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate commercial paper, bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term  investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate commercial paper, bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3df875ea96bc4acbbb5cb6759aaf23a8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfMy0xLTEtMS0x_5d5d1f10-cfb7-4488-8e7b-adff001e12a3"
      unitRef="usd">49018000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i752919577506410ea7bba33998b02ae8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfMy0zLTEtMS0x_38fe302f-28cd-432e-a16d-93408e839efe"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5cdf5782b2f94b21b2601d416cac0370_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfMy01LTEtMS0x_5751abf2-d0ad-4697-87ef-c4a360799632"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i43a2dff08c424d20b371f99c387f9552_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfMy03LTEtMS0x_969b4b6e-2921-4167-8965-1e1c10a9f4a4"
      unitRef="usd">49018000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <cris:ShortTermInvestmentsFairValueDisclosure
      contextRef="iad40040d3fdb4825b2d3d57150804fd8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfNS0xLTEtMS0x_071a6e78-cdfd-4bb8-a3c0-fa143a175d68"
      unitRef="usd">0</cris:ShortTermInvestmentsFairValueDisclosure>
    <cris:ShortTermInvestmentsFairValueDisclosure
      contextRef="i2274a8be63ab428c82beb8aa7d63ef65_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfNS0zLTEtMS0x_779a1fc8-e8dd-4b48-83f3-53190a0f76c7"
      unitRef="usd">75884000</cris:ShortTermInvestmentsFairValueDisclosure>
    <cris:ShortTermInvestmentsFairValueDisclosure
      contextRef="if877b50a8b61448bab75f25dec242c52_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfNS01LTEtMS0x_51e56abd-5cb1-4857-a470-64a7a67c7896"
      unitRef="usd">0</cris:ShortTermInvestmentsFairValueDisclosure>
    <cris:ShortTermInvestmentsFairValueDisclosure
      contextRef="ibba7a650ba3e471bad9894814e905a1f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfNS03LTEtMS0x_b7cfe1e6-de67-4a69-a479-929c03225556"
      unitRef="usd">75884000</cris:ShortTermInvestmentsFairValueDisclosure>
    <cris:LongTermInvestmentsFairValueDisclosure
      contextRef="iad40040d3fdb4825b2d3d57150804fd8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfNy0xLTEtMS0x_20fbbdc5-0c34-411c-8971-b8587f3436af"
      unitRef="usd">0</cris:LongTermInvestmentsFairValueDisclosure>
    <cris:LongTermInvestmentsFairValueDisclosure
      contextRef="i2274a8be63ab428c82beb8aa7d63ef65_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfNy0zLTEtMS0x_f0f8b6cb-39dc-4066-89e6-799b4e98e64e"
      unitRef="usd">20922000</cris:LongTermInvestmentsFairValueDisclosure>
    <cris:LongTermInvestmentsFairValueDisclosure
      contextRef="if877b50a8b61448bab75f25dec242c52_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfNy01LTEtMS0x_b538a725-7330-4c8b-b7b9-e79842d6dd99"
      unitRef="usd">0</cris:LongTermInvestmentsFairValueDisclosure>
    <cris:LongTermInvestmentsFairValueDisclosure
      contextRef="ibba7a650ba3e471bad9894814e905a1f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfNy03LTEtMS0x_dc952054-6784-49c8-894a-fac043e91a8f"
      unitRef="usd">20922000</cris:LongTermInvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i91bffd463f9a491d809bd7007380675e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfOC0xLTEtMS0x_8e82873b-342d-4436-868d-bad3d1f21053"
      unitRef="usd">49018000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i48c7eb38239442ad99050fe29f702ff5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfOC0zLTEtMS0x_b6851876-8881-4718-8203-d786d59f80b1"
      unitRef="usd">96806000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6f14473beda6447099b0a6cd272baf6a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfOC01LTEtMS0x_54229271-1185-423b-aff3-f6d27f7b1188"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifadf6a4b0d22481ba0be83763d78d4c5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjU1MWY0ZmVkY2RjMjRhNTZiNTQxNzA0NTYyNjBkYWE2L3RhYmxlcmFuZ2U6NTUxZjRmZWRjZGMyNGE1NmI1NDE3MDQ1NjI2MGRhYTZfOC03LTEtMS0x_619be368-5a0a-4736-83bd-117657f77378"
      unitRef="usd">145824000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i90b3b70b1ebe49e3b4887be14abc4f66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfMy0xLTEtMS0x_3f807cf7-75f9-48f1-b79f-de64411a89c1"
      unitRef="usd">115278000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7b067bfcfb3e48039d044d6458bfd391_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfMy0zLTEtMS0x_e9b55c3a-92a3-4a47-b998-180017eb8bca"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iadb4da6453d243de9db7f2235495b30b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfMy01LTEtMS0x_99fb23ea-cc3e-4bda-8331-ba2e378e4557"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib6ed47efff4d435ca7a150ad517661c2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfMy03LTEtMS0x_1d6d0ec2-6402-405c-968b-4eedcc145b7f"
      unitRef="usd">115278000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <cris:ShortTermInvestmentsFairValueDisclosure
      contextRef="i6e4fd250bac14a99a97209435af04856_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfNS0xLTEtMS0x_6694cbfb-bc05-42c1-b511-8a87c5c83f94"
      unitRef="usd">0</cris:ShortTermInvestmentsFairValueDisclosure>
    <cris:ShortTermInvestmentsFairValueDisclosure
      contextRef="i6695b4c7cf4241ad83f88137c23fe102_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfNS0zLTEtMS0x_e1fc4aa0-3709-4c17-8bc3-27de41563caf"
      unitRef="usd">38884000</cris:ShortTermInvestmentsFairValueDisclosure>
    <cris:ShortTermInvestmentsFairValueDisclosure
      contextRef="id80a7c2a02984bf79a96da6df2e5a2b6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfNS01LTEtMS0x_a8d15ced-42a1-4e4c-afef-e5df79f08be2"
      unitRef="usd">0</cris:ShortTermInvestmentsFairValueDisclosure>
    <cris:ShortTermInvestmentsFairValueDisclosure
      contextRef="i52426bd73b8d4aea9d57fb272e80b022_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfNS03LTEtMS0x_ed4662a2-383b-499a-84f9-83717f4b8a8f"
      unitRef="usd">38884000</cris:ShortTermInvestmentsFairValueDisclosure>
    <cris:LongTermInvestmentsFairValueDisclosure
      contextRef="i6e4fd250bac14a99a97209435af04856_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfNy0xLTEtMS0x_eef61adb-2912-44fd-890d-c647b075fbca"
      unitRef="usd">0</cris:LongTermInvestmentsFairValueDisclosure>
    <cris:LongTermInvestmentsFairValueDisclosure
      contextRef="i6695b4c7cf4241ad83f88137c23fe102_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfNy0zLTEtMS0x_a0ab3358-41b2-4eee-9cf5-c3191654c68b"
      unitRef="usd">14564000</cris:LongTermInvestmentsFairValueDisclosure>
    <cris:LongTermInvestmentsFairValueDisclosure
      contextRef="id80a7c2a02984bf79a96da6df2e5a2b6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfNy01LTEtMS0x_e0db5697-edcb-4fd9-abc2-c42a3dd92384"
      unitRef="usd">0</cris:LongTermInvestmentsFairValueDisclosure>
    <cris:LongTermInvestmentsFairValueDisclosure
      contextRef="i52426bd73b8d4aea9d57fb272e80b022_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfNy03LTEtMS0x_f8079b2d-1ca9-408c-a2d0-54a454b903a0"
      unitRef="usd">14564000</cris:LongTermInvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1c228f3130b24ff3970c7f263b1d41aa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfOC0xLTEtMS0x_f9aa6794-a4c8-4c2e-9987-c1397eb8ba3f"
      unitRef="usd">115278000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2b1c769aefa947ec9c248070d8b405b2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfOC0zLTEtMS0x_edd47f98-911c-4955-8203-3a4ee532c980"
      unitRef="usd">53448000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i51d5333ea5724b6b9ff7023272b24535_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfOC01LTEtMS0x_5b05b695-f25d-48b2-9e23-2571a911e580"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic4fdd2d8901b4eaca49139aa5b83e7bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180MC9mcmFnOjI5MjQyYjE1ZGFlNTQ2ZThhMzg0ZWVhYTQxODYwN2ZjL3RhYmxlOjJlMmEwODA3MTViZjQyNjhiMzM4ZmE3NTRiODBiZDFlL3RhYmxlcmFuZ2U6MmUyYTA4MDcxNWJmNDI2OGIzMzhmYTc1NGI4MGJkMWVfOC03LTEtMS0x_639b44c1-f6ef-47b1-822c-c04814596796"
      unitRef="usd">168726000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RleHRyZWdpb246NDRkZTEwMzQzNmIyNDYwYThkZGRiZmU2ZDExMjM4OGNfMTM3Mg_a9aed63c-93d1-43ef-904d-f9d3848b8a49">Investments&lt;div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost, unrealized gains and losses and fair value of investments available-for-sale as of September 30, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate bonds and notes&#x2014;short-term&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate bonds and notes&#x2014;long-term&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments have maturities ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RleHRyZWdpb246NDRkZTEwMzQzNmIyNDYwYThkZGRiZmU2ZDExMjM4OGNfMTk3_cb80bf15-17b4-45da-ba01-4fb8b0381751"&gt;one&lt;/span&gt; to twelve months with a weighted-average maturity of 0.6 years at September 30, 2021. The weighted average maturity of long-term investments was 1.6 years at September 30, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost, unrealized gains and losses and fair value of investments available-for-sale as of December 31, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate bonds and notes&#x2014;short-term&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate bonds and notes&#x2014;long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments have maturities ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RleHRyZWdpb246NDRkZTEwMzQzNmIyNDYwYThkZGRiZmU2ZDExMjM4OGNfNTEx_4f659141-f01a-4310-9378-77affc0e77d5"&gt;one&lt;/span&gt; to twelve months with a weighted-average maturity of 0.6 years at December 31, 2020. The weighted average maturity of long-term investments was 1.5 years at December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No credit losses on available-for-sale securities were recognized during the three and nine months ended September 30, 2021 or September 30, 2020. In its evaluation to determine expected credit losses, management considered all available historical and current information, expectations of future economic conditions, the type of security, the credit rating of the security, and the size of the loss position, as well as other relevant information. The Company does not intend to sell, and is unlikely to be required to sell, any of these available-for-sale investments before their effective maturity or market price recovery.&lt;/span&gt;&lt;/div&gt;As of September 30, 2021 and December 31, 2020, the Company held no investments that have been in a continuous unrealized loss position for 12 months or longer.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RleHRyZWdpb246NDRkZTEwMzQzNmIyNDYwYThkZGRiZmU2ZDExMjM4OGNfMTM3MA_2365d988-f6a5-4435-9a50-5fad4d43f2d1">&lt;div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost, unrealized gains and losses and fair value of investments available-for-sale as of September 30, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate bonds and notes&#x2014;short-term&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate bonds and notes&#x2014;long-term&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost, unrealized gains and losses and fair value of investments available-for-sale as of December 31, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate bonds and notes&#x2014;short-term&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate bonds and notes&#x2014;long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4abc2d093e574952b5b7a754de257c3a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOmZmOGViOWRjZGRlZjRiMzE4ODE1MWQ5ZWM1Y2ZhNzhlL3RhYmxlcmFuZ2U6ZmY4ZWI5ZGNkZGVmNGIzMTg4MTUxZDllYzVjZmE3OGVfMS0xLTEtMS0x_c6ca4e6b-5ea1-4baa-879e-2abbb50b5b04"
      unitRef="usd">75880000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4abc2d093e574952b5b7a754de257c3a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOmZmOGViOWRjZGRlZjRiMzE4ODE1MWQ5ZWM1Y2ZhNzhlL3RhYmxlcmFuZ2U6ZmY4ZWI5ZGNkZGVmNGIzMTg4MTUxZDllYzVjZmE3OGVfMS0zLTEtMS0x_aec10d56-636f-420a-ae84-30d35001029a"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4abc2d093e574952b5b7a754de257c3a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOmZmOGViOWRjZGRlZjRiMzE4ODE1MWQ5ZWM1Y2ZhNzhlL3RhYmxlcmFuZ2U6ZmY4ZWI5ZGNkZGVmNGIzMTg4MTUxZDllYzVjZmE3OGVfMS01LTEtMS0x_a4a6c81b-d029-4c99-baa5-fc10cebcba89"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4abc2d093e574952b5b7a754de257c3a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOmZmOGViOWRjZGRlZjRiMzE4ODE1MWQ5ZWM1Y2ZhNzhlL3RhYmxlcmFuZ2U6ZmY4ZWI5ZGNkZGVmNGIzMTg4MTUxZDllYzVjZmE3OGVfMS03LTEtMS0x_ef0aab9c-9847-4106-a010-08e4291351c0"
      unitRef="usd">75884000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibb8359146f7d40bdae64e9071788d92a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOmZmOGViOWRjZGRlZjRiMzE4ODE1MWQ5ZWM1Y2ZhNzhlL3RhYmxlcmFuZ2U6ZmY4ZWI5ZGNkZGVmNGIzMTg4MTUxZDllYzVjZmE3OGVfMi0xLTEtMS0x_d9adb295-ff92-42cb-9cae-b7fee95513b4"
      unitRef="usd">20929000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibb8359146f7d40bdae64e9071788d92a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOmZmOGViOWRjZGRlZjRiMzE4ODE1MWQ5ZWM1Y2ZhNzhlL3RhYmxlcmFuZ2U6ZmY4ZWI5ZGNkZGVmNGIzMTg4MTUxZDllYzVjZmE3OGVfMi0zLTEtMS0x_da02afd6-2d27-4b37-be9f-8c4d67969ff2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibb8359146f7d40bdae64e9071788d92a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOmZmOGViOWRjZGRlZjRiMzE4ODE1MWQ5ZWM1Y2ZhNzhlL3RhYmxlcmFuZ2U6ZmY4ZWI5ZGNkZGVmNGIzMTg4MTUxZDllYzVjZmE3OGVfMi01LTEtMS0x_a36af993-b57f-4b38-b5d0-5c78e0dcd11f"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibb8359146f7d40bdae64e9071788d92a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOmZmOGViOWRjZGRlZjRiMzE4ODE1MWQ5ZWM1Y2ZhNzhlL3RhYmxlcmFuZ2U6ZmY4ZWI5ZGNkZGVmNGIzMTg4MTUxZDllYzVjZmE3OGVfMi03LTEtMS0x_f7f78271-6681-468b-9594-741bb8f040d6"
      unitRef="usd">20922000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOmZmOGViOWRjZGRlZjRiMzE4ODE1MWQ5ZWM1Y2ZhNzhlL3RhYmxlcmFuZ2U6ZmY4ZWI5ZGNkZGVmNGIzMTg4MTUxZDllYzVjZmE3OGVfMy0xLTEtMS0x_599b583d-94ce-4e45-bbae-c74b92ba5c48"
      unitRef="usd">96809000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOmZmOGViOWRjZGRlZjRiMzE4ODE1MWQ5ZWM1Y2ZhNzhlL3RhYmxlcmFuZ2U6ZmY4ZWI5ZGNkZGVmNGIzMTg4MTUxZDllYzVjZmE3OGVfMy0zLTEtMS0x_8f4dfeaf-4ca1-4278-a727-20ccf08f0b6b"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOmZmOGViOWRjZGRlZjRiMzE4ODE1MWQ5ZWM1Y2ZhNzhlL3RhYmxlcmFuZ2U6ZmY4ZWI5ZGNkZGVmNGIzMTg4MTUxZDllYzVjZmE3OGVfMy01LTEtMS0x_73c7121f-c37d-47a3-9fce-0a59d3867390"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOmZmOGViOWRjZGRlZjRiMzE4ODE1MWQ5ZWM1Y2ZhNzhlL3RhYmxlcmFuZ2U6ZmY4ZWI5ZGNkZGVmNGIzMTg4MTUxZDllYzVjZmE3OGVfMy03LTEtMS0x_f2cd5135-ba1a-471c-be51-23e5764748d6"
      unitRef="usd">96806000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <cris:AvailableForSaleSecuritiesDateRange
      contextRef="i0d85f4c8792a4a81a3945294a14918cf_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RleHRyZWdpb246NDRkZTEwMzQzNmIyNDYwYThkZGRiZmU2ZDExMjM4OGNfMTM3Nw_2e1220f2-9b78-474f-8cbd-017a29db9f8e">P12M</cris:AvailableForSaleSecuritiesDateRange>
    <cris:AvailableForSaleSecuritiesWeightedAverageMaturity
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RleHRyZWdpb246NDRkZTEwMzQzNmIyNDYwYThkZGRiZmU2ZDExMjM4OGNfMjQ5_e1a43117-8d22-4834-8faa-e5bb8c49a093">P0Y7M6D</cris:AvailableForSaleSecuritiesWeightedAverageMaturity>
    <cris:AvailableForSaleSecuritiesWeightedAverageMaturity
      contextRef="i9957a5ac4bf142e78afb996c95c0ac64_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RleHRyZWdpb246NDRkZTEwMzQzNmIyNDYwYThkZGRiZmU2ZDExMjM4OGNfMzE4_770ed622-c96d-44a7-8811-4584daaedb16">P1Y7M6D</cris:AvailableForSaleSecuritiesWeightedAverageMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0d10b233f290481a9f06412946f6a2ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOjg3ZDViY2EyMjYwYzRlZDJhMjYwMGZlODM2ZGZjMWIwL3RhYmxlcmFuZ2U6ODdkNWJjYTIyNjBjNGVkMmEyNjAwZmU4MzZkZmMxYjBfMS0xLTEtMS0x_ff743afc-93c8-48be-be85-dc71a783c165"
      unitRef="usd">38888000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0d10b233f290481a9f06412946f6a2ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOjg3ZDViY2EyMjYwYzRlZDJhMjYwMGZlODM2ZGZjMWIwL3RhYmxlcmFuZ2U6ODdkNWJjYTIyNjBjNGVkMmEyNjAwZmU4MzZkZmMxYjBfMS0zLTEtMS0x_c3b76db6-809a-46a7-9d20-d84bff8152ad"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0d10b233f290481a9f06412946f6a2ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOjg3ZDViY2EyMjYwYzRlZDJhMjYwMGZlODM2ZGZjMWIwL3RhYmxlcmFuZ2U6ODdkNWJjYTIyNjBjNGVkMmEyNjAwZmU4MzZkZmMxYjBfMS01LTEtMS0x_5b8892b2-1e07-4825-b638-9f526eaa7796"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0d10b233f290481a9f06412946f6a2ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOjg3ZDViY2EyMjYwYzRlZDJhMjYwMGZlODM2ZGZjMWIwL3RhYmxlcmFuZ2U6ODdkNWJjYTIyNjBjNGVkMmEyNjAwZmU4MzZkZmMxYjBfMS03LTEtMS0x_5e519e5b-506b-4dcf-8075-ff3d4a9a8e20"
      unitRef="usd">38884000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifa1a4b9cd2ed47249f51596f460164a4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOjg3ZDViY2EyMjYwYzRlZDJhMjYwMGZlODM2ZGZjMWIwL3RhYmxlcmFuZ2U6ODdkNWJjYTIyNjBjNGVkMmEyNjAwZmU4MzZkZmMxYjBfMi0xLTEtMS0x_76a1ddd1-2d9a-454d-8604-14e94cbd1307"
      unitRef="usd">14563000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifa1a4b9cd2ed47249f51596f460164a4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOjg3ZDViY2EyMjYwYzRlZDJhMjYwMGZlODM2ZGZjMWIwL3RhYmxlcmFuZ2U6ODdkNWJjYTIyNjBjNGVkMmEyNjAwZmU4MzZkZmMxYjBfMi0zLTEtMS0x_41ef1e13-8a4f-4e03-a17b-03a35da19307"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifa1a4b9cd2ed47249f51596f460164a4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOjg3ZDViY2EyMjYwYzRlZDJhMjYwMGZlODM2ZGZjMWIwL3RhYmxlcmFuZ2U6ODdkNWJjYTIyNjBjNGVkMmEyNjAwZmU4MzZkZmMxYjBfMi01LTEtMS0x_b655a20a-95b4-48c3-be30-0dd67baf466c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifa1a4b9cd2ed47249f51596f460164a4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOjg3ZDViY2EyMjYwYzRlZDJhMjYwMGZlODM2ZGZjMWIwL3RhYmxlcmFuZ2U6ODdkNWJjYTIyNjBjNGVkMmEyNjAwZmU4MzZkZmMxYjBfMi03LTEtMS0x_5f8abf8b-04c3-42e1-9151-298edb0f40a6"
      unitRef="usd">14564000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOjg3ZDViY2EyMjYwYzRlZDJhMjYwMGZlODM2ZGZjMWIwL3RhYmxlcmFuZ2U6ODdkNWJjYTIyNjBjNGVkMmEyNjAwZmU4MzZkZmMxYjBfMy0xLTEtMS0x_3c4d0f8b-8bf2-40a3-b421-9fc68405390d"
      unitRef="usd">53451000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOjg3ZDViY2EyMjYwYzRlZDJhMjYwMGZlODM2ZGZjMWIwL3RhYmxlcmFuZ2U6ODdkNWJjYTIyNjBjNGVkMmEyNjAwZmU4MzZkZmMxYjBfMy0zLTEtMS0x_0f99bf49-be97-4846-b3b2-bb7e958b89ba"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOjg3ZDViY2EyMjYwYzRlZDJhMjYwMGZlODM2ZGZjMWIwL3RhYmxlcmFuZ2U6ODdkNWJjYTIyNjBjNGVkMmEyNjAwZmU4MzZkZmMxYjBfMy01LTEtMS0x_5565f3fb-5fc8-4927-bbea-6a6fb8c6c31c"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RhYmxlOjg3ZDViY2EyMjYwYzRlZDJhMjYwMGZlODM2ZGZjMWIwL3RhYmxlcmFuZ2U6ODdkNWJjYTIyNjBjNGVkMmEyNjAwZmU4MzZkZmMxYjBfMy03LTEtMS0x_21ec8fba-2a1d-41fd-82c0-22e03eb9971f"
      unitRef="usd">53448000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <cris:AvailableForSaleSecuritiesDateRange
      contextRef="i5de88db29d3e498087f6e6443e27c84c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RleHRyZWdpb246NDRkZTEwMzQzNmIyNDYwYThkZGRiZmU2ZDExMjM4OGNfMTM3OQ_73c02764-32e3-4c0e-b8a5-20b3527960ef">P12M</cris:AvailableForSaleSecuritiesDateRange>
    <cris:AvailableForSaleSecuritiesWeightedAverageMaturity
      contextRef="i8e5764c869674f6eaf807f9f08528150_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RleHRyZWdpb246NDRkZTEwMzQzNmIyNDYwYThkZGRiZmU2ZDExMjM4OGNfNTYz_7a8070db-ca0f-4e32-87dc-231b8214586b">P0Y7M6D</cris:AvailableForSaleSecuritiesWeightedAverageMaturity>
    <cris:AvailableForSaleSecuritiesWeightedAverageMaturity
      contextRef="i2f243344a43a416aa68d31546bb3c8b8_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RleHRyZWdpb246NDRkZTEwMzQzNmIyNDYwYThkZGRiZmU2ZDExMjM4OGNfNjM4_b170489c-e3ab-41d6-8a86-459fb79f900b">P1Y6M</cris:AvailableForSaleSecuritiesWeightedAverageMaturity>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180Ni9mcmFnOjQxYTZjMTUwYTQwMDQ1OGY5OGVlZWQ4MWZhMWRmNzQzL3RleHRyZWdpb246NDFhNmMxNTBhNDAwNDU4Zjk4ZWVlZDgxZmExZGY3NDNfNzk_6f3c039b-7782-4c02-be1e-1fd9c145a767">Accrued Liabilities&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:11pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Compensation and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Chemistry, manufacturing and controls costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Professional and legal fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;License fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180Ni9mcmFnOjQxYTZjMTUwYTQwMDQ1OGY5OGVlZWQ4MWZhMWRmNzQzL3RleHRyZWdpb246NDFhNmMxNTBhNDAwNDU4Zjk4ZWVlZDgxZmExZGY3NDNfNzg_31f6bc7a-75b8-44bc-a79f-704e5b7dab39">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:11pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Compensation and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Chemistry, manufacturing and controls costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Professional and legal fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;License fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180Ni9mcmFnOjQxYTZjMTUwYTQwMDQ1OGY5OGVlZWQ4MWZhMWRmNzQzL3RhYmxlOmViZTI5MDFhOGZkZTRhZWE5MmVmMzJhYjVkNzBiOTU4L3RhYmxlcmFuZ2U6ZWJlMjkwMWE4ZmRlNGFlYTkyZWYzMmFiNWQ3MGI5NThfMS0xLTEtMS0x_d44f8134-0d54-4560-91fe-8bd0a4269a64"
      unitRef="usd">2473000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180Ni9mcmFnOjQxYTZjMTUwYTQwMDQ1OGY5OGVlZWQ4MWZhMWRmNzQzL3RhYmxlOmViZTI5MDFhOGZkZTRhZWE5MmVmMzJhYjVkNzBiOTU4L3RhYmxlcmFuZ2U6ZWJlMjkwMWE4ZmRlNGFlYTkyZWYzMmFiNWQ3MGI5NThfMS0zLTEtMS0x_00f24462-27d9-4ca0-8778-3843aeafb918"
      unitRef="usd">2638000</us-gaap:AccruedSalariesCurrent>
    <cris:ChemistryManufacturingAndControlsCosts
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180Ni9mcmFnOjQxYTZjMTUwYTQwMDQ1OGY5OGVlZWQ4MWZhMWRmNzQzL3RhYmxlOmViZTI5MDFhOGZkZTRhZWE5MmVmMzJhYjVkNzBiOTU4L3RhYmxlcmFuZ2U6ZWJlMjkwMWE4ZmRlNGFlYTkyZWYzMmFiNWQ3MGI5NThfMi0xLTEtMS0x_a976763e-f8bd-40bc-b268-297785d47e12"
      unitRef="usd">1910000</cris:ChemistryManufacturingAndControlsCosts>
    <cris:ChemistryManufacturingAndControlsCosts
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180Ni9mcmFnOjQxYTZjMTUwYTQwMDQ1OGY5OGVlZWQ4MWZhMWRmNzQzL3RhYmxlOmViZTI5MDFhOGZkZTRhZWE5MmVmMzJhYjVkNzBiOTU4L3RhYmxlcmFuZ2U6ZWJlMjkwMWE4ZmRlNGFlYTkyZWYzMmFiNWQ3MGI5NThfMi0zLTEtMS0x_6dced8e6-4fbc-48f9-8c44-b770a788b2eb"
      unitRef="usd">0</cris:ChemistryManufacturingAndControlsCosts>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180Ni9mcmFnOjQxYTZjMTUwYTQwMDQ1OGY5OGVlZWQ4MWZhMWRmNzQzL3RhYmxlOmViZTI5MDFhOGZkZTRhZWE5MmVmMzJhYjVkNzBiOTU4L3RhYmxlcmFuZ2U6ZWJlMjkwMWE4ZmRlNGFlYTkyZWYzMmFiNWQ3MGI5NThfMy0xLTEtMS0x_698ded33-2cd9-4759-9f59-2a908e50013b"
      unitRef="usd">541000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180Ni9mcmFnOjQxYTZjMTUwYTQwMDQ1OGY5OGVlZWQ4MWZhMWRmNzQzL3RhYmxlOmViZTI5MDFhOGZkZTRhZWE5MmVmMzJhYjVkNzBiOTU4L3RhYmxlcmFuZ2U6ZWJlMjkwMWE4ZmRlNGFlYTkyZWYzMmFiNWQ3MGI5NThfMy0zLTEtMS0x_e8bde673-6f46-462d-b03d-3d5a401a73be"
      unitRef="usd">307000</us-gaap:AccruedProfessionalFeesCurrent>
    <cris:LicenseFees
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180Ni9mcmFnOjQxYTZjMTUwYTQwMDQ1OGY5OGVlZWQ4MWZhMWRmNzQzL3RhYmxlOmViZTI5MDFhOGZkZTRhZWE5MmVmMzJhYjVkNzBiOTU4L3RhYmxlcmFuZ2U6ZWJlMjkwMWE4ZmRlNGFlYTkyZWYzMmFiNWQ3MGI5NThfNC0xLTEtMS0x_846dc0fa-865e-40c3-a26a-d8a898e2ae2c"
      unitRef="usd">188000</cris:LicenseFees>
    <cris:LicenseFees
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180Ni9mcmFnOjQxYTZjMTUwYTQwMDQ1OGY5OGVlZWQ4MWZhMWRmNzQzL3RhYmxlOmViZTI5MDFhOGZkZTRhZWE5MmVmMzJhYjVkNzBiOTU4L3RhYmxlcmFuZ2U6ZWJlMjkwMWE4ZmRlNGFlYTkyZWYzMmFiNWQ3MGI5NThfNC0zLTEtMS0x_1fa7fe71-063d-4d33-ba15-f0fde6663659"
      unitRef="usd">375000</cris:LicenseFees>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180Ni9mcmFnOjQxYTZjMTUwYTQwMDQ1OGY5OGVlZWQ4MWZhMWRmNzQzL3RhYmxlOmViZTI5MDFhOGZkZTRhZWE5MmVmMzJhYjVkNzBiOTU4L3RhYmxlcmFuZ2U6ZWJlMjkwMWE4ZmRlNGFlYTkyZWYzMmFiNWQ3MGI5NThfNS0xLTEtMS0x_2aa670c4-e436-4285-b6fa-9a3f16a99138"
      unitRef="usd">198000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180Ni9mcmFnOjQxYTZjMTUwYTQwMDQ1OGY5OGVlZWQ4MWZhMWRmNzQzL3RhYmxlOmViZTI5MDFhOGZkZTRhZWE5MmVmMzJhYjVkNzBiOTU4L3RhYmxlcmFuZ2U6ZWJlMjkwMWE4ZmRlNGFlYTkyZWYzMmFiNWQ3MGI5NThfNS0zLTEtMS0x_1b22bf43-bf12-40e4-b593-1c06833d77bf"
      unitRef="usd">305000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180Ni9mcmFnOjQxYTZjMTUwYTQwMDQ1OGY5OGVlZWQ4MWZhMWRmNzQzL3RhYmxlOmViZTI5MDFhOGZkZTRhZWE5MmVmMzJhYjVkNzBiOTU4L3RhYmxlcmFuZ2U6ZWJlMjkwMWE4ZmRlNGFlYTkyZWYzMmFiNWQ3MGI5NThfNi0xLTEtMS0x_ba813040-c898-4d0d-ad08-080c4ccbb447"
      unitRef="usd">5310000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180Ni9mcmFnOjQxYTZjMTUwYTQwMDQ1OGY5OGVlZWQ4MWZhMWRmNzQzL3RhYmxlOmViZTI5MDFhOGZkZTRhZWE5MmVmMzJhYjVkNzBiOTU4L3RhYmxlcmFuZ2U6ZWJlMjkwMWE4ZmRlNGFlYTkyZWYzMmFiNWQ3MGI5NThfNi0zLTEtMS0x_81b25b93-8ef4-4b6d-a1b5-f9fd0daffa2e"
      unitRef="usd">3625000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180OS9mcmFnOmU2OTAwMWZkNzdlNDQ2NzQ5YjMwM2RkMjQ5Yzg1NzMyL3RleHRyZWdpb246ZTY5MDAxZmQ3N2U0NDY3NDliMzAzZGQyNDljODU3MzJfMTA3OA_956c5d9b-2028-4400-ab45-68a9031e9373">DebtIn April 2020, the Company entered into a promissory note evidencing an unsecured $0.9&#160;million loan (the &#x201c;PPP Loan&#x201d;) under the Paycheck Protection Program (&#x201c;PPP&#x201d;), of the Coronavirus Aid, Relief, and Economic Security Act (&#x201c;CARES Act&#x201d;) as administered by the U.S. Small Business Administration (the "SBA"). The PPP Loan was made by Silicon Valley Bank and had a term of 24-months and an interest rate of 1%. Under the terms of the CARES Act and the Paycheck Protection Program Flexibility Act of 2020, PPP Loan recipients can apply for and be granted forgiveness for all or a portion of loans granted under the PPP. The Company applied for such forgiveness in 2020 and received notification in June 2021 that the SBA had forgiven the PPP Loan in full, including interest accrued on the PPP Loan. During the nine months ended September 30, 2021, the Company recorded a gain of $0.9 million to Other income (expense), net for extinguishment of the debt. As of December 31, 2020, the Company recorded short- and long-term debt related to the PPP Loan of $0.6 million and $0.3 million, respectively.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LongTermDebt
      contextRef="i27e768c412c64fadbdb2a523fde1e521_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180OS9mcmFnOmU2OTAwMWZkNzdlNDQ2NzQ5YjMwM2RkMjQ5Yzg1NzMyL3RleHRyZWdpb246ZTY5MDAxZmQ3N2U0NDY3NDliMzAzZGQyNDljODU3MzJfOTY_92110e3d-afd0-4995-afd3-43cad9172ee2"
      unitRef="usd">900000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtTerm
      contextRef="i0d950297b01b4b72ae513d1a9aba345e_I20200430"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180OS9mcmFnOmU2OTAwMWZkNzdlNDQ2NzQ5YjMwM2RkMjQ5Yzg1NzMyL3RleHRyZWdpb246ZTY5MDAxZmQ3N2U0NDY3NDliMzAzZGQyNDljODU3MzJfMzc0_0b2d95f5-8d35-4b5a-8b7b-232de3e94778">P24M</us-gaap:LongTermDebtTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0d950297b01b4b72ae513d1a9aba345e_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180OS9mcmFnOmU2OTAwMWZkNzdlNDQ2NzQ5YjMwM2RkMjQ5Yzg1NzMyL3RleHRyZWdpb246ZTY5MDAxZmQ3N2U0NDY3NDliMzAzZGQyNDljODU3MzJfNDA4_a51672a8-e87f-43bd-b5bc-91c74fb8d219"
      unitRef="number">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="icb1c5fdb8979488fbe5bdf7ab44b6d01_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180OS9mcmFnOmU2OTAwMWZkNzdlNDQ2NzQ5YjMwM2RkMjQ5Yzg1NzMyL3RleHRyZWdpb246ZTY5MDAxZmQ3N2U0NDY3NDliMzAzZGQyNDljODU3MzJfODc2_92e33741-5960-4242-8c59-f71d047e71e9"
      unitRef="usd">900000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShortTermBorrowings
      contextRef="i8446755412e84406a49c98064e52b988_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180OS9mcmFnOmU2OTAwMWZkNzdlNDQ2NzQ5YjMwM2RkMjQ5Yzg1NzMyL3RleHRyZWdpb246ZTY5MDAxZmQ3N2U0NDY3NDliMzAzZGQyNDljODU3MzJfMTAzNA_03204cdc-75fb-40c7-bdf2-0b2c0e741e6b"
      unitRef="usd">600000</us-gaap:ShortTermBorrowings>
    <us-gaap:LongTermDebt
      contextRef="i8446755412e84406a49c98064e52b988_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180OS9mcmFnOmU2OTAwMWZkNzdlNDQ2NzQ5YjMwM2RkMjQ5Yzg1NzMyL3RleHRyZWdpb246ZTY5MDAxZmQ3N2U0NDY3NDliMzAzZGQyNDljODU3MzJfMTA0OQ_09a61bff-2af2-400d-b4c9-0f94c5fb1841"
      unitRef="usd">300000</us-gaap:LongTermDebt>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfMTQwOQ_747fc23c-a89e-4f7b-9cd2-fcd0fc81eb60">LeaseThe Company has a single lease for real estate, including laboratory and office space, and certain equipment. The lease at 128 Spring Street in Lexington, Massachusetts commenced on May 1, 2020 which is the date when the property became available for use to the Company. In accordance with the accounting requirements under ASC 842, the lease obligation was not recorded until its commencement. The discount rate associated with the Company's right-of-use asset is 9.95%. As of September 30, 2021, the Company had an operating lease liability of $5.2 million and related right-of-use asset of $6.0 million related to its operating lease. As of December 31, 2020, the Company had an operating lease liability of $6.8 million and related right-of-use asset of $6.6 million related to its operating lease. The Company recorded a lease cost of $0.3 million and $1.0 million for the three and nine months ended September 30, 2021, respectively. The Company recorded a lease cost of $0.4 and $1.0 million for the three and nine months ended September 30, 2020, respectively. The total cash obligation over the seven year term of this lease is approximately $9.3 million, of which $0.3 million was paid during the three months ended September 30, 2021 and $2.0 million was paid during the nine months ended September 30, 2021. The payments included a payment of $1.1 million for tenant improvements. The Company did not make cash payments during the three months ended September 30, 2020. The Company paid $0.2 million during the nine months ended September 30, 2020</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfNDgw_4596d477-9589-4444-8cc1-ab90e24dc1be"
      unitRef="number">0.0995</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfNTQz_c49dddbc-6726-40dc-943c-bad5f8813aad"
      unitRef="usd">5200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfNTg5_9fbc9c75-22f6-4c93-bd23-3a43305fce15"
      unitRef="usd">6000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfNjkw_39ef8acb-4e17-4765-94ab-09380cf05910"
      unitRef="usd">6800000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfNzM1_6b9ec0f5-67c0-483c-bcd2-e9dedd079e8a"
      unitRef="usd">6600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseExpense
      contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfMTA5OTUxMTYyOTE4OQ_5eb0b8c6-12ab-41c8-9f3b-88cf59f52377"
      unitRef="usd">300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfODMx_8d39068e-b145-4ee6-a42c-c78f48878a7e"
      unitRef="usd">1000000.0</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfOTI4_4af640f6-86bd-4fa9-8dcb-27dd2aea9c0b"
      unitRef="usd">400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfOTM1_e404d608-b25a-4828-be65-6ffc3f9af7ee"
      unitRef="usd">1000000.0</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfMTQxMA_4e8d263b-c9de-4577-b634-1de246eca479">P7Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfMTA3NA_67649360-3ae3-4f53-ba74-dc428fd3cd5c"
      unitRef="usd">9300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:OperatingLeasePayments
      contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfMTA5OTUxMTYyOTE5NA_2171fe29-d5a2-4a1e-a617-0dd0ce32df3a"
      unitRef="usd">300000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfMTE0OQ_72731cab-4a3f-4784-984e-1ebc7b26b125"
      unitRef="usd">2000000.0</us-gaap:OperatingLeasePayments>
    <cris:OperatingLeaseOneTimePaymentTenantImprovements
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfMTI0NA_9872ce06-4c3d-4b32-b9e7-cee31ef5c227"
      unitRef="usd">1100000</cris:OperatingLeaseOneTimePaymentTenantImprovements>
    <us-gaap:OperatingLeasePayments
      contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfMTI5Ng_8b83b08b-7077-4cc1-a16b-c81572e0ec66"
      unitRef="usd">0</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181Mi9mcmFnOjM1ZTNhZjI3MTVlMzRkNTA4MTYwYmMyZTk0ZTQ1Mjk4L3RleHRyZWdpb246MzVlM2FmMjcxNWUzNGQ1MDgxNjBiYzJlOTRlNDUyOThfMTM2Nw_ea56012f-8295-4274-84f7-62d1c7230655"
      unitRef="usd">200000</us-gaap:OperatingLeasePayments>
    <us-gaap:NonmonetaryTransactionsDisclosureTextBlock
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RleHRyZWdpb246NmY3NDZhZDk4ODlkNDMwYWE0YjIyMTQxNGM0NjFkOTVfNDIyMw_39759fe2-4f1d-4f20-9d5b-88da907efed7">Liability Related to the Sale of Future Royalties&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2019, the Company and Curis Royalty entered into the royalty interest purchase agreement (&#x201c;Oberland Purchase Agreement&#x201d;) with entities managed by Oberland Capital Management, LLC (the &#x201c;Purchasers&#x201d;). The Company sold to the Purchasers a portion of its rights to receive royalties from Genentech on potential net sales of Erivedge. Concurrently with the closing of the Oberland Purchase Agreement, Curis Royalty used a portion of the proceeds to terminate and repay the then existing loan with HealthCare Royalty Partners, III, L.P..&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As upfront consideration for the purchase of the royalty rights, at closing the Purchasers paid to Curis Royalty $65.0 million less certain transaction expenses. Curis Royalty will also be entitled to receive up to approximately $70.7 million in milestone payments based on sales of Erivedge as follows: (i) $17.2 million if the Purchasers and Curis Royalty receive aggregate royalty payments pursuant to the Oberland Purchase Agreement in excess of $18.0 million during the calendar year 2021, subject to certain exceptions and (ii) $53.5 million if the Purchasers receive payments pursuant to the Oberland Purchase Agreement in excess of $117.0 million on or prior to December 31, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Oberland Purchase Agreement provides that after the occurrence of an event of default as defined under the security agreement by Curis Royalty, the Purchasers shall have the option, for a period of 180 days, to require Curis Royalty to repurchase a portion of certain royalty and royalty related payments, excluding a portion of non U.S. royalties retained by Curis Royalty (the &#x201c;Purchased Receivables&#x201d;), at a price (the &#x201c;Put/Call Price&#x201d;), equal to a percentage, beginning at a low triple digit &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;percentage and increasing over time up to a low mid triple digit percentage of the sum of the upfront purchase price and any portion of the milestone payments paid in a lump sum by the Purchasers, if any, minus certain payments previously received by the Purchasers with respect to the Purchased Receivables. Additionally, Curis Royalty shall have the option at any time to repurchase the Purchased Receivables at the Put/Call Price as of the date of such repurchase. No events of default existed as of September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the obligation to pay future royalties to Oberland, the Company recorded the proceeds from this transaction as a liability on its Consolidated Balance Sheet that will be accounted for using the interest method over the estimated life of the Oberland Purchase Agreement. As a result, the Company imputes interest on the transaction and records imputed interest expense at the estimated interest rate. The Company's estimate of the interest rate under the agreement is based on the amount of royalty payments expected to be received by Oberland over the life of the arrangement. The projected amount of royalty payments expected to be paid to Oberland involves the use of significant estimates and assumptions with respect to the revenue growth rate in the Company's projections of sales of Erivedge. The Company periodically assesses the expected royalty payments to Curis Royalty from Genentech using a combination of historical results and forecasts from market data sources. To the extent such payments are greater or less than its initial estimates or the timing of such payments is materially different than its original estimates, the Company will adjust the amortization of the liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined the fair value of the liability related to the sale of future royalties at the time of the Oberland Purchase Agreement to be $65.0 million, with a current effective annual imputed interest rate of 7.6%. The Company incurred $0.6 million of transaction costs in connection with the agreement. These transaction costs are amortized to imputed interest expense over the estimated term of the Oberland Purchase Agreement. The Company determined that the fair value assessment of the liability related to the sale of future royalties is a Level 3 assessment within the valuation hierarchy. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the activity with respect to the liability related to the sale of future royalties during the nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.330%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying value of liability related to the sale of future royalties at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of capitalized issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Imputed interest expense recognized for the nine months ending September 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: payments to Oberland Capital, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying value of liability related to the sale of future royalties at September 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonmonetaryTransactionsDisclosureTextBlock>
    <cris:ProceedsFromRoyaltyPurchaseAgreement
      contextRef="ie5375dfdc8ee412588936e837f459f29_D20190301-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RleHRyZWdpb246NmY3NDZhZDk4ODlkNDMwYWE0YjIyMTQxNGM0NjFkOTVfNzEy_497c44b6-5426-4782-8d64-080f70c30950"
      unitRef="usd">65000000.0</cris:ProceedsFromRoyaltyPurchaseAgreement>
    <cris:RoyaltyPurchaseAgreementContingentConsiderationCashProceeds
      contextRef="ie5375dfdc8ee412588936e837f459f29_D20190301-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RleHRyZWdpb246NmY3NDZhZDk4ODlkNDMwYWE0YjIyMTQxNGM0NjFkOTVfODI1_97de9425-8786-4f86-a259-588437271bf0"
      unitRef="usd">70700000</cris:RoyaltyPurchaseAgreementContingentConsiderationCashProceeds>
    <cris:RoyaltyPurchaseAgreementContingentConsiderationCashProceeds
      contextRef="iffa498edbc73462ba0ffcf6335f33a3b_D20190301-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RleHRyZWdpb246NmY3NDZhZDk4ODlkNDMwYWE0YjIyMTQxNGM0NjFkOTVfOTAx_1878f1ce-8bb4-4e71-bb2e-bdb971dc6459"
      unitRef="usd">17200000</cris:RoyaltyPurchaseAgreementContingentConsiderationCashProceeds>
    <cris:RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold
      contextRef="iffa498edbc73462ba0ffcf6335f33a3b_D20190301-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RleHRyZWdpb246NmY3NDZhZDk4ODlkNDMwYWE0YjIyMTQxNGM0NjFkOTVfMTA0MA_f6fa5328-4a66-4e6b-b60b-29224a2ff71a"
      unitRef="usd">18000000.0</cris:RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold>
    <cris:RoyaltyPurchaseAgreementContingentConsiderationCashProceeds
      contextRef="ib033bd6eec734cf1826c9d37348e3df6_D20190301-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RleHRyZWdpb246NmY3NDZhZDk4ODlkNDMwYWE0YjIyMTQxNGM0NjFkOTVfMTEyMQ_50f5fbf7-b479-4301-aa86-f9b6ae4b01fa"
      unitRef="usd">53500000</cris:RoyaltyPurchaseAgreementContingentConsiderationCashProceeds>
    <cris:RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold
      contextRef="ib033bd6eec734cf1826c9d37348e3df6_D20190301-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RleHRyZWdpb246NmY3NDZhZDk4ODlkNDMwYWE0YjIyMTQxNGM0NjFkOTVfMTIyNA_d0d13ddd-a0b4-4272-9931-b420a28fb130"
      unitRef="usd">117000000.0</cris:RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold>
    <cris:RoyaltyPurchaseAgreementTermsPurchaserDefaultOptionPeriod
      contextRef="i1df2f708d5694cd7803b3b1cdb822461_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RleHRyZWdpb246NmY3NDZhZDk4ODlkNDMwYWE0YjIyMTQxNGM0NjFkOTVfMTQ3MQ_3d90b047-7ead-4f4a-a80e-d062a84d3d09">P180D</cris:RoyaltyPurchaseAgreementTermsPurchaserDefaultOptionPeriod>
    <cris:ProceedsFromRoyaltyPurchaseAgreement
      contextRef="ie5375dfdc8ee412588936e837f459f29_D20190301-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RleHRyZWdpb246NmY3NDZhZDk4ODlkNDMwYWE0YjIyMTQxNGM0NjFkOTVfMzYyOA_8fced041-e0cf-4743-afa6-3eb7297a1999"
      unitRef="usd">65000000.0</cris:ProceedsFromRoyaltyPurchaseAgreement>
    <cris:RoyaltyPurchaseAgreementInterestRate
      contextRef="if6e3f1f585a2476fb48ab5c48b4b4c0c_D20190301-20190331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RleHRyZWdpb246NmY3NDZhZDk4ODlkNDMwYWE0YjIyMTQxNGM0NjFkOTVfMzY5Nw_35585a6c-ba1b-4da9-bfe7-cd5ceebcd24f"
      unitRef="number">0.076</cris:RoyaltyPurchaseAgreementInterestRate>
    <cris:RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts
      contextRef="if6e3f1f585a2476fb48ab5c48b4b4c0c_D20190301-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RleHRyZWdpb246NmY3NDZhZDk4ODlkNDMwYWE0YjIyMTQxNGM0NjFkOTVfMzcyMg_bfdc87fd-9b60-42f3-8d2e-fa8776a7fedd"
      unitRef="usd">600000</cris:RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts>
    <us-gaap:ScheduleOfOtherSignificantNoncashTransactionsTextBlock
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RleHRyZWdpb246NmY3NDZhZDk4ODlkNDMwYWE0YjIyMTQxNGM0NjFkOTVfNDIyNQ_1567163e-1b81-4945-811a-f35b22024c42">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the activity with respect to the liability related to the sale of future royalties during the nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.330%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying value of liability related to the sale of future royalties at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of capitalized issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Imputed interest expense recognized for the nine months ending September 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: payments to Oberland Capital, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying value of liability related to the sale of future royalties at September 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherSignificantNoncashTransactionsTextBlock>
    <cris:RoyaltyPurchaseAgreementLiabilityCarryingValue
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RhYmxlOjU2NzUzZDI4MzFhODRjYzJiNzFmNTlkNDVlYjcwNzExL3RhYmxlcmFuZ2U6NTY3NTNkMjgzMWE4NGNjMmI3MWY1OWQ0NWViNzA3MTFfMS0xLTEtMS0x_f80bc189-e460-4892-b83b-8b72f0b967a4"
      unitRef="usd">58235000</cris:RoyaltyPurchaseAgreementLiabilityCarryingValue>
    <cris:RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RhYmxlOjU2NzUzZDI4MzFhODRjYzJiNzFmNTlkNDVlYjcwNzExL3RhYmxlcmFuZ2U6NTY3NTNkMjgzMWE4NGNjMmI3MWY1OWQ0NWViNzA3MTFfMi0xLTEtMS0x_62e34b0b-e3c5-4556-bb5f-42863269e05a"
      unitRef="usd">46000</cris:RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization>
    <cris:RoyaltyPurchaseAgreementAccretionExpense
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RhYmxlOjU2NzUzZDI4MzFhODRjYzJiNzFmNTlkNDVlYjcwNzExL3RhYmxlcmFuZ2U6NTY3NTNkMjgzMWE4NGNjMmI3MWY1OWQ0NWViNzA3MTFfMy0xLTEtMS0x_95e04801-1101-4cd8-9d18-b7205098e472"
      unitRef="usd">3320000</cris:RoyaltyPurchaseAgreementAccretionExpense>
    <cris:PaymentsOfFutureRoyaltyLiability
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RhYmxlOjU2NzUzZDI4MzFhODRjYzJiNzFmNTlkNDVlYjcwNzExL3RhYmxlcmFuZ2U6NTY3NTNkMjgzMWE4NGNjMmI3MWY1OWQ0NWViNzA3MTFfNC0xLTEtMS0x_7659cd3f-ee32-4193-9a2f-0f45cc35d241"
      unitRef="usd">6434000</cris:PaymentsOfFutureRoyaltyLiability>
    <cris:RoyaltyPurchaseAgreementLiabilityCarryingValue
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181NS9mcmFnOjZmNzQ2YWQ5ODg5ZDQzMGFhNGIyMjE0MTRjNDYxZDk1L3RhYmxlOjU2NzUzZDI4MzFhODRjYzJiNzFmNTlkNDVlYjcwNzExL3RhYmxlcmFuZ2U6NTY3NTNkMjgzMWE4NGNjMmI3MWY1OWQ0NWViNzA3MTFfNS0xLTEtMS0x_d0341fc7-149c-435b-a0ba-d041bbb0f9c1"
      unitRef="usd">55167000</cris:RoyaltyPurchaseAgreementLiabilityCarryingValue>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfOTI0Mw_404ba629-d4af-4b67-993d-5e16edb860b4">Research and Development Collaborations&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;Genentech&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2003, the Company licensed its proprietary Hedgehog pathway antagonist technologies to Genentech for human therapeutic use. The primary focus of the collaborative research plan has been to develop molecules that inhibit the Hedgehog pathway for the treatment of various cancers. The collaboration is currently focused on the development of Erivedge, which is being commercialized by Genentech in the U.S. and by Genentech&#x2019;s parent company, Roche, in several other countries for the treatment of advanced BCC. Pursuant to the agreement, the Company is eligible to receive up to an aggregate of $115.0 million in contingent cash milestone payments, exclusive of royalty payments, in connection with the development of Erivedge or another small molecule Hedgehog pathway inhibitor, assuming the successful achievement by Genentech and Roche of specified clinical development and regulatory objectives. Of this amount, the Company has received $59.0 million in cash milestone payments as of September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to these payments and pursuant to the collaboration agreement, the Company is entitled to a royalty on net sales of Erivedge that ranges from 5% to 7.5%. The royalty rate applicable to Erivedge may be decreased by 2% on a country-by-country basis in certain specified circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized $3.1 million and $2.7 million in royalty revenue under the Genentech collaboration during the three months ended September 30, 2021 and 2020, respectively. The Company recognized $7.6 million in royalty revenue under the Genentech collaboration during the nine months ended September 30, 2021 and $7.7 million during the nine months ended September 30, 2020. The Company also recorded costs of royalty revenues within the costs and expenses section of its Condensed Consolidated Statements of Operations and Comprehensive Loss of $0.2 million during the three months ended September 30, 2021 and $0.1&#160;million during the three months ended September 30, 2020. The Company recorded $0.4 million of costs of royalty revenues during the nine months ended September 30, 2021 and 2020. Cost of royalty revenues comprises 5% of the royalty payments that Curis Royalty receives from Genentech, through February 2022, which the Company is obligated to pay to university licensors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded receivables from Genentech under this collaboration, comprised primarily of Erivedge royalties earned in the first half of 2021 and 2020. The receivable recorded in the Company's current assets section of its Condensed Consolidated Balance Sheets amounted to $3.0 million as of September 30, 2021 and December 31, 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously discussed in Note 8, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liability Related to the Sale of Future Royalties,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; a portion of royalty revenues received from Genentech on net sales of Erivedge will be paid to the Purchasers pursuant to the Oberland Purchase Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Aurigene&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2015, the Company entered into an exclusive collaboration agreement with Aurigene for the discovery, development and commercialization of small molecule compounds in the areas of immuno-oncology and selected precision oncology targets, which was amended in September 2016. Under the collaboration agreement, Aurigene granted the Company an option to obtain exclusive, royalty-bearing licenses to relevant Aurigene technology to develop, manufacture and commercialize products containing certain of such compounds anywhere in the world, except for India and Russia, which are territories retained by Aurigene. In February 2020, the collaboration agreement was further amended whereby Aurigene received rights to develop and commercialize CA-170 in Asia in addition to its existing rights in India and Russia, and the Company became entitled to receive royalty payments on potential future sales of CA-170 in Asia at percentage rates ranging from the high single digits up to 10% subject to specified reductions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2021, the Company has exercised its option to license the following four programs under the collaboration:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:58.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;IRAK4 Program - a precision oncology program of small molecule inhibitors of IRAK4. The development candidate is CA-4948, an orally available small molecule inhibitor of IRAK4.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:58.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;PD1/VISTA Program - an immuno-oncology program of small molecule antagonists of PD1 and VISTA immune checkpoint pathways. The development candidate is CA-170, an orally available small molecule antagonist of VISTA and PDL1.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:58.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;PD1/TIM3 Program - an immuno-oncology program of small molecule antagonists of PD1 and TIM3 immune checkpoint pathways. The development candidate is CA-327, an orally available small molecule antagonist of PDL1 and TIM3.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:58.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;In March 2018, the Company exercised its option to license a fourth program, which is an immuno-oncology program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since January 2015, the Company has paid $14.5&#160;million in research payments and Aurigene has waived $19.5&#160;million in milestone payments. For each of the IRAK4, PD1/VISTA, and PD1/TIM3 programs, and the fourth immuno-oncology program: the Company has remaining unpaid or unwaived payment obligations of $42.5&#160;million per program, related to regulatory approval and commercial sales milestones, plus specified additional payments for approvals for additional indications, if any. The Company is further obligated to pay Aurigene tiered royalties on the Company's and its affiliates' annual net sales of products at percentage rates ranging from the high single digits up to 10%, subject to specified reductions. In addition, the Company agreed to make certain payments to Aurigene upon its entry into sublicense agreements on any program(s).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the collaboration agreement, the Company has entered into a master development and manufacturing agreement with Aurigene for the supply of drug substance and drug product. Under this agreement, the Company incurred $0.5&#160;million in research and development expense during the three months ended September 30, 2021 and $1.2&#160;million during the nine months ended September 30, 2021. The Company recorded less than $0.1&#160;million in prepaid expenses and $0.9&#160;million in accrued expenses as of September 30, 2021 associated with this agreement.  The Company expensed $0.6&#160;million and $0.8&#160;million related to Aurigene for the three and nine month periods ended September 30, 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;ImmuNext&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into an option and license agreement with ImmuNext (the &#x201c;ImmuNext Agreement&#x201d;). Under the terms of the ImmuNext Agreement, the Company agreed to engage in a collaborative effort with ImmuNext, and to conduct a Phase 1 clinical trial of CI-8993. In exchange, ImmuNext granted the Company an exclusive option, exercisable until the earlier of January 2024 or (b) 90 days after database lock for the first Phase 1 trial in which the endpoints are satisfied (the &#x201c;Option Period&#x201d;), to obtain an exclusive, worldwide license to develop and commercialize certain VISTA antagonizing compounds and products containing these compounds in the field of oncology.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the Option Period, the Company is obligated to pay a semi-annual fee of $0.4 million to ImmuNext and will conduct the Phase 1 trial, and ImmuNext will conduct certain agreed upon non-clinical research activities to support the Phase 1 trial. Additionally, the Company will assign to ImmuNext all right, title and interest in and to, inventions made by the Company alone or jointly with ImmuNext in conducting clinical and non-clinical activities under the ImmuNext Agreement and any &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;patent rights covering those inventions. If the option is exercised, ImmuNext will assign to the Company (i) all such inventions that were made solely by the Company and any patent rights covering those inventions that were assigned by the Company to ImmuNext during the Option Period and (ii) a joint ownership interest in all such inventions that were made jointly by the Company and ImmuNext and patent rights covering those inventions that were assigned by the Company to ImmuNext during the Option Period, except for any of those inventions that relates to certain compounds to which ImmuNext has retained exclusive rights. In addition, the Company has agreed to reimburse ImmuNext for certain documented external costs and expenses incurred by ImmuNext in carrying out non-clinical research activities approved by the joint steering committee, up to $0.3 million per calendar year, unless otherwise agreed to by both parties in writing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company elects to exercise the option, the Company has agreed to pay to ImmuNext an option exercise fee of $20.0&#160;million. ImmuNext will be eligible to receive up to $4.6&#160;million in potential development milestones, up to $84.3&#160;million in potential regulatory approval milestones, and up to $125.0&#160;million in potential sales milestone payments from us. ImmuNext is also eligible to receive tiered royalties on annual net sales on a product-by-product and country-by-country basis, at percentage rates ranging from high single digits to low double digits, subject to specified adjustments. In addition, the Company has agreed to pay ImmuNext a low double-digit percentage of sublicense revenue received by the Company or its affiliates.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <cris:CollaborationAgreementContingentConsiderationPotentialCashPayment
      contextRef="i6a3b34007b0a4945b84b16df5abc4a37_I20030630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfNjYz_9aae107f-7929-46f4-aa4a-41907a479cf5"
      unitRef="usd">115000000.0</cris:CollaborationAgreementContingentConsiderationPotentialCashPayment>
    <cris:CollaborationAgreementContingentConsiderationReceivedFromPartner
      contextRef="id3a04e3a472f4d30b82d08fe43d2c0b7_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMTAwNg_583711c2-d78e-4113-8625-a770d6d81f04"
      unitRef="usd">59000000.0</cris:CollaborationAgreementContingentConsiderationReceivedFromPartner>
    <cris:PercentageOfRoyaltyOnNetSales
      contextRef="i481f7ee4adb0442a9066ccee54707fa3_D20030601-20030630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMTIwOA_d5e05f35-160b-4d30-a655-db0b70338166"
      unitRef="number">0.05</cris:PercentageOfRoyaltyOnNetSales>
    <cris:PercentageOfRoyaltyOnNetSales
      contextRef="i1554d4e73abd4dabac3fe396586aa6c2_D20030601-20030630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMTIxNA_45209173-a348-49fd-ae79-cf173bd24e45"
      unitRef="number">0.075</cris:PercentageOfRoyaltyOnNetSales>
    <cris:ReducedRoyaltyRate
      contextRef="ic26067fcb23449e68eba5cd92cb0a49e_D20030601-20030630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMTI3OA_7adb0cb5-1c7a-43e6-8b86-14fc7442cd1a"
      unitRef="number">0.02</cris:ReducedRoyaltyRate>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia877710393f94f3f8c7e7cd08300f3eb_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMTM3MA_b4b8b059-d554-4fca-b254-77b0237abfc9"
      unitRef="usd">3100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied01dcd8f0fb415ba2f14add0c9df964_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMTM4NQ_9c303bf0-b621-4baf-8dde-a95148173b1e"
      unitRef="usd">2700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6bffc8f5f047450b936f6e0e45ee38ee_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMTUyNA_f8254152-2384-4b2d-8c75-39dca34cfc86"
      unitRef="usd">7600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i867de25d3dc74fc8a9604601d285b12c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMTYyMg_07bfa0d9-866b-4d62-b18e-c820e822cab8"
      unitRef="usd">7700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RoyaltyExpense
      contextRef="i6f251344683f457e89a14215c76f8256_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMTgzNg_02dd88ee-2b63-4a1a-bbad-417aac60b1d7"
      unitRef="usd">200000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="if18f2dacb57041919fa0284b6d6a3fd4_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMjE5OTAyMzI2NzE2Nw_3b14ead0-9ef7-481e-85b8-09385a48c811"
      unitRef="usd">100000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i46169f75ca7f4f9db86ac1e7a209d5bf_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMTkwNg_a06cd634-564f-4943-a666-56dade36472a"
      unitRef="usd">400000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i79ee3f9f0f4d480d8caee067d86e3ca8_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMTkwNg_ec8c15f7-4ddb-479a-8f35-b2e00c9d71f7"
      unitRef="usd">400000</us-gaap:RoyaltyExpense>
    <cris:RoyaltyRatePercentageOfSales
      contextRef="if99565915c7247d696c1777c7a44e409_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMjAxOQ_a7b55434-f4ca-4be7-83f6-038b34924d64"
      unitRef="number">0.05</cris:RoyaltyRatePercentageOfSales>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id3a04e3a472f4d30b82d08fe43d2c0b7_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMjg5OA_43d4bcf8-d1ca-434a-b074-c8d9d90ee804"
      unitRef="usd">3000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5a557708fb604f12961074aec6ae2ddc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMjg5OA_f7c9e651-21f7-4012-8019-9dd385ee6c82"
      unitRef="usd">3000000.0</us-gaap:AccountsReceivableNetCurrent>
    <cris:CollaborationAgreementTermsPercentageOfRoyaltyFeesReceivable
      contextRef="ia3409ba719834a2f9e98876189a4ceb1_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfNDIwNA_cb643c4c-dc60-4b6f-8e19-a49aad2b1240"
      unitRef="number">0.10</cris:CollaborationAgreementTermsPercentageOfRoyaltyFeesReceivable>
    <cris:CollaborationAgreementNumberofProgramsLicensed
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfNDMxMg_eff6dcd9-54eb-4422-8125-fea59043e94d"
      unitRef="program">4</cris:CollaborationAgreementNumberofProgramsLicensed>
    <cris:PaymentsforCollaborativeArrangementstoDate
      contextRef="i4bcee2e8132f40f29d06994aa69d5c75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfNTEyNw_3eb86b75-16d1-4d81-8596-cd4b7aa2ebf8"
      unitRef="usd">14500000</cris:PaymentsforCollaborativeArrangementstoDate>
    <cris:MilestonePaymentsWaivedToDate
      contextRef="i460702ed242d4892b13fa83e2f82d10c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfNTE3NQ_b05a2a9b-ac1f-4beb-9539-a141e1fa088b"
      unitRef="usd">19500000</cris:MilestonePaymentsWaivedToDate>
    <us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1
      contextRef="i55779509759a4442aa49e025489ef439_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfNTM2Ng_7f8d57a9-bd14-4e7a-8249-6eb077c12104"
      unitRef="usd">42500000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1>
    <cris:CollaborationAgreementTermsPercentageOfRoyaltyFeesReceivable
      contextRef="ia3409ba719834a2f9e98876189a4ceb1_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfNTcyNQ_d5b40a80-1077-4eab-9a0d-2d7d6c35cf8f"
      unitRef="number">0.10</cris:CollaborationAgreementTermsPercentageOfRoyaltyFeesReceivable>
    <cris:CollaborativeArrangementPaymentsAgreement
      contextRef="i1b4c90b7e43448599c53fc40d6662bc3_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMjc0ODc3OTA3OTA4NA_de279dfa-bc5a-4a6d-916d-31ec787aa4be"
      unitRef="usd">500000</cris:CollaborativeArrangementPaymentsAgreement>
    <cris:CollaborativeArrangementPaymentsAgreement
      contextRef="ib8625a7feacd4c3f8ea2bbf25583364c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMjc0ODc3OTA3OTA2NQ_efa2f44c-f132-4113-8139-133873876ffd"
      unitRef="usd">1200000</cris:CollaborativeArrangementPaymentsAgreement>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent
      contextRef="if724acf7f886498f936922f1b813133c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMjc0ODc3OTA3OTA0Ng_c72fcc1e-a24a-4ad7-90ee-9df3bfd87754"
      unitRef="usd">100000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="if724acf7f886498f936922f1b813133c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMjc0ODc3OTA3OTE1MA_192c521d-8515-40d6-b3c2-7087821f843f"
      unitRef="usd">900000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <cris:CollaborationAgreementExpense
      contextRef="i1233820bbb0f46f1ae495b371f0da3a3_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMjc0ODc3OTA3ODk5Ng_9550a1ac-d945-48f3-8d81-ea2e47180ff4"
      unitRef="usd">600000</cris:CollaborationAgreementExpense>
    <cris:CollaborationAgreementExpense
      contextRef="i0c0e449c262a4c9fb7ac84a67ca508ed_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMjc0ODc3OTA3OTAxMA_fc617641-6392-4ee0-a1be-2f1a77884ecf"
      unitRef="usd">800000</cris:CollaborationAgreementExpense>
    <cris:CollaborationArrangementSemiAnnualMaintenanceFeePayment
      contextRef="i2553b5bece3047dca87c108aef6cfd51_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfNzE5Mw_e3f740e2-8346-40dd-83f2-2bfbbf2106a5"
      unitRef="usd">400000</cris:CollaborationArrangementSemiAnnualMaintenanceFeePayment>
    <cris:CollaborationArrangementContingentConsiderationReimbursableExpenses
      contextRef="iae8e02ce92e14a61a403e503c35b7dd3_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfODQ1OA_e565f10d-025c-4206-9685-8d72b9378d1d"
      unitRef="usd">300000</cris:CollaborationArrangementContingentConsiderationReimbursableExpenses>
    <cris:CollaborationArrangementContingentConsiderationOptionExerciseFee
      contextRef="iae8e02ce92e14a61a403e503c35b7dd3_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfMTA5OTUxMTYzOTI2OA_d28bae55-f638-42fa-8d03-26c95f709996"
      unitRef="usd">20000000</cris:CollaborationArrangementContingentConsiderationOptionExerciseFee>
    <cris:CollaborationArrangementContingentConsiderationDevelopmentMilestonePayments
      contextRef="iae8e02ce92e14a61a403e503c35b7dd3_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfODU4Nw_ca2a67b5-7906-4d04-b526-e075384545f2"
      unitRef="usd">4600000</cris:CollaborationArrangementContingentConsiderationDevelopmentMilestonePayments>
    <cris:CollaborationArrangementContingentConsiderationRegulatoryApprovalMilestonePayments
      contextRef="iae8e02ce92e14a61a403e503c35b7dd3_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfODYzMw_db473a59-1e07-4e13-b066-e34880db1fa4"
      unitRef="usd">84300000</cris:CollaborationArrangementContingentConsiderationRegulatoryApprovalMilestonePayments>
    <cris:CollaborationArrangementContingentConsiderationSalesMilestonePayments
      contextRef="iae8e02ce92e14a61a403e503c35b7dd3_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY181OC9mcmFnOmNlZTU0ZTYwMGNmYTQzNGRiZDY5NzkyNjkwMmQ1ZmNlL3RleHRyZWdpb246Y2VlNTRlNjAwY2ZhNDM0ZGJkNjk3OTI2OTAyZDVmY2VfODY5MQ_5050f6da-f5ab-4f59-9e3d-272f44a0a597"
      unitRef="usd">125000000</cris:CollaborationArrangementContingentConsiderationSalesMilestonePayments>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNzgwMQ_dc64daea-24f6-4959-8d99-9086aa7a9db6">Common Stock&lt;div style="margin-top:6pt;padding-left:45pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.84pt"&gt;Charter Amendments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2020, the Company's stockholders approved an increase to the number of authorized shares of its common stock from 101,250,000 shares to 151,875,000 shares. The Company filed an amendment to its certificate of incorporation in June 2020 to effect such increase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Company's stockholders approved an increase to the number of authorized shares of its common stock from 151,875,000 shares to 227,812,500 shares. The Company filed an amendment to its certificate of incorporation in May 2021 to effect such increase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.84pt"&gt;2021 Sales Agreement with Cantor Fitzgerald &amp;amp; Co. and JonesTrading Institutional Services LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, the Company entered into a sales agreement (the &#x201c;2021 Sales Agreement&#x201d;) with Cantor Fitzgerald &amp;amp; Co., or Cantor, and JonesTrading Institutional Services LLC , or JonesTrading, to sell from time to time up to $100.0&#160;million of the Company&#x2019;s common stock through an &#x201c;at the market offering&#x201d; program under which Cantor and JonesTrading act as sales agents. Subject to the terms and conditions of the 2021 Sales Agreement, Cantor and JonesTrading can sell the common stock by any method deemed to be an &#x201c;at-the-market&#x201d; offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of the 2021 Sales Agreement, the aggregate compensation payable to each of Cantor and JonesTrading is 3% of the gross proceeds from sales of the common stock sold by Cantor or JonesTrading, as applicable. Each party agreed in the 2021 Sales Agreement to provide indemnification and contribution against certain liabilities, including liabilities under the Securities Act, subject to the terms of the 2021 Sales Agreement. To date, the Company has not made any sales of common stock pursuant to the 2021 Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The securities in this transaction were offered pursuant to an automatic shelf registration statement on Form S-3ASR (File No. 333-254362) that was filed with the SEC on March 16, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.41pt"&gt;2020 Public Offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company completed an underwritten public offering of 29,500,000 shares of the Company's common stock, including 3,847,826 shares issued and sold to the underwriters upon the exercise in full of their option to purchase additional shares, at a price of $5.75 per share, for aggregate gross proceeds of  $169.6  million, before deducting underwriting discounts and commissions and other offering expenses of $10.2&#160;million. The securities in this transaction were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-224627) that was filed with the SEC on May 3, 2018 and declared effective by the SEC on May 17, 2018 and an additional registration statement on Form S-3 (File No. 333-251211) filed pursuant to Rule 462(b) which became automatically effective on December 9, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.84pt"&gt;2020 Registered Direct Offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company entered into a securities purchase agreement with certain institutional investors, pursuant to which the Company issued and sold, in a registered direct offering, an aggregate of 14,000,000 shares of the Company's common stock at a purchase price per share of $1.25, for aggregate gross proceeds of $17.5&#160;million, before deducting fees of approximately $1.0&#160;million paid to the placement agent and other estimated offering expenses of approximately $0.5&#160;million paid by the Company. JonesTrading acted as the exclusive placement agent for the transaction, and the shares were offered by the Company pursuant to its universal shelf registration statement on Form S-3, which was filed with the SEC on May 3, 2018 and declared effective by the SEC on May 17, 2018 (File No. 333-224627), and a prospectus supplement thereunder. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.41pt"&gt;2020 Sales Agreement with JonesTrading Institutional Services LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the Company entered into a Capital on Demand&#x2122; Sales Agreement (the &#x201c;Sales Agreement&#x201d;) with JonesTrading to sell from time to time up to $30.0 million of the Company&#x2019;s common stock through an &#x201c;at-the-market&#x201d; equity offering program under which JonesTrading acted as sales agent. Subject to the terms and conditions of the Sales Agreement, JonesTrading could sell the common stock by any method deemed to be an &#x201c;at-the-market&#x201d; offering as defined in Rule 415 promulgated under the Securities Act, including sales made directly on the Nasdaq Global Market, on any other existing trading market for the common stock or to or through a market maker other than on an exchange. In addition, with the Company&#x2019;s prior written approval, JonesTrading could also sell the common stock by any other method permitted by law, including in privately negotiated transactions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of the Sales Agreement, the aggregate compensation payable to JonesTrading was 3% of the gross proceeds from sales of the common stock sold by JonesTrading pursuant to the Sales Agreement. Each party agreed in the Sales Agreement to provide indemnification and contribution against certain liabilities, including liabilities under the Securities Act, subject to the terms of the Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company terminated this sales agreement effective as of December 9, 2020. The Company did not incur any termination penalties as a result of the termination. As of the effective date of the termination of the Sales Agreement, the Company had sold an aggregate of 6,298,648 shares of common stock under the sales agreement for aggregate gross proceeds of $8.3&#160;million and net proceeds of $7.9&#160;million after deducting commissions and offering expenses. The $21.7 million of common stock that remained unsold at the time of termination is no longer available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.07pt"&gt;Aspire Capital Fund LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020, the Company entered into a common stock purchase agreement (the &#x201c;Agreement&#x201d;) with Aspire Capital Fund, LLC (&#x201c;Aspire Capital&#x201d;) for the sale of up to $30.0 million of the Company's common stock. Under the terms of the Agreement, Aspire Capital has committed to purchase such shares of the Company's common stock at the Company&#x2019;s request, from time to time during a 30-month period at prices based on the market price at the time of each sale, subject to specified terms and limitations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aspire Capital made an initial investment of $3.0 million through the purchase of 2,693,965 shares of the Company's common stock.  In 2020, Aspire Capital subsequently purchased an additional 4,650,000 shares of the Company's common stock for $5.4 million.  In addition, as consideration for Aspire Capital&#x2019;s obligation under the Agreement, the Company issued 646,551 shares of common stock to Aspire Capital as a commitment fee.  As of September 30, 2021 and December 31, 2020, a total of $21.6&#160;million remained available under the Agreement. The Company did not sell shares of common stock under the Agreement during the three and nine months ended September 30, 2021. For the three months ended September 30, 2020, 3,600,000 shares were sold representing net proceeds of $4.2&#160;million. For the nine months ended September 30, 2020, 6,293,965 shares were sold representing net proceeds of $6.8&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Agreement, the Company has the right to sell up to 150,000 shares of common stock per day to Aspire Capital, which total may be increased by mutual agreement up to an additional 2,000,000 shares per day. The extent to which the Company relies on Aspire Capital as a source of funding will depend on a number of factors, including the prevailing market price of its common stock and the extent to which it is able to secure working capital from other sources.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no warrants, derivatives, or other share classes associated with this Agreement. The Company will control the timing and amount of the further sale of its common stock to Aspire Capital. There are no restrictions on future financings and there are no financial covenants, participation rights, rights of first refusal, or penalties in the Agreement. The Company has the right to terminate the Agreement at any time without any additional cost or penalty.&lt;/span&gt;&lt;/div&gt;The Company also entered into a Registration Rights Agreement with Aspire Capital in connection with its entry into the Agreement.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6e2324829cfe492bb1ce3a18540cabae_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMTY2_3468e8ca-bee8-4053-a373-043130aa3498"
      unitRef="shares">101250000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5e926263e5b843dba11e03bf2ac934c5_I20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMTA5OTUxMTYzNTU4OA_3246de2e-9dbb-4766-9769-42360b4d90e1"
      unitRef="shares">151875000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5e926263e5b843dba11e03bf2ac934c5_I20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNDE2_0c7a8022-2bff-42b5-b3e9-9f4582be2c37"
      unitRef="shares">151875000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNDI5_dd59d4c0-0e85-4b47-88fb-d1bafb55e3f3"
      unitRef="shares">227812500</us-gaap:CommonStockSharesAuthorized>
    <cris:StockSaleAgreementAuthorizedAmount
      contextRef="i389b853ef28c48bfb67d977144cea2be_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfODYx_dc94ee37-342b-4a30-921f-4a36d07237e3"
      unitRef="usd">100000000</cris:StockSaleAgreementAuthorizedAmount>
    <cris:StockSaleAgreementCompensationFeePercentageOfGrossProceeds
      contextRef="i13cd005f3b784a00a03427270ff13a4e_I20210316"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMTM5NA_8f971f49-4319-4492-a177-e67081aa92e0"
      unitRef="number">0.03</cris:StockSaleAgreementCompensationFeePercentageOfGrossProceeds>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i1d46809b9cf44e11972741a203406eb1_D20201201-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMjA5NQ_f8c2a95c-2fb2-4b51-bb6e-70c04502a0f1"
      unitRef="shares">29500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ib2634e1ed79549308ba035250ef761a1_D20201201-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMjE0Ng_0017ce37-abf8-4179-acb1-5ac583282c7d"
      unitRef="shares">3847826</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i005697a4b0824bddb4df769ee739b32c_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMjI3OQ_cfb81304-2e1f-4f07-81dd-b46a9162214c"
      unitRef="usdPerShare">5.75</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="i531d173b436149d0977c73c89cfa4e0b_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMjMyNg_9c7e2027-1c81-4554-82e6-4f450644bb9b"
      unitRef="usd">169600000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProfessionalFees
      contextRef="i531d173b436149d0977c73c89cfa4e0b_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMjQyNg_76b59f1d-d43e-49c2-a070-5f1c2d5f956e"
      unitRef="usd">10200000</us-gaap:ProfessionalFees>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i0104cbc441b344aa8d7670c779cd19fc_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMzA0OQ_e7501006-7154-4347-bb7e-d96446f41811"
      unitRef="shares">14000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="if2e46877fa284075af8f8cd02a331c87_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMzEyMg_a00c3f42-1bac-4964-910c-df450250c1f7"
      unitRef="usdPerShare">1.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="ia64c5dfac95a49f2be056702512a4950_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMzE1OA_07567581-7926-46e4-8b48-bdf3ef28ee54"
      unitRef="usd">17500000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProfessionalFees
      contextRef="ia64c5dfac95a49f2be056702512a4950_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMzIwMQ_9cff5a69-cfa9-44ed-a4b6-fe65c47f56b8"
      unitRef="usd">1000000</us-gaap:ProfessionalFees>
    <cris:SaleOfStockIssuanceCosts
      contextRef="ia64c5dfac95a49f2be056702512a4950_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMzI4Nw_1230d2fd-01f4-4884-80e2-e4b7e0875d7a"
      unitRef="usd">500000</cris:SaleOfStockIssuanceCosts>
    <cris:StockSaleAgreementAuthorizedAmount
      contextRef="ic9dc8759604c4487a95552d9277d2945_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMzg3MA_b881a25d-d7bf-47cd-8412-874ead3a0c0a"
      unitRef="usd">30000000</cris:StockSaleAgreementAuthorizedAmount>
    <cris:StockSaleAgreementCompensationFeePercentageOfGrossProceeds
      contextRef="ib4c44bc6307042429eb5deaab3627f34_I20200304"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNDY4NA_49ecf27b-bec5-4b0c-b281-d3810c1344f1"
      unitRef="number">0.03</cris:StockSaleAgreementCompensationFeePercentageOfGrossProceeds>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ia614167954ff4147a511fd404c79e22a_D20201209-20201209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNTI2OA_7c3f0d33-1fea-4c69-a98c-5f0c3447e59e"
      unitRef="shares">6298648</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="ia614167954ff4147a511fd404c79e22a_D20201209-20201209"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNTM1Mg_17baff2d-acd4-4ca9-8ce6-99c606f5787e"
      unitRef="usd">8300000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ia614167954ff4147a511fd404c79e22a_D20201209-20201209"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNTM3NQ_77d42805-b29f-4f28-894a-d60abe04fe64"
      unitRef="usd">7900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cris:StockPurchaseProgramRemainingAuthorizedPurchaseAmount
      contextRef="i4f43d279bfc346499189eea5974d7564_I20201209"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNTQzMw_a0877f74-824f-4408-9cdc-fb8551272e3b"
      unitRef="usd">21700000</cris:StockPurchaseProgramRemainingAuthorizedPurchaseAmount>
    <cris:StockPurchaseProgramAuthorizedAmount
      contextRef="i59313702068b4ee9a458942cc6de5f0a_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNTcxNA_567cabf0-fb56-42a8-90c2-189d27a84a76"
      unitRef="usd">30000000</cris:StockPurchaseProgramAuthorizedAmount>
    <cris:StockPurchaseProgramPricePeriod
      contextRef="ia4d61c5f1c1a4c7b8b490d4990b8c9a1_D20200201-20200229"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNTkxOA_58a03e0e-1f37-4b2a-a5a0-df80be4307d3">P30M</cris:StockPurchaseProgramPricePeriod>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i7e2fb16ab10247c7bb59f0e0bb3f5e91_D20200226-20200226"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNjA4NQ_c101d218-b59e-447a-a04f-b786ec039118"
      unitRef="usd">3000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i7e2fb16ab10247c7bb59f0e0bb3f5e91_D20200226-20200226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNjExMg_8b82d137-1e0c-4190-a843-b051c2eb00ab"
      unitRef="shares">2693965</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i509ac601c8cb4988976c395f2c180da2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNjIxNQ_efef643f-a72e-4562-9015-7db6d38cdc9f"
      unitRef="shares">4650000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:CommonStockValue
      contextRef="i3e79259145d846dfb9168818ded77f22_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNjI1OQ_6373e28a-e24a-4ba4-ae6b-bebe84d4d165"
      unitRef="usd">5400000</us-gaap:CommonStockValue>
    <cris:StockPurchaseProgramCommitmentFeeShares
      contextRef="i6e1d7b28e07045f8b69914b45905559b_I20200226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNjM2Ng_4a9f1d52-14ba-4688-b0ef-4b9920845579"
      unitRef="shares">646551</cris:StockPurchaseProgramCommitmentFeeShares>
    <cris:StockSaleAgreementRemainingAuthorizedAmount
      contextRef="icd185c48c5a14633a53cc897fedfc27f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNjQ2MA_54f2ca5a-7585-4401-8d1a-306019a58678"
      unitRef="usd">21600000</cris:StockSaleAgreementRemainingAuthorizedAmount>
    <cris:StockSaleAgreementRemainingAuthorizedAmount
      contextRef="ic667076e7a4a430c82568988e947ba95_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNjQ2MA_c9984850-c970-4525-80c6-b038c28835f6"
      unitRef="usd">21600000</cris:StockSaleAgreementRemainingAuthorizedAmount>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i298a95e35ee2477b900f65f112daddfd_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMjc0ODc3OTA3Nzg2OA_735e8ccb-97e7-47c2-88cd-c7e549829b01"
      unitRef="shares">3600000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i298a95e35ee2477b900f65f112daddfd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMjc0ODc3OTA3Nzg3OQ_878468c7-78b5-4baa-bb17-20e17c5365f7"
      unitRef="usd">4200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i8feff43f83394d56b56b4cc6fe8050aa_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMjc0ODc3OTA3NzkwNw_ff4f212b-889a-4498-9b65-b5a5bd7d3f6a"
      unitRef="shares">6293965</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i8feff43f83394d56b56b4cc6fe8050aa_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfMjc0ODc3OTA3Nzg5Mw_a693ea9a-6014-4d0c-8127-aaa9eecc49e6"
      unitRef="usd">6800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <cris:StockPurchaseProgramTermsSharesAuthorizedPerDay
      contextRef="icd185c48c5a14633a53cc897fedfc27f_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNjgxMA_6377aaff-b2e2-4247-acba-0bb8531b12ec"
      unitRef="shares">150000</cris:StockPurchaseProgramTermsSharesAuthorizedPerDay>
    <cris:StockPurchaseProgramTermsSharesAuthorizedPerDayAfterMutualAgreement
      contextRef="icd185c48c5a14633a53cc897fedfc27f_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182MS9mcmFnOmQ2ZTMwMTk0NzViODRjYmJhODM3MTdlNDc1MDBhYmM5L3RleHRyZWdpb246ZDZlMzAxOTQ3NWI4NGNiYmE4MzcxN2U0NzUwMGFiYzlfNjkzMg_d5100c3f-f708-4776-bdc3-c43f2cb43394"
      unitRef="shares">2000000</cris:StockPurchaseProgramTermsSharesAuthorizedPerDayAfterMutualAgreement>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNjU2OA_0b3b6c1a-16a6-4364-bedb-879424593329">Stock Plans and Stock-Based Compensation&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2021, the Company had two shareholder-approved, stock-based compensation plans: (i) the Amended and Restated 2010 Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;), adopted by the Board of Directors in April 2017 and approved by shareholders in June 2017, and (ii)&#160;the Fourth Amended and Restated 2010 Stock Incentive Plan (&#x201c;2010 Plan&#x201d;). New employees are typically issued options as an inducement equity award under Nasdaq Listing Rule 5635(c)(4) outside of the 2010 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;The Fourth Amended and Restated 2010 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2010 Plan permits the granting of incentive and non-qualified stock options and stock awards to employees, officers, directors, and consultants of the Company and its subsidiaries at prices determined by the Company&#x2019;s Board of Directors.  In May 2021, the Company's shareholders approved the Company's Fourth Amended and Restated 2010 Stock Incentive Plan to reserve an additional 11,000,000 shares of common stock for issuance under the 2010 Plan. The Company can issue up to 23,190,000 shares of its common stock pursuant to awards granted under the 2010 Plan. Options become exercisable as determined by the Board of Directors and expire up to ten years from the date of grant. The 2010 Plan uses a &#x201c;fungible share&#x201d; concept under which each share of stock subject to awards granted as options and stock appreciation rights (&#x201c;SARs&#x201d;), will cause one share per share under the award to be removed from the available share pool, while each share of stock subject to awards granted as restricted stock, restricted stock units, other stock-based awards or performance awards where the price charged for the award is less than 100% of the fair market value of the Company&#x2019;s common stock will cause 1.3 shares per share under the award to be removed from the available share pool. As of September 30, 2021 the Company has only granted options to purchase shares of the Company&#x2019;s common stock with an exercise price equal to the closing market price of the Company&#x2019;s common stock on the Nasdaq Global Market on the grant date. As of September 30, 2021, 13,595,840 shares remained available for grant under the 2010 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September 30, 2021, the Company&#x2019;s board of directors granted options to purchase 1,086,000 shares of the Company&#x2019;s common stock to the officers and employees of the Company, under the 2010 Plan. Shares granted to officers and employees vest as to 25% of the shares underlying the award on the first anniversary of the grant date and as to an additional 6.25% of the shares underlying the award at the end of each subsequent quarter, based upon continued employment over a four year period, and are exercisable at a price equal to the closing price of the Company&#x2019;s common stock on the Nasdaq Global Market on the grant date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of 2021, the Company&#x2019;s board of directors granted options to its non-employee directors to purchase 132,000 shares of common stock under the 2010 Plan, which will vest and become exercisable one year from the grant date. There were no additional non-employee grants made in the three months ended September 30, 2021. In addition, during the nine months ended September 30, 2021 the Company's board of directors issued options to newly-hired employees as an inducement equity award under Nasdaq Listing Rule 5635(c)(4) outside of the 2010 Plan to purchase 613,850 shares of common stock. These options will vest as to 25% of the shares underlying the option on the first anniversary of the grant date, and as to an additional 6.25% of the shares underlying the option on each successive three-month period thereafter. All option awards are exercisable at a price equal to the closing price of the Company&#x2019;s common stock on the Nasdaq Global Market on the grant dates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity under the 2010 Plan and inducement awards are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.818%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&#160;per&lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining Contractual Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,668,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,831,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(85,751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled/Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(115,825)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding, September 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,298,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,689,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.96&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested and unvested expected to vest at September 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,963,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.56&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair values of the stock options granted during the nine months ended September 30, 2021 and 2020 were $9.21 and $0.75, respectively, and were calculated using the following estimated assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term (years) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4-1.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4-1.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected Dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As of September 30, 2021, there was approximately $11.4 million of unrecognized compensation cost related to unvested employee stock option awards outstanding, net of the impact of estimated forfeitures that is expected to be recognized as expense over a weighted average period of 2.27 years. The intrinsic value of employee stock options exercised during the nine months ended September 30, 2021 was $0.5&#160;million. The intrinsic value of employee stock options exercised during the nine months ended September 30, 2020 was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of unvested restricted stock awards (&#x201c;RSAs&#x201d;) under the 2010 Plan as of September 30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested, December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested, September 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2021, there were 10,312 shares outstanding covered by RSAs that are expected to vest. The weighted average grant date fair value of these shares of restricted stock was $3.45 per share and the aggregate fair value of these shares of restricted stock was $0.1 million. As of September 30, 2021, there was less than $0.1 million of unrecognized compensation costs, net of estimated forfeitures, related to RSAs granted to officers, which are expected to be recognized as expense over a remaining weighted average period of 0.31 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8.8pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amended and Restated 2010 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8.8pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has reserved 2,000,000 shares of common stock for issuance under the ESPP. Eligible employees may purchase shares of the Company&#x2019;s common stock at 85% of the lower closing market price of the common stock at the beginning of the enrollment period or ending date of the purchase period within a two-year enrollment period, as defined. The Company has four six-month purchase periods per each two-year enrollment period. If, within any one of the four purchase periods in an enrollment period, the purchase period ending stock price is lower than the stock price at the beginning of the enrollment period, the two-year enrollment resets at the new lower stock price. This aspect of the plan was amended in 2017. Prior to 2017, the plan included two six-month purchase periods per year with no defined enrollment period. During the three  months ended September 30, 2021, no shares were issued under the ESPP. During the nine months ended September 30, 2021, 20,791 shares were issued under the ESPP. As of September 30, 2021, there were 1,576,599 shares available for future purchase under the ESPP. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8.8pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ESPP compensation expense for the three and nine months ended September 30, 2021 and 2020 was not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8.8pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8.8pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September 30, 2021 and 2020, the Company recorded stock-based compensation expense to the following line items in its costs and expenses section of the Condensed Consolidated Statements of Operations and Comprehensive Loss, including expense related to its ESPP:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <cris:ShareBasedCompensationPlans
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNzc_7edb5c10-30db-42ad-93c5-6f2a42bb339d"
      unitRef="plan">2</cris:ShareBasedCompensationPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="id1737ae1a00346e48a3f3c4d2b81c90d_D20210501-20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfOTU5_d1ce1c0f-e33d-4497-9df6-ef65be086e9e"
      unitRef="shares">11000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i8f5c7a7ab0a4454988d74c383e8d95c1_I20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMTA0Nw_330e6da1-728f-4297-ae8e-fd514eca09b5"
      unitRef="shares">23190000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="iec9ed577995e4041bf1893f19ed4df11_D20210501-20210531"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMTIwOQ_157dd6a2-70f0-4f4c-8fca-7782f88f10d9">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <cris:SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare
      contextRef="iec9ed577995e4041bf1893f19ed4df11_D20210501-20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMTQwMg_f16a1497-9470-4472-b820-0903660acd4f"
      unitRef="usdPerShare">1</cris:SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i5d9cc7f517654e6a955f1150754f9212_D20210501-20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMTY3Nw_12ee6bc3-a97a-4c42-8426-3927bfc2002d"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <cris:SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare
      contextRef="i5d9cc7f517654e6a955f1150754f9212_D20210501-20210531"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMTc0Ng_a796e436-c3c1-4a32-be0a-4190b30c9ee9"
      unitRef="usdPerShare">1.3</cris:SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare>
    <cris:NumberOfSharesAwardedUnderStockValueLessThanSpecificPercentageOfFairMarketValue
      contextRef="i9f1f0ba40401473facc35d4c0efc7dbc_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMjA2Ng_34927b51-2fec-442a-832a-2740119576e6"
      unitRef="shares">13595840</cris:NumberOfSharesAwardedUnderStockValueLessThanSpecificPercentageOfFairMarketValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i1219b3d01e7b42a58ca53018ecff778b_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMjIzMg_fb1f1660-8622-49d9-8b50-c08cc4068976"
      unitRef="shares">1086000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ib8de22fdc1364771a9ce096bd4828f96_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMjM5MQ_53d1865c-4298-4fed-adad-8c0126b7a9c4"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ic13e507f88684f5ca74c1614332fef14_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMjQ5Ng_e36f825c-53e5-4a38-881c-3a6f7867d2d2"
      unitRef="number">0.0625</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i07e1ce19861a4ae59be352c43fd153c5_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNjU1NA_4f807826-1b9d-4e6e-a616-43e3431ae79b">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i9e4ba76c11bd4f45b6687b17d856c8d6_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMjg5MA_fe00b2f7-0f94-4e8f-b4d8-e3e3a90b7a4f"
      unitRef="shares">132000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9e4ba76c11bd4f45b6687b17d856c8d6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNjU0OA_5cfd8271-ad4c-44f2-83dc-2ce8e74489e7">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i8b2ded813e3c47c0b1ea5d0064b18933_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMzAxNg_402726cd-c67a-4fec-a20b-f6525152d567"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i5d000460f02348d9a57c3b6ac2c6626a_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMzMwMg_fb33fd53-9e4e-4abb-8ffa-ed7b29f529a9"
      unitRef="shares">613850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ib8de22fdc1364771a9ce096bd4828f96_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMzM2MA_53d1865c-4298-4fed-adad-8c0126b7a9c4"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ic13e507f88684f5ca74c1614332fef14_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMzQ2Nw_e36f825c-53e5-4a38-881c-3a6f7867d2d2"
      unitRef="number">0.0625</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNjU1MA_ec59f1e9-fde0-40d1-a281-3341443474c1">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity under the 2010 Plan and inducement awards are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.818%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&#160;per&lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining Contractual Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,668,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,831,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(85,751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled/Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(115,825)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding, September 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,298,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,689,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.96&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested and unvested expected to vest at September 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,963,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.56&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfMS0xLTEtMS0x_5e78b93b-b111-4297-8492-da810cb342ae"
      unitRef="shares">8668005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id4ae33930dfd48de8c0c9dab2d240035_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfMS0zLTEtMS0x_5b911f14-3342-49a2-9091-41fc9cf76241"
      unitRef="usdPerShare">2.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i8e5764c869674f6eaf807f9f08528150_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfMS01LTEtMS0x_1fa0a9fe-8c54-43e6-bb00-00a2f2e20bd7">P7Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfMi0xLTEtMS0x_1d161600-e421-4dee-b46c-f4e1b0997691"
      unitRef="shares">1831850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfMi0zLTEtMS0x_ebb8c72b-5d52-49ca-94b0-9a3c40f4db4c"
      unitRef="usdPerShare">9.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfMy0xLTEtMS0x_d1ee8081-9bc2-40a9-8d0e-1bb9789e15d4"
      unitRef="shares">85751</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfMy0zLTEtMS0x_b8341fe8-4a38-44b7-a9a3-0f3336877ea2"
      unitRef="usdPerShare">1.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfNC0xLTEtMS0x_67a3a671-3931-4384-99c8-0eaa035c3689"
      unitRef="shares">115825</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfNC0zLTEtMS0x_c16660d2-244e-4487-b646-6f717b361fe3"
      unitRef="usdPerShare">11.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfNS0xLTEtMS0x_32fa7324-a24c-4e17-b7e4-c4e7e047471f"
      unitRef="shares">10298279</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfNS0zLTEtMS0x_db51689a-5c60-49ec-8df0-ba63f3bd8550"
      unitRef="usdPerShare">3.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfNS01LTEtMS0x_aea7a0d8-45c6-40f1-a154-9215ccf52ceb">P7Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfNS03LTEtMS0x_8b44e3fe-759a-4b12-a8e3-1d9efa6143ed"
      unitRef="usd">47967000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfNi0xLTEtMS0x_8647c434-7874-4694-9c81-bb71adf078b5"
      unitRef="shares">5689507</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfNi0zLTEtMS0x_5c2b3d5a-24b8-4193-a236-181ea04b389d"
      unitRef="usdPerShare">3.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfNi01LTEtMS0x_d09c8ad4-73dc-4865-88d4-5813fbde8d00">P6Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfNi03LTEtMS0x_c49c8ecd-9661-4f21-a525-5dec173c97ce"
      unitRef="usd">29624000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfNy0xLTEtMS0x_dbce5ecf-a1db-4a7c-bc39-651e36475b42"
      unitRef="shares">9963214</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfNy0zLTEtMS0x_4692b514-5297-46b7-afec-4303f280e751"
      unitRef="usdPerShare">3.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfNy01LTEtMS0x_1c7c9d42-9a69-4fdb-9a05-4d35f91b5046">P7Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmQ1ZjNiNTcxYTU3NDQ5ODVhYWFmN2EwYTU5ODZkYWUyL3RhYmxlcmFuZ2U6ZDVmM2I1NzFhNTc0NDk4NWFhYWY3YTBhNTk4NmRhZTJfNy03LTEtMS0x_c865ae4a-d6e7-4f9c-a0df-16b3ae5c7d6d"
      unitRef="usd">46817000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNjU2MQ_20477119-40fa-4257-9103-277095c51e51">&lt;div style="margin-bottom:6pt;margin-top:4pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair values of the stock options granted during the nine months ended September 30, 2021 and 2020 were $9.21 and $0.75, respectively, and were calculated using the following estimated assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term (years) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4-1.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4-1.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected Dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMzkyNw_e4139256-0142-43f2-8de4-d455539a260b"
      unitRef="usdPerShare">9.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMzkzNA_f75954cc-b976-421d-93e9-6092ca353b23"
      unitRef="usdPerShare">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOjZhOThhMjc0YmJjYzRlMDg5NGJiZTY5YjIyYjVlYzU1L3RhYmxlcmFuZ2U6NmE5OGEyNzRiYmNjNGUwODk0YmJlNjliMjJiNWVjNTVfMi0xLTEtMS0x_0a51b489-2e04-414b-a35d-12482170e475">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOjZhOThhMjc0YmJjYzRlMDg5NGJiZTY5YjIyYjVlYzU1L3RhYmxlcmFuZ2U6NmE5OGEyNzRiYmNjNGUwODk0YmJlNjliMjJiNWVjNTVfMi0zLTEtMS0x_27db3540-ed3d-4842-a6b6-1c45570bebab">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOjZhOThhMjc0YmJjYzRlMDg5NGJiZTY5YjIyYjVlYzU1L3RhYmxlcmFuZ2U6NmE5OGEyNzRiYmNjNGUwODk0YmJlNjliMjJiNWVjNTVfNS0xLTEtMS0xL3RleHRyZWdpb246NWUxNWJlYzk4ZTUxNDk5NDg2Y2U1ZjMzODRjNmYxNWZfNA_d8f352f8-bc31-4ce2-bee7-278ee3b57922"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOjZhOThhMjc0YmJjYzRlMDg5NGJiZTY5YjIyYjVlYzU1L3RhYmxlcmFuZ2U6NmE5OGEyNzRiYmNjNGUwODk0YmJlNjliMjJiNWVjNTVfNS0xLTEtMS0xL3RleHRyZWdpb246NWUxNWJlYzk4ZTUxNDk5NDg2Y2U1ZjMzODRjNmYxNWZfNw_04019e69-6700-4bff-bfd7-17a74b127af8"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOjZhOThhMjc0YmJjYzRlMDg5NGJiZTY5YjIyYjVlYzU1L3RhYmxlcmFuZ2U6NmE5OGEyNzRiYmNjNGUwODk0YmJlNjliMjJiNWVjNTVfNS0zLTEtMS0xL3RleHRyZWdpb246NDNlNWNkN2U5MTJiNDY0NTgwZDU4Yjg3MWQwYjVhZjBfNA_145fc917-28da-48ba-bfcc-19cd354ad606"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOjZhOThhMjc0YmJjYzRlMDg5NGJiZTY5YjIyYjVlYzU1L3RhYmxlcmFuZ2U6NmE5OGEyNzRiYmNjNGUwODk0YmJlNjliMjJiNWVjNTVfNS0zLTEtMS0xL3RleHRyZWdpb246NDNlNWNkN2U5MTJiNDY0NTgwZDU4Yjg3MWQwYjVhZjBfNw_93d13c7b-16fe-4071-8b14-6427cb066d72"
      unitRef="number">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOjZhOThhMjc0YmJjYzRlMDg5NGJiZTY5YjIyYjVlYzU1L3RhYmxlcmFuZ2U6NmE5OGEyNzRiYmNjNGUwODk0YmJlNjliMjJiNWVjNTVfNi0xLTEtMS0x_90c9eb38-c1ef-462a-96bd-90e2392bc86f"
      unitRef="number">1.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOjZhOThhMjc0YmJjYzRlMDg5NGJiZTY5YjIyYjVlYzU1L3RhYmxlcmFuZ2U6NmE5OGEyNzRiYmNjNGUwODk0YmJlNjliMjJiNWVjNTVfNi0zLTEtMS0x_14bf8a05-cb09-42a7-af44-eb47e97b3c0d"
      unitRef="number">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i11c1bbbe971845e8b341c2dce21185d6_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNDA1Mg_7fd81a41-dd6c-4f36-a697-5aafd55990ed"
      unitRef="usd">11400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNDI4MQ_6cac1816-7164-449c-96c2-fc8ff42bf723">P2Y3M7D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNDM4MQ_9d73ab53-9918-4134-8591-b38c9867fcc9"
      unitRef="usd">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNjU2Mw_078d84fa-78a3-4f08-8ae8-a26df273833b">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of unvested restricted stock awards (&#x201c;RSAs&#x201d;) under the 2010 Plan as of September 30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested, December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested, September 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="if92fd01d600549e3966881e1346c980d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmRlOWJlMDNjMDNmMjQyYzRhOTYyMmFiNGU0MjQ2NDQ1L3RhYmxlcmFuZ2U6ZGU5YmUwM2MwM2YyNDJjNGE5NjIyYWI0ZTQyNDY0NDVfMS0xLTEtMS0x_f503c79d-84ed-4c9b-bf7d-57f7410d0c3c"
      unitRef="shares">20624</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="if92fd01d600549e3966881e1346c980d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmRlOWJlMDNjMDNmMjQyYzRhOTYyMmFiNGU0MjQ2NDQ1L3RhYmxlcmFuZ2U6ZGU5YmUwM2MwM2YyNDJjNGE5NjIyYWI0ZTQyNDY0NDVfMS0zLTEtMS0x_874e4ec9-40c0-4d0b-b6af-4f01a2effd5a"
      unitRef="usdPerShare">3.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i07e1ce19861a4ae59be352c43fd153c5_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmRlOWJlMDNjMDNmMjQyYzRhOTYyMmFiNGU0MjQ2NDQ1L3RhYmxlcmFuZ2U6ZGU5YmUwM2MwM2YyNDJjNGE5NjIyYWI0ZTQyNDY0NDVfMi0xLTEtMS0x_12d20038-e456-4fba-ad1d-5453ab888c19"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i07e1ce19861a4ae59be352c43fd153c5_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmRlOWJlMDNjMDNmMjQyYzRhOTYyMmFiNGU0MjQ2NDQ1L3RhYmxlcmFuZ2U6ZGU5YmUwM2MwM2YyNDJjNGE5NjIyYWI0ZTQyNDY0NDVfMi0zLTEtMS0x_adfa9cea-f5ab-4ba3-a226-7e0a1cb1640b"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i07e1ce19861a4ae59be352c43fd153c5_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmRlOWJlMDNjMDNmMjQyYzRhOTYyMmFiNGU0MjQ2NDQ1L3RhYmxlcmFuZ2U6ZGU5YmUwM2MwM2YyNDJjNGE5NjIyYWI0ZTQyNDY0NDVfMy0xLTEtMS0x_28515ee2-8e21-44ef-9fd6-34e47c5e267b"
      unitRef="shares">10312</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i07e1ce19861a4ae59be352c43fd153c5_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmRlOWJlMDNjMDNmMjQyYzRhOTYyMmFiNGU0MjQ2NDQ1L3RhYmxlcmFuZ2U6ZGU5YmUwM2MwM2YyNDJjNGE5NjIyYWI0ZTQyNDY0NDVfMy0zLTEtMS0x_efbafc65-c7fa-4cbc-b57d-2487f84e1b14"
      unitRef="usdPerShare">3.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i07e1ce19861a4ae59be352c43fd153c5_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmRlOWJlMDNjMDNmMjQyYzRhOTYyMmFiNGU0MjQ2NDQ1L3RhYmxlcmFuZ2U6ZGU5YmUwM2MwM2YyNDJjNGE5NjIyYWI0ZTQyNDY0NDVfNC0xLTEtMS0x_84b5f31a-8a71-4b3d-8de5-4330589dc0e9"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i07e1ce19861a4ae59be352c43fd153c5_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmRlOWJlMDNjMDNmMjQyYzRhOTYyMmFiNGU0MjQ2NDQ1L3RhYmxlcmFuZ2U6ZGU5YmUwM2MwM2YyNDJjNGE5NjIyYWI0ZTQyNDY0NDVfNC0zLTEtMS0x_66c2c97e-22d4-44d6-9671-e2d5e8468b22"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i82ceafb1c6a24cca84ef9a0241a19879_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmRlOWJlMDNjMDNmMjQyYzRhOTYyMmFiNGU0MjQ2NDQ1L3RhYmxlcmFuZ2U6ZGU5YmUwM2MwM2YyNDJjNGE5NjIyYWI0ZTQyNDY0NDVfNS0xLTEtMS0x_d4f3e9d3-c388-4c3f-9d6f-459e57173a3b"
      unitRef="shares">10312</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i82ceafb1c6a24cca84ef9a0241a19879_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmRlOWJlMDNjMDNmMjQyYzRhOTYyMmFiNGU0MjQ2NDQ1L3RhYmxlcmFuZ2U6ZGU5YmUwM2MwM2YyNDJjNGE5NjIyYWI0ZTQyNDY0NDVfNS0zLTEtMS0x_9b381967-0e8a-4a87-abfb-d7b0abd724c6"
      unitRef="usdPerShare">3.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i82ceafb1c6a24cca84ef9a0241a19879_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNDY1MA_9108281a-a179-4b84-bfb8-50fe221c4c82"
      unitRef="shares">10312</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i07e1ce19861a4ae59be352c43fd153c5_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNDc5OQ_efbafc65-c7fa-4cbc-b57d-2487f84e1b14"
      unitRef="usdPerShare">3.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i07e1ce19861a4ae59be352c43fd153c5_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNDg4MQ_ac6d3e39-2525-443d-9732-8f361c507e8c"
      unitRef="usd">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i19989054788e4da19d8b3a02d19f3af8_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNDkyMw_24d021f6-71a4-4cf4-a5b8-2e8a6d6abad2"
      unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="iab7e84e85b8043f69c8eee23b3053c8a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNTEyOA_35145192-5f32-4970-bc98-469ca34a8fbc">P0Y3M21D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i20919e06b4f743a294203290cd8726b2_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNTIxOA_5d59550d-09c7-4891-9c87-5f7f5de693a2"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="ibb5cbdbb686f429fb1f8c8cc33874d76_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNTM0NQ_b4e71700-c695-4d0e-a1a4-46f0a8a7ec04"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <cris:EmployeeStockPurchasePlanEnrollmentPeriod
      contextRef="ibb5cbdbb686f429fb1f8c8cc33874d76_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNjU1OQ_9d817b4d-0bee-41f8-9ab0-52db8f98148b">P2Y</cris:EmployeeStockPurchasePlanEnrollmentPeriod>
    <cris:NumberOfPurchasePeriodsPerEnrollmentPeriod
      contextRef="ibb5cbdbb686f429fb1f8c8cc33874d76_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNTU0Ng_ea2a66dc-15e8-4714-9b8e-3c5af13f0769"
      unitRef="purchase_period">4</cris:NumberOfPurchasePeriodsPerEnrollmentPeriod>
    <cris:SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod
      contextRef="ibb5cbdbb686f429fb1f8c8cc33874d76_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNjU2Ng_d3f7b392-df6f-4ba6-92e7-6dee29b83bd5">P6M</cris:SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod>
    <cris:EmployeeStockPurchasePlanEnrollmentPeriod
      contextRef="ibb5cbdbb686f429fb1f8c8cc33874d76_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNjU3MQ_7fcfc07e-8381-448a-886e-f3f724b5543d">P2Y</cris:EmployeeStockPurchasePlanEnrollmentPeriod>
    <cris:NumberOfPurchasePeriodsPerEnrollmentPeriod
      contextRef="ibb5cbdbb686f429fb1f8c8cc33874d76_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNTYzNw_ea2a66dc-15e8-4714-9b8e-3c5af13f0769"
      unitRef="purchase_period">4</cris:NumberOfPurchasePeriodsPerEnrollmentPeriod>
    <cris:EmployeeStockPurchasePlanEnrollmentPeriod
      contextRef="ibb5cbdbb686f429fb1f8c8cc33874d76_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNjU2NA_569c17ad-79cd-4b26-8d79-d39fceaf4281">P2Y</cris:EmployeeStockPurchasePlanEnrollmentPeriod>
    <cris:NumberOfPurchasePeriodsPerEnrollmentPeriod
      contextRef="iace147228c5946e7856c18ea03d6b20c_D20160101-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNTkzMg_ef4f995b-507a-4a18-bcbf-3a9fc3b7ebee"
      unitRef="purchase_period">2</cris:NumberOfPurchasePeriodsPerEnrollmentPeriod>
    <cris:SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod
      contextRef="iace147228c5946e7856c18ea03d6b20c_D20160101-20161231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNjU2MA_9fc71b6e-3e9f-42ad-b105-ce4f1af987f2">P6M</cris:SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="idb9ad9cc9e894c4a8591a01bc5b0e7a3_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMjc0ODc3OTA3NjEzMw_594c7d83-5e11-45ce-84b1-ee7dcf41c773"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i2bcecdf0c0fb4a72b6e837d5f3fe2504_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfMTA5OTUxMTYzNDQxNA_c39dcd9f-f16b-43df-9a79-6f678e4917d9"
      unitRef="shares">20791</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <cris:StockAvailableForFuturePurchaseUnderEmployeeStockPurchasePlans
      contextRef="i20919e06b4f743a294203290cd8726b2_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNjEwMg_0302e99a-c9f3-497b-8ddf-c4d970f0f171"
      unitRef="shares">1576599</cris:StockAvailableForFuturePurchaseUnderEmployeeStockPurchasePlans>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RleHRyZWdpb246Y2MxMzNjYzg3NzViNDc4NTlmODUwNmY4M2U4NDc4ZTlfNjU1Mg_d3fa2431-a003-41d2-b948-c1058f1e5106">&lt;div style="margin-top:8.8pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September 30, 2021 and 2020, the Company recorded stock-based compensation expense to the following line items in its costs and expenses section of the Condensed Consolidated Statements of Operations and Comprehensive Loss, including expense related to its ESPP:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id7e33ac900a448798f0a8d5fac3e7c9a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmVhMDZlNmFiMDIzZDQ4YWNhZWQwYzMxYjVhYTQ1NGQ4L3RhYmxlcmFuZ2U6ZWEwNmU2YWIwMjNkNDhhY2FlZDBjMzFiNWFhNDU0ZDhfMi0xLTEtMS0x_6a5b154d-b054-4daf-b7d4-c5eff758fb47"
      unitRef="usd">553000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2e0e7bd086684b51905901766d082679_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmVhMDZlNmFiMDIzZDQ4YWNhZWQwYzMxYjVhYTQ1NGQ4L3RhYmxlcmFuZ2U6ZWEwNmU2YWIwMjNkNDhhY2FlZDBjMzFiNWFhNDU0ZDhfMi0zLTEtMS0x_51a41efd-6da4-4405-b741-f20eab8bc931"
      unitRef="usd">193000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3ed4bd4d72e5471aae94ac0a3df1cd55_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmVhMDZlNmFiMDIzZDQ4YWNhZWQwYzMxYjVhYTQ1NGQ4L3RhYmxlcmFuZ2U6ZWEwNmU2YWIwMjNkNDhhY2FlZDBjMzFiNWFhNDU0ZDhfMi01LTEtMS0x_8a6ed898-9e04-40bc-9fc3-425bec5d85b2"
      unitRef="usd">1331000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9179bb8d8abc4e7a966aa44e418032fa_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmVhMDZlNmFiMDIzZDQ4YWNhZWQwYzMxYjVhYTQ1NGQ4L3RhYmxlcmFuZ2U6ZWEwNmU2YWIwMjNkNDhhY2FlZDBjMzFiNWFhNDU0ZDhfMi03LTEtMS0x_f8bbb5cc-e75c-4c6e-9ba9-acccdc6e60a5"
      unitRef="usd">548000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4d1e27447c134e8b8836cf1c2b82cc83_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmVhMDZlNmFiMDIzZDQ4YWNhZWQwYzMxYjVhYTQ1NGQ4L3RhYmxlcmFuZ2U6ZWEwNmU2YWIwMjNkNDhhY2FlZDBjMzFiNWFhNDU0ZDhfMy0xLTEtMS0x_0403226f-0c3a-469e-9e7c-38003d302789"
      unitRef="usd">911000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i19eea75f02854b849783be2ececc8962_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmVhMDZlNmFiMDIzZDQ4YWNhZWQwYzMxYjVhYTQ1NGQ4L3RhYmxlcmFuZ2U6ZWEwNmU2YWIwMjNkNDhhY2FlZDBjMzFiNWFhNDU0ZDhfMy0zLTEtMS0x_dd3df1c9-945f-4363-acb4-082cc8bb527b"
      unitRef="usd">431000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1569ff1a3c7e4c1a828aa4de4ce7b739_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmVhMDZlNmFiMDIzZDQ4YWNhZWQwYzMxYjVhYTQ1NGQ4L3RhYmxlcmFuZ2U6ZWEwNmU2YWIwMjNkNDhhY2FlZDBjMzFiNWFhNDU0ZDhfMy01LTEtMS0x_9f07a549-bbd2-4ef4-a881-fd10cc0660c8"
      unitRef="usd">2507000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibb8cdae355c147d78b1f92ad1395fbb7_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmVhMDZlNmFiMDIzZDQ4YWNhZWQwYzMxYjVhYTQ1NGQ4L3RhYmxlcmFuZ2U6ZWEwNmU2YWIwMjNkNDhhY2FlZDBjMzFiNWFhNDU0ZDhfMy03LTEtMS0x_b7ace800-4661-42cf-94af-ef1120584b6d"
      unitRef="usd">1285000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmVhMDZlNmFiMDIzZDQ4YWNhZWQwYzMxYjVhYTQ1NGQ4L3RhYmxlcmFuZ2U6ZWEwNmU2YWIwMjNkNDhhY2FlZDBjMzFiNWFhNDU0ZDhfNC0xLTEtMS0x_37a18c5b-be3e-446c-90df-d6878b4b3441"
      unitRef="usd">1464000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibb46041a97d04636a793883ccc2b2728_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmVhMDZlNmFiMDIzZDQ4YWNhZWQwYzMxYjVhYTQ1NGQ4L3RhYmxlcmFuZ2U6ZWEwNmU2YWIwMjNkNDhhY2FlZDBjMzFiNWFhNDU0ZDhfNC0zLTEtMS0x_eb165043-99fb-4be3-be04-d1e20e3221e3"
      unitRef="usd">624000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmVhMDZlNmFiMDIzZDQ4YWNhZWQwYzMxYjVhYTQ1NGQ4L3RhYmxlcmFuZ2U6ZWEwNmU2YWIwMjNkNDhhY2FlZDBjMzFiNWFhNDU0ZDhfNC01LTEtMS0x_abe7e977-b6ff-4771-ba68-93a196e657b7"
      unitRef="usd">3838000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i74c8ba9c9c5448b3b7c79846b68254c2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182NC9mcmFnOmNjMTMzY2M4Nzc1YjQ3ODU5Zjg1MDZmODNlODQ3OGU5L3RhYmxlOmVhMDZlNmFiMDIzZDQ4YWNhZWQwYzMxYjVhYTQ1NGQ4L3RhYmxlcmFuZ2U6ZWEwNmU2YWIwMjNkNDhhY2FlZDBjMzFiNWFhNDU0ZDhfNC03LTEtMS0x_3594cedc-16c1-4303-8427-154faf96facc"
      unitRef="usd">1833000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182Ny9mcmFnOjg1OTk3NzU2Y2FmZTRjMzZhMTM0OWQzMThmODMwMDlhL3RleHRyZWdpb246ODU5OTc3NTZjYWZlNGMzNmExMzQ5ZDMxOGY4MzAwOWFfNTgx_34c4107f-91b1-47f8-a08d-83ba357f82b5">Loss Per Common ShareBasic and diluted loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is the same as basic net loss per common share for the three and nine months ended September 30, 2021 and 2020, because the effect of the potential common stock equivalents would be antidilutive due to the Company&#x2019;s net loss position for these periods. Antidilutive securities consist of stock options outstanding of 10,298,279 and 9,128,896 as of September 30, 2021 and 2020, respectively.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id1569a19d3534733a5351d7321844968_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182Ny9mcmFnOjg1OTk3NzU2Y2FmZTRjMzZhMTM0OWQzMThmODMwMDlhL3RleHRyZWdpb246ODU5OTc3NTZjYWZlNGMzNmExMzQ5ZDMxOGY4MzAwOWFfNTQx_6b14f8ff-5e17-4e52-ae92-5cda00a9a136"
      unitRef="shares">10298279</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i85ee1298708f4cd9b83af95152514d48_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY182Ny9mcmFnOjg1OTk3NzU2Y2FmZTRjMzZhMTM0OWQzMThmODMwMDlhL3RleHRyZWdpb246ODU5OTc3NTZjYWZlNGMzNmExMzQ5ZDMxOGY4MzAwOWFfNTQ4_08b6d272-bf0e-4ec7-a983-59c7ff5826e9"
      unitRef="shares">9128896</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY183MC9mcmFnOjhlYTBkYmQzNDkxNjQyMmM5OTQzNGNjMGU4YzI3NDlmL3RleHRyZWdpb246OGVhMGRiZDM0OTE2NDIyYzk5NDM0Y2MwZThjMjc0OWZfMTcxNA_8189da0f-d2a7-4bba-85ca-92a5eb157c26">Related Party Transactions&lt;div style="margin-top:6pt;padding-left:45pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.41pt"&gt;Agreement with Head of Research and Development - Robert E. Martell, M.D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Ph.D.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company entered into an exclusive option and license agreement with Epi-Cure Pharmaceuticals, Inc., (&#x201c;Epi-Cure&#x201d;) a privately held early stage biotechnology company. Robert E. Martell, M.D., Ph.D., the Company&#x2019;s Head of Research and Development and a former director of the Company, is a founder of Epi-Cure, was formerly an officer and director of Epi-Cure, and is currently a holder of a convertible promissory note to Epi-Cure. Under the terms of the option and license agreement, Epi-Cure granted Curis an exclusive option to certain program compounds that may arise during the initial research and development period, and any extension thereof. Upon execution of the option and license agreement, the Company paid Epi-Cure an upfront payment of $0.1 million for legal and consulting costs incurred by Epi-Cure in connection with the transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, Epi-Cure had primary responsibility for conducting research and development activities and Curis was responsible for funding up to $0.5 million of the research and development program costs and expenses during the initial research and development period. After the end of the research and development period, which ended in April 2020, Curis had sixty days to elect to exercise its option to license the program compounds. In June 2020, the Company decided not to exercise its option to license the program compounds, and the agreement expired.&lt;/span&gt;&lt;/div&gt;In 2020, the Company expensed $0.1&#160;million of fees related to this agreement. No expense has been incurred following the expiration of the agreement in June 2020</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="i10387d0e7a2b43aea7787dd2ecda9786_D20181018-20181018"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY183MC9mcmFnOjhlYTBkYmQzNDkxNjQyMmM5OTQzNGNjMGU4YzI3NDlmL3RleHRyZWdpb246OGVhMGRiZDM0OTE2NDIyYzk5NDM0Y2MwZThjMjc0OWZfODg5_ac449c22-eebe-4d8f-ad8d-9cc04942c5f1"
      unitRef="usd">100000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <cris:RelatedPartyTransactionMaximumFundingAmount
      contextRef="i272602d3cc7643438ce9826f03bb4e8d_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY183MC9mcmFnOjhlYTBkYmQzNDkxNjQyMmM5OTQzNGNjMGU4YzI3NDlmL3RleHRyZWdpb246OGVhMGRiZDM0OTE2NDIyYzk5NDM0Y2MwZThjMjc0OWZfMTE1NA_354db0ac-42ce-4387-8e7d-c3deb1b71a83"
      unitRef="usd">500000</cris:RelatedPartyTransactionMaximumFundingAmount>
    <cris:RelatedPartyTransactionTermsAndMannerOfSettlementMinimumDaysNoticeToTerminatePriorToWrittenNotice
      contextRef="i272602d3cc7643438ce9826f03bb4e8d_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY183MC9mcmFnOjhlYTBkYmQzNDkxNjQyMmM5OTQzNGNjMGU4YzI3NDlmL3RleHRyZWdpb246OGVhMGRiZDM0OTE2NDIyYzk5NDM0Y2MwZThjMjc0OWZfMTM2Nw_c49a6a6f-eded-43ed-94a7-da2f23ee0e3c"
      unitRef="day">60</cris:RelatedPartyTransactionTermsAndMannerOfSettlementMinimumDaysNoticeToTerminatePriorToWrittenNotice>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="i1b869695d75c4d90a845094790292154_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY183MC9mcmFnOjhlYTBkYmQzNDkxNjQyMmM5OTQzNGNjMGU4YzI3NDlmL3RleHRyZWdpb246OGVhMGRiZDM0OTE2NDIyYzk5NDM0Y2MwZThjMjc0OWZfMTU5Mw_40024e25-4953-4cc8-a22a-f221b89d11ab"
      unitRef="usd">100000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="i476e1229fc4b40faa3024587e5c8cf5c_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY183MC9mcmFnOjhlYTBkYmQzNDkxNjQyMmM5OTQzNGNjMGU4YzI3NDlmL3RleHRyZWdpb246OGVhMGRiZDM0OTE2NDIyYzk5NDM0Y2MwZThjMjc0OWZfMTYzMQ_56aa6eb4-6020-4e43-8fbc-4bf22a3e15a2"
      unitRef="usd">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457410406712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Nov. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CURIS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3505116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">128 Spring Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Building C - Suite 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Lexington<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">503-6500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CRIS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,609,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001108205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457411350360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 53,020<span></span>
</td>
<td class="nump">$ 129,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">75,884<span></span>
</td>
<td class="nump">38,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">2,959<span></span>
</td>
<td class="nump">3,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,088<span></span>
</td>
<td class="nump">1,215<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">134,951<span></span>
</td>
<td class="nump">172,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">20,922<span></span>
</td>
<td class="nump">14,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">543<span></span>
</td>
<td class="nump">663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, long-term</a></td>
<td class="nump">726<span></span>
</td>
<td class="nump">816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">5,962<span></span>
</td>
<td class="nump">6,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">8,982<span></span>
</td>
<td class="nump">8,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">172,086<span></span>
</td>
<td class="nump">204,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,506<span></span>
</td>
<td class="nump">4,166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">5,310<span></span>
</td>
<td class="nump">3,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">657<span></span>
</td>
<td class="nump">1,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">557<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,473<span></span>
</td>
<td class="nump">10,079<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liability</a></td>
<td class="nump">4,537<span></span>
</td>
<td class="nump">5,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_RoyaltyGuaranteesCommitmentsAmountNoncurrent', window );">Liability related to the sale of future royalties, net</a></td>
<td class="nump">55,167<span></span>
</td>
<td class="nump">58,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">69,177<span></span>
</td>
<td class="nump">73,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value&#8212;227,812,500 shares authorized; 91,609,165 shares issued and outstanding at September 30, 2021; 151,875,000 shares authorized; 91,502,461 shares issued and outstanding at December 31, 2020</a></td>
<td class="nump">916<span></span>
</td>
<td class="nump">915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,180,701<span></span>
</td>
<td class="nump">1,176,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,078,705)<span></span>
</td>
<td class="num">(1,046,889)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">102,909<span></span>
</td>
<td class="nump">130,670<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 172,086<span></span>
</td>
<td class="nump">$ 204,358<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_RoyaltyGuaranteesCommitmentsAmountNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Guarantees, Commitments, Amount, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_RoyaltyGuaranteesCommitmentsAmountNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457414893384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="nump">227,812,500<span></span>
</td>
<td class="nump">151,875,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (in shares)</a></td>
<td class="nump">91,609,165<span></span>
</td>
<td class="nump">91,502,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="nump">91,609,165<span></span>
</td>
<td class="nump">91,502,461<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457410884600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues, net</a></td>
<td class="nump">$ 3,039<span></span>
</td>
<td class="nump">$ 2,742<span></span>
</td>
<td class="nump">$ 7,514<span></span>
</td>
<td class="nump">$ 7,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Cost of royalties</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="nump">376<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">8,602<span></span>
</td>
<td class="nump">4,705<span></span>
</td>
<td class="nump">24,112<span></span>
</td>
<td class="nump">17,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,334<span></span>
</td>
<td class="nump">2,613<span></span>
</td>
<td class="nump">12,524<span></span>
</td>
<td class="nump">8,593<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">13,087<span></span>
</td>
<td class="nump">7,453<span></span>
</td>
<td class="nump">37,012<span></span>
</td>
<td class="nump">26,434<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(10,048)<span></span>
</td>
<td class="num">(4,711)<span></span>
</td>
<td class="num">(29,498)<span></span>
</td>
<td class="num">(18,623)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_NonCashImputedInterestExpense', window );">Imputed interest expense related to the sale of future royalties</a></td>
<td class="num">(1,057)<span></span>
</td>
<td class="num">(1,266)<span></span>
</td>
<td class="num">(3,366)<span></span>
</td>
<td class="num">(3,848)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">890<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense</a></td>
<td class="num">(1,003)<span></span>
</td>
<td class="num">(1,263)<span></span>
</td>
<td class="num">(2,318)<span></span>
</td>
<td class="num">(3,768)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (11,051)<span></span>
</td>
<td class="num">$ (5,974)<span></span>
</td>
<td class="num">$ (31,816)<span></span>
</td>
<td class="num">$ (22,391)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share (basic ) (in dollars per share)</a></td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (0.52)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share (diluted) (in dollars per share)</a></td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (0.52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares (basic) (in shares)</a></td>
<td class="nump">91,601,362<span></span>
</td>
<td class="nump">54,554,129<span></span>
</td>
<td class="nump">91,552,433<span></span>
</td>
<td class="nump">42,884,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares (diluted) (in shares)</a></td>
<td class="nump">91,601,362<span></span>
</td>
<td class="nump">54,554,129<span></span>
</td>
<td class="nump">91,552,433<span></span>
</td>
<td class="nump">42,884,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (11,051)<span></span>
</td>
<td class="num">$ (5,974)<span></span>
</td>
<td class="num">$ (31,816)<span></span>
</td>
<td class="num">$ (22,391)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(11,051)<span></span>
</td>
<td class="num">(5,974)<span></span>
</td>
<td class="num">(31,816)<span></span>
</td>
<td class="num">(22,391)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cris_GrossRoyaltyRevenueMember', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues, net</a></td>
<td class="nump">3,058<span></span>
</td>
<td class="nump">2,720<span></span>
</td>
<td class="nump">7,593<span></span>
</td>
<td class="nump">7,681<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cris_OtherRevenueMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cris_ContraRevenueMember', window );">Contra revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues, net</a></td>
<td class="num">$ (19)<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="num">$ (80)<span></span>
</td>
<td class="num">$ (81)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_NonCashImputedInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Imputed Interest Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_NonCashImputedInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cris_GrossRoyaltyRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cris_GrossRoyaltyRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cris_OtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cris_OtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cris_ContraRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cris_ContraRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457404142008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Aspire Capital Fund, LLC</div></th>
<th class="th"><div>Demand Sales Agreement</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Private Placement</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Aspire Capital Fund, LLC</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Demand Sales Agreement</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Private Placement</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Aspire Capital Fund, LLC</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Demand Sales Agreement</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,241,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="num">$ (33,911)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 982,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,016,981)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Recognition of stock-based compensation</a></td>
<td class="nump">625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,340,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9,709)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,709)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,582,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="num">(40,269)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">986,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,026,690)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,241,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="num">(33,911)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">982,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,016,981)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(22,391)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,652,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="num">(28,608)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,010,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,039,372)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,582,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="num">(40,269)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">986,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,026,690)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Recognition of stock-based compensation</a></td>
<td class="nump">585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock</a></td>
<td class="nump">15,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under Employee Stock Purchase Plan</a></td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(6,708)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,708)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,639,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="num">(30,380)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,002,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,033,398)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Recognition of stock-based compensation</a></td>
<td class="nump">624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="nump">2,413,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,155<span></span>
</td>
<td class="nump">$ 3,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,119<span></span>
</td>
<td class="nump">$ 3,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Fees for issuance of shares in connection with Capital on Demand&#8482; Sales Agreement</a></td>
<td class="num">(262)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(262)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,974)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,974)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,652,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="num">$ (28,608)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,010,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,039,372)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">91,502,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,502,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 130,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,176,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,046,889)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Recognition of stock-based compensation</a></td>
<td class="nump">1,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9,927)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,927)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,534,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">$ 121,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,177,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,056,816)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">91,502,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,502,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 130,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,176,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,046,889)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">85,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (31,816)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="nump">91,609,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,609,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 102,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,180,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,078,705)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,534,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">121,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,177,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,056,816)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Recognition of stock-based compensation</a></td>
<td class="nump">1,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan', window );">Issuance of stock under Employee Stock Purchase Plan</a></td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(10,838)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,838)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,596,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">112,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,179,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,067,654)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Recognition of stock-based compensation</a></td>
<td class="nump">1,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (11,051)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,051)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="nump">91,609,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,609,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 102,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,180,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,078,705)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109244457&amp;loc=d3e16649-113920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457410993992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (31,816)<span></span>
</td>
<td class="num">$ (22,391)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_NonCashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">616<span></span>
</td>
<td class="nump">431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">3,838<span></span>
</td>
<td class="nump">1,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_NonCashImputedInterestExpenseNetOfImputedInterest', window );">Non-cash imputed interest expense related to the sale of future royalties</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization of premiums and discounts on marketable securities</a></td>
<td class="nump">1,013<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on forgiveness of PPP Loan</a></td>
<td class="num">(890)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(1,870)<span></span>
</td>
<td class="num">(940)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued and other liabilities</a></td>
<td class="nump">1,025<span></span>
</td>
<td class="nump">684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_IncreaseDecreaseOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(1,577)<span></span>
</td>
<td class="num">(327)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Total adjustments</a></td>
<td class="nump">2,368<span></span>
</td>
<td class="nump">2,367<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(29,448)<span></span>
</td>
<td class="num">(20,024)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchase of investments</a></td>
<td class="num">(70,977)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales and maturities of investments</a></td>
<td class="nump">26,605<span></span>
</td>
<td class="nump">5,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(657)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(44,372)<span></span>
</td>
<td class="nump">4,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from PPP Loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts', window );">Proceeds of direct placement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from issuance of common stock under the Company's share-based compensation plan</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest', window );">Payment of liability of future royalties, net of imputed interest</a></td>
<td class="num">(3,077)<span></span>
</td>
<td class="num">(3,175)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(2,860)<span></span>
</td>
<td class="nump">23,575<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents and restricted cash</a></td>
<td class="num">(76,680)<span></span>
</td>
<td class="nump">7,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">130,426<span></span>
</td>
<td class="nump">16,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash, end of period</a></td>
<td class="nump">53,746<span></span>
</td>
<td class="nump">24,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow data:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">3,357<span></span>
</td>
<td class="nump">3,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue', window );">Non-cash commitment shares issued to Aspire Capital</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cris_AspireCapitalFundLLCMember', window );">Aspire Capital Fund, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds of Aspire Capital Agreement, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cris_DirectPlacementMember', window );">Direct Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,535)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cris_DemandSalesAgreementMember', window );">Demand Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds of Aspire Capital Agreement, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (262)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_IncreaseDecreaseOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Operating Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_IncreaseDecreaseOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_NonCashImputedInterestExpenseNetOfImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Imputed Interest Expense, Net Of Imputed Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_NonCashImputedInterestExpenseNetOfImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Or Part Noncash Acquisition, Noncash Financial Or Equity Instrument Consideration, Shares Issued, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments Of Future Royalty Liability, Net Of Imputed Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Private Placement, Net Of Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cris_AspireCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cris_AspireCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cris_DirectPlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cris_DirectPlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cris_DemandSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cris_DemandSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457409185416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
<td class="text">Nature of Business<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Curis, Inc. is a biotechnology company focused on the development of first-in-class and innovative therapeutics for the treatment of cancer. Throughout these Condensed Consolidated Financial Statements, Curis, Inc. and its wholly owned subsidiaries are collectively referred to as &#8220;the Company&#8221; or &#8220;Curis.&#8221;</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducts its research and development programs both internally and through strategic collaborations. The Company&#8217;s clinical stage drug candidates are:</span></div><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">CA-4948, an orally available  small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 ("IRAK4"), which is currently undergoing testing in a Phase 1/2 open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas, including those with myeloid Differentiation Primary Response Protein 88 (&#8220;MYD88&#8221;) alterations. The trial was amended to include a combination study of CA-4948 and ibrutinib, a BTK inhibitor, in patients with non-Hodgkin lymphomas for which the Company enrolled the first patient in February 2021. The Company is also conducting a separate Phase 1/2 open-label, single arm dose escalating and expansion trial in patients with acute myeloid leukemia (&#8220;AML&#8221;) and myelodysplastic syndromes (&#8220;MDS&#8221;). The study was amended in April 2021 to include dose escalation cohorts of CA-4948 in combination with azacitidine or venetoclax. In April 2021, CA-4948 was granted Orphan Drug Designation for the treatment of AML and MDS by the U.S. Food and Drug Administration ("FDA"). In June 2021, we reported updated preliminary clinical data from the Phase 1/2 study in patients with AML or MDS and announced the recommended Phase 2 dose for monotherapy dose expansion.</span></div><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation (&#8220;VISTA&#8221;) signaling pathway. In June 2020, the Company announced that the FDA had cleared its Investigational New Drug (&#8220;IND&#8221;) application for CI-8993. In September 2020, enrollment for a Phase 1 trial in patients with solid tumors commenced. The Company has an option to license CI-8993 from ImmuNext, Inc. ("ImmuNext").</span></div><div style="margin-top:6pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s pipeline also includes the following:</span></div><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fimepinostat, a small molecule that potently inhibits the activity of histone deacetylase and phosphotidyl-inositol 3 kinase enzymes, which has been granted Orphan Drug Designation and Fast Track Designation for the treatment of diffuse large B-cell lymphoma and nuclear protein in testis (NUT) midline carcinoma. The Company is currently evaluating future studies for fimepinostat.</span></div><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CA-170, a small molecule antagonist of VISTA and PDL1, for which the Company announced initial data from a clinical study in patients with mesothelioma, in conjunction with the Society of lmmunotherapy of Cancer conference in November 2019. Based on this data, no further patients will be enrolled in the study. The Company is currently evaluating future studies for CA-170.</span></div><div style="margin-top:9pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CA-327, a small molecule antagonist of TIM3 and PDL1, is a pre-IND stage oncology drug candidate.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a collaboration with Genentech Inc. (&#8220;Genentech&#8221;), a member of the Roche Group, under which Genentech and F. Hoffmann-La Roche Ltd (&#8220;Roche&#8221;) are commercializing Erivedge&#174; (vismodegib), a first-in-class orally administered small molecule Hedgehog signaling pathway antagonist. Erivedge is approved for the treatment of advanced basal cell carcinoma (&#8220;BCC&#8221;).</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2015, the Company entered into an exclusive collaboration agreement with Aurigene Discovery Technologies Limited (&#8220;Aurigene&#8221;) for the discovery, development and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology, which was amended in September 2016 and February 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September 30, 2021, the Company had licensed four programs under the Aurigene collaboration.</span></div><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">IRAK4 Program - a precision oncology program of small molecule inhibitors of IRAK4. The development candidate is CA-4948, an orally available small molecule inhibitor of IRAK4.</span></div><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PD1/VISTA Program - an immuno-oncology program of small molecule antagonists of PD1 and VISTA immune checkpoint pathways. The development candidate is CA-170, an orally available small molecule antagonist of VISTA and PDL1.</span></div><div style="margin-top:6pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PD1/TIM3 Program - an immuno-oncology program of small molecule antagonists of PD1 and TIM3 immune checkpoint pathways. The development candidate is CA-327, an orally available small molecule antagonist of PDL1 and TIM3.</span></div><div style="margin-top:9pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company exercised its option to license a fourth program, which is an immuno-oncology program. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The COVID-19 pandemic has had and may continue to have an adverse effect on the Company&#8217;s business, financial condition, results of operations, and prospects. With respect to ongoing clinical trials, the anticipated timing of enrollment and the overall timelines of the trials have experienced delays and could be further delayed to the extent the Company experiences further delays in enrollment due to the COVID-19 pandemic. The Company&#8217;s ability to collect patient data in a timely fashion may also be impacted. The Company experienced delays in closing down its clinical trial sites related to its fimepinostat and CA-170 trials due to restrictions on non-essential workers imposed at those sites in response to COVID-19, which delayed the winding down of these trials.  In addition, the Company and its collaborators, third-party contract manufacturers, contract research organizations and clinical sites could experience delays or disruptions in supply and release of product candidates and/or procuring items that are essential for the Company's research and development activities, including, for example, raw materials used in the manufacturing of its product candidates, basic medical and laboratory supplies used in its clinical trials or preclinical studies, or animals that are used for preclinical testing, in each case, for which there may be shortages or supply chain disruptions as a result of the pandemic. The Company cannot be certain what the overall impact of the COVID-19 pandemic will be on its business.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry as well as risks that are specific to the Company&#8217;s business, including, but not limited to: the Company&#8217;s ability to obtain adequate financing to fund its operations; the Company&#8217;s ability to advance and expand its research and development programs; the impacts of the COVID-19 pandemic and responsive actions related thereto; the Company&#8217;s relationship with Aurigene to support development of drug candidates under the parties&#8217; collaboration agreement; the Company&#8217;s reliance on Roche and Genentech to successfully commercialize Erivedge in the approved indication of advanced BCC and to progress its clinical development in indications other than BCC; the ability of the Company and its wholly owned subsidiary, Curis Royalty, LLC (&#8220;Curis Royalty&#8221;) to satisfy the terms of the royalty interest purchase agreement (the &#8220;Oberland Purchase Agreement&#8221;) with TPC Investments I LP and TPC Investments II LP (the &#8220;Purchasers&#8221;) each of which is a Delaware limited partnership managed by Oberland Capital Management, LLC, and Lind SA LLC (the &#8220;Agent&#8221;) a Delaware limited liability company managed by Oberland Capital Management, LLC, as collateral agent for the Purchasers; the Company&#8217;s ability to obtain and maintain necessary intellectual property protection; development by the Company&#8217;s competitors of new or better technological innovations; the Company's dependence on key personnel; the Company&#8217;s ability to comply with regulatory requirements; the Company's ability to obtain and maintain applicable regulatory approvals and commercialize any approved product candidates; the Company&#8217;s ability to execute on its overall business strategies; and the Company&#8217;s ability to maintain its listing on the Nasdaq Global Market.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s future operating results will largely depend on the progress of drug candidates currently in its development pipeline and the magnitude of payments that it may receive and make under its current and potential future collaborations. The results of the Company&#8217;s operations have varied and will likely continue to vary significantly from year to year and quarter to quarter and depend on a number of factors, including, but not limited to: the timing, outcome and cost of the Company&#8217;s preclinical studies and clinical trials for its drug candidates; Aurigene&#8217;s ability to support advancement of development candidates  under the Company&#8217;s collaboration with Aurigene, as well as the Company&#8217;s ability to further develop programs under this collaboration; and Roche and Genentech&#8217;s ability to successfully commercialize Erivedge.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will require substantial funds to maintain research and development programs and support operations. The Company has incurred net losses and negative cash flows from operations since its inception. As of September 30, 2021, the Company had an accumulated deficit of approximately $1.1 billion, and for the nine months ended September 30, 2021, the Company incurred a net loss of $31.8 million and used $29.4 million of cash in operations. The Company expects to continue to generate operating losses in the foreseeable future. The Company anticipates that its $149.8 million of existing cash, cash equivalents and investments at September 30, 2021 will be sufficient to fund operations for at least 12 months from the date of filing this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to raise additional funds will depend, among other factors, on financial, economic and market conditions, many of which are outside of its control and it may be unable to raise financing when needed, or on terms favorable to the Company. If necessary funds are not available, the Company will have to delay, reduce the scope of, or eliminate some of its development programs, potentially delaying the time to market for or preventing the marketing of any of its product candidates.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457407678136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:10pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.84pt">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements have been prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. These statements, however, are condensed and do not include all disclosures required by accounting principles generally accepted in the U.S. (&#8220;GAAP&#8221;), for complete financial statements and should be read in conjunction with the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;), on March&#160;16, 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of the management of the Company, the unaudited financial statements contain all adjustments (all of which were considered normal and recurring) necessary for a fair statement of the Company&#8217;s financial position at September 30, 2021; the results of operations for the three and nine-month periods ended September 30, 2021 and 2020; stockholders' equity (deficit) for the three and nine-month periods ended September 30, 2021 and 2020; and the cash flows for the nine-month periods ended September 30, 2021 and 2020. The Condensed Consolidated Balance Sheet at December 31, 2020 was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts within the statement of cash flows have been reclassified to conform to the current period presentation.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.84pt">Use of Estimates and Assumptions</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosure of certain assets and liabilities at the balance sheet date. Such estimates include the performance obligations under the Company&#8217;s collaboration agreements; the estimated repayment term of the Company&#8217;s debt and related short- and long-term classification; the collectability of receivables; the carrying value of property and equipment and goodwill; and the assumptions used in the Company&#8217;s valuation of stock-based compensation and the value of certain investments and liabilities. Actual results may differ from such estimates.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These interim results are not necessarily indicative of results to be expected for a full year or subsequent interim periods.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 has had and may continue to have impacts on the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of the COVID-19 pandemic, the extent to which it has impacted and may continue to impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business responses to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of September 30, 2021 and through the date of this report. The Company&#8217;s future assessment of the magnitude and duration of the COVID-19 pandemic, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.41pt"> Cash Equivalents, Restricted Cash, and Investments</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments purchased with original maturities of three months or less. All other liquid investments are classified as marketable securities. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classified $0.7&#160;million of its cash as restricted cash as of September 30, 2021 and $0.8&#160;million as of December 31, 2020. This amount represents the security deposit delivered to the landlord of the Company's current Massachusetts headquarters. The restricted cash balance was reduced as of September 30, 2021 in accordance with the lease agreement.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's combined cash and restricted cash balances were $53.7 million and $24.4&#160;million as of September 30, 2021 and September 30, 2020, respectively, as presented on the Company's Condensed Consolidated Statements of Cash Flows. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s short-term investments are marketable debt securities with original maturities of greater than three months from the date of purchase, but less than twelve months from the balance sheet date, and long-term investments are marketable debt securities with original maturities of greater than twelve months from the balance sheet date. Marketable securities consist of commercial paper, corporate bonds and notes, and/or government obligations. All of the Company&#8217;s investments have been designated available-for-sale and are stated at fair value. Unrealized gains and temporary losses on investments are included in accumulated other comprehensive income (loss) as a separate component of stockholders&#8217; equity (deficit). Realized gains and losses, dividends and interest income are included in other income (expense) in the period during which the securities are sold. Any premium or discount arising at purchase is amortized and/or accreted to interest income.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.84pt">Leases</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at contract inception. Operating lease assets represent the Company's right to use an underlying asset for the lease term and operating lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of the Company's leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate, which is based on rates that would be incurred to borrow on a collateralized basis over a term equal to the lease payments in a similar economic environment, in determining the present value of lease payments.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The lease payment used to determine the operating lease asset may include lease incentives, stated rent increases and was recognized as an operating lease right-of-use asset in the Condensed Consolidated Balance Sheets. The Company's lease agreements may include both lease and non-lease components, which are accounted for as a single lease component when the payments are fixed. Variable payments included in the lease agreement are expensed as incurred. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operating lease is reflected in operating lease right-of-use asset and operating lease liability in the Condensed Consolidated Balance Sheets. Lease expense for lease payments is recognized on a straight-line basis over the lease term. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.41pt">Revenue Recognition</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business strategy includes entering into collaborative license and development agreements with biotechnology and pharmaceutical companies for the development and commercialization of the Company&#8217;s drug candidates. The terms of the agreements typically include non-refundable license fees, funding of research and development, payments based upon achievement of clinical development and regulatory objectives, and royalties on product sales. </span></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">License Fees and Multiple Element Arrangements</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to its intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, up-front fees allocated to the license at such time as the license is transferred to the licensee and the licensee is able to use, and benefit from, the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, will adjust the measure of performance and related revenue recognition. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company is involved in a steering committee as part of a multiple element arrangement, the Company assesses whether its involvement constitutes a performance obligation or a right to participate. Steering committee services that are not determined to be distinct performance obligations are combined with other research services or performance obligations required under an arrangement, if any, in determining the level of effort required in an arrangement and the period over which the Company expects to complete its aggregate performance obligations.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Appropriate methods of measuring progress include output methods and input methods. In determining the appropriate method for measuring progress, the Company considers the nature of service that it promises to transfer to the customer. When the Company decides on a method of measurement, the Company will apply that single method of measuring progress for each performance obligation satisfied over time and will apply that method consistently to similar performance obligations and in similar circumstances. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company cannot reasonably measure its progress toward complete satisfaction of a performance obligation because the Company lacks reliable information that would be required to apply an appropriate method of measuring progress, but it can reasonably estimate when the performance ceases or the remaining obligations become inconsequential and perfunctory, then revenue is not recognized until the Company can reasonably estimate when the performance obligation ceases or becomes inconsequential. Revenue is then recognized over the remaining estimated period of performance.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Contingent Research Milestone Payments</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Codification ("ASC") 606 constrains the amount of variable consideration included in the transaction price in that either all, or a portion, of an amount of variable consideration should be included in the transaction price. The variable consideration amount should be included only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The assessment of whether variable consideration should be constrained is largely a qualitative one that has two elements: the likelihood of a change in estimate, and the magnitude thereof. Variable consideration is not constrained if the potential reversal of cumulative revenue recognized is not significant, for example. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the consideration in a contract includes a variable amount, a company will estimate the amount of consideration in exchange for transfer of promised goods or services. The consideration also can vary if a company&#8217;s entitlement to the consideration is contingent on the occurrence or nonoccurrence of a future event. The Company considers contingent research milestone payments to fall under the scope of variable consideration, which should be estimated for revenue recognition purposes at the inception of the contract and reassessed ongoing at the end of each reporting period. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether contingent research milestones should be considered variable consideration that should be constrained and thus not part of the transaction price. This includes an assessment of the probability that all or some of the milestone revenues could be reversed when the uncertainty around whether or not the achievement of each milestone is resolved, and the amount of reversal could be significant. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP provides factors to consider when assessing whether variable consideration should be constrained. All of the factors should be considered, and no factor is determinative. The Company considers all relevant factors. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Reimbursement of Costs</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement of research and development costs by third-party collaborators is recognized as revenue over time provided the Company has determined that it transfers control (i.e. performs the services) of a service over time and, therefore, satisfies a performance obligation according to the provisions outlined in ASC 606-10-25-27, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Royalty Revenue</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes royalty revenues related to Genentech&#8217;s and Roche&#8217;s sales of Erivedge. For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and where the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). The Company expects to continue recognizing royalty revenue from Genentech&#8217;s sales of Erivedge in the U.S. and in other markets where Genentech and Roche successfully obtain marketing approval, if any (see Note&#160;9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Collaborations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). However, a portion of potential Erivedge royalties will be paid to the Purchasers pursuant to the Oberland Purchase Agreement (see Note 8, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liability Related to the Sale of Future Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Contra Revenue, Net</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contra revenue, net represents shared costs, primarily related to intellectual property, with the Company's collaboration partners, and reserves for potential royalty reductions.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to each of the foregoing areas of revenue recognition, the Company exercises significant judgment in determining whether an arrangement contains multiple elements, and, if so, how much revenue is allocable to each element. In addition, the Company exercises its judgment in determining when its significant obligations have been met under such agreements and the specific time periods over which the Company recognized revenue, such as non-refundable, up-front license fees. To the extent that actual facts and circumstances differ from the Company's initial judgments, its revenue recognition with respect to such transactions would change accordingly and any such change could affect the Company's reported financial results.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Summary</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2021, total gross revenues were 99% from the Company&#8217;s collaboration with Genentech. During the three and nine months ended September 30, 2020 total gross revenues were 100% and 97%, respectively, from the Company&#8217;s collaboration with Genentech. In addition to the revenues received from Genentech, the Company received a milestone payment from a previously out-licensed technology in the first quarter of 2020 that was recorded in other revenues. There were no such revenues recorded during the three and nine months ended September 30, 2021. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.07pt">Segment Reporting</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in a single reportable segment, which is the research and development of innovative cancer therapeutics. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.84pt">New Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This standard requires that for most financial assets, losses be based on an expected loss approach which includes estimates of losses over the life of exposure that considers historical, current and forecasted information. Expanded disclosures related to the methods used to estimate the losses as well as a specific disaggregation of balances for financial assets are also required. The targeted transition relief standard allows filers an option to irrevocably elect the fair value option of ASC 825-10, Financial Instruments-Overall, applied on an instrument-by-instrument basis for eligible instruments. In November 2019 the effective date for smaller reporting companies was extended to January 1, 2023 with the issuance of ASU 2019-10 Financial Instruments-Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates. The Company adopted ASU 2016-13 as of January 1, 2021 and the adoption did not have a material impact on the Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457409229512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value of Financial Instruments<div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has adopted the provisions of the FASB Codification Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;Topic 820&#8221;) for its financial assets and liabilities that are re-measured and reported at fair value each reporting period and the non-financial assets and liabilities that are re-measured and reported at fair value on a non-recurring basis. Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it would transact and consider assumptions that market participants would use when pricing the asset or liability. Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. Financial assets and liabilities are categorized within the valuation hierarchy based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:</span></div><div style="margin-top:6pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.783%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quoted prices in active markets for identical assets or liabilities.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the fair value hierarchy, the following table shows the fair value as of September 30, 2021 and December 31, 2020 of those financial assets and liabilities that are measured at fair value on a recurring basis, according to the valuation techniques the Company used to determine their fair value. No financial assets or liabilities are measured at fair value on a nonrecurring basis at September 30, 2021 and December 31, 2020.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.448%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in<br/>Active Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other&#160;Observable<br/>Inputs&#160;(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable<br/>Inputs&#160;(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2021:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate commercial paper, bonds and notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term  investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate commercial paper, bonds and notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,018&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,806&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,824&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.448%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in<br/>Active Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other&#160;Observable<br/>Inputs&#160;(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unobservable<br/>Inputs&#160;(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate commercial paper, bonds and notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term  investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate commercial paper, bonds and notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,278&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,448&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,726&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457407685496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">Investments<div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, unrealized gains and losses and fair value of investments available-for-sale as of September 30, 2021 are as follows:</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gain</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds and notes&#8212;short-term</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds and notes&#8212;long-term</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,809&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,806&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments have maturities ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RleHRyZWdpb246NDRkZTEwMzQzNmIyNDYwYThkZGRiZmU2ZDExMjM4OGNfMTk3_cb80bf15-17b4-45da-ba01-4fb8b0381751">one</span> to twelve months with a weighted-average maturity of 0.6 years at September 30, 2021. The weighted average maturity of long-term investments was 1.6 years at September 30, 2021. </span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, unrealized gains and losses and fair value of investments available-for-sale as of December 31, 2020 are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gain</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds and notes&#8212;short-term</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,888&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds and notes&#8212;long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,451&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,448&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments have maturities ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwODEwYmM2OGQ1OTQ5NDE5MTJjNmNmZGE2MzE3ODFjL3NlYzo5MDgxMGJjNjhkNTk0OTQxOTEyYzZjZmRhNjMxNzgxY180My9mcmFnOjQ0ZGUxMDM0MzZiMjQ2MGE4ZGRkYmZlNmQxMTIzODhjL3RleHRyZWdpb246NDRkZTEwMzQzNmIyNDYwYThkZGRiZmU2ZDExMjM4OGNfNTEx_4f659141-f01a-4310-9378-77affc0e77d5">one</span> to twelve months with a weighted-average maturity of 0.6 years at December 31, 2020. The weighted average maturity of long-term investments was 1.5 years at December 31, 2020. </span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No credit losses on available-for-sale securities were recognized during the three and nine months ended September 30, 2021 or September 30, 2020. In its evaluation to determine expected credit losses, management considered all available historical and current information, expectations of future economic conditions, the type of security, the credit rating of the security, and the size of the loss position, as well as other relevant information. The Company does not intend to sell, and is unlikely to be required to sell, any of these available-for-sale investments before their effective maturity or market price recovery.</span></div>As of September 30, 2021 and December 31, 2020, the Company held no investments that have been in a continuous unrealized loss position for 12 months or longer.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457409236536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text">Accrued Liabilities<div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following:</span></div><div style="margin-bottom:7pt;margin-top:11pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.496%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,638&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chemistry, manufacturing and controls costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional and legal fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,310&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,625&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457409409384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">DebtIn April 2020, the Company entered into a promissory note evidencing an unsecured $0.9&#160;million loan (the &#8220;PPP Loan&#8221;) under the Paycheck Protection Program (&#8220;PPP&#8221;), of the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) as administered by the U.S. Small Business Administration (the "SBA"). The PPP Loan was made by Silicon Valley Bank and had a term of 24-months and an interest rate of 1%. Under the terms of the CARES Act and the Paycheck Protection Program Flexibility Act of 2020, PPP Loan recipients can apply for and be granted forgiveness for all or a portion of loans granted under the PPP. The Company applied for such forgiveness in 2020 and received notification in June 2021 that the SBA had forgiven the PPP Loan in full, including interest accrued on the PPP Loan. During the nine months ended September 30, 2021, the Company recorded a gain of $0.9 million to Other income (expense), net for extinguishment of the debt. As of December 31, 2020, the Company recorded short- and long-term debt related to the PPP Loan of $0.6 million and $0.3 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457409224120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lease</a></td>
<td class="text">LeaseThe Company has a single lease for real estate, including laboratory and office space, and certain equipment. The lease at 128 Spring Street in Lexington, Massachusetts commenced on May 1, 2020 which is the date when the property became available for use to the Company. In accordance with the accounting requirements under ASC 842, the lease obligation was not recorded until its commencement. The discount rate associated with the Company's right-of-use asset is 9.95%. As of September 30, 2021, the Company had an operating lease liability of $5.2 million and related right-of-use asset of $6.0 million related to its operating lease. As of December 31, 2020, the Company had an operating lease liability of $6.8 million and related right-of-use asset of $6.6 million related to its operating lease. The Company recorded a lease cost of $0.3 million and $1.0 million for the three and nine months ended September 30, 2021, respectively. The Company recorded a lease cost of $0.4 and $1.0 million for the three and nine months ended September 30, 2020, respectively. The total cash obligation over the seven year term of this lease is approximately $9.3 million, of which $0.3 million was paid during the three months ended September 30, 2021 and $2.0 million was paid during the nine months ended September 30, 2021. The payments included a payment of $1.1 million for tenant improvements. The Company did not make cash payments during the three months ended September 30, 2020. The Company paid $0.2 million during the nine months ended September 30, 2020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457407649528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Sale of Future Royalties<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionsAbstract', window );"><strong>Nonmonetary Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionsDisclosureTextBlock', window );">Liability Related to the Sale of Future Royalties</a></td>
<td class="text">Liability Related to the Sale of Future Royalties<div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, the Company and Curis Royalty entered into the royalty interest purchase agreement (&#8220;Oberland Purchase Agreement&#8221;) with entities managed by Oberland Capital Management, LLC (the &#8220;Purchasers&#8221;). The Company sold to the Purchasers a portion of its rights to receive royalties from Genentech on potential net sales of Erivedge. Concurrently with the closing of the Oberland Purchase Agreement, Curis Royalty used a portion of the proceeds to terminate and repay the then existing loan with HealthCare Royalty Partners, III, L.P..</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As upfront consideration for the purchase of the royalty rights, at closing the Purchasers paid to Curis Royalty $65.0 million less certain transaction expenses. Curis Royalty will also be entitled to receive up to approximately $70.7 million in milestone payments based on sales of Erivedge as follows: (i) $17.2 million if the Purchasers and Curis Royalty receive aggregate royalty payments pursuant to the Oberland Purchase Agreement in excess of $18.0 million during the calendar year 2021, subject to certain exceptions and (ii) $53.5 million if the Purchasers receive payments pursuant to the Oberland Purchase Agreement in excess of $117.0 million on or prior to December 31, 2026.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Oberland Purchase Agreement provides that after the occurrence of an event of default as defined under the security agreement by Curis Royalty, the Purchasers shall have the option, for a period of 180 days, to require Curis Royalty to repurchase a portion of certain royalty and royalty related payments, excluding a portion of non U.S. royalties retained by Curis Royalty (the &#8220;Purchased Receivables&#8221;), at a price (the &#8220;Put/Call Price&#8221;), equal to a percentage, beginning at a low triple digit </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">percentage and increasing over time up to a low mid triple digit percentage of the sum of the upfront purchase price and any portion of the milestone payments paid in a lump sum by the Purchasers, if any, minus certain payments previously received by the Purchasers with respect to the Purchased Receivables. Additionally, Curis Royalty shall have the option at any time to repurchase the Purchased Receivables at the Put/Call Price as of the date of such repurchase. No events of default existed as of September 30, 2021.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the obligation to pay future royalties to Oberland, the Company recorded the proceeds from this transaction as a liability on its Consolidated Balance Sheet that will be accounted for using the interest method over the estimated life of the Oberland Purchase Agreement. As a result, the Company imputes interest on the transaction and records imputed interest expense at the estimated interest rate. The Company's estimate of the interest rate under the agreement is based on the amount of royalty payments expected to be received by Oberland over the life of the arrangement. The projected amount of royalty payments expected to be paid to Oberland involves the use of significant estimates and assumptions with respect to the revenue growth rate in the Company's projections of sales of Erivedge. The Company periodically assesses the expected royalty payments to Curis Royalty from Genentech using a combination of historical results and forecasts from market data sources. To the extent such payments are greater or less than its initial estimates or the timing of such payments is materially different than its original estimates, the Company will adjust the amortization of the liability. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the fair value of the liability related to the sale of future royalties at the time of the Oberland Purchase Agreement to be $65.0 million, with a current effective annual imputed interest rate of 7.6%. The Company incurred $0.6 million of transaction costs in connection with the agreement. These transaction costs are amortized to imputed interest expense over the estimated term of the Oberland Purchase Agreement. The Company determined that the fair value assessment of the liability related to the sale of future royalties is a Level 3 assessment within the valuation hierarchy. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity with respect to the liability related to the sale of future royalties during the nine months ended September 30, 2021.</span></div><div style="margin-top:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:81.330%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying value of liability related to the sale of future royalties at January 1, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of capitalized issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imputed interest expense recognized for the nine months ending September 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: payments to Oberland Capital, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,434)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying value of liability related to the sale of future royalties at September 30, 2021</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,167&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for exchanges with other entities that involve principally nonmonetary assets or liabilities or relate to a transfer of nonmonetary assets for which the entity receives no assets in return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 845<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123385986&amp;loc=d3e32049-108421<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 845<br> -URI http://asc.fasb.org/topic&amp;trid=2127423<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457409674152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Collaborations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Research and Development Collaborations</a></td>
<td class="text">Research and Development Collaborations<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.91pt">Genentech</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2003, the Company licensed its proprietary Hedgehog pathway antagonist technologies to Genentech for human therapeutic use. The primary focus of the collaborative research plan has been to develop molecules that inhibit the Hedgehog pathway for the treatment of various cancers. The collaboration is currently focused on the development of Erivedge, which is being commercialized by Genentech in the U.S. and by Genentech&#8217;s parent company, Roche, in several other countries for the treatment of advanced BCC. Pursuant to the agreement, the Company is eligible to receive up to an aggregate of $115.0 million in contingent cash milestone payments, exclusive of royalty payments, in connection with the development of Erivedge or another small molecule Hedgehog pathway inhibitor, assuming the successful achievement by Genentech and Roche of specified clinical development and regulatory objectives. Of this amount, the Company has received $59.0 million in cash milestone payments as of September 30, 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to these payments and pursuant to the collaboration agreement, the Company is entitled to a royalty on net sales of Erivedge that ranges from 5% to 7.5%. The royalty rate applicable to Erivedge may be decreased by 2% on a country-by-country basis in certain specified circumstances.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $3.1 million and $2.7 million in royalty revenue under the Genentech collaboration during the three months ended September 30, 2021 and 2020, respectively. The Company recognized $7.6 million in royalty revenue under the Genentech collaboration during the nine months ended September 30, 2021 and $7.7 million during the nine months ended September 30, 2020. The Company also recorded costs of royalty revenues within the costs and expenses section of its Condensed Consolidated Statements of Operations and Comprehensive Loss of $0.2 million during the three months ended September 30, 2021 and $0.1&#160;million during the three months ended September 30, 2020. The Company recorded $0.4 million of costs of royalty revenues during the nine months ended September 30, 2021 and 2020. Cost of royalty revenues comprises 5% of the royalty payments that Curis Royalty receives from Genentech, through February 2022, which the Company is obligated to pay to university licensors. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded receivables from Genentech under this collaboration, comprised primarily of Erivedge royalties earned in the first half of 2021 and 2020. The receivable recorded in the Company's current assets section of its Condensed Consolidated Balance Sheets amounted to $3.0 million as of September 30, 2021 and December 31, 2020, respectively. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed in Note 8, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liability Related to the Sale of Future Royalties,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a portion of royalty revenues received from Genentech on net sales of Erivedge will be paid to the Purchasers pursuant to the Oberland Purchase Agreement.</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.34pt">Aurigene</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2015, the Company entered into an exclusive collaboration agreement with Aurigene for the discovery, development and commercialization of small molecule compounds in the areas of immuno-oncology and selected precision oncology targets, which was amended in September 2016. Under the collaboration agreement, Aurigene granted the Company an option to obtain exclusive, royalty-bearing licenses to relevant Aurigene technology to develop, manufacture and commercialize products containing certain of such compounds anywhere in the world, except for India and Russia, which are territories retained by Aurigene. In February 2020, the collaboration agreement was further amended whereby Aurigene received rights to develop and commercialize CA-170 in Asia in addition to its existing rights in India and Russia, and the Company became entitled to receive royalty payments on potential future sales of CA-170 in Asia at percentage rates ranging from the high single digits up to 10% subject to specified reductions.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, the Company has exercised its option to license the following four programs under the collaboration:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">IRAK4 Program - a precision oncology program of small molecule inhibitors of IRAK4. The development candidate is CA-4948, an orally available small molecule inhibitor of IRAK4.</span></div><div style="padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">PD1/VISTA Program - an immuno-oncology program of small molecule antagonists of PD1 and VISTA immune checkpoint pathways. The development candidate is CA-170, an orally available small molecule antagonist of VISTA and PDL1.</span></div><div style="padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">PD1/TIM3 Program - an immuno-oncology program of small molecule antagonists of PD1 and TIM3 immune checkpoint pathways. The development candidate is CA-327, an orally available small molecule antagonist of PDL1 and TIM3.</span></div><div style="padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">In March 2018, the Company exercised its option to license a fourth program, which is an immuno-oncology program.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since January 2015, the Company has paid $14.5&#160;million in research payments and Aurigene has waived $19.5&#160;million in milestone payments. For each of the IRAK4, PD1/VISTA, and PD1/TIM3 programs, and the fourth immuno-oncology program: the Company has remaining unpaid or unwaived payment obligations of $42.5&#160;million per program, related to regulatory approval and commercial sales milestones, plus specified additional payments for approvals for additional indications, if any. The Company is further obligated to pay Aurigene tiered royalties on the Company's and its affiliates' annual net sales of products at percentage rates ranging from the high single digits up to 10%, subject to specified reductions. In addition, the Company agreed to make certain payments to Aurigene upon its entry into sublicense agreements on any program(s).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the collaboration agreement, the Company has entered into a master development and manufacturing agreement with Aurigene for the supply of drug substance and drug product. Under this agreement, the Company incurred $0.5&#160;million in research and development expense during the three months ended September 30, 2021 and $1.2&#160;million during the nine months ended September 30, 2021. The Company recorded less than $0.1&#160;million in prepaid expenses and $0.9&#160;million in accrued expenses as of September 30, 2021 associated with this agreement.  The Company expensed $0.6&#160;million and $0.8&#160;million related to Aurigene for the three and nine month periods ended September 30, 2020, respectively. </span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.91pt">ImmuNext</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into an option and license agreement with ImmuNext (the &#8220;ImmuNext Agreement&#8221;). Under the terms of the ImmuNext Agreement, the Company agreed to engage in a collaborative effort with ImmuNext, and to conduct a Phase 1 clinical trial of CI-8993. In exchange, ImmuNext granted the Company an exclusive option, exercisable until the earlier of January 2024 or (b) 90 days after database lock for the first Phase 1 trial in which the endpoints are satisfied (the &#8220;Option Period&#8221;), to obtain an exclusive, worldwide license to develop and commercialize certain VISTA antagonizing compounds and products containing these compounds in the field of oncology.  </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the Option Period, the Company is obligated to pay a semi-annual fee of $0.4 million to ImmuNext and will conduct the Phase 1 trial, and ImmuNext will conduct certain agreed upon non-clinical research activities to support the Phase 1 trial. Additionally, the Company will assign to ImmuNext all right, title and interest in and to, inventions made by the Company alone or jointly with ImmuNext in conducting clinical and non-clinical activities under the ImmuNext Agreement and any </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patent rights covering those inventions. If the option is exercised, ImmuNext will assign to the Company (i) all such inventions that were made solely by the Company and any patent rights covering those inventions that were assigned by the Company to ImmuNext during the Option Period and (ii) a joint ownership interest in all such inventions that were made jointly by the Company and ImmuNext and patent rights covering those inventions that were assigned by the Company to ImmuNext during the Option Period, except for any of those inventions that relates to certain compounds to which ImmuNext has retained exclusive rights. In addition, the Company has agreed to reimburse ImmuNext for certain documented external costs and expenses incurred by ImmuNext in carrying out non-clinical research activities approved by the joint steering committee, up to $0.3 million per calendar year, unless otherwise agreed to by both parties in writing. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company elects to exercise the option, the Company has agreed to pay to ImmuNext an option exercise fee of $20.0&#160;million. ImmuNext will be eligible to receive up to $4.6&#160;million in potential development milestones, up to $84.3&#160;million in potential regulatory approval milestones, and up to $125.0&#160;million in potential sales milestone payments from us. ImmuNext is also eligible to receive tiered royalties on annual net sales on a product-by-product and country-by-country basis, at percentage rates ranging from high single digits to low double digits, subject to specified adjustments. In addition, the Company has agreed to pay ImmuNext a low double-digit percentage of sublicense revenue received by the Company or its affiliates.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457409202296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text">Common Stock<div style="margin-top:6pt;padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.84pt">Charter Amendments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2020, the Company's stockholders approved an increase to the number of authorized shares of its common stock from 101,250,000 shares to 151,875,000 shares. The Company filed an amendment to its certificate of incorporation in June 2020 to effect such increase.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company's stockholders approved an increase to the number of authorized shares of its common stock from 151,875,000 shares to 227,812,500 shares. The Company filed an amendment to its certificate of incorporation in May 2021 to effect such increase.</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.84pt">2021 Sales Agreement with Cantor Fitzgerald &amp; Co. and JonesTrading Institutional Services LLC</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company entered into a sales agreement (the &#8220;2021 Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co., or Cantor, and JonesTrading Institutional Services LLC , or JonesTrading, to sell from time to time up to $100.0&#160;million of the Company&#8217;s common stock through an &#8220;at the market offering&#8221; program under which Cantor and JonesTrading act as sales agents. Subject to the terms and conditions of the 2021 Sales Agreement, Cantor and JonesTrading can sell the common stock by any method deemed to be an &#8220;at-the-market&#8221; offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the 2021 Sales Agreement, the aggregate compensation payable to each of Cantor and JonesTrading is 3% of the gross proceeds from sales of the common stock sold by Cantor or JonesTrading, as applicable. Each party agreed in the 2021 Sales Agreement to provide indemnification and contribution against certain liabilities, including liabilities under the Securities Act, subject to the terms of the 2021 Sales Agreement. To date, the Company has not made any sales of common stock pursuant to the 2021 Sales Agreement.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The securities in this transaction were offered pursuant to an automatic shelf registration statement on Form S-3ASR (File No. 333-254362) that was filed with the SEC on March 16, 2021.</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.41pt">2020 Public Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company completed an underwritten public offering of 29,500,000 shares of the Company's common stock, including 3,847,826 shares issued and sold to the underwriters upon the exercise in full of their option to purchase additional shares, at a price of $5.75 per share, for aggregate gross proceeds of  $169.6  million, before deducting underwriting discounts and commissions and other offering expenses of $10.2&#160;million. The securities in this transaction were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-224627) that was filed with the SEC on May 3, 2018 and declared effective by the SEC on May 17, 2018 and an additional registration statement on Form S-3 (File No. 333-251211) filed pursuant to Rule 462(b) which became automatically effective on December 9, 2020.</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.84pt">2020 Registered Direct Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into a securities purchase agreement with certain institutional investors, pursuant to which the Company issued and sold, in a registered direct offering, an aggregate of 14,000,000 shares of the Company's common stock at a purchase price per share of $1.25, for aggregate gross proceeds of $17.5&#160;million, before deducting fees of approximately $1.0&#160;million paid to the placement agent and other estimated offering expenses of approximately $0.5&#160;million paid by the Company. JonesTrading acted as the exclusive placement agent for the transaction, and the shares were offered by the Company pursuant to its universal shelf registration statement on Form S-3, which was filed with the SEC on May 3, 2018 and declared effective by the SEC on May 17, 2018 (File No. 333-224627), and a prospectus supplement thereunder. </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.41pt">2020 Sales Agreement with JonesTrading Institutional Services LLC</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Company entered into a Capital on Demand&#8482; Sales Agreement (the &#8220;Sales Agreement&#8221;) with JonesTrading to sell from time to time up to $30.0 million of the Company&#8217;s common stock through an &#8220;at-the-market&#8221; equity offering program under which JonesTrading acted as sales agent. Subject to the terms and conditions of the Sales Agreement, JonesTrading could sell the common stock by any method deemed to be an &#8220;at-the-market&#8221; offering as defined in Rule 415 promulgated under the Securities Act, including sales made directly on the Nasdaq Global Market, on any other existing trading market for the common stock or to or through a market maker other than on an exchange. In addition, with the Company&#8217;s prior written approval, JonesTrading could also sell the common stock by any other method permitted by law, including in privately negotiated transactions. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Sales Agreement, the aggregate compensation payable to JonesTrading was 3% of the gross proceeds from sales of the common stock sold by JonesTrading pursuant to the Sales Agreement. Each party agreed in the Sales Agreement to provide indemnification and contribution against certain liabilities, including liabilities under the Securities Act, subject to the terms of the Sales Agreement.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company terminated this sales agreement effective as of December 9, 2020. The Company did not incur any termination penalties as a result of the termination. As of the effective date of the termination of the Sales Agreement, the Company had sold an aggregate of 6,298,648 shares of common stock under the sales agreement for aggregate gross proceeds of $8.3&#160;million and net proceeds of $7.9&#160;million after deducting commissions and offering expenses. The $21.7 million of common stock that remained unsold at the time of termination is no longer available.</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.07pt">Aspire Capital Fund LLC</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the Company entered into a common stock purchase agreement (the &#8220;Agreement&#8221;) with Aspire Capital Fund, LLC (&#8220;Aspire Capital&#8221;) for the sale of up to $30.0 million of the Company's common stock. Under the terms of the Agreement, Aspire Capital has committed to purchase such shares of the Company's common stock at the Company&#8217;s request, from time to time during a 30-month period at prices based on the market price at the time of each sale, subject to specified terms and limitations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aspire Capital made an initial investment of $3.0 million through the purchase of 2,693,965 shares of the Company's common stock.  In 2020, Aspire Capital subsequently purchased an additional 4,650,000 shares of the Company's common stock for $5.4 million.  In addition, as consideration for Aspire Capital&#8217;s obligation under the Agreement, the Company issued 646,551 shares of common stock to Aspire Capital as a commitment fee.  As of September 30, 2021 and December 31, 2020, a total of $21.6&#160;million remained available under the Agreement. The Company did not sell shares of common stock under the Agreement during the three and nine months ended September 30, 2021. For the three months ended September 30, 2020, 3,600,000 shares were sold representing net proceeds of $4.2&#160;million. For the nine months ended September 30, 2020, 6,293,965 shares were sold representing net proceeds of $6.8&#160;million. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Agreement, the Company has the right to sell up to 150,000 shares of common stock per day to Aspire Capital, which total may be increased by mutual agreement up to an additional 2,000,000 shares per day. The extent to which the Company relies on Aspire Capital as a source of funding will depend on a number of factors, including the prevailing market price of its common stock and the extent to which it is able to secure working capital from other sources.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no warrants, derivatives, or other share classes associated with this Agreement. The Company will control the timing and amount of the further sale of its common stock to Aspire Capital. There are no restrictions on future financings and there are no financial covenants, participation rights, rights of first refusal, or penalties in the Agreement. The Company has the right to terminate the Agreement at any time without any additional cost or penalty.</span></div>The Company also entered into a Registration Rights Agreement with Aspire Capital in connection with its entry into the Agreement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457409674152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans and Stock Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Plans and Stock Based Compensation</a></td>
<td class="text">Stock Plans and Stock-Based Compensation<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, the Company had two shareholder-approved, stock-based compensation plans: (i) the Amended and Restated 2010 Employee Stock Purchase Plan (&#8220;ESPP&#8221;), adopted by the Board of Directors in April 2017 and approved by shareholders in June 2017, and (ii)&#160;the Fourth Amended and Restated 2010 Stock Incentive Plan (&#8220;2010 Plan&#8221;). New employees are typically issued options as an inducement equity award under Nasdaq Listing Rule 5635(c)(4) outside of the 2010 Plan.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Fourth Amended and Restated 2010 Stock Incentive Plan</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2010 Plan permits the granting of incentive and non-qualified stock options and stock awards to employees, officers, directors, and consultants of the Company and its subsidiaries at prices determined by the Company&#8217;s Board of Directors.  In May 2021, the Company's shareholders approved the Company's Fourth Amended and Restated 2010 Stock Incentive Plan to reserve an additional 11,000,000 shares of common stock for issuance under the 2010 Plan. The Company can issue up to 23,190,000 shares of its common stock pursuant to awards granted under the 2010 Plan. Options become exercisable as determined by the Board of Directors and expire up to ten years from the date of grant. The 2010 Plan uses a &#8220;fungible share&#8221; concept under which each share of stock subject to awards granted as options and stock appreciation rights (&#8220;SARs&#8221;), will cause one share per share under the award to be removed from the available share pool, while each share of stock subject to awards granted as restricted stock, restricted stock units, other stock-based awards or performance awards where the price charged for the award is less than 100% of the fair market value of the Company&#8217;s common stock will cause 1.3 shares per share under the award to be removed from the available share pool. As of September 30, 2021 the Company has only granted options to purchase shares of the Company&#8217;s common stock with an exercise price equal to the closing market price of the Company&#8217;s common stock on the Nasdaq Global Market on the grant date. As of September 30, 2021, 13,595,840 shares remained available for grant under the 2010 Plan.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, the Company&#8217;s board of directors granted options to purchase 1,086,000 shares of the Company&#8217;s common stock to the officers and employees of the Company, under the 2010 Plan. Shares granted to officers and employees vest as to 25% of the shares underlying the award on the first anniversary of the grant date and as to an additional 6.25% of the shares underlying the award at the end of each subsequent quarter, based upon continued employment over a four year period, and are exercisable at a price equal to the closing price of the Company&#8217;s common stock on the Nasdaq Global Market on the grant date. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2021, the Company&#8217;s board of directors granted options to its non-employee directors to purchase 132,000 shares of common stock under the 2010 Plan, which will vest and become exercisable one year from the grant date. There were no additional non-employee grants made in the three months ended September 30, 2021. In addition, during the nine months ended September 30, 2021 the Company's board of directors issued options to newly-hired employees as an inducement equity award under Nasdaq Listing Rule 5635(c)(4) outside of the 2010 Plan to purchase 613,850 shares of common stock. These options will vest as to 25% of the shares underlying the option on the first anniversary of the grant date, and as to an additional 6.25% of the shares underlying the option on each successive three-month period thereafter. All option awards are exercisable at a price equal to the closing price of the Company&#8217;s common stock on the Nasdaq Global Market on the grant dates.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity under the 2010 Plan and inducement awards are summarized as follows:</span></div><div style="margin-top:6pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.818%"><tr><td style="width:1.0%"/><td style="width:48.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.995%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.000%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price&#160;per<br/>Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining Contractual Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,668,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.98</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,831,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(85,751)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled/Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115,825)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding, September 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,298,279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at September 30, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,689,507&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.31&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.96</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and unvested expected to vest at September 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,963,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.56</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:4pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair values of the stock options granted during the nine months ended September 30, 2021 and 2020 were $9.21 and $0.75, respectively, and were calculated using the following estimated assumptions:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (years) </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.5</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4-1.4%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4-1.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected Dividends</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">None</span></td></tr></table></div><div style="margin-top:1pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of September 30, 2021, there was approximately $11.4 million of unrecognized compensation cost related to unvested employee stock option awards outstanding, net of the impact of estimated forfeitures that is expected to be recognized as expense over a weighted average period of 2.27 years. The intrinsic value of employee stock options exercised during the nine months ended September 30, 2021 was $0.5&#160;million. The intrinsic value of employee stock options exercised during the nine months ended September 30, 2020 was not material.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of unvested restricted stock awards (&#8220;RSAs&#8221;) under the 2010 Plan as of September 30, 2021:</span></div><div style="margin-bottom:7pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.575%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested, December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested, September 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,312&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.45&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, there were 10,312 shares outstanding covered by RSAs that are expected to vest. The weighted average grant date fair value of these shares of restricted stock was $3.45 per share and the aggregate fair value of these shares of restricted stock was $0.1 million. As of September 30, 2021, there was less than $0.1 million of unrecognized compensation costs, net of estimated forfeitures, related to RSAs granted to officers, which are expected to be recognized as expense over a remaining weighted average period of 0.31 years.</span></div><div style="margin-top:8.8pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amended and Restated 2010 Employee Stock Purchase Plan</span></div><div style="margin-top:8.8pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reserved 2,000,000 shares of common stock for issuance under the ESPP. Eligible employees may purchase shares of the Company&#8217;s common stock at 85% of the lower closing market price of the common stock at the beginning of the enrollment period or ending date of the purchase period within a two-year enrollment period, as defined. The Company has four six-month purchase periods per each two-year enrollment period. If, within any one of the four purchase periods in an enrollment period, the purchase period ending stock price is lower than the stock price at the beginning of the enrollment period, the two-year enrollment resets at the new lower stock price. This aspect of the plan was amended in 2017. Prior to 2017, the plan included two six-month purchase periods per year with no defined enrollment period. During the three  months ended September 30, 2021, no shares were issued under the ESPP. During the nine months ended September 30, 2021, 20,791 shares were issued under the ESPP. As of September 30, 2021, there were 1,576,599 shares available for future purchase under the ESPP. </span></div><div style="margin-top:8.8pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ESPP compensation expense for the three and nine months ended September 30, 2021 and 2020 was not material. </span></div><div style="margin-top:8.8pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Stock-Based Compensation Expense</span></div><div style="margin-top:8.8pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021 and 2020, the Company recorded stock-based compensation expense to the following line items in its costs and expenses section of the Condensed Consolidated Statements of Operations and Comprehensive Loss, including expense related to its ESPP:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">624&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,838&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457409409384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Common Share</a></td>
<td class="text">Loss Per Common ShareBasic and diluted loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is the same as basic net loss per common share for the three and nine months ended September 30, 2021 and 2020, because the effect of the potential common stock equivalents would be antidilutive due to the Company&#8217;s net loss position for these periods. Antidilutive securities consist of stock options outstanding of 10,298,279 and 9,128,896 as of September 30, 2021 and 2020, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457409674152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:6pt;padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.41pt">Agreement with Head of Research and Development - Robert E. Martell, M.D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Ph.D.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an exclusive option and license agreement with Epi-Cure Pharmaceuticals, Inc., (&#8220;Epi-Cure&#8221;) a privately held early stage biotechnology company. Robert E. Martell, M.D., Ph.D., the Company&#8217;s Head of Research and Development and a former director of the Company, is a founder of Epi-Cure, was formerly an officer and director of Epi-Cure, and is currently a holder of a convertible promissory note to Epi-Cure. Under the terms of the option and license agreement, Epi-Cure granted Curis an exclusive option to certain program compounds that may arise during the initial research and development period, and any extension thereof. Upon execution of the option and license agreement, the Company paid Epi-Cure an upfront payment of $0.1 million for legal and consulting costs incurred by Epi-Cure in connection with the transaction. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Epi-Cure had primary responsibility for conducting research and development activities and Curis was responsible for funding up to $0.5 million of the research and development program costs and expenses during the initial research and development period. After the end of the research and development period, which ended in April 2020, Curis had sixty days to elect to exercise its option to license the program compounds. In June 2020, the Company decided not to exercise its option to license the program compounds, and the agreement expired.</span></div>In 2020, the Company expensed $0.1&#160;million of fees related to this agreement. No expense has been incurred following the expiration of the agreement in June 2020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457407478696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text">Basis of Presentation and Principles of ConsolidationThe accompanying Condensed Consolidated Financial Statements have been prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. These statements, however, are condensed and do not include all disclosures required by accounting principles generally accepted in the U.S. (&#8220;GAAP&#8221;), for complete financial statements and should be read in conjunction with the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;), on March&#160;16, 2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates and Assumptions</a></td>
<td class="text">Use of Estimates and Assumptions<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosure of certain assets and liabilities at the balance sheet date. Such estimates include the performance obligations under the Company&#8217;s collaboration agreements; the estimated repayment term of the Company&#8217;s debt and related short- and long-term classification; the collectability of receivables; the carrying value of property and equipment and goodwill; and the assumptions used in the Company&#8217;s valuation of stock-based compensation and the value of certain investments and liabilities. Actual results may differ from such estimates.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These interim results are not necessarily indicative of results to be expected for a full year or subsequent interim periods.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 has had and may continue to have impacts on the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of the COVID-19 pandemic, the extent to which it has impacted and may continue to impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business responses to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of September 30, 2021 and through the date of this report. The Company&#8217;s future assessment of the magnitude and duration of the COVID-19 pandemic, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash Equivalents, Restricted Cash, and Investments</a></td>
<td class="text">Cash Equivalents, Restricted Cash, and Investments<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments purchased with original maturities of three months or less. All other liquid investments are classified as marketable securities. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classified $0.7&#160;million of its cash as restricted cash as of September 30, 2021 and $0.8&#160;million as of December 31, 2020. This amount represents the security deposit delivered to the landlord of the Company's current Massachusetts headquarters. The restricted cash balance was reduced as of September 30, 2021 in accordance with the lease agreement.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's combined cash and restricted cash balances were $53.7 million and $24.4&#160;million as of September 30, 2021 and September 30, 2020, respectively, as presented on the Company's Condensed Consolidated Statements of Cash Flows. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s short-term investments are marketable debt securities with original maturities of greater than three months from the date of purchase, but less than twelve months from the balance sheet date, and long-term investments are marketable debt securities with original maturities of greater than twelve months from the balance sheet date. Marketable securities consist of commercial paper, corporate bonds and notes, and/or government obligations. All of the Company&#8217;s investments have been designated available-for-sale and are stated at fair value. Unrealized gains and temporary losses on investments are included in accumulated other comprehensive income (loss) as a separate component of stockholders&#8217; equity (deficit). Realized gains and losses, dividends and interest income are included in other income (expense) in the period during which the securities are sold. Any premium or discount arising at purchase is amortized and/or accreted to interest income.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at contract inception. Operating lease assets represent the Company's right to use an underlying asset for the lease term and operating lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of the Company's leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate, which is based on rates that would be incurred to borrow on a collateralized basis over a term equal to the lease payments in a similar economic environment, in determining the present value of lease payments.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The lease payment used to determine the operating lease asset may include lease incentives, stated rent increases and was recognized as an operating lease right-of-use asset in the Condensed Consolidated Balance Sheets. The Company's lease agreements may include both lease and non-lease components, which are accounted for as a single lease component when the payments are fixed. Variable payments included in the lease agreement are expensed as incurred. </span></div>The Company's operating lease is reflected in operating lease right-of-use asset and operating lease liability in the Condensed Consolidated Balance Sheets. Lease expense for lease payments is recognized on a straight-line basis over the lease term.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business strategy includes entering into collaborative license and development agreements with biotechnology and pharmaceutical companies for the development and commercialization of the Company&#8217;s drug candidates. The terms of the agreements typically include non-refundable license fees, funding of research and development, payments based upon achievement of clinical development and regulatory objectives, and royalties on product sales. </span></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">License Fees and Multiple Element Arrangements</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to its intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, up-front fees allocated to the license at such time as the license is transferred to the licensee and the licensee is able to use, and benefit from, the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, will adjust the measure of performance and related revenue recognition. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company is involved in a steering committee as part of a multiple element arrangement, the Company assesses whether its involvement constitutes a performance obligation or a right to participate. Steering committee services that are not determined to be distinct performance obligations are combined with other research services or performance obligations required under an arrangement, if any, in determining the level of effort required in an arrangement and the period over which the Company expects to complete its aggregate performance obligations.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Appropriate methods of measuring progress include output methods and input methods. In determining the appropriate method for measuring progress, the Company considers the nature of service that it promises to transfer to the customer. When the Company decides on a method of measurement, the Company will apply that single method of measuring progress for each performance obligation satisfied over time and will apply that method consistently to similar performance obligations and in similar circumstances. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company cannot reasonably measure its progress toward complete satisfaction of a performance obligation because the Company lacks reliable information that would be required to apply an appropriate method of measuring progress, but it can reasonably estimate when the performance ceases or the remaining obligations become inconsequential and perfunctory, then revenue is not recognized until the Company can reasonably estimate when the performance obligation ceases or becomes inconsequential. Revenue is then recognized over the remaining estimated period of performance.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Contingent Research Milestone Payments</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Codification ("ASC") 606 constrains the amount of variable consideration included in the transaction price in that either all, or a portion, of an amount of variable consideration should be included in the transaction price. The variable consideration amount should be included only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The assessment of whether variable consideration should be constrained is largely a qualitative one that has two elements: the likelihood of a change in estimate, and the magnitude thereof. Variable consideration is not constrained if the potential reversal of cumulative revenue recognized is not significant, for example. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the consideration in a contract includes a variable amount, a company will estimate the amount of consideration in exchange for transfer of promised goods or services. The consideration also can vary if a company&#8217;s entitlement to the consideration is contingent on the occurrence or nonoccurrence of a future event. The Company considers contingent research milestone payments to fall under the scope of variable consideration, which should be estimated for revenue recognition purposes at the inception of the contract and reassessed ongoing at the end of each reporting period. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether contingent research milestones should be considered variable consideration that should be constrained and thus not part of the transaction price. This includes an assessment of the probability that all or some of the milestone revenues could be reversed when the uncertainty around whether or not the achievement of each milestone is resolved, and the amount of reversal could be significant. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP provides factors to consider when assessing whether variable consideration should be constrained. All of the factors should be considered, and no factor is determinative. The Company considers all relevant factors. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Reimbursement of Costs</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement of research and development costs by third-party collaborators is recognized as revenue over time provided the Company has determined that it transfers control (i.e. performs the services) of a service over time and, therefore, satisfies a performance obligation according to the provisions outlined in ASC 606-10-25-27, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Royalty Revenue</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes royalty revenues related to Genentech&#8217;s and Roche&#8217;s sales of Erivedge. For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and where the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). The Company expects to continue recognizing royalty revenue from Genentech&#8217;s sales of Erivedge in the U.S. and in other markets where Genentech and Roche successfully obtain marketing approval, if any (see Note&#160;9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Collaborations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). However, a portion of potential Erivedge royalties will be paid to the Purchasers pursuant to the Oberland Purchase Agreement (see Note 8, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liability Related to the Sale of Future Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Contra Revenue, Net</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contra revenue, net represents shared costs, primarily related to intellectual property, with the Company's collaboration partners, and reserves for potential royalty reductions.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to each of the foregoing areas of revenue recognition, the Company exercises significant judgment in determining whether an arrangement contains multiple elements, and, if so, how much revenue is allocable to each element. In addition, the Company exercises its judgment in determining when its significant obligations have been met under such agreements and the specific time periods over which the Company recognized revenue, such as non-refundable, up-front license fees. To the extent that actual facts and circumstances differ from the Company's initial judgments, its revenue recognition with respect to such transactions would change accordingly and any such change could affect the Company's reported financial results.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment ReportingThe Company operates in a single reportable segment, which is the research and development of innovative cancer therapeutics.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text">New Accounting Pronouncements<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This standard requires that for most financial assets, losses be based on an expected loss approach which includes estimates of losses over the life of exposure that considers historical, current and forecasted information. Expanded disclosures related to the methods used to estimate the losses as well as a specific disaggregation of balances for financial assets are also required. The targeted transition relief standard allows filers an option to irrevocably elect the fair value option of ASC 825-10, Financial Instruments-Overall, applied on an instrument-by-instrument basis for eligible instruments. In November 2019 the effective date for smaller reporting companies was extended to January 1, 2023 with the issuance of ASU 2019-10 Financial Instruments-Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates. The Company adopted ASU 2016-13 as of January 1, 2021 and the adoption did not have a material impact on the Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value of Financial Instruments<div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has adopted the provisions of the FASB Codification Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;Topic 820&#8221;) for its financial assets and liabilities that are re-measured and reported at fair value each reporting period and the non-financial assets and liabilities that are re-measured and reported at fair value on a non-recurring basis. Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it would transact and consider assumptions that market participants would use when pricing the asset or liability. Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. Financial assets and liabilities are categorized within the valuation hierarchy based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:</span></div><div style="margin-top:6pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.783%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quoted prices in active markets for identical assets or liabilities.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457514452024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Financial Assets or Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:1pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the fair value hierarchy, the following table shows the fair value as of September 30, 2021 and December 31, 2020 of those financial assets and liabilities that are measured at fair value on a recurring basis, according to the valuation techniques the Company used to determine their fair value. No financial assets or liabilities are measured at fair value on a nonrecurring basis at September 30, 2021 and December 31, 2020.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.448%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in<br/>Active Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other&#160;Observable<br/>Inputs&#160;(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable<br/>Inputs&#160;(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2021:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate commercial paper, bonds and notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term  investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate commercial paper, bonds and notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,018&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,806&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,824&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.448%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in<br/>Active Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other&#160;Observable<br/>Inputs&#160;(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unobservable<br/>Inputs&#160;(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate commercial paper, bonds and notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term  investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate commercial paper, bonds and notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,278&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,448&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,726&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457409409384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock', window );">Schedule of Amortized Cost of Unrealized Gains and Losses and Fair Value of Investments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, unrealized gains and losses and fair value of investments available-for-sale as of September 30, 2021 are as follows:</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gain</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds and notes&#8212;short-term</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds and notes&#8212;long-term</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,809&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,806&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, unrealized gains and losses and fair value of investments available-for-sale as of December 31, 2020 are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gain</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds and notes&#8212;short-term</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,888&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds and notes&#8212;long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,451&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,448&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457409228680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following:</span></div><div style="margin-bottom:7pt;margin-top:11pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.496%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,638&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chemistry, manufacturing and controls costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional and legal fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,310&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,625&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457409090376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Sale of Future Royalties (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionsAbstract', window );"><strong>Nonmonetary Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherSignificantNoncashTransactionsTextBlock', window );">Schedule of Liability Due to Non-Cash Transaction</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity with respect to the liability related to the sale of future royalties during the nine months ended September 30, 2021.</span></div><div style="margin-top:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:81.330%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying value of liability related to the sale of future royalties at January 1, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of capitalized issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imputed interest expense recognized for the nine months ending September 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: payments to Oberland Capital, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,434)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying value of liability related to the sale of future royalties at September 30, 2021</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,167&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherSignificantNoncashTransactionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of noncash investing and financing activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherSignificantNoncashTransactionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457406137176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans and Stock Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity under the 2010 Plan and inducement awards are summarized as follows:</span></div><div style="margin-top:6pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.818%"><tr><td style="width:1.0%"/><td style="width:48.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.995%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.000%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price&#160;per<br/>Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining Contractual Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,668,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.98</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,831,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(85,751)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled/Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115,825)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding, September 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,298,279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at September 30, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,689,507&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.31&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.96</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and unvested expected to vest at September 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,963,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.56</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Key Assumptions for Options Awarded</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:4pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair values of the stock options granted during the nine months ended September 30, 2021 and 2020 were $9.21 and $0.75, respectively, and were calculated using the following estimated assumptions:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (years) </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.5</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4-1.4%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4-1.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected Dividends</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">None</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Award Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of unvested restricted stock awards (&#8220;RSAs&#8221;) under the 2010 Plan as of September 30, 2021:</span></div><div style="margin-bottom:7pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.575%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested, December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested, September 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,312&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.45&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:8.8pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021 and 2020, the Company recorded stock-based compensation expense to the following line items in its costs and expenses section of the Condensed Consolidated Statements of Operations and Comprehensive Loss, including expense related to its ESPP:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">624&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,838&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457411313896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborationAgreementNumberofProgramsLicensed', window );">Number of program licensed | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 1,078,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,078,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,046,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">11,051<span></span>
</td>
<td class="nump">$ 10,838<span></span>
</td>
<td class="nump">$ 9,927<span></span>
</td>
<td class="nump">$ 5,974<span></span>
</td>
<td class="nump">$ 6,708<span></span>
</td>
<td class="nump">$ 9,709<span></span>
</td>
<td class="nump">31,816<span></span>
</td>
<td class="nump">$ 22,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,448<span></span>
</td>
<td class="nump">$ 20,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and investments</a></td>
<td class="nump">$ 149,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborationAgreementNumberofProgramsLicensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Number of Programs Licensed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborationAgreementNumberofProgramsLicensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457502520200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, restricted cash and restricted cash equivalents</a></td>
<td class="nump">$ 53,746<span></span>
</td>
<td class="nump">$ 24,371<span></span>
</td>
<td class="nump">$ 53,746<span></span>
</td>
<td class="nump">$ 24,371<span></span>
</td>
<td class="nump">$ 130,426<span></span>
</td>
<td class="nump">$ 16,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Genentech, Inc. | Revenue Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cris_GenentechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cris_GenentechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457411256920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Summary (Details) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosureAbstract', window );"><strong>Long-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 145,824<span></span>
</td>
<td class="nump">$ 168,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate commercial paper, bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_ShortTermInvestmentsFairValueDisclosure', window );">Corporate commercial paper, bonds and notes</a></td>
<td class="nump">75,884<span></span>
</td>
<td class="nump">38,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosureAbstract', window );"><strong>Long-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_LongTermInvestmentsFairValueDisclosure', window );">Corporate commercial paper, bonds and notes</a></td>
<td class="nump">20,922<span></span>
</td>
<td class="nump">14,564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">49,018<span></span>
</td>
<td class="nump">115,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted&#160;Prices&#160;in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosureAbstract', window );"><strong>Long-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">49,018<span></span>
</td>
<td class="nump">115,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted&#160;Prices&#160;in Active Markets (Level 1) | Corporate commercial paper, bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_ShortTermInvestmentsFairValueDisclosure', window );">Corporate commercial paper, bonds and notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosureAbstract', window );"><strong>Long-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_LongTermInvestmentsFairValueDisclosure', window );">Corporate commercial paper, bonds and notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted&#160;Prices&#160;in Active Markets (Level 1) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">49,018<span></span>
</td>
<td class="nump">115,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Other&#160;Observable Inputs&#160;(Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosureAbstract', window );"><strong>Long-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">96,806<span></span>
</td>
<td class="nump">53,448<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Other&#160;Observable Inputs&#160;(Level 2) | Corporate commercial paper, bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_ShortTermInvestmentsFairValueDisclosure', window );">Corporate commercial paper, bonds and notes</a></td>
<td class="nump">75,884<span></span>
</td>
<td class="nump">38,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosureAbstract', window );"><strong>Long-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_LongTermInvestmentsFairValueDisclosure', window );">Corporate commercial paper, bonds and notes</a></td>
<td class="nump">20,922<span></span>
</td>
<td class="nump">14,564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Other&#160;Observable Inputs&#160;(Level 2) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Unobservable Inputs&#160;(Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosureAbstract', window );"><strong>Long-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Unobservable Inputs&#160;(Level&#160;3) | Corporate commercial paper, bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_ShortTermInvestmentsFairValueDisclosure', window );">Corporate commercial paper, bonds and notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosureAbstract', window );"><strong>Long-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_LongTermInvestmentsFairValueDisclosure', window );">Corporate commercial paper, bonds and notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Unobservable Inputs&#160;(Level&#160;3) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_LongTermInvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Investments, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_LongTermInvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_ShortTermInvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short Term Investments, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_ShortTermInvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=cris_CorporateCommercialPaperStockBondsAndNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=cris_CorporateCommercialPaperStockBondsAndNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457410399032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Amortized Cost of Unrealized Gains and Losses and Fair Value of Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 96,809<span></span>
</td>
<td class="nump">$ 53,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 96,806<span></span>
</td>
<td class="nump">$ 53,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_AvailableForSaleSecuritiesWeightedAverageMaturity', window );">Weighted-average maturity of short-term investments</a></td>
<td class="text">7 months 6 days<span></span>
</td>
<td class="text">7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Corporate bonds and notes&#8212;short-term | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_AvailableForSaleSecuritiesDateRange', window );">Range of maturities</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">1 month<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Corporate bonds and notes&#8212;short-term | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_AvailableForSaleSecuritiesDateRange', window );">Range of maturities</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember', window );">Corporate bonds and notes&#8212;long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_AvailableForSaleSecuritiesWeightedAverageMaturity', window );">Weighted-average maturity of short-term investments</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities | Corporate bonds and notes&#8212;short-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 75,880<span></span>
</td>
<td class="nump">$ 38,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">75,884<span></span>
</td>
<td class="nump">38,884<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities | Corporate bonds and notes&#8212;long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">20,929<span></span>
</td>
<td class="nump">14,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(7)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 20,922<span></span>
</td>
<td class="nump">$ 14,564<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_AvailableForSaleSecuritiesDateRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities date range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_AvailableForSaleSecuritiesDateRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_AvailableForSaleSecuritiesWeightedAverageMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available-for-sale securities weighted average maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_AvailableForSaleSecuritiesWeightedAverageMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457409775544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities - Summary (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Compensation and related costs</a></td>
<td class="nump">$ 2,473<span></span>
</td>
<td class="nump">$ 2,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_ChemistryManufacturingAndControlsCosts', window );">Chemistry, manufacturing and controls costs</a></td>
<td class="nump">1,910<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional and legal fees</a></td>
<td class="nump">541<span></span>
</td>
<td class="nump">307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_LicenseFees', window );">License fees</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 5,310<span></span>
</td>
<td class="nump">$ 3,625<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_ChemistryManufacturingAndControlsCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Chemistry Manufacturing And Controls Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_ChemistryManufacturingAndControlsCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_LicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_LicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457409994552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Unsecured loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="nump">$ 890<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cris_CaresActPPPLoanMember', window );">Cares Act PPP Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cris_SiliconValleyBankMember', window );">Silicon Valley Bank | Cares Act PPP Loan | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Unsecured loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTerm', window );">Unsecured loan term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Unsecured loan interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cris_CaresActPPPLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cris_CaresActPPPLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cris_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cris_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457410020040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">9.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">5,962,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,962,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,578,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease, expense</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Lease obligations</a></td>
<td class="nump">$ 9,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_OperatingLeaseOneTimePaymentTenantImprovements', window );">One time payment, tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_OperatingLeaseOneTimePaymentTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, One Time Payment, Tenant Improvements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_OperatingLeaseOneTimePaymentTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457410107880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Sale of Future Royalties - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionLineItems', window );"><strong>Nonmonetary Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_RoyaltyPurchaseAgreementInterestRate', window );">Non-cash interest rate</a></td>
<td class="nump">7.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts', window );">Transaction fees</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cris_OberlandCapitalMember', window );">Oberland Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionLineItems', window );"><strong>Nonmonetary Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_ProceedsFromRoyaltyPurchaseAgreement', window );">Proceeds from royalty interest purchase agreement with Oberland Capital Management, LLC</a></td>
<td class="nump">65.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_RoyaltyPurchaseAgreementContingentConsiderationCashProceeds', window );">Cash proceeds from royalty purchase agreement</a></td>
<td class="nump">70.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_RoyaltyPurchaseAgreementTermsPurchaserDefaultOptionPeriod', window );">Purchaser default option period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cris_OberlandCapitalMember', window );">Oberland Capital | Royalty Amounts in 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionLineItems', window );"><strong>Nonmonetary Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_RoyaltyPurchaseAgreementContingentConsiderationCashProceeds', window );">Cash proceeds from royalty purchase agreement</a></td>
<td class="nump">17.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold', window );">Royalty amount threshold</a></td>
<td class="nump">18.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cris_OberlandCapitalMember', window );">Oberland Capital | Aggregate Net Royalties Prior to 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionLineItems', window );"><strong>Nonmonetary Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_RoyaltyPurchaseAgreementContingentConsiderationCashProceeds', window );">Cash proceeds from royalty purchase agreement</a></td>
<td class="nump">53.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold', window );">Royalty amount threshold</a></td>
<td class="nump">$ 117.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_ProceedsFromRoyaltyPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Royalty Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_ProceedsFromRoyaltyPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_RoyaltyPurchaseAgreementContingentConsiderationCashProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Purchase Agreement, Contingent Consideration, Cash Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_RoyaltyPurchaseAgreementContingentConsiderationCashProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_RoyaltyPurchaseAgreementInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Purchase Agreement, Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_RoyaltyPurchaseAgreementInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_RoyaltyPurchaseAgreementTermsPurchaserDefaultOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Purchase Agreement, Terms, Purchaser Default Option Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_RoyaltyPurchaseAgreementTermsPurchaserDefaultOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Purchase Agreement, Terms, Royalty Amount Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Purchase Agreement, Transaction Fees And Closing Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cris_OberlandCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cris_OberlandCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_ContingentPaymentBenchmarkAxis=cris_RoyaltyAmountsIn2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_ContingentPaymentBenchmarkAxis=cris_RoyaltyAmountsIn2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_ContingentPaymentBenchmarkAxis=cris_AggregateNetRoyaltiesPriorTo2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_ContingentPaymentBenchmarkAxis=cris_AggregateNetRoyaltiesPriorTo2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457414960424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Sale of Future Royalties - Liability Due to Non-Cash Transaction (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_NonmonetaryTransactionRollForward', window );"><strong>Nonmonetary Transaction [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_RoyaltyPurchaseAgreementLiabilityCarryingValue', window );">Carrying value of liability related to the sale of future royalties beginning balance</a></td>
<td class="nump">$ 58,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization', window );">Amortization of capitalized issuance costs</a></td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_RoyaltyPurchaseAgreementAccretionExpense', window );">Imputed interest expense recognized</a></td>
<td class="nump">3,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_PaymentsOfFutureRoyaltyLiability', window );">Less: payments to Oberland Capital, LLC</a></td>
<td class="num">(6,434)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_RoyaltyPurchaseAgreementLiabilityCarryingValue', window );">Carrying value of liability related to the sale of future royalties ending balance</a></td>
<td class="nump">$ 55,167<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_NonmonetaryTransactionRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonmonetary Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_NonmonetaryTransactionRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_PaymentsOfFutureRoyaltyLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments Of Future Royalty Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_PaymentsOfFutureRoyaltyLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_RoyaltyPurchaseAgreementAccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Purchase Agreement, Accretion Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_RoyaltyPurchaseAgreementAccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Purchase Agreement, Issuance Costs Capitalized, Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_RoyaltyPurchaseAgreementLiabilityCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Purchase Agreement, Liability, Carrying Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_RoyaltyPurchaseAgreementLiabilityCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457413636792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Collaborations (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2003 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,039<span></span>
</td>
<td class="nump">$ 2,742<span></span>
</td>
<td class="nump">$ 7,514<span></span>
</td>
<td class="nump">$ 7,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Cost of royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="nump">376<span></span>
</td>
<td class="nump">382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborationAgreementNumberofProgramsLicensed', window );">Number of program licensed | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cris_GrossRoyaltyRevenueMember', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,058<span></span>
</td>
<td class="nump">2,720<span></span>
</td>
<td class="nump">$ 7,593<span></span>
</td>
<td class="nump">7,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cris_GenentechIncMember', window );">Genentech, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner', window );">Amount received for specified clinical development and regulatory objectives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_ReducedRoyaltyRate', window );">Percentage of royalty rate decrease</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Cost of royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_RoyaltyRatePercentageOfSales', window );">Royalty rate, percentage of sales (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cris_GenentechIncMember', window );">Genentech, Inc. | Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">7,600<span></span>
</td>
<td class="nump">$ 7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cris_GenentechIncMember', window );">Genentech, Inc. | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment', window );">Eligible to receive contingent cash payment for specified clinical development and regulatory objectives (up to)</a></td>
<td class="nump">$ 115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_PercentageOfRoyaltyOnNetSales', window );">Percentage of royalty on net sales</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cris_GenentechIncMember', window );">Genentech, Inc. | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_PercentageOfRoyaltyOnNetSales', window );">Percentage of royalty on net sales</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_MilestonePaymentsWaivedToDate', window );">Milestone payments waived to date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborationAgreementExpense', window );">Collaboration Agreement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene | Programs Three and Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_PaymentsforCollaborativeArrangementstoDate', window );">Payments made under collaboration arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene | IRAK4, PD1/VISTA, and PD1/TIM3 Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1', window );">Waived payment of milestone and other payments (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene | Master Development and Manufacturing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene | Master Development and Manufacturing Agreement | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementPaymentsAgreement', window );">Collaborative arrangement payments agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborationAgreementTermsPercentageOfRoyaltyFeesReceivable', window );">Royalty fees receivable (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cris_ImmuNextMember', window );">ImmuNext</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborationArrangementSemiAnnualMaintenanceFeePayment', window );">Semi-annual maintenance fee payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cris_ImmuNextMember', window );">ImmuNext | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborationArrangementContingentConsiderationReimbursableExpenses', window );">Maximum reimbursable expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborationArrangementContingentConsiderationOptionExerciseFee', window );">Option exercise fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborationArrangementContingentConsiderationDevelopmentMilestonePayments', window );">Development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborationArrangementContingentConsiderationRegulatoryApprovalMilestonePayments', window );">Regulatory approval milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborationArrangementContingentConsiderationSalesMilestonePayments', window );">Sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement contingent consideration potential cash payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborationAgreementContingentConsiderationPotentialCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement contingent consideration received from partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborationAgreementContingentConsiderationReceivedFromPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborationAgreementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborationAgreementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborationAgreementNumberofProgramsLicensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Number of Programs Licensed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborationAgreementNumberofProgramsLicensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborationAgreementTermsPercentageOfRoyaltyFeesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Terms, Percentage Of Royalty Fees Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborationAgreementTermsPercentageOfRoyaltyFeesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborationArrangementContingentConsiderationDevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Contingent Consideration, Development Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborationArrangementContingentConsiderationDevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborationArrangementContingentConsiderationOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Contingent Consideration, Option Exercise Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborationArrangementContingentConsiderationOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborationArrangementContingentConsiderationRegulatoryApprovalMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Contingent Consideration, Regulatory Approval Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborationArrangementContingentConsiderationRegulatoryApprovalMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborationArrangementContingentConsiderationReimbursableExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Contingent Consideration, Reimbursable Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborationArrangementContingentConsiderationReimbursableExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborationArrangementContingentConsiderationSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Contingent Consideration, Sales Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborationArrangementContingentConsiderationSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborationArrangementSemiAnnualMaintenanceFeePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Semi-Annual Maintenance Fee Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborationArrangementSemiAnnualMaintenanceFeePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborativeArrangementPaymentsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement Payments Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborativeArrangementPaymentsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_MilestonePaymentsWaivedToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Waived To Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_MilestonePaymentsWaivedToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_PaymentsforCollaborativeArrangementstoDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments made under collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_PaymentsforCollaborativeArrangementstoDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_PercentageOfRoyaltyOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty on net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_PercentageOfRoyaltyOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_ReducedRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduced Royalty Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_ReducedRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_RoyaltyRatePercentageOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Rate, Percentage Of Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_RoyaltyRatePercentageOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the noncash (or part noncash) consideration received in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cris_GrossRoyaltyRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cris_GrossRoyaltyRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cris_GenentechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cris_GenentechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cris_ThirdandFourthProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cris_ThirdandFourthProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cris_IRAK4PD1VISTAPD1TIM3ProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cris_IRAK4PD1VISTAPD1TIM3ProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cris_MasterDevelopmentAndManufacturingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cris_MasterDevelopmentAndManufacturingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cris_ImmuNextMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cris_ImmuNextMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457403847048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 09, 2020</div></th>
<th class="th"><div>Feb. 26, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 16, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 04, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,875,000<span></span>
</td>
<td class="nump">101,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,875,000<span></span>
</td>
<td class="nump">227,812,500<span></span>
</td>
<td class="nump">151,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Value of shares of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 915,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 915,000<span></span>
</td>
<td class="nump">$ 916,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cris_DemandSalesAgreementMember', window );">Demand Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_StockSaleAgreementCompensationFeePercentageOfGrossProceeds', window );">Compensation fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cris_AspireCapitalFundLLCMember', window );">Aspire Capital Fund, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,693,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds of aspire capital agreement, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_StockPurchaseProgramPricePeriod', window );">Stock purchase program price, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Value of shares of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from direct offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,600,000<span></span>
</td>
<td class="nump">$ 17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Fees payable expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_SaleOfStockIssuanceCosts', window );">Other estimated offering expenses payable expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares of common stock sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,847,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_StockSaleAgreementAuthorizedAmount', window );">Common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_StockSaleAgreementCompensationFeePercentageOfGrossProceeds', window );">Compensation fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_CommonStockMember', window );">Common Stock | Demand Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_StockSaleAgreementAuthorizedAmount', window );">Common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares of common stock sold (in shares)</a></td>
<td class="nump">6,298,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from direct offering</a></td>
<td class="nump">$ 8,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds of aspire capital agreement, net of issuance costs</a></td>
<td class="nump">7,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_StockPurchaseProgramRemainingAuthorizedPurchaseAmount', window );">Remaining authorized stock purchase amount</a></td>
<td class="nump">$ 21,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_CommonStockMember', window );">Common Stock | Aspire Capital Fund, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares of common stock sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="nump">6,293,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_StockPurchaseProgramAuthorizedAmount', window );">Authorized amount of stock repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_StockPurchaseProgramCommitmentFeeShares', window );">Commitment fee (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_StockSaleAgreementRemainingAuthorizedAmount', window );">Sale of stock remaining authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,600,000<span></span>
</td>
<td class="nump">$ 21,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="nump">$ 6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_StockPurchaseProgramTermsSharesAuthorizedPerDay', window );">Stock purchase program, authorized per day (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_StockPurchaseProgramTermsSharesAuthorizedPerDayAfterMutualAgreement', window );">Stock purchase program, authorized per day, after mutual agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_CommonStockMember', window );">Common Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,500,000<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_SaleOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_SaleOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_StockPurchaseProgramAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Purchase Program, Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_StockPurchaseProgramAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_StockPurchaseProgramCommitmentFeeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Purchase Program, Commitment Fee, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_StockPurchaseProgramCommitmentFeeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_StockPurchaseProgramPricePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Purchase Program Price, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_StockPurchaseProgramPricePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_StockPurchaseProgramRemainingAuthorizedPurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Purchase Program, Remaining Authorized Purchase Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_StockPurchaseProgramRemainingAuthorizedPurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_StockPurchaseProgramTermsSharesAuthorizedPerDay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Purchase Program, Terms, Shares Authorized Per Day</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_StockPurchaseProgramTermsSharesAuthorizedPerDay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_StockPurchaseProgramTermsSharesAuthorizedPerDayAfterMutualAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Purchase Program, Terms, Shares Authorized Per Day, After Mutual Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_StockPurchaseProgramTermsSharesAuthorizedPerDayAfterMutualAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_StockSaleAgreementAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_StockSaleAgreementAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_StockSaleAgreementCompensationFeePercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Compensation Fee, Percentage Of Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_StockSaleAgreementCompensationFeePercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_StockSaleAgreementRemainingAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Remaining Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_StockSaleAgreementRemainingAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cris_DemandSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cris_DemandSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cris_AspireCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cris_AspireCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457409320216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans and Stock Based Compensation - Narrative (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>plan </div>
<div>purchase_period </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>purchase_period</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_ShareBasedCompensationPlans', window );">Number of shareholder-approved, share-based compensation plans | plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,831,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair values of stock options (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.21<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost, net of estimated forfeitures | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, weighted average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic values of employee stock options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awarded (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awarded (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">613,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Officers and Non-Employee Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost, net of estimated forfeitures | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, weighted average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cris_AmendedAndRestatedTwoThousandTenStockIncentivePlanMember', window );">Amended and Restated 2010 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">23,190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_NumberOfSharesAwardedUnderStockValueLessThanSpecificPercentageOfFairMarketValue', window );">Shares awarded under plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,595,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cris_AmendedAndRestatedTwoThousandTenStockIncentivePlanMember', window );">Amended and Restated 2010 Stock Incentive Plan | Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized (in shares)</a></td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cris_AmendedAndRestatedTwoThousandTenStockIncentivePlanMember', window );">Amended and Restated 2010 Stock Incentive Plan | Stock Options, or Stock Appreciation Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare', window );">Shares removed from pool (in shares per share) | $ / shares</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cris_AmendedAndRestatedTwoThousandTenStockIncentivePlanMember', window );">Amended and Restated 2010 Stock Incentive Plan | Restricted Stock, RSUs, Other Stock-Based Awards, or Performance Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare', window );">Shares removed from pool (in shares per share) | $ / shares</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cris_TwoThousandAndTenPlanMember', window );">2010 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,086,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cris_TwoThousandAndTenPlanMember', window );">2010 Plan | Non-Employee Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">132,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cris_TwoThousandAndTenPlanMember', window );">2010 Plan | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vested shares which are exercisable under stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cris_TwoThousandAndTenPlanMember', window );">2010 Plan | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vested shares which are exercisable under stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cris_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock issued under employee stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cris_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan | Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_EmployeeStockPurchasePlanEnrollmentPeriod', window );">Enrollment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_NumberOfPurchasePeriodsPerEnrollmentPeriod', window );">Number of purchase periods per year | purchase_period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod', window );">Stock plan offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_StockAvailableForFuturePurchaseUnderEmployeeStockPurchasePlans', window );">Stock available under ESPPs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,576,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,576,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_EmployeeStockPurchasePlanEnrollmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan, Enrollment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_EmployeeStockPurchasePlanEnrollmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_NumberOfPurchasePeriodsPerEnrollmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of purchase periods per enrollment period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_NumberOfPurchasePeriodsPerEnrollmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_NumberOfSharesAwardedUnderStockValueLessThanSpecificPercentageOfFairMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares awarded per share under stock value less than specific percentage of fair market value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_NumberOfSharesAwardedUnderStockValueLessThanSpecificPercentageOfFairMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_ShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation, number of plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_ShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Shares Removed From Available Share Pool, Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_StockAvailableForFuturePurchaseUnderEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock available for future purchase under employee stock purchase plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_StockAvailableForFuturePurchaseUnderEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cris_OfficersAndNonEmployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cris_OfficersAndNonEmployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cris_AmendedAndRestatedTwoThousandTenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cris_AmendedAndRestatedTwoThousandTenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cris_StockOptionsorStockAppreciationRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cris_StockOptionsorStockAppreciationRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cris_RestrictedStockRSUsOtherStockBasedAwardsOrPerformanceAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cris_RestrictedStockRSUsOtherStockBasedAwardsOrPerformanceAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cris_TwoThousandAndTenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cris_TwoThousandAndTenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cris_NonEmployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cris_NonEmployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cris_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cris_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457410858120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans and Stock Based Compensation - Stock Option Activity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">8,668,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,831,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(85,751)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled/Forfeited (in shares) | shares</a></td>
<td class="num">(115,825)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">10,298,279<span></span>
</td>
<td class="nump">8,668,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares) | shares</a></td>
<td class="nump">5,689,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and unvested expected to vest at end of period (in shares) | shares</a></td>
<td class="nump">9,963,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price&#160;per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">9.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">1.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled/Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">11.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">3.77<span></span>
</td>
<td class="nump">$ 2.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">3.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and unvested expected to vest at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at end of period</a></td>
<td class="text">7 years 7 months 2 days<span></span>
</td>
<td class="text">7 years 11 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at end of period</a></td>
<td class="text">6 years 11 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and unvested expected to vest at end of period</a></td>
<td class="text">7 years 6 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at end of period | $</a></td>
<td class="nump">$ 47,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at end of period | $</a></td>
<td class="nump">29,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and unvested expected to vest at end of period | $</a></td>
<td class="nump">$ 46,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457414866616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans and Stock Based Compensation - Key Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk -free Interest rate (minimum)</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk -free Interest rate (maximum)</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">109.00%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457411169304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans and Stock Based Compensation - Restricted Stock Award Activity (Details) - Restricted Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">20,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awarded (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(10,312)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">10,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awarded (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">3.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457413465704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans and Stock Based Compensation - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,464,000<span></span>
</td>
<td class="nump">$ 624<span></span>
</td>
<td class="nump">$ 3,838,000<span></span>
</td>
<td class="nump">$ 1,833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">553,000<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">1,331,000<span></span>
</td>
<td class="nump">548<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 911,000<span></span>
</td>
<td class="nump">$ 431<span></span>
</td>
<td class="nump">$ 2,507,000<span></span>
</td>
<td class="nump">$ 1,285<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457409086024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">10,298,279<span></span>
</td>
<td class="nump">9,128,896<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140457411350232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - Epi-Cure Pharmaceuticals, Inc. - Affiliated Entity<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 18, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>day</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Amount paid for transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cris_EpiCurePharmaceuticalsInc.Member', window );">Agreement With Head of Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Purchases from related party</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_RelatedPartyTransactionMaximumFundingAmount', window );">Maximum funding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_RelatedPartyTransactionTermsAndMannerOfSettlementMinimumDaysNoticeToTerminatePriorToWrittenNotice', window );">Minimum days notice to terminate prior to written notice | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_RelatedPartyTransactionMaximumFundingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Maximum Funding Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_RelatedPartyTransactionMaximumFundingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_RelatedPartyTransactionTermsAndMannerOfSettlementMinimumDaysNoticeToTerminatePriorToWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Terms And Manner Of Settlement, Minimum Days Notice To Terminate Prior To Written Notice</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_RelatedPartyTransactionTermsAndMannerOfSettlementMinimumDaysNoticeToTerminatePriorToWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cris_EpiCurePharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cris_EpiCurePharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=cris_AgreementWithHeadOfResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=cris_AgreementWithHeadOfResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>56
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M'JINEO7$R,KUFX4TV+W<L,#O"R@;@/>74IKGB6UAS1<K_0]02P,$%     @
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M8B,#/PA\3":F,%#,0+M+2DUM;*1/XM@GWL">(IWE(F[+]98\>^GC$(C8WFA
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MS\P\7=X,D4F]0RRS1:C'+#=BEIF9QS0F0U'>+4;0 J,BGT0DP'K0FI*VH%5
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M!JR:(^KF1O*=/N5]Y%+R0E]N&8462 G ^PWG<G^C%NC^4>#J;U!+ P04
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MJ?_XZ-6SZK^[^G@\T#ZW D"^?:!*+"6M*4)/L%Y3;C&*,@#*(UA=+UB#@G]
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M#85ZE'53*42Y7$(C*'K8VCS:CJ5#KZ<8IZ3@;=9'5'H!EVI5LHJ(B6R#5=
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M6_.?"X6NO:4%>#^ST$3\00?DKZ'?_P=02P,$%     @ ;(9I4\ZP9)VG%P
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MK1O^6-!^A]HQT'NNJ$_;BS/0;XRKOP%02P,$%     @ ;(9I4\^!;AND @
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M,^&C!>YI5R 5-1K&I'%"Q6>D!5MG/)U".AE!^[KQ%5G1"+XJ2Z@+& U2(K^
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M.F46YHM[&(_R?C"-\LQ2R;4(_;VCK&KCR9%QB3\#*9 GFH[)*:4+D<"R$$J
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MPXJ>=FC9@/97QOC#A -TC\79-U!+ P04    " !LAFE3"5O-9VX(   )%P
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M"_NH&1HT;VT7<LT*MD6H<GM5U%[WN)#9X@]\1'6L?1 5F\,B/QT_^6825FA
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M B5P8*1= 9SK#L28.3?S:,)1%Q7'<R0<E;<PV#B/7@MU2PZ-#.($LTDFBQ'
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M7^_I<IR_O#JKQOENS+\C2CO!_3?/M@NVAP,&-<*C\<1IA!U<SX8OJ_\>\XX
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MU:96"G2'AYH2L!PY%*2FEBQ#B;.=$AW#X]G;E8((([N\KB47_A5%D- L#YU
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MN0/%H=;B-*!1;6J>'=[UP0/N5AJ$>_W^UQ^_GUX^@6B"$85Q')<!S@3H#*J
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M-XVII"]2\VB;GBO47B/I=;WO8'E@[ZU;*&OWWE2I$I<^0/(6*G:="WG97+5
MQED;D_+Q&1ZCQ3_B:0L@QAQ6D [+@NK@74V<O1>>O<:HZ<3O7;V,9SI<F:/G
M6NG#L4R@2YS5C^]#/X@ $-+$W_(B+!J/#QSM((<M5"5"+2Q(;(QN.1:0@MMZ
M@JPW/<=+DALT*<!7")-KF-I0Q60->,H)!7P+3NG8_2$WV!C'26HT!N(C <R^
M;@W]VI+BPQ'%6N-)XTD,SZK /_=*AFDM\<AB-V$#E?7OG?-[@Q7:*P^3HM0V
M0_ ,/;!'+2F;-9"!UX'T>,6@B["GO5=DNI E$GQ(L8[^K9H8B@ZX5"A_N[3E
M[.PT&;V)B;O7OJ.R_2$;H#.8E&F@'*%</Q.W^Z)B:J2KTN:1G!X&DD/(P8?O
MP3H+=TG8FR8RA^$G'<CS<6(_'9MPAK8;)9(-@C/J6RT6>#">1L(MZF=U$2F"
MY9#UYR0Y&2*=:5'BD,[R<3OD$LQPB;YQ8!&0 .PYD#O@03&0F<YO.I\>YA)
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MQBF:E='+)^)GY>-G-G[6JEX7GEO1E1_"U@E&WS5WCA>>/WIP,=F[[/+=\-8
MFEJK;#Q=X7Z.4(#.?#E94QVN%LW$;SAR:&&C'@ ,L3%> 80&VH-4*,;4 :GJ
MNVL\\7>]'"IGY?U,/(;40;J-OD!YZK RS.LCVW.&+C;!(\3!4FV!O3*<:]!J
MPKM4(I1U?51H3-6/"-O2 ^7*REP^]VVM8>.9R-)I37%&%VD**AS'"(&2VWH/
M%1:*.)MLBP=VAX\.RL,^0)W]U%>RE2VH2YE.)<LZ7>]61-_T-&X\O!D5A5'$
MNS';8,,MS(L/KS('=:'4%O*@%(L;/EC%Q=,KX7MF<L4MGZ)S*-[WV;O)<*S+
MZDDZOWYR].CY5K%)W$2R/W9Z_2>'* ,!-RBHU"5")5Y>4NA-7')E.#6P<*P[
M0-^PT;AM :<I(:YP0RFGLG)#A]1'=7)YD6_07AQ=TL_JKG=?%NS.=*&+9+0E
M[5\9#VD6ESZN:T,7#<&?_]$!7;FZP+MUJ)!\SVRT-/;*8 GY].3M]>VKDS/0
MHNM@F-%'/VZH"P;K9Q_AT9_-C*:97MZ;%+/\2-<T23P*QE?/7@.X IO]B;LK
M3W\Q&_#Q>U</SYZ*=[G"3Y2\]R3>4QP;-J1G+@B6+\>1"]-Q!K929:/G%J!)
M[.^<%YT\LLWU2?R:@SE"9+"JU"61;K9AJT\0,+7XZ 4%11B*;]*1)#DC 7$A
M/\"&@$GJ&Z<;1OFZ25%OGXDWG^F:13VX>-H+Q/'<)S80]0HL0<#BBH;,\ J#
MQ@.I0#%2.S@J;Z@W;L'!>DHL"(>6"ZR,D4"(73I<?VFT6N2MP<ASQY=';>@Z
MBJ12@QJV%)9V@J[EAWPP=NO&1T$\3#,>0X)Q>7' T*;OMW2S9T('$CIMK4Z/
M3.>[:?XKM*E1N0MBE>8#C\+ P(U^AMVEMG:P\2<<* AC$3W(#_!MMX99Z< R
M%CQRHPMV77'[(&_0/V3;83&*+R;<*^X/.>1H7#\"UZ()8:T'EGK0FR; +H$@
M$KYQ\/H!R"+*%!YZ?/G@C,E0Z&F-G]^_.A-OTN*^SUTUJ6(3T"5(ARX?+@7T
M%W692PYUV+Y:4R<X$P$YO J4KP-\Y6;L47 N?M[@\BB8OD7K^I6LJT"><5C^
MYI%Z]_^+G>II$-.AJ,5A0LW,$@&X?U 1=@<O5!P0G'.* B/BG>OT:KQY3=:*
MC&3?NP>]NNE(WZII.'6L X..MX?+IOK#K15\5 Q4[-\^)1T3,\E#-,5IR:%G
MK"=^*/ !/I49GF#B'5[D172]%1"2"'VX]4R]!C&=B@5HF03>A>X (&78AMVK
M'LZ5OR.N2[EA;J.@K>HUE*2FTI$>Y;S28X?PX0<')!4=*>#)&BM><JGP2FH0
M 61--T5Y_5'>T'07ZGI[U\;'EL #=+'Q&56;^@JBYI*:9ME^,38!SFNWHJ(3
MW::9<NDD7VM>:8!P(&X[,M7^K?1B[PO]X7Y_S;2HPP0;'B'\?@E'2J$0,#;U
MH.<<@A<V5J<J#_=7< FIG_.DH-SC,^7=$PJ9=(^(ADM^GR='6?'>1\NUPX6A
MX/D4T!JGOQ3_[ P=_EKJB-'Q1VQ2_8)<G'KQJJR08DOH3AX/=B7>SS$?#D?]
ML*IXB9,N"\49>:J<6/W1DX "8.AG&)WMV>"%5#49- [Q.I[AV_&2"DF4'C)9
M6/R9#-ERH=A:0]F^HA_C*!X*Q@O^)5G*;HZ4)%2>B&?@=?/R-P..JNN>^-B:
M/84E\5RW"3@UQYN8WC?A<"@*0@O4/E[]C:_MVT\)<L?D&HN&Y\7O_JP5<#/\
M=2,Z<&@]_P10^C3]@M(U_VY0?IQ_?ND=4#NL-31J :]>S!X]..'FL/B'-QOZ
M%:&Y\=ZLZ9]X\U%9? "^7QC8]_ '3I!^5^KE_P%02P,$%     @ ;(9I4XU
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M6X'FPRRTE,'YA5F'MFK1DC?0KN!&25L:^"1SS%_&A\2LIY<<Z*V2DX!W6%]
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MW1OD'OC,J,P$>*(I3COPRWY\W(.W5:!-M.XIVIG;2[C&^WO@P3O@0M?YNEZ
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M7!NH]RNFJK.XT0.49X^S_P%02P,$%     @ ;(9I4Y1A'@6^ @  I <  !D
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M"]GXBZT_LQU?9L%H'$[<E\-R#1C%8=(9O4,==:BC\ZAX5C#,_.T:>ZVJ<ZQ
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MN,3N'X0VP/=SSM5VH!>H_T\,_@%02P,$%     @ ;(9I4TEH=QZ= P  8PP
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M=Z=.F=]=\7N@8A.E.8K9&H9RS@.86+&[-;=[D#RK[F MN90\J3YN&6Q,12D
MWZ\YE_N'<H#F[N+5_P!02P,$%     @ ;(9I4S-?Q].B!@  +B(  !D   !X
M;"]W;W)K<VAE971S+W-H965T,S8N>&ULM5I13^,X$/XK5G4G[4HLC>TD;5:
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M4=W45!W%M^5EQP-7BN=E<T-P2H09H-^O.%>'CIF@OB^;_0]02P,$%     @
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M!A+1KMJ.O\+VHJ1[Q;*QN,S9BN63=JKGTV88V(&-VE[@<(A<-Y<?P7P<YD<
MP^)@"C ?YX7%^9_V,T3WXS!,V]"+#%&?(>KCO'S(I/E@<?P^J;W\.TW3.$X2
M+*.3B5?!!,M;DL#7SX9I P\L#D3ZLUSCU<8[Y/D^P&KZ7(=@.\4[$=LIGFM
M_'D#CS3U5QN+ QY8%;#>@?C^.-!3?I\XAJIBVK G&$?2%$.@%_T]FB1(=A+X
M^.N#/25QG*9^!#"_@CC&$'@:<013 !HP)(Z;<_#@/ HWYU2X_?5G_!M02P,$
M%     @ ;(9I4Y>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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M$T+V(GF.0)Z?$C(-($<(Y(@6<L%=;8#I#;NIK5!@;<!U@7!=T'+E=55Q\]:
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M<:W*YNC/NC]'\T]02P$"% ,4    " !LAFE3!T%-8H$   "Q    $
M        @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( &R&:5,>
MS1Q)[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    ( &R&:5.97)PC$ 8  )PG   3              "  <P!
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ;(9I4\I;P;%'!0
M_Q4  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;%!+ 0(4 Q0    ( &R&:5-0ZH66ZP4  $(7   8              " @8H-
M  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " !LAFE3S+CA
MSI4"  "]!@  &               @(&K$P  >&PO=V]R:W-H965T<R]S:&5E
M=#,N>&UL4$L! A0#%     @ ;(9I4U$F5\]U!@  .QT  !@
M ("!=A8  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( &R&
M:5,8ZG15=0H  &8_   8              " @2$=  !X;"]W;W)K<VAE971S
M+W-H965T-2YX;6Q02P$"% ,4    " !LAFE3TT1=89D'   T(   &
M        @(',)P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%
M  @ ;(9I4ULQ"@AO$   &2T  !@              ("!FR\  'AL+W=O<FMS
M:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( &R&:5/.L&2=IQ<  .I&   8
M              " @4!   !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"
M% ,4    " !LAFE3%E]$]<(%  #W#P  &               @($=6   >&PO
M=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ ;(9I4_<-/X4.!
M/0H  !D              ("!%5X  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX
M;6Q02P$"% ,4    " !LAFE3SX%N&Z0"  "A!0  &0              @(%:
M8@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( &R&:5-1
MD4VR 00  )<(   9              " @35E  !X;"]W;W)K<VAE971S+W-H
M965T,3(N>&UL4$L! A0#%     @ ;(9I4X)V20'R P  . H  !D
M     ("!;6D  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &R&:5/H+#,.^0(  ,<&   9              "
M@3.;  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ ;(9I
M4V)<3]U(!   APH  !D              ("!8YX  'AL+W=O<FMS:&5E=',O
M<VAE970Q.2YX;6Q02P$"% ,4    " !LAFE3B0]2)F88  !C2@  &0
M        @('BH@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0
M   ( &R&:5.-0%P<M ,  +()   9              " @7^[  !X;"]W;W)K
M<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ ;(9I4\>D(#P, P  N <
M !D              ("!:K\  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q0
M2P$"% ,4    " !LAFE3G.,/0+0"  "B!0  &0              @(&MP@
M>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( &R&:5,E1&<K
M"@,  ,H&   9              " @9C%  !X;"]W;W)K<VAE971S+W-H965T
M,C0N>&UL4$L! A0#%     @ ;(9I4XYE$9^4!0  C@T  !D
M ("!V<@  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " !L
MAFE3B3B4^Z #  !J#   &0              @(&DS@  >&PO=V]R:W-H965T
M<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( &R&:5,5-A@QA0,  .<+   9
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M970S,2YX;6Q02P$"% ,4    " !LAFE3.\$8*5@#  !;#   &0
M    @($BY@  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    (
M &R&:5-):'<>G0,  &,,   9              " @;'I  !X;"]W;W)K<VAE
M971S+W-H965T,S,N>&UL4$L! A0#%     @ ;(9I4U\=+,?P @  3P<  !D
M             ("!A>T  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"
M% ,4    " !LAFE3A!F],KD'  #'*   &0              @(&L\   >&PO
M=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( &R&:5,S7\?3H@8
M "XB   9              " @9SX  !X;"]W;W)K<VAE971S+W-H965T,S8N
M>&UL4$L! A0#%     @ ;(9I4[STDN4P"   1"L  !D              ("!
M=?\  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " !LAFE3
MDY7'6*@$   [$P  &0              @('<!P$ >&PO=V]R:W-H965T<R]S
M:&5E=#,X+GAM;%!+ 0(4 Q0    ( &R&:5,RWTI=GP(  ,,'   9
M      " @;L, 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%
M  @ ;(9I4RB]-3S] @  ' H  !D              ("!D0\! 'AL+W=O<FMS
M:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " !LAFE3P,@!ES8#   0"P
M&0              @('%$@$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+
M 0(4 Q0    ( &R&:5/CQR.Z:@(  *,%   9              " @3(6 0!X
M;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ ;(9I4^WGJ@CG
M @  &@@  !D              ("!TQ@! 'AL+W=O<FMS:&5E=',O<VAE970T
M,RYX;6Q02P$"% ,4    " !LAFE3VQ[%3QH#   *$@  #0
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:+GAM;%!+!08     ,P S -P-  "U)P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>230</ContextCount>
  <ElementCount>340</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>59</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/NatureofBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/FairValueofFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2109104 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2112105 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2115106 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2117107 - Disclosure - Lease</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/Lease</Role>
      <ShortName>Lease</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2119108 - Disclosure - Liability Related to the Sale of Future Royalties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyalties</Role>
      <ShortName>Liability Related to the Sale of Future Royalties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2123109 - Disclosure - Research and Development Collaborations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/ResearchandDevelopmentCollaborations</Role>
      <ShortName>Research and Development Collaborations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2125110 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2127111 - Disclosure - Stock Plans and Stock Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/StockPlansandStockBasedCompensation</Role>
      <ShortName>Stock Plans and Stock Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2134112 - Disclosure - Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/LossPerCommonShare</Role>
      <ShortName>Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2136113 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.curis.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/FairValueofFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curis.com/role/FairValueofFinancialInstruments</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curis.com/role/Investments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curis.com/role/AccruedLiabilities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - Liability Related to the Sale of Future Royalties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables</Role>
      <ShortName>Liability Related to the Sale of Future Royalties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyalties</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2328305 - Disclosure - Stock Plans and Stock Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/StockPlansandStockBasedCompensationTables</Role>
      <ShortName>Stock Plans and Stock Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curis.com/role/StockPlansandStockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Nature of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/NatureofBusinessDetails</Role>
      <ShortName>Nature of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curis.com/role/NatureofBusiness</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curis.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Fair Value of Financial Instruments - Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Investments - Amortized Cost of Unrealized Gains and Losses and Fair Value of Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails</Role>
      <ShortName>Investments - Amortized Cost of Unrealized Gains and Losses and Fair Value of Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2414405 - Disclosure - Accrued Liabilities - Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/AccruedLiabilitiesSummaryDetails</Role>
      <ShortName>Accrued Liabilities - Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2416406 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/DebtDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curis.com/role/Debt</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2418407 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curis.com/role/Lease</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2421408 - Disclosure - Liability Related to the Sale of Future Royalties - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails</Role>
      <ShortName>Liability Related to the Sale of Future Royalties - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2422409 - Disclosure - Liability Related to the Sale of Future Royalties - Liability Due to Non-Cash Transaction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesLiabilityDuetoNonCashTransactionDetails</Role>
      <ShortName>Liability Related to the Sale of Future Royalties - Liability Due to Non-Cash Transaction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2424410 - Disclosure - Research and Development Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails</Role>
      <ShortName>Research and Development Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curis.com/role/ResearchandDevelopmentCollaborations</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2426411 - Disclosure - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/CommonStockDetails</Role>
      <ShortName>Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curis.com/role/CommonStock</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2429412 - Disclosure - Stock Plans and Stock Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock Plans and Stock Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2430413 - Disclosure - Stock Plans and Stock Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/StockPlansandStockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock Plans and Stock Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2431414 - Disclosure - Stock Plans and Stock Based Compensation - Key Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/StockPlansandStockBasedCompensationKeyAssumptionsDetails</Role>
      <ShortName>Stock Plans and Stock Based Compensation - Key Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2432415 - Disclosure - Stock Plans and Stock Based Compensation - Restricted Stock Award Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/StockPlansandStockBasedCompensationRestrictedStockAwardActivityDetails</Role>
      <ShortName>Stock Plans and Stock Based Compensation - Restricted Stock Award Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2433416 - Disclosure - Stock Plans and Stock Based Compensation - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/StockPlansandStockBasedCompensationStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock Plans and Stock Based Compensation - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2435417 - Disclosure - Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/LossPerCommonShareDetails</Role>
      <ShortName>Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curis.com/role/LossPerCommonShare</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="cris-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2437418 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curis.com/role/RelatedPartyTransactions</ParentRole>
      <Position>43</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cris-20210930.htm">cris-20210930.htm</File>
    <File>cris-20210930.xsd</File>
    <File>cris-20210930_cal.xml</File>
    <File>cris-20210930_def.xml</File>
    <File>cris-20210930_lab.xml</File>
    <File>cris-20210930_pre.xml</File>
    <File>cris-9302021x10qexx31.htm</File>
    <File>cris-9302021x10qexx311.htm</File>
    <File>cris-9302021x10qexx312.htm</File>
    <File>cris-9302021x10qexx321.htm</File>
    <File>cris-9302021x10qexx322.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>62
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cris-20210930.htm": {
   "axisCustom": 1,
   "axisStandard": 24,
   "contextCount": 230,
   "dts": {
    "calculationLink": {
     "local": [
      "cris-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cris-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cris-20210930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cris-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cris-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cris-20210930.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 445,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 1,
    "http://www.curis.com/20210930": 2,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 8
   },
   "keyCustom": 61,
   "keyStandard": 279,
   "memberCustom": 27,
   "memberStandard": 28,
   "nsprefix": "cris",
   "nsuri": "http://www.curis.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.curis.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109104 - Disclosure - Investments",
     "role": "http://www.curis.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112105 - Disclosure - Accrued Liabilities",
     "role": "http://www.curis.com/role/AccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115106 - Disclosure - Debt",
     "role": "http://www.curis.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117107 - Disclosure - Lease",
     "role": "http://www.curis.com/role/Lease",
     "shortName": "Lease",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NonmonetaryTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119108 - Disclosure - Liability Related to the Sale of Future Royalties",
     "role": "http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyalties",
     "shortName": "Liability Related to the Sale of Future Royalties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NonmonetaryTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123109 - Disclosure - Research and Development Collaborations",
     "role": "http://www.curis.com/role/ResearchandDevelopmentCollaborations",
     "shortName": "Research and Development Collaborations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125110 - Disclosure - Common Stock",
     "role": "http://www.curis.com/role/CommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127111 - Disclosure - Stock Plans and Stock Based Compensation",
     "role": "http://www.curis.com/role/StockPlansandStockBasedCompensation",
     "shortName": "Stock Plans and Stock Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134112 - Disclosure - Loss Per Common Share",
     "role": "http://www.curis.com/role/LossPerCommonShare",
     "shortName": "Loss Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136113 - Disclosure - Related Party Transactions",
     "role": "http://www.curis.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i11c1bbbe971845e8b341c2dce21185d6_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i11c1bbbe971845e8b341c2dce21185d6_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.curis.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "role": "http://www.curis.com/role/FairValueofFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - Investments (Tables)",
     "role": "http://www.curis.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Accrued Liabilities (Tables)",
     "role": "http://www.curis.com/role/AccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherSignificantNoncashTransactionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - Liability Related to the Sale of Future Royalties (Tables)",
     "role": "http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables",
     "shortName": "Liability Related to the Sale of Future Royalties (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherSignificantNoncashTransactionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328305 - Disclosure - Stock Plans and Stock Based Compensation (Tables)",
     "role": "http://www.curis.com/role/StockPlansandStockBasedCompensationTables",
     "shortName": "Stock Plans and Stock Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cris:CollaborationAgreementNumberofProgramsLicensed",
      "reportCount": 1,
      "unitRef": "program",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Nature of Business (Details)",
     "role": "http://www.curis.com/role/NatureofBusinessDetails",
     "shortName": "Nature of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i11c1bbbe971845e8b341c2dce21185d6_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.curis.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "id4ae33930dfd48de8c0c9dab2d240035_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "ifadf6a4b0d22481ba0be83763d78d4c5_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Fair Value of Financial Instruments - Summary (Details)",
     "role": "http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails",
     "shortName": "Fair Value of Financial Instruments - Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "ifadf6a4b0d22481ba0be83763d78d4c5_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i11c1bbbe971845e8b341c2dce21185d6_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411404 - Disclosure - Investments - Amortized Cost of Unrealized Gains and Losses and Fair Value of Investments (Details)",
     "role": "http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails",
     "shortName": "Investments - Amortized Cost of Unrealized Gains and Losses and Fair Value of Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i11c1bbbe971845e8b341c2dce21185d6_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i11c1bbbe971845e8b341c2dce21185d6_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i11c1bbbe971845e8b341c2dce21185d6_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i11c1bbbe971845e8b341c2dce21185d6_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414405 - Disclosure - Accrued Liabilities - Summary (Details)",
     "role": "http://www.curis.com/role/AccruedLiabilitiesSummaryDetails",
     "shortName": "Accrued Liabilities - Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i11c1bbbe971845e8b341c2dce21185d6_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i27e768c412c64fadbdb2a523fde1e521_I20200430",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416406 - Disclosure - Debt (Details)",
     "role": "http://www.curis.com/role/DebtDetails",
     "shortName": "Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i27e768c412c64fadbdb2a523fde1e521_I20200430",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i11c1bbbe971845e8b341c2dce21185d6_I20210930",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418407 - Disclosure - Leases (Details)",
     "role": "http://www.curis.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "id4ae33930dfd48de8c0c9dab2d240035_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "if6e3f1f585a2476fb48ab5c48b4b4c0c_D20190301-20190331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "cris:RoyaltyPurchaseAgreementInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421408 - Disclosure - Liability Related to the Sale of Future Royalties - Narrative (Details)",
     "role": "http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
     "shortName": "Liability Related to the Sale of Future Royalties - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "if6e3f1f585a2476fb48ab5c48b4b4c0c_D20190301-20190331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "cris:RoyaltyPurchaseAgreementInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherSignificantNoncashTransactionsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "id4ae33930dfd48de8c0c9dab2d240035_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cris:RoyaltyPurchaseAgreementLiabilityCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422409 - Disclosure - Liability Related to the Sale of Future Royalties - Liability Due to Non-Cash Transaction (Details)",
     "role": "http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesLiabilityDuetoNonCashTransactionDetails",
     "shortName": "Liability Related to the Sale of Future Royalties - Liability Due to Non-Cash Transaction (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherSignificantNoncashTransactionsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "id4ae33930dfd48de8c0c9dab2d240035_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cris:RoyaltyPurchaseAgreementLiabilityCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424410 - Disclosure - Research and Development Collaborations (Details)",
     "role": "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails",
     "shortName": "Research and Development Collaborations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "ic26067fcb23449e68eba5cd92cb0a49e_D20030601-20030630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "cris:ReducedRoyaltyRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "id4ae33930dfd48de8c0c9dab2d240035_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426411 - Disclosure - Common Stock (Details)",
     "role": "http://www.curis.com/role/CommonStockDetails",
     "shortName": "Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i6e2324829cfe492bb1ce3a18540cabae_I20200630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cris:ShareBasedCompensationPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "plan",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429412 - Disclosure - Stock Plans and Stock Based Compensation - Narrative (Details)",
     "role": "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails",
     "shortName": "Stock Plans and Stock Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cris:ShareBasedCompensationPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "plan",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "id4ae33930dfd48de8c0c9dab2d240035_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430413 - Disclosure - Stock Plans and Stock Based Compensation - Stock Option Activity (Details)",
     "role": "http://www.curis.com/role/StockPlansandStockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock Plans and Stock Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431414 - Disclosure - Stock Plans and Stock Based Compensation - Key Assumptions (Details)",
     "role": "http://www.curis.com/role/StockPlansandStockBasedCompensationKeyAssumptionsDetails",
     "shortName": "Stock Plans and Stock Based Compensation - Key Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "if92fd01d600549e3966881e1346c980d_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432415 - Disclosure - Stock Plans and Stock Based Compensation - Restricted Stock Award Activity (Details)",
     "role": "http://www.curis.com/role/StockPlansandStockBasedCompensationRestrictedStockAwardActivityDetails",
     "shortName": "Stock Plans and Stock Based Compensation - Restricted Stock Award Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i07e1ce19861a4ae59be352c43fd153c5_D20210101-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433416 - Disclosure - Stock Plans and Stock Based Compensation - Stock-based Compensation Expense (Details)",
     "role": "http://www.curis.com/role/StockPlansandStockBasedCompensationStockbasedCompensationExpenseDetails",
     "shortName": "Stock Plans and Stock Based Compensation - Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i77a1992dbb95410db0ce8900e5d162cc_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "id1569a19d3534733a5351d7321844968_D20210101-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435417 - Disclosure - Loss Per Common Share (Details)",
     "role": "http://www.curis.com/role/LossPerCommonShareDetails",
     "shortName": "Loss Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "id1569a19d3534733a5351d7321844968_D20210101-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i476e1229fc4b40faa3024587e5c8cf5c_D20200601-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437418 - Disclosure - Related Party Transactions (Details)",
     "role": "http://www.curis.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i476e1229fc4b40faa3024587e5c8cf5c_D20200601-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i59d2a236085c4461b444f9e731b5d83a_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)",
     "role": "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "ib3df11fcc545447489bc72b8df5ec6a5_D20200101-20200331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Nature of Business",
     "role": "http://www.curis.com/role/NatureofBusiness",
     "shortName": "Nature of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.curis.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Fair Value of Financial Instruments",
     "role": "http://www.curis.com/role/FairValueofFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cris-20210930.htm",
      "contextRef": "i3c78dbdccb1b451eb1f9c422560ccca9_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 59,
   "tag": {
    "cris_AggregateNetRoyaltiesPriorTo2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Net Royalties Prior To 2027 [Member]",
        "label": "Aggregate Net Royalties Prior To 2027 [Member]",
        "terseLabel": "Aggregate Net Royalties Prior to 2027"
       }
      }
     },
     "localname": "AggregateNetRoyaltiesPriorTo2027Member",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cris_AgreementWithHeadOfResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement With Head Of Research And Development [Member]",
        "label": "Agreement With Head Of Research And Development [Member]",
        "terseLabel": "Agreement With Head of Research and Development"
       }
      }
     },
     "localname": "AgreementWithHeadOfResearchAndDevelopmentMember",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cris_AmendedAndRestatedTwoThousandTenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended and restated two thousand ten stock incentive plan.",
        "label": "Amended And Restated Two Thousand Ten Stock Incentive Plan [Member]",
        "terseLabel": "Amended and Restated 2010 Stock Incentive Plan"
       }
      }
     },
     "localname": "AmendedAndRestatedTwoThousandTenStockIncentivePlanMember",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cris_AspireCapitalFundLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aspire Capital Fund, LLC [Member]",
        "label": "Aspire Capital Fund, LLC [Member]",
        "terseLabel": "Aspire Capital Fund, LLC",
        "verboseLabel": "Aspire Capital Fund, LLC"
       }
      }
     },
     "localname": "AspireCapitalFundLLCMember",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.curis.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cris_AurigeneDiscoveryTechnologiesLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aurigene Discovery Technologies Ltd [Member]",
        "label": "Aurigene Discovery Technologies Ltd [Member]",
        "terseLabel": "Aurigene"
       }
      }
     },
     "localname": "AurigeneDiscoveryTechnologiesLtdMember",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cris_AvailableForSaleSecuritiesDateRange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale securities date range.",
        "label": "Available For Sale Securities Date Range",
        "terseLabel": "Range of maturities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDateRange",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cris_AvailableForSaleSecuritiesWeightedAverageMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available-for-sale securities weighted average maturity.",
        "label": "Available For Sale Securities Weighted Average Maturity",
        "terseLabel": "Weighted-average maturity of short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesWeightedAverageMaturity",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cris_CaresActPPPLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cares Act PPP Loan [Member]",
        "label": "Cares Act PPP Loan [Member]",
        "terseLabel": "Cares Act PPP Loan"
       }
      }
     },
     "localname": "CaresActPPPLoanMember",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cris_ChemistryManufacturingAndControlsCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.curis.com/role/AccruedLiabilitiesSummaryDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chemistry Manufacturing And Controls Costs",
        "label": "Chemistry Manufacturing And Controls Costs",
        "terseLabel": "Chemistry, manufacturing and controls costs"
       }
      }
     },
     "localname": "ChemistryManufacturingAndControlsCosts",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/AccruedLiabilitiesSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_CollaborationAgreementContingentConsiderationPotentialCashPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement contingent consideration potential cash payment.",
        "label": "Collaboration Agreement Contingent Consideration Potential Cash Payment",
        "terseLabel": "Eligible to receive contingent cash payment for specified clinical development and regulatory objectives (up to)"
       }
      }
     },
     "localname": "CollaborationAgreementContingentConsiderationPotentialCashPayment",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_CollaborationAgreementContingentConsiderationReceivedFromPartner": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement contingent consideration received from partner.",
        "label": "Collaboration Agreement Contingent Consideration Received From Partner",
        "terseLabel": "Amount received for specified clinical development and regulatory objectives"
       }
      }
     },
     "localname": "CollaborationAgreementContingentConsiderationReceivedFromPartner",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_CollaborationAgreementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Expense",
        "label": "Collaboration Agreement, Expense",
        "terseLabel": "Collaboration Agreement, expense"
       }
      }
     },
     "localname": "CollaborationAgreementExpense",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_CollaborationAgreementNumberofProgramsLicensed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Number of Programs Licensed",
        "label": "Collaboration Agreement, Number of Programs Licensed",
        "terseLabel": "Number of program licensed"
       }
      }
     },
     "localname": "CollaborationAgreementNumberofProgramsLicensed",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/NatureofBusinessDetails",
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cris_CollaborationAgreementTermsPercentageOfRoyaltyFeesReceivable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Terms, Percentage Of Royalty Fees Receivable",
        "label": "Collaboration Agreement, Terms, Percentage Of Royalty Fees Receivable",
        "terseLabel": "Royalty fees receivable (as a percent)"
       }
      }
     },
     "localname": "CollaborationAgreementTermsPercentageOfRoyaltyFeesReceivable",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cris_CollaborationArrangementContingentConsiderationDevelopmentMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Contingent Consideration, Development Milestone Payments",
        "label": "Collaboration Arrangement, Contingent Consideration, Development Milestone Payments",
        "terseLabel": "Development milestone payments"
       }
      }
     },
     "localname": "CollaborationArrangementContingentConsiderationDevelopmentMilestonePayments",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_CollaborationArrangementContingentConsiderationOptionExerciseFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Contingent Consideration, Option Exercise Fee",
        "label": "Collaboration Arrangement, Contingent Consideration, Option Exercise Fee",
        "terseLabel": "Option exercise fee"
       }
      }
     },
     "localname": "CollaborationArrangementContingentConsiderationOptionExerciseFee",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_CollaborationArrangementContingentConsiderationRegulatoryApprovalMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Contingent Consideration, Regulatory Approval Milestone Payments",
        "label": "Collaboration Arrangement, Contingent Consideration, Regulatory Approval Milestone Payments",
        "terseLabel": "Regulatory approval milestone payments"
       }
      }
     },
     "localname": "CollaborationArrangementContingentConsiderationRegulatoryApprovalMilestonePayments",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_CollaborationArrangementContingentConsiderationReimbursableExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Contingent Consideration, Reimbursable Expenses",
        "label": "Collaboration Arrangement, Contingent Consideration, Reimbursable Expenses",
        "terseLabel": "Maximum reimbursable expenses"
       }
      }
     },
     "localname": "CollaborationArrangementContingentConsiderationReimbursableExpenses",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_CollaborationArrangementContingentConsiderationSalesMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Contingent Consideration, Sales Milestone Payments",
        "label": "Collaboration Arrangement, Contingent Consideration, Sales Milestone Payments",
        "terseLabel": "Sales milestone payments"
       }
      }
     },
     "localname": "CollaborationArrangementContingentConsiderationSalesMilestonePayments",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_CollaborationArrangementSemiAnnualMaintenanceFeePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Semi-Annual Maintenance Fee Payment",
        "label": "Collaboration Arrangement, Semi-Annual Maintenance Fee Payment",
        "terseLabel": "Semi-annual maintenance fee payments"
       }
      }
     },
     "localname": "CollaborationArrangementSemiAnnualMaintenanceFeePayment",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_CollaborativeArrangementPaymentsAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement Payments Agreement",
        "label": "Collaborative Arrangement Payments Agreement",
        "terseLabel": "Collaborative arrangement payments agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementPaymentsAgreement",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_ContingentPaymentBenchmarkAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Payment, Benchmark [Axis]",
        "label": "Contingent Payment, Benchmark [Axis]",
        "terseLabel": "Contingent Payment, Benchmark [Axis]"
       }
      }
     },
     "localname": "ContingentPaymentBenchmarkAxis",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cris_ContingentPaymentBenchmarkDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Contingent Payment, Benchmark [Axis]",
        "label": "Contingent Payment, Benchmark [Domain]",
        "terseLabel": "Contingent Payment, Benchmark [Domain]"
       }
      }
     },
     "localname": "ContingentPaymentBenchmarkDomain",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cris_ContraRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contra Revenue [Member]",
        "label": "Contra Revenue [Member]",
        "terseLabel": "Contra revenue, net"
       }
      }
     },
     "localname": "ContraRevenueMember",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "cris_CorporateCommercialPaperStockBondsAndNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Commercial Paper, Stock, Bonds And Notes [Member]",
        "label": "Corporate Commercial Paper, Stock, Bonds And Notes [Member]",
        "terseLabel": "Corporate commercial paper, bonds and notes"
       }
      }
     },
     "localname": "CorporateCommercialPaperStockBondsAndNotesMember",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cris_DemandSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Demand Sales Agreement",
        "label": "Demand Sales Agreement [Member]",
        "terseLabel": "Demand Sales Agreement"
       }
      }
     },
     "localname": "DemandSalesAgreementMember",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.curis.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cris_DirectPlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Direct Placement",
        "label": "Direct Placement [Member]",
        "terseLabel": "Direct Placement"
       }
      }
     },
     "localname": "DirectPlacementMember",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "domainItemType"
    },
    "cris_EmployeeStockPurchasePlanEnrollmentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan, Enrollment Period",
        "label": "Employee Stock Purchase Plan, Enrollment Period",
        "terseLabel": "Enrollment period"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanEnrollmentPeriod",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cris_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cris_EpiCurePharmaceuticalsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Epi-Cure Pharmaceuticals, Inc. [Member]",
        "label": "Epi-Cure Pharmaceuticals, Inc. [Member]",
        "terseLabel": "Epi-Cure Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "EpiCurePharmaceuticalsInc.Member",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cris_GenentechIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genentech, Inc.",
        "label": "Genentech Inc [Member]",
        "terseLabel": "Genentech, Inc."
       }
      }
     },
     "localname": "GenentechIncMember",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails",
      "http://www.curis.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cris_GrossRoyaltyRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross Royalty Revenue [Member]",
        "label": "Gross Royalty Revenue [Member]",
        "terseLabel": "Royalties"
       }
      }
     },
     "localname": "GrossRoyaltyRevenueMember",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cris_IRAK4PD1VISTAPD1TIM3ProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IRAK4, PD1/VISTA,PD1/TIM3 Program [Member]",
        "label": "IRAK4, PD1/VISTA,PD1/TIM3 Program [Member]",
        "terseLabel": "IRAK4, PD1/VISTA, and PD1/TIM3 Programs"
       }
      }
     },
     "localname": "IRAK4PD1VISTAPD1TIM3ProgramMember",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cris_ImmuNextMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ImmuNext [Member]",
        "label": "ImmuNext [Member]",
        "terseLabel": "ImmuNext"
       }
      }
     },
     "localname": "ImmuNextMember",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cris_IncreaseDecreaseOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) Operating Lease Liability",
        "label": "Increase (Decrease) Operating Lease Liability",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseOperatingLeaseLiability",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_LicenseFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.curis.com/role/AccruedLiabilitiesSummaryDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Fees",
        "label": "License Fees",
        "terseLabel": "License fees"
       }
      }
     },
     "localname": "LicenseFees",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/AccruedLiabilitiesSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_LongTermInvestmentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Investments, Fair Value Disclosure",
        "label": "Long Term Investments, Fair Value Disclosure",
        "verboseLabel": "Corporate commercial paper, bonds and notes"
       }
      }
     },
     "localname": "LongTermInvestmentsFairValueDisclosure",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_MasterDevelopmentAndManufacturingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Master Development And Manufacturing Agreement [Member]",
        "label": "Master Development And Manufacturing Agreement [Member]",
        "terseLabel": "Master Development and Manufacturing Agreement"
       }
      }
     },
     "localname": "MasterDevelopmentAndManufacturingAgreementMember",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cris_MilestonePaymentsWaivedToDate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments Waived To Date",
        "label": "Milestone Payments Waived To Date",
        "terseLabel": "Milestone payments waived to date"
       }
      }
     },
     "localname": "MilestonePaymentsWaivedToDate",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_NonCashImputedInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Imputed Interest Expense",
        "label": "Non-Cash Imputed Interest Expense",
        "negatedTerseLabel": "Imputed interest expense related to the sale of future royalties"
       }
      }
     },
     "localname": "NonCashImputedInterestExpense",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_NonCashImputedInterestExpenseNetOfImputedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Imputed Interest Expense, Net Of Imputed Interest",
        "label": "Non-Cash Imputed Interest Expense, Net Of Imputed Interest",
        "terseLabel": "Non-cash imputed interest expense related to the sale of future royalties"
       }
      }
     },
     "localname": "NonCashImputedInterestExpenseNetOfImputedInterest",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_NonCashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Lease Expense",
        "label": "Non-Cash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NonCashLeaseExpense",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_NonEmployeeDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-employee directors.",
        "label": "Non Employee Directors [Member]",
        "terseLabel": "Non-Employee Directors"
       }
      }
     },
     "localname": "NonEmployeeDirectorsMember",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cris_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Or Part Noncash Acquisition, Noncash Financial Or Equity Instrument Consideration, Shares Issued, Value",
        "label": "Noncash Or Part Noncash Acquisition, Noncash Financial Or Equity Instrument Consideration, Shares Issued, Value",
        "terseLabel": "Non-cash commitment shares issued to Aspire Capital"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_NonmonetaryTransactionRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonmonetary Transaction",
        "label": "Nonmonetary Transaction [Roll Forward]",
        "terseLabel": "Nonmonetary Transaction [Roll Forward]"
       }
      }
     },
     "localname": "NonmonetaryTransactionRollForward",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesLiabilityDuetoNonCashTransactionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cris_NumberOfPurchasePeriodsPerEnrollmentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of purchase periods per enrollment period.",
        "label": "Number Of Purchase Periods Per Enrollment Period",
        "terseLabel": "Number of purchase periods per year"
       }
      }
     },
     "localname": "NumberOfPurchasePeriodsPerEnrollmentPeriod",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cris_NumberOfSharesAwardedUnderStockValueLessThanSpecificPercentageOfFairMarketValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares awarded per share under stock value less than specific percentage of fair market value.",
        "label": "Number Of Shares Awarded Under Stock Value Less Than Specific Percentage Of Fair Market Value",
        "terseLabel": "Shares awarded under plan (in shares)"
       }
      }
     },
     "localname": "NumberOfSharesAwardedUnderStockValueLessThanSpecificPercentageOfFairMarketValue",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cris_OberlandCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oberland Capital [Member]",
        "label": "Oberland Capital [Member]",
        "terseLabel": "Oberland Capital"
       }
      }
     },
     "localname": "OberlandCapitalMember",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cris_OfficersAndNonEmployeeDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Officers And Non Employee Directors [Member]",
        "label": "Officers And Non Employee Directors [Member]",
        "terseLabel": "Officers and Non-Employee Directors"
       }
      }
     },
     "localname": "OfficersAndNonEmployeeDirectorsMember",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cris_OperatingLeaseOneTimePaymentTenantImprovements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, One Time Payment, Tenant Improvements",
        "label": "Operating Lease, One Time Payment, Tenant Improvements",
        "terseLabel": "One time payment, tenant improvements"
       }
      }
     },
     "localname": "OperatingLeaseOneTimePaymentTenantImprovements",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_OtherRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Revenue [Member]",
        "label": "Other Revenue [Member]",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "OtherRevenueMember",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "cris_PaymentsOfFutureRoyaltyLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments Of Future Royalty Liability",
        "label": "Payments Of Future Royalty Liability",
        "negatedLabel": "Less: payments to Oberland Capital, LLC"
       }
      }
     },
     "localname": "PaymentsOfFutureRoyaltyLiability",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesLiabilityDuetoNonCashTransactionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments Of Future Royalty Liability, Net Of Imputed Interest",
        "label": "Payments Of Future Royalty Liability, Net Of Imputed Interest",
        "negatedTerseLabel": "Payment of liability of future royalties, net of imputed interest"
       }
      }
     },
     "localname": "PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_PaymentsforCollaborativeArrangementstoDate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments made under collaborative arrangements.",
        "label": "Payments for Collaborative Arrangements to Date",
        "terseLabel": "Payments made under collaboration arrangements"
       }
      }
     },
     "localname": "PaymentsforCollaborativeArrangementstoDate",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_PercentageOfRoyaltyOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty on net sales.",
        "label": "Percentage Of Royalty On Net Sales",
        "terseLabel": "Percentage of royalty on net sales"
       }
      }
     },
     "localname": "PercentageOfRoyaltyOnNetSales",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cris_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Issuance Of Private Placement, Net Of Issuance Costs",
        "label": "Proceeds From Issuance Of Private Placement, Net Of Issuance Costs",
        "terseLabel": "Proceeds of direct placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_ProceedsFromRoyaltyPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Royalty Purchase Agreement",
        "label": "Proceeds From Royalty Purchase Agreement",
        "terseLabel": "Proceeds from royalty interest purchase agreement with Oberland Capital Management, LLC"
       }
      }
     },
     "localname": "ProceedsFromRoyaltyPurchaseAgreement",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_ReducedRoyaltyRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduced Royalty Rate",
        "label": "Reduced Royalty Rate",
        "terseLabel": "Percentage of royalty rate decrease"
       }
      }
     },
     "localname": "ReducedRoyaltyRate",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cris_RelatedPartyTransactionMaximumFundingAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Maximum Funding Amount",
        "label": "Related Party Transaction, Maximum Funding Amount",
        "terseLabel": "Maximum funding amount"
       }
      }
     },
     "localname": "RelatedPartyTransactionMaximumFundingAmount",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_RelatedPartyTransactionTermsAndMannerOfSettlementMinimumDaysNoticeToTerminatePriorToWrittenNotice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Terms And Manner Of Settlement, Minimum Days Notice To Terminate Prior To Written Notice",
        "label": "Related Party Transaction, Terms And Manner Of Settlement, Minimum Days Notice To Terminate Prior To Written Notice",
        "terseLabel": "Minimum days notice to terminate prior to written notice"
       }
      }
     },
     "localname": "RelatedPartyTransactionTermsAndMannerOfSettlementMinimumDaysNoticeToTerminatePriorToWrittenNotice",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cris_RestrictedStockRSUsOtherStockBasedAwardsOrPerformanceAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock, RSUs, Other Stock-Based Awards, Or Performance Awards [Member]",
        "label": "Restricted Stock, RSUs, Other Stock-Based Awards, Or Performance Awards [Member]",
        "terseLabel": "Restricted Stock, RSUs, Other Stock-Based Awards, or Performance Awards"
       }
      }
     },
     "localname": "RestrictedStockRSUsOtherStockBasedAwardsOrPerformanceAwardsMember",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cris_RoyaltyAmountsIn2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Amounts In 2021 [Member]",
        "label": "Royalty Amounts In 2021 [Member]",
        "terseLabel": "Royalty Amounts in 2021"
       }
      }
     },
     "localname": "RoyaltyAmountsIn2021Member",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cris_RoyaltyGuaranteesCommitmentsAmountNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Guarantees, Commitments, Amount, Noncurrent",
        "label": "Royalty Guarantees, Commitments, Amount, Noncurrent",
        "terseLabel": "Liability related to the sale of future royalties, net"
       }
      }
     },
     "localname": "RoyaltyGuaranteesCommitmentsAmountNoncurrent",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_RoyaltyPurchaseAgreementAccretionExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Agreement, Accretion Expense",
        "label": "Royalty Purchase Agreement, Accretion Expense",
        "terseLabel": "Imputed interest expense recognized"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementAccretionExpense",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesLiabilityDuetoNonCashTransactionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_RoyaltyPurchaseAgreementContingentConsiderationCashProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Agreement, Contingent Consideration, Cash Proceeds",
        "label": "Royalty Purchase Agreement, Contingent Consideration, Cash Proceeds",
        "terseLabel": "Cash proceeds from royalty purchase agreement"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementContingentConsiderationCashProceeds",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_RoyaltyPurchaseAgreementInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Agreement, Interest Rate",
        "label": "Royalty Purchase Agreement, Interest Rate",
        "terseLabel": "Non-cash interest rate"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementInterestRate",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cris_RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Agreement, Issuance Costs Capitalized, Amortization",
        "label": "Royalty Purchase Agreement, Issuance Costs Capitalized, Amortization",
        "terseLabel": "Amortization of capitalized issuance costs"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesLiabilityDuetoNonCashTransactionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_RoyaltyPurchaseAgreementLiabilityCarryingValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Agreement, Liability, Carrying Value",
        "label": "Royalty Purchase Agreement, Liability, Carrying Value",
        "periodEndLabel": "Carrying value of liability related to the sale of future royalties ending balance",
        "periodStartLabel": "Carrying value of liability related to the sale of future royalties beginning balance"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementLiabilityCarryingValue",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesLiabilityDuetoNonCashTransactionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_RoyaltyPurchaseAgreementTermsPurchaserDefaultOptionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Agreement, Terms, Purchaser Default Option Period",
        "label": "Royalty Purchase Agreement, Terms, Purchaser Default Option Period",
        "terseLabel": "Purchaser default option period"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementTermsPurchaserDefaultOptionPeriod",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cris_RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Agreement, Terms, Royalty Amount Threshold",
        "label": "Royalty Purchase Agreement, Terms, Royalty Amount Threshold",
        "terseLabel": "Royalty amount threshold"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementTermsRoyaltyAmountThreshold",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Agreement, Transaction Fees And Closing Costs",
        "label": "Royalty Purchase Agreement, Transaction Fees And Closing Costs",
        "terseLabel": "Transaction fees"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_RoyaltyRatePercentageOfSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Rate, Percentage Of Sales",
        "label": "Royalty Rate, Percentage Of Sales",
        "terseLabel": "Royalty rate, percentage of sales (percent)"
       }
      }
     },
     "localname": "RoyaltyRatePercentageOfSales",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cris_SaleOfStockIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Issuance Costs",
        "label": "Sale Of Stock, Issuance Costs",
        "terseLabel": "Other estimated offering expenses payable expense"
       }
      }
     },
     "localname": "SaleOfStockIssuanceCosts",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/CommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_ShareBasedCompensationPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation, number of plans.",
        "label": "Share Based Compensation Plans",
        "terseLabel": "Number of shareholder-approved, share-based compensation plans"
       }
      }
     },
     "localname": "ShareBasedCompensationPlans",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cris_SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Shares Removed From Available Share Pool, Per Share",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Shares Removed From Available Share Pool, Per Share",
        "terseLabel": "Shares removed from pool (in shares per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardSharesRemovedFromAvailableSharePoolPerShare",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cris_SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period",
        "terseLabel": "Stock plan offering period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardStockPlanOfferingPeriod",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cris_ShortTermInvestmentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short Term Investments, Fair Value Disclosure",
        "label": "Short Term Investments, Fair Value Disclosure",
        "terseLabel": "Corporate commercial paper, bonds and notes"
       }
      }
     },
     "localname": "ShortTermInvestmentsFairValueDisclosure",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_SiliconValleyBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Silicon Valley Bank [Member]",
        "label": "Silicon Valley Bank [Member]",
        "terseLabel": "Silicon Valley Bank"
       }
      }
     },
     "localname": "SiliconValleyBankMember",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cris_StockAvailableForFuturePurchaseUnderEmployeeStockPurchasePlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock available for future purchase under employee stock purchase plans.",
        "label": "Stock Available For Future Purchase Under Employee Stock Purchase Plans",
        "terseLabel": "Stock available under ESPPs (in shares)"
       }
      }
     },
     "localname": "StockAvailableForFuturePurchaseUnderEmployeeStockPurchasePlans",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cris_StockOptionsorStockAppreciationRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options, or Stock Appreciation Rights [Member]",
        "label": "Stock Options, or Stock Appreciation Rights [Member]",
        "terseLabel": "Stock Options, or Stock Appreciation Rights"
       }
      }
     },
     "localname": "StockOptionsorStockAppreciationRightsMember",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cris_StockPurchaseProgramAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Program, Authorized Amount",
        "label": "Stock Purchase Program, Authorized Amount",
        "terseLabel": "Authorized amount of stock repurchase"
       }
      }
     },
     "localname": "StockPurchaseProgramAuthorizedAmount",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/CommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_StockPurchaseProgramCommitmentFeeShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Program, Commitment Fee, Shares",
        "label": "Stock Purchase Program, Commitment Fee, Shares",
        "terseLabel": "Commitment fee (in shares)"
       }
      }
     },
     "localname": "StockPurchaseProgramCommitmentFeeShares",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/CommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cris_StockPurchaseProgramPricePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Program Price, Period",
        "label": "Stock Purchase Program Price, Period",
        "terseLabel": "Stock purchase program price, period"
       }
      }
     },
     "localname": "StockPurchaseProgramPricePeriod",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/CommonStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cris_StockPurchaseProgramRemainingAuthorizedPurchaseAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Program, Remaining Authorized Purchase Amount",
        "label": "Stock Purchase Program, Remaining Authorized Purchase Amount",
        "terseLabel": "Remaining authorized stock purchase amount"
       }
      }
     },
     "localname": "StockPurchaseProgramRemainingAuthorizedPurchaseAmount",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/CommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_StockPurchaseProgramTermsSharesAuthorizedPerDay": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Program, Terms, Shares Authorized Per Day",
        "label": "Stock Purchase Program, Terms, Shares Authorized Per Day",
        "terseLabel": "Stock purchase program, authorized per day (in shares)"
       }
      }
     },
     "localname": "StockPurchaseProgramTermsSharesAuthorizedPerDay",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/CommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cris_StockPurchaseProgramTermsSharesAuthorizedPerDayAfterMutualAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Program, Terms, Shares Authorized Per Day, After Mutual Agreement",
        "label": "Stock Purchase Program, Terms, Shares Authorized Per Day, After Mutual Agreement",
        "terseLabel": "Stock purchase program, authorized per day, after mutual agreement (in shares)"
       }
      }
     },
     "localname": "StockPurchaseProgramTermsSharesAuthorizedPerDayAfterMutualAgreement",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/CommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cris_StockSaleAgreementAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sale Agreement, Authorized Amount",
        "label": "Stock Sale Agreement, Authorized Amount",
        "terseLabel": "Common stock authorized"
       }
      }
     },
     "localname": "StockSaleAgreementAuthorizedAmount",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/CommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_StockSaleAgreementCompensationFeePercentageOfGrossProceeds": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sale Agreement, Compensation Fee, Percentage Of Gross Proceeds",
        "label": "Stock Sale Agreement, Compensation Fee, Percentage Of Gross Proceeds",
        "terseLabel": "Compensation fee"
       }
      }
     },
     "localname": "StockSaleAgreementCompensationFeePercentageOfGrossProceeds",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/CommonStockDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cris_StockSaleAgreementRemainingAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sale Agreement, Remaining Authorized Amount",
        "label": "Stock Sale Agreement, Remaining Authorized Amount",
        "terseLabel": "Sale of stock remaining authorized amount"
       }
      }
     },
     "localname": "StockSaleAgreementRemainingAuthorizedAmount",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/CommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cris_ThirdandFourthProgramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third and Fourth Programs [Member]",
        "label": "Third and Fourth Programs [Member]",
        "terseLabel": "Programs Three and Four"
       }
      }
     },
     "localname": "ThirdandFourthProgramsMember",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cris_TwoThousandAndTenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand And Ten Plan [Member]",
        "label": "Two Thousand And Ten Plan [Member]",
        "terseLabel": "2010 Plan"
       }
      }
     },
     "localname": "TwoThousandAndTenPlanMember",
     "nsuri": "http://www.curis.com/20210930",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.curis.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r301",
      "r413",
      "r414",
      "r417",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r45",
      "r47",
      "r98",
      "r99",
      "r218",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.curis.com/role/CommonStockDetails",
      "http://www.curis.com/role/DebtDetails",
      "http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
      "http://www.curis.com/role/RelatedPartyTransactionsDetails",
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r166",
      "r287",
      "r289",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r217",
      "r255",
      "r303",
      "r304",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r453",
      "r501",
      "r504",
      "r534",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails",
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r217",
      "r255",
      "r303",
      "r304",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r453",
      "r501",
      "r504",
      "r534",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails",
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r166",
      "r287",
      "r289",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OfficerMember": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officer [Member]",
        "terseLabel": "Officer"
       }
      }
     },
     "localname": "OfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r164",
      "r287",
      "r288",
      "r454",
      "r500",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r164",
      "r287",
      "r288",
      "r454",
      "r500",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r217",
      "r255",
      "r293",
      "r303",
      "r304",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r453",
      "r501",
      "r504",
      "r534",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails",
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r217",
      "r255",
      "r293",
      "r303",
      "r304",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r453",
      "r501",
      "r504",
      "r534",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails",
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r46",
      "r47",
      "r98",
      "r99",
      "r218",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.curis.com/role/CommonStockDetails",
      "http://www.curis.com/role/DebtDetails",
      "http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
      "http://www.curis.com/role/RelatedPartyTransactionsDetails",
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r167",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r34",
      "r422"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r22",
      "r168",
      "r169"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Net amortization of premiums and discounts on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.curis.com/role/AccruedLiabilitiesSummaryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/AccruedLiabilitiesSummaryDetails",
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r478",
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.",
        "label": "Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r37"
     ],
     "calculation": {
      "http://www.curis.com/role/AccruedLiabilitiesSummaryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional and legal fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/AccruedLiabilitiesSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r37"
     ],
     "calculation": {
      "http://www.curis.com/role/AccruedLiabilitiesSummaryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "terseLabel": "Compensation and related costs"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/AccruedLiabilitiesSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r51",
      "r52",
      "r53",
      "r491",
      "r509",
      "r510"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r50",
      "r53",
      "r59",
      "r60",
      "r61",
      "r101",
      "r102",
      "r103",
      "r356",
      "r505",
      "r506",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r337",
      "r338",
      "r339",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r305",
      "r307",
      "r343",
      "r344"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Recognition of stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r269",
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "negatedTerseLabel": "Fees for issuance of shares in connection with Capital on Demand\u2122 Sales Agreement"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Total adjustments"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r307",
      "r333",
      "r342"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/LossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/LossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/LossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/LossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r97",
      "r147",
      "r156",
      "r162",
      "r183",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r354",
      "r357",
      "r375",
      "r420",
      "r422",
      "r470",
      "r487"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r44",
      "r97",
      "r183",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r354",
      "r357",
      "r375",
      "r420",
      "r422"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r364"
     ],
     "calculation": {
      "http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r175"
     ],
     "calculation": {
      "http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r172",
      "r190"
     ],
     "calculation": {
      "http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r171",
      "r173",
      "r190",
      "r476"
     ],
     "calculation": {
      "http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r308",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CommonStockDetails",
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails",
      "http://www.curis.com/role/StockPlansandStockBasedCompensationRestrictedStockAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r31",
      "r85"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r11",
      "r86",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash Equivalents, Restricted Cash, and Investments"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents, and investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r79",
      "r85",
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash and cash equivalents and restricted cash, beginning of period",
        "terseLabel": "Cash and cash equivalents, restricted cash and restricted cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.curis.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r79",
      "r376"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r350",
      "r351",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Research and Development Collaborations"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r101",
      "r102",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.curis.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.curis.com/role/CommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21",
      "r422"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value\u2014227,812,500 shares authorized; 91,609,165 shares issued and outstanding at September 30, 2021; 151,875,000 shares authorized; 91,502,461 shares issued and outstanding at December 31, 2020",
        "verboseLabel": "Value of shares of common stock issued"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.curis.com/role/CommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r55",
      "r57",
      "r58",
      "r63",
      "r480",
      "r498"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r137",
      "r138",
      "r166",
      "r373",
      "r374",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r137",
      "r138",
      "r166",
      "r373",
      "r374",
      "r512",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r137",
      "r138",
      "r166",
      "r373",
      "r374",
      "r512",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r137",
      "r138",
      "r166",
      "r373",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "verboseLabel": "Concentration risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r137",
      "r138",
      "r166",
      "r373",
      "r374",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r294",
      "r302",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "verboseLabel": "Corporate Debt Securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r136",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r93",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r231",
      "r238",
      "r239",
      "r241",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r16",
      "r18",
      "r19",
      "r96",
      "r100",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r221",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r243",
      "r244",
      "r245",
      "r246",
      "r385",
      "r471",
      "r472",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r40",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Unsecured loan interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r41",
      "r96",
      "r100",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r221",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r243",
      "r244",
      "r245",
      "r246",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r41",
      "r96",
      "r100",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r221",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r240",
      "r243",
      "r244",
      "r245",
      "r246",
      "r270",
      "r273",
      "r274",
      "r275",
      "r383",
      "r384",
      "r385",
      "r386",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]",
        "terseLabel": "Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails",
      "http://www.curis.com/role/StockPlansandStockBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r83",
      "r197"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Plans and Stock Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r308",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r64",
      "r106",
      "r107",
      "r109",
      "r110",
      "r111",
      "r115",
      "r117",
      "r119",
      "r120",
      "r121",
      "r125",
      "r126",
      "r362",
      "r363",
      "r481",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share (basic ) (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r64",
      "r106",
      "r107",
      "r109",
      "r110",
      "r111",
      "r117",
      "r119",
      "r120",
      "r121",
      "r125",
      "r126",
      "r362",
      "r363",
      "r481",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share (diluted) (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/LossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost, net of estimated forfeitures"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation cost, weighted average period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options Outstanding"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/LossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r59",
      "r60",
      "r61",
      "r101",
      "r102",
      "r103",
      "r105",
      "r112",
      "r114",
      "r128",
      "r184",
      "r269",
      "r276",
      "r337",
      "r338",
      "r339",
      "r348",
      "r349",
      "r361",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r505",
      "r506",
      "r507",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]",
        "terseLabel": "Error Corrections and Prior Period Adjustments Restatement [Line Items]"
       }
      }
     },
     "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r364",
      "r365",
      "r366",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Financial Assets or Liabilities Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/FairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r229",
      "r243",
      "r244",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r302",
      "r365",
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r364",
      "r365",
      "r367",
      "r368",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r229",
      "r294",
      "r295",
      "r300",
      "r302",
      "r365",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted\u00a0Prices\u00a0in Active Markets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r229",
      "r243",
      "r244",
      "r294",
      "r295",
      "r300",
      "r302",
      "r365",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Other\u00a0Observable Inputs\u00a0(Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r229",
      "r243",
      "r244",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r302",
      "r365",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Unobservable Inputs\u00a0(Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.",
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/FairValueofFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r229",
      "r243",
      "r244",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r302",
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r369",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r176",
      "r177",
      "r180",
      "r181",
      "r182",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r191",
      "r192",
      "r193",
      "r194",
      "r240",
      "r267",
      "r360",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails",
      "http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r83",
      "r247",
      "r248"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Gain on forgiveness of PPP Loan",
        "verboseLabel": "Gain on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.curis.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r195",
      "r196",
      "r422",
      "r469"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r199",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails",
      "http://www.curis.com/role/StockPlansandStockBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails",
      "http://www.curis.com/role/StockPlansandStockBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r78",
      "r80",
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r70",
      "r146"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Fair Value Disclosure [Abstract]",
        "terseLabel": "Long-term investments:"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r179",
      "r467",
      "r482",
      "r530",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r396"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Lease obligations"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Lease"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/Lease"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r36",
      "r97",
      "r157",
      "r183",
      "r203",
      "r204",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r355",
      "r357",
      "r358",
      "r375",
      "r420",
      "r421"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r28",
      "r97",
      "r183",
      "r375",
      "r422",
      "r473",
      "r493"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r39",
      "r97",
      "r183",
      "r203",
      "r204",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r355",
      "r357",
      "r358",
      "r375",
      "r420",
      "r421",
      "r422"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r19",
      "r228",
      "r242",
      "r243",
      "r244",
      "r472",
      "r489"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Unsecured loan"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Current portion long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTerm": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Long-term Debt, Term",
        "terseLabel": "Unsecured loan term"
       }
      }
     },
     "localname": "LongTermDebtTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/DebtDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r41",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized gain (loss) on marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r131",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/NatureofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r79",
      "r81",
      "r84"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Cash used in operations",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.curis.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r54",
      "r56",
      "r61",
      "r62",
      "r84",
      "r97",
      "r104",
      "r106",
      "r107",
      "r109",
      "r110",
      "r113",
      "r114",
      "r118",
      "r147",
      "r155",
      "r158",
      "r161",
      "r163",
      "r183",
      "r203",
      "r204",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r363",
      "r375",
      "r479",
      "r497"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.curis.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonmonetaryTransactionByTypeTable": {
     "auth_ref": [
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transactions involving exchanges with other entities that involve principally nonmonetary assets or liabilities or relate to a transfer of nonmonetary assets for which the Entity receives no assets in return.",
        "label": "Nonmonetary Transaction, by Type [Table]",
        "terseLabel": "Nonmonetary Transaction, by Type [Table]"
       }
      }
     },
     "localname": "NonmonetaryTransactionByTypeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonmonetaryTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Nonmonetary Transaction [Line Items]",
        "terseLabel": "Nonmonetary Transaction [Line Items]"
       }
      }
     },
     "localname": "NonmonetaryTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonmonetaryTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonmonetary Transactions [Abstract]",
        "terseLabel": "Nonmonetary Transactions [Abstract]"
       }
      }
     },
     "localname": "NonmonetaryTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonmonetaryTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r407",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for exchanges with other entities that involve principally nonmonetary assets or liabilities or relate to a transfer of nonmonetary assets for which the entity receives no assets in return.",
        "label": "Nonmonetary Transactions Disclosure [Text Block]",
        "terseLabel": "Liability Related to the Sale of Future Royalties"
       }
      }
     },
     "localname": "NonmonetaryTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyalties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other expense:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r147",
      "r155",
      "r158",
      "r161",
      "r163"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r389"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease, expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r388"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease, liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r390",
      "r393"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r387"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.curis.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r395",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/LeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r37"
     ],
     "calculation": {
      "http://www.curis.com/role/AccruedLiabilitiesSummaryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/AccruedLiabilitiesSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r48",
      "r49",
      "r51"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized gain (loss) on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]",
        "terseLabel": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other liabilities.",
        "label": "Other Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/AccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLongTermInvestmentsMember": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term investments classified as other.",
        "label": "Other Long-term Investments [Member]",
        "terseLabel": "Corporate bonds and notes\u2014long-term"
       }
      }
     },
     "localname": "OtherLongTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1": {
     "auth_ref": [
      "r88",
      "r89",
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the noncash (or part noncash) consideration received in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Other Significant Noncash Transaction, Value of Consideration Received",
        "terseLabel": "Waived payment of milestone and other payments (up to)"
       }
      }
     },
     "localname": "OtherSignificantNoncashTransactionValueOfConsiderationReceived1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payments of stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedTerseLabel": "Purchase of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r308",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r29",
      "r30"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrentAndNoncurrent": {
     "auth_ref": [
      "r477",
      "r495"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.",
        "label": "Prepaid Expense",
        "terseLabel": "Prepaid balance"
       }
      }
     },
     "localname": "PrepaidExpenseCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.curis.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds of Aspire Capital Agreement, net of issuance costs",
        "verboseLabel": "Proceeds of aspire capital agreement, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.curis.com/role/CommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from PPP Loan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from direct offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r75",
      "r336"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Proceeds from issuance of common stock under the Company's share-based compensation plan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Sales and maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r513",
      "r514"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional Fees",
        "terseLabel": "Fees payable expenses"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r198",
      "r422",
      "r483",
      "r494"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r301",
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r413",
      "r417"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Amount paid for transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r301",
      "r413",
      "r414",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Purchases from Related Party",
        "terseLabel": "Purchases from related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r301",
      "r413",
      "r417",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r411",
      "r412",
      "r414",
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expenses",
        "verboseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails",
      "http://www.curis.com/role/StockPlansandStockBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r91",
      "r468",
      "r490"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r7",
      "r14",
      "r91",
      "r531"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash, long-term"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails",
      "http://www.curis.com/role/StockPlansandStockBasedCompensationRestrictedStockAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r24",
      "r276",
      "r340",
      "r422",
      "r492",
      "r508",
      "r510"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.curis.com/role/NatureofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r101",
      "r102",
      "r103",
      "r105",
      "r112",
      "r114",
      "r184",
      "r337",
      "r338",
      "r339",
      "r348",
      "r349",
      "r361",
      "r505",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r144",
      "r145",
      "r154",
      "r159",
      "r160",
      "r164",
      "r165",
      "r166",
      "r286",
      "r287",
      "r454"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues, net"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues, net:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r394",
      "r397"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Cost of royalties"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Sale of stock, consideration received"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.curis.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "verboseLabel": "Shares of common stock sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r137",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/AccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/LossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable": {
     "auth_ref": [
      "r291",
      "r292",
      "r308",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule, table or text reflecting equity-based arrangements (such as stock or unit options and stock or unit awards) with individual employees, which are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain equity-based awards at future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares or units issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Schedule of Deferred Compensation Arrangement with Individual, Share-based Payments [Table]",
        "terseLabel": "Schedule of Deferred Compensation Arrangement with Individual, Share-based Payments [Table]"
       }
      }
     },
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails",
      "http://www.curis.com/role/StockPlansandStockBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r307",
      "r332",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r111",
      "r112",
      "r113",
      "r114",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments.",
        "label": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]",
        "terseLabel": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]"
       }
      }
     },
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfOtherSignificantNoncashTransactionsTextBlock": {
     "auth_ref": [
      "r88",
      "r89",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of noncash investing and financing activities, classified as other.",
        "label": "Schedule of Other Significant Noncash Transactions [Table Text Block]",
        "terseLabel": "Schedule of Liability Due to Non-Cash Transaction"
       }
      }
     },
     "localname": "ScheduleOfOtherSignificantNoncashTransactionsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r415",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r308",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationRestrictedStockAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Award Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Key Assumptions for Options Awarded"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r42",
      "r94",
      "r129",
      "r130",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r262",
      "r267",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).",
        "label": "Schedule of Unrealized Loss on Investments [Table Text Block]",
        "terseLabel": "Schedule of Amortized Cost of Unrealized Gains and Losses and Fair Value of Investments"
       }
      }
     },
     "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationRestrictedStockAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationRestrictedStockAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Awarded (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails",
      "http://www.curis.com/role/StockPlansandStockBasedCompensationRestrictedStockAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Awarded (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationRestrictedStockAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Outstanding shares (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails",
      "http://www.curis.com/role/StockPlansandStockBasedCompensationRestrictedStockAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationRestrictedStockAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationRestrictedStockAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationRestrictedStockAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationRestrictedStockAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r324"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationRestrictedStockAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationKeyAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk -free Interest rate (maximum)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationKeyAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk -free Interest rate (minimum)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationKeyAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationRestrictedStockAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CommonStockDetails",
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r324"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic values of employee stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Canceled/Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of options granted (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails",
      "http://www.curis.com/role/StockPlansandStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair values of stock options (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r335"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r315",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price\u00a0per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Vested and unvested expected to vest at end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r325"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and unvested expected to vest at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and unvested expected to vest at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r306",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CommonStockDetails",
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails",
      "http://www.curis.com/role/StockPlansandStockBasedCompensationRestrictedStockAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled/Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Percentage of vested shares which are exercisable under stock option"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r329",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationKeyAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r335"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and unvested expected to vest at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r15",
      "r422",
      "r471",
      "r488"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-term Debt",
        "terseLabel": "Short-term debt"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r17",
      "r474",
      "r475",
      "r486"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term Investments [Abstract]",
        "terseLabel": "Short-term investments:"
       }
      }
     },
     "localname": "ShortTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r526",
      "r527",
      "r528",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Corporate bonds and notes\u2014short-term"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r43",
      "r59",
      "r60",
      "r61",
      "r101",
      "r102",
      "r103",
      "r105",
      "r112",
      "r114",
      "r128",
      "r184",
      "r269",
      "r276",
      "r337",
      "r338",
      "r339",
      "r348",
      "r349",
      "r361",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r505",
      "r506",
      "r507",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r128",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r20",
      "r21",
      "r269",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Stock issued under employee stock purchase plans (in shares)",
        "verboseLabel": "Issuance of stock under Employee Stock Purchase Plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r269",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of stock (in shares)",
        "verboseLabel": "Common stock issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.curis.com/role/CommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Issuance of stock under Employee Stock Purchase Plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r21",
      "r269",
      "r276",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.curis.com/role/StockPlansandStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan": {
     "auth_ref": [
      "r20",
      "r21",
      "r269",
      "r276",
      "r345"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Value, Employee Stock Ownership Plan",
        "terseLabel": "Issuance of stock under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r20",
      "r21",
      "r269",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of stock under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r269",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r43",
      "r269",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r26",
      "r27",
      "r97",
      "r170",
      "r183",
      "r375",
      "r422"
     ],
     "calculation": {
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r95",
      "r254",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.curis.com/role/CommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow data:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r176",
      "r177",
      "r180",
      "r181",
      "r182",
      "r240",
      "r267",
      "r360",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/FairValueofFinancialInstrumentsSummaryDetails",
      "http://www.curis.com/role/InvestmentsAmortizedCostofUnrealizedGainsandLossesandFairValueofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/ResearchandDevelopmentCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r139",
      "r140",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates and Assumptions"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/StockPlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r116",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares (diluted) (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r115",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares (basic) (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.curis.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409961&loc=d3e20517-108367"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "40",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244457&loc=d3e16649-113920"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "http://asc.fasb.org/topic&trid=2155941"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29470-108402"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29470-108402"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29470-108402"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29470-108402"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29502-108402"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29515-108402"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29515-108402"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29515-108402"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=123385986&loc=d3e32049-108421"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=123385986&loc=d3e32049-108421"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=6457341&loc=d3e32102-108422"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "845",
   "URI": "http://asc.fasb.org/topic&trid=2127423"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.10)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r536": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r537": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r538": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r539": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r540": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r541": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r542": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r543": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r544": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r545": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r546": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r547": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r548": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r549": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>63
<FILENAME>0001108205-21-000012-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001108205-21-000012-xbrl.zip
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MX@487MPR3(/&GB J 7:A.<=V\8">?.Q@\J@J1[RR2 B4^LK GU@S882E@HC
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MD''MB2%4(,4=8P);L#BB#I)BR[VBY9Z;=&#-W)<\3$@I83VV30%2.L^I95&
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M]YQ2"RI=NG![\]@2TN\TGB=_4#R5D5$9B'3",99DE'>6.DDQ$S10O$!<N@&
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M,B>$1%($:=)I9<BE-CP*-&S03%JC^:\DC^<%_?%)?J(58!PH#P$L9&DU0E&
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ML;/_K\W=FSLS?T >WD?/"\%M<V6+X/4Y9[M?1%6IE1?)+VN\,J[?RY<6R.+
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M'0GN WSMO[(.Z2P1UQ[XX4$?J7ZAG77*XH:R,.SR]J+!>XO3X,KC/,J3P=L
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M.4M$9T"?5CJT= *RSV!%'_=ZOO(8C@;MQ)^7Z;#LTE$H':G3=*XC:,LE>#,
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MT(--D@(R3<"A2\ H38F*)*WV:^MMJAVO.&U?B57%Z8/@="( :;4PU'D$E44
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MS2Q+$I@1AGG#A(YR;?WZ3+<9COU58F\QL<\ASE*QO% LCZ,L+*$T2FKP*2A
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M4Y5Q=YKR!#0I+;QP41FYMHZTR\G,!SYKDFDIC,,JIK;0\2-'8>K,I'F0[40
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M)#)/!1KDQ/L,7:R875W,2JFC4TA3#!HE<\9%XD29K."8H/PN3LCLRK@">A9
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MFJF44#-I*9..8DS6Q*!)TUI@]HJ6VC)N#I0TV3(N29?M=NL@49<)R<@(1I(
MV6;W@6O%C2PMXV17:-;E\YX'LA*CDI[T,*0G,^[H?OQ6&]#-G[S&13PI:(9Y
MU2%8*@!I#&"MH1"\M=DDQA#+R&(NYSSFO;)66_!;6>L[K.5%DIHPQW7DZ#,N
MD$A,C 81@TQ,W\Y:M:/! BEM7,9DD#O/N04;1;;'J'=@E5# HPS908PZ45[:
MV<DN$3.?EU@F6GN( 'ZERE6GRJER&$YS%SWW"3G&0 T)BB4BC3,9=XBW<V5M
M _,8I#G.7T@9&;$F09*,9M)$ I9Y U;([,%:QJT637,\)KO2D+G- 6XW8U9V
M6W5VFX+<.#?:&AY0!8:"D$QVUIE  EIB;21W,P1KJ[T'C,E-M-I+CBIGJ06#
M 0&U3:"#)H"6VR24%S[0>;?:JYQ6.:T%=SV-Q19X<,IEXG)&(7/H++-!>D$4
M22*,AD)4BZU-%#?.A!J>Y4^]!FI%MMEBU)#-; 2B98H2.>$VNVI(NDS.D@I=
M"+D]A6KB*\T""A(ZS?3ISB"^ZPU/XR"&3N@-HB\M 5(LE?;S;!"PO-4=TV51
MHQ):"69\5 95TLZBLEXR9C%Y5/&BO@,OZSLD)[5!0+MH[O-$=I4)IY)-"ASZ
M!)@8 <V- ^%M-L.MHHR8[)AB-^_!\K=%#5!J[=:</; 9H5T[!"P$N^/DHF/&
MB40D)&Y-]L%"!*>8 ,G16HDR!MU@MX)VA4$K8AE*P!GAFJ'CP5CKJ$PJ>I*(
M8>P.H*V'%1\7T>/<&K&.<&4=*),T(+<6G*8&HO+*Q."R/$N86'1UJUJ1U1,P
MM8!^[J)_W,]8S>TRU<B)Q!Q-UJ$TF'T#$WF2W%.CJ%+2I:I76J]7)H-9VBJ2
M),W>G319LT0=H53:@$04)E II:&-9C&R39KE*13W/^0HBN7MUU';JE0Q53$]
M@N+/@BSG] CJH+/BI\YI'K7-/B9:9;R;.@I4&U^WR"S8F^Q(1UW"1"@'(GTQ
M"D0"EWU,B#81(;51*K&U=:'G5<;91KS7?G1/ENK;\AFKN5T6ZVM6E=-FE7/%
M$\U"C2$ER%)D9?X1R\Z.<I"4XC2B9=2)MBF=IUP^L77\\>CD<XR=)D;3^>UL
MX \S:CJ_'=FG-AYQNDJ)@%:F%*-2S")7I9VD428PA9IQ+^PB*R7V3@_CH%9)
M3,-:^Q-5$D1GCXAR 0:5 !1<0O:$&"C*)8I$(DMV;1UI5VC>HNA9#8H_R1S*
M:HKI,4,8WTI/7.K'YC67VK$HQVHD3D>WX[@$8J#YKX.02K>W;!2"MLR "I&S
MZ AR+M?6V<RM/EJ,X9H"K_1=Q53%U&(M._>H3=6RBW!J)D(QE%H=2H<_0ED"
MI,:""XJ"BX9YS:R.3+5,SSZ%@H"M3W'@>\.)2,S)Q[+L=7+ELH1;FB?W1D*[
ME&9M 3C5@-Z#C=.)X\9>$"ECHB"),X J&; ^"0B:9J82)@DKF_(E*MHTQ*-F
MBIYD8G$UQ=36 ,RWR;::A7<CV]TQV1I,+C!T8$GI[>"2!ZUM!*I$D(H0Q17+
M9*M7F&AK54@E[RJF*J86Z]B%AE^JCIV+0W.P<^G4O(TT2D-2!!=*&TWO$)P+
M!)C//BR7Y4BO:)F2?0I5,'4D88W._W_VWKTIBF3K%_XJ'9QSXIF)()G*JLRJ
M3&>_1C"BL]E'P!&<>?4?(V\%I4T7NR\J?OJS5F;=^H*  C903SS;T>[JK+RL
M]<MU7_TQ]<?4'U/OC;[UXG":YTZGB=9",!UG@DJ91]SESL1.B*N4;NA;9=VM
M#/=\>M#:26PJG12"$FJ$($PQ;$\8IX2J.':92SBW0/GI9A8M2W%]4\*U9>$'
MA]X/\YBN@[0WH"OW2'O72-O5EJET',[%$DHC@%H**K-(X;1XG";6,9WGG*T5
MU#Z&.(7_S$9ND$1]4\(?B%K0E#*NG# @]+'4*6ECIVB>QTK&3O*Z_<T/!BOT
M30EO I)VNQ$)(J(:H$<32;&C@Y4)T8EC1$8F$;EU0F;1QE,>;::)W(S83=GQ
M^AKH:P:"C[,&^G4:0G\7PO5M"6\#OKJAGX(JGDEB*,->S\X1Z1@G(G$933*>
MPOD@?/6-"7O<>IRXQ7.K6>)B"A<]8TDNE,TC%TDF=!Z+.+H8M_J.#7<):IW
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ME]K?*Y=K$6V^;<S8>>=[AYP.\IV:?K9']E5%6+NC3ZZ*DNNA]5K0^KPK%S'
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M,I(I22,+V^ILJJ(H*.S%:.;L-FK94DOFI..,1S'+N17,\EAIJ@0PCZ)J8^!
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M8;1TW5U,#:V<Y,D!QO/W6QC3#P.L?>+,Q[.R&$UK\6IR.<4$]?1R@OF6PKI
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M'] DSXQ#NJ,[/1N6 <C&#92?.#7TG3( G#UV^F)L /]AKI,SAS4X\Z4T:"R
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M/+LW@YTY@^-Z/@Q[O-T:.";WKZ3B;HXFF6J157NTU<TUBDFK)]@JY\CZ^I=
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MT0)Q"N:F38FA)&'5DG+P]L/ED#> V0!F YBSAR*9D]QRAP.E7!-GL8N:*<G
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MS[I@H+C7#BYHO. <_ 6GO#*:2R<U%=S3A=ZUS7*NNYQ@"42.>9!8(T>%!4N
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M(A2-.'HIGSSM#Y:DXJQU8C_'RHV80,2:FPZ>%YV"41ODNC9;T'Z;=BX.HP6
M)C0A38U G(+UJ7E22-) O*(,2R&R67+#(>=Z.P]>3A+8OG]VHK@M.Y%N?':B
M;K(3Y_2T,^B#!,4S.[S<'\(#5.*V>1W<26><+0R?=*[>T(\?WHB]W2-QL/OF
MJOWRQ7'GY:O+]J?GN+W_]E-G]^.7@]W/9*GS]DG.#CXXAL_XWF[O<V>W??'Q
MPW/\\1/\%N[=>=G&G4\O/N_M_YTZN_!>/FU4PH G ?XBR>%#BI$)(I\I!&NP
MBBF&I2;N8&82!9LQ; :<6RH,U289N#\HO*2"+64J3LZ9W\X7 ;P#K,R6X8OS
M,U@)D+-+V[MGB_?;QS3_#$%Q*G6,)L+$6<\L5D9&:U+0 /_)7MMB7&Y49?.K
MG",X!'^=8F+F#_VSE_8,P'14S^M"S7+^ZK#^8%)S='H.URIIBT>P)Q?#?5PX
MN@>HV\O7?#W^SL[X.Y-2TI*\!V]4K<[AX>Q155 Z^?$S>]K-,<5V^2S_>*OU
MUU_/Y@MFZQL,1^,+SV_^HT%O6D8R^>Y\T5<^ BTGWZ/\S;I@JW[>/+8T')RT
M7L9^GA*8/?C1Z> LCQS&EJMB1B"9);/B^3!7>AW%;;A]WU<T)[W+:9IB1I&\
M7]4U,S?,TM;":IR/*@=I.N@ZE1/L[%"&G0-RW7Y)D"P'^F \U093[+?BE^ZH
M.M\M!;=Y//\3X<+'S^Q$E2Y;K^WPK ^SL]5Z]>H53/7VZ^WMNV31;9:4[XQ:
MYZ>P9"".H,6C;HAU!?(XU#V1VWH6QX)=B<!6SL(=+]2"U!1+$N9Z?FW6,2VC
M8$J$%#R@"0<76VO#9-1,)0[(2LLF10QF99/*+Z[+DRBNZNMZ_5^ @-:C&8]V
M(DD;8V5^]SWKZOGE(3?*Y^QP)'A.I%.:(ATDSX1C26'/L!$Y/T;<%.?HY9+.
M<=[VV=0N:-6U<>"IS@O$!?RP!>LUR-6G!>%ZU38VAI;ST_S7_8/E#RM%UTG.
ML[(''E6OIGKT#%RSL> ]6N':VWU%#HT*T7 JD%8Z=Q>#?[(Q@6 ].%-4$9=
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MTL]>Z]+>=#\B[B0C2R0)+2SE2B;'M77"<^VXXQ[[6Z2#W2E\,TO+O3GL6#]
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M?2MMS/2!O\\=X"]6HY<2]$=D:_VVF0 U)M'92Q4?1 U8RVT!&F"Z'9@ZSV:
M24EA?& )Q<@HXL0P9"Q-""<NO&<"/'ORY*G<XFR9)7@I^O:KV%K5'7^4H?5
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M993[CUY 6.?-H</"4FL<LIYDKB[PC8Q@!EG"223)8JU=3G"YBX L\Q9LMUZ
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MFI8P/MP23:!P&N[+5D3Q0LM1POEIKJM;OMEV:V=R?M:[G!?E<F=PE[I'"X\
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MA/5",ZJI5P$,R2W-U9:FRYG'8\GIEJFMV@AF8[$V<B;@DT];2OURH3T8%TB
MN9#.>[U:[KK#F18$I^.>G#.,O]6]2B9>SM_K^MO+*P ORMHO$O5@(8VRW&%-
MN0O!\0"B:&)4S#A&K^D_3&^0M-=Y.-.[/5JI>L7VWASZE+G6,$<TYKA+P@II
M$@)R7%I#)+CGW#]Y*K;5,J5E*4TJ"[U5E?M-?-L%EP56?CW&<D8"4<R!L4BX
M"=@HY17S&G8R\%>QNP6$EGM/CYW1%^ [963)1 I[">3@'QCMZY[U&\4]^0-$
MH7V9J;B\BC"?"A&O">)"<*1IE" 4L#-)SITSF5E?FA5E#:UQO=I6RT40AMQR
M9LP0,$&6_$=IDWH^[L50BAQ'HQ((RW\/*@KPL<TSJ;A<E_+^ZP5H+?K)08KE
M(6PO$VX_8CEZD^5(22=,(@$%SB+*'&O(8H612/G@5"0C9"P)M;<0EU8G=O=V
M6>_LIRXZJ?#45-W!2;ULL:W2J:>F\/4]FP=1'0KF#/<Z4WOF!T3-_,+V9W?,
M]<<I""7D7_7P9A^]"ME*FLF/JJAUW;YUXL.73D_3@0YF?!1349[]JEYWV&2O
M>^88$[?>%H$H<KW;'>;HUP8ZX U+RR)+"VE86C9C+-^1I>76S/B%3'I#C"8P
M"AV2XT0FXUS" OX_\&!3<C=FTF]29&MU-O529L%T"Y_ZBO/I&>-3@NY<-D#F
M#!GE?JA;<_O;E)5O2NXVY]-N522&PRF"A@I!QY9E:7@X]5?6CJUA@KEWGG/B
M&.?6ZJ"DPEXIXP,QR=?LL7+,'ON5F=I-;.UFN_-J!X,K&Y6 =<$2*0*N"V=<
M(>=41,& \R(3)Z!SN75<CJO=/[96AS3&<ES%-B:>\'VC'(E&+K52R5+-L1(V
MZ:1]P-0R!NZ86IWQWT0Y;A>-YY?MHT.+L6>)4T2<]>"22(X,P1Z%[-I2@3U)
MJK126(YRW![;6*MR6G(O0K+>",M-HBYB <B1;7GX6^!;@&-]S[2)>]PH')FD
M!]1-*J$)4H9*Q&7D2#NND0NI)(?%F!LB$'5;5Y<5H8\4*S@IV>M?8(G.,A79
M1@M,$\JH1.-5KN(T/B5AI4$^V9R\$0.RW$F4HA2>JR2DRY5 MV:GE2X9=:#]
M=*QW59K83-P+;)TB(F%U!&S3A:C*%)KN0&/$>989U!ZS)&7&&$(9#C0%A$D"
MXT1K )E,7ALYF"A8*Q&4O4OGJ"))\Q0 VTN9B-D4'M7G-V.FO$6QFQ#B3X-I
MTQZFM2$T%UQ;X!V8-<A+2\0^W&4X*F<_=XN[C5M4?ZL8V\JP7O6,A5.B,/KG
MQI:Y[5N=X 1J&(L+>7>ZM)\L !8W.0 VEW:R,H__ ?/T-\V9GN3IW^Q-/[.G
M>7*KH"W<-S/-<TW_LS1?<WFW-^7NS\WI0V;8>Q/ =Q%&@K?,N5;6""%H,%2I
M0 T7M5?39-A_HYWGB+5W#IW6Q%(14% N(:Y\0)H3BK3BT09FL<>P\[!5*?:M
MK\VN7Y%F'@M7R-3"695DOWH_F\FM7RNU?BD1>SZ5?G#>"QN93#^;Q5-S+N6\
MU2J4E?N45BD:'3L*]G];+WL#!ZC0+L/8&K>'K0W++[ 5%^6N'[HN>!C; ',/
MG=\;E'_'"SK^>FY?.ZPO63H!#L8M+4I#CP4NI,EFOB@UI\,N7'V<YS:F)5NY
M+(4\ZL:UJ493K] I2$&^:C%6>O9B=@9+N[KB^,+4]>/1X*SJ-39C_XQ^0H[4
M&^L0[EF",+<0V3I;K^# 9;!W'IP(A3GEU$0G0K36,3# $N-CU,?\ID;73<G!
M?2IF/^8NM=Q$GZARR$6?:V:Q1XYJ@@+3!'O".,])A@]><C G-HLY]$L)^M=6
M'OP410>_1#7 A-@]PV:_0L.<7[%8"3KUMJKFC4NY G.EU:$;2I%%84EOS5Z_
MHK/NUW1_N1(E$Z.?]\[&LSKSQ>W6SF2RI_</]6G-PI=OQ+MI\4>=\/AU1S]6
M$DYD3H]-B1.NK" D!0X6KC*14CO)+3)H_*+)D/W6N%=Q/"O/$@[@ZY,4+>)>
M&F2-]D@D[ 'T5!0F/GDJMZC16Y(O=Q&<.?^9 [@I1"QJQL,>#7R58#5' P\K
M46W2/CHDRMF4:$"Y13I(E#5(^RB1,5YBF832"B1*W\K)6WHC@07],\O&#$7)
M8Q8+UGESJ%3@5&,!9I7)2=-4(VVX14%BZR+F*4K^Y*FZM3]RW9%P<ERTE Z[
M> Q0[;3K2 Y/G 6JC$L @9(;0[2),3/_\J"$Y./T^7L)S-10?UV?A[^NO/FW
M\:1J/#@-QHR_\<B#,IW]-YGMV^)\V*]RAC4'">)8(^.#1\EI(0A5-#*7D\FV
MU8U!F84 3&FK<U+UR#GO5\9.Q7!0 GC92IHQFKJY&+;5&X#K#KO8/[;;*S7!
MOVC<.VURW)MM8Y4G:V=TVAW&28CW!5@>/VLT^T5TPW$KUIL#VHNUUXL)8K-Q
M[&LBV"OF;:M0R/PV_MW<%R8_'@? LEV7U6/]$+<PC# %CRBUXS$:RX7.R8!>
MA@AVIZV#'93>RPNX%F";(/<$3^&]G4.1&[>[A % A43_/WM?WMPVDN3[51C>
MV?=Z(EAJ%%  "MW['*&V[![/MB0?<COL?QR%0D&"31(:@K0L?_J7F54X>.D^
M*(D;.VZ1Q%%'5M[Y2^$KX*>>]AE(.Y!^2@H51Y=S<L^E?:WLK]RQ-N>H$-$&
MZBY>V4RA' &&7339;)D+=6S^,S45O'(Q2N,ZLZG>6?C?2F01UUB0P17HD"G0
M;N)EH!UXJ=1)7>;IU04REGP[] I\0?\&;Z+VZ><2:YV*5I39DZ/.;S_ , VE
M\@+C&3!,@YB)U%=,A<IC62Z]U(C B[, J7,>Q)MUV]-35X,Q!3BQ?W56^_^=
M<]XF(LZ)>P*30>:VHI-!&S89%$"GRGK!'YRXF3MX#MX#Y$LQ*9HT8IM^<#F[
M*S9^GO)(I=SS10P'!2N;/..E:9"')FG.B1_5YR3:V%VW<8Z^;@NPNS3W>.9S
MR6 ;#&C-,9PCL+98&LO(:"](.)=PCLYB\G50BS*Q:GY\:2?@->EBD_]]P]3Q
M\L?NX1>92C\#90P[*&DF>.(Q$/S81BGDVC>I!\8YV%3]* GZ2;2DGODB$GFK
MAU%.J]/.L1W@L!7*96K+6M/6?)G?)6&'O43IR.-::I#04B9QI(,DS'W-I9<I
MW]$9ORDX!AS#'SCJ;JRMTW[IC]/V$M=E:?M$C;/:-=WV+-^@V#;$^?H'L"Z3
MFSP20<X4V/9,A)$/"BH/69RE419(L/V3_-EST8_.090_6UU$>^92$)@F3OPP
MX2+,I(BR/$UX)"67F<GB./?]Y> *EQ1K'0'VMQI,UZ8MY7V0 M]_^R4*XL#X
M4C'C"P7:H!),F0BCM:F1(A,9CT*$7! KI9AE0FVJ!1D:G79H1 >+)B^9#F4Z
M* Z5(XS:HED1,G-E59=M7L&S./6EP?!_F,LT2H# 4A$F7AB&2=I8Q%<2B2N-
MC!=D:>$<7AGSW@WLR?*<77_O\(M06(8?@A4,1,8$G&R0A28'DDL2WY,B#./D
MV?-(1/TPY!>.AH$!,2?X*)*KF_7'J@>@4!N_?6^.)S98''@6SXW,C2:$'/"^
MDZ8*GDQYC9=3T77&9:B%U*'B(@H"%09:@Z#,399K/\ZOWXMP,1-EB7O[J;MA
MOK[U=\'0%:":@&G+XA#1V@7H)3+CB@586Y"H4$:Q;#J376AWHRCVXLC$2BBP
MD[7TPTB"(F02$:<J":\EH#:[>[G=U4DBA0P]II/8 QW&#YGT= 1,!1087\H@
MS",*6BSBPYP3"&NB%DT88IEP6IYG0NF!YT;NVWPBYR C-\D1?&F#L_#V'GE;
MJIY%+5YD7%M8N="Y[^S+X=_+R4T_D4#0)@@-Z 5QG":>EV/W>.YG(.GSS.GZ
M<>V3NV;'B4UBR840;;2WOZ.#_8/M ,9 22:P05+KE"6QB3&=VF<2U'>F8Q."
MB>8GJ8?)=?WHG")CJJVA$-W8',,7AAK;7BM+X)H4=$FUOD- <[V>;:/2_:44
M]-18YQP%(>2:C,'6DCIFL4PQ/5,IEJ8\ACTQ/-9A %L68_/P<^&1:G9T >9U
M:6XDP5[-P5Z509"(+(Q2^'^A=90;Z86>4G.>APTWNG-:^G:R=_(%]BCWN9\"
M#TH4HHM+EJ11R-)0A6D69T$>*9OR=K;/ZQ:XT34I:,.-;I\;A9B)$B6!44 \
MH*$+)C)/,\G]F"FE$F.T%HD!I2[:6DR7G.-&#RYJ='Y =QX['C^/\0E-E9Q-
M&+@<:[V:Q7IM!\D!3G+>+?O&C'?4Z9/EJ'M?86S;Z)&+E<ISEOK&9P*4)X36
M5<Q+L4$03[EO-+:7.]<U.YO*@KE]ZG3185(7/EM_QQ N24W3/XQ**8;3R10=
M*XW18NGL.J&$]:.Z;<Q^W*69-F?N"5/BMY^[AU^RD!-4#<MC3X)U$8-UG>F
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MB> )]W6D\TQ% 8\EUU_B9\^I6Q"*F!<H(D:3ZG]^5<^7[>0<O5O&'.=&@JA
M5241L0>*LN B%QGW@EB%PE_956?=\GXH.<RF]C!*(NEUS<'>2\M5[J</U(62
MW;8'@U+37_OY?#H;)KI53[@C%+:\S()<^2+@3'D>R%2>^0R(%5O0>Z',N0FY
M%UVP(]2Z"<%7UQ-U_6ZV#>6$(JBT=?DQ<GLLE["3DFYLVU'AR'H%O(:\UL6D
MLCFL]")W4]6KC%51FR0?7$%[WD94(J9L\S7X#V6TXX7[8.DKVYP.GX5#'9LC
MN U$:>^OLJKZSIV(HZB'UTF-Q:&@IG#%CE7ALGX[#ZF%50@_)E=K-G768SG\
M&(@'TL,*!AOQY($,-MGRY=6>>C]CO='F8/=:NC[?X&IYD?;RBMEF3LG#;-MU
M0/)CUXJ-ER@V;#NSKNBXB:YF#W1Y]E"\76)U'@^Y_U)@Y+B<PB.R:@$!=ADN
MQB7@.-9[TV>0A:XYX0NT^7M4"[>ZF=V56B ^JK79$-6-$-5CQ[=_9RJCQEB]
M!W9/9KZ;07E,L<_:GKJ]'F>/&4+H,;=XFX]=QR8(E$X\3PDAXT1B!446YDH'
M)M:).B=VS8)YOY1S-)ELN1_*><H>>G6P _+Y^PA^&^P-7Q6[.Z]_?MYY*SY]
MW#OZ_/'MR:>?NS\^??W[Z-/!6[[WYUNQ .3S\>7)WO"#_^GCZY/=KWO?]G:.
MCC[YKP:?=_[XNOOS5;'W\=71WLX'[_/.T6R7HDB%*0]%QE(O%$QD*F=IG FF
M0R#@.)1Y*N)GS\,P>"A=V#;-*S><[38XFV\\$Z>9)Z,(P9YYXH6)Q^,H@J_\
M*+8^=J_F;-Z-<[9@P]DNPME:B+*0*\%-GK$HPUH^X87 V01GN>\9E<I4)P&&
MM9,-9]MPMB?-V0*3B3036>R;4,1<*9,(I3T59#G767@NP%!PJ2RPC4)W&VR/
MMYT(5&0RF4B6& _8GI=JAMG03/AA:G28R3!%!+=^$"QFB&T8WX;Q/2'&E_ X
M25.9295J86*51)$"L]4(+KW SY53Z?A&I;M7WA8TO"V7*=9]:6;B4#.A(\.2
M5"5,::TS^!1Y*@1C5<B'PMD>>RNI/\W(C-6 _(DJ&Q:CHIJ,*2=QI4OQZ;:2
MF>-.(N/&CX6(-0^$D:F40:1!(_-3Z6LMSRL#V;C2[H([=3M=>@*DAA_ES-.!
M0MPRX$XFUBR0GA=D@>?',GGV/.'7UKLV_9_6]M#RQ!@5A[GGRQ#1DY-8!JGQ
MC39P9)/(WWB)UN+0MEZB+",S-V&)"',F@B@ ;2(5S",F"]J&C^UIQ?6-I<VA
M7=]#&T9)GG,5Z-@(S97T)=@!&?QMXC0.EJ=/;QP@:W6B6P=(DGM8#)"P-,U\
M)@PBY4K)69YQ3VLOBCPM$6LP].+-F7ZT9QKL>ITI$X2AYB+.8HDU$;[*>)"$
M>9K&%[#M;^],;Z3TA<YT:_BGL=(&U&C0JB/.A*]SD-<J9R;GW/="*=(H0Z>F
MOP2D\8DT2;R'XVBKF,ZKW+B_[FN/VD][$^OS6)A]'"N>)'Z6IDDHN)>E'G"+
MQ/-,F/$(]/@+N$HV"MQ],ON97MH![*;48<I2$Q@F1*19XF4YRR()8ERD@1!4
MCRXB<>_-Q1YFB&O#6S>\]>**M(@\P5429YZ(@DC%22!EH+7V4S_VY<:CM1;L
ML_5HF91'H2<"EB1YR@0P46"DGF 83O!,X/O<!,^>1_Z&>6Z8YX9YWG)JU56
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MQI_2:06#:GO;&?(\GJAQQ@9E^0V?7C7+TN_9<F^<CO4T$K/1DT[;O(Y(<JV
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MX7N1M8&NV358G$BM9=,[CM0@QZG!<WUZ+O'O055V [B@ 9ACA7QE*?7T>Z
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M[#V8X5#5LKF6NK['DY5,IM'EERAYQ%=:A8)4'!Q7PWFZROHL-Z(,1L+*H%
MW$GVYNZG%XT+$A[D]P[AZ7U[",GS.':LOG(P#.RHF,RNS!'0%8,-R98OW+_^
M_..O2^KXME)Y4<'MJ',\H97<)9-ZJ9P >@4KXXC,9_BI3.&H?*=0$8F<(H?7
MPHJCL<S(8B;3VT7CYYA]8RODG5.R5/EK-X<&!"8X9>)45(R,!<7P5GWJA)X=
MI2T:/E%CI.G>3&:*BU/1Z[=ZVUJ78]S:P6D?IU&'-SH;#8N?=JR..B3E'N ,
M@=::--_58&HU>A?VP2L+&V2:F>R-29X-,[Z(#K;->.PM8<.UQF6KOJT"A<?W
MS<Y?O#]K>K9G8=&$5%V7T5*M'::'NO>@0/:U*F+[OM2%L8P?-9166T>UB/QV
M>!^Y!S3%1_?*[]T#_(=J_(88;X7A78:NS17)VB[N%0DZW!#T%0DZ\.-S"1K)
MF.CYX/5NT/%_8>608:#&.P]G.=+6!SWKZKR8ESA9)]77T>XQU6JBG)UU\-JS
MANW:1NAY;RV"YBNRTTP-OH&GXEVIX=\_Q^7TN.]"S78A7VWU_E7F.8QYQ/Y2
M[KJ_)AD]D#Y9_:9]'1TK--#'F E0_,03]7)<@!@]-+="8!$=IO,I;"&LB1O+
MZ-@M8#L!D[$QK__S7SP6O_?NL[;QE^]%-2PS<UBD_\2=FXN.6)]RTY*/2O3F
M#LR_<.V/RL-%N[ESEK::7:+3<XS.1,HO6Z+ZJNR[(C$!"X4)/:C -9HKD<8?
M+UX\K/@+1:W0B:!&SKW*P[YUQZXJ>YP]=6VB72>X59"(8PWOL7E F,=M=5I=
MV&R,^O<)VA*-%VPZ+E"U[F$I/&P&C.J@#J6A8/H+%&)XCG6.NFMK!CCGK.PZ
M*WAD39V.(]FC/(JE: VT!N2%<(X')(GIN U!M?DWS7AG%N:WBY*!V_/G_Y..
M?UV-Q#0C*$*Y1)#>!;;#\I/*;[L,^1(2U)XB"@IA.(6R]9D5BO-$5R?S(R;0
MBG@4$0<]S'K$N\'(1I0BWW#NZ=6:TCKOG[]V^_=FA_]J-?;.'BZRE=4[V/+W
MRBI+5E>RSZ3'P'$],OK;<5E0W2N)A>K\73Y3'5[G30[6<I-1>;WA/:9'7F>+
M0?M^F%LLUFZ+.VXGA%5 M<(56=E0Q*)[GV $,%G8[7O7LEE)'&>H7$\RR2]:
MG>2WR==[C/EZCEB360>,7)?4N!ID!5F$#6F>S-ORHPN@J32AO=Z;Z;B:H@O8
M92!? N'C9#ZXV*]YDJJ+[8%^CD%;S#%[VU8YHT^_K6-P+K5S\#;*7ID2.LB,
M\=14DY:U#'*("ZWGP#2X(K73TH6.+1Y#4WG:AB_JA?F_56^ 92/U1?U>&Z'&
M>-*XQ(26)N'<54]5I@-<TN3&(.@,YOD[5GNA-((%=]&]$ESC,BV[>7\S^814
M3%+7C]1A5:(1C'",,IM=9+(20S#D+R4CERYOL]G&IH(O-$*XCIHD=L+YFL_P
M;)+BR$V\X+QJK5E"@ZCW;OG%;>S;[=D( VUX$L[W0"SG%\E])/R2 ^*OXC_3
M GC#Z=4&OE B=J]T][Y %SZ2"/YQW# \8CL(Y-$H/TW9EX41@:$T6:P._LF>
MVVD*; .I5;N*$5> @Y41P#];G-M^PU^PIK;O"/'0:KG548WO4_57Y]C62",4
M_*"34XZ/2TI]:XD0+.,^W)5.ZMJGT6%;:#8L1V92_&S"<C4W&Y>G:@##)5CY
M3IK'"-X^MK%JX%!Y84&5B;-B9 8K<1#*V+Z@YMU*Z^EP:NNS,I,7NK"H17R+
M]U)76KP*B1.3OJSKYB* Q[AWMA"R*3Y5+1@QOC/@6[+![*"2+JIR]Y,MT87R
MH!W :.GQ3#YGG<>(\4U<[W]PD72>AW?U[;U=^&2;'(Z)/*[*;Q7JJ*LE,R-:
MU2E5QV#F$6U)75&'24H=<B2?']PMVDVRU7*V,KNJ3%59EH:+7$V'#DRY0;TB
M)RJ^*36]DW$Y.K0<[<2X,BOSXTA-J\D<']7J&,LN._RT*H&6<*M@QT_JI=KJ
M79&_K16TPD=C8W4C8[,&D._3*>M&W,=8<#@UM&E*'Q7PL3DCA#1DUS4K*7+>
M9L0NO;:M+L/#;ZRZ0S$_6X2'20 #6-S78&E/,?I>U/R \N+I%<UF$4>C"1!Y
MD#HS4*?(6$#'L$ENE0:: K(D3ZW+8\ )NK+2"Z7Z=]6<NAYS-C>[ZE9=8CVK
M@\#IMRCD@U,[NKI<? (;:<_!^)O5ZG"$Q[3:D_HB^Z/#!<?B#3=DIT5UJ@9J
M&]72MLJ G54(W*<<)GJG-A7OIGK6MHBTWAU"D;=ZPYQX<(>'GF[Y'U#-H:T*
M*8;'2D]J+6=5L7'G'<>H.IO90=4E$\;"I<RHZ7B<@5J^$4+*Z!!#BL@X;,+N
ML*2 <5UP0:GJ(QH8#+J:XKYB1+*] A5^H//JJ#BV6DSW0?@C"3%<?BO("F0=
ME1K015E!B8L4I49W4(>.D">A7*3M =EI)NCBGW3#!H[EVX?E3K0Y_,*4RB>Q
M!A%V%9G6J"3&-L9PCTL],1W(>H?Z3T:^Y99VLEWP,WIA!U&6F"61'I"&%6A(
M=R-GO.3J.TA6]^"IS>EV1_(!:7/$VE[L__UZA_&D]P9HSPP+_?!L!_01-M,X
M=M.@G#JJ$,[@6 !'.,3HU,@*8$R&'QY;F*C>T"A$<*9OJT%I:[BKX[%#VR0H
MH?JAM<;WGZG"K"8\D7T\,06R\C$<=Q*(]-DR SM0@S+;]O<!1DNE&$X:4&I)
M,P3K[VS>AA>TP^X,5'TC>(T:><Z)?<P=5C,BR3*<ODV)LPB>3AFQ'_I(TC5G
M<;AVSKHUH$X<%0,K'):O+KW/,E#74J*J>5O#K9PFT>A-W;4L6P5QYBGS#^DO
M8Y5UU?\R8(9:=CIYZ?P7TU%]8M%*+-QP"+%S@@<8>*%C5NW-5K29IAY]^6)@
M 3D,XJPUZ(Q.N>IOY"X/T%*OE<PZ:<D)/-0N6M&#/_5=C6.;[X2V\;PZ, &"
MQ6(^U^ZLKA:T-1\CC!U;?(Q:BW9"JZ1:0D3/;87]7!F8?2Z-%6$$D!%TSZ:5
M=I: 5FYMFZ!;GR^L[5&GK?1OJ'B5F)]5&9JZR;F%:)5W,]*(2D3Q_&5OR\&P
MI+S>0B/L)Z$Q 4LIFOJEL:G]1=V%)RUE9"OLR$YUEL3\AC@GG3L6S1.HT(KH
MNT5)^%Z,IR07J4$-J(;YE"H'OA>5'8T5JM\-97,X3)"EFU0WIYECMXL*CE.>
MVY2X;R/'L+-IC2E$4 <GJ 9D!EU\P#<S>B.L'&X%:2VMHKIJ4'U+T]VE3^N]
M;=>@'2J:J>:'0K&"><:#,ZFR=F/5.])6&\U=[A+[ZJ*L:]0USM<G]NV>3EQN
MN-+*,K-&R\>$=C3QG*FX^B AOO%H BI<YZS B$CE*T;8L0?-0^"D%*BO.0;2
MI$,QJ2\A:[1C!]2WS#/TN34:EB,;_R>ZKE>(?"*D]#661+L!;?&@Z^P!^N*8
MH#ZLHKMJW_#\4=4&%>L<3HN,O)#5/(CL_*GJ('PNX3&=W':+06,-J"'"9+O)
MN1/4/9IE92%GR6; ).M#<@75JC-H[;4GDPX >D^LU.\"HBR9)4G(ALZ.2EJG
M;HHJKHZ=%]FB#O,C^QTHY@3=0WVGGH.,FU'-K=I-(W6NL3H!%GZ!_:^ ?U"2
M3\V6^TW*[&*]4GUR[O"\-%4:9)^N8,^IF?FY&4 GBW<NV]<1,3['(!=HL]@Z
M#;9F#ER+7F/AA3"G'?W)<[P7E*96]M /[=;5QV!FM6=7V2HI='$S<]2/:Q^/
MU>G</&M+G0I$:L"?N9LOMFQS3)\0X0:G;2V$+:S$Q+[516QS1#%;V+I8QNE*
M3;=Z+U;QZD[YK97V5,SEF.&R^=C?9K>M*D =4PZ)!W^=V\>YW7#V/,J[&3,6
M)]U=WW+6-5CO0I-EU\5*LHO<!,6PR1T^K-ZX9JKTY*W>>SMBK,N8*^9Q6[[P
MA-98OW!!^DQV_]+=W20,=!,&XDW"P'J,Y2X!?N["0;2<WN;Q'/J-,W0%M^T4
M(5_D<!>+9<HVB'$)2=L1E U8G@5C:WGKP8SVM%2[0T6')!QZZ4_(E,#V7M;G
MOUH%.<.<ZM=5?^1L1J'AC,4:G*YQ?<P:C7/#:X$4:T9K747S$H::F#C1I)RA
M.6-_#@B>NX;JH,*IHN/IS!6HC=@*8H7=1=;6R9$AG4S9D#M96HU.6K<2!>6
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MNJ0#KXJ3J:,'+D"#Z!N8KV1,9A$X_'@KK,>P-;<YQ/HI7$2PZ$ Q SNS.GL
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M=3^I=F)PVQ$H7F! :]M6M[9:E85G12<"YBW,P)LV.]:TA*%@,]EL0 B$VM/
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M+G53)>3< -0JY-:M%;7]X5MC%R3AB- 0@9[%5@3D0&(MT? "V%V4W8WQE^\
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M$@!NF$2+O"#V[X3#! 9D[4AQ@E*R1P&"KA"//J$W2"><IO&<1RWL!-^_'P>
M^O>"Q[!9$0!;H(_Q[9N+<Z @'_G()$)K0U]5DFM4=,(P,P@DX&]"Z^/Y /MQ
M,J#."1Q;@.XZ$H&*T*0JB )M1K1EX\\\%9R_@L)-+C>M,P] H;,Q^OMJ#$G'
M0/2D<M_Z_I26,''G\ \)S&5HE4"_ >_@\"L,O ]P ORK8TNW&0R,@R%)@8VJ
M?&UL62*Z?W>#D-R8I1-^)=T6;.<I6,6@STRC%/2',%R%=26#+%\-X&(K.;U0
M":[L=8'_MNU>LT"MY*\$=1RMBQD:&&1_D#4]BR,/D(Z5PDZCI8CW8W7+&O[;
MLUM%+E1USIY20QN5-(IZV9";Y?&]L#+Q9V(A)-<0>5CH.TN<M:B!H+$#1+)$
M&K9@'(S:DHZFFLMHDJ49,KP<!7G"(FMOX>3Z L2$C/2"<<!7.9>*?1 4L+PR
MMLHF"NY!6JOW %KL.@B8@Q^YUC0CS,%77(_M55;3)7$ LB QXC\+^D*IBB(,
MVY)EHA%"!$VG[:&7YCZ*O^&PGE@R6])D3@K;ZA Q$!3S)'-Y]\NH1^>/#H<X
M"J6^13H;7F],HHP5#7+Q"<M:\O)E[KV(@20V9V HX:,L\07X!'&C=)=7#\I5
M 1K&+$K\ M17N3S E(7M8AB !>8HXAA(U>_2 ;4 3<+7F.$^C7(3E@PUU#78
M4:>\(A)WU"?*RO.B[S[\'47JS,5 !+"_-17 EJH (G$0)RG,-LH2)$G8,Z"Z
M&Y)X%#<YFASYHXP7(.. J5-_06"X:.3.64%&72#*^ >->/$21<TYKRGZ;FEV
M7K#_[,MHY*/$/$#'(JB]OQ%"K[(Q)=,$E/H *LAT"(IOI]]Z9]T \24:#I .
M^'=0_I*OL4O$<JD\$.A/D]=ITM#4W[5S2;-LNE4T.'.K PY1> 2%W29X<R2@
M)'V"0/YWL3L1&A!SX\+Z77(K@;1(:*ONG22,G R&[ V4S^51^#"31S>7+E%>
MKN<-6 >A0:1R!LPEBYE\Q+"X046:)*V 1V1ASO^T%Z6&2:(EGU9ZHQ9>YI^6
M%RPD_Y"5(!2Z=_#H3@R"^E+?[G7ZFU7(Q8,@1V@^UET<)<EJNG^6821M$T92
MC[7L,HQD?^R^8,_TM?@YLO 6#9Y3/6:#, ]TGF'FD7E$?@FZUF %1;+7//:$
MU7*T8D]UOKUL9N>F;38E!B3Y20EG7?#$Z;P-W@;-"/WLZ#671G(]O=NK8.1T
M623+2^I2B:QN TI\OBR&I8LD*$A@]MB1'3/3-/'<#A&>#7*W !Q0[\T=2[2
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MZ>?LYGJ)A#KM7NLUJZ'K)!MBB]/;(K*WQ@$31 /%H,9:[F@3#9^!] A7:LE
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M+MMNPWJOU[7P"[+H)]FE_5 ^CC,)#QF"RQ8S4% .M_ZIN#*J_J=UO$T%?91
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M"UJ;']K-M*E 1!2H21!R%#@[U"YG#;[=X+ 8!CZ?B\^BGV:C:3=:=K8GE^_
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MRF@Q0U)777$7"9$=+W>\E2,2F=9! 'NO)UI7: $3%*^^G929EZDO,U6%<?2
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M1E$/919I-,!75W,@;R465,3HQ.=T<=1U(J;8C1SL9I*IBHK%?--:U$MT5\"
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M*FO +GD'=.BLL8\^_?0?4$L#!!0    ( &R&:5.DV62$XQ0  !J]   5
M8W)I<RTR,#(Q,#DS,%]C86PN>&ULY5W9<ELYDGVOK]"X7P<E[$M%5W6H)'G:
M$2K+8;FZ^HV!)6%QBB+5]Y*V-5\_"6I?S060J*@(!RU2U+T'F><F3@()X.__
M^'8RVOH"73^<C']^PWZD;[9@'"=I./[\\YO?/[TE]LT_?OGAA[__%R'__O7C
MP=;>),Y.8#S=VNW 3R%M?1U.C[?^2-#_N96[R<G6'Y/NS^$73\@O\S_:G9R>
M=<//Q],M3CF[^]ON)VUBLC8F(IUF1-*<2#  )%.@,@<J.+#__OQ3 BJHL)Z$
M&/!KFB9B>3"$4\-92$K3(.<7'0W'?_Y47H+O80L;-^[G;W]^<SR=GOZTO?WU
MZ]<?OX5N]..D^[S-*17;E]]^<_'U;_>^_U7,O\V<<]OSWUY]M1\^]$6\+-O^
M]V\'1_$83CP9CONI'\=R@W[X4S__\& 2_71N\^_BVGKT&^4=N?P:*1\1QHE@
M/W[KTYM??MC:.C='-QG!1\A;Y?_?/[Z[=<LXZX;]CW%RLEU^N[U[^'YO__W1
M_A[^<'1X\&YOY]/^WJ\[!SOO=_>/_KF__^D(&S&_Z/3L%'Y^TP]/3D=P^=EQ
M!_GG-Q&O2(JWJ1.T0/G; E?=OH8;_2C.1G/K'.#[BVL7>#61P[<IC!.<V^GR
MUJ-)O/6E4?'2I+O\RY$/,)I_.ICUY+/WIX.#H0_#T7 ZA'YWUG7X9 Q,RDZE
M$(@#KXF42%@+7!,#5FDEM;4AW[98:56/S9I[-_L^S%U\<8OM8LIM&$W[RT_F
MQB6477CZ;X]C.3?KZJW;B7$R&T_[#_[,AQ%<MI ;!Y8S("QX063 Y]7A4TR
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MY2CW1CWCD[@V:NRL"EL>6HA;R2]U#^MYO+FY!-&RG4JTQF,(E8XX<):PK$1
MTRJ1V@RY/HUKH^11$ZY4]$O53000#G:,OKN!A2<+QO! I-64R*P3L38J@I1-
M@M)4MF%L&4_NX-DH\=(RCJSCATH#[L-8EL>6(#;@DEO#$][.EOW2>,@8O0(0
MEUAP%!-%!_Y[VN/N13=JNY&JKES+?'6<MWL,)^5<DK/?_'B&HKF4,HP_E[F=
M<M;U9-2?UTX&$X7.(1+&02(P:XEWV#IK!"92D&V0="&_+G:_3:II;>#R!D9?
M,+VX^+R\!-_#+S_\/U!+ P04    " !LAFE3/Y\^"5A2  "[CP, %0   &-R
M:7,M,C R,3 Y,S!?9&5F+GAM;.R]6W=;.9(F^MZ_(D_.ZXE.W"^UNGJ6TI=J
MKW&F?&Q7U<P3%RX!FY,2Z2(II]V__@1(ZDY*F^(&24GNKE))E+SWAX@/0$0@
M$/$?__/;Z<E/7W$R'8Y'?_V9_SO[^2<<I7$>CC[]]>>_?WP-[N?_^9__]F__
M\?\ _.]?W[_]Z>4XG9WB:/;3BPF&&>:?_AS./O_TSXS3/WXJD_'I3_\<3_X8
M?@T _SG_1R_&7[Y/AI\^SWX23/";OYW\Q=B4G4L9E#<<%"L9HD6$PI"I$ID4
MR/_?3W_)R"23+D!,D?[,L Q.1 N"6<%CUH9%-7_HR7#TQU_JEQBF^!,-;C2=
M__C7GS_/9E_^\LLO?_[YY[]_BY.3?Q]//OTB&)._G/_US\L__W;K[_^4\[_F
MWOM?YK^]^-/I<-4?TF/Y+__[M[<?TF<\#3 <36=AE"Y?0*_/LXM_>!6-_F7Q
M2_K3Z? OT_F_?SM.8397S[U#^&GM7]2?X/S/H'X$7(#D__YMFG_^SW_[Z:>%
MY,(D3<8G^![+3\MO__[^S6VDP]'LESP\_67Y-[^$DQ-"/'_"[/L7_.O/T^'I
MEQ,\_^SS!,M:].=#KJ!TA?,_ZM-^V1K39P(R26<1@3[%425XCQA7/7U[S!?/
M@HPEG)W,>D1\^]F]XAV?AF&? K[UZ![0SA\$IW@:<=(GU&O/O8+S'.1-A/61
MZ6PRG/Y[&I_^,L?VXOCWEZ]^__#J)7WSX?CMFY=''U^]_/"1OO[VZO>/'XY?
M'[][]?[HXQOZ[='O]$>_O7O_ZK_H'[SYQZNWQQ\^W#^:1*^#N@8S+]D<]K:O
MO#)08M1P-*R+U%OZ<?G>.JZ=#1F_S7"4,?_\TS#_]>=AX@F%-=9KJ53FR1D>
M!&II>68V.#'8]N5U[.>C/QFG:UA.ZH(]OF#828AX,O]T<#:%3R%\&7R8T=Y9
MMU$2%[ZA;Z<#SR5SBM83:;,')44"[V(!D6B#<[SD)-QM?D[/^5["-,X9NGS%
M+U75O^#);'K^R5SYP/ART?\?Z[$L-/OPT;W'KS@ZP^E1G,XF(<T&23%C'>W>
MJ4C:Z94,$**28$T1WA9%VZ5M,K:;2*Z/[)*U1Y/S,2[7B@<N)M4"ZE73LW&/
MHEWHCP;P\T_C2<;)7W]F/:GZ-8W[Q7@TA_1/,@A?G$UGXU.<O/J63LZJ+7DT
MG2+])W\,WP:2L>(S!M LD2U'/T*PCNR^S 2+IEC%2TLV; )V]X393L.KZ=),
M/;<9Q;=EU(OQ=#8]&N57W[[0_G]%#D8[-%X6\)Q;4"@B31MA")>R):B23#!-
M:+,.T:-?3'H1=0,*O!]_#R>S[TM8 R%-8#DP\-$AJ*(*!),,>!:*<TPEJT2;
M]>(:CMVKNQ_]W%P2'B[<%JK&*=(#/],H7]):=3+^4NF]!'>Y/*5_G0TGF-^,
MWDW&B5:J*AE:J(Q7@=1&AAXMC"[0&L63A6)S+EQR$56;!6$+T$^%1#M2VVW&
MB6T9]S<<X22<$/*C?$K2K]*8#;_B^81 K8U@AF: R+3]1<DAL.2@"&."%CE8
MT<96O0?8$V%.G^*_S0[9M_4Q$)X9QI"!DR[2^BC)&E+9@53"Q")1HV [L3J>
MB/ZW$O!MA:MM%7[\!2L!1Y_>C!*9Q&_'T^F QN*4JFA"(9LJDV'E/5G<R9.-
M5;*5W+0Q.%: >?1&YK8";K %_#X>C:^C6K+Q@N$Y69<*\R"9$* ,]PL?2 >&
MSDL=N(Q-&' OM$?/AWZ%WV +>#/ZBM-9'? "WIO1#"?TR< 9G1EM0F ]F2LJ
M%5U]8@TE&XS>Q( I-2'%.D2[YT+/RALWD'R/3DH-F=<AOPC3SV].OYS-JBF[
M@'3A/K'HI+:1G";C:/<*M!4&7@!%""9B#B'J^^+P][_FJ2BZ9X$VV!J.9Y]Q
MLG;P@ZRY])DK<E82#=IS!X[&"SI''E+0V:<V^\+=N)X*/QIHH<$&L1Z84*ZP
M(A!,B*K:-1R<U0F,Q.R(RS:QL%NSX:DQHQ_9-_ C?L?9%0/7:,YSUF36DJ=$
M!E+(X+,C*RG$0A]YQ:-J0X2K,!Z_K?A@H3;0\*LP&1'KIN]P\N%SF."O83I,
M@R@\K\X,L"(EF285GA7DRE@OT>@2I&D3A%P)Y]%K?'LAW]:\[EOS+X<GU709
MR.B#S2F %"P!C=A!-+0C9>.%BB7+DMO$AM8 >G+:?XB@;^O?;*O_?V)-8,1\
M])5VGD_X^UD5RG&90YP>G\UJ=E^-=R_(BBQH-$*!1U,%$ U$6IS(3O&HC8N&
MRS9&P$8P'SU7VBGE-H-L(P8M^7T+\R#D8#$G"9J5 $J) B$K"X$'9Z1AG(LV
M]L.&0)\JBWI1S&T>N7ZM3"]*XL[0MHB)!AZ\!&^0L$D=C= IB]PF3GV'E?E
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M^?FJ%"2A"BF$%Y967S9/+=,!?)0)& LJT#K,],UKL'TU<MCI.!]]X.N :='
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MW";9Y& :.&]E*#U<F ?3P'EM-6]IO,\%.1B14FW,+L'7'M>HI)6!_I-XF_2
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MD"1]*.$V9?2V.]&-[?,&_,7A42DV(1,2N*OURYEWX!+WD'Q 63@6H]IL0AW
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M9:B5JFOS72Z;G9+=C>O)$:1'-?2X>M3&C?/CE_D*&6(J6@A?3W9K<T4;(9I
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MB5AN$F1NR0(JT5C1IK)D-WR/F4 --=&@VULE^7+8BUX&],,<X0+YF]&5L-"
M_KE(K%[Z$H7$D6K=0DO&LV$83#:^I)M]3?IBS08HGP1W6FFE0>K!%:SO)L-4
ME\8YUH%(LN20(NBB!7GZM'4ZQR44I8VVOF3:7ENSY1JB)\:,ATN[05#U?/^K
MO04K26LQRN-"$+_6'F$G(2V*>CO,F@<6P&>3R8(F1S\*VB(33TP:%:27;5H
M=,/W%!C20!,-NK01RH+3&E<,)[4'$]E-PH54-+&6%*B,\^"85Y!\*MP%+I-O
MTX?^)I(GPH&'2[?O5FI7EJQS/KX83VO))A:D5&@A)4$4%)E<+:XYE.R4I$U-
MD:O=S5-9\X;'K,K^1-=CG[*[UY@KH9-!"#HX)QT4HVHZDY%$/85 6Q':E+AP
M-Y.1FR[T5Z ]9E*TD7_?_<<6ULGR.OLR_>0]5E'5](*+,,OY7RS#+9D''QQ3
M)(7:>H_7I.XH Q2;Z6/K:O'J[G&+35__F%FQ(Z'WWFEL%>1;4;AL J;H,H1Y
MHDN):OF=L2&C85)UK.?1Y6U/D@5;B;3//F)K$9Y[,L-Q'F1?N#"!02)*@K*U
M^::V"-X0:I^TE1UK<M[SHB>IZH<*LL_66Q>>:G5+?R5L^6KL]$K"T:_?+_]D
M6<;SZ,\PR><1CZ.<YQH))[<.8LC$,<&B (.UKTK,'*(I"9)52=FBG&2^B771
M<%"/F9"'IO,6_<"N6%?SGG<#;Z064F@@8[PVV% !7"X%1-8V:&')W6KCL=Y$
M\A28LY5T^VS1M79MK0B'L\I8\J@7[!QD3$%J7D FYD %LIQ"R"0 7;1B2?HB
MNR4H=WSA8]9T,\'VWCCK]NG?"D-Z:4M%2X-7C($IG%8E7EL\)V\@6&.$L8;G
MFQ>M.Y^VKGWITV!! P'WV2MK1<!]98_3XVMG,8[6J& *^=E&)5"9Q9H]H""'
M6&TQ@3:VV1,V@OF8"=1>+[TWPUJUZ'W$R>GTIHU#EOO+\'W C'+)$3I2=;7<
MDP"'Y)Z;J*02N9;MZU;0<,,7/V9:-!=T[YVI-@1[5&8X^>UL=A9.+GOD*J$]
MJZX[2JS)U#6;588(.3*42D>5W<.#(QN">6[LV5HA??::NGT+:#Z:7[_/9;2X
MSA.]QA"<)X\I%]I)243>10V<3&H>14:NVX3D[P"UL[X0_>\_/4EZWYT:+BX@
M5C>\7DV?W]>0CBDI,P(OFNSOJ"QX[PKMESI;SAV/KE'GX:LP]G^7;DO=WKRG
M_V 9-[BY<F^L9KHN6',YC%%^=Q)&5XH3=QE3T]MS+4:UGTMW6Y!ETZC<KC3]
M6%B,R0F?/0=O+>T+-?W;L5(@H&,A!H/B9F_L9\?>>^X"'CAY-U%P ])>"7:>
MURT59!TZPX&':C<F'B"XR,$RE5+DQLG<QC:[!67W9OS^-;P^%OT ]32H#O?A
M+$Z'>1@FWZ]$/>8SRTA=N"67-<I4BS,D#\'01$O<!X^"%=_(3EL+Z:G9;/W(
MOL5-CRLYXL3[XW(EWG5>)[$#PK;6V+T8]V-;]:34.[+V>]1("ZOI?J2IGKN%
M@#13G $EZKT4HVGQ4U+;;)PP-YOX/G+.W&/1[(TRFRBB 55N)HZ?ETB7Z'0R
M"")AK/?T9;U';R%'*U2R)9;2*K]S%9X]6"T]:^Y6AN?68F]@B!Q_Q<G1R<EX
M?EI[_*6.=0F,!6N3(SC( FVQ11@(]7:!*30?A&69-3)$UD)Z<I3H1_@]ER!?
MV590*15C(@!%>04JE A>D]-7<O)*1+0Q=TK/>L1-7OLQ0GN1<,^-![IW*NL"
M\MEW:]U(DP]JP?D0-?3=&:HS6((19"&_W:%BM,%Q#L$7 ZQD%W2.,8A.5XP?
M U<V[=;:GBJ;2+_ODA<O\32,<MU#IS=+4"+!"5%FX-J7>MM)TJZI%&#$@CYY
MBZE;3OCZ=QQJM\>--#+N7YQ]E[$YFGX93O!%^#*<A9/79Z/\]NV+\^:R6'Q.
MY$+)R,@V8K49L78)"E>)]D:C<L<^GNO?\>2TW),XU\[E_BJ=+;(K3JI!3+2<
M6T<W0[Z_UY*WM2KI%J70'O*:;6NE;3VT&\74A+1%9Z9I/M:P,QF.7"*M[9'F
M$F,>!P]YX7:.WTM:&2:3M1'Z?PYGG]^,\O#K,)\M4_>O!NNG;R]2+IC6)1EM
M:+%1H;H]B3@O'$0CN#?69H%M;F[T-8+M<KY6'G7,-3EPTCOAA8*L2@9EC0!2
M.$U:5;1,T4KR^+OE<JU_R>Y]XKT0YWI:5T\R;W&NT_"ZC"@R\< RY"A5S40C
M47EG066MK4.6@FU3'_!)79':*WT/C2;[2-^X;VBW!L14R$PD#89E,GN,#^ \
MC8II[I(.,I1&%4!['\H/MN^!$BT.:BN>>/^ XLT!O?I&QOUBMUI<Z?5&9,6"
MA!(];5=!(<02,H@0#;*ZAYF&W.YC",^9TSNG0(^!WTM+ZB&C6,S(]W@Z_HJY
MUBPY^DH^28V*SW_S;CP^N:ACYJO?PWP]TJH%NJT+$-'4 MT).>:<1.Q8OG0'
M:)\9G0^3!2UJ&CYTC)?71X8W*O(L*\8.ZBT0Z<C"DL9H4#):"(X+T#H9Y21I
M!-OT]&PWIF<V"PZ,)#T6<YS/[QMF5 6,^>\C>O+E[?RW.)U^_!Q&'[Y@&I9A
MNEH.^7483GX+DS]PMKS([T06DFDHC'-0OG (P9&/;9'VLJQ#\MW:$O<,[)FQ
M=N^Z;5!$\L&NPB)[8OHW^L/9],W2MIK7\1X@3R8(DJB.FF1K@P(O=8%D:1/2
M)<14.G5.WYW_N'XPSXSBAT*+'@MH;KW7S+_\ Z>SX>C3^^&GS[/IY7P>F,RB
M1.>!"55(R YKM14!WG!OD1=/[L5AV2)W#><YLWVOU&A08/3!4_CJH!;SEP^$
MY#8;Y<E3YHEV*?(CO&<D;&%S2K$8LZ_K7!N,XCFS>Q]$Z+$HZM9C>?6OL^'L
M^YO1=#8YF\OV>/89)]5(6[EC#51,+D9TP!-99 H- Z<0P7&MG+$J\=S0Q]S!
M"'],AL,A4)]E8=M8</_$NKMA/OJ*$]K;YK]\&698O9F%'R.0&>&R AMICU-<
M)(C"!RA&8W*.68:-KM'M=J _YLW!T:G/ KOGXWUU^N5D_!WQ TZ^#A.N'O[O
MX]%7VAYQL5-./XYGX>3J[VNA^=_'L_^#L_>8QI]&\Z.T$,BO=^3\9%DBJ.(T
M[:4R0)0!)6,956G3OZ/9D)[IE#@,BK2H.]QL9(O9_WH\67Y4_XX/BHFBD,3!
MYQ3JU7 '05D!TIF .M)*8,WCFA$KQ_ECFAP:F5K4.-YVHWSU#2=I.,6+O7(N
MBS>CV60XF@[38G>DS2^)8 ((QSTHIRUXXQC0X()U03+.V^PANQC=,YTG!T><
M/DM"MW>_+E:0Q0'-@*/U)KD,R;)J0'H&(4M;+_Z@C\JFD@XL>7/3(?Z8)P=$
MH3XK:+<?Z3_FP[RV4%RZ7D9GX:S.0%X6*4<&!YZ&"DP*D8N1OK #\^2W&N^/
M:72HY.JS%OG\[/["%+U6IO8DC%Z-2'\G=33+Z!T+R2GE)&1GY_FNK+:I+Z"8
MDZB+UHIWNTG2^97/C(8-]=%[\?'SE(\+A'-,]:CO%LZB0@H"$61*\R:1 1P7
MM'F$Z!5Z(XKL5DVZ^SN?(W$:::3_ N4/3O0\OYYX7$C6%^=O@Q)<RF3"0[8A
M@O)>@4<>P9:0DS))Y>@[\:MO9,^1A7O5;I/2Y^==4C&_/+O$M4AU6[M83P>"
M88FR=L45EG"[:"$Z*2!YSIU+-HC4*.'K88"?&5EWJ=X5EW]ZZ'!YD>;^>CQY
M?38[F^ YPGGFY1W893U(JO7DO*XE@W)6X 1/@$X5)2TF<_.R]%WM'1Z,XYDQ
M;M>:6\&Z[>]57A2BVE*4B]I5%HM3QGH(*=,DRAS!\V3!9<9]=#Q%W2@>U>LX
M=M5MXC 6S/U1X%!Z6IS7A%Y43\K68ZF=PUPM0BYLAN@+F2M*65=T9,+G)AR^
MBF+_A>EV3X:;E2T?JI06Q4VO%PWO@J9IO>1#Z#OQ</VL4?06PFVO<D3N=# )
MK!"*5E@1(;(8P+@LDD8ON&N[*NRQI'$K36\BT[ZKR!V=SBLI'8WR>YS.P@SS
MQS_''S^/SVJII(^XN&;W9E33W(=?Y\;:LEQ62=(F5QPDG9'\!(DU9ZN ]@EU
MX5I;'3K9V@]%L'LK>QNUC7<M\[X+T5V!>#1'>157)D"B2'"A!FQM;1[A9 $?
MA.)%1!Y,MSOH=[SD\:J[+\GU/?77NF/GV-!89S"#2381MGDDP-6[B[$P:] 9
MV^TBZCTO>KR:[5."#0JI7&\JI)U2VBH-P90:$4^U>J(MD(014NN4K7@6+>KV
M;M _7"VMBNW<=3+\D&9"7<;THZM=)^]B"[+LHC'80S3]6+K:Z<QY3,Q"H=T,
ME+>AIIEF2#[*PND[5'NZ%78P[-VHJ]WAD7<#!3<@[37K86DQA, 560@&F%,<
M%.,*@F8*&&,BR2A9-HVSXY]<9[N-M+PNG?V!*NK;"9OC6&9>C1<U2(Z^?)E@
M&LXEM;B5OL1I/8M.L@ ,A0:EL3J+HD"6.7FFC?+BWNK0F[[T&5.FJ7[Z=OUJ
MW&$R3#-<9">\__#W16+?96WLQ=6,X\D[G)3QY#2,$BX^.F^L9!E:9R4$)GPU
M@&D68"%/QWH38^",*=.)75M#>>Z<VZTN&[@@-P:P!!63RSX:2RB$JZ62%$T/
MQZ!HG576BNM&1Z@KX3QCDO6GIA[K:YZ#6A:LF-N767AM D\$Q=2$JD0+*C(!
MB7;D(BQZLCZ;,.8*B!_AC0>KI!T[EN3O J9I5.(:G/V$$QZLG-5*WD*R#1RJ
MZZ"<RBI*)4 F(T'Q1&N=B/1=#-D+&X04;?(4=Z#F>_SN-EK>1*"[B_',-SM:
MWF@!/![A<E?RZ'S2O(!PM"$IJRR$$$E9.B2N.+>!ZUV&;E:!W+U)L84ZNX5C
MMM;%[GJ&7('Z\<_Q$JH*5A0?$TCIY:*,3["823CHI>?!B[S36I:K0#YMVCQ,
M%SUW7_PXG%5+ZM),FB^DHA@KN?2D.U]M(B0>LY@!K8I"&9.%[D2.3IT65T)X
MQL9E/VKIL?+Y2D!U_._Q9"Z6Z>?AEX_C5Z/9</9].76Z0.V]O^N&('??Y;4'
MM=Y%D@8Z:;W<W /9Y1S)QW9@L&85*";!2>=!%^:-%K1NYDXI>(^'/G<T?MTO
M>S911=\QW-_'H_/CB9?#"2;ZT_. 7LI*J<0<<%$T*),SK;!:0K9)R"!0Y7"C
M[\VZBZEKW[';SJ!-]3+N7Z@]VK%U^,>E#!-.SAN5!GJ3%A*8KYFGQ0F(16@(
M,GLBME+>=2K/VVG^7WOUTU/Z=M+M>THOD4R/1OD.(M(H=5(J@N7>D-VM/<0<
M"&$)T09T)I=N1R^=7O?T=-Y(U&M/1G;:$_A&E'YQ()!F)$V26=,VP5W>O(/.
MP1L+X$8S89EB"44A>9])I:*]Y<Z:'+TAMT3HU*69<!<,>ZH6]/;BKIS@PNG@
M$$QM0Z)BKE4VI ://I@:F DMF^-MA?UP:RU=5)5Z/SXY>3V>U'\TP* $Y\(
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M$1U#C"C<@?5$ZUL$/Z;T84[IEDQ^C%&^LPE..RQL4D4ODP-:S1 4+[5W=G3
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M2!:9XWD*]O1/W+LG^3'PP__-$N!C=-8>2>!#=_EM_BZ74E3LQ;-?4$L#!!0
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M@2H* W-+2R C$8-9EF@S(T94B'#1O2L? ;*+=_YS \UNT1_\[8R\J!L$:L'
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M^JY2H-QJ-3PQEY^QLW0HF7I$QO8:Z0[&3B'0:@0,%X".3H;#6ZW,;5MMW-^
M6C./#B0^@?;K)>)%LFE=07R">>3OX;7Q@9;ZDRRHJ:'XWO@V':2ZKTIWZ3Z,
M,Z/NE>ME8\'3D&<RB*#$2!H'#09)3!7D 4&1B' 04R>F=A5@;J2\K:]!F_H:
MHI$9%'T^RWX&P])R'A'BL8WD5G10R7ZBG$DK?^4B7D53&14\6L,#P?-K^+H*
M,:V-.Q"B(W-V:#O#J.^3-I#U2R9LZ;7\)E?YD[&+FYC>-FE,$,M * 53'!.(
M*(L@57$,XRR.,(FP#%"RT *RW);O+'IUF7_=OL?T=*Z%KC:F';'=@OY=@ ^B
M((DC'D JA=X0)(08/T "99A$4420))%5MIZ18)_&O;P#NNB WN2R<,SK:(.Z
MW7KB&<N1EY!+WZ['<K # /*Z3-CT.^G*X #$X6+@\NK ^T[C"?NN+)^E>*UM
M[_5#[4]6>9"U-ZS5,W>_KO5T_[I\^J@_K$46)2P.DQ!&TMQK1J&$!!$$L10J
MS4*>$&SE"7:=&',C*Z. 21F^#80!SVL]%#N_B4J%76X3HX/CQ>2PX;*\@!Q]
M$,:^:*S@K34 M0I;E]Y*BYO#H=AJTC\6[K>)5T'I]]9PF"C3W@Y>!=?1+>!U
MK0TDTF=6+L62%M]-\;4[575P^]NR7,1)0H.4)##!J0DS#"ED,<9ZG (IPTP@
M26,GKCS7T]SHL*U"5T^U+T9$5S^,LZ!:,IH/J,8F+1>4W(GH$@)^N>9L;]/2
MR26ECQCCX@L#_&RK7-^?M-FV?FZW%BFF*:.II@*3(@.15%M,- Y@2,*,8;W;
MH\2*"LZT/S<"J#/-%[6(#AZB)Y#KG^\>\!C[#*^"HI%NB-?L"4P<O&6OPV8B
M+UE'C-R<9,\CT.L<>^*UZ9QBS\N\YPS;\]CP9'QZRWDIS]%A=J-\M>3?%YA'
M,HPY@316B39W @QID@J(>1HBD80T4DZ'5M<(,S="O)@I[:8ZH'FW_B:;&&CW
M['B#!\[.I)IJ.$;FXVU:.KOD=2<RUE4:@2_-GZ,4 /:!M??\<H,%FCQ;W+70
MG<K]=G6;PQCY8Z&;V\C#=.M$X# (:0"3F$40A4IO+6FL1RX.!4=A@N/4*;S@
M=#=S8]%&2M><_A>PM*._ZQ$:F=B.P!GA:+\?!*^,<Z:K2;FD7]U#EKCP],1I
M1PP1;;Z_6VN.JDSXLC(6[[_2=1-*_C?=Q&8;1WYPWUS]\K769IOO:R%C$6-.
M"!2D*B079A#'QE-16W=I1E(2**="<K/1;&XL5RG95!P5^6I%BQ(\Z?U1Y>0X
M5?%1[Y^/Y;G=7.2=$;%[2'I2HP,Z\(!ZS[W1 .U2HM08=?.A'#D<58\  U4G
M@^4,TJ2,-?[SR*7B7;O?1\*5L0;56U:6T02<F['PKWJO(\5>TID=M6.9A%B&
M$90!Q1!)'$"6A0B2((Y5@N($!=-D+;M*C;F9 16]?NNEUSE]!"^]OOL:VO\T
MBWD-2'<Q_WTMV#8#^CM9G7M5^4^R%-L,UW3KKI4T;HML66P6]\N-N27>!9";
M</)/<E7);?Q)[O,WZXT6[77^2)?K!14A0I3'D"(<0Y1R"FD:13!4)L-T$!.1
M6JV, _J>VW)6B6_<'78*@"^UJ):WH4,&H']5&AG6D9>208A:$_P5V/2QLFZV
MP\CZ7X=L/*3?22CT"D!:WKNFB0%^**_,X1'+BT-6?96O39Q)_;=R*631I%%^
M>%Z9K^'[[=-3D6O3\^?E2O-HOI9M=HP%"A(>ACB"0IA(99XH2"E+H<D21\,X
M""2V.@0<2;ZYD=Y.9$ ;F<%C*S1X:J1V< 8984@M'&Q>=J#&OA#N*K>?]'ZG
M']A3T%P5;P>VU1%LE=PF*WK9@77P$GK9 9[(R^@E!MK-56F\8>AU=1JAV^E<
MI<;#;,_5:L1N1CKK*\]MGJK_W.M>39X4/4,^Z#G3F,N*J91CED$>( )1&"!(
ML4JAC$26!HJG89AX/<D;(.3<UOA*4F!$==S/C#J2GH[C1AZ?D9=VEZ'Q?_)U
M!7;3GFL-$71>IU970.U\)G5-7P.33)6E["2,RZ)()(3%D,<F,:#^]"'A)I8@
M($$4,RPH<?+]VF]^=O3Z^?.;^\^.F9WV ;/CPN$PC,UBE6"C)+L[K;/?M$?[
M74R;O^BD>D>)B$X_-32MAC;[#"\4F^_WFC-*W:0YV-E^C#C(1!1GH:DX'YA(
M( YI1!2D"B4D"R,BD5-0X*4.YS:?&WE!)3#H2CPX#^=%S.T(P">2(U/"=2 .
MR.A@AXSG= X7.ITXEX,=!,>)'"S?>YFJ=+LZ>R;#T"HOG_5GNDM!'%.4R32!
ML1 )1%@F$".204H02V6 B=X53EF.KE?:N1'=D>O<)VEL09.:P!P:&)'-C<W[
MI9K*P<-JS$?VX_ ]DO-WU]@Z9.QT!AVE1R'L289G'LX75A+/:[?J WS?A>7L
M.GW1TJDF,_^'YSHQG<QX*((4!HDI2A<E#+((4\@%(3(,92H3I]SXWB6<VV+4
M$1#0#9!K81P'GBKOF.$9E/T/[#2KSU7#]3M:<3IZWH!:T_FL,6<'85;KRK&4
MOZNUY"S((Q4F/='1RZP9M0/@[5J8G'DF1O<^-S_:FKF2R2S!5473JN"AWN1@
M5>6Q2Q+*TBPD:M*MS05YY[:>W#X\%/+!1 '95DQ^D5&>9CGQ.':_H\6E\2\W
M21):O<$FKWX\RSV-Y2C-:O6Y)//O:BVR' #?*Y-MM\/6J??Y^N%>%H^O)=N8
M/Q<J3M) F 0X">(0H4PO+#+(($DEPU$<1''B=+Y_V,'<5H)?UE4M%CWY5SE=
M ]WEH]L:<(2@'6E?@\O(+&M$@P8(8(2[ ?=]F#CSX#G%O1+742>3,LTY%0^I
MX>QS5SM+:^NFS[WK8[[1/UK2E4GYTG#.(D:AQ!G%$&/C&QW$&:0\BB".-"$@
MA>-0605[^!%G;CSQ9K5\6)KC!VTC%))+4SB([]PNN<FSU#A$ Y47H-1DO51+
MS2M<2[0T)>:[6>"-V5'L?#-S]F^:VW6;)?CA^4GW87F2X6GH^REK^@$=F> .
M/&E;9<ZZT8*M/G4^K4:C28=HL#?TR$/U(L[/=#MDW2FX-V1/VR'K3DU?E<N]
M0>S@V#RDEY?R8[X"D1ZWY6M:';"D_JW(R_)3_IVN-M_W$YBB &7<E#E,22H@
MXHQ"&G$"(T[#($LXDLPJ561_-W-; FL9E[:E2RY@:+'F>$%FY+6DDA$T0EZ3
M)_<\4@[4[P6QB2A](')N1'T1D%X"/O_V=,1Z48,]PKS\]-Q2L^RGF%D$"BF)
M*(51S"E$@F!(:1A!3L(@PH2G 8GFD8QE7_"YD74W"]NTEZ.N(S[R(?>(XSC_
MT^Z!B=-F<.H]<-CF<?SM*OSOXQQ\X)"\5+:R*U>\#_GZ,5_+#2VZCJ_OEVOY
M;B,?RP6BC$F]*$$:T$@O5"B#E 7ZGPE*B!"4I5BY+%07^IO;^M(1M^O #;X8
MB4$ELJ,;_"7 [=8)CS".3.]7(>A,Q):X>.7/2WU.2GN6 !RRE>UK(U2QK6N)
M+]</MUPS7U'E@RIR+LOR55YN%B25(>8)AQ*K#*(HQ9!D1$'$@TAF*3-E*[P5
M6>V796[D=*[XJL>:JQ<&QXZL)H)\9"*[6*/UAZTJH-6ELC5K;8!1Y_SFQ&_]
M5CM0IZOK>D&>^=1[M0/.J0ZL99,#2P$9G4V8BJ'K3\OR'TW9<?H@PT4<)20D
M@81I&B"(I B@ILL$AH1+(;A* Q*[%0;OZ\YEJDY3$7Q/6E!H<1W+]?2!:T=]
MO@ ;_:JPBY21\P;L)/58,<<"#K\5<?HZG+;BC87J1Q5M;-X9<.5S>F]JLB&4
M"QP0%8A0P"S0_T%90"'#)("*:.J0 0U"NW*HESJ:FS%5^T-7I:&-T%_SE083
MUOG@I+BI?]H</_'N,=63T<;A!J0/?(O;(D^03G&H!WXZ/M3[Z!$MAQLC3ZA-
M=&?T^<RW=@/6VZ^T^NQ\7?1;P--[@]3W_G1W2!9:[-TBV3P_A%U-==JVB+PV
M]1X*^KB-*KY]WGS-B^5_2-$^<?N8/QO/%R5QP+" -*5Z=RL" 3&B @8JD1%%
M2)ML]CD[!XDP-T;>16+3K<2@K,HP/S6" UI)[L(G@P;'AI?'AGQLQJZ ;<4#
MC08WG7CXG1*[QVZGP=^%Z<<>AZG6@#'&PW%5N ;*_O5B4,L3KB37:+Z_QES5
MTLM$Y=T];\H-79LSBR;@%Z41(P&)]%8@22"*0P8IPX%>H0(49I*Q),"+.D[Y
M\X86FY&=%L[)Z3*-#Z4=;R;_)!^6ZVK&,JI_P>7+A7(?CVS 5$8#1F&BK0V(
ME#3;O816N415$B"&(MF,[)NU^-V,:ROK>*/ZII)OCD,ZLJ>)CT&:OTO)UFFD
MH^?\HO//#L(\'$3.2OG[\ 2Y!++O&,CS';G9 4(N%V^JZA2W0A3FHD'_]:ZX
MSW]=+T3 4<!C#C%/,HAXJ!=QK'>=,:)1EC"6)@S;;#-[^IC;/K(6$S1RW@ C
MJ<81&%GMN+H/T'ZV]033R'PY""%KLK/ X 1=E9+_^2'_]J-^NV8J_9>*H"IJ
MZFMS$G*Q4*JE!YM'A_I5;/1&0HHWM##V9=EZTH=)D"@E8)#)""(<Z#D>)RF,
MDH2&)$R%8]:,T]W,;9K?<KTO?ZXS;KZ6:LF7SHX0)]&T]7&X%J/1W1=J 4$K
MX0B%Y_M!\.QN<+*KB3T)^M0]=A+H?7H8 YB8ZIVKZ.UORW(1)Q$+)2=0Q('0
MLS\3D' D8293%A(:1*EP"BTX[F)N,]](V''^!E^,D(YNF2> M)OXU\$S\J1W
M1,9YPI]7WNMD/]'-I!/]O)J'D[SGR6$3_-V:%U+O%U[+^D_C/"2?Z%+H)4X6
MA12-E]'M6E1^XG6:]$4<"IEF*((D%<97,M5_DSR%!+&0!4(0C-1B7>6&LCS4
M&2:(U5P@]5SHBC/>E&BD!K(6MZS<^?(J6H16(KOQQL#QL>.6$3&?AG]:!< /
MK0I_JETBZS%H/2?-$-0!.[?]0^!,4-<AZ)7$!HHR*=%=!]<A&5[9VC#"K%IZ
MOZ1LN5J:*.Y=HMQ.<0<J44(DE!$-(:(JAE2E"@:$JX %81PKI[RTE[N<F\54
M3[:.R)U<UX,+/%@@;T=[?O$<F>*NA=*9TNS1\4I?%MU.2E7V,!S2DL.; [Q_
MFJCT[85NF\WCW5I/;%EN/FD;9T'"+,V$Y) 'J80HT989S02&,8E#%I$HDMQJ
MCV;=X]P(Z$.^AE7&FF4C)"BTE Y^)%8P]]/-*."-?8K3Y)'8.7RT M^ 5F3P
M:00H'3QP?$,ZD</-]="Z>=>XP-3K3&/5T'2^,RYZ[;G*.+TX@)G?+[FQ-M]*
M62X23;R", 0EEGI_+*7>&D<AA2RB.(@B$2<QLR;@3L-SX]E&-*"D4SZC+E06
M)#H0@)&YLM7][7#='5AO( 83D9L5%F[\=4+A7IKJ/C\=&YV0<H]T3OU^H-<=
M_RK%\TK>J=OU9BF6JV>3Z?*S2;M;F9EU'* 4;[6 QC_@N1[S.]5>"'R41>4>
M<&_2\R]4@&,9AS%4*$DA0@&%E*L$BD@@PC 2*K2ZJ!]'O+GQ7*N=B8SHZ@=V
M"H)60V ^$=#1T;RTO173:M9^0>!+I:EKF6B_7X'=AOGEQG9D"G^)875WXAH%
M?;\>7'Y%G-9]:Q1XCWRWQNG%;WG:G[YW?U-=4JHDB .J*%1$4I.C,X,X0"D4
M@<::F[\2+X5JC[N>VQ*P7VUUR!VP ^QVO#P.F&,?,;C@Z*U([7E()BE7>Z+[
M612N/0^+;0G;GA9\W4C?<FZB5LI/5<+XRFY))<L8QA'$+&80":$@X2J& IO;
MYP#S+$FOO7\^[G9^M\VMC$TR?2/DM??+)] >>IL\$,$7O3O>(OKI,J(>KHO/
M0S3RY?")CE_X*O@\%)<O?GO>'6@BF;+-=^J74E:WQG>L=JY[M]:&VE?C;_\V
M+^Z>JI3IZX?W1HCVQN?[ G&I2!!$,$B9.?SC'&(B0R@9,4DN:)+$3AYR5\@R
M.R/*J )S!9^-6T9U'P_R1A\S^V2C457\8U5-S]7N)LW1W+IB""WMKVD&9FR#
MK!V37\REA%$$W'6&Y$UW2+;:@$J=[;WT=X\6W/6@^C7IKI!G6AOO>N".C#X/
M30ZX2?F0KTWQB:K!QH=G(6.$XRS%D),LA AQ!$F6A) $B(=9%BB:$>L;E1,=
MS(TIMS?8-0LV[H0.]PRG0+2X:[D2FI&YRJ!2%0^JZ>>-%U0<;F&N1&>BVQA'
ME-SN97H@Z+V?.?7>=/<T/5+OW=?T/7=%M@1V.6J3'49M5O\Q12HUMU9$7.[2
MLRU$&""29 02A"1$ <D@"Z2 89(@&;(LDE(Z%WCP+>7<.'4GF3F[_U:7KJVC
MZL&O7Y<F]VIAJ'9;Q!H\K_5 -TF!\BJ*=D#TO??!M[RU>>DA'?ORYOHH_.H/
MT*@*:EW'R4PYZF#XC\;W+NGT$?EC@7TR*G^TSJYP4O^\?%@OU9+3]4:O:L:6
M[)S;5F7:[]1>Y;?Z\,3D@5-I&&=)'$*.:0*12!)M9\=2?RTBS@A%QO)V]F ?
M+L_<UI&_4R/6ME"I7DL>ERL]D/E:=L)]FE\[UB+U-81V:\2$ S/R:E#[R7=4
M 8TNW:H0-Z!2QXS8?FG25B//;O37(^O?Q_X*F:9WP+\>P)/>^1Z:O29ZJ"E8
M_6YM3-"*(YI< &&:"<2I@FG,A+;JA;;O98 ARQ@+DY#$&:7ND4/GNIL;K;[*
MBR=3I%0"EJ]%'3FYSC>R_*<_XBB,_KIJ*ZH/B1LZB[D#47I!<A(>W!6?[\@Z
M0D8&.UA&"!0ZV^4+! E=4O]T@-#%MX8F9:K\V6E5!_TUW=!7ST6A6U_@ (4J
M% E4H?'D04D$J4*I^6>L&,<ARJRRMESJ:&ZLTB0?Z@@+C+2@$=<U0],9=/M9
MQ"=F(_/'4+@&I&OJQ^**G$UG&IXX<5._>L?9FRX\/\S@.'0?_(F62RVD$I&*
M&(4A0C'4%@>%&&M6B'!*D(QI))%5Y>W>7N9&!!_D!JQ,L>0GO4#R_/$Q;U)J
M@A^8D1?\J<JR*4RQ]*)^JOJUX\;M-.)V5L;5.(Y-#D?NSC>@DM&?1=$+@5=#
MXG1/D]H/O<H>F@W]#P_<C^Q=WK878AF)HQ2E"*:I--N0#$,LE(0XPR@3+,8X
M<-N&G.IE;O2P<VVH;EQOW*Y<^P&UW&-<"]/86XM]YX\;?Q>+5@CXW46<[&G:
MS4.?LD=[AMZ'ATW^JDR<%*6).7A7EL\FT?2=JKBE_,5<?+VKRD-I>^1V+?H*
MY019K+<3)($T"DSZ]B2%).&9_@\+M(41<1$X%?'U)=C<**;5JPXE6C::F=/(
MUARI+AKK2T>]2:RNM>CZ^W\M^\M#N5&4MV&W8[67&,R1B;!5Z0:\ZXQAK=+-
MZ?O&W770#=C5\:P3,^L?5#?./H^??:/NE7R]"3<I7_N&])#BO;<_P//N_NNR
M$'0MWNJYLOG:U!-I3THEY3S%.#3&H*9YFH:0DE!!(3@EE(@LBZQ*)5_L:8:\
M74D'[O4TJ*_XC-@.;F>]N/;SJ%>T1B;&2LPM/INO8(O<Q:-G1\P<?/9\83>1
M\]X5&+HY\MG@TNO1U]O =*Y]-GKL^?A9O3!Q::0W__Y<'0&VJ5W+ZI+@_BM=
M-\4;/N3KVF&MJ<(2Q0E+,,60*,H@2F(!B="[]3C0>W2:I7$F$F<'P"DDGQNY
M=ZIBM+Z TQ?;<1[^((AXD- (DHS%9O@II"K#,(TYC@3'+,+)A!6SQOP(_N^J
MI.7\):0XU(99JF"BC3 3&*&WX5AQO1</XT#() BC=+(*6^-_!_\75-YR_@3L
M-N*S'-21#5(//L*U]ITL]V632WJC =C5\=IB,*,J7D,';A[5O9RE_WU4_1HZ
M*-ZJ@0T6P-TAY76S9;K7KRZ"1/]OF#&(E2D<@E $<4I"R+ ,8Q%G62"LC@\.
M&YZ;0=G*!HQP]NXE>UA==B<9BL#(A&NGO).SR"E-!SF'[#4TF3/(*?&[SA\G
M?S_;W>>G?+5ZFQ?FI06CE <8:WL311(B:3:CB8IAQK"2V$0*L&!F6]".^'.C
MC9IL=Q<)LS,VNT,_&XMSX(#^YS4[=Q\0^&+  0TZ/A,2OLBP_MZ,TJX*_]DL
MTQ/#\P+FZ2DI/%94Z(2$F/2]MVOQ:I67R_7#J[S<E N)&&="F)!KE$#$900U
M+620,)$(&<H0IU8'L%?(,+<EK".M:T;P@8-@<74V/K0C+R9]A0.ZB!LM@%8#
M-'J 2I'QQ\!#Z09_8S&#8@Y7C(F?"@]V: ZJ^7"AZ9>O F&GNU5=",NFAH;I
M-/[]G^137AC'OL_ZFWTN%\;QEL946RS$)/8($P$QXR'$(5,R0DD8VI57O=31
MW-:.)NZD$19LI06UN*YA.F?0O7RNX@NSD1>%H7 -"-/IQ^**,)TS#4\<IM.O
MWG&8SH7G!QB@KTS$"<N+0POY5;XV'=1_Z\8B+Q_9<U$EJ&D<@35M)#+51F<"
M91 %FC9"#FD0*ZB9A&<T$T0AJYJ#O@2:&[W\3'];/CX_@J(CZ[9&JX.-Y&.L
M+(S6B4=@9++:TV;?%W:GT'Y&AAO0U:F--)AZI!Q,VXE';"([=X*1<[-Y/<+<
M:P#[Z&<Z:]@C*GNFL<]VAUUIO,H?'XUS/%U]I$^R:+P_4R$P-I75>!8HO=II
M^YCQQ)17"U622<;"S*J\6F\O<UO"=D*"2DJW"X+30-J=XU\-S^CKRSXR(R2Z
MZ(7 Z]'TZ9XF/4'N5?;PH+?_X8DO,NL[D#9JXO9Y\S4OEO\AQ2(S'K*,4!BF
M*FK<95' 8$0SEF*<<8JF<9<])^'<V*:Y0Z); 5_ $>[L:(Y\_>ACC.9_PWAT
M7[A3= 9WA9?&8![7@6>E_'W<^%T"V=NEWL6.?*0O:#HL%Z&,*<5!HNW!.($H
M(B&DF:;]S%2X#(4D,G(B^]/=S(VQ#Q(8;/-/7I/ 8 NI'>->#]3(M'F4PN#C
M)9"NS&%PB,&(20RV7;U@%H-#=?O3&!P]/:Q6Q&.^EAM:=,N2=7V5A$H5B64*
MTXP2B((X@BS$#*8D2I60G CE5#FBO[NYL4)'X+V;24OGH"& 6YQO>H5Q9,YX
M 03=*E+X0W*Z^A2G$/57H,(.D4OE*BZT,FGQ"CN-#DM96+XU,'V,'M,/>I2K
M@J5ABAB3800QIU*;7%$"2:CI5JD@3/2OLBQVJD?1;7QNE&ID T:X055@]V"S
M,ZN&@C$R,5KCX)Z]Y(3"?C.0=#N8-HO("=6.,H&<>F;8)&W3S+Z6;+-(F"!*
M1 P&)%(0L9A S#"&3"0H86EHBCV[3-)NXW.;I+^L2U-<6PJPRETS).V!9C=%
MAT(Q\A3=Y8$V@OF;H*?4]3I!]SJ8=(*>4NUP@IY\9F@2-OE$EZ*Y+FN<2V[7
MPN2E;W(+AT312*8Q3*7&"C$20X)B ;.$R!#S2$HEW-*K7>IR;I.YD;B-R7;-
M=W818<MEV"MN8R_.#63><S3:H^ Y9]C%;B?.!F8+PW&>+^LWAU%*5:NS?$N7
M157*XO6RY*N\U&OA(L9(!2P2>L57*42QM@(P00&4*!%91)%*3:+&?$-7=DQR
MMB<G MGV-]YLN#=]N-'&>13MV,(+-B.31"WC#3!2-J5Q=G+ZHXR+4'AEBO.]
M34H0%Y4^Y(7++PR\3.=?I7A>R3MUN?9->2]_V_RDU?C'0L2:$D+$M=6A]&8A
M31%D01;",%(QHIHZ,NGD8S-,C+E9(JT6YMIT6^L8O-839Y.#;=U5FT,MGV-E
MQTCCC\#(=-4%WZK>5PF^W%=>B$8;4*GC,P[V*CS]7F /$V7:6^JKX#JZBKZN
MM6%4NB7G=^NGYTWY7GZ3J[!QI<-<D3A,,YB(4/.E# 0DIKX.CM* 1 $.66Q5
M7\>BK[F1XO]ZSC=2_-,?PS3XZ\=BR4W%+O/WY1K<UB5D?J;%/Z0IA5BI 4)'
M#Z(^W.VXSQ.:(Q/<S@Z[ ;6@-Z!!; 2?1@M,O))47W^3,I&%XH=T8_/*,$[Y
M(#?&9OA8Y-^60HJ?OO]22O%N7=<%6ZX?JAFTW"QE><O*C2D0M,!!+(G^'RAH
M'$-$0@Y9%*10((P5CV-.,Z?RK.XBS(V!*JM+K?)?V]SZK>B ;F7_BQOG#!@7
M.RH:%^V1&<H44:K ;L4W3H8_& TTYG\"6R7 3@OPI=7#(W<-!]$KI0T08U*F
M&P[3(0%>T=(5>>.,#;>L0TM,N.6")C(6<2)A@F@ $<Y22&6209DB086V.7!@
M=<W<U\G<N&V74FTK:!/O.R"YW"&@_93E"Z:126D 0L,RT)V!X+IL=(>-3I^9
M[HQ:)[/4G7O68^*=[;G**UH4WS6W5(;7 G$>L9!1B%%6I9LS!4PYAC&AF&8H
M"3,J[%->#Y# Y8N?+FEU*R+XUI8V7VW/I0JYHGIG9LZF3#FADM9G)^IY\UQ(
M4%3:FQ6:'2:^]I UYLPH)B1 21I'>E^<8'.LF$ 21QA&"!.JHH@3HFS354\R
MAN,GG/8Q@G(O:?5XP]>_7HP\(",O(WU)?;;"WX#M<%7RCP>UA[Q*UT,^@WQ*
M[M#[2:/4#]Z@]$EGFGSYM$G]NEJE2[K0Q$#WM:;1995_Z;,IC_<U7^GWRSI-
MX()SE:K05$")3%+IB"C(%#&5C#,1(ZRR.,0N-]J7.ISEQ?9VO3 K@:D<5';D
M_J<_XBC,_@ID);^C(]PE^.U./'R".O(:\/X R3?]J+D[SEE"X=>9[E*GTSK8
M64)PY'1G^][ 6$)SC73+>?$L1:>KQC]GD3 D),V,6SOGQL$]AHRQ&'(>!"A(
M)4\R[!13V-O=W,X@*FD= PG[\;1C#G\HC<P;]75T(RGHB'K3YFCS&&%H!8K?
M2,/^+J>-.+12_RCRT.ZM8=Q1GX)6L8S&)5C34TU)GXT+^N'=#46I9A*(N#G%
MH"B$F/,4)E@DG&4XR9!5-*)[UW/CE([D-Y5[>F?!!3OQ;:X/KAT4.S(:!^J1
MB<DCRLY$Y0Z85])RZ'Y2 G.'Y9#,!K0P++3:7/F\>WQZWIB['DT*NM?&;WDA
M9<+26!.99%1!%- $,IP$4"H694*D*L#)8BT?S/'5O7UT]?D>K285J2?54;\C
M3K!:6+!LI&VS2MH>W;D%#O<,B,71W/7X3A9R73M2MN"VHEX,9W %S2W2V@]X
MTT59#P31.=[Z,BZ78JU[6I@TSOJR)H<QUA9O>$V"9B*WS2T<_RKOUK)Q@M,;
M4RD2FD$J4VU5FG*@) U3R$.6\)B+$#.GR$Z'ON=F5C;R 2V@ES1E)_&V,QA'
M0G%D\CV9,JR;^;6#\ A>B0- FR(7V,G^YY#EJP\8R_Q=O4V,E,&Q/)<JK*GR
M\^8WDU2RE.6[]<?J'O;O<OGP59/L[3=9T ?9_K[R-UY(G!*F0861BO36.@DC
M2(,T@@D1@>9!DJ7$JK;DRX@_-PIMA:MS/@J3!+@H@4FL6N5_])W^T>^G<!4U
MSV" )V3W<XDCRPN9([?5Y[8@Z-T/J&&X 2T0H$%B^Q2HL)@PM^0H8SAMXDF_
M*LQAO1IY>)Q35HXCQ;!5\Y/>/.AF=.-F5[&(0I($&3:)*],8(IJDD&4DA0I+
MH;BYW,96M8!.-S^W56<G'3#Q6VZ+S %R=HO <#Q&)ND.%*_ZH'"FS-,:>Z6T
M@RXFI9S3ZAU2PIFG!IR05I?0G^EJYP7S23[2I?&DW.6XO7W,G]>;129I$""]
M,0^S@$&4HAC2.",PDD+B2'$F,+5.0^G0\=RF^>?F'+3R40%%*W8WTSBM!'<X
MXW,9!XMCTI'0'=NRJP"MX.UXSVTE[Z3W!K=C NQPI#H2T!,=L/H#W.W =0!J
MO<>O+NU-=Q@[0,N]H]DA[P\)8JAO>3[28M--LVFR@QDWI9_I>ETE/I>;S:J2
MXF<MPN/SXVOZO?R0;[3->)^;AY=KW8RV(?/B/O][L=QLY+K^]2(11"6*<KU<
M,&'R%V.(*=6FH$R3+) H#:C5V>XTXLYMN6GD!T(K -:5B-6-7*L#>#)*F!_]
M6JO1/.3BUSWZ)V"Q9LUJ8$<WC^N;U4K9;KZ/&U#I6U7<K34&=PKL=+X![>=@
MU :U8N ^!UO-0:6Z^5&C?//0K#X'E\B .7T64P43S.CS< Q%F&JT^J,71I=B
MPH"'J1#=CY&8K-=QPBJVCG&$J4R@-(4B(!E$IMH>E2F% 0\EBA1A5#DE ;/M
M>&Y6Q/MWMS^]>__N_MV;S^#VPVOP^?[NU?_\'W?O7[_Y]+D-L'CSOWYY=_]_
M_ 98.'HHC@'OR&OYZ8"+4=P17=&9- ;C95P172%QC<FXT@VQ[>8-+<R^K?PH
MB^JL?I?Y#A.>QIB$4%-1:C9')OZ+ZVT2244B9,"$6]V!LSW-CI'RLC17;N82
M[S%?U]=U;N1S'E4[MO&"U<CTTLI8055)";Z,D@SP(AA>V>1\;Y/2QT6E#_GB
M\@O^CF":DN]OGZO0^.9PDBD4R#0,H4Q5 E$2!)")4, D)0I3$6":77V8<JKC
MN=%'(R-0M9#N1^XNH \_OK@6RI<[B&@!;D1W/W)W ?CZ X%K@7[YK;TCX%XV
MYGVH#=EBGVSOQ3?+?5K:;'M[W_?A**%-3_.',3F_T97QZ3C]T\9YERF:)BD+
M8,1-/8TT$I &+($D"A,L1(AHR(>[5;@),[=UH0H8,/NPZB\=<<&7U[FY/G$,
MPKMJH(9X<8P'_\AKR17(7^D&,@RR$9U&' 5Z01>38=#U.Z0,;'.@G[;9LK\K
MRV<I7C\7FIYK'[<J=TOUNP,O.+'( I(DC$N8XBR#2&($B40<<LF5S%+S4Z?D
ML\X2S(TRM^ZM6Z>6O);8T4W:>23LZ'%4?"=Q::F%![7T6S?C)DUV_4BCP];5
MV&<%^Z'X^744=I9B6E_?H2 =N>L.;LB-_\IBLV@N71IC@R=IQ#!*H5*IR<Z@
M8HAIR&"5EY!C3$5FY6Q[U/+<^*H1SHZ=CG'J9YVKM!^93=K+77\Q:V>U[9O[
M^J7.O-?_.ISSQZU.,I?/*M/.T?,/#,RX5#S0]?(_JB.#5WI.YZNEJ+WSU^*C
M'OCV..%.O5VNZ9HOZ>JS_DGMM;\KC[0[MN9!&L<JEI A0B *I=[8$2)AH 1#
M*@I0@ITV=KX%G!L3?'Y^?#0UN+7ATBVD<\NYV:)7BZU6F5LG*1AM8.TLG9<<
MKI&IJZO:#=A3KMHS=M4SP[E5$.PT[)1V&^D.9*P!\)O*RK>0TR:_&@GBHW19
M8_7C;J;=*K5<+<W!XAM-2IOO6WLMDEAO12$*L"9[16+(LD1 (57 5$QBE5C;
M:Z>[F!M=[Z0$M9CV)MP9#"_;<M<C,S(S'H'BV;SK!^!J.^],\Y,9?/WJ=2V_
M"T]ZB9[JAFB^E5+O_;@AF@=YI_Y6Y&7YL<BYE*)<B#!E G,$48HU \@L@!1S
MC6RDDB0.D!+<*M[_2CGFQA![ =U*NG@M7S$8%M>[TT \R6G48;S/'N9:DQNP
MT\6X%U?:@%:=:4;DJA"L,4;F12.R/(W0M4%:KK@ZQFQ9-_^2(5RN&%R(Z')N
M;F!!]6]TN3)U9-_FA>G?Y%SLI%KD^MM^KFZ^JTY_61>2KDQTV=_H<OV35+FV
M@^EOBT *@E <0\5CO7 Q1"%C)( $T<3D[HJ0*;YN?SKA1:JYK6 [,8&1T[%D
MNY=QLCMLF!S]D1>W*C7L3H$;L%40:F&AR5YY SIJ-:QY,%XW@%6Z :V<Q_KQ
M/K'V6VO>BV33UJ7W">91#7NOC;L7#KPOJ/$Q^OS]D>5Z#@<IX2EA$ >(0X04
MABP(4AB2&,<H0:$*K*)7CEJ>&VLVPH%:.ONR@/MP]1/?52",3%Z6^CL5_3NI
MZZ!*?_LM35;>[Z0"W9I^IQ^X.J*L2:F_#5V2H>1((0RS( T@"O0VG:H@AH2D
M3!&<*AHZY>8[W]7<IF4C7K<\CV,1XAY8[<P4/V"-/'U/E<L8.P+L#!ICQ7P=
M=O=245YGU.Z)ZSKWAG]_LP_RU^HWY4(%-$IBF<$,)]24^<T@1IQ6I<XYSS*]
MJ#LE/K/J=6[L8:0RQ1RW?F7^_,EV2-NQB'?\)CFIZ_4;TV+7#W@X\!D$TV3N
M8;N>9^,2=@2&BQO8\<O#J.AO<BT+NKI=BUOQN%PO#;]MEM]D6QH@5AQ11F*8
M,,&,-TD*:<05C)D441RAF KA0D(7^IL;_33B5NX%=$]@-QZZ!+,= WD$;V3N
MZ>*V+ZN_N@N.J'BEFDM]3DHRE@ <THOM:\.(Q1QZG/)BDCPF42H)#$A((,I,
MN085(1@P+@,F TZE4PG!,_W,C4B,F&Z4<0Y .ZKP ,L49ZVC>V-=P,$K*9SK
M:U(RN*#P(0E<>GRDP@=VZ:;-&6IOFGLL8XIC+B%)6:RM$TP@R50*&<Y$$D>*
M\-AMBS2-W',CIX[8@&Z U(NVWFX]5=;F--4//'T/EANY^8WRV%M!BWH'CN4.
MC/9S*G/@=\RFK6_@2?9Y%3;P.R#.%0T\=S_0"-ZNK'>J*V>3(^!57F[*(S'+
M3F(G)01#+(2,*Z2-9;W2,2&UQ<QDB#.44D2=$CM=*<_<UJWZA.NC_EF=-JW^
M]T]'-.=H>%\Y:)8&^G1#,>'B<J)4VEB&O1_\_&X KI1IVHV"'P"/-A2>FAU&
MN&_ILJC.1]^MGYXWY7OY3:[BQL\?!U@*B5(81 A#%.E] HEC!+$R":\"(4CH
M=/+0T]?<B/*7=<Y*67RK+/Q:W'_Z8Y@&?_VADKK^>^QHU/=A;<>!GA <F=^,
ME.V%22WH#:A$!?$(E1\M,/'*67W]3<I'%HH?<HW-*P,].6192OE>:HXJJ_#/
M[[OUG9*,)3A)8,8Y@2A-8L@DR32MA)316,1Q2)Q<.<[W-3<>J85T]-[H@=+2
M?<,/0&/[;U12&FHP<H(OM:1@%./' A&_/AP]_4WKQ'%9\2,O#HM7!L1MO=(F
M3'G+-Q\_?GR?TW6S[D5"X3#2>S7,F;8Q*"60BI!!Q022/(I3G%IMV,YW,3=*
MJ(0$6DJ@Q01&3H?HGM,@]K."'VA&)H-C5"Z;"K;P.,0U70W31"%+0^!RBT3J
M1:(WR.CTF]/%#_5*OA<:U/_D%3<Y[/(Y&SMSSG:G[;(-K7)>'IRS;0M1O<K7
ME5/=,UV9<@_1(E&""QH&D$8D@@A'"23ZKS ,"96"(ZSLXEI?4(>YL71'A:,;
MG@%7.1-_$ [7.O,=YM_1%4\'B1-7/+O:?ATXJNI GJ][7F8L_5_]3*S']-=
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M',=)+!$4RE1;XEQ;YWKB0Q0BA5 44H6U=9YOZ,INPI_MR6DEV/8WWA=];_H
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M!X\\!!/9P&,,A9L!? 6.O<;OD':G,WROT'K/Z+VFG:%%.QX?\W6GQ/F"X23
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MI&Y\E3\:U]]ZRJ0BB1.4!!!GJ8*(Z[]1215,,2.8XRR.L5/L_NENYF9Y5S9
MD\B2=^1TJU1_ 5H[,_IZP$;F_XM)/]LDRF\N8.=^+]X+C=\+\--=37O3W:ON
MT95V_]-#$WV>S%+7^*;%F$8\3D(H!=)<$:<IQ"*44,6:Q3,>Q#Q63J51^WJ;
M&V4<I'>$N_2.KODU^R"VO.;Q!=S(U'$>LQ%B*:U \9S>LJ_'B?-76BA_G*#2
MYJ6!]QTF[?E:F#_,)OL;71E[YW;SBA;%]^7ZH:Y@$ <2(XD03 7#VOH(":0Q
M(1 AA1-$8X$S)T:QZG5NS&*DK>XWJE54[N1VO-6P0MSR/L,WCF/?9+005G_I
MB'P#Z :T4ONJU# ();_7%U8]3WMQX0+&T96%T\M#-T!Y4:6.V(67EMLLKX&4
MF$1Z!Y30D&GZR2AD*0X@1S1$.(B5E-QM&W2^L[GQ3R4KU#T]@N5.VK^X[H%Z
MT+7="?G!;/3]T!:NCJ"C9-BU0<3S-JBGPXDW0Y=5/]X26;PSM'YYY2!B:KI\
MO]=[WY)6B?CK[#/EG>K\;,'#E"<J(E P8\KP3&^3(A;#D/ D0QAG0>04O^#0
M]]RHI4FK]&3RX9O"!IN=J*YUR^WQMV.;D5 =F7P:J:N25M]!1\:;)H55:2Y!
M[BU@'E"=W!DPSU7)[?N?N!JY,S#'5<C=FQA&9._S]8-9NXP/W+UNXG5N\F,O
M2,J2,$RXWG[A&"*:Q! +&4$D0BR1B -$G.R?T]W,C9Z,E/5*;N2\ 492\*66
MU=''X@RN=EQT/5HCT\XPH)PIIA\'KVQRIJM)B:-?W4..N/"TUV.:UG!'DD5Z
M7T1ADIC8>L4%)#P(("(!YRAAFC:<3)G^[N9&#Z\.SF,<MT3_/W?OVN,XCJ4)
M_Q4! \Q6 <$974A1?.=3Y*TWL5D5^69E]V!1'PQ>,SWEL&,L.[MB?_V2DFS+
M85LF:5*A6@RF.B-"(L]Y*#X\),_E"K8WG<1,;UMT\0@FRL[(#I8QSEQ>97=D
MI[[E*4N8'5+O2K#6G?RZ6M+#;WKV2]W==&B#(T\QAH"D2 %8E@@P) N@5)J*
MMC:<5?5JS_XGQS47?;'-G.K__+#Y+O5.ZCM=)L<O^1DNKN-F>4,5;S1B\]@(
M ^%^M^4'9]C;+D<9QKW_\@/HY$;,LYE;TV*<O\S_(C4SS[G>&#;^*G]?SK54
MQDOU7@OQ8ZZWBB:HZ1"KPI0D5<5S@(6J )04 H93!B!/"5%EIJ!TBAL*+-_4
M*'>GGCDQ.:C2Y?IM]$AVBOAFU0@SKI;'YZ\W6M%/W*]X()V,GE'N;C]ZR>^-
M:DF42*9(L$=*[Q%&QE=* !(4X,LI0L)VXYE$Q-@6>OE9':?4ZUSL9E+OR_-,
M$2 +10%D$ %*20E*B)"VGGDFB5L2D<'NID;<K>$U[Q([=BZ;/S<A (XY0X91
MMN/=<-A%IM$6MKZD^^28G; A\V-:H1(V9\APE^/F#+%2_R1GB-U;'K%)YZY&
M]\69#H&A,UR2G!4X!T6>24TLD@*:R0PP1:H,YJ+*4RN'+)=.IT8O;U?K)[.5
MD\8U_%&N^9PNDB>JQ^0N8:NEJ)N=X'*UL4V>[30"PZ03"]?H%IR6N*FYT_>9
MN$MZ1=X.<D< U2%,* *X(T4&A0'9+1+($:W!X!_;ML:+]W'4[BC$Q_5=#U+_
M^.7^?\'/[[)_?/SMZ[W^WZ\??RD^KU??UO2Q.ZSC>9Y712% 654"0*G73<JX
M!"F$5)K2!VEA%7!OU]W4B+P1^"[1HOY[(_-=0]SF1R-ZTLGN0N+7$;>@[Z X
M1B;N$PA?HN>3"ODZB@Y\'13-D9@Z *IN-&T-TB!!7V]E/&JVUNB(E.W?\BPQ
MT\5U?EW=\__>SM=2-Z[MQLWS9SW^F_NE,/=N30*C&5-,P@I3P/-24[-0"%0E
MH:"05*(4HTJFPBWYGGWG5E-BU Q[^Q*-*Y4\=6(W;"UW,CO6J;$?"+M=?F!P
M1P[=WZR23NQD)[>F'R-YNR:^OXJR>_$;9\#"EL6Q[W[<@CG.L)R4TG%OP>?
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MM-,RUF\%W=DTO[G#UUEP_B%KLT-8"N-4;]*-?UV97W5[!7,M-WQPA265/"4
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M >I2W/^0:_I-=B4+Y>?UG,L9SC.BRM0X*^8<0"8*0$2& <Y*5(F4$YZ609.
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M  8S!0J.B<GS75&!9MJ 9ZL18>WW]U<%UF)1"P-6Y*7L$DH^E8$'X')8N<+
M-M)ZY0^?VT)U'93!Y6G@]?$6I>LZ'"U%%H][+$#=HO:W+37G%5+6>M?R.&\]
MA^\?S;W^KUJ5SL>TJ&0F18H PI@ B)4 E)>Y248J9)E7*6;VI=9=>I[:(K5/
M'YVLY<)D_S.^^IOO,JF[1)MJN]GJ>=#N0>:RODN6TL7\=1H6"^Z-!7;L6\/.
MX#W(?9?T)+]+6MGODH/TL4!V8.Q88(_$X2%!=V-U'^ &>=ZIP?&8WT?/H[7
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MQ4_J@EF\XDLH;',HY[P[5?I"-[(I-BD.V3]G0L&<,JA-#*A, FF& <DUU+3
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MD$0&*!44P%QB4%4Y ;1"E"%92BB@RX':[2)-;6/>:&2N\GI&Q;S1Z?]SH[P
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M-+9&3PF'^$W741EFJMA81V:L<S _]&"^/X;9)U[6%6^'6-J(N(\49QL<?[=
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M'Z]FKK;E6.W98&SJG\^%WAGM-?VRUI/%L'+[.5+^"C0V-UV;FAX\H$D"JB5
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MR1MP#MA)UH>= G:XS+0SP$ZR>3 ![/25;F_X3HI9-\"$!IZ?13YD$:40A8F
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M6N.F_L9!19:Z28MH\O=6.DQC? CM*#.#4/.HDAA9$2DAZ++?ED30T=CEN=\
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M=J?I+"PKSG;L++MO.E:9Z)QUI?_;V&;.JZ_%BI.E<IY_(7GQJ:RJ1>ICCEG
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MQ_L#9+Z"TT$ \F8^^W3_4E8.!6J36<J&"(^!,_"T!70<$B<-J^&IB.'^,-E
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M.B!)L @^,%MLDB$'4MAM]-=F>KJQGAJ&FPX71 ]P^LZJB7'.6\R:_(8Z8Y6
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MO3N%=%O/<A^(&9;4=JA=BY/SY))ZP:0'F[*&P&V;W/C-](R,I8&E/A]<!!T
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M.1V6M,[O7U,QG2\NNY!\G]U5XQI75'Q<CY85*8"A(T\<<Y(N$9,8"%LGA&&
MR$7@N4T?CL-I_S/$]7?![P/3]KC2[\!Z(#[7)GV7Z=_OI\M__';QD7[UV;?I
M<F+MVK6DFPRT(M]2( O<$NR2=\9S[R*T>0!X@JB1"]>/C(_[@=6!A-4C[NI&
M7LS/8#J;1,,U&=F*94B9Z8"1!:D4\P'!IZ"EMFT>/Y\@:ES<#2;X'P%J3RGT
M *BK -F#+?V.M91E4CQ YH6S4.?&:@.)>4R!A<!+$AAX+(VZ8SU-6&? VA<
M]X$UH#1&!-=RL9K\#O^7-/W5?I;K(U<B*JV<IS.F(],9:J:4M0QU*:*@MB5O
M];!#'W\+1_35?0QM7G_DMACCW($#B&)D(+V%,ZSCUV[MX>JD"5\4.'#,^$(F
MJR,]3HJ[L!*%I+,G+,]Y,#P]2L8XFF@(N<Z'9O+8#8#^BC-B&:;/KV?I2F-*
MGZW43K!4IQ!HHTA9"DF^3726"P$RWA]9\DAM[,//'D_P TEK/ASK>K!D'AI[
MO^$L?3Z#Q3_69R-%=-;5X<WK5E8*:X%:=,P95R173H;[9=+M_+([E(W<T:8[
MYVQ_L74)P^O=7!U1[I2W(&K^60U!QVS)AJ.S)8VQTMNLHSH6#.]2UIE)?1 .
M?@BR X32 <CJ=-KE5<K#6UQ=*>R<,R8PGB6M.7&H)N)H^H-+CCF(6B?1)O"T
MD9S>X'2(Q._'.P]F?P<8VE;;+V^I^S<W34NS2XJLRU+C)4";S;5I*=F=F)6U
M0G&'L8T6.XCLD9O"CWO3'D_@':#[;MKLA-/MH%T*M2FXKP/Q' M.:)8Q5I;6
M%E1M8J-WZ1A7)QX1  ^R\_:61@=8.JS5-]J@U_-.K-+B,AY(AS607ZZD5,8Z
M'W_6^0+-@F7C(?5XLNX!V/>-).)O_09\0C&A>\;Q0.:,4S4AIXYY\L9%IISP
MQJ+VKE&/G:>H&M=5'A&60TFJB]JFRS9I)^4R%[8:-E?)L<2D%#"%$IFSGJX&
MFVO'BU"8E'1ZZ R)(MOX,(_3-*[1.![F!I)2EVET-QF#\^]),=\;A.^5./>C
MCSP\56XGH@=*CKM9\WO#@^\Y0S[$*'B=^F>A$ QX9EZ8.F8Z9A4(=M*W*3AX
MBJH6B<&O9U_.-_=\( 9(HV-F1GFZ\5.(]3&6+%OPH M/"G6;,8$[D3FNWS$8
MAK;)^QU&5#^CTEI'"%JHKJL/;J[ -FW@&&HLDEDN)<$AF9 (&&2_!XZ!%1DS
M**>E;]3*]"AJ;#U#8'EU0O+)[#V25!;3V:=U-X9;71?(\W8A(MWITM&AH.L\
MD/-2.SD6[Y0UME&/PUTI[5B9[8*D1Y59"X']C/KLJC+@@%J&W19HKM^>VM Q
M]!Q'YWU*MC82K%/#2V80":(JJ@0:$OD"C4]X>SU'[M'U,)0I;CI$] -OY[/%
MW3.UCJT[B2%S<F6 5QZ1\\S 9_*5-(;BA/1.MJG@&&P+'6O&7;#W \UX)!%W
M$)^[V?AO%[<LW%<+_,]SG*6+];.XB#8&G8F=0:E:=AD8\5,RYZ)5&)60JLV8
MA"V(ZP2/QX7-8^ =2(8]P7+3AJX3T0QJGHID/*7(M,^)1>,"\RGS6N$.2K>)
M'F]!7">P' H06SC%ATBG4\ M;\[M5?I%2-QK+1S+ >OD,] ,"GA6@B#+VVI4
MJ<T[VS;4=0*YH2"Q!>0.DD]/F/OMXN:O_S[%!1'U^>(-?L73]4EU$""*Q)GE
MJG;HYK7K0?*,?*^0A8\VV,:H>Y*^<9]QN[N!AY)D3_B\?>8>[N_J=#NOE$ Z
M=RX:SC3/A04N#,,H?-$<5'!'5(Z/D=F)EAP0)]LHRD&$UA,B+T/P:XZ)*^7O
MBPT9K:,-*%+^%@WS]!UF43IN"_U?:&P./B2J$[0-#X7'0'>@7#J%F+S:2DHY
M.<L=2U'5NDL!#!SM3(><7>0U]-JX3<]#HCJY?D>!V#YRZ11BZOJT1*5%5F2X
MQIIH0X8K\U(:!LHC70'!FT:3=9\@:MR,J'$AMH]<.H#8YD:^:^."G'PC)=;9
MNAS(\0=>YPK5^51&9*FP=BUHEBRZF:9. #:J"S&0Q#K WH_:26_^[M4Y(]O6
MYU"0)=3$0B$2"X$V;)-"""%[[^$(6?2[43UR'=) R'DRH;ZA&#N [._S&5[\
M#HM_X.K5^2Q?[\)#0D!A6:(=T&7B,NTB$_L@2T$GFJZ8-L]UF^D9%V;'P\-\
M<.%T +$-K_7K(\K!&9"64%"M"XU(OGXNGIDZX4EPM&1?M#'X-A,T;BIR'W?Q
M$++J '(?%S!;EMJW8Y8_X.+K-!&+3C;GQ=%'+C?_TY5A742-IR,9P&#(C1?9
MU@Y!A"J9(JBD?8(V.!UR%R/'8X: U;P3&8_=B.7Y?/%EOH 5/I^?G>&B;N@=
M?,'%A]4\_>.W.=T3:]VPPNO[0I0BG Z:.5X3YV36S'MNF:(OB<U0DKG7RN>1
M-BV[KCPNZ,8#R/Q8TNI U0YQ;[VY*:E!R%DBV3+H:SS+U!Q/GPWC3I+EKGB4
MLDTI\:#;&'=>2">6Q&BXZ.!0/.*87N?K:0V*0PIDL0,YITYR%JWC3%HK!6+R
MOAQS@MCF;-&?,:-L3\!L%Y#:1WK=8G%#/NDDV1RS29&9X!W=<=4:*]$R+RS7
M6+24J8VANS6)78:;]L+%5I [5$@=H._#Y_EB]1$79Z]G7_&JF/:&8]*%"-X8
M5OL!,YW(!PA&!(;6R9B4$H&W =Q35'7RK#BZ%AQ,<F/[2YLVLNED@0_"8.8L
M64',RIF8E>B,*?H\B89[.E];N4E;+CARV_C!Q#MOS.L.M-C3N[EA&PB5(X)G
M*=/6M#21!>$Y<XD[#2G+$-MX+]O1]_,_-@ZCV1I(<VP=]V8^^[3%L>/>I>@@
M,HLV,!W1D(D2%2N2&Z^L= 6W4W';K3>NAFLAYGE;GG?10.;R?&[:BB[$* 3#
MY+I#?BG 8@B:838\9Y=S:%3+_2A)/_^;S3 J;1B9[:_%YBLX;53(?.MXW:5S
MNS+EV[]^>!'RH\0,5&)\Z_-?8%P18*H[N+KX4#&SAM6-WG)0G-$<F>-8!6LR
M\SE*AM'*R%%$W6BDU_8T#FAVO9Y=K77Y'%[#DP]6)?\9%RN8SCXN(-?CMCX4
MF[J5:!X%SY*\YO4X35OG(0KCF4^DDX601><VZ:RM=M3-33LD:I^PV\:#0Y?-
M'FYQ9O]&-0\_9%!]V; !S0[XX]8;#3&P()-B.AC)(@1@:**P**2PHDUKY>-I
MS>^=D/]&M@:<3O])")TOER>S^]*X-;(]2B^0"'<.;'7X@7FEZ0^/:+&D$J&-
MY[H'L3^-KML%:X]/?6PCQ-[5V+.S.LB=-OU\OES-;S'AKZ30ES!;,P/K7V[U
MA;DCF[T;VS2@8E!%VH0UQ]?$ I0TQA661"9+($@Z'8D\<&MXM-HJD76;9J3'
MT\3UXV]]ZE=B>SVQK^:+.N3@\HV]%)>02\6$KT.E>*AFAP@L!4!5!!:KV_C4
M6Q#WTVC:7;!T7],.+:0.PM6/I=M%#P9<]"R8VD';6,Z@<$Y_(Q,7G;$B-:KB
M.R#CMAF^!A?\EKFTNTBA S -FD9GHM8"?&*(/#$=)6?!"\<28G;9H!6AC?G]
MY\^EW0E6+7-I=Y%Q!_B^2="\JP^NRS><S49ZI+.?:@UW#<IJVEM2SAA><HC8
MJE'_$V3]B1)K=T++@\;]0XFNBX>7[P;/S2!MI#,-11NFLZL/\9GNGTB'FA?+
M;0'(PK8I"GQ(R[AY,:TOZP-YWX$>N[N#YW0J/LT7TW^N)70]=-2$8!S9Q877
MSF?96A9B1D9'@2>#DDY;FQ+[']/6BZNQG_2?!-/!HN@ 7)OR>J[K%1* ##DS
MDXA^G6IK (Z.N: -2 XB\C95]8_3U!.8#I?^%GEY>XBB U"=K#[C8D,6Q=5N
ME.0V&FZ8M5#-6+)JHX*:*%9G/PD%UK6)C#Q-U[CW8&-P#2B2D2?;OX?9ITM-
M#C$5(V5@1N8Z:MM%%BV0GU2XR5"BL78KGW.K2?8WRXZ;;-?*7-J?LSW X0K%
M-5(8M3.,RW5)?@(6L'[IH[!%6A[55F&P[0$Q]DS[/45V7^A[\&]DL?\^G4W/
MSL^N"2=(R^@R4TF01^A3#9%DPKXL*6G%G79;O7)N)?@[2X\L^GT$-Q^"BV.+
M'[[=(CR2'80^ XNXQOZZ!;10#$OR G0P2:?AQ'][Z7%LAL'$OS<7.S ROS^D
MW[\%O]^/;VYR,+FQ@O.@29+H:\5K9"&#9C8XJ5(BX/LVX;Z=R!PWZ[5U**:=
MQ#J X_TMW6/F[:?]=7KP)/E,?AQ6GZZV]2MD<@?PM-T(X'26+HHV-7*[4CIR
M.5,[T-Q/M6XIP<$RL)LA-*7SL_-3\COS7Q?SY?)N]LEO6.8+4@'?)J@Q\@B.
M&4C$81$B\[HHEE2*-@3R0^\7TQT'MMN1/ZZ/WPV6&\BZ?Q7\Z*9K6M7W3:LZ
M*R22!42.E"$K6"?F;7U]126)'RYQT1? [Y _;G2B?X#O+^O= 1XN 3[#3Y60
M)A#_ON6[#)@4'XV/R3%, 9F.6K-(.V6\J,!+XLUBK-M2.*ZI.QY0!Y'8V%6I
M3VR*H+YV32<B..6MJ0TQ)7D**A9B&@_,!YXD#P%<O#=B[9&2U"T6&[<O4WLP
M-6%ZOR#Z.TX_?2:5^>PK+N 3_@ZK^@\7DY(]1B&11:RLRRHQ@"09BA*\L#J5
M^T[\SI!Z9.FM &;_M  ;0B!=%B:0H; XQ]O5O?L4%FSXE,,+ WY$VD")_9</
M@]\7V5!(KU7P(67'O"%]HI5T+,K:_TAI[:V(F1R!AN^U3]$VS$OUIA6^5]]X
MF55&Y$P50T9B5(5!0F1*&4 D?XC ?N3M=U(R-3!V-K]9#R><GT0#[5_H^>AG
MM=!&#<L^M\"51Z-$!L/ 2\4TNE"[I1661;:%0(?JOG7YT^BD6[?]9J9_1[_2
MT:<Z&H; #W40E6(UMXT9;4WR,D:;VW!A>QJ[UU"[(.F)%XTA1?63**H/YV=G
ML+@XH"+SAY_90G$]1?;Q%%@(K@09Z3H,OJ;'&W+W X_,9>Z= *$U'MNJ&$J!
M7;&<7 A8T +/SQ?UJ$YD#-D[-$Q*NJ6U=N2;.E,8.23&.6Z\]VUVO)F>[A73
M+@AY$'4Z7 1CAP>>?\:S*;'BXG>8G1=BR/E5IZ7G\]F*%EK6A[CEQ)0H=):D
M4DTD+KD0&8@@2*^B$*2ZQ;:=S[9;;]P'I$:H:<7O'MZ$+@_"N\6\X'))8H+3
M5_C]0*1< +//Y)244E^X' LY6(9)&V,3$90:A<F?I&O<5YSCZ*8A1#*VCGHS
M33A;8B5_@D5$8\G3Q5"[1">NB.[$629/%W,)24J^E2*Z]:'C/I*TU#;[<JX#
ME;)FRT.S\AJ_-H(6SB #F\F?4!;(GZ!]H0P1-5CM>6YGV#U*U[A/)(U5RH B
MZ0!@CV]$ ;F)@()EK$ZD(U\5$#)YK9% 09L,C?S]PV#5[&'D.#?5@8+HLOEF
M?7S>QV-?_][A7OG#Y0?RO.L';T!!,LEZK1++.I*4%!CF2ZY%3HC1Y^*E:C/V
M<C,]0_0?VA0-1S*>2@U_>QEHFR+23:J39T%YEY0*3N0V5>6/$#1^'Y@#L;"I
MI]"AC.\RNK?>V/Z!O-N_/HQV:!F>>P08QL?"R28@T2EDN@Z%\UD)!F!%,!:4
MU6UJ!-HIB>]M.:[2]S,*NKCHWI+"UCI/Q3R2F\6S\B$%&U6C\;\;B.E2.>R"
M@4W*X1"&CUQ3]7Q^/J-/(O:M+M["V56W!&DE.>*&A4 ^N"93F8$C!\T$HT.4
M.GNW597"5J55FR@8'R4'B70^('_'KK3%+^>+]!F6^.S3 K$RY/Z6KEK_")>2
MMX*SP%T-X7!'F\J>*0Q1*RGH@MU*RVQ7A[LM6>.5:AXN^7EK,8P=2?M #E::
MS_X#3D_QXC>8_>.J*!$S1EY;GA6EB$M%6A:%#BPF(=&B<F#@1\;)4PN,6+_;
M1H[S@9G:03SDKA)>'QYB!Q3C,Y,.7;VFR?\NWC!K,$.N<S!2FT#(0UK&;Y\U
MQ 4U$*^[0\NM8T3;$%6M,LXA5=3[.J$@$V^$=0ILA'P,VW?L"VDH23\)G#W9
M/O8M])PXMWR65N_>O7LSA]GWPGB+0D0F3.!,<T5WMB'%65S!D'1.7H2M[J"-
M']\3"O85VWQ0'G:@1&JG)/JTL\J>F\YQ$))R/@%#6Y^^H_(LAMHD29<4B26H
M3)M+9Q,UX[<A&O+:.9C?'6+FZB I=$*KPIFPM6L7!,>\,)'9Z&)R AV'-G7^
MF^D95]T<+N<? &</IG< G>?SLS-<U#ZZ[^ ++JYT9LDA<!T**]DATTH! \-U
M;<WB$;B7#MI$\S>2TQ=P]I'S@R;#AS*] ^3<5<1O;HK //BL:Z_ 8,G/T[%$
M%J6*S+DBE$2/:-ITA'V$H/$[V[3SDO;C>@?@N>X'6;=36T!FQSF2R6^!:5$,
M\S95XS]9[X4#"6WR5FY3T9,QO*=8-UQ0>_&X,WS4_TZX5S%(%QBJ2 XB;9R%
M$@PKT2C049*^;6?+W*:DIZ#+\#C9F=<=8.4N3U[7."8N5^]AA1]6M?W%.[IJ
MJXP^X21*<$'KS J/Q":AR=[+-K/@I<HBH;>AC:;9GL:>O*MA\-5(/AT@;ST=
M[7(TVLGLY;?5=/;I?+K\7+=Y4M9JMW"@@Z3H[,B:_U<?=2$[Q>I0YB04]PG;
M=#+_(6D]F47#X&Q8:70QON.F,?MO\\5B_@?M:#G)B?N8=6 %3'43(C*OC6.!
M2(@^F$)^21-(;2!FW-3>%B ZE.-=IEB]05C>*XW9+KGJ\A</3ZO:0,! "57K
M3_X^M2]$F[.,FAF7;9W20Z+B/#,)L7#AK=*YS=#9NW0<;/XB:3$\^8(+J&KL
M\L._Y_P1#GFQR;.,1=9I7)9![9[/4S'69 01VXP\>YJND>,T^R/A@44\'/O[
MU0>'S+.]^P$#Z8>F4V3OH4,:RU%XSTPFE&N9R!)(7C+IM2PQ<[1\J[[=(^N)
MNQ"]URNIYAC6M(YJ:5_9V!,;K0X1-$/"*D%7D&L7A&7>ZY!\C%:41@UU=J2T
M*UVR"UH>% BU%%$'/M#=_5T7K%Q,7/89LA8,G<EUXE5D/KK"A!9* $?D_!A(
MNR%HW+A-,T#MQ_#N</.^'HN3\K<E/J.K=S6)*(M.1C+,H4X$2);1D>#,%1 R
M<"-=HXR9)\D:-S;3#$.',+\[)+W\]J66]TY4\%[D)%E(-74QDZ468NT_80"B
M /#.RR,@Z(J<<:,MS9"S#[,[0,PF^_X]UF?=ZZ_6<7!32M&UPYN&9.J\1LVB
MXIPI SX$=#JJ1F\.6]$W;O!E0$PU$$>G(+NYK=_!Q>7$XG.<&"6$(*N.U7IP
MI@MYDD%IQ823$DT6&6P;2VE;"L>MM&X,M(-%T@'4[N[H>B,3329?P))8@8*T
M"SHU$"$P*<&AC*5DW^;Q83,]6\'(_00P&H#=8Z<;W]W"R0P_3L^N=_(19S!;
MO3[[LIA_Q<NM22@N2Z.8DX:XY1)G'HTCGQ12-(F<#11WD?1('O)NZVZ%&-\Q
M8EKSNL_HXK5&?8_K.1BK^>HSUJ[>\_+J?'6^P/?S"SC=M^/U#I\^0%QRSZT,
M%+1\.Y^=S6>X@L7%QP7,E@1#HO\[)*.3 H//#%'R"I7,HO'(N(R6FR"] M%$
MP?^ L$/OLT<^?E/[ R!D!.T368%T9,A7=0SH=F9@D MMR31,;3(ZMJ=QW%#F
MD!BZ?Q$VDM-/KM7V[Z*]\QK'U' -NV[_"*-2R@R@#2M:U82TVN.DD'7NC"Q>
M1]2>MTEY:*SGOC=Q7K>3^C#]-)N6:2*+@!9.L/Q\>]'O9RF B!$49Q$2&9IT
M=)@72C( !%5<=5S:A+;VH[=O_;<+MAYOPMU,?C^Y+GP+BVK[?L5#'IOW7^V8
M^O'IK1Y)4_(D%21-&/8V7 [2]B%G9JSD.00AHFH32QK%(OSMHA;D7!95<&_)
MV1::G*7UQ$@D[YN#JG%"KU%P#=NUBQEHY[=(ZUO_[8*8[>R_?:728Q,B"!I=
M+?"2I=*?7& ^A<Q UU1"C9EO=YY^TB9$ POX1RV)=N'V3].2J 0+.7.ZWKG7
M=6YY85!B9(I\*UX2N5EF*P_U3]V2:"?)[]62:!<QC!Z=C;@XA5E^#E^F*SB]
M;F10?.90)W26&A@47K(8:E^#)(-'FT4JVXVUW/CQ/T,[HIUD.!^4H6-#HHY"
MF,X^$6^N(L>_X2Q]/H/%/];G1Z$%SP4R!;5G1@+:B@N)63I7IBCEN4];8>/I
M=<9-HFIS&PW-WGZ1<G6*9,P@E4=6;&TT*1RP8(QE6,?EU6J&$-V!6!GSCAE<
MGMOA9 _FCHV42]?UXME9U;;+U[,JX>L^;3XXIZ1B66KR"HIVS&L1&'=*!!F3
M,\ENA9''U^@2'?M(<3X\2\=&QK-/=!/7V?%O<743X'BWF,X7'^>T)7>U)6E1
M)1>)+^!)W49,+$HH#(O*H)6T";9#R7;KC7/[-$9, U9WD)&R^:I^<U.B!X*[
MS+FFZ]G1=B"[.G(^L2RTEE)).B/'?+E\LU.SD&89OFT,G!8R&5M!O5O,$V)>
MOB(>7NG<=_>=B$D6WOLL T.=(KD+)K/HZQ\J&Y^M=0G-5NIIF]5Z#-3L*=MY
M2T:/C9S'-O%=P]/?EM.\SMF9SY[#\O,U#R91QXA1&%:4-'6D=&(@;&$R::W!
MTN'4<A>K:!\B>G3!!L#9L<32*_QJAO/RCO7XD1"T_#P_S9-,EF$RZ&I,7M?*
M'E-+6>L 7\A62+!1;Q?XV6/Q'B_$AG ;2@Q=P^SZNXL76.#\='7RI7+U'9+1
MF2>:<W01=>U&5E.?96%!>,NR=<I$4W@RVPT3W)N$<6MEQH'<8"+I%7BWV_Y,
M? %+SE)ARAO'='"B<A.9H(T:T%;#_1[J.V+L]FKCELD<'4Y[,[I7Y-QB6YW9
M6<<"G\Z79!-<3@46SG&4Y&D7!;8ZQE '2R=6LD%/_I'+WA^FKYY<?]S:F.,K
MJ^&$\9-G-MW\Y(MS7,W?7IJDM]ASE(2G;8DX9A[47HPY4GJ4-S[$&IO+/JTG
M/'L6;6V%&6H C5#*CYLM?FAZU/JL;O[L]_/3TU?SQ1^PR+7Y9Y$HR2&O7;%T
M <\"ANJIRV1M$NY!DOPC.O*'2_48!=E/_'?4X; L[O6FO3FYSV&QN""E_A]P
M>KXN[B;_N@ZF,[4B4EK+ , PNCV"]!("%]N]+>^V[HCO0P.+>YN+=0#>[PVK
M+VLWXP-M=]70 5@NSV&6<&TH7.5A3/^)F;SLQ6KZS[5@)P)CG8P,3$2=F$8R
M';PIFH4 SH5D; G;U1D>0L6(STPC &]PN?2JW>I(;:R[N6Y:8106"<3 3#9K
M?;++S',/3.F49!3<*K73&_</5QPGEC86L [B]]@@NB[J/KECW5Y\[[8$.2:?
MR=.)6I-B=K5!5Y:1N<!KEXH4ROW$X,?>EGZPTCC1L-:@&92_NX,E7()EMGYX
MST>WJ'P(G$=9ZEPKQW2=>^:Q^@V:)^>C##P>=LT=8%$-'@GKS*+:A?<'6E0O
M9[E1F.(]?0;4_<[R"_R*I_,OEV]EIP3,^>4+V5Z1AZT^]_!@PN[D#Q0?.%E\
M@MF545/?$^>GTWQY &;YW:V]D%J:SL@JFL+IND?]6E?=N)&"FY1=$@PDAOK>
M:!@HGIDPU@"03:1]F^250<@_?&+4C9B^XK,%G>9/ZP4V57U' 9:;FM8?4AUD
M)"7I<U<M@&+ &(\1VC0JWH'(<4,6QT?DPV%4;>3997QW&\US0.1VEX\_CAIM
M&6T=!KM.Y^(Q148 (NPZ .:CE<R)5%2=HQ9SF^+^+K3I]Q+RQ\YA?62IY>2/
M_/.=$O-UCJ B)SUCL,QJ7E-1@V9>.?+84\XZ%G+#=)L!;,/OY<^@FW?!]^,-
M!D9!1X\5N5Y9G8TV3%DDQU#5*((UY!BF(&VL\5+8"MT_:47NV(CX40GO+N+Y
M:4IXL[(^6U L6Z_H"&<@+U5)XE#,ZPFR)6UE\/^I2WAWDOQ>);R[B&'L .)?
M<48;P?3Y]2Q=EW#0!<"#K!-#'#"=4+&@A&%>\")!:97*=NGH#S_[9RC>W4EZ
M\^%8.382GI'1_HFVL)[U\!47%Q]I*[/YZ?Q33998Y:LM@30VDY_&$M0D9HZ.
MA3J4VHNBC5")>*>V0L=VZXWSR'4DQ#1@^=@H>GUV=OZ6_+;KTG4;LR/BR8K,
MGNE@/?,N&R9"2042G0BW703Y[N>.\T)U)%0<P,*Q+95JO*TO62VB%3P)EDW.
M3&/,+!;O&%<Y6YML"K!52^?M+)'K9<>M.>G(Y-U/$#V@YPKTR<; M3(L<Y[J
M9'DRTI*U+(189S5HY_. S6B^+SRB@;*?R.X+?0_^C2SVW^';].S\[)IP$RRX
M LQB@IH)7*OST#+AP7BOI!/W4^X/$/R=I4<6_3Z"FP_!Q;'%/YW=(MR !B)=
M5.>,+DTA+(/$"S,^<_+:2G!ZJ[F8VXG_]M(C&II#B']O+HXL_G>+>3Y/JY/%
M!UQ\G:9+#1BD#I&7.O!8$1>J ^6#TDR!$6B3UW*[22-;H6 3!>-6$W9D2!PL
MGC[@5?EUM8/EE7EN@9.+@?5D.#HC*A$S- !#P#H!(V7OAHO//DK&>)?.X9)]
M"),#V3RV[_K7Q7QY753['K_B[/Q:+>O">80DF:I;T:J0!RZX8=9PKJ-2.=CM
M"NH?76)T(!PJN_G@C.R@/4QM:')2;FG6]2FI=?P9Z9(VD8Z*+HFS:(-@4BK0
MB7QU+=0VJF/GA\N-Y(Q;AMS)736<P#I W4/FP69^71VJ8HN7LB!+LE;/@B\L
MZ&0)11" DSTI-#3!XXZ$COLB.0 TYL>3T]AWX<?/TT6&67XU/U^L:@N33PLX
MN]Z(P.RD#)XY7GMQ9ZW(3!"<61]J6)-\#Q&WN@Z?6F5<M#25[;P%H\=&S.OW
MS_ZG?O="_,?K#Q^?T7\_OOY=76WG:C>A%"\ -8L<:NITIMU(Y9@QKA2K (K=
MKI#EATN-&P@^&G:&9?G8 /H=EJO:6.0F0Y!X]SO,S@MQZWPQG7VZ>7&Y?A?S
M1I!Y()G B)<3Z".8VB<UZ#KL+NC[CPR/X&G7E<<-#QP-7DT%TH&=]9J,TC.\
M285[4W^ARG"=)5*T$,X)1G]&VH!/C%P3TL'226M(!^O[[84&LJF>(&K<#C&=
M6?I#":]?'%YYX8:3LXV<,Z<R,!U#)'^\1&:YISUFHU$?%8EC!JX&%_YVH-I#
M$AW ZCKM_MF=M/NK*M<KC5W+\[DNEIE,-X*N4X$#V0NDMFW)WB41<VH"KBV(
MZQ)B^T!AWE8N>T/M*R[B?""P#7 GO+EI!Q5=-#RG3 9KJ-P%PP+JS#!'GJ+0
MV=DV,[*&W,6X';<ZNZU'@\?83LV=*J<?=8M]-U_1MZ9PNFX;>UEZ/M&E:)EC
M9@;K1%JG/?/< !.*YY"+*#QOEW!Y,"GC*N3Q(#0?39X_%7K?8T+B?:XMN-_!
M8C6C>TR%Y*20F0$WG&DNZA.2$4RF;'RHK31\ _!NH&3<B-!/B-U#I3DV=-_A
M(E41?Z(K\.HI\F3V%E>U%^!RHE&0H98ED[)V<8A)T"$L]&7)DOR#(GW8;K;0
MD\N,&R?J W3#R6%L1+TG@RIAOG[7KGUKA<FDK7E@&!+I<EL"B\%"'4]:P"MO
MROT)UX\U2'GPV>,^Z_:!G0,YWH4/OLY^J$JTZME::/OWZ>KS\_/EBKS+Q<MO
MZ?0\UTCJ<HGTO_P1ODVD=T9YFYDUY/%I2<8V&+(74'J)TAKG19NZZ#V('3<D
M.3I*CR7F'I!\>0BOFZ0Y)*<O>\]"LJ4^+ $+H!(=QB1$0FL1&@6.[M QKI/=
M#_[V%\[HM^IWY7[;5+@T#S@$E3.2KQ2#)VVO.)F>4C&E%=D-,L6(9;O[]8E5
MML*0^]-B:%@I=*"IGJ6TGFIXZ<'4T!69F\_/%U4:$^_0B20M,R'RFM-(WK</
MEDF+P8A(3')M.FL_1=56"/1_6@0.+KBQ==IF1_MR@,I#=Z@.*/B^Y8DK@?0S
M)Y9Y'>FT14L;)5T._O]O[\N:VSJ2-=_GO^1$[<O+C: MJ4=Q;4LAJ[OC/B%J
MM1!- FH 5%OSZR?K -Q 0CP 3N$4X'DP@R8I5&7FEVM597JIF=?1]DQ-C]E%
M+T3:BT7D::78)EQ_NRTG4?-\=R7MEVDHP46<6$4X*J, $Q-J8C09T$&@3^#4
M626)BN88@.Y:MU_UF?P5,3F(J,9&X5VKW3Q?[.3U:OZF% &4$)*XH"%9R]<!
MB648GRC\64XV"BGV:VK\^IK]T'?AAQ^51#0V\GZ=8I2[FL_2'7W_=*7R_7E-
M"9.!.DT94&50ARA^<4(%1),UU$J9G;&]P/;#9?KAZ\(/*(831 -IR(?5E[3X
M??K';)JGP:&11C8^G3#4-7HN!_0O'+O020I9*A%$:<"70!A,*8REMES@#!Y9
MF=7VC(FA^DT>M_%^2+[<4X\QY#^V!=W%]#L]?AC!S+4G5*<$DN4,2)X KT*&
M&&-*V@H1>;\A/;V7[(?'"S])J2.@!JSLQT7ZZJ9Q4_G<% LVK-U4#JR3.63%
MP#/4(6$Q"O$V&0C6BR1C5C37*56_OK=^V+S\\Y.!I=@ +LM4F5M<=3/<89J6
M+U*EH['$\0A$2^2<E &<B02BC2PR:6DF=9I*]]M?/WQ>_OE*!6DVY+(?51+N
M3I!"=#8ZB5L/EI2F<QYC;4%0VVP,Q!A"6+_IVC]<IA^\+OSH93A!M 6I!X;]
MGFZF5[/9K;O^U4UGJU1ZD*=WZ2[+FRB;N8X4(UTA5.DZ$L#'$" 8ESG3F3#=
M[Q;-@1OH!\/+/7\YF?!:!>C.*Y#3&W^[6):"_D8?EQ.=LG;61"0PAM*,58#)
MRJ&-QX Y6I6SZ??H=(#-] /N7^J8IKY0SPS$'[Z6KV__3(LP71;%G9B(/H4I
M XH[AL26XP$M+=A(B1/6>N=%#00_VTF_.]E_J1.=RN(\,^P^>A[WK#0\X1+C
M(JO0W9 H2RLI5<ZV1'EL[D467&O5[V[0@)OJA^@+/R4:2\AG!NY/Z8_;Z_)Y
MWZ^^?EW,OV& ]8Q\8U $BBI0AJ,,$J=@O4]@G97HL0BE:>]JZ4![ZP?U"S^P
M&EGD9X;X[C;A<XJMD)SJ;$!+C+M$:<9E,XG HR6>9,Q_^2&UA@.WTP_7EWM\
M-9)@FYS"^//\Y@:I6Y7IFT_VV6_*XN-_?OP4Q9V;&6A*XMM_WTY7WQ_&P7F=
M-&,<""E#1VQYIDIY&:'IF#-2B1SJG)H\W<?1<PL+O[[,KQ&JR_4G_S9?I9=F
MAD;.C""H'9ZEA 1;#B91"R'2<ETJ!1;K-!WHO<5QWU\?@8]GXP*K"*5U$W+$
MO-87/F50@U)S^NH6;H(.,=K,(1I5XGC"P3FCP41N=5(Z,5GG O[ =N6^OT;'
MP)^^_WSMEIM&&=[*A#0A2G7,("C2:8V70!&LU+.8J&1U+,GN335E._;!P.Y1
MH\<QOH4SXO^X12QM:;N^5=P0P7E,0+,T&*P)#=::#)@ 1TVIH=Y4.@I^O(U6
MIH8>*=SM\]N#.=T 3'[_@KS[R2U31(M="M;;4?GRI^\/?[.)OCN*'\B>Q8_7
M;O9H.ED*AMEH,;G46H,@TI>']QE<,L1YIQ+;/N =RD95H&;D5L&'@VO;MHTM
MZ0;0_B@JN9N)P[B01E' >,^BMZ"NO**AH(D(F,4JPV,==_IL*R,;Q]'1\:RI
MUS&B:@!KO]_ZY31.W>)[J6!LG$ZGQ8K+3+7PX'FY?"N#!:=0J0.USB9&LJWD
MC'=NJ979AL,ZYF$DT *4'K9?M.M#?E21VZA:L,0IYQ)RQR@0+ 6D2**:""YU
M5(:I[6+^4)AZ=6\C&[9A0+ -K6$ET@#&/BZFW\H#_6L7'G?=ECP9&50"%I(O
MO4AYZ16J(7K-1-#9/VM"--C]YI?V,S*6!I;ZLXO*1XN@ 2!]^)865]?7\U4A
M87VC8$,(<5H'@]M/Q)7.(4QA9DX<J(RZQS2)I)+?V[FED?U>73@-(XB19^QM
MS[]>#[$5PON &\[""A N>[ 2<Z$<@Q7,)^VC[0.D7N/U7MI!*R,<AXF7!N'S
MV/.=>X].3]DYGC$I,4F4KH"4@K-9 <G18!KMO6-Z,/#TWM9X(_J.E_R\MAC&
MOHKP)MVX6>P.HK>GDB3<OO,\ I46]8U%C@9:"$@>]VF#U2GTNU^P>XT19T?7
MD>9\>-:.C9"KY=?I(OWLODY7[OK=[2S^\LO/&S)8RC8&S#"X)ZI<H8Q@I F0
MJ0AHC)6(FO9"R.XU1APO71\A [&VC4$&Q5%OW/8O]S=I3&;!(+2!4:5!&*K+
M9",.S'NF/0E*T#JY^XO;:67DY["UH.,YWT!J]:@FVM5BEU>WJR_SQ?3_ICA1
M05O/4 V4HN7*!'YQ3"C0,F27(XTY^CH@VKVID7OZ'R_RW37IH_@_MK=:4X ^
M]]YH/Q!R=5/L]\1(S3.QJ71C]R T&EG?M4<)A@7FK:*Y7Q^NU]<:N7O^8"BI
MP=KVD/+X>*B\U'O4K*Z;S/UQ,0\I14PAM+5<8/BF3!DO2E$A?$*[+1FCG&H3
M18H'(JCO'D9ND5\;655$T8";ZRA]OUS>IOBF&P6)E$WG<6UR?TO_Z7ZUG"3T
M]]:55@W<(U6\U,:("A"IICYFKS2K=(S6:W\C]]@?W/E5D$H3,?GC*FS7ZA#_
MIZ-I3>O[V:.J[ 3_.0LD<; L(P-#>3&O70)%DE-1V1RV^Z=6.&9[;9<C]\T?
M'GFU)-0:_CXNIJ&8\8ZZ"0L\1Q<\R"P9"(8A@C&40Q9226USQ#"B-M:>[&CD
M?O@U<74XYQOPEW=^ODR(*"I1FBA\R-NGB1.3,$TNQSPVJH@9"B'@&88"@0;"
ME7#<\CH]__KM;^1.^8.CJX)4VL!:3LLE2L5=EZ[4&%LRXT*6J"$H?*&,!4.L
M@&!#IL91'FR=ERW;.QFYSWT-_!S.Z='SQ@?3>H?]G^?+\FR/.,Y%TA "BZ6H
MCVDPE11R-(*CZQ:,J*=PV945[EAAY.;R ^=\0["Q#:OQ@BU\5$Z;.">=,=Q
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M.>[ &^N%^&HS@\;W&6/*N17W<$@JM7GY\C?\P]7R_29^_-MBOEQ.$@W*,92
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M.-M2R=XP(7L?=(H.,)@4A1,2?! "%/$82+K(LFFSG/6,E)$[VIYO)>LX4%Q
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MT$Q_W%8@U O:!\JS 7R^Q1AU_CVE[BK-^KK5IC!+G**4,0O2989<,F@ 3'#
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MFDU+*+[T>H.6Q26PF9DR:]J^%+PU]@YO_4?!>75P6@M.SDV.J+P9P12AHDC
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M20LJ24@#>*6)BH0E5GFY#8&8!]P8JN<H$M$'#N.NZ33PCH$Q,*1T*13&0(%
M:$B9(!9#=["$<4UF$Q%,B$GQSZK_C&N>*<$)1,)(R*V8IF?"3F"")N&!,Q#U
M)F":8C#-*71C9#1?=\-;@6#MKP-!3D(10Y 1+ZN@Y@%_( [->JU=Q"%P!\7*
M#GX',F6@$X"S%L$\@$X@WR00=X0L0EG*%28S.)@G0P/LF2L9\RB12A  ("I
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M+_\<8*$C<*?Q1>9(I?9Y"W;)$'0IS;&"#K^^Z2&C16WNUB#WG@!['-YP@+>
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M20BN8]A?(]Y-G!17F+L4.5JAVQWL$9+-BB<"[P>S</)ZXH_"R?D4SE]#>!K
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ME-D! &-R:7,M,C R,3 Y,S N>'-D4$L! A0#%     @ ;(9I4Z399(3C%
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M>'@S,3(N:'1M4$L! A0#%     @ ;(9I4R"^RS#4!   :A(  !H
M     ( !:<X# &-R:7,M.3,P,C R,7@Q,'%E>'@S,C$N:'1M4$L! A0#%
M  @ ;(9I4V[6QG;1!   5Q(  !H              ( !==,# &-R:7,M.3,P
H,C R,7@Q,'%E>'@S,C(N:'1M4$L%!@     +  L \0(  '[8 P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
